quinazolines has been researched along with Lung Neoplasms in 4140 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (0.22) | 18.7374 |
| 1990's | 14 (0.34) | 18.2507 |
| 2000's | 1420 (34.30) | 29.6817 |
| 2010's | 2530 (61.11) | 24.3611 |
| 2020's | 167 (4.03) | 2.80 |
| Authors | Studies |
|---|---|
| Altan, M; Blumenschein, G; Carter, BW; Elamin, YY; Feng, L; Fossella, FV; Gibbons, DL; Heymach, JV; Lam, VK; Le, X; Mott, FE; Negrao, MV; Patel, AB; Robichaux, JP; Tsao, AS; Zhang, J | 1 |
| Dahal, A; El-Sadek, M; Emam, AM; Enriz, RD; Ibrahim, SM; Jois, SD; Kothayer, H; Singh, SS; Tosso, RD | 1 |
| Chan, YC; Chang, CJ; Chao, JI; Chen, C; Chen, CH; Hsu, YP; Liang, MC; Liu, KK; Pan, PY; Wang, RH; Wang, SP; Wong, KK; Wu, YH; Yang, CM; Yang, JM | 1 |
| Jiang, D; Liu, J; Liu, X; Pan, Y; Qiu, Y; Shi, Y; Wan, H; Wang, P; Ying, K; Zhu, Y | 1 |
| Brainson, CF; Byrd, AL; Chen, F; DuCote, TJ; Liu, J; Song, X; Wang, C | 1 |
| Chen, H; Ding, L; He, X; Ma, Y; Shen, Z; Wang, Y; Yang, M; Yuan, X | 1 |
| Gao, X; Li, H; Lian, S; Lin, J; Song, C | 1 |
| Asano, K; Hayama, N; Ito, Y; Niimi, K; Obayashi, S; Oguma, T; Tanaka, J; Tomomatsu, K; Urata, M | 1 |
| Akudugu, JM; Hamid, MB; Serafin, AM | 1 |
| Deng, Q; Ma, S; Mao, Y; Yin, W; Yu, Q; Zhang, K; Zhao, R | 1 |
| Chiba, M; Fujino, T; Hamada, A; Koga, T; Mitsudomi, T; Nishino, M; Ohara, S; Shimoji, M; Soh, J; Suda, K; Takemoto, T; Uchida, T | 1 |
| Chen, K; Chen, P; Dai, CH; Li, J; Shi, ZH; Su, JY; Wang, Y; Wu, JN | 1 |
| Akiyama, M; Chiba, S; Hirano, K; Maemondo, M; Nagashima, H; Sato, H; Sugai, T; Utsumi, Y; Yakuwa, K | 1 |
| Bhat, G; Clarke, JM; Cornelissen, R; Garassino, M; Goldman, JW; Heymach, JV; Le, X; Lebel, F; Leu, SY; Socinski, MA; Tchekmedyian, N | 1 |
| Cui, J; Jiang, P; Li, Y; Wang, X; Zhang, Y | 1 |
| Anderman, MF; Bhargava, D; Boccuzzi, L; de Miguel, FJ; Doroshow, JH; Durkin, ME; Lowy, DR; Papageorge, AG; Politi, K; Qian, X; Tripathi, BK; Walters, KJ; Wang, D | 1 |
| Gammon, ST; Muzzioli, R; Pisaneschi, F; Piwnica-Worms, D; Radaram, B; Sutton, MN; Yang, P | 1 |
| Lee, JY; Lin, CF; Liu, SY; Lo, TK; Su, PL | 1 |
| Du, X; Liu, W; Wang, Z; Xiong, X; Yang, L; Yang, P; Zhang, Y; Zhou, C | 1 |
| Dezfouli, AA; Dezfuli, MM; Heshmatnia, J; Lotfabadi, AS; Mirtavoos-Mahyari, H; Rismani, E; Sheikhy, K | 1 |
| Imoto, S; Miyano, S; Park, H; Yamaguchi, R | 1 |
| Chen, S; Deng, Q; Fang, Q; Huang, X; Li, X; Lin, Z; Liu, X; Miao, Y; Wang, J; Yang, L; Yu, XY | 1 |
| Feng, X; Jiang, H; Meng, J; Meng, W; Wang, K; Zhang, F; Zhao, F | 1 |
| Ahn, D; Bekaii-Saab, T; Walden, D | 1 |
| Das, S; Haider, K; Joseph, A; Yar, MS | 1 |
| Alonso Horcajo, N; Castañón López, C; Delgado Sillero, I; Díez Tascón, C; Diz Tain, P; García Palomo, A; Garrido Onecha, ML; Lopetegui Lia, N; López González, A; Martín, V; Medina Valdivieso, S; Pedraza Lorenzo, M; Rojas Piedra, M; Sánchez Cousido, LF; Távara Silva, B | 1 |
| Mir, SA; Nayak, B | 1 |
| Cai, Y; Dong, Z; Sheng, Z; Wang, J | 1 |
| Akangunduz, B; Akdeniz, N; Aksoy, A; Akyol, M; Alan, Ö; Arak, H; Atci, MM; Balli, S; Bayram, E; Bekmez, ET; Bilgin, B; Bilici, A; Cavdar, E; Celik, E; Demirci, NS; Demirkazik, A; Ellez, Hİ; Erdem, D; Erdoğan, AP; Goker, E; Gursoy, P; Hedem, E; Katgi, N; Kilickap, S; Kut, E; Menekse, S; Nart, D; Oyan, B; Ozturk, A; Pilanci, KN; Sakalar, T; Sakin, A; Selçukbiricik, F; Tatli, AM; Telli, TA; Topcu, A; Turhal, S; Turkoz, FP; Yapar, B; Yildirim, HÇ; Yumuk, PF | 1 |
| Guo, H; Hui, H; Shi, B; Wang, M; Wang, Y | 1 |
| Koshlan, TV; Kulikov, KG | 1 |
| Bagal, SK; Bickerton, S; Bodnarchuk, MS; Boyd, S; Breed, J; Carbajo, RJ; Cassar, DJ; Chakraborty, A; Cosulich, S; Cumming, I; Davies, M; Davies, NL; Eatherton, A; Evans, L; Feron, L; Fillery, S; Gleave, ES; Goldberg, FW; Hanson, L; Harlfinger, S; Howard, M; Howells, R; Jackson, A; Kemmitt, P; Kettle, JG; Lamont, G; Lamont, S; Lewis, HJ; Liu, L; Niedbala, MJ; Phillips, C; Polanski, R; Raubo, P; Robb, G; Robinson, DM; Ross, S; Sanders, MG; Tonge, M; Whiteley, R; Wilkinson, S; Yang, J; Zhang, W | 1 |
| Chang, JS; Hsieh, KP; Huang, YB; Lee, CH; Shen, MC; Tsai, MJ; Yang, YH | 1 |
| Ali, SM; Chen, G; Chen, J; Chen, S; Chen, Y; Cui, J; Dong, X; Duan, J; Fang, J; Feng, J; Guo, R; Hu, C; Hu, J; Hu, Y; Ji, Y; Jian, H; Jiang, L; Jie, W; Jie, Z; Li, B; Li, C; Li, J; Li, W; Lin, Z; Liu, C; Lu, J; Lu, S; Lu, Y; Lv, D; Ma, L; Ma, R; Miller, VA; Shi, J; Sun, C; Sun, M; Sun, Y; Tong, W; Wang, Q; Wang, Z; Wei, H; Wu, Q; Wu, X; Xiong, J; Xu, X; Xu, Z; Yang, H; Yang, N; Yao, Y; Ye, X; Yu, X; Yu, Z; Zhang, G; Zhang, H; Zhang, L; Zhang, Z; Zhou, J; Zhou, X | 1 |
| Abbasi, AM; Ayaz, Z; Darwish, NM; Gatasheh, MK; Rashid, U; Zainab, B | 1 |
| Cao, L; Chen, G; Cheng, Y; Cui, J; Feng, J; Gu, C; Hao, Y; Jiang, Y; Li, Y; Liu, C; Liu, F; Liu, J; Liu, Y; Shi, Y; Wang, X; Wu, L; Yang, N; Zang, A; Zhang, S; Zhang, X; Zhao, H; Zhu, S | 2 |
| Chen, G; Chen, Y; Li, W; Liu, B; Lyu, X; Ming, Z; Shi, J; Sun, R; Yang, S; Yang, X; Yuan, B; Yuan, J; Zeng, L; Zhao, N | 1 |
| Cai, Y; Cao, HQ; Fang, L; He, ML; Jiang, YY; Li, YP; Qian, XD; Wang, DG; Wang, GR; Wang, J; Zhao, ZT | 1 |
| Guo, J; Li, M; Xie, Y | 1 |
| Biswal, BK; Panda, M | 1 |
| Fan, D; Gan, W; Guo, Y; Li, Y; Pan, Q; Peng, Y; Rao, Z; Wang, C; Xu, S; Zheng, P; Zhu, W | 1 |
| Altan, M; Blumenschein, G; Byers, LA; Carter, BW; Cascone, T; Cross, JB; Elamin, YY; Feng, L; Fossella, FV; Gibbons, DL; Heeke, S; Heymach, JV; Lam, VK; Le, X; Lu, C; Luthra, R; Mantha, G; Negrao, MV; Nilsson, MB; Patel, A; Robichaux, JP; Routbort, M; San Lucas, FA; Tran, H; Tsao, AS; Vijayan, RSK; Zhang, J | 1 |
| Chatterjee, E; Dhingra, A; Grewal, AS; Guru, SK; Lee, SB; Liou, JP; Mathew, J; Nepali, K; Pan, CH; Rao, NV; Sharma, R; Sharma, S | 1 |
| Bai, H; Dong, G; Du, N; Duan, J; Gao, L; Guo, J; Huang, Y; Ji, D; Li, B; Li, L; Li, Q; Li, X; Liu, Z; Lv, Q; Wan, R; Wang, J; Wang, T; Wang, Z; Xu, J; Yang, Z; Zang, A; Zhang, C; Zhang, J; Zhao, J; Zhao, Y; Zhong, D; Zhong, J | 1 |
| Dai, X; Feng, C; Guo, D; Huang, L; Jiang, S; Liu, Y; Ma, S; Qahar, M; Wang, L | 1 |
| Chairoungdua, A; Janpipatkul, K; Panvongsa, W; Reungwetwattana, T; Worakitchanon, W | 1 |
| Asquith, CRM; Bieberich, AA; Crona, DJ; Fatig, RO; Laitinen, T; Maffuid, K; Morris, DC; Torrice, CD | 1 |
| Cha, HJ; Choi, SK; Jang, SJ; Kim, M; Kwon, Y; Lee, H; Lee, YS; Na, Y | 1 |
| Ho, JCM; Ip, MSM; Kwok, WC; Lam, DCL; Tam, TCC | 1 |
| Li, B; Liao, H; Wang, Y; Zhou, B | 1 |
| Espinoza, JL; Fujii, A; Fujimoto, K; Fujiwara, R; Hanamoto, H; Iwata, Y; Kumode, T; Matsumura, I; Morita, Y; Rai, S; Serizawa, K; Tanaka, H; Taniguchi, Y | 1 |
| Dong, W; Gong, Y; Hu, S; Li, M; Wang, C; Xie, C; Zhao, K | 1 |
| Fujii, R; Hayashi, K; Honda, T; Ishida, T; Kawamura, M; Matsutani, N; Ochiai, R; Saichi, N; Seki, N; Shimizu, T; Shinchi, H; Ueda, K; Yamamoto, H | 1 |
| Hong, J; Kang, S; Kim, JH; Ko, SG; Kwon, YY; Moon, JH | 1 |
| Chen, D; Li, J; Mao, C; Xia, S; Ye, F; Yu, W; Yuan, X; Zhang, M | 1 |
| Fujita, M; Igata, F; Ikeuchi, N; Ito, K; Masutani, K; Morita, D; Murayama, H; Nakamura, T; Nishida, Y; Oda, T; Takahashi, K; Uesugi, N; Watanabe, M; Yasuno, T | 1 |
| Cai, Y; Chen, T; Chen, W; Cui, D; Guo, H; Wang, L; Wang, X; Xie, D; Xie, S; Zhang, X | 1 |
| Gao, J; Li, X; Liu, Z; Teng, Y; Yin, P; Yu, P | 1 |
| Fan, XX; Feng, SL; He, F; Leung, EL; Xie, Y; Yan, PY; Yao, XJ; Zhou, H | 1 |
| Chen, Z; Chu, L; Diao, Y; Dou, D; Gong, M; He, H; Jiang, W; Li, H; Li, S; Li, W; Ma, X; Mei, W; Qiao, Y; Sha, W; Su, R; Sun, B; Wang, C; Wang, J; Wumaier, G; Xie, L; Xu, Y; Yang, T; Zhang, C; Zhao, Z; Zhu, L | 1 |
| Cheng, Y; Song, R; Zheng, T | 1 |
| Aggarwal, G; Ahsan, A; Ahsan, W; Javed, S; Kumar, P; Mangla, B; Musyuni, P | 1 |
| Brueckl, WM; Ficker, JH; Griesinger, F; Kokowski, K; Krüger, S; Laack, E; Möller, M; Neben, K; Rawluk, J; Reck, M; Schäfer, H; Schueler, A | 1 |
| Amrhein, JA; Beyett, TS; Eck, MJ; Feng, WW; Hanke, T; Jänne, PA; Knapp, S; Krämer, A; Rana, JK; Schaeffner, IK; Weckesser, J | 1 |
| Ballet, S; De Grève, J; Elsocht, M; Giron, P | 1 |
| Daga, H; Fujisaka, Y; Hattori, Y; Ikeda, N; Iwamoto, Y; Katakami, N; Kozuki, T; Morita, S; Nakagawa, K; Nishino, K; Oguri, T; Okamoto, T; Oki, M; Sato, Y; Sugawara, S; Takahashi, T; Urata, Y; Yamamoto, N; Yokoyama, T | 1 |
| Hatakeyama, N; Ichihara, S; Kadota, N; Kunishige, M; Machida, H; Naruse, K; Okano, Y; Shinohara, T; Takeuchi, E | 1 |
| Amelia, T; Kartasasmita, RE; Ohwada, T; Setiawan, AN; Tjahjono, DH | 1 |
| Li, M; Lu, S; Zhang, Y; Zhao, B | 1 |
| Harada, H; Katagiri, H; Miyagi, M; Mori, K; Murakami, H; Murata, H; Takahashi, M; Takahashi, T; Wasa, J | 1 |
| Jia, YY; Lv, WH; Nie, F; Wu, H; Zhu, YY | 1 |
| Bai, M; Li, C; Li, M; Li, Y; Liu, H; Lu, S; Ma, S; Su, P; Yin, X; Zhang, C | 1 |
| Chen, CH; Hour, MJ; Hsieh, HH; Kuo, YH; Wu, TY | 1 |
| Igai, H; Kamiyoshihara, M; Numajiri, K; Ohsawa, F | 1 |
| Mohammadnejadi, E; Razzaghi-Asl, N | 1 |
| Lai, XY; Shi, YM; Zhou, MM | 1 |
| Huang, Z; Jiang, H; Li, J; Shao, Z; Tang, Y; Wang, Y; Zhang, G; Zhou, Z; Zhu, Y | 1 |
| Ali, I; Azizov, S; Gupta, MK; Kumar, D; Kumar, S; Lalhlenmawia, H; Sengupta, S | 1 |
| Cui, Y; Dai, J; Guo, R; Qu, T; Yin, D; Zhang, C; Zhang, E | 1 |
| Gu, S; Song, P; Wang, W; Wu, K; Zhou, J | 1 |
| Chen, Y; Dai, J; Guo, R; Jin, S; Li, J; Zhang, C; Zhang, Z | 1 |
| Borm, FJ; Smit, EF | 1 |
| Chen, H; Cui, J; Fan, L; Fu, Y; Han, K; Hu, H; Yin, S; Zhao, C; Zhao, S | 1 |
| Chang, X; Chen, Y; Ding, L; He, Y; Lei, C; Ma, C; Tang, Q; Xiao, Z; Yu, Y; Zhang, H; Zhu, Y | 1 |
| Rai, GP; Shanker, A | 1 |
| Chen, MC; Li, YH; Liao, WL; Lin, H; Yang, TY | 1 |
| Cui, Y; Kang, X; Liang, J; Liu, M; Zhang, H; Zhang, Q | 1 |
| Chen, J; Chen, Q; Chen, Y; Jiang, C; Jiao, D; Liu, X; Liu, Y; Tang, X | 1 |
| Ahn, MJ; Arslan, C; Bondarenko, I; Cho, BC; Cicin, I; Danchaivijitr, P; Fong, CH; Kang, JH; Kilickap, S; Kim, JH; Lee, H; Lee, KH; Lee, SS; Lee, YG; Lim, CS; Lim, YN; Orlov, S; Pang, YK; Park, SN; Soo, RA; Yang, JC; Zimina, A | 1 |
| Fan, D; Gan, W; Lv, Q; Pan, Q; Zhang, H; Zheng, P; Zhu, W | 1 |
| Ding, T; Guo, N; Jiang, L; Ma, J; Shao, L; Song, D; Wang, J; Yan, L; Zhai, W; Zhang, W; Zhao, F | 1 |
| Chang, L; Dai, Q; Du, L; He, P; Li, G; Yu, B | 1 |
| Adelson, DL; Aung, TN; Chen, Z; Cui, J; Lin, L; Liu, X; Qu, Z; Sun, L; Wang, J; Zhang, J | 1 |
| Chuang, Q; Heng, W; Mingzhe, X; Shangli, C; You, C | 1 |
| Asquith, CRM; Crona, DJ; Laitinen, T; Maffuid, KA; Tizzard, GJ; Torrice, CD; Zuercher, WJ | 1 |
| Cheng, D; Hu, P; Lin, Q; Si, Z; Xiu, Y; Zhou, J | 1 |
| Ban, S; Chen, X; Li, X; Qian, J; Yang, J | 1 |
| Pan-Pan, L; Qing, L; Yang, F; Ye, H; Yue-Yun, C; Zhen-Yu, D | 1 |
| Chu, P; Lou, M; Wang, Z; Yin, M | 1 |
| Berger, W; Brankovic, J; Cufer, T; Dome, B; Grasl-Kraupp, B; Grusch, M; Gschwandtner, E; Hegedus, B; Hoda, MA; Kern, I; Klepetko, W; Klikovits, T; Laszlo, V; Mohorcic, K; Peter-Vörösmarty, B; Pirker, C; Rozman, A; Schelch, K; Sinn, K; Vlacic, G | 1 |
| Choowongkomon, K; Kuaprasert, B; Srisook, P; Tabtimmai, L; Thumanu, K | 1 |
| Cheng, Y; Enatsu, S; He, J; Hozak, RR; Kang, JH; Kim, JH; Murakami, H; Nakagawa, K; Nguyen, TS; Orlando, M; Puri, T; Yang, JC; Yang, PC; Zhang, WL | 1 |
| Abudula, M; Chen, Y; Chen, Z; Li, C; Yu, Y; Zhang, Y | 1 |
| Hata, AN; Klempner, SJ | 1 |
| Fang, MY; Fang, Y; Lei, L; Li, JL; Lv, TF; Song, Y; Wang, H; Wang, LP; Wang, WX; Wang, XJ; Xu, CW; Zhang, YB; Zhu, YC; Zhuang, W | 2 |
| Chae, JI; Cho, SS; Choi, JS; Kim, E; Kwak, AW; Lee, MH; Lee, SM; Oh, HN; Seo, JH; Seo, KS; Shim, JH; Yoon, G | 1 |
| Hu, ZY; Wang, GH | 1 |
| Chen, BY; Clark, PM; Damoiseaux, R; Ghezzi, C; Ribalet, B; Wong, A | 1 |
| He, X; Jia, Y; Jiang, Y; Li, Z; Qiu, Y | 1 |
| Buttachon, S; Castro-Carvalho, B; Dethoup, T; Kijjoa, A; Malhão, F; Prata-Sena, M; Ramos, AA; Rocha, E | 1 |
| Arulananda, S; John, T; Loh, Z; Mitchell, P | 1 |
| Chen, J; Li, X; Liu, H; Liu, M; Zhang, H | 1 |
| Chen, P; Cheng, J; Guan, S; Sun, J; Zhao, Q | 1 |
| Bai, L; Bai, R; Chen, N; Cui, J; Han, F; Li, J; Li, W; Qian, L; Yu, Y; Zhao, Y | 1 |
| Huang, JJ; Jiang, WQ; Kipps, TJ; Lin, X; Wu, L; Zhang, J; Zhang, S | 1 |
| Chu, CY; Lin, MH; Sheen, YS; Tzeng, WC | 1 |
| Huang, Y; Lu, L; Qi, X; Su, T; Wang, Y; Yang, X; Zhang, Y | 1 |
| An, G; Cheng, G; Ding, C; Ding, L; He, X; Hu, X; Jiang, D; Li, X; Li, Y; Liang, L; Liu, J; Mao, L; Su, W; Wang, H; Wang, Y; Wu, J; Zang, A; Zhang, C; Zhang, L; Zhang, S; Zhang, Y; Zhao, M; Zhong, D | 1 |
| Ahn, JS; Ahn, MJ; Ku, BM; La Choi, Y; Lee, J; Lee, SH; Park, K; Shim, JH; Sun, JM | 1 |
| Han, C; Hu, X; Li, M; Ren, J; Su, F; Wang, Z; Wu, L | 1 |
| Jha, RK; Jia, M; Li, K; Liu, Y; Zhan, W; Zhao, Y; Zhou, L | 1 |
| Chen, Y; Haase, D; Li, Y; Lu, G; Ma, Y; Nenkov, M; Petersen, I; Zhou, Z | 1 |
| Amendt, C; Blaukat, A; Dahmen, H; Fuchss, T; Grombacher, T; Kirkin, V; Pehl, U; Sirrenberg, C; Vassilev, LT; Wilm, C; Zenke, FT; Zimmermann, A | 1 |
| Chen, YJ; Jiang, HG; Jin, J; Li, J; Li, MY; Shu, Y; Wu, JN; Xiang, M; Zhu, YM | 1 |
| Cheng, Z; Chu, J; Ke, M; Liu, S; Liu, X; Liu, Y; Miao, S; Sun, X; Wang, K; Wang, Y; Wu, L; Xiao, Y; Yang, L; Yu, C; Yu, L; Zhang, Q | 1 |
| Hsu, JC; Lee, YC; Lin, PC; Lu, CY; Wei, CF; Yang, SC | 1 |
| Liu, L; Liu, S; Wang, Y; Yuan, Y | 1 |
| Chen, S; Gu, Y; Li, S; Lin, X; Liu, M; Ouyang, M; Qin, Y; Xiang, J; Xie, X; Zhou, C | 1 |
| Guo, C; Li, W; Pangeni, RP; Raz, DJ; Sun, T; Wang, J; Yang, L; Yun, X; Zhang, K | 1 |
| Harada, T; Inoue, S; Jingu, D; Nakagawa, T; Nakamura, A; Saito, R; Sugawara, S; Suzuki, A; Tanaka, H; Yamada, T | 1 |
| Che, X; Chen, Y; Cheng, Y; Deng, M; Hou, K; Hu, X; Liu, Y; Qu, X; Wang, Y; Wu, J; Yan, H; Yang, Y; Zhang, Y; Zou, D | 1 |
| Bai, C; Cao, L; Chang, J; Chen, G; Chen, Y; Chen, Z; Cheng, Y; Fang, J; Gong, Y; Guan, S; He, J; Hu, C; Hu, Y; Huang, D; Huang, Y; Jie, Z; Li, W; Liang, L; Liao, W; Liu, M; Liu, X; Liu, Z; Lu, J; Lu, S; Ma, R; Ma, S; Mao, W; Pan, H; Peng, M; Qin, S; Qiu, F; Shan, L; Shi, J; Song, Y; Su, W; Sun, S; Sun, Y; Tao, M; Wang, B; Yang, J; Yang, Z; Yao, Y; Ye, F; Zhang, Y; Zheng, Z; Zhou, J | 1 |
| Akher, FB; Farrokhzadeh, A; Kuttel, MM; Ravenscroft, N | 1 |
| Kumar, T; Pandey, M; Soni, K | 1 |
| Chen, CJ; Chiu, LY; Hsin, IL; Ko, JL; Ou, CC; Sheu, GT; Tsai, JN; Wu, WJ | 1 |
| Bohra, GK; Kumar, D; Meena, DS; Midha, N | 1 |
| Bu, H; Chen, X; Cui, JZ; Guo, L; Guo, XS; Han, WX; He, JY; Li, C; Meng, ZQ; Wang, X; Yan, LT; Zhao, Y; Zou, YL | 1 |
| Chen, J; Fan, Y; Hua, H; Huang, DC; Shu, Y; Wang, H; Zhang, J; Zhou, C | 1 |
| Chen, M; Chen, W; Han, G; Jiang, Y; Mao, S; Shi, N; Yu, W; Zhang, X | 1 |
| Ding, HW; Fan, YH; Hong, JY; Kim, D; Lee, SK; Liu, JY; Wang, D; Xu, YN; Yang, XS | 1 |
| Wang, J; Wu, S; Xie, X; Zeng, F; Zhan, C | 1 |
| Li, M; Xiang, J; Zhang, C | 1 |
| Cao, F; Gao, WB; Guo, XC; Pan, L; Zhang, YH; Zhu, HJ | 1 |
| Cai, J; Jiang, X; Li, X; Sun, L; Tu, L; Wei, M; Wu, Z | 1 |
| Bedir, S; Celik, E; Cikman, DI; Degerli, E; Demirci, NS; Demirelli, FH; Derin, S; Karadag, M; Oruc, K; Oztas, NS; Samanci, NS | 1 |
| Arrieta, O; Bosch-Barrera, J; Caro, RB; Dómine, M; Drozdowskyj, A; Garcia-Campelo, R; Granados, ALO; Guirado, M; Insa, A; Karachaliou, N; Lianes, P; Majem, M; Massuti, B; Molina-Vila, MA; Reguart, N; Rodriguez-Abreu, D; Rosell, R; Sala, MÁ; Vázquez-Estevez, S; Verdú, A; Vicente, D | 1 |
| Chen, X; Guo, Z; Hou, X; Li, J; Li, M; Liu, L; Sun, M; Wang, Q; Xi, N; Xie, C; Xie, N | 1 |
| Guo, Y; Ma, K; Qiu, S; Shao, J; Sun, C; Sun, M; Wang, X; Xu, Y | 1 |
| Chang, C; Fan, XX; Huang, JM; Jiang, ZB; Lai, HL; Leung, EL; Wang, MF; Wang, W; Wu, QB; Xie, C; Xie, YJ; Yao, XJ; Zhang, YZ | 1 |
| Dou, Z; Fang, G; Han, X; Huo, R; Li, X; Liu, W; Shang, Y; Shi, X; Wang, K; Yuan, S; Zang, A; Zhang, J; Zhang, L; Zhang, Y | 1 |
| Lian, X; Liao, M; Quan, J; Wang, G; Wu, Y; Xie, W; Yang, ZZ; Zhang, Z | 1 |
| Ahn, MJ; Ham, SY; Kim, JH; Lee, JW; Moon, JW; Park, K; Yi, CA | 1 |
| Chen, S; Li, S; Li, W; Wang, G; Wang, M; Wang, Q; Xia, J; Xu, Y; Zhang, D | 1 |
| Feng, LX; Ge, H; Wang, J; Yu, Z; Zhang, LW; Zhang, Y | 1 |
| Ballet, S; De Grève, J; Elsocht, M; Giron, P; Gutierrez, GJ; Maes, L; Versées, W | 1 |
| Geat, D; Girolomoni, G; Gisondi, P; Lombardo, F; Mattiucci, A; Santo, A | 1 |
| Kaul, SC; Kumar, V; Malik, V; Sundar, D; Wadhwa, R | 1 |
| Chen, L; Chen, Q; Guo, X; Huang, L; Jiang, C; Liu, X; Shu, X; Wang, H; Wang, X; Wang, Z; Wei, T; Wu, Q; Xiao, J; Yang, B; Zhang, X; Zhang, Y; Zheng, S | 1 |
| Goto, K; Ikeno, T; Kohno, T; Matsumoto, S; Murakami, H; Nishio, M; Nogami, N; Nomura, S; Nosaki, K; Sato, A; Satouchi, M; Seto, T; Tsuta, K; Wakabayashi, M; Yamamoto, N; Yoh, K | 1 |
| Bates, V; Boland, A; Chaplin, M; Dundar, Y; Green, JA; Greenhalgh, J; Vecchio, F | 1 |
| Cameron, MG; Kersten, C | 1 |
| Bottiglieri, A; Brambilla, M; de Braud, F; De Toma, A; Ferrara, R; Galli, G; Gallucci, R; Ganzinelli, M; Garassino, MC; Greco, GF; Labianca, A; Lo Russo, G; Lobefaro, R; Manglaviti, S; Nichetti, F; Occhipinti, M; Prelaj, A; Proto, C; Signorelli, D; Torri, V; Viscardi, G; Zilembo, N | 1 |
| Chen, DS; Jin, LL; Li, S; Wang, YL; Wu, ZZ; Xiao, M; Zhao, X | 1 |
| Cui, H; Dong, H; Hu, Z; Jiang, X; Li, J; Tan, K; Xue, C; Yu, Y; Zhang, J; Zhang, X; Zheng, H | 1 |
| Gan, L; Guo, M; Guo, Z; Liu, Z; Si, J; Xie, Y; Zhang, H; Zhang, J; Zhao, J | 1 |
| Liu, Q; Wu, L; Zhang, S | 1 |
| Cheng, G; Li, L; Nie, X; Wu, XN; Zhang, P | 1 |
| Ji, YX; Mu, XY; Sun, L; Zhang, L | 1 |
| Singh Badhan, RK; Yu, H | 1 |
| Cui, J; Du, X; Fan, Y; Fang, Y; Fu, X; Gu, K; Gu, W; Hou, Z; Hu, C; Jiang, O; Liu, J; Miao, L; Min, X; Wang, Q; Wu, G; Yao, W; Yu, G; Yu, Q; Yuan, X; Zhang, L; Zhang, Z; Zhao, H; Zheng, R; Zhou, X; Zhu, X | 1 |
| Nakano, M; Sato, Y; Yoshino, H | 1 |
| Ikeda, Y; Nakayama, Y; Saito, Y; Yasutake, R; Yuki, R | 1 |
| Hu, X; Li, N; Liu, H; Qi, D; Wang, T; Zhang, J; Zhang, X; Zhong, C | 1 |
| Akamatsu, H; Daga, H; Harada, H; Hasegawa, Y; Hayashi, H; Kato, T; Kim, YH; Murakami, H; Nakagawa, K; Nishimura, Y; Shimizu, J; Tokunaga, S; Yamamoto, N | 1 |
| Fan, Y; Han, N; Lu, H; Qin, J | 1 |
| Jiang, Z; Li, Y; Pan, Z; Sun, H; Wang, C; Zhang, J; Zhang, Y | 1 |
| Ahmad, I; Ansari, A; Belamkar, S; Nath Kundu, C; Nayak, D; Patel, H; Patil, C; Pawara, R; Surana, S; Wadkar, A; Wagh, S | 1 |
| Awasthi, S; Bansal, M; Belkina, N; Biswas, R; Califano, A; Chaerkady, R; Charles Jacob, HK; Cultraro, CM; Gao, S; Guha, U; Kashyap, MK; Kirkali, G; Maity, T; Marimuthu, A; Pandey, A; Pitts, S; Singh, S; Venugopalan, A; Zhang, X | 1 |
| Fan, Y; Fang, L; Gong, L; Han, N; Huang, Z; Lu, H; Qin, J; Qiu, G; Xie, F; Xu, Y | 1 |
| Berghmans, T; Besse, B; De Maio, E; Dziadziuszko, R; Hasan, B; Menis, J; Novello, S; Peric, A; Reck, M; Remon, J; Wasag, B | 1 |
| Kaneda, H; Koyama, A; Matsuoka, H; Nakagawa, K; Nishio, K; Sakai, K | 1 |
| Cao, H; Fan, F; Feng, J; Hu, Y; Liu, S; Ma, R; Ni, J; Qin, X; Sha, H; Wu, J; Xu, X; Yan, D; Yu, S; Zang, J; Zhou, L | 1 |
| Agarwal, SM; Gupta, M; Pal, D; Saini, R | 1 |
| Li, J; Ma, J; Wang, Y; Wang, Z; Wu, X | 1 |
| Ansari, A; Noolvi, M; Patel, HM; Pawara, R; Surana, S | 1 |
| Davies, L; Fukuoka, M; Gebski, V; Gralla, RJ; Inoue, A; Lee, CK; Lord, S; Marschner, I; Mitsudomi, T; Mok, T; Nakagawa, K; Rosell, R; Thongprasert, S; Tu, YK; Wu, YL; Yang, JC; Zhou, C | 1 |
| Higo, H; Hotta, K; Ichihara, E; Kato, Y; Kayatani, H; Kiura, K; Kubo, T; Kudo, K; Kurata, Y; Makimoto, G; Minami, D; Ninomiya, T; Ohashi, K; Sato, A; Takami, Y; Tanimoto, M; Yoshino, T | 1 |
| Asano, M; Hasegawa, Y; Ito, H; Kobayashi, H; Miura, H; Miura, M; Niioka, T; Okuda, Y; Sano, M; Sato, K; Sudo, K; Takeda, M; Watanabe, H | 1 |
| Huang, S; Jiang, Y; Li, Y; Liu, K; Ma, X; Meng, Q; Shu, X; Song, Z; Sun, H; Wang, C; Yu, H | 1 |
| Bai, Y; Chen, H; Chen, ZH; Chuai, S; Gan, B; Gao, H; Gou, LY; Han-Zhang, H; Jiang, BY; Li, A; Liu, SY; Su, J; Wang, BC; Wang, Z; Wu, SP; Wu, YL; Xie, Z; Xu, CR; Yang, JJ; Yang, XN; Yang, Z; Zhang, Q; Zhang, XC; Zhang, Z; Zhong, WZ; Zhou, Q | 1 |
| Mitsudomi, T | 2 |
| Belli, V; Ciaramella, V; Ciardiello, F; Della Corte, CM; Malapelle, U; Martinelli, E; Morgillo, F; Pepe, F; Troiani, T; Troncone, G; Vigliar, E | 1 |
| Cho, YJ; Chung, JH; Eo, EY; Jung, MH; Kim, CH; Kim, S; Lee, CT; Lee, JH; Lee, SH; Lee, YJ; Park, JS; Park, MY; Yoon, HI | 1 |
| Boyer, M; Dodd, N; Fan, J; Hirsh, V; Kim, DW; Kölbeck, K; Laskin, J; Laurie, SA; Lee, DH; Lee, KH; Lu, S; Märten, A; Mok, T; O'Byrne, K; Park, K; Paz-Ares, L; Shi, Y; Tan, EH; Yang, JC; Zhang, L | 1 |
| Qu, J; Qu, Q; Wang, YN; Wei, W; Xiang, DX; Xu, P; Yang, R | 1 |
| Bai, H; Hong, C; Mei, TH; Wang, J | 1 |
| Dokuni, R; Kiriu, T; Kobayashi, K; Kunimasa, K; Nagano, T; Nishimura, Y; Satouchi, M; Shimono, Y; Tachihara, M; Tamura, D; Tokunaga, S; Yamamoto, M | 1 |
| Amin, Z; Jayalie, VF; Rajabto, W | 1 |
| Chen, G; Huang, X; Huang, Y; Kang, S; Miao, S; Wu, M; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H | 1 |
| Altavilla, G; Bulotta, A; Gonzalez-Cao, M; Gregorc, V; Karachaliou, N; Lazzari, C; Rosell, R; Santarpia, M; Verlicchi, A | 1 |
| Liu, S; Liu, X; Pan, X; Qin, A; Ren, H; Yang, B; Yu, G; Zhang, K | 1 |
| Cochin, V; Godbert, Y; Gross-Goupil, M; Le Moulec, S; Ravaud, A | 1 |
| Acunzo, M; Coppola, V; Croce, CM; Fadda, P; Fassan, M; Fattore, L; Kladney, R; Laganà, A; Nigita, G; Rizzotto, L; Romano, G; Veneziano, D; Zanesi, N | 1 |
| Chong, IW; Chou, SH; Hsu, JS; Huang, MS; Hung, JY; Lee, JY; Liu, TC; Tsai, MJ; Wu, KL; Yang, CJ | 1 |
| Kai, W; Shen, B; Song, Y; Sun, X; Xiao, Z | 1 |
| Beadling, C; Corless, CL; Gay, ND; Neff, T; Tolba, K; Wang, Y; Warrick, A | 1 |
| Chen, JS; Chen, KY; Chih-Hsin Yang, J; Ho, CC; Liao, WY; Lin, CC; Lin, ZZ; Shih, JY; Yao, ZH; Yu, CJ | 1 |
| Bivona, TG; Chaib, I; Codony-Servat, C; Codony-Servat, J; de Los Llanos Gil, M; Karachaliou, N; Molina, MA; Ramirez, JL; Rosell, R; Solca, F | 1 |
| Chic, N; Mayo-de-Las-Casas, C; Reguart, N | 1 |
| Chen, KL; Cheng, YP; Cho, YT; Chu, CY; Liau, JY; Sheen, YS; Yang, CW | 1 |
| Chu, T; Dong, Y; Gu, A; Han, B; Jin, B; Lou, Y; Niu, Y; Pei, J; Shi, C; Wang, H; Xu, J; Zhang, W; Zhang, X; Zhang, Y; Zhong, H; Zhu, L | 1 |
| Höllhumer, R; Jacob, K; Moloney, G | 1 |
| Ardizzoni, A; Bühnemann, C; Cobo, M; Dupuis, N; Ehrnrooth, E; Felip, E; Gadgeel, S; Georgoulias, V; Göker, E; Goss, G; Guclu, SZ; Isla, D; Krämer, N; Lee, KH; Lu, S; Morabito, A; Solca, F; Soria, JC; Syrigos, K | 1 |
| Chen, H; Hu, J; Li, D; Li, J; Shi, M; Wang, X; Zhang, H; Zhang, L; Zhang, R | 1 |
| Asano, M; Ito, H; Kobayashi, H; Miura, M; Okuda, Y; Sato, K; Takeda, M; Yokota, H | 1 |
| Duan, YJ; Huo, XK; Liu, KX; Liu, ZH; Ma, XD; Meng, Q; Sun, HJ; Wang, CY; Zhang, Y | 1 |
| Hida, T; Horio, Y; Inaba, Y; Kuroda, H; Oya, Y; Sakao, Y; Shimizu, J; Yatabe, Y; Yoshida, T | 1 |
| Gandara, DR; Kalemkerian, GP; Kelly, K; Moon, J; Redman, MW; Tsao, AS; Vogelzang, NJ; Wistuba, II | 1 |
| Dong, Z; Gao, H; Hu, H; Li, X; Liu, B; Liu, X; Liu, Y; Shi, W; Sun, Y; Tang, C; Xu, H; Zhu, G | 1 |
| Döring, E; Engel, J; Günther, M; Juchum, M; Keul, M; Lategahn, J; Laufer, S; Rauh, D; Tumbrink, HL | 1 |
| Bosch-Barrera, J; Costa, EC; Insa, A; Isla, D; Kraemer, S; Lee, C; Majem, M; Moran, T; Palmero, R; Provencio, M; Puig, M; Reguart, N; Rosell, R; Schnell, D | 1 |
| Atallah, JP; Ibrahim, U; Saqib, A | 1 |
| Chang, CH; Chang, LY; Ko, JC; Lee, CH; Lee, MC; Wang, JY; Yu, CJ | 1 |
| Chen, SF; Zhang, JL; Zhang, ZY | 1 |
| Bennouna, J | 1 |
| Bernatowicz, PL; Pancewicz-Wojtkiewicz, J | 1 |
| Fukagawa, S; Ishikawa, T; Katsuda, T; Manabe, S; Miyahara, D; Miyamoto, S; Miyata, K; Nam, SO; Odawara, T; Yasunaga, S; Yotsumoto, F | 1 |
| Chen, HJ; Chen, WC; Hsia, TC; Li, CH; Liao, WC; Shen, YC; Tseng, GC; Tu, CY | 1 |
| Bobos, M; Christodoulou, C; Fountzilas, G; Goudopoulou, A; Kalogera-Fountzila, A; Kalogeras, KT; Karavasilis, V; Kouvatseas, G; Papadopoulos, G; Papandreou, CN; Rallis, G; Razis, E; Samantas, E; Syrigos, KN; Varaki, K | 1 |
| Bai, P; Chen, L; Li, W; Luo, H; Peng, A; Tang, M; Wan, L; Wang, F; Wen, J; Wu, W; Yang, J; Yang, L; Yang, S; Ye, H; Zheng, L | 1 |
| Cherubini, C; Drudi, F; Fantini, M; Lazzari-Agli, L; Papi, M; Sartori, S; Tamburini, E; Tassinari, D | 1 |
| Fu, J; Hong, T; Huang, J; Ji, Q; Jin, S; Li, L; Li, Y; Liang, Y; Liu, Y; Lyu, Z; Song, Q; Wang, T; Xu, X; Ye, Q; You, W; Zhao, W | 1 |
| Cao, Y; Jiang, AY; Jiang, XF; Jin, H; Wang, H; Wu, Y | 1 |
| Chiba, R; Kudo, K; Moriguchi, S; Morikawa, N; Nihei, S; Saito, H; Sato, J; Yamauchi, K | 1 |
| Fan, Y; Gong, L; Huang, Z; Xu, Y | 1 |
| Chen, G; Cheng, Y; Feng, J; Hu, C; Huang, C; Huang, Y; Liu, X; Lu, S; Song, Y; Tan, FL; Wu, G; Wu, YL; Yan, HH; Yang, JJ; Zhang, L; Zhong, W; Zhou, C | 1 |
| Cui, Y; Flamini, V; Jiang, WG | 1 |
| Bennouna, J; Chouaid, C; de Pouvourville, G; Do, P; LeLay, K; Luciani, L; Moro-Sibilot, D; Perol, M; Vergnenègre, A | 1 |
| Fei, Z; Jiang, H; Wang, H | 1 |
| Chen, X; Chen, Z; Kong, R; Li, Y; Lu, D; Niu, K; Sun, J; Wang, Y; Xia, L | 1 |
| Chang, CC; Chang, J; Chang, YC; Chang, YF; Cheng, CC; Ho, AS; Huang, L; Huang, SC; Lim, KH; Lin, HC; Wu, CW | 1 |
| Hayashi, R; Inomata, M; Kambara, K; Kashii, T; Konishi, H; Miwa, T; Okazawa, S; Shimokawa, K; Tanaka, H; Tobe, K; Tokui, K; Yamada, T | 1 |
| Akiyama, N; Enomoto, N; Fujisawa, T; Furuhashi, K; Hozumi, H; Inui, N; Iwaizumi, M; Karayama, M; Kono, M; Kusama, Y; Nakamura, Y; Suda, T; Suzuki, Y | 1 |
| Guo, R; Jin, S; Min, H; Shu, Y; Wen, W; Wu, H; Xu, T; Zhang, Z | 1 |
| Cao, B; Li, F; Liang, L; Wang, J; Zhu, T | 1 |
| Arata, S; Ohba, M; Ohmori, T; Yamaoka, T | 1 |
| Benveniste, MF; de Groot, PM; Papadimitrakopoulou, VA; Shroff, GS; Truong, MT; Viswanathan, C; Wu, CC | 1 |
| Arulananda, S; Do, H; Dobrovic, A; John, T; Mitchell, P; Musafer, A | 1 |
| Chen, H; Chen, J; Cui, L; Li, M; Liu, X; Ren, Y; Sun, Y; Wang, L; Wang, X; Wu, C; Yang, J; Zhang, J; Zhou, W | 1 |
| Groen, HJM; Heideman, DAM; Hiltermann, TJN; Kok, K; Kuiper, JL; Saber, A; Schuuring, E; Smit, EF; Terpstra, MM; Thunnissen, E; Timens, W; van den Berg, A; van der Wekken, AJ; Wei, J | 1 |
| Hu, J; Huang, J; Huang, X; Leng, D; Sun, J; Yang, S; Yao, Q | 1 |
| Fukushima, T; Gomi, D; Katou, A; Kobayashi, T; Koizumi, T; Mamiya, K; Oguchi, K; Sekiguchi, N; Tateishi, K | 1 |
| Hu, X; Tam, KY; Yang, Z; Zhang, S; Zhang, W | 1 |
| Fujii, I; Hagiwara, M; Katayama, M; Kobayashi, SS; Nakase, I; Sugiyama, A; Takatani-Nakase, T; Takenaka, T | 1 |
| Hamaguchi, R; Hasegawa, M; Okamoto, T; Sato, M; Wada, H | 1 |
| Chen, CY; Lee, H; Lin, PL; Wang, L; Wu, DW; Wu, TC | 1 |
| Baek, YM; Hwang, YE; Jang, D; Kim, DE; Park, H | 1 |
| Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Bejjanki, H; Bishnoi, R; Reisman, D | 1 |
| Gao, W; Liu, Z | 1 |
| Baba, T; Ikeda, S; Iwasawa, T; Kato, T; Ogura, T; Okudela, K; Sekine, A; Yamakawa, H; Yamanaka, Y | 1 |
| Chen, GY; Ding, CM; Ding, LM; Feng, JF; Han, BH; Han, XH; Li, K; Li, W; Lin, YC; Liu, XQ; Liu, YP; Ma, ZY; Ren, XL; Shi, YK; Shu, YQ; Song, W; Song, X; Song, Y; Sun, Y; Tan, FL; Wang, L; Wu, N; Yao, C; Ye, XQ; Yu, P; Zhang, HL; Zhang, SC; Zhao, SJ | 1 |
| Ch'ng, C; Chia, S; Gelmon, K; Ho, C; Ho, J; Ionescu, D; Jones, MR; Jones, SJM; Laskin, J; Leelakumari, S; Lim, H; Ma, Y; Marra, MA; Moore, RA; Mungall, AJ; Mungall, KL; Ng, T; Pleasance, E; Reisle, C; Renouf, DJ; Schaeffer, DF; Shen, Y; Yip, S; Zhao, C; Zhao, Y; Zhong, E | 1 |
| Ando, M; Fujiwara, T; Hasegawa, Y; Inoue, A; Katakami, N; Nagase, K; Shimizu, S; Takahashi, T; Takeuchi, S; Yano, S; Yoshimura, K | 1 |
| Cheng, Y; Corral, J; Lee, KH; Linke, R; Migliorino, MR; Mok, TS; Nadanaciva, S; Nakagawa, K; Niho, S; Pluzanski, A; Rosell, R; Sandin, R; Sbar, EI; Tsuji, F; Wang, T; White, JL; Wu, YL; Zhou, X | 1 |
| Chen, LX; Chen, Y; Fu, SZ; Liu, J; Ni, XL; Wu, JB; Wu, M; Xu, S; Yang, B; Yang, LL; Zhang, H | 1 |
| Arqués, O; Cedrés, S; Fasani, R; Felip, E; Guillaumet-Adkins, A; Heyn, H; Martinez de Castro, A; Martinez-Marti, A; Matito, J; Mereu, E; Miquel, JM; Nadal, E; Navarro, A; Nuciforo, P; Palmer, HG; Pardo, N; Remon, J; Rodriguez-Esteban, G; Villanueva, A; Vivancos, A | 1 |
| Jiang, Q; Jin, Y; Xin, T | 1 |
| Planchard, D | 1 |
| Ahn, JS; Ahn, MJ; Cho, BC; Goldman, JW; Harrop, B; John, T; Kao, S; Kim, DW; Kim, HR; Kim, SW; Kim, TM; Lee, JS; Lin, CC; Natale, R; Overend, P; Rabbie, S; Su, WC; Yang, JC; Yang, Z | 1 |
| Katsuta, E; Rashid, OM; Takabe, K | 1 |
| Cao, H; Ding, L; Dong, S; Du, Y; Fan, F; Feng, J; Li, H; Liu, S; Lou, R; Ma, R; Ni, J; Wang, Z; Wu, J; Zhao, X; Zhou, LL | 1 |
| Epistolio, S; Forcella, M; Frattini, M; Freguia, S; Fusi, P; Monti, E; Oldani, M | 1 |
| Chang, S; Choi, BW; Han, K; Hong, YJ; Hur, J; Kim, YJ; Lee, HJ | 1 |
| Gotoda, H; Hotta, K; Ichihara, E; Ichimura, K; Kato, Y; Kiura, K; Kubo, T; Maeda, Y; Makimoto, G; Ninomiya, K; Ohashi, K; Tamura, T; Tanaka, T | 1 |
| Andersson, C; Blom, K; Edqvist, PH; Fryknäs, M; Gustafsson, MG; Jarvius, M; Larsson, R; Nazir, M; Nyberg, F; Nygren, P; Senkowski, W | 1 |
| Chen, Z; Feng, X; Gao, Y; He, J; Li, X; Liu, T; Lv, Z; Pan, H; Wang, Y; Xie, S; Yang, W; Yang, X; Zhang, J | 1 |
| Camidge, DR; Chand, VK; Fan, J; Freiwald, M; Gettinger, S; Groen, HJM; Horn, L; Janjigian, YY; Miller, VA; Pao, W; Smit, EF; Wang, B | 1 |
| Diao, L; Fan, Y; Gomez, D; Haddad, V; Herbst, R; Heymach, JV; Hong, WK; Howells, K; Hung, MC; Kim, ES; Lee, JJ; Li, L; Lim, SO; Liu, D; Nilsson, MB; Pena, GA; Poteete, A; Sequist, LV; Sood, AK; Sun, H; Tong, P; Tran, H; Wang, J; Wistuba, I; Yang, JC | 1 |
| Cheng, Y; Chewaskulyong, B; Cho, BC; Cho, EK; Dechaphunkul, A; Gray, JE; Hodge, R; Imamura, F; Kurata, T; Lee, KH; Lee, SM; Marotti, M; Nogami, N; Ohe, Y; Okamoto, I; Planchard, D; Ramalingam, SS; Reungwetwattana, T; Rukazenkov, Y; Soria, JC; Su, WC; Vansteenkiste, J; Voon, PJ; Zhou, C | 1 |
| Boumber, Y; Chaudhary, S; Kesari, K; Khan, H; Khan, M; Smith, S; Wahab, A | 1 |
| Kodama, K; Maniwa, T; Takeda, M; Yamamoto, Y | 1 |
| Cheema, PK; Doherty, M; Tsao, MS | 1 |
| Fang, YF; Hsu, PC; Kao, KC; Li, SH; Liu, CY; Tseng, LC; Wang, CC; Yang, CT | 1 |
| Bai, XY; Chen, HJ; Chen, ZH; Dong, ZY; Jiang, BY; Ke, EE; Luo, DL; Mei, P; Su, J; Sun, YL; Tu, HY; Wang, BC; Wang, Z; Wu, SP; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zheng, MY; Zhong, WZ; Zhou, Q | 1 |
| Feng, J; Geater, SL; Hirsh, V; Hu, CP; Huang, Y; Lu, S; Lungershausen, J; Märten, A; Massey, D; Mok, T; O'Byrne, K; Schuler, M; Sequist, LV; Wu, YL; Yamamoto, N; Yang, JC; Zhou, C | 1 |
| Gao, XX; Han, B; Jiang, ZM; Li, C; Wang, P; Wang, XH; Yang, RF; Yu, B; Zhang, L; Zhang, RQ; Zhang, Y | 1 |
| Cho, HJ; Choi, CM; Choi, YD; Hur, JY; Kim, TO; Kim, YC; Lim, JH; Oh, IJ; Park, CK; Shin, HJ | 1 |
| Wu, X | 1 |
| Fukumoto, S; Harada, M; Kiuchi, S; Oizumi, S; Watanabe, M; Yamada, N; Yokouchi, H | 1 |
| Chong, IW; Hsu, JF; Huang, MS; Hung, JY; Lee, MH; Liu, TC; Tsai, MJ; Tsai, YC; Tsai, YM; Yang, CJ | 1 |
| Akizuki, R; Endo, S; Ikari, A; Maruhashi, R; Matsunaga, T; Sakai, H; Sato, T; Yamaguchi, M; Yamazaki, Y | 1 |
| Li, Z; Lu, C; Ma, L; Wang, J; Zhang, K; Zhang, T; Zhang, Y; Zhu, M; Zhuang, X | 1 |
| Deng, Y; Fan, X; Fu, X; Gao, Y; Li, W; Ping, W | 2 |
| Kastelijn, EA; Peters, BJM; Roepman, P; Schramel, FMNH; Sluga, R; VAN DEN Borne, BEEM | 1 |
| Fan, T; Liu, XL; Song, YJ; Wei, YN; Yang, H; Zhou, J | 1 |
| Wang, N; Zhang, T | 1 |
| D'Alessandro-Gabazza, CN; Fujimoto, H; Fujiwara, A; Gabazza, EC; Hataji, O; Ito, K; Kobayashi, T; Nakahara, H; Nishihama, K; Taguchi, O; Yasuma, T; Yoshida, M | 1 |
| Bowman, RV; Fong, KM; Sim, EH; Wood-Baker, R; Yang, IA | 1 |
| Chen, J; Guo, R; Wang, X; Yao, J | 1 |
| Hu, Z; Li, R; Ma, Y; Peng, H; Wei, Z; Yue, C; Zhang, W; Zhou, M | 1 |
| Chiba, M; Gemma, A; Ishikawa, A; Kobayashi, K; Kubota, K; Kunugi, S; Noro, R; Seike, M; Zou, F | 1 |
| Cappuzzo, F; Cseh, A; Forman, ND; Hilbe, W; Hochmair, M; Jazieh, AR; Lam, KC; Linden, S; Lorence, RM; Schuler, M; Soo, R; Stehle, G; Tsai, CM | 1 |
| Loong, HHF; To, KKW; Wu, WKK | 1 |
| Bai, R; Bode, AM; Dong, Z; Fan, S; Liu, K; Lu, B; Yang, R; Yeung, YT; Yin, S; Zhang, C | 1 |
| Dietel, M; Eberhardt, WEE; Muehlenhoff, L; Schirmacher, P; Schuette, W; Thomas, M; Zirrgiebel, U | 1 |
| Baba, K; Hasegawa, Y; Ishioka, Y; Itoga, M; Nakagawa, H; Taima, K; Takanashi, S; Tanaka, H; Tanaka, Y; Tasaka, S | 1 |
| Li, X; Wang, J; Wang, Y; Xing, L; Yang, Z; Yu, J; Zhang, T; Zheng, L | 1 |
| Araki, M; Chauhan, R; Goto, K; Ichikawa, H; Ishii, G; Knowles, PP; Kohno, T; Matsumoto, S; McDonald, NQ; Mimaki, S; Nagatoishi, S; Nakaoku, T; Niho, S; Okuno, Y; Shimada, Y; Tsuchihara, K; Tsumoto, K; Yoh, K | 1 |
| Cheng, M; Guo, J; Hao, C; Pang, Y; Wang, J; Wang, K; Wu, T; Yin, W; Zhao, D; Zhu, M | 1 |
| Furukawa, R; Matsumoto, Y; Ohara, S; Taniguchi, Y; Usui, K | 1 |
| Feng, M; Li, L; Li, Y; Liu, W; Liu, Z; Ma, X; Wang, L; Yi, Y; Zhang, W | 1 |
| Karpov, I; Kovalenko, S; Kozlov, V; Shamanin, V | 1 |
| Hirashima, T; Iwata, K; Masuhiro, K; Morishita, N; Morita, S; Nasu, S; Okamoto, N; Ryota, N; Shiroyama, T; Suzuki, H; Takata, SO; Tanaka, A; Ueda, Y | 1 |
| Lokhande, KB; Murthy, PS; Nagar, S; Reddy, PS; Reddy, VD; Swamy, KV | 1 |
| Lee, VHF | 1 |
| Chan, RT | 1 |
| Lee, VHF; Yan, H; Zou, B | 1 |
| Alqahtani, S; Ashby, CR; Bates, SE; Chen, ZS; Deng, T; Gupta, P; Kaddoumi, A; Lei, YX; Wang, YJ; Wurpel, JND; Zhang, GN; Zhang, YK | 1 |
| An, T; Chang, J; Chen, M; Hua, Y; Li, W; Liu, X; Liu, Z; Lu, S; Lu, Y; Shi, J; Su, W; Wang, J; Yang, JJ; Yang, L; Zhou, J; Zhou, X | 1 |
| Miyoshi, S; Namba, K; Sakaguchi, M; Sato, H; Shien, K; Soh, J; Suzawa, K; Takeda, T; Tomida, S; Torigoe, H; Toyooka, S; Tsukuda, K; Yamamoto, H; Yoshioka, T | 1 |
| Dziadziuszko, R; Palczewski, P; Płatek, AE; Szymański, FM; Łęgosz, P | 1 |
| Han, R; He, Y; Jiao, L; Li, L; Wang, Y; Zheng, J | 1 |
| Cao, J; Chen, Y; Cui, Y; Jiang, N; Jiang, W; Ke, Z; Lei, Y; Sun, Y; Wang, H; Wang, Y; Xu, D; Zhang, Y | 1 |
| Chen, CY; Chen, HY; Cheng, ZY; Chou, YC; Chueh, FS; Chung, JG; Hsia, TC; Hsiao, YT; Huang, YP; Jiang, YW; Peng, SF | 1 |
| Arimoto, T; Chihara, Y; Date, K; Imabayashi, T; Iwasaki, Y; Kaneko, Y; Morimoto, Y; Seko, Y; Takayama, K; Takemura, Y; Tanimura, K; Ueda, M | 1 |
| Feng, W; Ji, Y; Jin, L; Li, C; Liu, S; Wang, C; Xie, Q | 1 |
| Imamura, Y; Matsuda, S; Sano, K; Umeda, Y; Yoshida, H; Yoshimura, H | 1 |
| Gao, F; Jiang, AY; Luo, HL; Lv, YF; Zhang, J | 1 |
| Hutton, D; Li, Q; Wen, F; Zhang, P; Zheng, H | 1 |
| Peng, J; Wei, Y; Xu, J; Yu, D; Zhang, W | 1 |
| Altan, M; Brahmer, JR; Carter, BW; Chen, T; Doebele, RC; Elamin, YY; Estrada-Bernal, A; Goldberg, SB; Heymach, JV; Le, AT; Li, S; Liu, S; Lu, C; Nilsson, MB; Papadimitrakopoulou, V; Politi, K; Poteete, A; Roarty, E; Robichaux, JP; Sun, H; Tan, Z; Truini, A; Wong, KK; Zhang, S | 1 |
| Chang, E; Gambhir, SS; Hori, SS; Hughes, NP; Kani, K; Kjær, A; Lee, S; Mallick, P; Natarajan, A; Nielsen, CH; Wang, SX; Xu, L | 1 |
| Fukui, T; Harada, S; Igawa, S; Kasajima, M; Katagiri, M; Kubota, M; Kusuhara, S; Mitsufuji, H; Naoki, K; Nishinarita, N; Okuma, Y; Ozawa, T; Sasaki, J; Sugita, K; Yokoba, M | 1 |
| Chai, Y; Wu, Y; Yao, Y; Zhu, Z | 1 |
| Chen, JY; Jiang, Z; Long, F; Ren, YG; Tang, JC; Zhao, J | 1 |
| Romero, D | 1 |
| Ghaedi, K; Mojtabavi Naeini, M; Tavassoli, M | 1 |
| Bao, Y; Chen, Q; Liu, L; Sun, X; Wang, Y; Xu, Y | 1 |
| Homma, S; Isobe, K; Iyoda, A; Kaburaki, K; Kakimoto, A; Kobayashi, H; Makino, T; Mikami, T; Nakano, Y; Otsuka, H; Sakamoto, S; Sano, G; Sugino, K; Takai, Y; Tochigi, N; Yoshizawa, T | 1 |
| Chen, G; Du, KQ; Lv, TF; Song, Y; Song, ZB; Wang, WX; Xu, CW; Zhu, YC; Zhuang, W | 1 |
| Bai, C; Chang, M; Fang, T; Hu, J; Li, J; Zhou, J | 1 |
| Burslem, K; Earnshaw, S; Graham, J; Lim, J | 1 |
| Fan, T; Zhou, JY | 1 |
| Goto, Y; Hasegawa, Y; Hosomi, Y; Inoue, A; Isobe, H; Kaburagi, T; Kato, T; Kim, YH; Kunitoh, H; Minato, K; Mori, Y; Nishio, M; Ohashi, Y; Sakai, H; Tanai, C; Tomizawa, Y; Yamada, K; Yoh, K | 1 |
| Alexandre, J; Allard, M; Arrondeau, J; Bellesoeur, A; Blanchet, B; Boudou-Rouquette, P; Chapron, J; Giraud, F; Goldwasser, F; Labat, L; Reis, R; Thomas-Schoemann, A; Vidal, M | 1 |
| Che, X; Hou, K; Hu, X; Kang, J; Liu, Y; Qu, X; Wang, J; Wang, Y; Zhang, T; Zheng, C | 1 |
| Hu, X; Li, Y; Liu, S; Yan, S; Yang, L; Zeng, M; Zhang, J; Zhang, Y; Zhao, H; Zhao, J | 1 |
| Li, F; Liang, L; Wang, J; Yue, Y; Zhu, T; Zhu, X | 1 |
| Fujita, S; Fukushima, S; Imamichi, F; Irie, K; Katakami, N; Masago, K; Okada, Y; Yatabe, Y | 1 |
| Qi, Y; Qian, S; Wu, X; Xing, K; Zhang, L; Zhang, P | 1 |
| Bin, L; Guo-Qiang, LI; Liang, S; Yu-Hua, Z | 1 |
| Gu, J; Jin, Y; Liang, X; Liu, T; Ma, H; Ma, X; Tao, J; Yang, T | 1 |
| Bai, C; Chang, M; Hu, J; Kwak, KJ; Lee, LJ; Li, J; Song, Y; Wu, Z; Yang, D; Zeng, H; Zhou, J | 1 |
| Che, X; Fan, Y; Hou, K; Hu, X; Kang, J; Liu, Y; Qu, X; Wang, J; Zhang, T; Zhang, Y; Zhao, H; Zheng, C | 1 |
| Elinoff, JM; Kleiner, DE; Lee, JM; Peer, CJ; Pratt, D; Solomon, MA; Suffredini, DA | 1 |
| Graziano, S; Sharma, N | 1 |
| Ahmed, M; Carrascosa, LG; Mainwaring, P; Trau, M; Wuethrich, A | 1 |
| Chen, J; Kang, C; Li, Y; Liu, H; Liu, M; Ren, D; Wang, R; Zhang, H | 1 |
| Goto, K; Hotta, K; Ichihara, E; Kato, Y; Kiura, K; Kubo, T; Kudo, K; Maeda, Y; Makimoto, G; Matsumoto, S; Ninomiya, K; Ninomiya, T; Ohashi, K; Sato, A; Tabata, M; Tomida, S; Toyooka, S; Umemura, S; Watanabe, H | 1 |
| Aarons, L; Martin, EC; Yates, JWT | 1 |
| Hagiwara, K; Kondoh, Y; Lasky, JA; Saito, S | 1 |
| Ishimoto, O; Kawashima, Y; Kikuchi, T; Kobayashi, K; Maeno, Y; Masumoto, AI; Nukiwa, T; Sugawara, S; Watanabe, S; Yamaguchi, OU; Yoshizawa, H | 1 |
| Bai, C; Chang, M; Fang, T; Hong, Q; Li, J; Zhang, G; Zhou, J | 1 |
| Ding, L; Liang, S; Ma, Y; Tan, F; Wang, M; Xu, Y | 1 |
| Hanada, S; Kishi, K; Miyamoto, A; Mochizuki, S; Moriguchi, S; Morokawa, N; Murase, K; Ogawa, K; Takahashi, Y; Takaya, H; Uruga, H | 1 |
| Charles Victor, J; Cheema, PK; Cheng, SY; Khanna, S; Leake, J; Thawer, A | 1 |
| Ansarin, K; Baghban, R; Farajnia, S; Khalili, M; Pashapour, S; Zarredar, H | 1 |
| Choi, CM; Hur, JY; Kim, HJ; Kim, SJ; Kim, YC; Lee, JC; Lee, KY; Lee, MK; Oh, IJ; Park, CK | 1 |
| Jassem, J | 1 |
| Hagiwara, K | 1 |
| Chen, HY; Chou, YC; Chung, JG; Hsia, TC; Hsiao, YT; Huang, YP; Jiang, YW; Peng, SF; Yang, JL | 1 |
| Chung, JG; Hsu, FT; Lin, SS; Wu, JY | 1 |
| Endo, T; Furukawa, K; Hayashihara, K; Hizawa, N; Ichimura, H; Inagaki, M; Kaburagi, T; Kikuchi, N; Kimura, M; Kurishima, K; Miyazaki, K; Nakamura, H; Nawa, T; Saito, K; Satoh, H; Tamura, T; Yamashita, T | 1 |
| Liu, S; Lv, X; Sun, K; Yang, X; Yin, J | 1 |
| Harada, T; Kawano, Y; Kimura, S; Liu, R; Nakanishi, Y; Okamoto, I; Shibahara, D; Tanaka, K | 1 |
| Li, J; Li, Y; Pan, W; Yang, M; Zhang, L; Zhang, N; Zhu, H | 1 |
| Chihara, Y; Hasegawa, I; Hiranuma, O; Hiraoka, N; Kaneko, Y; Kubota, Y; Shiotsu, S; Takayama, K; Takeda, T; Takumi, C; Tamiya, N; Tanimura, K; Uchino, J; Yamada, T; Yoshimura, A | 1 |
| Hao, X; Hu, X; Li, J; Liu, Y; Shi, Y; Wang, Y; Zhou, L; Zhou, S | 1 |
| MacGregor, FB; Milner, TD; Reed, N; Ronghe, M; Shaikh, MG | 1 |
| Gu, P; Hu, F; Hu, P; Li, C; Nie, W; Shen, Y; Wang, H; Wang, S; Xu, J; Zhang, B; Zhang, X; Zhang, Y | 1 |
| Bonner, M; Kim, JY; Liu, Z; Pangeni, R; Raz, DJ; Tong, TR; Wang, J; Wu, J; Yang, L; Yuan, YC; Yuchi, T; Yun, X; Zhang, K | 1 |
| Shirley, M | 1 |
| Dagogo-Jack, I; Ferris, L; Gainor, JF; Lin, JJ; Nagy, R; Shaw, AT; Stevens, SE | 1 |
| Li, XF; Liu, GF; Miao, YY; Yu, SN; Zhang, SH | 1 |
| Chiba, M; Fujino, T; Jänne, PA; Kobayashi, Y; Koga, T; Kosaka, T; Mitsudomi, T; Nishino, M; Ohara, S; Sesumi, Y; Shimoji, M; Suda, K; Suzuki, M; Takemoto, T; Tomizawa, K | 1 |
| Dai, L; Lu, L; Lv, D; Su, X | 1 |
| Aisa, HA; Cao, JG; Huang, GZ; Liu, FZ; Nie, LF; Wang, SS; Xiamuxi, H | 1 |
| Ikeuchi, T; Ishikawa, S; Tokuyasu, H | 1 |
| Chen, SM; Chen, X; Han, SW; Long, SQ; Wu, WY; Yang, XB | 1 |
| Golabiewska, E; Holownia, A; Niechoda, A; Rybak, A; Zarzecki, M | 1 |
| Kawai, S; Kitazono, M; Murata, K; Ohashi, K; Takahashi, Y; Takamori, M; Wada, A; Yamamoto, M | 1 |
| Jing, Z; Wang, XJ; Zhang, N; Zhou, RJ | 1 |
| Chen, DL; Chen, Y; Guo, XX; Jiang, R; Li, J; Li, XP; Lv, XT; Lv, YW; Ran, JH; Tian, K; Yuan, DZ; Zhou, P | 1 |
| Bai, C; Chang, M; Fang, T; Hu, J; Li, J; Liu, J; Qu, G; Song, Y; Wu, Z; Yang, D; Zeng, H; Zhang, G; Zhou, J | 1 |
| Ansarin, K; Aria, M; Asadi, M; Baradaran, B; Farajnia, S; Zarredar, H | 1 |
| Hu, Y; Peng, L; Wang, C; Xu, S; Zhang, B; Zhang, H; Zheng, P; Zhu, W | 1 |
| Alcindor, T; Awan, A | 1 |
| Fang, Y; Pan, HM; Ren, YL; Sheng, J; Zhou, XY | 1 |
| Han, B; Qiao, R; Wang, S; Xu, J; Zhang, B; Zhang, L; Zhang, Y; Zhao, Y | 1 |
| Barasa, L; Gupta, V; Kulkarni, NS; Muth, A; Parvathaneni, V; Perron, JC; Shukla, SK; Yoganathan, S | 1 |
| Chen, H; Chen, M; Deng, W; Gan, H; Jin, L; Lin, Z; Liu, J; Liu, T; Lu, W; Wang, S; Zhang, F; Zhang, H | 1 |
| Bertran-Alamillo, J; Burbridge, M; Cantero, F; Cardona, AF; Castellví, J; Cattan, V; Codony-Servat, C; Codony-Servat, J; García-Román, S; Giménez-Capitán, A; Karachaliou, N; Molina-Vila, MA; Rodríguez, S; Roman, R; Rosell, R; Schoumacher, M; Teixidó, C; Viteri, S | 1 |
| Ji, YX; Nie, KK; You, YH; Zhu, C | 1 |
| Guo, C; Li, R; Wu, K | 1 |
| Guan, Y; Guo, H; Li, Y; Shi, J; Song, Z; Yao, M; Zhang, X | 1 |
| Liu, X; Shi, F; Su, L; Sun, W; Sun, X; Wang, Y; Yao, S; Zhang, Y | 1 |
| Li, K; Li, Q; Li, Z; Liu, L; Meng, R; Wu, G; Zhang, S; Zhou, F; Zhou, Y | 1 |
| Ando, C; Hara, N; Hirabae, A; Ichihara, E; Iwamoto, Y; Kiura, K; Maeda, Y; Nakasuka, T; Umeno, T | 1 |
| Cui, J; Li, Y; Liu, R; Qi, Q; Xu, L; Zhang, Y | 1 |
| Aisner, J; Burley, SK; Castellano, GM; Ganesan, S; Pine, SR; Vallat, B; Yu, HA | 1 |
| Ayaz, M; Bryant, AT; Ctortecka, C; Eschrich, SA; Fang, B; Haura, EB; Hu, Q; Kinose, F; Koomen, JM; Lawrence, HR; Remsing Rix, LL; Rix, U; Sumi, NJ; Welsh, EA | 1 |
| Heymach, J; Nakano, T; Nowak, AK; Popat, S; Scagliotti, GV; Tsao, A | 1 |
| Jin, B; Liu, J; Liu, Y; Qu, X; Su, H | 1 |
| Cressey, R; Khaodee, W; Kunnaja, P; Udomsom, S | 1 |
| Chen, G; Li, XL; Lv, T; Song, Y; Wang, WX; Xu, CW; Zhu, YC; Zhuang, W | 1 |
| Box-Noriega, B; Fossella, FV; Gadgeel, S; Gandara, DR; Heymach, JV; Hueftle, JG; Kelly, K; Lu, C; Miao, J; Redman, MW; Tsao, AS; Velasco, MR; Vogelzang, NJ; Wistuba, II | 1 |
| Cao, Z; Ding, X; Lin, G; Liu, D; Su, B; Wang, N; Wu, C; Xu, W; Zhou, X | 1 |
| Ahsmann, EJ; Eshuis, M; van Egmond, NH | 1 |
| Bertran-Alamillo, J; Carcereny, E; Costa, C; Gasco, A; Gimenez-Capitan, A; Jimeno, J; Karachaliou, N; Majem, M; Massuti, B; Mayo, C; Molina-Vila, MA; Moran, T; Rosell, R; Sanchez, JJ; Souglakos, J; Viteri, S; Wannesson, L | 1 |
| Fujiwara, Y; Horinouchi, H; Kanda, S; Kubota, K; Nakamichi, S; Nokihara, H; Tamura, T; Yamamoto, N | 1 |
| Gwak, HS; Han, JY; Joo, J; Kim, HT; Kim, S; Lee, JS; Lee, SH; Shin, SH; Yoo, H | 1 |
| Díaz-Rubio, E; González-Larriba, JL; Hernández, S; Manzano, A; Pérez, P; Puente, J; Sanz, J; Sotelo, M; Zugazagoitia, J | 1 |
| Huber, RM; Reck, M; Thomas, M | 1 |
| Chen, HJ; Cheng, YP; Chiu, HC | 1 |
| Couraud, S | 1 |
| Bastida, C; Falchook, GS; Fu, S; Hong, DS; Jiang, Y; Kurzrock, R; Morgan-Linnell, SK; Naing, A; Piha-Paul, SA; Tsimberidou, AM; Wheler, JJ; Zinner, R | 1 |
| Cao, HX; Feng, JF; Li, XY; Ma, R; Wu, JQ; Wu, JZ; Zhong, YJ | 1 |
| Honda, Y; Ichihara, E; Kiura, K; Kubo, T; Kudo, K; Minami, D; Murakami, T; Ninomiya, T; Ochi, N; Takigawa, N; Tanimoto, M | 1 |
| Braakhuis, BJ; Brakenhoff, RH; Martens-de Kemp, SR; Nagel, R; Stigter-van Walsum, M; van Beusechem, VW; van der Meulen, IH | 1 |
| Akerley, WL; Cowie, RH; Hornberger, J; Nelson, RE; Spinella, DG | 1 |
| Alesini, D; Bria, E; Cantile, F; Ciardiello, F; Cortesi, E; Fasano, M; Morgillo, F; Passaro, A; Pellegrino, A | 1 |
| Brekken, RA; Buettner, R; Chatterjee, S; Christofori, G; Frasca, D; Heukamp, LC; Koker, M; König, K; Meder, L; Neumaier, B; Peifer, M; Rauh, D; Schöttle, J; Siobal, M; Thomas, RK; Ullrich, RT; Wieczorek, C; Wolf, J | 1 |
| Sterman, DH | 1 |
| Altavilla, G; De Pas, TM; Rosell, R; Santarpia, M; Spaggiari, L | 1 |
| Cho, BC; Kim, HR; Lim, SM; Shim, HS; Soo, RA | 1 |
| Arcila, ME; Kris, MG; Ladanyi, M; Miller, VA; Pao, W; Rekhtman, N; Riely, GJ; Sima, CS; Yu, HA; Zakowski, MF | 1 |
| Juhász, E; Kim, JH; Klingelschmitt, G; Walzer, S | 1 |
| Arriola, E; Martínez-Avilés, L; Mompradé, E | 1 |
| Eckert, R; Faehling, M; Griese, U; Kamp, T; Kuom, S; Ott, G; Spengler, W; Sträter, J | 1 |
| Bayne, M; Cherrett, L; Davis, R; Fenton, P; Laurence, V | 1 |
| Atagi, S; Fukuoka, M; Imai, M; Katakami, N; Kudoh, S; Matsui, S; Ogiwara, A; Ueda, M; Yoshioka, H | 1 |
| Armand, JP; Bahleda, R; Baselga, J; Berman, D; Calvo, E; Felip, E; Hanna, N; Harbison, CT; Herbst, RS; Kurland, JF; Laurie, SA; Park, JS; Pathak, AK; Shepherd, FA; Soria, JC; Vakkalagadda, B; Zhang, S | 1 |
| Clément-Duchêne, C; Lamaze, R; Martinez, L | 1 |
| Chang, CY; Chang, SC; Liu, YC; Wang, KF; Yang, YH; Yuan, MK | 1 |
| Adachi, E; Matsugo, S; Matsumoto, K; Michikoshi, H; Nakamura, T; Sakai, K; Suzuki, Y | 1 |
| Hayashi, N; Igawa, S; Ishihara, M; Kasajima, M; Katono, K; Masuda, N; Nagashima, Y | 1 |
| Cai, J; He, C; Lin, B; Shao, L; Song, Z; Yu, X; Zhang, B; Zhang, Y | 1 |
| Akashi, M; Chin, TM; Doan, NB; Koeffler, HP; Mori, S; Said, JW; Sudo, M | 1 |
| Ke, S; Pan, G; Zhao, J | 1 |
| Irifune, K; Ito, R; Miyawaki, S; Sayama, K; Tohyama, M | 1 |
| Li, J; Lu, Q; Ouyang, L; Peng, L; Tan, C; Wang, S; Zeng, X | 1 |
| Dong, Z; Kang, Y; Liu, G; Ma, X; Qian, Q; Zhang, X | 1 |
| Acharyya, S; Chakraborty, A; Dasgupta, P; Gangopadhyay, S; Sau, S | 1 |
| Chen, Y; Huang, Y; Mei, Q; Xia, S; Yu, S | 1 |
| Fukudo, M; Ikemi, Y; Inui, K; Katsura, T; Kim, YH; Masago, K; Mio, T; Mishima, M; Terada, T; Teramukai, S; Togashi, Y | 1 |
| Megahed, M; Wahl, RU | 1 |
| Giuliani, J; Marzola, M | 2 |
| Arai, D; Betsuyaku, T; Hamamoto, J; Ikemura, S; Ishioka, K; Nakayama, S; Naoki, K; Ohgino, K; Sato, T; Satomi, R; Soejima, K; Terai, H; Yasuda, H; Yoda, S | 1 |
| Burton, L; Cowan, KJ; Hampton, GM; Hegde, PS; Lackner, MR; Li, C; Merchant, M; Parab, V; Patel, P; Penuel, E; Peterson, A; Yauch, RL | 1 |
| Chu, DT; Fukuoka, M; Mok, TS; Rukazenkov, Y; Saijo, N; Thongprasert, S; Wu, YL; Yang, JC; Yang, JJ | 1 |
| Beasley, MB; Cagle, PT; Chitale, DA; Dacic, S; Giaccone, G; Jenkins, RB; Kwiatkowski, DJ; Ladanyi, M; Lindeman, NI; Saldivar, JS; Squire, J; Thunnissen, E | 1 |
| Chhatwani, L; Jacobs, CD; Lopez-Anaya, A; Padda, SK; Wakelee, HA; Zhou, L | 1 |
| Chen, X; Guo, R; Liu, Y; Qian, Y; Røe, OD; Shu, Y; Yin, Y; Zhu, L | 1 |
| Chung, DH; Heo, DS; Jeon, YK; Keam, B; Kim, DW; Kim, JI; Kim, JY; Kim, S; Kim, TM; Koh, Y; Lee, JK; Lee, S; Lee, SH; Min, HS; Park, C; Shin, JY | 1 |
| Furukawa, T; Hamasaki, S; Itakura, S; Miyata, M; Suenaga, M; Tabata, S; Yamamoto, M | 1 |
| Goishi, K; Higashiyama, S; Ise, N; Kurokawa, M; Omi, K | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Matsuura, K; Mitsuoka, S; Nagata, M; Nakai, T; Oka, T; Suzumura, T; Umekawa, K; Yoshimura, N | 1 |
| Ettinger, DS; Kris, MG | 1 |
| Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G | 1 |
| Ling, YH; Perez-Soler, R; Piperdi, B; Schwartz, EL; Sironi, J; Zou, Y | 1 |
| Chang, CX; Hu, RH; Li, R; Qi, JL; Shi, SB; Tang, XY; Tian, J | 1 |
| Esumi, H; Goto, K; Ishii, G; Kohno, T; Makinoshima, H; Matsumoto, S; Matsushima, K; Mimaki, S; Ochiai, A; Shibata, T; Suzuki, A; Suzuki, M; Suzuki, Y; Tsuchihara, K; Tsuta, K; Yoh, K | 1 |
| Belaid, I; Ben Ayed, F; Debbiche, G; Jlassi, H; Rais, H | 1 |
| Alden, CM; Blumenschein, GR; Davis, SE; Herbst, R; Heymach, J; Hong, WK; Kim, E; Lee, JJ; Lippman, S; Liu, S; Tang, X; Tran, H; Tsao, AS; Wistuba, I | 1 |
| Aebi, S; Diebold, J; Gautschi, O; Hirschmann, A; Keller, FA; Strobel, K; Zander, T | 1 |
| Akamatsu, H; Inoue, A; Kobayashi, K; Mitsudomi, T; Mori, K; Nakagawa, K; Nakanishi, Y; Nukiwa, T; Yamamoto, N | 1 |
| Hou, K; Hu, X; Kang, J; Liu, Y; Mu, X; Qu, X; Zhang, Y | 1 |
| Chao, T; Chen, Y; Chu, Q; Gui, Q; Han, N; Peng, P; Xia, S; Yu, S; Zhuang, L; Zou, M | 1 |
| Fujimoto, D; Fujita, S; Hata, A; Kaji, R; Katakami, N; Kawamura, T; Matsumoto, T; Monden, K; Nagata, K; Nakagawa, A; Otoshi, T; Otsuka, K; Tachikawa, R; Takeshita, J; Tamai, K; Tanaka, K; Tomii, K | 1 |
| Barlési, F; Bylicki, O; Chouaid, C; Corre, R; Créquit, J; Dubos, C; Falchero, L; Ferlay, C; Fournel, P; Lavolé, A; Le Caer, H; Linard, P; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Vaylet, F; Vergnenègre, A; Westeel, V; Zalcman, G | 1 |
| Chen, G; Guo, Y; Li, Z; Liu, H; Wang, Y; Zhang, L | 1 |
| Bae, S; Jeong, JH; Kang, S; Kim, CH; Kim, EJ; Lim, YB | 1 |
| Au, JS; Brown, C; Chu, da T; Gebski, V; Gralla, RJ; Hirsh, V; Ho, JC; Inoue, A; Lee, CK; Lee, SM; Osorio Sanchez, JA; Tan, EH; Thongprasert, S; Tsai, CM; Vu, VV; Yang, JC; Zaatar, A | 1 |
| Aragane, N; Harada, T; Ichinose, Y; Kawakami, S; Kishimoto, J; Morinaga, R; Nagata, S; Nakanishi, Y; Saruwatari, K; Takayama, K; Yamada, K | 1 |
| Chen, L; Huang, Y; Liu, J; Ma, Y; Wu, H; Zhao, H; Zhou, N | 1 |
| Avila Martínez, RJ; Hernández Voth, A; Villena Garrido, V | 1 |
| Kishi, A; Kiyohara, Y; Yamazaki, N | 1 |
| Chachoua, A; Desai, AM; Garcia-Reglero, V; Marquez-Medina, D; Martin-Marco, A; Muggia, F; Salud-Salvia, A | 1 |
| Barlesi, F; Beau-Faller, M; Besse, B; Blons, H; Chouaid, C; Cortot, AB; Dansin, E; Diebold, J; Felip, E; Gautschi, O; Lepage, B; Mansuet-Lupo, A; Mazières, J; Milia, JD; Moro-Sibilot, D; Peters, S; Rouquette, I; Urban, T; Wislez, M | 1 |
| Fan, YX; Johnson, GR; Marino, MP; Ou, W; Reiser, J; Shen, Y; Wong, KK; Wong, L; Wu, WJ | 1 |
| Chouaid, C; Pérol, D; Pérol, M | 1 |
| Liang, JQ; O'Connell, J; Ramalingam, SS | 1 |
| Cappuzzo, F; D'Arcangelo, M | 1 |
| Brenner, R; Hirsch, FR; Ikeda, N; Ilouze, M; Kato, Y; Mascaux, C; Ohira, T; Peled, N; Qian, J; Wynes, MW; Yoshida, K | 1 |
| Hou, YH; Pan, JB; Zhang, GJ | 1 |
| Bai, H; Chen, J; Fang, F; Fang, J; Feng, Q; Feng, Y; Li, S; Lv, C; Ma, Y; Pei, Y; Wang, J; Wang, Y; Wu, N; Yan, S; Yang, Y; Zhao, B; Zheng, Q | 1 |
| Abbruzzese, JL; Carlson, P; Fogelman, DR; George, B; Javle, M; Khalil, MA; Overman, M; Qiao, W; Varadhachary, G; Wolff, RA | 1 |
| Evans, T; Gettinger, S; Hensing, TA; Ireland, B; Socinski, MA; Stinchcombe, TE; VanDam Sequist, L | 1 |
| Agelaki, S; Agelidou, M; Christofillakis, C; Georgoulias, V; Giassas, S; Karampeazis, A; Kentepozidis, N; Kotsakis, A; Mavroudis, D; Papakotoulas, P; Rapti, A; Samonis, G; Souglakos, J; Vamvakas, L; Voutsina, A | 1 |
| Chen, X; Liu, Y; Pei, D; Schuler, M; Shu, Y; Yin, Y; Zhu, L; Zhu, Q | 1 |
| Azuma, J; Fujio, Y; Furukawa, M; Imamura, F; Kijima, T; Komuta, K; Kumanogoh, A; Minami, S; Mori, M; Namba, Y; Nonen, S; Otani, Y; Tachibana, I; Takimoto, T; Tsuruta, N; Uchida, J; Yokota, S | 1 |
| Cho, YS; Kim, HU; Kim, JI; Nam, KH; Park, J; Yun, SK | 1 |
| Fujimura, Y; Himeno, A; Hirata, H; Inoue, K; Kida, H; Kijima, T; Kumanogoh, A; Matsumoto, M; Nagatomo, I; Nishijima, Y; Otani, Y; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Lv, J; Nong, J; Qin, N; Wang, J; Wu, Y; Yang, X; Zhang, H; Zhang, Q; Zhang, S | 1 |
| Barzotti, E; Crinò, L; Drudi, F; Mangianti, M; Papi, M; Poggi, B; Ravaioli, A; Salvi, M; Santelmo, C | 1 |
| Aisner, J; Dakhil, SR; Manola, JB; Schiller, JH; Sovak, MA; Stella, PJ | 1 |
| Chen, TC; Lee, KM; Lien, CT; Lin, SY; Lu, PL | 1 |
| Ciardiello, F; D'Aiuto, E; De Palma, R; De Vita, F; Della Corte, CM; Martinelli, E; Morgillo, F; Orditura, M; Sasso, FC; Troiani, T; Vitagliano, D | 1 |
| Fang, X; Gu, P; Huang, B; Liang, A; Liu, F; Ren, S; Wu, Y; Yi, X; Zeng, Y; Zhang, Z; Zhao, Y; Zhou, C | 1 |
| Chen, J; Li, JY; Shi, JY; Su, B; Tang, L; Yang, XJ; Zhang, J; Zhao, YM | 1 |
| Lazarus, DR; Ost, DE | 1 |
| Chen, PC; Chu, CY; Shih, YH | 1 |
| Wang, J; Wang, P; Yuan, Z; Zhao, L; Zhuang, H | 1 |
| Essenburg, C; Kaufman, D; Lewis, S; Staal, B; Vande Woude, GF; Zhang, YW | 1 |
| Carr, LL; Jett, JR | 1 |
| Fujita, Y; Horiike, A; Irwin, DL; Kaburaki, K; Kudo, K; Nishio, K; Nishio, M; Ohyanagi, F; Saito, R; Sakai, K; Sakatani, T; Tanimoto, A; Yanagitani, N | 1 |
| Bian, L; Jiang, Z; Wang, T; Zhang, S | 1 |
| Bode, AM; Byun, S; Dong, Z; Farrand, L; Jeong, CH; Kim, JY; Lee, HJ; Lee, J; Lee, MH; Lee, SY; Lim, S; Reddy, K; Won Lee, K | 1 |
| Arpin, D; Bringuier, PP; Couraud, S; Locatelli-Sanchez, M; Riou, R; Souquet, PJ | 1 |
| Nguyen, DM; Xin, HW; Yang, JH | 1 |
| Fukuoka, J; Ichihara, E; Iioka, H; Kiura, K; Kondo, E; Kuwahara, K; Ohtani, N; Saito, K; Takigawa, N; Tomita, Y; Ueda, R | 1 |
| Ho, JC; Lam, SK; Li, YY; Mak, JC; Zheng, CY | 1 |
| Gao, H; Guo, W; Liu, X | 1 |
| Lin, B; Shao, L; Song, Z; Zhang, Y | 1 |
| Costanzo, R; De Lutio, E; Franco, R; Montanino, A; Morabito, A; Normanno, N; Pasquale, R; Rachiglio, AM; Rocco, G; Sandomenico, C | 1 |
| Idowu, MO | 1 |
| Bellevicine, C; Carlomagno, C; De Luca, C; de Rosa, N; De Stefano, A; Iaccarino, A; Illiano, A; Malapelle, U; Micheli, P; Pepe, F; Piantedosi, FV; Rocco, D; Russo, S; Salatiello, M; Troncone, G; Vitiello, F | 1 |
| Bara, I; Chang, GC; Chen, YM; Cheng, A; Fuerte, F; Ho, J; Jin, K; Kurnianda, J; Ladrera, G; Lee, JS; Lee, V; Liao, M; Liu, HE; Margono, B; Mok, T; Pan, H; Qian, X; Sandoval-Tan, J; Seetalarom, K; Srimuninnimit, V; Sriuranpong, V; Sun, Y; Syahruddin, E; Thongprasert, S; Truman, M; Wang, J; Wu, YL; Yu, CJ; Zhang, L; Zhou, C; Zhu, Y | 1 |
| Kieszko, R; Kowalski, DM; Krawczyk, KW; Krawczyk, P; Krzakowski, M; Milanowski, J; Mlak, R; Rolski, A; Szczyrek, M; Szudy, A; Winiarczyk, K | 1 |
| Chen, MJ; Li, LY; Wang, MZ; Zhang, L; Zhao, J; Zhong, W | 1 |
| Baas, P; Blumenschein, GR; Butts, CA; Chao, RC; Chmielowska, E; Gao, F; Gridelli, C; Groen, HJ; Grossi, F; Harmon, C; Juhasz, E; Selaru, P; Socinski, MA; Tye, L; Usari, T; Williams, JA | 1 |
| Bae, MK; Cho, BC; Haack, H; Hwang, SK; Jewell, SS; Kang, DR; Kim, HJ; Kim, HR; Kim, JH; Lim, SM; Ou, SH; Park, JK; Shim, HS; Shin, E; Soo, RA; Wang, J | 1 |
| Cardarella, S; Hatabu, H; Jackman, DM; Jänne, PA; Johnson, BE; Nishino, M; Rabin, MS; Ramaiya, NH | 1 |
| Cheng, F; Chu, DT; Du, CX; Li, WG; Liu, ZD; Mi, YL; Peng, Y; Tang, KK; Wang, Y; Xi, XM; Yang, HY; Zhang, XR; Zhao, LM; Zheng, YQ | 1 |
| Belani, CP; Benner, RJ; Chachoua, A; Cuevas, JD; Eisenberg, PD; Mather, CB; Meech, SJ; Nemunaitis, JJ; Raez, LE | 1 |
| Adamo, V; David, A; Franchina, T; Gangemi, S; Kennez, I; Minciullo, PL; Profita, M; Zanghì, M | 1 |
| Chen, SS; Falchook, G; Fok, JY; Fu, S; Heymach, J; Hong, D; Janku, F; Kurzrock, R; Naing, A; Piha-Paul, S; Stephen, B; Tsimberidou, AM; Wheler, J | 1 |
| Han, ZG; Shan, L; Wang, Q; Zhang, Y | 1 |
| Aydiner, A; Seyidova, A; Yildiz, I | 1 |
| Chung, DH; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, E; Lee, SH | 1 |
| Castellanos-Rizaldos, E; Guha, M; Makrigiorgos, GM | 1 |
| Hayakawa, H; Honda, Y; Hotta, K; Ichihara, E; Kato, Y; Kiura, K; Kudo, K; Minami, D; Sato, A; Tabata, M; Takigawa, N; Tanimoto, M | 1 |
| Aieta, M; Bulotta, A; Conteduca, V; Gregorc, V; Improta, G; Lazzari, C; Lerose, R; Tartarone, A; Zupa, A | 1 |
| He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 2 |
| Bennouna, J; Boyer, M; Geater, SL; Gorbunova, V; Hirsh, V; Kato, T; Lee, KH; Massey, D; Mok, T; O'Byrne, K; Orlov, S; Schuler, M; Sequist, LV; Shah, R; Shahidi, M; Su, WC; Tsai, CM; Yamamoto, N; Yang, JC; Zazulina, V | 1 |
| Atagi, S; Ebisawa, R; Goto, K; Hida, T; Horai, T; Ichinose, Y; Inoue, A; Katakami, N; Kiura, K; Koboyashi, K; Nishio, K; Seki, Y; Shahidi, M; Takeda, K; Yamamoto, N | 1 |
| Hirsh, V; Lungershausen, J; Massey, D; Mok, TS; O'Byrne, KJ; Palmer, M; Schuler, M; Sequist, LV; Shahidi, M; Yamamoto, N; Yang, JC; Zazulina, V | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, GK; Lee, JS; Lee, Y; Yun, T | 1 |
| Barry, ST; Bradford, JR; Brown, H; Carr, TH; Delpuech, O; Dry, JR; Farren, M; Gibson, NJ; Powell, SJ; Runswick, S; Smith, NR; Wappett, M; Weston, SL | 1 |
| Gavine, P; Huang, XS; Ji, Q; Li, M; Su, X; Wu, YL; Xie, L; Yang, XN; Zhan, P; Zhang, J; Zhang, L; Zhang, XC; Zheng, L; Zhong, WZ; Zhou, M; Zhu, G | 1 |
| Grossman, S; Mehta, M; O'Neill, A; Robins, HI | 1 |
| Sperduto, PW | 1 |
| Chen, S; Ding, W; Gu, J; Kim, S; Li, X; Pan, M; Tian, W; Zhang, L; Zheng, L | 1 |
| Aoki, Y; Fujii, T; Ishii, N; Kondoh, O; Mio, T; Ono, N; Sakata, K; Suda, A; Tsukaguchi, T; Tsukuda, T; Yamazaki, T | 1 |
| An, J; Gao, H; Guo, W; Li, J; Li, X; Liu, X; Qin, H; Qu, L; Tang, C; Wang, W | 1 |
| Li, X; Lv, J; Nong, J; Qin, N; Wu, Y; Yang, X; Zhang, H; Zhang, Q; Zhang, S | 1 |
| Aloj, SM; Chiaviello, A; Palumbo, G; Postiglione, I | 1 |
| Costa, C; Fujita, H; Kage, M; Kanda, R; Kawahara, A; Kuwano, M; Maeda, M; Murakami, Y; Ono, M; Sonoda, K; Uramoto, H; Watari, K | 1 |
| Piccart, M | 1 |
| Gao, FH; Guo, YH; Jiang, B; Shi, J; Yuan, HH | 1 |
| Jacobson, BA; Jay-Dixon, J; Kratzke, RA; Patel, MR; Sadiq, AA | 1 |
| Dziadziuszko, R; Jassem, J | 2 |
| Bettini, A; Bianchi, F; Broggini, M; Farina, G; Floriani, I; Ganzinelli, M; Garassino, MC; Giaccone, G; Labianca, R; Lauricella, C; Longo, F; Marabese, M; Marsoni, S; Martelli, O; Moscetti, L; Rulli, E; Scanni, A; Tomirotti, M; Torri, V; Veronese, S | 1 |
| He, C; Li, Y; Liu, M; Xu, J; Xu, Y; Zheng, L | 1 |
| Ellis, PM; Leighl, NB; Sehdev, S; Verma, S; Younus, J | 1 |
| Altug, S; Digumarti, R; Han, B; Kim, HK; Kim, SW; Lee, DH; Lee, JS; Orlando, M; Rodrigues-Pereira, J; Sahoo, TP; Song, XQ; Wang, J; Wang, X | 1 |
| Aurisicchio, L; Ciliberto, G; Coluccia, P; D'Andrilli, A; De Vitis, C; Fattore, L; Giovagnoli, MR; Luberto, L; Malpicci, D; Mancini, R; Marra, E; Normanno, N; Noto, A; Roscilli, G; Ruco, L | 1 |
| Bhatt, VR; Ganti, AK; Kedia, S; Kessinger, A | 1 |
| Chamberlain, MC | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Minarik, M; Pesek, M | 1 |
| Thompson, CA | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Havel, L; Hrnciarik, M; Krejci, J; Minarik, M; Pesek, M; Salajka, F | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Matsuura, K; Mitsuoka, S; Nagata, M; Oka, T; Suzumura, T; Umekawa, K; Yoshimura, N | 1 |
| Chikamori, K; Fukuyama, T; Goto, K; Hida, T; Katakami, N; Kozuki, T; Maemondo, M; Nishio, M; Seto, T; Tamura, T; Yamamoto, N; Yoshioka, H | 1 |
| Bradbury, PA; Hilton, JF; Seymour, L; Shepherd, FA; Tu, D | 1 |
| Chen, B; Li, B; Xiao, F; Xie, B; Zhang, W; Zheng, J; Zhou, J | 1 |
| He, CS; Wei, SH; Xie, M; Zhang, L | 1 |
| Kato, H; Oizumi, H; Sadahiro, M; Watarai, H | 1 |
| Gao, BL; Hang, JB; Hu, JA; Xu, ZH | 1 |
| Bedi, A; Chang, X; Chatterjee, A; Goodman, SN; Harari, PM; Hidalgo, M; Izumchenko, E; Kim, MS; Ling, S; Monitto, CL; Sidransky, D; Solis, LM; Wistuba, II | 1 |
| Gao, X; Guo, F; He, S; Li, D; Lin, Z; Ma, X; Sun, J; Wan, Y; Wang, Y; Ye, T; Yin, T | 1 |
| Izumi, Y; Nomori, H; Yamamoto, J; Yamauchi, Y | 1 |
| Brown, PD; Komaki, R; McGovern, SL; Soh, HE; Wefel, JS; Welsh, JW | 1 |
| Chen, W; Dai, H; Xia, C; Xu, L | 1 |
| Aisner, DL; Berge, EM; Doebele, RC | 1 |
| Camidge, DR | 1 |
| Bai, C; Chen, J; Cheng, Y; Dai, H; Ding, L; Feng, J; Hu, C; Jiao, S; Jin, Y; Li, Q; Liang, L; Liu, W; Liu, X; Luo, R; Qin, S; Shi, Y; Song, Y; Sun, Y; Tan, F; Wang, D; Wang, J; Wang, Y; Wei, Z; Wu, YL; Xu, N; Zhang, H; Zhang, L; Zhang, S; Zhang, W; Zhang, Y; Zhou, C; Zhou, J | 1 |
| Pao, W; Yu, HA | 1 |
| Chen, JJ; Chen, X; Ma, SN; Zhao, J; Zhou, JY | 1 |
| Goto, K; Ishii, G; Matsumoto, S; Nagai, K; Niho, S; Ochiai, A; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Yoshida, T | 1 |
| Chen, JQ; Giaccone, G; Goldsmith, PK; Heldman, MR; Herrmann, MA; Lee, JH; Park, KS; Wang, Y | 1 |
| Langer, CJ | 4 |
| Butts, C; Choy, H; Ding, K; Edelman, MJ; Gandara, D; Goss, GD; Hensing, TA; Jett, J; Kernstine, K; Khuri, F; Lilenbaum, R; Lorimer, I; Masters, GA; Noble, J; O'Callaghan, C; Pisters, K; Rowland, K; Schiller, J; Shepherd, FA; Tsao, MS | 1 |
| Dungo, RT; Keating, GM | 1 |
| Alberti, AM; Apolone, G; Cammilluzzi, E; Cesario, A; D'Angelillo, RM; De Quarto, AL; Fiore, M; Greco, C; Ippolito, E; Ramella, S; Ramponi, S; Trodella, L | 1 |
| Popat, S; Yap, TA | 1 |
| Fujii, T; Matsumura, S; Okamoto, T; Shinyama, M; Tanaka, H | 1 |
| Biddinger, P; Dillard, T; Hao, Z; Patel, V | 1 |
| Chen, L; Fan, W; He, G; Lei, K; Lin, Y; Mo, Y; Xiang, M; Yang, M | 1 |
| Gao, HJ; Liu, H; Qin, HF; Qu, LL; Wang, SS | 1 |
| Amoroso, D; Chao, TY; Chung, CY; Ciuleanu, T; Groen, HJ; Heo, DS; Klingelschmitt, G; Klughammer, B; Middleton, G; Milanowski, J; Szczesna, A; Thatcher, N; Tsai, CM; Tsao, CJ; Zeaiter, A | 1 |
| Hamaguchi, M; Kawase, I; Kida, H; Kijima, T; Koba, T; Komuta, K; Minami, S; Nagatomo, I; Nakatani, T; Tachibana, I; Takahashi, R; Takeuchi, Y; Yamamoto, S | 1 |
| Stinchcombe, TE | 1 |
| Chen, Y; Wang, M; Zhao, J; Zhong, W | 1 |
| Imamura, F; Kijima, T; Komuta, K; Kumagai, T; Kumanogoh, A; Minami, S; Mori, M; Morita, S; Nakazawa, Y; Namba, Y; Nishino, K; Okuyama, T; Tachibana, I; Takahashi, R; Uchida, J; Yamamoto, S; Yano, Y | 1 |
| Hasegawa, Y; Hatano, K; Iizasa, T; Itakura, M; Iuchi, T; Kageyama, H; Kawasaki, K; Nagano, O; Sakaida, T; Shingyoji, M; Yokoi, S | 1 |
| Chiu, HC; Chiu, HY | 1 |
| Fishbein, M; Marchevsky, A; Reckamp, KL; Saldivar, JS; Scher, KS | 1 |
| Hayakawa, H; Ichihara, E; Kiura, K; Matsumoto, K; Ninomiya, T; Ohashi, K; Sakai, K; Takata, S; Takigawa, N; Tanimoto, M; Yasugi, M | 1 |
| Diao, P; Wang, LY; Wei, Y; Xie, H; Yao, WX; Zeng, C; Zhao, X; Zhou, H; Zhou, J | 1 |
| Boisdron-Celle, M; Fey, L; Hureaux, J; Morel, A; Rieux, C; Urban, T | 1 |
| Baty, F; Betticher, D; Brutsche, M; Bubendorf, L; Cathomas, R; Crowe, S; Dröge, C; Früh, M; Gautschi, O; Pless, M; Rauch, D; Rothschild, S; Zappa, F | 1 |
| Bronte, G; Castiglia, M; Cicero, G; Fiorentino, E; Giovannetti, E; Passiglia, F; Pauwels, P; Rizzo, S; Rolfo, C; Russo, A; Van Meerbeeck, J; Vullo, FL | 1 |
| Shen, W; Turchi, JJ; Xu, J; Zeng, LF; Zhang, ZY | 1 |
| Barrajón-Catalán, E; Bosch-Barrera, J; Corominas-Faja, B; Cuyàs, E; Joven, J; Martin-Castillo, B; Menendez, JA; Micol, V; Oliveras-Ferraros, C; Segura-Carretero, A | 1 |
| Köhler, J; Schuler, M | 2 |
| Chen, CH; Chen, MC; Liou, JP; Pan, SL; Teng, CM; Tsai, AC; Wang, JC | 1 |
| Bai, F; Ding, K; Ku, X; Li, H; Liu, X; Tu, Z; Xu, Y; Zhang, L; Zhao, Z; Zhou, W | 1 |
| Chang, KT; Chen, JT; Chiu, CH; Hsiao, SY; Lai, CL; Tsai, CM | 1 |
| Gilbert, JA | 1 |
| Chen, YM; Lee, YC; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J; Wu, WS | 1 |
| Cho, SY; Choi, J; Hwang, JJ; Jang, SJ; Kim, CS; Lee, G; Lee, JH; Lee, SW; Lim, C; Seo, J; Song, JY | 1 |
| Bi, H; Chen, J; Hou, J; Liu, B; Liu, D; Liu, J; Shi, H; Wen, X; Yuan, J; Yue, L; Zhang, C; Zhang, X | 1 |
| Digumarthy, S; Goldberg, SB; Jackman, DM; Lennes, IT; Muzikansky, A; Oxnard, GR; Sequist, LV | 1 |
| Ahn, JS; Ahn, MJ; Cho, EK; Kang, ES; Kang, JH; Kim, SW; Lee, DH; Lee, GW; Lee, JS; Lee, JW; Lee, KH; Park, K; Sun, JM | 1 |
| Bowles, DW; Jimeno, A; Weickhardt, A | 1 |
| Baska, F; Breza, N; Kékesi, L; Kéri, G; Németh, G; Őrfi, L; Pató, J; Sipos, A | 1 |
| Deng, CH; Li, HQ; Li, L; Li, MY; Lu, W; Wu, Q; Zhou, TY | 1 |
| Day, RO; Kerridge, IH; Lewis, JR; Lipworth, WL | 1 |
| Hu, F; Kuang, C; Li, X; Li, Y; Yan, J; Yang, Q; Yang, S; Yang, Y | 1 |
| Ashinuma, H; Chiba, T; Iwama, A; Kitamura, A; Kitazono, S; Kurosu, K; Saito-Kitazono, M; Sakaida, E; Sakao, S; Sekine, I; Tada, Y; Takiguchi, Y; Tanabe, N; Tatsumi, K; Yokosuka, O | 1 |
| Brautnick, L; Dotson, T; Laudadio, J; Lovato, J; Miller, AA; Petty, WJ; Streer, NP; Weaver, KE | 1 |
| Barlesi, F; Blumenschein, GR; Daniel, DB; Ervin, TJ; Godbert, B; Goldschmidt, JH; Govindan, R; Krzakowski, MJ; Orlov, SV; Patel, PH; Patel, T; Peterson, AC; Phan, SC; Ramlau, RA; Robinet, G; Spigel, DR; Wertheim, MS; Yauch, RL; Yu, W; Zha, J | 1 |
| Bowden, C; Fehrenbacher, L; Hainsworth, J; Johnson, BE; Kabbinavar, F; Kasubhai, S; Kressel, B; Lin, CY; Marsland, T; Miller, V; Patel, T; Polikoff, J; Rubin, M; White, L; Yang, JC | 1 |
| Baudrin, L; Bigay-Game, L; Dansin, E; Dauba, J; Debieuvre, D; Herman, D; Lavolé, A; Mennecier, B; Milleron, B; Molinier, O; Moreau, L; Morin, F; Moro-Sibilot, D; Pichon, E; Poudenx, M; Quoix, E; Sennelart, H; Souquet, PJ; Tredaniel, J; Vaylet, F; Westeel, V; Zalcman, G | 1 |
| Liou, JP; Pai, HC; Pan, SL; Teng, CM; Tsai, AC; Wang, CY; Wang, JC | 1 |
| Fukuda, M; Iida, T; Ikeda, T; Ikegami, Y; Kohno, S; Mizoguchi, K; Motoshima, K; Nagashima, S; Nakamura, Y; Sano, K; Takemoto, S; Tsukamoto, K | 1 |
| Araya, T; Demura, Y; Kasahara, K; Matsuoka, H; Nishi, K; Nishitsuji, M | 1 |
| Dai, B; Fang, B; Gao, W; Hofstetter, WL; Lu, H; Meng, J; Minna, J; Roth, JA; Swisher, SG; Wang, L; Wu, S | 1 |
| Pang, Q; Wang, J; Wang, P; Yuan, Z; Zhao, L; Zhuang, H | 1 |
| Döme, B; Fehniger, TE; Jansson, B; Laurell, T; Marko-Varga, G; Rezeli, M; Végvári, Á; Welinder, C | 1 |
| Li, YQ; Sun, H; Xue, D | 1 |
| Abrams, JS; Conley, BA; Freidlin, B; Korn, EL; McShane, LM; Polley, MY | 1 |
| Chen, CY; Chen, HJ; Chiu, HC; Huang, YC; Huang, YJ; Jian, YJ; Jian, YT; Ko, JC; Lin, YW; Syu, JJ; Tseng, SC; Wo, TY | 1 |
| Abraham, I; Bustin, F; De Vos, L; Galdermans, D; Lechat, I; Van Meerbeeck, J | 1 |
| Cai, HR; Ding, JJ; Liu, L; Miao, LY; Ren, SX; Schmid-Bindert, G; Wang, YS; Zhou, CC | 1 |
| Alfieri, RR; Ardizzoni, A; Bonelli, M; Caffarra, C; Cavazzoni, A; Cretella, D; Fumarola, C; Galetti, M; Galvani, E; Gatti, R; Giovannetti, E; La Monica, S; Petronini, PG; Saccani, F; Sirangelo, R; Tiseo, M | 1 |
| Goss, GD; Hirsh, V; Laurie, SA; Leighl, NB; Nicholas, G; Oza, A; Philip, L; Reaume, MN; Schwock, J; Shepherd, FA; Tsao, MS; Wang, L; Wright, JJ | 1 |
| Akinaga, S; Fujisaka, Y; Hayashi, H; Hirashima, T; Miyoshi, K; Murakami, H; Nakagawa, K; Satouchi, M; Takahashi, T; Takeda, K; Yamamoto, N | 1 |
| Mennecier, B; Quoix, A; Sakhri, L | 1 |
| Beau-Faller, M; Bièche, I; Blons, H; Bringuier, PP; Cadranel, J; Cayre, A; de Cremoux, P; de Fraipont, F; Denis, MG; Domerg, C; Escande, F; Gajda, D; Legrain, M; Lizard, S; Morin, F; Mosser, J; Nanni-Metellus, I; Olschwang, S; Piard, F; Pignon, JP; Pretet, JL; Richard, N; Rouquette, I; Saulnier, P; Solassol, J; Voegeli, AC; Zalcman, G | 1 |
| Bosdet, I; Ho, C; Ionescu, D; Karsan, A; Laskin, JJ; Mariano, C; Melosky, B; Murray, N; Sun, S; Zhai, Y | 1 |
| Fujimoto-Ouchi, K; Furugaki, K; Harada, N; Iwai, T; Moriya, Y | 1 |
| Ema, T; Enomoto, Y; Kawano, R | 1 |
| Li, X; Shen, Y; Tang, D; Wang, M; Wang, Y; Yao, R; Yao, Y; Zhang, H | 1 |
| Gröschel, A; Reck, M; Reinmuth, N | 1 |
| Costa, DB; de Figueiredo-Pontes, LL; Gonzalez, DA; Kobayashi, S; Lucena-Araujo, AR; Nakayama, S; Yamaguchi, N; Yasuda, H | 1 |
| Ahmad, A; Bao, B; Gadgeel, SM; Ginnebaugh, KR; Li, Y; Maitah, MY; Sarkar, FH | 1 |
| Bennouna, J; Dansin, E; Favrel, S; Hiret, S; Kowalski, D; Krzakowski, M; Penel, N; Tourani, JM | 1 |
| Hishima, T; Hosomi, Y; Kato, K; Nagamata, M; Okamura, T; Okuma, Y; Sekihara, K; Yamada, Y | 1 |
| Koyama, N; Uchida, Y | 1 |
| Azuma, K; Hoshino, T; Itoh, K; Kasama-Kawaguchi, Y; Kim, J; Matsueda, S; Muta, E; Nishio, K; Sasada, T; Sugawara, S; Yamada, T; Yamashita, T; Yamashita, Y; Zhang, GL | 1 |
| Botting, GM; Fong, JT; Jacobs, RJ; Moravec, DN; Nlend, M; Puri, N; Uppada, SB | 1 |
| Brahmer, JR; Guaglianone, PP; Hidalgo, MM; Keppen, MD; Kolesar, JM; Lee, JW; Patel, JD; Schiller, JH; Siegfried, JM; Traynor, AM | 1 |
| Fang, X; Gu, P; Luo, BF; Ren, SX; Wu, YJ; Yi, XH; Zeng, Y; Zhao, YM; Zhou, CC; Zhu, XY | 1 |
| Song, Z; Zhang, Y | 1 |
| Gemma, A; Kitamura, K; Kubota, K; Matsuda, K; Minegishi, Y; Miyanaga, A; Mizutani, H; Noro, R; Okano, T; Seike, M | 1 |
| Alfieri, RR; Ardizzoni, A; Bartolotti, M; Bordonaro, R; Bortesi, B; Bruzzi, P; Caffarra, C; Cavazzoni, A; Cosentino, S; Fumarola, C; Ippolito, M; Latteri, F; Petronini, PG; Ruffini, L; Scarlattei, M; Soto Parra, HJ; Spadaro, P; Tiseo, M | 1 |
| Ciuleanu, T; Cobo, M; Douillard, JY; McCormack, R; Milenkova, T; Ostoros, G; Webster, A | 1 |
| Han, JY; Kim, H; Kim, HT; Lee, GK; Lee, YJ; Yun, T | 1 |
| Chen, Q; Li, Q; Liu, J; Qian, X; Shen, H; Shi, Z; Shu, Y; Wang, L; Wang, R; Xu, R; Xu, T; Zheng, J | 1 |
| Chang, Q; Chen, B; Chen, F; Kowluru, A; Li, L; Lu, Y; Qiu, P; Sun, J; Thakur, C; Wu, K | 1 |
| Lee, VH; Lee, VW; Schwander, B | 1 |
| Gu, YF; Mo, ML; Song, P; Su, D; Zhang, F; Zhang, H; Zhang, SC | 1 |
| Ito, S; Itoh, K; Nishimura, Y; Takiguchi, S | 2 |
| Gu, QH; Hu, CP; Li, YY; Lu, RL; Wu, L; Yang, HP | 1 |
| Molina-Pinelo, S; Pastor, MD; Paz-Ares, L | 1 |
| Jang, SH; Jang, TW; Kim, HJ; Kim, HR; Kim, KS; Kim, SY; Kim, YC; Lee, GH; Lee, JC; Lee, JE; Lee, KY; Lee, MK; Lee, SY; Oh, IJ; Ryu, JS; Shin, KC; Son, JW | 1 |
| Gong, XD; Guo, YH; Jiang, B; Shi, J; Wang, JY; Yuan, HH | 1 |
| Meng, X; Teng, FF; Yu, JM; Zhang, JD | 1 |
| Besse, B; Bonardel, G; Chargari, C; Farace, F; Gontier, E; Hadoux, J; Helissey, C; Lamand, V; Le Moulec, S; Soria, JC; Tanz, R; Vedrine, L | 1 |
| El Touny, LH; Green, JE; Hoenerhoff, MJ; Khanna, C; Mendoza, A; Vieira, A | 1 |
| Koh, Y; Serizawa, M; Takahashi, T; Yamamoto, N | 2 |
| Deng, HB; Gong, YB; Kang, XH; Wang, LF; Wang, ZQ; Wu, J; Xu, ZY; Zhao, XZ | 1 |
| Gauler, TC; Harbeck, N; Solca, F | 1 |
| Chen, M; Chen, X; Fan, L; Fei, K; Gao, G; Garfield, D; He, Y; Kuang, P; Li, B; Li, X; Ren, S; Schmit-Bindert, G; Su, C; Wang, Y; Zhou, C; Zhou, S | 1 |
| Liu, Z; Shi, L; Tang, J; Tong, L | 1 |
| Liang, YC; Liu, Q; Liu, T; Shi, LL; Wu, G; Wu, HG; Xue, HJ | 1 |
| Fu, S; Jiang, L; Lin, YB; Long, H; Shao, JY; Su, XD; Wang, F; Wang, JF; Zhang, SL; Zhang, YG; Zhao, ZR | 1 |
| Choi, CM; Choi, YJ; Kim, HR; Kim, SY; Lee, JC; Park, GM; Rho, JK; So, GS | 1 |
| Eicheler, W; Holler, M; Meier, F; Minjgee, M; Rodemann, HP; Saki, M; Toulany, M | 1 |
| Afonso-Afonso, FJ; Alonso-Jáudenes, G; Amenedo, M; Barón-Duarte, FJ; Campos-Balea, B; Casal Rubio, J; Fírvida-Pérez, JL; Huidobro, G; Lázaro-Quintela, M; López-Vázquez, MD; Santomé, L; Vázquez, S | 1 |
| Arcila, ME; Chaft, JE; Cohen, DW; Costa, DB; Eck, MJ; Hanna, M; Huberman, MS; Ishioka, K; Kobayashi, SS; Lathan, CS; Lucena-Araujo, AR; Meyerson, M; Moran, T; Nakayama, S; Oxnard, GR; Park, E; Riely, GJ; Sequist, LV; Sng, NJ; Soo, RA; Yamaguchi, N; Yasuda, H; Yeo, WL; Yun, CH | 1 |
| Arnold, AM; Boyer, MJ; Bradbury, PA; Chen, EX; Clingan, P; Ding, K; Ellis, PM; Fenton, D; Goss, GD; Hirsh, V; Laberge, F; Laurie, SA; Lee, CW; Montenegro, A; Seymour, L; Shepherd, FA; Solomon, BJ; Stockler, MR; Zukin, M | 1 |
| Chan, V; Fukuoka, M; Kurnianda, J; McCormack, R; McWalter, G; Mok, TS; Nakagawa, K; Saijo, N; Wu, YL; Yang, JC | 1 |
| Bennouna, J; Besse, B; Blais, N; Gogov, S; Jehl, V; Johnson, BE; Leighl, N; Miller, N; Papadimitrakopoulou, VA; Soria, JC; Traynor, AM | 1 |
| Choi, CM; Chun, SM; Jang, SJ; Ji, W; Kim, SW; Kim, WS; Lee, DH; Lee, JC; Lee, JS; Park, YS; Rho, JK | 1 |
| Guan, Y; Jiao, S; Meng, J; Yan, X; Zhao, H | 1 |
| Nakagawa, T; Yano, S | 1 |
| Brambilla, E; Busser, B; Cadranel, J; Coll, JL; Hurbin, A; Jeannot, V; Robin, B; Wislez, M | 1 |
| Cao, F; Fan, FT; Kang, XH; Wang, LF; Xu, ZY | 1 |
| Borczuk, AC; Siegelin, MD | 1 |
| Afonso, J; Amenedo, M; Casal, J; Fírvida, JL; Lázaro, M; Santomé, L; Vázquez, S | 1 |
| Ebi, H; Ishikawa, D; Matsumoto, K; Nakagawa, T; Nanjo, S; Nishihara, H; Sano, T; Takeuchi, S; Yamada, T; Yano, S; Yasumoto, K; Zhao, L | 1 |
| Bannerji, R; Edelman, MJ; Jou, YM; Joy, AA; Martin, JC; Nemunaitis, J; Small, K; Statkevich, P; Stephenson, JJ; Yao, SL; Zhang, D; Zhou, H; Zhu, Y | 1 |
| Dandekar, G; Dandekar, T; Fecher, D; Göttlich, C; Nietzer, SL; Stratmann, AT; Walles, H; Walles, T; Wangorsch, G | 1 |
| Hager, H; Khalil, AA; McCulloch, T; Meldgaard, P; Mellemgaard, A; Nexo, E; Sorensen, BS; Weber, B | 1 |
| Andreoli, R; Ardizzoni, A; Azzoni, C; Bartolotti, M; Bortesi, B; De Palma, G; Gelsomino, F; Goldoni, M; Mozzoni, P; Mutti, A; Silini, EM; Tiseo, M | 1 |
| Antoine, M; Bonnette, P; Cadranel, J; Cazes, A; Duruisseaux, M; Girard, N; Mazieres, J; Monnet, I; Ung, M; Vieira, T; Wislez, M | 1 |
| Chan, AW; Lo, SH; To, KF; Tong, JH | 1 |
| Bria, E; Garassino, M; Massari, F; Pelosi, G; Peretti, U; Pilotto, S; Tortora, G | 1 |
| Dhanda, R; Mallick, R; Nadler, E; Pan, IW | 1 |
| An, J; Gao, H; Li, J; Li, X; Liu, X; Liu, Y; Qin, H; Qu, L; Tang, C; Wang, W; Yang, S | 1 |
| Baresic, T; Basso, SM; Del Conte, A; Lumachi, F; Minatel, E; Schinella, D | 1 |
| Fiegl, M; Hilbe, W; Manzl, C; Pircher, A; Pirker, R; Popper, H | 1 |
| Ito, H; Kobayashi, H; Miura, H; Miura, M; Narita, C; Niioka, T; Sato, K | 1 |
| Bellezza, G; Bennati, C; Chiari, R; Crinò, L; Duranti, S; Ludovini, V; Minotti, V; Pireddu, A | 1 |
| Gemma, A; Hagiwara, K; Harada, M; Inoue, A; Ishii, Y; Isobe, H; Kobayashi, K; Maemondo, M; Minegishi, Y; Sugawara, S; Watanabe, S; Yoshizawa, H | 1 |
| Nakagawa, K; Okamoto, I; Takeda, M | 2 |
| Hida, T; Horio, Y; Kondo, C; Park, J; Shimizu, J; Yoshida, K | 1 |
| Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M | 1 |
| Fang, MH; Li, RC; Yu, SY; Zheng, LJ | 1 |
| Yaqub, F | 1 |
| Akar, A; Altiok, S; Bepler, G; Chiappori, A; Gray, JE; Haura, E; Kish, JA; Kreahling, J; Lush, R; Neuger, A; Pinder-Schenck, M; Schell, MJ; Tanvetyanon, T; Tetteh, L; Williams, CC; Zhao, X | 1 |
| Keating, GM | 2 |
| He, C; Lin, B; Lou, G; Shao, L; Song, Z; Yu, X; Zhang, B; Zhang, Y | 1 |
| Feng, J; Geater, SL; Hou, M; Hu, CP; Huang, Y; Kim, M; Lee, KY; Li, W; Lu, S; Massey, D; Shi, JH; Shi, Y; Wu, YL; Xu, CR; Zhou, C | 1 |
| Garassino, MC; Torri, V | 1 |
| Harada, D; Hotta, K; Ichihara, E; Kiura, K; Ochi, N; Tabata, M; Takigawa, N; Tanimoto, M; Yasugi, M | 1 |
| Ju, L; Zhou, C | 1 |
| Liu, XQ; Qiao, TK | 1 |
| Chen, CY; Chiu, HC; Huang, YJ; Jian, YJ; Jian, YT; Ko, JC; Lin, YW; Syu, JJ; Wo, TY | 1 |
| Horn, L; Lammers, PE; Lovly, CM | 1 |
| Fukihara, J; Hasegawa, Y; Kataoka, K; Kimura, T; Kondoh, Y; Matsuda, T; Taniguchi, H; Watanabe, N; Yokoyama, T | 1 |
| Amler, L; Eaton, K; Fine, BM; Gitlitz, B; Hicks, R; Hughes, B; Loecke, D; Mileshkin, L; Mitchell, P; Pirzkall, A; Townley, P; Wood, K | 1 |
| Ikegami, Y; Inoue, Y; Ishikawa, T; Nakagawa, H; Nakamura, Y; Sano, K; Suzuki, T; Yoshida, H | 1 |
| Iwasaki, T; Mitsudomi, T; Mizuuchi, H; Sato, K; Suda, K; Takemoto, T | 1 |
| Cao, X; Hong, Z; Lan, L; Li, N; Luo, L; Pan, X; Shen, L; Yin, Z; Zhang, Y; Zhou, Y | 1 |
| Arcila, ME; Hellmann, MD; Kris, MG; Ladanyi, M; Riely, GJ; Yu, HA | 1 |
| Li, N; Liu, QW; Ou, W; Wang, BX; Wang, SY; Yang, H; Zhang, SL | 1 |
| Hashimoto, M; Iwakami, S; Kato, M; Kobayashi, I; Koizumi, F; Minakata, K; Moriyama, H; Moriyama, M; Murakami, A; Nara, T; Nurwidya, F; Shimada, N; Tajima, K; Takahashi, F; Takahashi, K | 1 |
| Cinquini, M; De Braud, F; Garassino, MC; Gelsomino, F; Haspinger, ER; Torri, V | 1 |
| de Marinis, F; Passaro, A | 1 |
| Sequist, LV; Yang, JC | 2 |
| Chan, DC; Jensen, RT; Mantey, SA; Moody, TW; Moreno, P | 1 |
| Azuma, K; Hattori, S; Hoshino, T; Itoh, K; Kawahara, A; Komatsu, N; Matsueda, S; Sasada, T | 1 |
| Camidge, DR; Campbell, AK; Engelman, JA; Gadgeel, SM; Gernhardt, D; Giaccone, G; Jänne, PA; Khuri, FR; Koczywas, M; Letrent, S; Liang, J; O'Connell, JP; Rajan, A; Reckamp, KL; Ruiz-Garcia, A; Taylor, I | 1 |
| Couturier, O; Fosse, P; Hachemi, M; Hureaux, J; Lacœuille, F; Urban, T; Vervueren, L | 1 |
| Fan, X; Jiang, L; Li, S; Liu, Z; Wu, X; Zhao, H; Zhu, F | 1 |
| Ando, M; Asami, K; Atagi, S; Ishii, M; Kanazu, M; Kawaguchi, T; Kubo, A; Kusunoki, Y; Maruyama, K; Matsuda, Y; Minomo, S; Ogawa, Y; Takada, M; Uehira, K | 1 |
| Song, T; Wu, SX; Yu, W | 1 |
| Dong, XL; Dong, Z; Li, G; Li, XL; Mu, XY; Ni, YH; Sun, EL; Sun, J; Yi, Z | 1 |
| Cho, S; Choi, DL; Choi, HE; Jang, SJ; Lee, JY; Lee, KT; Rim, HK | 1 |
| Dinglin, X; Fang, W; Hou, X; Hu, Z; Huang, P; Huang, Y; Liang, W; Ma, Y; Qin, T; Tian, Y; Wu, X; Xue, C; Yan, Y; Yang, Y; Zhang, J; Zhang, L; Zhao, H; Zhao, Y; Zhou, T | 1 |
| Bader, AG; Kelnar, K; Zhao, J | 1 |
| Bohnet, S; Deppermann, KM; Eiff, MV; Fischer, JR; Heigener, DF; Koester, W; Kortsik, C; Pawel, JV; Reck, M; Schnabel, PA; Thomas, M | 1 |
| Funakoshi, Y; Maeda, H; Takeuchi, Y | 1 |
| Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O | 1 |
| Barinow-Wojewódzki, A; Krawczyk, P; Kucharczyk, T; Milanowski, J; Milecki, P; Powrózek, T; Ramlau, R; Sura, S; Szumiło, J; Szyszka-Barth, K; Walczyna, B; Wojas-Krawczyk, K | 1 |
| Heideman, DA; Kuiper, JL; Postmus, PE; Smit, EF; Thunnissen, E; van Wijk, AW | 1 |
| Hirata, M; Kagawa, S; Kanai, Y; Kawai, K; Naka, S; Nishii, R; Ohmomo, Y; Yoshimoto, M | 1 |
| Fang, Q; Li, N; Ou, W; Sun, HB; Wang, BX; Wang, SY; Ye, X; Zhang, L; Zhang, SL | 1 |
| Beltran-Alamillo, J; Benlloch, S; Bordogna, W; Botero, ML; Chen, D; de Aguirre, I; Gimenez-Capitán, A; Klughammer, B; Kovach, B; Lawrence, HJ; Mayo, C; Palma, JF; Queralt, C; Ramirez, JL; Ramón y Cajal, S; Schlegel, M; Shieh, F; Taron, M; Wu, L; Zhang, G | 1 |
| Guan, YS; He, Q; Li, M | 1 |
| Liu, J; Sun, W; Zhou, YM | 1 |
| Bokobza, SM; Devery, AM; Jiang, Y; Ryan, AJ; Weber, AM | 2 |
| Karachaliou, N; Morales-Espinosa, D; Rosell, R; Viteri, S | 1 |
| Rerknimitr, P; Rungtrakulchai, R | 1 |
| Katanasaka, Y; Kitamura, Y; Kodera, Y; Koizumi, F; Tamura, T; Yunokawa, M | 1 |
| Chi, HS; Cho, YU; Jang, S; Kim, SW; Kim, YJ; Park, CJ; Park, SH | 1 |
| Fukuoka, M; Suzumura, T; Tsukuda, H; Yonesaka, K | 1 |
| Harada, H; Kojima, S; Takai, E; Tsukimoto, M | 1 |
| Chen, C; Cretoiu, SM; Shi, L; Wang, B; Wang, L; Wang, Q; Wang, X | 1 |
| Bae, MK; Cho, BC; Kang, DR; Kim, EY; Kim, HR; Kim, JH; Kim, MH; Lee, CY; Lee, JS | 1 |
| Liu, D; Yang, Y; Zhao, S | 1 |
| Kato, M; Kobayashi, I; Murakami, A; Nurwidya, F; Shimada, N; Shukuya, T; Tajima, K; Takahashi, F; Takahashi, K | 1 |
| Li, S; Ren, S; Zhou, C; Zhou, F | 1 |
| Carcereny, E; Cardenal, F; Cardona, AF; De Castro, J; Insa, A; Isla, D; Majem, M; Molina, MA; Moran, T; Pallarès, MC; Palmero, R; Queralt, C; Reguart, N; Rolfo, C; Rosell, R; Taron, M | 1 |
| Chen, H; Han, R; He, Y; Jiang, J; Li, K; Li, L; Lin, C; Liu, H; Sun, F; Wang, Y; Xiao, H; Yang, Z | 1 |
| Alama, A; Barletta, G; Biello, F; Boccardo, F; Burrafato, G; Coco, S; Dal Bello, MG; Genova, C; Grossi, F; Rijavec, E; Truini, A | 1 |
| Baumann, M; Benes, CH; Chowdhury, D; Efstathiou, JA; Greninger, P; Hülskötter, M; Kern, AM; Krause, M; Pan, Y; Settleman, J; Singh, A; Wang, M; Willers, H | 1 |
| Altimari, A; Di Tullio, P; Fiorentino, M; Giunchi, F; Gruppioni, E; Martorana, G; Pinto, C | 1 |
| Jo, U; Kim, YH; Park, JK; Park, KH; Sung, JS; Whang, YM; Won, NH | 1 |
| Fan, XX; He, JX; Leung, EL; Li, N; Liu, L; Wu, JL; Zhou, YL | 1 |
| Adamczak, J; Chatterjee, S; Florin, A; Franz, T; Heukamp, LC; Hinze, Y; Neumaier, B; Schöttle, J; Siobal, M; Ullrich, RT; Wieczorek, C | 1 |
| Lin, CC; Tsai, CM; Wang, SY | 1 |
| Beal, K; Chan, TA; Gerber, NK; Riely, GJ; Rimner, A; Shi, W; Wu, AJ; Yamada, Y; Yu, HA; Zhang, Z | 1 |
| Pan, YY; Wu, M; Yuan, Y; Zhang, Y | 2 |
| Chen, X; Fan, L; Fei, K; Gao, G; He, Y; Li, A; Li, J; Li, S; Li, W; Li, X; Ren, S; Schmid-Bindert, G; Shi, J; Zhao, C; Zhou, C | 1 |
| Dafni, U; Karlis, D; Peters, S; Smit, E | 1 |
| Iwase, T; Kishimoto, Y; Mori, H; Yano, T | 1 |
| Ebina, M; Iida, S; Ise, K; Iwabuchi, E; Kondo, T; Maemondo, M; Miki, Y; Mori, K; Narumi, S; Nihira, K; Ono, K; Saito, M; Sasano, H; Sato, I; Yamada-Okabe, H | 1 |
| Horai, T; Horiike, A; Kudo, K; Murakami, H; Naito, T; Nishio, M; Ohyanagi, F; Ono, A; Tanaka, H; Yamamoto, N; Yanagitani, N | 1 |
| Catania, C; de Marinis, F; Passaro, A | 1 |
| Koh, Y; Murakami, H; Serizawa, M; Takahashi, T; Watanabe, M; Yamamoto, N | 1 |
| Behringer, D; Desaiah, D; Dittrich, C; Hartmann, JT; Kazeem, G; Leschinger, MI; Papai-Szekely, Z; Sederholm, C; Vinolas, N; von Pawel, J | 1 |
| Chang, CX; Li, P; Qi, JL; Shi, SB; Tang, XY; Tian, J | 1 |
| Barni, S; Brandes, AA; Caffo, O; Cerea, G; Ciardiello, F; Crinò, L; Cruciani, G; De Marinis, F; Fasola, G; Favaretto, AG; Ferrari, S; Ferraù, F; Galetta, D; Genestreti, G; Gridelli, C; Grossi, F; Iannacone, C; Luciani, A; Novello, S; Zilembo, N | 1 |
| Hirai, F; Ichinose, Y; Inamasu, E; Seto, T; Shiraishi, Y; Taguchi, K; Takenaka, T; Takenoyama, M; Takeo, S; Toyokawa, G; Toyozawa, R; Ushijima, C; Yamaguchi, M; Yoshida, T | 1 |
| Chang, JY; Hsiao, CJ; Liou, JP; Pai, HC; Pan, SL; Teng, CM; Tsai, AC; Wang, CY; Wang, JC | 1 |
| Chang, YW; Chen, HA; Chen, JC; Chiu, CF; Su, JL; Su, YH; Tseng, CF; Yu, YH | 1 |
| Qi, WX; Shen, Z; Sun, YJ; Yao, Y | 1 |
| Ali, CW; Bates, AT; Button, M; Califano, R; Chan, S; Chaudhuri, A; Danson, SJ; Dorey, N; Dua, D; Ellis, S; Khan, F; Lee, L; Mulvenna, P; Nicolson, M; Ottensmeier, C; Popat, S; Shaw, HM; Szabo, M; Upadhyay, S | 1 |
| Fang, Q; Jiang, Y; Yuan, Q | 1 |
| Choi, JW; Jeong, Y; Jung, SH; Kim, HW; Kim, J; Park, KH; Wairagu, PM; Yeh, BI; Yong, SJ | 1 |
| Ahn, JS; Ahn, MJ; Lee, JY; Lim, SH; Park, K; Sun, JM | 1 |
| Imyanitov, EN; Ivantsov, AO; Iyevleva, AG; Karaseva, NA; Kulikova, YE; Lozhkina, AM; Mitiushkina, NV; Orlov, SV; Tiurin, VI; Togo, AV; Volodina, LN | 1 |
| Bernstein, E; Burrows, F; Gitlitz, BJ; Milne, G; Otterson, GA; Santos, ES; Syto, M; Zaknoen, S | 1 |
| Han, JY; Hwang, JA; Kim, HT; Kim, JH; Kim, SH; Lee, GK; Lee, JS; Lee, Y; Lee, YS; Nam, BH; Yun, T; Zhang, W | 1 |
| Fujiwara, K; Hosokawa, A; Ichiba, Y; Kajiume, S; Kiba, T; Kimoto, S; Nakano, K; Nakashima, T; Ogawa, Y; Okada, Y; Taniguchi, H | 1 |
| Bergbower, E; Dennis, PA; Dogan, I; Ekmekci, A; Gills, JJ; Kawabata, S; Rudin, CM; Wilson, W | 1 |
| Anand, S; Camargo, MF; Cascone, T; Cheresh, DA; Desgrosellier, JS; Diao, L; Elliott, KC; Franovic, A; Heymach, JV; Husain, H; Kato, S; Lesperance, J; Lippman, SM; Lowy, AM; Mielgo, A; Seguin, L; Wang, J; Weis, SM; Wistuba, II; Yebra, M | 1 |
| Berezo, JÁ; de la Cruz, V; Sanz Rubiales, A; Torres, MÁ | 1 |
| Hayakawa, Y; Kaneto, N; Kato, S; Saiki, I; Sakurai, H; Yokoyama, S | 1 |
| Audigier Valette, C; Cadranel, J; Chabaud, S; Moro-Sibilot, D; Perol, D; Perol, M | 1 |
| Chang, J; Feng, Y; Luo, Z; Peng, W; Qiao, J; Sun, S; Wang, H; Wang, J; Wu, X; Yu, H; Zhang, J | 1 |
| Geissler, M; Steins, M; Thomas, M | 2 |
| Hong, W; Lin, B; Mao, W; Zhang, B; Zhang, Y | 1 |
| Guo, L; Li, M; Liu, Z; Meng, Q; Shi, L; Tang, J; Tao, H; Tong, L; Wu, H; Wu, W; Xu, L; Zhu, Y | 1 |
| Dziadziuszko, R; Peters, S; Zimmermann, S | 1 |
| Harada, D; Honda, Y; Ichihara, E; Kiura, K; Murakami, T; Ninomiya, T; Ochi, N; Ohashi, K; Takigawa, N; Tanimoto, M; Yasugi, M | 1 |
| Bexon, AS; Boyd, TE; Conkling, P; de La Bourdonnaye, G; Mita, AC; Nemunaitis, JJ; Richards, DA; Smith, DA; Wages, D | 1 |
| Chung, JH; Jheon, S; Jin, Y; Kim, H; Kim, JE; Kim, K; Lee, CT; Sun, PL; Yoo, SB | 1 |
| Fang, H; Huang, S; Li, S; Liu, R; Pan, H; Wang, Z; Zhou, J | 1 |
| Wu, YL; Yan, HH; Yang, JJ; Zhang, XC; Zhao, N | 1 |
| Aimiuwu, J; Blachly, JS; Gao, Y; Hicks, WJ; Li, J; Otterson, GA; Papp, A; Phelps, MA; Poi, M; Schaaf, LJ; Socinski, MA; Starrett, SL; Stinchcombe, TE; Villalona-Calero, MA; Wang, D; Wei, L; Zhao, W | 1 |
| de Castro, G; Haaland, B; Lopes, G; Tan, PS | 1 |
| Kassem, MG; Korashy, HM; Rahman, AF | 1 |
| Yano, S | 2 |
| Bendell, J; Burris, HA; Dowlati, A; Infante, JR; Jones, SF; Kane, MP; Levinson, KT; Stein, MN; Suttle, AB; Tan, AR | 1 |
| Fukai, T; Hasegawa, T; Hirasawa, Y; Ikeda, S; Kamiya, Y; Kudo, Y; Matsumura, M; Nagata, A; Shiraishi, E | 1 |
| Kuang, K; Yang, K; Yang, X | 1 |
| Aukema, TS; Burgers, SA; Klomp, HM; Rijna, H; Schaake, EE; Valdés Olmos, RA; van Gool, MH; van Pel, R; van Tinteren, H | 1 |
| Farias-Hesson, E; Finigan, JH; Heasley, LE; Kang, J; Kern, JA; Kim, J; Leach, SM; Mason, RJ; Mishra, R; Ramamoorthy, P; Singleton, KR; Tan, AC; Vasu, VT; Yoo, M | 1 |
| Cai, G; Carbone, DP; de Stanchina, E; Gale, M; Gettinger, S; Horn, L; Jia, P; Miller, V; Nebhan, C; Pao, W; Pirazzoli, V; Politi, K; Shapiro, EM; Song, X; Stephens, PJ; Walther, Z; Wurtz, A; Yin, R; Zhao, Z | 1 |
| Garzon, F; Geater, SL; Gopalakrishna, P; Iannotti, N; Lee, V; Lim, WT; Mok, TS; Reyderman, L; Reynolds, C; Smith, D; Spira, A; Thongprasert, S; Wang, B; Xu, L | 1 |
| Ebi, H; Ishikawa, D; Matsumoto, K; Nakade, J; Nakagawa, T; Nanjo, S; Sano, T; Takeuchi, S; Yamada, T; Yano, S; Yasumoto, K; Yonekura, K; Zhao, L | 1 |
| Chang, JY; Pang, Q; Wang, J; Wang, P; Yuan, Z; Zhao, L; Zhuang, H | 1 |
| Berger, MF; Kris, MG; Krug, LM; Ladanyi, M; Pietanza, MC; Rekhtman, N; Riely, GJ; Varghese, AM; Wang, L; Won, HH; Yu, HA; Zakowski, MF | 1 |
| Arriola, E; Luque, A; Martínez-Avilés, L; Vollmer, I | 1 |
| Butts, CA | 1 |
| Aieta, M; Bachi, A; Barni, S; Bearz, A; Bulotta, A; Cattaneo, A; de Marinis, F; De Pas, T; Doglioni, C; Floriani, I; Foti, S; Gregorc, V; Grigorieva, J; Grossi, F; Lazzari, C; Levra, MG; Mencoboni, M; Novello, S; Petrelli, F; Roder, H; Roder, J; Torri, V; Tsypin, M; Viganò, M | 1 |
| Cai, H; Chen, X; Miao, L; Wang, Y; Xia, H; Zhuang, Z | 1 |
| Ali, SM; Chan, CA; Halmos, B; Jia, Y; Miller, VA; Saad, S | 1 |
| Chen, SB; Gu, LQ; Huang, ZS; Li, D; Liu, HY; Ou, TM; Tan, JH; Yan, JW; Ye, WJ | 1 |
| Asada, M; Funahashi, Y; Ito, K; Semba, T; Uenaka, T; Wakabayashi, T | 1 |
| Ando, M; Asami, K; Endo, T; Fukuda, M; Ibata, H; Isa, S; Kamimura, M; Kawaguchi, T; Kozuki, T; Kubo, A; Nakagawa, H; Okano, Y; Saka, H; Sakamoto, K; Soejima, Y; Takada, M; Tamura, A; Tomizawa, Y; Yoshimi, M | 1 |
| Leighl, NB; Zer, A | 2 |
| Liu, C; Qu, G; Sun, B; Wang, P; Zhang, Z; Zhou, C | 1 |
| Agrawal, R; Kumar, S | 1 |
| Aukema, TS; Burgers, SA; Codrington, HE; Klomp, HM; Rijna, H; Schaake, EE; Teertstra, HJ; Valdés Olmos, RA; van Gool, MH; van Pel, R; van Tinteren, H | 1 |
| Wakelee, HA | 1 |
| Nakanishi, Y | 2 |
| Al-Batran, SE; Allgäuer, M; Atmaca, A; Jäger, E | 1 |
| He, C; Hong, W; Lou, G; Shao, L; Song, Z; Xie, F; Zhang, B; Zhang, Y; Zheng, L | 1 |
| Hao, X; Hu, X; Li, J; Liu, Y; Shi, Y; Sun, Y; Wang, H; Wang, Y; Wang, Z; Zhang, X | 1 |
| Costa, DB; Gandhi, L; Gerber, DE | 1 |
| DiPiro, PJ; Hatabu, H; Jackman, DM; Jänne, PA; Johnson, BE; Nishino, M | 1 |
| Meng, X; Sun, X; Yu, J; Zhang, J | 1 |
| Ahn, JS; Ahn, MJ; Cho, BC; Kim, M; Kim, SW; Lee, DH; Massey, D; Park, K; Shi, Y; Sun, JM | 1 |
| Blumenthal, GM; Boyd, K; He, K; Jiang, X; Justice, R; Keegan, P; Khozin, S; Murgo, A; Pazdur, R | 1 |
| Chiou, TT; Gallacchi, D; Kwiatkowski, DJ; Lee, PS; Li, C; Malinowska, IA; Pereira, AM; Reynolds, SB; Robinson, L; Sun, Y; Yu, JJ; Zhang, EY | 1 |
| Fore, M; Mennecier, B; Prim, N | 1 |
| Ding, HR; Han, SY; Li, PP; Teng, F; Zhao, W | 1 |
| Bianco, R; D'Amato, C; D'Amato, V; Damiano, V; De Placido, S; Formisano, L; Iommelli, F; Marciano, R; Nappi, L; Parsons, SJ; Raimondo, L; Rosa, R; Scorziello, A; Troncone, G; Veneziani, B | 1 |
| Han, Y; Jiang, T; Li, Q; Shang, Y; Wang, P; Yong, X; Yu, W; Zhang, P | 1 |
| Aisner, DL; Berge, EM; Damek, D; Doebele, RC; Poonia, S | 1 |
| Alfieri, RR; Ampollini, L; Ardizzoni, A; Bonelli, M; Caffarra, C; Cavazzoni, A; Cretella, D; Frati, C; Fumarola, C; Galetti, M; La Monica, S; Lagrasta, C; Petronini, PG; Quaini, F; Saccani, F; Tiseo, M | 1 |
| Ambudkar, SV; Chen, ZS; Fu, LW; Kathawala, RJ; Patel, A; Sodani, K; Talele, TT; Wang, YJ; Zhang, H; Zhang, YK; Zhu, H | 1 |
| Chang, J; Hu, A; Luo, Z; Sun, S; Wang, H; Wang, J; Wu, X; Xing, K; Yu, H; Zhao, X; Zhou, X | 1 |
| Bianco, C; Giaccone, G; Lee, LC; Luo, J; Mitsudomi, T; Mok, T; Moon, YW; Okamoto, I; Park, KS; Pham, T; Raffeld, M; Rosell, R; Salomon, DS; Subramaniam, D; Wang, Y; Xi, L; Yatabe, Y | 1 |
| Alden, CM; Bashoura, L; Eapen, GA; Faiz, SA; Herbst, RS; Hong, WK; Jack Lee, J; Jimenez, CA; Liu, DD; Marom, EM; Massarelli, E; Mino, B; Morice, RC; Onn, A; Tran, HT; Wistuba, II | 1 |
| Lam, KC; Mok, TS | 2 |
| Fujimura, S; Fukaya, K; Katsumata, H; Minowa, M; Tabata, T | 1 |
| Altiok, S; Doshi, P; Fulp, W; Haura, EB; Sasser, K; Smith, MA; Song, L | 1 |
| Koh, Y; Kusuhara, M; Serizawa, M; Takahashi, T; Urakami, K; Watanabe, M; Yamaguchi, K; Yamamoto, N; Zangiacomi, V | 1 |
| Gillissen, A; Nieber, K; Oelkrug, C; Schubert, A; Simasi, J | 2 |
| Ardizzoni, A; Artioli, F; Bersanelli, M; Lucchi, L; Tiseo, M | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Minarik, M; Pesek, M; Topolcan, O | 1 |
| Ardizzoni, A; Cappuzzo, F; Cortinovis, D; de Marinis, F; Fontanini, G; Galetta, D; Gridelli, C; Grossi, F; Iurlaro, M; Lorusso, V; Novello, S; Santo, A | 1 |
| Conte, M; Ellingrod, VL; King, AN; O'Malley, M; Ramnath, N | 1 |
| Ma, D; Mathur, G | 1 |
| Hu, G; Liu, D; Long, G; Sun, W; Wang, J | 1 |
| Baty, F; Betticher, DC; Brauchli, P; Brutsche, M; Droege, C; Früh, M; Gautschi, O; Joerger, M; Klingbiel, D; Ochsenbein, A; Pless, M; Rothschild, S; Stahel, RA; von Moos, R; Zappa, F | 1 |
| Li, QX; Lu, X; Wu, HL; Yang, M; Yu, SY; Yuan, XL; Zhang, L | 1 |
| Fonseca, T; Griebsch, I; Lungershausen, J; Mok, T; Paz-Ares, L; Popat, S; Stammberger, U; Wu, YL; Yang, JC | 1 |
| Li, H; Ma, D; Qu, Y; Wu, X; Yang, Y; Yin, Y | 1 |
| Ambudkar, SV; Chen, ZS; Kathawala, RJ; Patel, A; Sim, HM; Talele, TT; Wang, DS; Wang, YJ; Xu, RH; Zhang, H; Zhang, YK | 1 |
| Choi, DY; Freeman, MR; Jung, JH; Kim, J; Kim, KP; Lee, JC; Lee, KY; Rho, JK; You, S | 1 |
| Ahn, MJ; Altug, S; Barraclough, H; Kang, JH; Kim, DW; Lin, CC; Mok, T; Orlando, M; Park, K; Srimuninnimit, V; Tsai, CM; Yang, JC | 1 |
| de Marinis, F; Del Signore, E; Di Maio, M; Gori, B; Passaro, A | 1 |
| Chang, FY; Chao, TT; Chen, KF; Chen, YL; Huang, YC; Lin, HI; Shiau, CW; Tsai, YT; Wang, CY; Yu, CJ | 1 |
| Banerji, U; Bhosle, J; de Bono, JS; O'Brien, ME; Popat, S; Puglisi, M; Stewart, A; Thavasu, P | 1 |
| Adjei, AA; Foster, NR; Grainger, AV; Marks, R; Molina, JR; Nelson, GD; Reungwetwattana, T; Steen, PD; Stella, PJ; Wright, J | 1 |
| Aieta, M; Gregorc, V; Lazzari, C; Lerose, R; Tartarone, A | 1 |
| Bode, AM; Chen, H; Dong, Z; Jeong, CH; Jung, SK; Kim, JE; Lee, HJ; Lee, KW; Lee, MH; Lee, SY; Lim, DY; Lim, TG | 1 |
| Bennouna, J; Bensadoun, RJ; Dielenseger, P; Malka, D; Moro-Sibilot, D; Mortier, L; Rey, JB; Scotté, F; Sicard, J; Wislez, M | 1 |
| Bao, Z; Chen, X; Liu, ZF; Zhang, P; Zhao, J; Zhou, JY | 1 |
| Deng, Q; He, J; Liu, X; Xu, X; Yang, H; Yang, X; Zhang, Y; Zhao, M | 1 |
| Escudero-Vilaplana, V; Gonzalez-Haba, E; Ribed, A; Sanjurjo, M | 1 |
| Fekrat, S; Proia, AD; Rao, V; Schneider, E | 1 |
| Ayoubi, JM; Broutin, S; Couderc, LJ; Friard, S; Gil, S; Goetgheluck, J; Paci, A; Picone, O; Tcherakian, C | 1 |
| Ho, CC; Kuo, YW; Lin, CH; Lin, MT | 1 |
| An, F; Li, M; Lin, P; Liu, J; Liu, L; Wang, P; Zhang, B; Zhao, L; Zhuang, X | 1 |
| Chung, DH; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, SH; Sim, SH | 1 |
| Li, M; Lv, L; Lv, S; Lv, W; Song, B; Wang, J; Wei, H; Zhao, B | 1 |
| Fernandes, J; Jampol, LM; Johnson, ML; Mets, M; Munk, MR; Patel, JD | 1 |
| Meldgaard, P; Nissen, PH; Sorensen, BS; Weber, B; Winther Larsen, A | 1 |
| De, S; Dermawan, JK; Dowlati, A; Gurova, K; Narla, G; Pink, J; Sharma, N; Stark, GR | 1 |
| Krainhöfer, J; Reissig, A; Steinert, M; Walther, M | 1 |
| Akay, A; Dragomir, A; Erlandsson, BE | 1 |
| Bates, A; Counsell, N; Faivre-Finn, C; Hackshaw, A; Lee, SM; Lewanski, CR; Ngai, Y; Ottensmeier, C; Patel, N; Wadsworth, C | 1 |
| Asakuma, M; Hiyoshi, Y; Igawa, S; Ishihara, M; Kasajima, M; Katono, K; Kimura, M; Masuda, N; Otani, S; Sasaki, J | 1 |
| Iwata, T; Kim, YH; Mishima, M; Nagai, H; Nishimura, T; Ozasa, H; Sakamori, Y; Sunadome, H | 1 |
| Cao, R; Li, ZS; Shao, JH; Tang, YT; Xiao, N; Zhao, XH; Zou, JM | 1 |
| Arakawa, H; Fukuoka, M; Harada, R; Johkoh, T; Kudoh, S; Kusumoto, M; Sakai, F; Ueda, M | 1 |
| Calcasola, M; Cane, P; Izatt, L; Michalarea, V; Spicer, J; Tobal, K | 1 |
| Brunetti, A; De Rosa, V; Del Vecchio, S; Fonti, R; Gargiulo, S; Gramanzini, M; Greco, A; Iommelli, F; Monti, M; Ortosecco, G; Panico, M | 1 |
| Balansky, R; Camoirano, A; D'Agostini, F; De Flora, S; Ganchev, G; Iltcheva, M; Izzotti, A; La Maestra, S; Longobardi, M; Micale, RT; Steele, VE | 1 |
| McCulloch, T; Røe, OD; Szejniuk, WM | 1 |
| Blanchet, B; Cessot, A; Goldwasser, F | 1 |
| Chen, Q; Jiang, B; Li, Q; Liu, J; Pei, D; Qian, Y; Shen, H; Shi, Z; Shu, Y; Wang, L; Wang, R; Xu, T; Zheng, J; Zhu, F | 1 |
| Imai, T; Ishigame, T; Kohno, T; Kumamoto, K; Saito, M; Tsuta, K | 1 |
| Cao, Y; Du, P; Kim, HJ; Lee, HJ; Settleman, J; Zhuang, G | 1 |
| Camidge, DR; Chand, VK; Fu, Y; Gettinger, S; Groen, HJ; Horn, L; Janjigian, YY; Miller, VA; Pao, W; Riely, GJ; Smit, EF; Wang, B | 1 |
| Auliac, JB; Berard, H; Bizieux, A; Bota, S; Chouaid, C; Corre, R; Descourt, R; Falchero, L; Fournel, P; Greiller, L; Greillier, L; Labrunie, A; Le Caer, H; Marin, B; Monnet, I; Schott, R; Vergnenegre, A | 1 |
| Ando, M; Hasegawa, Y; Kimura, T; Kojima, E; Nomura, F; Ogasawara, T; Saito, H; Shindoh, J; Sugino, Y; Suzuki, R; Takahashi, K; Yamamoto, M; Yoshida, N | 1 |
| Ali, SK; Chakraborty, C; Doss, GP; NagaSundaram, N; Rajith, B; Zhu, H | 1 |
| Bosch-Barrera, J; Brunet, J; Izquierdo, A; Lorencio, C; Menéndez, JA; Porta, R; Rosell, R; Sais, E; Sirvent, JM | 1 |
| Meldgaard, P; Nexo, E; Sorensen, BS; Tsai, J; Weber, B; Wei, W; Wu, L | 1 |
| Jänne, PA; Paweletz, CP | 1 |
| Chen, HW; Chen, WJ; Ho, CC; Ho, CL; Hsieh, WY; Lee, JY; Li, LH; Li, PR; Wang, CC; Wu, P; Yang, SM; Yen, MY | 1 |
| Hayashi, H; Nakagawa, K; Nishio, K; Togashi, Y | 1 |
| Azuma, K; Hoshino, T; Izumi, H; Kage, M; Kawahara, A; Kuwano, M; Nakashima, K; Ono, M; Sonoda, K; Tashiro, K; Watari, K | 1 |
| Bae, MK; Hong, YS; Jang, WJ; Jeong, CH; Jeong, JW; Joo, SH; Jung, SK; Kang, JS; Kundu, JK; Park, GH | 1 |
| Ciuleanu, T; Cobo, M; Cole, R; Dearden, S; Douillard, JY; McCormack, R; McWalter, G; Milenkova, T; Ostoros, G; Walker, J; Webster, A | 1 |
| Colburn, D; Fehrenbacher, L; Hainsworth, J; Johnson, BE; Kabbinavar, F; Kasubhai, S; Klughammer, B; Kressel, B; Marsland, T; Miller, V; Patel, T; Rubin, M; White, L; Yang, JC | 1 |
| Song, Z; Wu, W; Zhang, Y | 1 |
| Bode, AM; Chen, H; Dong, Z; Li, H; Li, W; Lim, DY; Liu, K; Ma, WY; Oi, N; Peng, C; Reddy, K; Sheng, Y; Yao, K; Zhu, F | 1 |
| Akiyama, Y; Fujita, K; Hirose, T; Kusumoto, S; Nakashima, M; Sasaki, Y; Shirai, T; Sugiyama, T | 1 |
| Amann, JM; Arasada, RR; Carbone, DP; Huppert, SS; Rahman, MA | 1 |
| Dome, B; Francovszky, E; Galffy, G; Hegedus, B; Losonczy, G; Ostoros, G; Sarosi, V; Tolnay, E; Torok, S | 1 |
| Jiao, SC; Peng, L; Song, ZG | 1 |
| Brandes, AA; Buttitta, F; Centi, I; Chella, A; Crinò, L; Cuccurullo, F; De Pas, T; Del Grammastro, M; Felicioni, L; Filice, G; Malatesta, S; Marchetti, A; Santoro, A; Venturino, P | 1 |
| Ahn, HK; Cho, EK; Hong, J; Kim, YS; Lee, HY; Lee, JH; Park, I; Park, J; Shin, DB; Sym, SJ; Woo, HS | 1 |
| Ho, C; Laskin, J; Melosky, B; Murray, N; Ramsden, K; Sun, S; Zhai, Y | 1 |
| Hata, A; Imai, Y; Katakami, N; Masago, K; Yatabe, Y | 1 |
| Carretero, J; Costa, DB; Hayashi, Y; Kobayashi, SS; Li, D; Nakayama, S; Sng, N; Soejima, K; Soo, RA; Tan, AJ; Welner, R; Wong, KK; Yamaguchi, N; Yamamoto, M; Yasuda, H | 1 |
| Asakuma, M; Harada, S; Hiyoshi, Y; Igawa, S; Ishihara, M; Kasajima, M; Katono, K; Kimura, M; Kusuhara, S; Masuda, N; Niwa, H; Otani, S; Sasaki, J | 1 |
| Rosell, R | 1 |
| Atagi, S; Fukuoka, M; Goto, K; Harada, R; Hida, T; Hosomi, Y; Kato, T; Maemondo, M; Nagase, S; Nakagawa, K; Nishio, M; Okamoto, I; Seto, T; Tajima, K; Yamamoto, N; Yamanaka, T | 1 |
| Ablack, A; Carmine-Simmen, K; Chambers, AF; Chien, AE; Chin, CA; Courtneidge, SA; Hague, MN; Leith, SJ; Leong, HS; Lewis, JD; McPherson, VA; Postenka, CO; Robertson, AE; Stoletov, K; Turley, EA | 1 |
| Chao, TT; Chen, KF; Chen, PT; Chen, YL; Huang, YC; Lai, CC; Lin, HI; Shiau, CW; Tsai, YT; Wang, CY; Yu, CJ | 1 |
| Ge, N; Jiao, W; Qiu, T; Shen, Y; Tang, D; Wang, Y; Xuan, Y; Yan, G; Yao, R | 1 |
| Bustos, D; Kirkpatrick, DS; Lin, E; Nicholes, K; Settleman, J; Song, Q; Stephan, JP; Wilson, C | 1 |
| Bi, F; Chen, L; Chen, Q; Ge, X; Leng, W; Pang, X; Tang, Q; Wu, YP; Xia, H; Yuan, D; Zhang, Y | 1 |
| Kim, EO; Kim, J; Kim, JH; Kim, SH; Lee, D; Lee, H; Lee, J; Yun, M | 1 |
| Luo, J; Shen, L; Zheng, D | 1 |
| Fukuoka, M; Hasegawa, Y; Ozaki, T; Sugiura, T; Suzumura, T; Tsukuda, H; Yonesaka, K | 1 |
| Arai, M; Hayashihara, K; Iwasawa, T; Kato, T; Ogura, T; Ohashi, K; Okudela, K; Saito, T; Satoh, H; Sekine, A; Tamura, K | 1 |
| Cecconi, M; Lane, K; Thomas, C | 1 |
| Dai, B; Fang, B; Gao, W; Gold, KA; Heymach, JV; Hofstetter, WL; Lu, H; Minna, J; Ou, Z; Roth, JA; Swisher, SG; Wang, L; Wang, M; Wu, S; Zhang, L | 1 |
| Chang, CY; Chang, GC; Chen, CY; Chen, KC; Chen, YM; Hsu, KH; Huang, MS; Su, KY; Tsai, CR; Tsai, MH; Tseng, JS; Wang, CL; Wu, CW; Yang, CT; Yang, TY; Yu, SL | 1 |
| Bai, C; Chen, S; Ning, X; Sun, Z; Wang, Y; Yang, XD; Ying, H | 1 |
| Frechen, S; Fuhr, U; Kahraman, D; Kobe, C; Nogova, L; Scheffler, M; Suleiman, AA; Wolf, J; Zander, T | 1 |
| Ahmed, ZA; Moatter, T; Pervez, S; Siddiqui, A | 1 |
| Chen, J; Hu, P; Jiang, J; Liu, DY; Tan, FL; Wang, YX; Wu, YW; Zhao, Q; Zheng, X | 1 |
| Ahn, SH; Jeong, EH; Kim, CH; Kim, HR; Kim, SY; Lee, TG | 1 |
| Fischer, JR; Grohé, C; Gütz, S; Kimmich, M; Laack, E; Märten, A; Schneider, CP; Schuler, M; Thomas, M | 1 |
| Halmos, B; Hibshoosh, H; Jin, C; Li, G; Wang, X | 1 |
| Clause, AL; Pieters, T; Vanderheyde, K | 1 |
| Bender, C; Fichtner, I; Fröhlich, H; Herwig, R; Hülsmann, HJ; Jarahian, M; Korf, U; Kuner, R; Merk, J; Rolff, J; Sültmann, H; Thomas, M | 1 |
| Berrino, L; Capuano, A; Ciardiello, F; Della Corte, CM; Fasano, M; Morgillo, F; Papaccio, F; Sasso, FC | 1 |
| Banna, G; Cappuzzo, F; Catino, A; Chiari, R; Cortinovis, D; Crinò, L; D'Incecco, A; de Marinis, F; Facchinetti, F; Galetta, D; GiajLevra, M; Haspinger, ER; Landi, L; Milella, M; Minuti, G; Novello, S; Ricciardi, S; Rossi, E; Salvini, J; Santo, A; Tibaldi, C; Tiseo, M | 1 |
| Groen, HJ; Grünberg, K; Heideman, DA; Kuiper, JL; Smit, EF; Würdinger, T | 1 |
| Basappa, N; Butts, CA; Chambers, CR; Chu, MP; Chu, Q; Fenton, D; Ghosh, S; Joy, AA; Sangha, R; Sawyer, MB; Smylie, M | 1 |
| Dickgreber, NJ; Hoffknecht, P; Maria Huber, R; Märten, A; Pelzer, T; Schütz, M; Serke, M; Stöhlmacher-Williams, J; Tufman, A; Wehler, T; Wiewrodt, R | 1 |
| Celik, T; Kosker, M | 1 |
| Demura, Y; Fujita, Y; Gemma, A; Harada, M; Ishii, Y; Ishimoto, O; Kobayashi, K; Maemondo, M; Matsumoto, Y; Miura, S; Morikawa, N; Okudera, K; Saijo, Y; Sato, I; Takamura, K; Usui, K | 1 |
| Alifano, M; Damotte, D; Dupouy, S; Fléjou, JF; Forgez, P; Lupo, AM; Mourra, N; Régnard, JF; Takahashi, T; Trédaniel, J; Wu, Z; Younes, M | 1 |
| Ding, L; Gu, A; Han, B; He, J; Hu, X; Jia, X; Jiao, SC; Ma, K; Peng, J; Sun, Y; Tan, F; Wang, CL; Wang, J; Wang, Y; Wu, M; Ying, K; You, C; Zhang, L; Zhang, S; Zhang, Y | 1 |
| Boukovinas, I; Briasoulis, E; Dimopoulos, MA; Fountzilas, G; Kalogera-Fountzila, A; Karavasilis, V; Klouvas, G; Kosmidis, P; Kotoula, V; Mavropoulou, P; Papandreou, CN; Pectasides, D; Syrigos, KN | 1 |
| Bal, C; Gupta, RK; Kumar, K; Kumar, R; Singh, H | 1 |
| Fukuoka, M; Imamura, F; Komuta, K; Kudoh, S; Seki, A; Yoshioka, H | 1 |
| Chen, HJ; Chen, JH; Chen, ZH; Cheng, Y; Feng, WN; Liu, YP; Song, Y; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Zhang, L; Zhang, XC; Zhao, MF; Zhong, WZ; Zhou, Q | 1 |
| Ando, M; Arakawa, H; Ebina, M; Fukuda, Y; Fukuoka, M; Gemma, A; Inoue, Y; Ishii, T; Johkoh, T; Kudoh, S; Kusumoto, M; Kuwano, K; Nakagawa, K; Ohe, Y; Sakai, F; Seki, A; Taniguchi, H; Yamazaki, N | 1 |
| Costa, DB; Jorge, SE; Kobayashi, SS | 1 |
| Ferrer, L; Ferretti, G; Meynet, E; Moro-Sibilot, D; Pirvu, A; Sakhri, L | 1 |
| Leung, JS | 1 |
| Chen, M; Gao, B; Qin, X; Wang, J; Wang, Y; Zhang, Z | 1 |
| Adler, KB; Arif, M; Chen, CH; Chiu, CL; Statt, S; Thai, P; Wu, R | 1 |
| Chinn, DC; Gandara, DR; Holland, WS; Lara, PN; Mack, PC | 1 |
| Fu, S; Guo, XM; Qi, WX; Zhang, Q | 1 |
| Chu, NM; Feng, AC; Hsu, LH; Kao, SH; Liu, KJ; Tsai, MF; Wu, CR | 1 |
| Bi, F; Ge, X; Huang, M; Wang, Y; Zheng, L | 1 |
| Alama, A; Ballestrero, A; Barletta, G; Boccardo, F; Carminati, E; Coco, S; Dal Bello, MG; Garuti, A; Genova, C; Grossi, F; Rijavec, E; Sini, C; Truini, A; Venè, R | 1 |
| Bai, F; Han, R; Jiang, F; Liu, Y; Pang, W; Shen, H; Tian, X; Wang, J; Xing, L; Yan, X; Zhang, X | 1 |
| Akamatsu, H; Endo, M; Hisamatsu, Y; Imai, H; Kenmotsu, H; Ko, R; Mori, K; Murakami, H; Naito, T; Nakashima, K; Ohde, Y; Omori, S; Ono, A; Oyakawa, T; Shukuya, T; Taira, T; Takahashi, K; Takahashi, T; Wakuda, K | 1 |
| Furuyama, K; Gotanda, K; Harada, T; Ieiri, I; Iwama, E; Li, H; Nakanishi, Y; Okamoto, I; Shiraishi, Y; Takayama, K; Wang, S | 1 |
| Ali, SA; Burotto, M; O'Sullivan Coyne, G | 1 |
| Engle, JA; Kolesar, JM | 2 |
| Abdulrahman, R; Ahn, C; Bunn, PA; Camidge, DR; Choy, H; Doebele, RC; Dowell, J; Gaspar, LE; Gerber, DE; Hughes, R; Iyengar, P; Kavanagh, BD; Smith, I; Timmerman, R; Wardak, Z | 1 |
| Jabbour, SK | 1 |
| Arai, D; Betsuyaku, T; Hamamoto, J; Ikemura, S; Ishioka, K; Kanai, Y; Naoki, K; Ohgino, K; Sato, T; Soejima, K; Terai, H; Yasuda, H | 1 |
| Chen, XQ; Lin, GN; Liu, DY; Liu, PP; Peng, JW; Xiao, JJ | 1 |
| Ellis, S; Fayers, PM; Griebsch, I; Palmer, M | 1 |
| Bastida, CC; Falchook, GS; Gaido, L; Jackson, T; Karp, DD; Miller, VA; Ordóñez, NG; Stephens, PJ | 1 |
| Gao, HM; Gao, Z; Jia, YF; Tan, W; Tian, YL; Wang, YS; Zhang, MX; Zhang, N; Zhang, RX; Zhao, JQ | 1 |
| Cui, J; Guo, QQ; Han, LL; Jiang, LL; Jing, L; Liang, X; Liu, Y; Liu, ZY; Ma, JQ; Nan, KJ; Wang, J; Wang, MC; Wu, T; Yang, CC; Yao, Y | 1 |
| Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L | 1 |
| Byeon, JH; Jung, YH; Kim, HR; Kim, TJ; Lim, JU; Park, CK; Woo, IS | 1 |
| Jeong, EH; Kim, CH; Kim, HR; Kim, SY; Lee, TG | 1 |
| Bogart, J; Bradley, J; Hodgson, L; Jänne, PA; Katragadda, S; Kong, FM; Lilenbaum, R; Masters, G; Samuels, M; Vokes, E; Wang, X | 1 |
| Goto, K; Hashimoto, H; Iida, S; Ishii, G; Matsumoto, S; Nagai, K; Neri, S; Niho, S; Niimi, A; Ochiai, A; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Yoshida, T | 1 |
| Gan, B; Huang, Y; Liao, R; Lou, N; Wu, Y; Xu, C; Yan, H; Yang, J; Yang, X; Yang, Y; Zhou, Q | 1 |
| Jang, C; Li, J; Wang, J; Wu, F; Xiong, J | 1 |
| Li, ZX; Qiu, XS; Qu, LY; Wang, EH; Wen, H; Xu, K; Zhong, HS | 1 |
| Cho, HJ; Chung, DH; Jeon, YK; Keam, B; Kim, DW; Kim, TM; Koh, J; Lee, DS; Lee, SH; Won, JK | 1 |
| Belkina, N; Biswas, R; Chaerkady, R; Guha, U; Jacob, HK; Kim, MS; Maity, T; Pandey, A; Shaw, PG; Venugopalan, A; Zhang, X | 1 |
| Du, YJ; Hu, YM; Li, J; Qian, H; Shi, WL; Wu, Y; Zhu, LR | 1 |
| Liu, Z; Mao, JH; Wang, Q; Wang, Y; Wei, G; Wen, M; Yuan, H; Zhang, P | 1 |
| Jain, P; Khanal, R; Sharma, A; Sharma, N; Yan, F | 1 |
| Chen, LK; Dinglin, XX; Hou, X; Huang, JJ; Ma, SX; Qin, T; Wang, Z; Zeng, YD | 1 |
| Enoki, H; Katahira, K; Teraoka, A; Tsuchiya, Y; Yoshikawa, T | 1 |
| Jenks, S | 1 |
| Guo, S; Li, Z; Liu, Y; Ren, G; Ren, J; Song, G; Wang, Y; Zhang, L | 1 |
| Chen, H; Du, N; Li, F; Yang, P; Zhao, X; Zhu, G | 1 |
| Guo, R; Huang, X; Shu, Y; Wu, H; Xiang, C; Yin, Y; Yu, Q; Yu, S; Zhang, B | 1 |
| Nukiwa, T | 2 |
| Takeuchi, S; Yano, S | 1 |
| Deng, H; Long, SQ; Pan, ZQ; Wu, WY; Yang, XB | 1 |
| Agarwal, VR; Ahmed, T; Bhatia, D; Bose, J; Choudhari, S; Damre, A; Deore, V; Joshi, A; Kumar, S; Lad, VJ; Pandey, PK; Sahu, B; Sangana, R; Sharma, S; Sonawane, V; Srivastava, A; Tannu, P; Venkataraman, M; Venkatesha, VA | 1 |
| Frank, M; Golpon, H; Lange, A; Prenzler, A; von der Schulenburg, JM; Welte, T | 1 |
| Huang, J; Ji, LJ; Liu, H; Liu, Y; Ma, W; Qi, X; Xu, M; Zhu, Y | 1 |
| Chen, B; Li, B; Xie, B; Zeng, Y; Zhang, W; Zheng, J; Zhou, J | 1 |
| Chen, X; Cross, DA; de Stanchina, E; Eisenberg, R; Hutchinson, KE; Jia, P; Jin, H; Ladanyi, M; Lovly, CM; Lu, P; Meador, CB; Nebhan, CA; Pao, W; Pirazzoli, V; Politi, K; Vuong, H; Wang, L; Zhao, Z | 1 |
| Assaraf, YG; Azzariti, A; Giovannetti, E; Jansen, G; Kathman, I; Paradiso, A; Peters, GJ; Porcelli, L; Scheffer, GL | 1 |
| Choi, CM; Choi, YJ; Chun, YJ; Kim, CH; Kim, SY; Kim, WS; Lee, JC; Rho, JK; So, KS; Song, JS | 1 |
| Byers, L; Coombes, KR; Date, H; Diao, L; Girard, L; Giri, U; Heymach, JV; Komaki, R; Lin, SH; Menju, T; Minna, JD; Saintigny, P; Wang, J; Weinstein, JN; Wistuba, II; Wu, CC; Zhang, J | 1 |
| Duan, J; Fan, J; Fan, S; Li, X; Pan, Y; Wang, Y; Xiaokaiti, Y; Yang, H; Yuan, L | 1 |
| Sheng, Z; Zhang, Y | 1 |
| Bortlicek, Z; Bruha, F; Fiala, O; Minarik, M; Mukensnabl, P; Pesek, M; Racek, J; Svaton, M | 1 |
| Fan, X; Fang, C; Liu, L; Luo, J; Qi, D; Tan, Q; Zhang, J | 1 |
| Cai, Z; Yang, X; Zhang, L; Zhao, B | 1 |
| Borget, I; Chabaud, S; Chouaïd, C; Crequit, J; Dô, P; Falchero, L; Fournel, P; Greillier, L; Lavolé, A; Le Caer, H; Léna, H; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Vaylet, F; Vergnenegre, A; Westeel, V; Zalcman, G | 1 |
| Aokage, K; Hishida, T; Nagai, K; Tsuboi, M; Yoshida, J | 1 |
| Bidoli, P; Cappuzzo, F; Clementi, L; Cseh, A; Favaretto, A; Finocchiaro, G; Grossi, F; Marchetti, A; Massey, D; Santoro, A; Valente, ML | 1 |
| Balikó, Z; Sárosi, V | 2 |
| Ahn, MJ; Campbell, AK; Cho, BC; Gernhardt, D; Giri, N; Heo, DS; Kim, DW; Lee, SY; Letrent, SP; O'Connell, J; Park, K; Taylor, I; Zhang, H | 1 |
| Arcila, ME; Hellmann, MD; Kris, MG; Reva, B; Rizvi, NA; Rusch, VW; Yu, H | 1 |
| Abe, M; Aoki, M; Fujii, T; Fujimoto-Ouchi, K; Hashimoto, E; Motegi, H; Nagahashi, S; Nakatani, N; Sakata, K; Sano, Y; Sasaki, E; Satoh, Y; Sugimoto, M; Yatabe, Y | 1 |
| Cappuzzo, F; Landi, L | 1 |
| Koeffler, HP; Leong, G; Madan, V; Mori, S; Sudo, M; Yang, H | 1 |
| Chang, FY; Chao, CH; Chao, TT; Chen, KF; Chen, YL; Huang, YC; Lai, CC; Shiau, CW; Tsai, YT; Wang, CY; Yu, CJ | 1 |
| Cai, M; Jiang, B; Mao, F; Pan, Y; Shen-Tu, Y; Teng, F; Yang, X | 1 |
| Cheng, Y; Fan, Y; Han, B; Huang, C; Liu, X; Liu, Y; Lu, S; Ma, S; Song, X; Wang, J; Wang, M; Yang, S; Zhang, L; Zhang, S; Zhao, H; Zhou, C | 1 |
| Anderson, JC; Arafat, W; Bonner, JA; Denton, AJ; Dobelbower, MC; Dussaq, AM; Gilbert, AN; Minnich, DJ; Rohrbach, TD; Welaya, K; Willey, CD | 1 |
| Bugés, C; Capdevila, L; Carcereny, E; Cardona, AF; Cros, S; Moran, T; Reguart, N; Rosell, R | 1 |
| Han, JY; Hwang, KH; Kim, HT; Kim, JY; Lee, GK; Lee, SH; Lee, YJ; Yun, T | 1 |
| Ito, H; Kobayashi, H; Miura, H; Miura, M; Niioka, T; Sato, K | 1 |
| Chou, YH; Hsieh, MS; Hua, SF; Jhuang, JY | 1 |
| Jonstrup, SP; Lindahl, KH; Loeschke, S; Olsen, KE; Sørensen, FB | 1 |
| Amadori, D; Burgio, MA; Calistri, D; Capelli, L; Casanova, C; Chiadini, E; Crinò, L; Dazzi, C; Delmonte, A; Dubini, A; Gamboni, A; Mariotti, M; Papi, M; Puccetti, M; Ragazzini, A; Ulivi, P; Verlicchi, A | 1 |
| He, C; He, J; Wei, S; Xie, M | 1 |
| Jensen, RT; Moody, TW; Nakamura, T; Nuche-Berenguer, B | 1 |
| Chen, Y; Liu, J; Wang, C; Wang, M; Zhang, L; Zhao, X | 1 |
| Igishi, T; Izumi, H; Kodani, M; Kurai, J; Makino, H; Matsumoto, S; Nakazaki, H; Nirodi, CS; Nishii-Ito, S; Sakamoto, T; Shimizu, E; Takata, M; Takeda, K; Tanaka, N; Touge, H; Ueda, Y; Yanai, M | 1 |
| Chang, H; Chang, WC; Ho, CL; Hsu, HH; Hsu, YC; Huang, TW; Ko, KH; Tung, HJ; Wu, YC | 1 |
| Ma, H; Tian, JH; Tian, X; Wang, F; Wang, X; Wang, Y; Zhang, Y; Zhou, JG | 1 |
| Biswas, B | 1 |
| Socinski, MA; Spitzer, G | 1 |
| Ando, M; Kawaguchi, T; Kubo, A | 1 |
| Chen, X; Zhou, C; Zhou, F | 1 |
| Di Maio, M; Rossi, A | 1 |
| Bennouna, J; Boyer, M; Feng, J; Geater, SL; Gorbunova, V; Hirsh, V; Hu, CP; Huang, Y; Kato, T; Lee, KH; Lee, KY; Lu, S; Massey, D; Mok, T; O'Byrne, K; Orlov, S; Popat, S; Schuler, M; Sebastian, M; Sequist, LV; Shahidi, M; Su, WC; Tsai, CM; Wu, YL; Yamamoto, N; Yang, JC; Zazulina, V; Zhou, C | 1 |
| Chen, GY; Cheng, Y; Feng, JF; Gu, CP; Huang, Y; Li, XL; Ma, LX; Shi, MQ; Song, XQ; Zhang, L; Zhang, YP; Zhao, HY; Zhou, D | 1 |
| Chang, YL; Chao, SW; Chen, CC; Huang, WJ; Lin, YC; Shih, JY | 1 |
| Bantikassegn, A; Fan, PD; Guha, U; Politi, K; Song, X; Threadgill, DW; Varmus, H | 1 |
| Gemma, A; Hagiwara, K; Harada, M; Inoue, A; Kobayashi, K; Maemondo, M; Minegishi, Y; Morikawa, N; Nukiwa, T; Oizumi, S; Okinaga, S; Sugawara, S | 1 |
| Bregni, G; de Braud, F; Di Cosimo, S; Galli, G; Gevorgyan, A; Porcu, L; Serpico, D; Tessari, A; Torri, V | 1 |
| Fang, H; Lin, RY; Sun, MX; Tian, Y; Wang, Q; Wang, XY; Yu, JL; Zhao, YL | 1 |
| Cohen, DE; Colozza, S; Okereke, UR | 1 |
| Asano, H; Furukawa, M; Hashida, S; Kanazawa, S; Maki, Y; Miyoshi, S; Ohtsuka, T; Shien, K; Soh, J; Suzawa, K; Toyooka, S; Tsukuda, K; Yamamoto, H | 1 |
| Liao, BC; Lin, CC; Yang, JC | 1 |
| Barberis, M; Catania, C; Conforti, F; de Marinis, F; De Pas, T; Lazzari, C; Noberasco, C; Spitaleri, G; Stufano, V; Toffalorio, F; Vecchio, F | 1 |
| Atagi, S; Hirashima, T; Kurata, K; Minomo, S; Nakatani, T; Okamoto, N; Okishio, K; Omachi, N; Saijo, N; Shiroyama, T; Suzuki, H; Takeuchi, N; Tamiya, A; Tamiya, M; Tsuji, T | 1 |
| Wang, H; Yang, B; Zhang, H | 1 |
| Hutchinson, L | 1 |
| Reguart, N; Remon, J | 1 |
| Andratschke, N; Hildebrandt, G; Kuhnt, T; Lewitzki, V | 1 |
| Chen, J; Han, H; Hu, H; Liu, C; Lu, H; Yang, Y; Yin, H; Zhang, P; Zhou, W; Zhu, L | 1 |
| Chang, CH; Ho, CC; Lee, CH; Wang, JY; Yu, CJ | 1 |
| Dhillon, S | 1 |
| Izumi, H; Kuwano, M; Maeda, M; Murakami, Y; Ono, M; Watari, K | 1 |
| Kaur, J; Tikoo, K | 1 |
| Deeken, JF; He, AR; Hwang, J; Marshall, JL; Pishvaian, MJ; Ramos, C; Steadman, K; Subramaniam, D; Urso, CE; Wang, H; Wang, Y | 1 |
| Beijersbergen, RL; Bernards, R; Grernrum, W; Hölzel, M; Huang, S; Knijnenburg, TA; Nijkamp, W; Papadakis, AI; Sun, C; Wessels, LF; Xue, Y | 1 |
| Becker, A; Heideman, DA; Kuiper, JL; Ronden, MI; Smit, EF; Thunnissen, E; van Hengel, P; Ylstra, B | 1 |
| Chang, PY; Chen, CY; Jian, YJ; Jian, YT; Lin, YW; Syu, JJ; Tung, CL; Wang, TJ | 1 |
| Abraham, RR; Girotra, M; Jones, J; Klair, JS | 1 |
| Abdullaev, Z; Beadling, C; Berman, A; Carter, CA; Corless, CL; Doyle, A; Giaccone, G; Guha, U; Kelly, R; Killian, K; Lau, CC; Liewehr, DJ; Lopez-Chavez, A; Meltzer, PS; Morrow, B; Pack, S; Raffeld, M; Rajan, A; Sandler, A; Steinberg, SM; Szabo, E; Thomas, A; Wang, Y; Warrick, A; Xi, L | 1 |
| Chang, FK; Chih-Hsin Yang, J; Chiu, CH; Chuang, CY; Ho, CL; Hsia, TC; Hsiao, SH; Huang, MS; Lai, CL; Lai, RS; Lee, KY; Lin, CB; Lin, YC; Perng, RP; Shih, JY; Su, WC; Tsai, CM; Wang, CC; Wu, MF; Yang, CT; Yu-Wung Yeh, D | 1 |
| Bahleda, R; Burris, H; Jiang, J; Lager, J; Liu, L; LoRusso, P; Macé, S; Martini, JF; Soria, JC | 1 |
| Fujita, Y; Gemma, A; Hagiwara, K; Harada, M; Harada, T; Inoue, A; Isobe, H; Ito, K; Kinoshita, I; Kobayashi, K; Kurihara, M; Maemondo, M; Minato, K; Morita, S; Nishitsuji, M; Nukiwa, T; Oizumi, S; Sugawara, S; Yoshizawa, H | 1 |
| Ding, L; Shi, Y; Sun, Y; Tan, F; Wang, Y; Yuan, X | 1 |
| Carcereny, E; de Marinis, F; Drozdowskyj, A; Dubos-Arvis, C; Passaro, A; Perez-Moreno, P; Rosell, R; Vergnenegre, A; Zeaiter, A | 1 |
| Garber, K | 1 |
| Alama, A; Barisione, G; Bello, MG; Ferrini, S; Gangemi, R; Grossi, F; Orengo, AM; Truini, M | 1 |
| Fujii, A; Furuyama, K; Harada, T; Ijichi, K; Iwama, E; Nakanishi, Y; Okamoto, I; Okamoto, T; Ota, K; Takayama, K | 1 |
| Canon, JL; Chand, VK; De Grève, J; Decoster, L; Galdermans, D; Graas, MP; Massey, D; Moran, T; Schallier, D; Teugels, E; Vansteenkiste, J; Vuylsteke, P | 1 |
| Chang, SM; Chen, LH; Chen, TS; Chiu, KL; Liu, CM; Ma, WL; Ni, YL; Sher, YP; Yang, SY; Yu, SL | 1 |
| Aoe, K; Bessho, A; Chikamori, K; Fujii, M; Harada, D; Hisamoto-Sato, A; Hosokawa, S; Hotta, K; Ichihara, E; Kishino, D; Kiura, K; Kozuki, T; Kubo, T; Kuyama, S; Nogami, N; Oze, I; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H | 1 |
| Barlesi, F; Braun, D; Debieuvre, D; Des Guetz, G; Fraboulet, G; Landre, T; Milleron, B; Molinier, O; Monnet, I; Morère, JF; Morin, F; Moro-Sibilot, D; Souquet, PJ; Urban, T; Uzzan, B; Vaylet, F; Westeel, V | 1 |
| Berghmans, T; Grigoriu, B; Meert, AP | 1 |
| Kaneko, T; Lau, MR; Lunec, J; Margetts, J; Novello, S; Nutt, J; Plummer, R; Ramlau, R; Reck, M; Scagliotti, GV; Thomas, M | 1 |
| Ambrosio, F; Barbato, C; Cartenì, G; Mocerino, C; Otero, M; Riccardi, F; Scagliarini, S; Vitale, MG | 1 |
| de Velasco, MA; Fujita, Y; Fumita, S; Hayashi, H; Nakagawa, K; Nishio, K; Okamoto, K; Sakai, K; Terashima, M; Togashi, Y; Tomida, S | 1 |
| Belani, CP; Joshi, M; Liu, X; Miller, B; Rice, SJ | 1 |
| Chen, X; Huang, H; Ma, S; Wang, B; Wu, K; Zhang, S; Zheng, X | 1 |
| Cai, N; Chen, X; Kong, X; Liu, P; Xu, L; Zhang, Y; Zhou, Y; Zou, H | 1 |
| Abera, MB; Kazanietz, MG | 1 |
| Fujita, Y; Fukuhara, T; Gemma, A; Hagiwara, K; Harada, M; Inoue, A; Isobe, H; Kinoshita, I; Kobayashi, K; Maemondo, M; Morita, S; Nukiwa, T; Oizumi, S; Saijo, Y; Sugawara, S; Yoshizawa, H | 1 |
| Cai, X; Chen, S; Deng, H; Fang, Y; Hu, M; Li, J; Li, Z; Vaughn, A; Wan, W; Wu, S; Xiao, J; Xu, L; Yang, X | 1 |
| Aerts, JG; Boons, CC; Boven, E; Hugtenburg, JG; Moes-Ten Hove, J; Smit, EF; Swart, EL; Timmers, L; van de Ven, PM | 1 |
| Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Azuma, H; Sakai, K; Suzuki, S; Takahashi, N | 1 |
| Chang, WA; Chong, IW; Chou, SH; Huang, MS; Hung, JY; Kuo, TY; Lee, JY; Liu, TC; Shen, CH; Tsai, MJ; Wu, KL; Yang, CJ; Yen, CJ | 1 |
| Lee, JG; Wu, R | 2 |
| Fan, ZW; Li, J; Liu, Y; Xu, GG | 1 |
| Bernardo, LA; Borger, DR; Costa, C; Costa, DB; Engelman, JA; Fulton, LE; Garcia, AR; Getz, G; Howe, E; Iafrate, AJ; Jänne, PA; Katayama, R; Lockerman, EL; Mermel, CH; Mino-Kenudson, M; Miyoshi, N; Mohamoud, F; Moran, T; Mulvey, HE; Niederst, MJ; Poirier, JT; Ramaswamy, S; Ross, KN; Rudin, CM; Sequist, LV; Shioda, T; VanderLaan, PA | 1 |
| Bae, SY; Hong, JY; Lee, HJ; Lee, SK; Park, HJ | 2 |
| Beom, SH; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, JO; Lee, SH; Park, JH; Sim, SH | 1 |
| Ahn, HK; Cho, EK; Hong, J; Jeong, SH; Kang, SM; Kim, YS; Kyung, SY; Lee, JH; Park, I; Park, J; Park, JW; Shin, DB; Sym, SJ; Woo, HS | 1 |
| Jensen, RT; Moody, TW; Moreno, P; Nuche-Berenguer, B | 1 |
| Baek, IJ; Bivona, TG; Choi, CM; Choi, SH; Choi, YJ; Kim, SY; Kim, WS; Lee, JC; Rho, JK; So, KS | 1 |
| Cioffredi, LA; Jackman, DM; Jacobs, L; Johnson, BE; Kesari, S; Lucca, J; Lynch, TJ; Marcoux, PJ; Morse, LK; Plotkin, SR; Rabin, MS; Sharmeen, F | 1 |
| Chen, LK; Dinglin, XX; Liang, JZ; Liao, H; Ma, SX; Qin, T; Wei, WD; Xu, F; Zeng, YD; Zhang, L | 1 |
| Kortmann, RD; Seidel, C | 1 |
| Burotto, M; Fojo, T; Manasanch, EE; Wilkerson, J | 1 |
| Baumann, M; Brammer, I; Can, Y; Dikomey, E; Dorniok, F; Gal, A; Grob, TJ; Gurtner, K; Kasten-Pisula, U; Krause, M; Kriegs, M; Laban, S; Oertel, R; Petersen, C; Rieckmann, T; Wysocki, M | 1 |
| Abdel-Rahman, O; Elhalawani, H | 1 |
| Chang, YT; Huang, HJ; Hwang, MH; Lin, AM; Tang, MC; Wu, MY; Yang, JC | 1 |
| Han, S; Pu, R; Shi, LW; Zhao, YL | 1 |
| Liang, J; Su, N; Xie, Y | 1 |
| Cui, A; Hua, H; Jiang, Y; Kong, Q; Luo, T; Shao, T; Song, P | 1 |
| Chinda, J; Fujino, T; Hasebe, N; Kabara, M; Kuroshima, T; Maruyama, K; Nakagawa, N; Ogawa, Y; Ohsaki, Y; Yamamoto, Y | 1 |
| Castellanos, EH; Horn, L; Rivera, G; Wakelee, H | 1 |
| Ackley, E; Balak, M; Bhang, HE; Caushi, JX; Chiang, DY; Cooke, VG; Hims, MM; Kao, I; Keen, N; Korn, JM; Krishnamurthy Radhakrishna, V; Leary, RJ; Michor, F; Palmer, M; Rakiec, D; Raza, A; Ruddy, DA; Schlabach, MR; Sellers, WR; Shaw, P; Singh, AP; Stegmeier, F; Zhao, R | 1 |
| Bidart, JM; Broutin, S; Gil, S; Goffinet, F; Jovelet, C; Mir, O; Paci, A; Seck, A; Simasotchi, C | 1 |
| Seo, YH | 1 |
| Chung, C | 2 |
| Bai, C; Huang, Y; Liao, M; Luo, F; Ma, S; Qin, S; Shi, Y; Wang, C; Yu, S; Zhang, L; Zhang, Q; Zhi, X; Zhou, C | 1 |
| Che, XF; Hiramoto, M; Ito, K; Miyazawa, K; Moriya, S; Sugita, S; Yamashiro, Y; Yokoyama, T | 1 |
| Hart, EM; Johnson, ML; Kris, MG; Patel, JD; Rademaker, AW; Riely, GJ; Weitner, BB; Yu, HA | 1 |
| Cai, JZ; Deng, H; He, WF; Li, QP; Liao, GY; Long, SQ; Pan, ZQ; Wu, WY; Xiao, SJ; Yang, XB; Zhou, YS | 1 |
| Dahlberg, SE; Jackman, DM; Jänne, PA; Johnson, BE; Lo, PC; Nishino, M; Oxnard, GR; Sequist, LV | 1 |
| Han, X; Liu, M; Lv, G; Ma, L; Shi, Y; Wang, S; Zeng, C | 1 |
| Gemma, A; Hagiwara, K; Inoue, A; Isobe, H; Kobayashi, K; Maemondo, M; Miyauchi, E; Nukiwa, T; Oizumi, S; Saijo, Y; Sugawara, S; Yoshizawa, H | 1 |
| Bigley, G; Blockley, L; Cresswell, C; Dale, A; Davies, A; de Boer, R; Donald, E; Elvin, P; Fan, S; Fu, H; Gladwin, A; Gray, N; Harrod, G; Herbst, RS; Ji, Q; Lee, JS; Morten, J; Platt, A; Read, J; Stevens, J; Su, X; Vasselli, J; Williams, V; Womack, C; Ye, Q; Zhang, T; Zheng, L | 1 |
| Chudacek, Z; Pesek, M; Svaton, M; Vosmiková, H | 1 |
| Arrieta, O; Bacon-Fonseca, L; de la Garza-Salazar, J; Flores-Estrada, D; López-Macías, D; Macedo-Pérez, EO; Martínez-Hernández, JN; Ramírez-Tirado, LA; Vega-González, MT | 1 |
| Kempf, E; Le Chevalier, T; Planchard, D; Soria, JC | 1 |
| Gemma, A; Kitamura, K; Kosaihira, S; Kubota, K; Matsuda, K; Matsumoto, M; Minegishi, Y; Nishijima, N; Noro, R; Seike, M; Soeno, C; Sugano, T; Yoshimura, A; Zou, F | 1 |
| Huang, Y; Lee, VH; Ma, L; Wang, DD; Wong, MP; Yan, H | 1 |
| Kohno, T; Makinoshima, H; Matsushima, K; Sugano, S; Suzuki, A; Suzuki, Y; Tsuchihara, K | 1 |
| Gao, K; Li, XY; Liang, Y; Wu, N; Zhang, LF; Zhou, LN | 1 |
| Bassett, P; Chicklore, S; Chua, S; Cook, GJ; Goh, V; Loi, HY; O'Brien, ME; Punwani, R; Sharma, B; Siddique, M | 1 |
| Ahn, JS; Ahn, MJ; Chang, WJ; Choi, MK; Choi, YL; Do, IG; Hong, JY; Jung, HA; Kim, MJ; Kim, SM; Park, K; Sun, JM | 1 |
| Amato, E; Bria, E; Brunelli, M; Chilosi, M; Corbo, V; Fassan, M; Giglioli, E; Kinspergher, S; Milella, M; Novello, S; Peretti, U; Pilotto, S; Righi, L; Santo, A; Scarpa, A; Sperduti, I; Tortora, G; Vavalà, T | 1 |
| Fujita, S; Hata, A; Hayashi, M; Katakami, N; Kawamura, T; Takeshita, J; Tomii, K | 1 |
| Chen, X; Dong, S; Li, P; Li, W; Qu, X; Shao, M; Yang, S; Zhang, L; Zhong, X | 1 |
| Feng, J; Geater, SL; Hou, M; Hu, CP; Huang, Y; Lee, KY; Li, W; Lu, S; Lungershausen, J; Palmer, M; Shi, JH; Shi, Y; Wu, YL; Xu, CR; Zhou, C | 1 |
| Julka, PK; Mallick, S; Singh, A; Venkatesulu, BP | 1 |
| Hu, C; Li, M; Wang, Q | 1 |
| Gao, C; Gao, Y; He, W; Qu, W; Yu, Y; Zhang, S; Zhang, Y; Zhu, S | 1 |
| Bonetti, A; Giuliani, J; Martelli, S; Remo, A | 1 |
| Aoyama, A; Chen, F; Date, H; Menju, T; Omasa, M; Sato, M; Sato, T; Sonobe, M; Yamada, T; Yokoyama, Y | 1 |
| Delaney, C; Frank, S; Huang, RS | 1 |
| Busto, ME; Koch, H; Kramer, K; Kuster, B; Médard, G | 1 |
| Allen, PK; Blumenschein, GR; Hong, WK; Komaki, R; Lee, JJ; Liu, DD; Tang, X; Wei, X; Welsh, JW; Wistuba, II | 1 |
| Fan, LL; Gao, S; Li, WC; Li, XQ; Liu, JT; Sun, GP; Wang, F; Wang, H; Wei, W; Yu, HQ | 1 |
| Chang, YH; Hong, SE; Hong, SI; Hong, YJ; Jin, HO; Kim, B; Kim, CS; Kim, JH; Kim, JY; Lee, JK; Park, IC; Park, JA | 1 |
| Daito, H; Ishikawa, R; Kawashima, A; Kobayashi, K; Maeno, Y; Masumoto, A; Murayama, Y; Okano, T; Shiono, A; Utsugi, H; Yamaguchi, O | 1 |
| Ali, SM; Berry, J; Cascone, T; Guha-Thakurta, N; Heymach, JV; McMahon, C; Miller, V; Pai, S; Roxas, M; Subbiah, IM; Subbiah, V; Tang, Z | 1 |
| Hisada, T; Imai, H; Ishihara, S; Kaira, K; Kuwako, T; Masuda, T; Minato, K; Miura, Y; Mogi, A; Saito, R; Shimizu, K; Sunaga, N; Takise, A; Tomizawa, Y; Yamada, M; Yoshino, R | 1 |
| Lee, VH; Ma, L; Wang, DD; Wong, MP; Yan, H | 1 |
| Fujiwara, Y; Goto, Y; Hamada, A; Horinouchi, H; Kanda, S; Katsuya, Y; Nokihara, H; Ohe, Y; Osawa, S; Sunami, K; Takashima, Y; Tamura, T; Utsumi, H; Yamamoto, N | 1 |
| Ahn, JS; Ahn, MJ; Jung, HA; Kim, H; Kim, M; Kim, S; Ku, BM; Lee, JY; Lee, MY; Lim, SH; Park, K; Sun, JM | 1 |
| Alama, A; Barletta, G; Biello, F; Boccardo, F; Coco, S; Dal Bello, MG; Genova, C; Grossi, F; Rijavec, E; Rosano, C; Truini, A; Vanni, I; Venè, R | 1 |
| Asada, K; Imokawa, S; Inoue, Y; Inui, N; Karayama, M; Kasamatsu, N; Koshimizu, N; Matsuda, H; Shirai, T; Suda, T; Yamada, T; Yokomura, K | 1 |
| Doyle, KP; Flores, EJ; Kamdar, MM; Maytal, G; Mino-Kenudson, M; Rinehart, TJ; Sequist, LV | 1 |
| Cho, S; Kang, YK; Kim, BY; Kwon, T; Lee, JC; Park, YH; Rho, JK; Shin, HJ; Yoon, DY; Yu, DY | 1 |
| Hotta, K; Ichihara, E; Iwasaku, M; Kato, Y; Kiura, K; Kudo, K; Kunimasa, K; Oze, I; Takigawa, N; Tanimoto, M; Tsubouchi, K; Yoshioka, H | 1 |
| Ciardiello, F; Della Corte, CM; Fasano, M; Morgillo, F; Papaccio, F | 1 |
| Aydiner, A; Ciftci, R; Sen, F | 1 |
| Ai, YQ; He, WJ; Li, RQ; Li, WH; Li, YF; Wang, Y; Xia, YX; Zhang, J; Zhao, PZ | 1 |
| Chicchinelli, N; De Luca, A; Fenizia, F; Forgione, L; Franco, R; Iannaccone, A; Lambiase, M; Morabito, A; Normanno, N; Pasquale, R; Piccirillo, MC; Rocco, G; Rossi, A; Sacco, A | 1 |
| Kagohashi, K; Satoh, H; Tamura, T | 1 |
| Chang, SN; Hsu, KH; Lin, CH; Pan, HC; Sheehan, J; Sheu, ML; Tsou, HK | 1 |
| Broggini, M; Garassino, MC; Torri, V | 1 |
| Geater, SL; Massey, D; Mok, TS; Ou, SH; Schuler, M; Sequist, LV; Tsai, CM; Wu, YL; Yamamoto, N; Yang, JC; Yu, CJ; Zazulina, V; Zhou, C | 1 |
| James, M; Jeong, JH; Lee, Y; Wang, Y; You, M | 1 |
| Busch, TM; Cengel, KA; Gallagher-Colombo, SM; Miller, J; Putt, ME; Vinogradov, SA | 1 |
| Chen, L; Chen, X; Luo, S; Xie, X | 1 |
| Fan, F; Liu, Z; Lu, Y; Shen, C; Wang, A; Wu, H | 1 |
| Carpentier, O; Jégu, J; Prim, N; Purohit, A; Quoix, E; Selvaggi, L; Velten, M | 1 |
| Addison, CL; Bar, J; Bradbury, PA; Dimitroulakos, J; Ding, K; Goss, GD; Han, L; Laurie, SA; Seymour, L; Shepherd, FA; Zhao, H | 1 |
| Chubenko, VA; Imyanitov, EN; Ivantsov, AO; Kramchaninov, MM; Moiseenko, FV; Moiseenko, VM | 1 |
| Alama, A; Barletta, G; Biello, F; Boccardo, S; Bottoni, G; Coco, S; Dal Bello, MG; Genova, C; Grossi, F; Rijavec, E; Sambuceti, G; Truini, A; Vanni, I | 1 |
| Asano, H; Hatakeyama, S; Jida, M; Kawahara, E; Kiura, K; Kubo, T; Miyoshi, S; Naomoto, Y; Otani, H; Sakaguchi, M; Soh, J; Takaoka, M; Toyooka, S; Tsukuda, K; Ueno, T; Yamamoto, H | 1 |
| Hida, T; Kato, T; Kiura, K; Massey, D; Okamoto, I; Seki, Y; Seto, T; Yamamoto, N; Yokoyama, A; Yoshioka, H | 1 |
| An, T; Bai, H; Ding, X; Duan, J; Li, Z; Liu, Z; Shen, Z; Sun, Y; Wang, J; Wang, S; Wang, Y; Wang, Z; Wu, M; Zhao, J; Zhong, J; Zhuo, M | 1 |
| Chen, HL; Hsiao, FY; Lu, HM; Shen, LJ; Wei, CP | 1 |
| Li, Y; Qian, K; Wang, R; Yao, S; Zhang, Y | 1 |
| Vignot, S; Zalcman, G | 1 |
| Girard, N | 1 |
| Guckenberger, M | 1 |
| Hirsh, V | 2 |
| Hata, A; Hattori, Y; Imamura, F; Kaji, R; Kaneda, T; Katakami, N; Mori, M; Morita, S; Negoro, S; Nishino, K; Otsuka, T; Tachihara, M; Uchida, J; Urata, Y; Yano, Y; Yokota, S | 1 |
| Allo, G; Ishizawa, K; John, T; Jurisica, I; Kim, L; Leighl, NB; Li, M; Liu, G; Liu, N; Martin, P; Mascaux, C; Neel, BG; Ng, C; Pham, NA; Pintilie, M; Sakashita, S; Shepherd, FA; Stewart, EL; Sykes, J; Tsao, MS; Waddell, TK; Wang, D; Yanagawa, N; Zhu, CQ | 1 |
| Bagust, A; Beale, S; Boland, A; Dickson, R; Dundar, Y; Dwan, K; Greenhalgh, J; Hockenhull, J; Marshall, E; Mullard, A; Proudlove, C; Richardson, M | 1 |
| Gow, CH; Liao, WY; Liu, YN; Shih, JY | 1 |
| Hata, A; Katakami, N | 1 |
| Fang, WF; Hong, SD; Huang, Y; Ma, YX; Sheng, J; Tian, Y; Xue, C; Yang, YP; Zhang, L; Zhao, YY | 1 |
| Fan, Y; Gong, L; Huang, Z; Miao, L; Xiong, M | 1 |
| Fuchs, BC; Gilpin, SE; Lanuti, M; Ott, HC; Ren, X; Tanabe, KK; Tapias, LF; Wei, L | 1 |
| Chang, Y; Gao, Y; He, Z; Li, S; Liu, K; Ma, J; Ma, W; Ma, Z; Tang, H; Wang, Q; Wei, B; Zhang, Z | 1 |
| Fan, Y; Fang, L; Gong, L; Huang, Z; Lei, T; Mao, W; Miao, L; Yang, H; Yu, H | 1 |
| Eisele, DW; McCormick, F; Phuchareon, J; Tetsu, O | 1 |
| Gandara, DR; Herbst, RS; Hirsch, FR | 1 |
| Ardizzoni, A; Chand, VK; Cobo, M; Felip, E; Gadgeel, SM; Georgoulias, V; Göker, E; Goss, GD; Guclu, SZ; Isla, D; Lee, KH; Li, W; Lu, S; Min, YJ; Morabito, A; Soria, JC; Syrigos, K; Wang, B | 1 |
| Ahn, MJ; Atagi, S; Jiang, H; Kim, SW; Lee, DH; Liu, Y; Lu, Y; Mok, TS; Nakagawa, K; Ponce, S; Shi, X; Soria, JC; Wang, J; Webster, A; Wu, YL; Yang, JC; Yang, JJ; Yoh, K; Zhou, JY | 1 |
| Chang, VH; Chen, CC; Jiang, X; Lin, HY; Liu, YR; Wang, J; Yang, SH; Yen, Y; Zhang, K | 1 |
| Hu, P; Jiang, J; Liu, D; Liu, Y; Tan, F; Wang, Y; Wu, Y; Zhang, L | 1 |
| Cao, W; Chen, H; Huang, L; Liu, Y; Mei, L; Ming, P; Wang, T; Zhang, B; Zhang, H; Zhang, R; Zhu, X | 1 |
| Bi, Z; Jiang, Y; Li, D; Liu, Y | 1 |
| Akerley, W; Barlesi, F; Favaretto, A; Hirsh, V; Novello, S; Orlov, S; Ramlau, R; Ross, JS; Sandler, A; Santoro, A; Scagliotti, G; Schwartz, B; Sequist, LV; Shepherd, FA; Shuster, D; Spigel, D; von Pawel, J; von Roemeling, R; Wang, Q | 1 |
| Chen, Q; Ding, L; Hong, X; Liang, Y; Quan, Q; Wu, H; Zhou, N | 1 |
| Arrieta, O; Baracos, VE; De la Torre-Vallejo, M; López-Macías, D; Macedo-Pérez, EO; Orta, D; Ramírez-Tirado, LA; Sánchez-Lara, K; Turcott, J | 1 |
| Aono, H; Azuma, K; Hosomi, Y; Kato, T; Komase, Y; Kunitoh, H; Morita, S; Nakahara, Y; Nishikawa, M; Oba, MS; Okamoto, H; Okuma, Y; Sato, A; Takeoka, H; Watanabe, K; Yamada, K | 1 |
| Bokobza, SM; Devery, AM; Jiang, Y; Ryan, AJ; Wadekar, R; Weber, AM | 1 |
| Bai, C; Chen, G; Ding, C; Feng, J; Gu, A; Han, B; He, J; Huang, C; Jian, H; Jiao, S; Li, F; Ling, Y; Liu, X; Luo, H; Luo, R; Pang, Q; Shi, Y; Shu, Y; Sun, Y; Wang, C; Wang, Z; Wu, M; Yang, Y; Zhang, S; Zhang, Y; Zhao, H; Zhao, Q; Zhou, C; Zhou, Y | 1 |
| Chu, W; Gao, L; Liu, J; Lv, B; Tan, G; Wang, R; Zhang, Y; Zhao, X; Zhen, Q | 1 |
| Sala González, MÁ | 1 |
| Cheong, JG; Choi, J; Jung, JW; Kang, M; Kim, HJ; Kim, TY; Lee, GH; Lee, HY; Lee, JW; Nam, SH; Ryu, J | 1 |
| Ando, T; Hirose, Y; Ishikawa, T; Kameyama, H; Kobayashi, T; Kosugi, S; Koyama, Y; Maruyama, T; Minagawa, M; Nagahashi, M; Ohtsubo, A; Okabe, Y; Sakata, J; Shimada, Y; Takizawa, K; Wakai, T; Watanabe, S | 1 |
| Erasmus, JJ; Gold, KA | 1 |
| Chung, DH; Chung, JK; Heo, DS; Jeon, YK; Kang, KW; Keam, B; Kim, DW; Kim, TM; Lee, SH; Lee, SJ; Paeng, JC | 1 |
| Kim, YH; Mishima, M | 1 |
| Zhang, L; Zhao, H | 1 |
| Asano, H; Hashida, S; Maki, Y; Miyoshi, S; Miyoshi, Y; Ohtsuka, T; Shien, K; Soh, J; Suzawa, K; Toyooka, S; Tsukuda, K; Watanabe, M; Yamamoto, H | 1 |
| Chen, J; Li, L; Luo, M; Pan, L; Qin, G; Qin, S; Yang, J; Zhang, Q | 1 |
| Kempf, E; Lacroix, L; Soria, JC | 1 |
| Hida, T; Jangchul, P; Kobayashi, Y; Kondo, C; Mitsudomi, T; Mizuuchi, H; Nishio, K; Sato, K; Shimoji, M; Suda, K; Takemoto, T; Togashi, Y; Tomizawa, K; Yatabe, Y | 1 |
| Adachi, K; Okamoto, S | 1 |
| Asakuma, M; Fukui, T; Hamada, A; Hayashi, N; Hiyoshi, Y; Igawa, S; Ishihara, M; Kasajima, M; Katagiri, M; Katono, K; Kimura, M; Kubota, M; Maki, S; Masuda, N; Mitsufuji, H; Otani, S; Ryuge, S; Saito, H; Sasaki, J; Takakura, A; Toyooka, I; Wada, M; Yamamoto, M; Yokoba, M | 1 |
| Azzoli, CG | 1 |
| Cao, X; Dong, W; Feng, W; Hong, S; Jia, J; Li, N; Lin, D; Peng, J; Wang, S; Xue, C; Zhang, H; Zhang, L; Zhang, W | 1 |
| Huang, XE; Shi, B; Xu, J; Zhang, XB | 1 |
| Chen, L; Guo, Y; Hu, Z; Huang, M; Huang, Y; Li, H; Li, J; Ma, Y; Wang, X; Xin, S; Zhang, J; Zhang, L; Zhao, Y | 1 |
| Cascone, T; Heymach, JV | 1 |
| Ando-Makihara, R; Hayashi, Y; Makino, Y; Motonaga, M; Ohe, Y; Takano, M; Yamamoto, N | 1 |
| Watzka, SB | 1 |
| Cruz, FM; Del Giglio, A; Normando, SR | 1 |
| Asai, K; Hirata, K; Kawaguchi, T; Kimura, T; Kudoh, S; Matusura, K; Mitsuoka, S; Nakai, T; Oka, T; Suzumira, T; Tochino, Y; Yoshimoto, N; Yoshimura, N | 1 |
| Hisada, T; Imai, H; Ishihara, S; Ishizuka, T; Kaira, K; Kuwako, T; Masuda, T; Minato, K; Miura, Y; Mogi, A; Saito, R; Seki, K; Shimizu, K; Sunaga, N; Takise, A; Tomizawa, Y; Utsugi, M; Yamada, M; Yoshino, R | 1 |
| Chiba, K; Kurokawa, T; Matsushima, Y; Nakanishi, Y; Narita, Y; Shiroiwa, T; Urushihara, H | 1 |
| Boone, E; Breyne, J; De Laere, E; Dedeurwaerdere, F; Demedts, I; Oyaert, M; Vandorpe, J | 1 |
| Fujita, A; Gotoh, N; Higashiyama, M; Higuchi, T; Imoto, S; Kimura, T; Kondoh, K; Miyano, S; Nakata, A; Nishihara, H; Nokihara, H; Nomura, M; Shimamura, T; Tamada, Y; Tojo, A; Yamaguchi, R; Yamauchi, M; Yano, S; Yoshida, R | 1 |
| Becker, C; Engel, J; Eppmann, S; Getlik, M; Grütter, C; Heil, J; Heuckmann, JM; Hoffgaard, F; Kast, SM; Keul, M; Kibies, P; Krüll, J; Lategahn, J; Mayer-Wrangowski, S; Menninger, S; Ortiz-Cuaran, S; Rauh, D; Richters, A; Schaumann, N; Schultz-Fademrecht, C; Sos, ML; Termathe, M; Thomas, RK; Tinnefeld, V; Tomassi, S; Uhlenbrock, N; Zahedi, RP | 1 |
| Ashinuma, H; Sekine, I | 1 |
| Al-Shahrour, F; Becker, JH; Capelletti, M; Carretero, J; Jänne, PA; Kikuchi, E; Kuang, Y; Patel, TB; Paweletz, CP; Pulido, I; Shapiro, GI; Shimamura, T; Soucheray, M; Wong, KK; Xu, C | 1 |
| Ali, SM; Bailey, M; Chandramohan, R; Gallant, JN; Kris, MG; Ladanyi, M; Lipson, D; Lovly, CM; Meiler, J; Miller, VA; Pietenpol, JA; Red Brewer, M; Shaver, TM; Sheehan, JH; York, SJ | 1 |
| Bora-Singhal, N; Chellappan, S; Nguyen, J; Perumal, D | 1 |
| Chan, CH; Chan, HL; Chen, JT; Chou, HC; Chung, TW; Lin, CC; Lin, MW; Lyu, KW; Wen, YF; Wu, SB | 1 |
| Adamo, V; Ferraro, G; Franchina, T; Giordano, A; Picone, A; Ricciardi, GR; Russo, A; Toscano, G; Zanghì, M | 1 |
| Fang, L; Li, F; Lin, N; Ma, S; Song, Y; Sun, X; Xu, Y; Zhang, Y | 1 |
| Chang, GC; Chen, HW; Chen, JJ; Chen, MH; Lai, YH; Lin, SY; Wong, YH; Yang, CH; Yu, SL | 1 |
| Marquez-Medina, D; Popat, S | 1 |
| Bianco, R; Carillio, G; Costanzo, R; Daniele, G; Giordano, P; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Azuma, Y; Futagami, S; Hamaguchi, M; Hikita, A; Hirashima, T; Iwata, K; Morishita, N; Okamoto, N; Ryota, N; Sando, M; Shiroyama, T; Suzuki, H; Tamiya, M; Tanaka, A; Tani, E | 1 |
| Goto, K; Kirita, K; Matsumoto, S; Niho, S; Nomura, S; Ohe, Y; Ohmatsu, H; Sugiyama, E; Tsuboi, M; Umemura, S; Yoh, K | 1 |
| Allen, D; Bokobza, SM; Devery, AM; Jiang, Y; Kersemans, V; Ryan, AJ; Smart, S | 1 |
| Bianco, R; Brillante, S; Cosconati, S; D'Amato, V; De Placido, S; Di Mauro, C; Formisano, L; Marciano, R; Montuori, N; Orsini, RC; Parsons, SJ; Raimondo, L; Randazzo, A; Rosa, R; Servetto, A; Veneziani, BM | 1 |
| Dai, D; Li, XF; Liu, JJ; Wang, J; Wang, Q; Xu, WG; Zhang, Y; Zhu, YJ | 1 |
| Igawa, S; Ishihara, M; Katagiri, M; Masuda, N; Otani, S; Sasaki, J; Takakura, A | 1 |
| Anaya, P; Arrieta, O; Morales-Oyarvide, V; Polanco, AC; Ramírez-Tirado, LA | 1 |
| Fu, F; Geng, J; Sun, D; Wang, H; Xie, X; Yu, G; Zhang, L | 1 |
| Cao, M; Chen, H; Chu, Q; Han, R; He, Y; Sun, J; Wang, D; Wang, Y; Yao, W | 1 |
| Ayeni, D; de Stanchina, E; Goldberg, SB; Hyder, F; Meador, CB; Pao, W; Pirazzoli, V; Politi, K; Sanganahalli, BG | 1 |
| Cho, BC; Choi, JM; Choi, YR; Jang, JY; Kim, HR; Lee, HW | 1 |
| Fujita, S; Hata, A; Kaji, R; Katakami, N; Masago, K; Okuda, C; Otsuka, K; Takeshita, J | 1 |
| Ettinger, DS; Forde, PM | 1 |
| Griesinger, F; Heigener, DF; Lüers, A; Märten, A; Sadjadian, P; Scheffler, M; Schumann, C; Sebastian, M; Stehle, I | 1 |
| Chua, KN; Goh, BC; Huynh, H; Kong, LR; Ng, HC; Ong, WR; Sim, WJ; Thiery, JP | 1 |
| Liu, X; Shi, Y; Xu, J; Yang, S; Zhang, X | 2 |
| Bessho, A; Hotta, K; Ichinose, Y; Katsui, K; Kishimoto, J; Kiura, K; Nogami, N; Saeki, S; Sasaki, J; Shioyama, Y; Takayama, K; Takigawa, N; Tanimoto, M | 1 |
| Abdel-Sattar, M; Sugay, A; Tien Ho, P; Ting, J; Wilson, L; Xiang, P | 1 |
| Bruzzese, F; Budillon, A; Ciardiello, C; Ciliberto, G; Di Gennaro, E; Leone, A; Mancini, R; Roca, MS; Terranova-Barberio, M; Vitagliano, C | 1 |
| Addison, CL; Bradbury, PA; Ding, K; Goss, GD; Laurie, SA; Seymour, L; Shepherd, FA; Zhao, H | 1 |
| Iwasa, T; Kaneda, H; Kudo, K; Nakagawa, K; Nishida, S; Nishio, K; Okamoto, I; Takahama, T; Takeda, M; Tanaka, K; Yonesaka, K; Yoshida, T | 1 |
| Kiessling, R; Lundqvist, A; Maeda, A; Nakata, M; Nakayama, E; Oka, M; Okita, R; Saisho, S; Seliger, B; Shimizu, K; Wolf, D; Yamaguchi, Y; Yasuda, K; Yukawa, T | 1 |
| Cappuzzo, F; D'Incecco, A; Minuti, G | 1 |
| Cui, Y; Gong, Y; Kang, X; Lu, P; Wang, Y; Xu, Z; Zhang, Q | 1 |
| Gong, P; Li, H; Li, J; Li, N; Ma, X; Su, F | 1 |
| Agerbaek, M; Cerbone, L; Collette, S; Daugaard, G; Marreaud, S; Sengeløv, L; Sternberg, CN; Van Herpen, C; Zhang, J | 1 |
| Fukusumi, M; Hamamoto, Y; Honma, C; Ibe, T; Kameyama, N; Kamimura, M; Mouri, A; Takeoka, S | 1 |
| Fang, YF; Hsieh, MH; Li, SH | 1 |
| Cao, HX; Feng, JF; Hu, Y; Liu, SW; Wu, Y; Yu, DD; Yu, SR | 1 |
| Cai, K; Feng, S; Wang, H; Wang, Y; Wu, H; Xiong, G; Zhang, Z | 1 |
| Cui, F; He, X; Wang, M; Wang, W; Wu, D; Wu, J | 1 |
| Liu, G; Liu, H; Ma, T; Zhang, X | 1 |
| Ahn, JH; Choi, CM; Choi, YJ; Kim, SW; Lee, DH; Lee, JS; Lee, SJ | 1 |
| Maeda, A; Nakata, M; Nojima, Y; Okita, R; Saisho, S; Shimizu, K; Yukawa, T | 1 |
| Amellal, N; Bahleda, R; Deutsch, E; Farace, F; Gazzah, A; Hollebecque, A; Marzin, K; Massard, C; Ould-Kaci, M; Roux, F; Soria, JC; Varga, A | 1 |
| Alharbi, KK; Chakravarthy, S; Goud, I; Khan, IA; Lakshmi M, AM; Matam, K; Prasad, SV; Ravi, V; Shaik, NA; Sridhar, K; Syed, R; Tabassum, SN; Vijayanand, PR | 1 |
| Bode, AM; Chang, X; Chen, H; Dong, Z; Jiang, Y; Liu, K; Reddy, K; Ryu, J; Shi, C; Yao, K; Zhang, C; Zhang, Y; Zhao, S | 1 |
| Dickson, JM; Flanagan, JU; McKeage, MJ; Patterson, AV; Silva, S; Smaill, JB; Squire, CJ; Yosaatmadja, Y | 1 |
| Hayashi, H; Hirose, C; Iihara, H; Itoh, Y; Kita, Y; Kitaichi, K; Minatoguchi, S; Ohno, Y; Sugiyama, T; Todoroki, K; Yamada, M; Yanase, K | 1 |
| Fan, XX; Jiang, ZH; Leung, EL; Liu, L; Liu, ZQ; Lu, LL; Tin, VP; Wong, MP; Yao, XJ; Yau, LF; Zhou, YL | 1 |
| Ali, HR; Bentley, D; Caldas, C; Chin, SF; Contente-Cuomo, T; Dawson, SJ; Farahani, H; Gale, D; Grant, J; Humphray, S; Kingsbury, Z; Marass, F; Murtaza, M; Pogrebniak, K; Provenzano, E; Rosenfeld, N; Rueda, OM; Shah, P; Shah, SP; Shumansky, K; Tsui, DWY; Wallis, M | 1 |
| Alfieri, RR; Andreoli, R; Ardizzoni, A; Bonelli, M; Caffarra, C; Cavazzoni, A; Cretella, D; Fumarola, C; Galetti, M; La Monica, S; Mutti, A; Petronini, PG; Saccani, F; Tiseo, M | 1 |
| Hsiue, TR; Hwang, JS; Lai, WW; Lin, CK; Su, WC; Wang, JD; Yang, SC | 1 |
| Asano, H; Hashida, S; Maki, Y; Miyoshi, S; Morita, M; Ohtsuka, T; Sakaguchi, M; Soh, J; Suzawa, K; Tomida, S; Toyooka, S; Tsukuda, K; Watanabe, M; Yamamoto, H | 1 |
| Cho, KM; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, SH | 1 |
| Abdel-Rahman, O; Ahmed, H; ElHalawani, H | 1 |
| Arcila, ME; Chaft, JE; Cooper, W; Kris, MG; Lee, A; Li, BT; O'Toole, S; Pavlakis, N; Yu, B | 1 |
| Protsenko, SA; Rudakova, AV | 1 |
| Kim, H; Kim, HS; Kwon, JW; Shin, S; Sohn, HS | 1 |
| Iwasa, T; Kaneda, H; Nakagawa, K; Nonagase, Y; Okamoto, K; Shimizu, T; Takeda, M; Tanaka, K; Tsurutani, J; Yoshida, T | 1 |
| Chao, TT; Chen, KF; Chen, YL; Chu, PY; Hsiao, YJ; Hung, MH; Shiau, CW; Tai, WT; Wang, CY; Yu, HC | 1 |
| Diao, L; Fan, Y; Giri, U; Gudikote, J; Herbst, R; Heymach, JV; Johnson, BE; Koo, A; Lu, W; Nilsson, MB; Rowe, P; Ryan, A; Tang, X; Tong, P; Tran, H; Wang, J; Webster, A; Wistuba, II | 1 |
| Chen, CS; Chen, CY; Chen, JJ; Hong, TM; Hsiao, TH; Huang, KY; Kao, SH; Salunke, SB; Su, KY; Wang, WL; Yang, PC; Yang, SC | 1 |
| Barlesi, F; Beau-Faller, M; Besse, B; Cappuzzo, F; Cortot, A; Dansin, E; Filleron, T; Fournel, P; Früh, M; Gautschi, O; Mazières, J; Milia, J; Monnet, I; Moro-Sibilot, D; Peters, S; Pless, M; Rosell, R; Westeel, V; Wislez, M | 1 |
| Aebersold-Keller, F; Aebi, S; Baumann, C; Betticher, D; Buser, K; Büttner, R; Calderoni, A; Casty, A; Diebold, J; DʼAddario, G; Gautschi, O; Heukamp, LC; Irlé, C; Jehle-Schwertfeger, S; König, K; Mamot, C; Morant, R; Pellicioli, E; Stadelmann, C; Trojan, A | 1 |
| Goto, K; Matsumoto, S; Niho, S; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Yoshida, T | 1 |
| Jin, J; Liu, BZ; Wu, ZM | 1 |
| Liu, K; Ma, X; Shu, X; Sun, Y; Wang, C; Wang, Q; Wu, B; Zhen, Y; Zhou, Y; Zhu, X | 1 |
| Cai, XH; Feng, CJ; Huang, CY; Liu, XK; Lu, Y; Wang, L; Wang, Y; Wang, YS; Xu, Y; Yao, WX; Yu, P; Zhou, J; Zhu, WJ | 1 |
| Dong, M; He, X; Li, J; Wang, J; Wang, Y; Wang, Z; Wu, Y | 1 |
| Inoue, A; Kobayashi, K; Nukiwa, T; Watanabe, S | 1 |
| Bertrán-Alamillo, J; Bosch-Barrera, J; Bria, E; Carcereny, E; Chaib, I; Codony-Servat, C; Codony-Servat, J; Crisetti, E; de Marinis, F; Drozdowskyj, A; Felip, E; Felipe Cardona, A; García-Campelo, R; Gervais, R; Giménez-Capitán, A; González-Cao, M; Karachaliou, N; López-Vivanco, G; Luis Ramírez, J; Majem, M; Massuti, B; Miguel Sánchez, J; Molina-Vila, MA; Morales-Espinosa, D; Morán, T; Pilotto, S; Rosell, R; Sánchez Hernández, JJ; Santarpia, M; Sperduti, I; Teixidó, C; Vergnenegre, A; Verlicchi, A; Viteri, S | 1 |
| Barone, C; Basso, M; Cassano, A; Cerchiaro, E; D'Argento, E; Dadduzio, V; Martini, M; Rossi, S; Strippoli, A | 1 |
| Bennouna, J; Chand, VK; Chen, YM; Chouaid, C; De Marinis, F; Feng, JF; Grossi, F; Kim, DW; Kim, JH; Liu, X; Lu, S; Park, K; Planchard, D; Schuler, M; Strausz, J; Vinnyk, Y; Wang, B; Wiewrodt, R; Yang, JC; Zhou, C | 1 |
| Chen, KL; Cho, YT; Chu, CY; Lin, CC; Sheen, YS; Tsai, HE; Yang, CW | 1 |
| Bae, SY; Hong, JY; Jung, C; Kang, JI; Lee, HJ; Lee, SK; Park, HJ | 1 |
| Ahn, JS; Ahn, MJ; Bae, YH; Jung, KS; Kim, HS; Koh, J; Ku, BM; Lee, JY; Lee, SH; Lim, SH; Park, K; Song, HN; Sun, JM; Yoo, KH | 1 |
| Liu, YH; Zhu, WL | 1 |
| Li, X; Lv, J; Nong, J; Qin, N; Wang, J; Wu, Y; Yang, X; Zhang, H; Zhang, Q; Zhang, S; Zhang, X | 1 |
| Brower, V | 1 |
| Mitsudomi, T; Mizuuchi, H; Murakami, I; Nishio, K; Sakai, K; Sato, K; Suda, K; Tomizawa, K | 1 |
| Chen, X; Ding, L; Jin, L; Liang, GK; Wu, HH; Yao, ZT; Zhang, JQ | 1 |
| Iwakami, S; Katsura, Y; Kido, K; Ko, R; Namba, Y; Sasaki, S; Shukuya, T; Takahashi, K; Tominaga, S; Yoshioka, Y | 1 |
| Deng, Y; Feng, W; Liang, J; Wu, J; Xian, H; Yang, S; Zhang, H | 1 |
| Gao, B; Li, GH; Shao, GG; Yang, B; Yang, ZG | 1 |
| Chonan, M; Narita, N; Tominaga, T | 1 |
| Ahn, MJ; Kim, SW; Lin, CC; Mok, T; Orlando, M; Park, K; Puri, T; Srimuninnimit, V; Tsai, CM; Wang, X; Yang, JC | 1 |
| Dong, X; Li, K; Li, Q; Li, Z; Liu, L; Meng, R; Wu, G; Zhang, S; Zhou, F; Zhou, Y | 1 |
| Jia, L; Li, S; Li, W; Li, Y; Niu, M; Wang, T; Xu, S; Yang, Z; Zhang, S | 1 |
| Hasegawa, T; Hirai, S; Kojima, T; Niki, T; Nishikiori, H; Sakuma, Y; Takahashi, H; Watanabe, A; Yamada, G; Yamaguchi, M | 1 |
| Kang, HH; Kim, IK; Lee, HI; Lee, HY; Lee, SH; Mo, JY; Moon, HS; Yeo, CD | 1 |
| Dong, JY; Li, YL; Lin, NM; Mao, SY; Pan, JP; Pan, YN; Sun, J; Wu, WJ; Zhang, C; Zhang, DY; Zhao, YM | 1 |
| Chen, Z; Wu, JH; Zhang, X; Zhao, J | 1 |
| Altun, B; Cintosun, U; Tasci, I | 1 |
| Arrieta, O; Baracos, V; de la Torre-Vallejo, M; Turcott, J | 1 |
| Dahlberg, SE; Digumarthy, SR; Fulton, LE; Hatabu, H; Johnson, BE; Nishino, M; Sequist, LV | 1 |
| Asai, K; Hirata, K; Isa, S; Kawaguchi, T; Kimura, T; Kubo, A; Kudoh, S; Matsuura, K; Mitsuoka, S; Nakai, T; Oka, T; Sawa, K; Suzumura, T; Tanaka, H; Uji, M; Watanabe, T; Yoshimoto, N; Yoshimura, N | 1 |
| Chiba, M; Gemma, A; Kubota, K; Matsumoto, M; Miyanaga, A; Nishijima, N; Noro, R; Seike, M; Soeno, C; Sugano, T | 1 |
| Chang, BC; Hong, GR; Shim, CY; Shim, HS; Song, S | 1 |
| Bao, H; Li, H; Wang, Q; Zhang, H; Zhuang, Y | 1 |
| Atobe, O; Fujimori, A; Hachiya, T; Ikuyama, Y; Imai, A; Shiba, H; Sonehara, K | 1 |
| Dong, QZ; Han, Y; Jiang, GY; Liu, Y; Wang, EH; Wang, L; Wang, S | 1 |
| Hirsh, V; Massey, D; Mok, T; O'Byrne, K; Popat, S; Schuler, M; Sequist, LV; Wu, YL; Yamamoto, N; Yang, JC; Zazulina, V | 1 |
| Archibald, HL; Bardelli, A; Bhang, HE; Costa, C; Crystal, AS; Damon, LJ; Engelman, JA; Faber, AC; Getz, G; Gomez-Caraballo, M; Hata, AN; Hu, H; Iafrate, AJ; Ji, F; Kalsy, A; Keating, CL; Krishnamurthy Radhakrishna, V; Lee, D; Lockerman, E; Maruvka, YE; Mulvey, HE; Niederst, MJ; Piotrowska, Z; Raoof, S; Ruddy, DA; Sadreyev, RI; Sequist, LV; Siddiqui, FM; Siravegna, G; Stegmeier, F | 1 |
| Ge, Y; Han, X; Huang, S; Jin, Y; Li, Y; Liu, K; Ma, X; Song, Z; Wang, C; Yu, H; Zhen, Y; Zhou, Y | 1 |
| Ni, J; Zhang, L | 1 |
| Chiba, M; Kobayashi, Y; Mitsudomi, T; Mizuuchi, H; Murakami, I; Nishio, K; Sakai, K; Sato, K; Sekido, Y; Sesumi, Y; Shimoji, M; Suda, K; Takemoto, T; Tomizawa, K | 1 |
| Du, LW; Feng, JG; Jiang, H; Li, JH; Ma, SL; Song, SC; Zhao, PJ; Zhou, GH; Zhu, XH | 1 |
| Chou, SH; Han, DX; Hu, P; Ruan, RS; Tzeng, CM; Zheng, LM | 1 |
| Groen, HJ; Hiltermann, TJ; Kok, K; Saber, A; van den Berg, A; van der Wekken, AJ | 1 |
| Chang, YL; Liu, YN; Shih, JY; Tsai, MF; Wen, YF; Wu, SG; Yang, JC; Yang, PC; Yu, CJ | 1 |
| Huo, Z; Jiang, SY; Wang, MZ; Xu, Y; Zhang, J; Zhao, J; Zhong, W | 1 |
| Jang, JY; Jeon, YK; Keam, B; Kim, CW; Kim, TM; Kim, YG; Nam, SJ | 1 |
| Chan, LW; Cho, WC; Meng, F; Sin, TK; Siu, PM; Wang, F; Wong, SC; Yung, BY | 1 |
| Syed, YY | 1 |
| Fujita, K; Hirose, T; Ishida, H; Kusumoto, S; Murata, Y; Nakashima, M; Ohmori, T; Oki, Y; Okuda, K; Sasaki, Y; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Dong, XR; Li, K; Li, QW; Li, ZY; Liu, L; Ma, H; Meng, R; Wu, G; Zhang, S; Zhou, FZ; Zhou, Y | 1 |
| Seton-Rogers, S | 1 |
| Choy, TS; Kwong, DL; Lam, KO; Lam, PM; Lee, VH; Leung, DK; Leung, TW | 1 |
| Bogdanowicz, BS; Hartranft, ME; Hoch, MA | 1 |
| Chen, L; Li, Q; Peng, S; Wang, R; Wang, W; Yang, H | 1 |
| Ke, EE; Wu, YL | 1 |
| Booth, L; Chen, J; Dent, P; Leon, D; McGuire, WP; Poklepovic, A; Roberts, JL; Tavallai, M; Webb, T | 1 |
| Addeo, A | 1 |
| An, SJ; Bai, XY; Chen, ZH; Gou, LY; Su, J; Wu, YL; Xie, Z; Yang, SQ; Zhang, XC | 1 |
| Goto, K; Matsumoto, S; Niho, S; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Zenke, Y | 1 |
| Hong, D; Liang, X; Zhang, G; Zhang, X | 1 |
| Lee, VH; Ma, L; Wang, DD; Yan, H; Zhu, G; Zou, B | 1 |
| Costa, DB; Freed, JA; Huberman, MS; Jorge, SE; Kobayashi, SS; Moran, JP; Zerillo, JA | 1 |
| Fukuoka, M; Imamura, F; Inoue, A; Morita, S; Muto, S; Nakagawa, K; Okamoto, I; Seto, T; Yamamoto, N; Yoshida, K | 1 |
| Blumenthal, GM; He, K; Kazandjian, D; Keegan, P; Pazdur, R; Yuan, W | 1 |
| Hanawa, T; Hyuga, M; Hyuga, S; Itoh, K; Nishimura, Y; Takiguchi, S | 1 |
| Ebata, T; Ishiwata, T; Iwama, A; Iwasawa, S; Koide, S; Kurimoto, R; Sekine, I; Tada, Y; Takiguchi, Y; Tatsumi, K | 1 |
| Ahn, JS; Ahn, MJ; Lee, HY; Lee, JH; Lee, KS; Park, K; Sun, JM | 1 |
| Du, H; Guo, L; He, L; Huang, H; Jiang, J; Li, M; Li, Y; Luan, M; Ma, C; Qin, S; Ruan, Y; Shen, L; Zhang, X | 1 |
| Adamo, V; Alù, M; Bazan, V; Blasi, L; Bronte, G; Celesia, C; De Tursi, M; Franchina, T; Gambale, E; Laudani, A; Natoli, C; Passiglia, F; Picone, A; Rizzo, S; Russo, A; Savio, G; Sortino, G | 1 |
| Watanabe, A | 1 |
| Hashimoto, M; Hidayat, M; Kobayashi, I; Moriyama, H; Moriyama, M; Murakami, A; Nara, T; Nurwidya, F; Sasaki, S; Shimada, N; Suina, K; Tajima, K; Takahashi, F; Takahashi, K; Yagishita, S; Yoshioka, Y | 1 |
| Chen, C; Lian, ZZ; Sun, YF | 1 |
| Alfieri, R; Ardizzoni, A; Barocelli, E; Bonelli, M; Cavazzoni, A; Cretella, D; Falco, A; Fumarola, C; Galetti, M; Gervasi, A; La Monica, S; Lagrasta, CA; Madeddu, D; Naldi, N; Petronini, PG; Quaini, F; Tiseo, M; Vivo, V | 1 |
| Huo, LM; Sun, HT; Tian, JH; Xu, JG; Yang, G; Yang, KH; Zhang, P; Zheng, MH | 1 |
| Heo, DS; Keam, B; Kim, DW; Kim, TM; Kim, YW; Lee, SH; Park, S; Suh, B | 1 |
| Daga, H; Fujimoto, D; Goto, I; Ikeda, N; Imamura, F; Iwamoto, Y; Kaji, R; Kanehara, M; Katakami, N; Morita, S; Murakami, H; Nakagawa, K; Nakanishi, Y; Negoro, S; Nogami, N; Oguri, T; Saka, H; Satouchi, M; Seto, T; Sugawara, S; Urata, Y; Yoshioka, H | 1 |
| Cheng, L; Fan, LL; Gao, J; Li, XQ; Liu, JT; Liu, Y; Sun, GP; Wang, F; Wang, H; Wei, W; Yu, HQ | 1 |
| Bessho, A; Fujii, M; Gemba, K; Harita, S; Hotta, K; Inoue, K; Kiura, K; Kozuki, T; Kudo, K; Kuyama, S; Nogami, N; Oda, N; Okada, T; Takigawa, N; Tanimoto, M | 1 |
| Carbonnaux, M; Couraud, S; Meert, AP; Peters, M; Scherpereel, A; Souquet, PJ | 1 |
| Arrieta, O; Astudillo-de la Vega, H; Caballe-Perez, E; Cruz-Rico, G; Macedo-Pérez, EO; Martinez-Alvarez, I; Martínez-Hernández, JN; Ramírez-Tirado, LA; Soca-Chafre, G; Soto-Perez-de-Celis, E | 1 |
| Bowen, JM; Gibson, RJ; Van Sebille, YZ; Wardill, HR | 1 |
| Sakiyama, S; Takizawa, H; Tangoku, A; Toba, H | 1 |
| Brueckl, WM; Debus, D; Doesch, J; Ficker, JH; Meyer, C; Papadopoulos, T; Schultz, ES | 1 |
| Chiba, R; Maeyama, K; Moriguchi, S; Morikawa, N; Nakamura, Y; Nitanai, H; Ogasawara, M; Ohta, M; Saito, H; Sugai, T; Takaoka, Y; Tanita, T; Yamauchi, K | 1 |
| Contreras-Díaz, M; López-Herrero, F; Martínez-Bernal, G; Medina-Tapia, A; Molina-Socola, FE; Rueda-Rueda, T; Sánchez-Vicente, JL | 1 |
| Dandekar, G; Dandekar, T; Göttlich, C; Kunz, M; Müller, LC; Nietzer, SL; Schmitt, F; Walles, H; Walles, T | 1 |
| Cai, F; Cao, W; Duan, C; Fan, C; He, Z; Huang, Q; Liu, Y; Wang, J; Wang, X; Xiao, X; Zhang, L | 1 |
| Chen, L; Huang, M; Li, J; Ma, Y; Wang, X; Xin, S; Yang, Y; Zhang, L; Zhang, Y; Zhao, H; Zhao, Y; Zhu, C; Zhu, X; Zhuang, W | 1 |
| Chang, YW; Chen, FC; Cheng, CC; Chiu, CF; Hsu, MK; Kuo, KT; Kuo, TC; Lee, KY; Liu, CY; Ma, JT; Shen, YS; Su, JL; Yu, YH | 1 |
| Mitsudomi, T; Mizuuchi, H; Nishio, K; Sakai, K; Sato, K; Shimizu, S; Suda, K; Takemoto, T; Tomizawa, K | 1 |
| Feng, C; Guo, F; Huang, C; Li, X; Liu, X; Qin, Q; Wang, Y | 1 |
| Jiang, X; Wang, W; Zhang, Y | 1 |
| Ahn, JS; Ahn, MJ; Cho, BC; Cho, EK; Jeong, HC; Kim, EK; Kim, HR; Kim, JH; Lee, JH; Lim, SM; Min, YJ; Park, K | 1 |
| Buiting, HM; de Kanter, W; Linn, SC; Smorenburg, CH | 1 |
| Fei, Z; Jiang, H; Li, J; Xu, J; Zhu, X | 1 |
| An, C; Chu, H; Gu, C; Lu, R; Shi, H; Xiao, F; Yi, X; Zhang, H; Zhang, J; Zhu, F | 1 |
| Conte, P; Fassan, M; Frega, S; Pasello, G; Polo, V | 1 |
| Ding, L; Ding, Z; He, J; Hou, M; Huang, M; Li, L; Liang, M; Liu, Y; Lu, Y; Ren, L; Tan, F; Xiang, J; Xiong, W; Yu, Q; Zhou, L; Zhou, X; Zhu, J | 1 |
| Choi, YL; Han, J; I, H; Kim, J; Kim, RN; Kim, YD; Kim, YJ; Lee, CH; Lee, MK; Lee, MS; Lira, ME; Mao, M; Noh, KW; Oh, DY; Song, JY; Yang, JW | 1 |
| Au-Yeung, SC; Fei, R; Lam, AS; Poon, DC; To, KK; Wei, Y | 1 |
| Ikegami, D; Kuzumaki, N; Narita, M | 1 |
| Huang, HY; Ji, H; Wang, Y; Yang, L; Zhang, Z | 1 |
| Asano, M; Ito, H; Kobayashi, H; Miura, M; Niioka, T; Okuda, Y; Sato, K; Takeda, M | 1 |
| Chang, N; Duan, Q; Liu, W; Pang, C; Zhang, J | 1 |
| Cho, E; Han, H; Han, JY; Jung, J; Kim, HY; Kim, SW; Lee, GK; Lee, JS; Lee, KH; Lee, SH; Lee, Y; Min, YJ; Nam, BH | 1 |
| Barone, C; Cassano, A; D'Argento, E; Dadduzio, V; Di Noia, V; Rossi, S; Schinzari, G | 1 |
| Hattori, Y; Honda, Y; Katsura, S; Manabe, T; Miyachi, Y; Otsuka, A; Terashima, T | 1 |
| Hsiue, EH; Lee, JH; Lin, CC; Yang, JC | 2 |
| Gong, J; Hu, P; Sun, S; Tang, F; Wang, Y; Wang, Z; Xie, C | 1 |
| Bates, V; Boland, A; Dundar, Y; Dwan, K; Green, JA; Greenhalgh, J; Jain, P; Vecchio, F | 1 |
| Hu, L; Li, Z; Liu, P; Pan, Z; Qin, X; Yang, L; Zeng, C | 1 |
| Choi, YS; Kong, SH; Seong, JY; Suh, HS | 1 |
| David, JM; Dominguez, C; Fernando, RI; Hamilton, DH; McCampbell, KK; Palena, C | 1 |
| Han, W; Jiang, L; Jing, J; Jing, Z; Pan, H; Shou, J; Sui, X; Xie, J; Yao, J; You, L | 1 |
| Arai, J; Matsumoto, K; Miyazaki, T; Mochinaga, K; Nagasaki, T; Nagayasu, T; Nanashima, A; Tominaga, T; Tsuchiya, T; Tsukamoto, K; Yamasaki, N | 1 |
| Choi, YR; Kim, KY; Lee, Y; Shin, DH | 1 |
| Cai, XW; Chang, JH; Fu, XL; Huang, QL; Liu, Q; Liu, ZB; Lu, YN; Pan, SY; Wang, JL; Wu, XH; Zhao, XM | 1 |
| Jia, L; Li, S; Li, W; Li, Y; Wang, S; Wang, T; Xu, S; Yang, Z; Zhang, S | 1 |
| Fujita, M; Hirano, R; Hirota, T; Kubo, A; Matsumoto, T; Nabeshima, K; Uchino, J; Watanabe, K; Yamaguchi, E; Yokoi, T | 1 |
| Chin, TM; Lee, JZ; Leow, YN; Lim, B; Lim, EH; Lim, EK; Lim, PX; Lim, WT; Lunny, DP; Malusay, SR; Nga, ME; Pang, YH; Shyh-Chang, N; Soo, RA; Sun, LL; Tai, BC; Tam, WL; Tan, BJ; Tan, DS; Tan, EH; Yang, H; Zhang, WC | 1 |
| Fukuda, M; Ikeda, T; Ikegami, Y; Izumikawa, K; Mizoguchi, K; Motoshima, K; Mukae, H; Nakamura, Y; Nakatomi, K; Ogawara, D; Sano, K; Sato, S; Senju, H; Sugasaki, N; Takemoto, S; Yamaguchi, H | 1 |
| Bai, C; Chen, G; Ding, C; Feng, J; Gu, A; Han, B; He, J; Hu, X; Huang, C; Jian, H; Jiao, S; Li, F; Ling, Y; Liu, X; Luo, H; Luo, R; Pang, Q; Shi, Y; Shu, Y; Sun, Y; Wang, C; Wang, Z; Wu, M; Yang, Y; Zhang, S; Zhang, Y; Zhao, H; Zhao, Q; Zhou, C | 1 |
| Chabre, O; Dupuis, C; Durand, C; Piolat, C; Plantaz, D; Segura, D | 1 |
| Chen, TC; Huang, HS; Lee, H; Wu, DW | 1 |
| Batliner, J; Fey, MF; Gautschi, O; Gugger, M; Rothschild, SI; Tschan, MP | 1 |
| Silakari, O; Singh, H; Singh, PK | 1 |
| Addeo, A; Di Maio, M | 1 |
| Hu, C; Ma, JA; Wu, F; Zhang, H; Zhang, Y | 1 |
| Barone, C; Calegari, MA; Orlandi, A | 1 |
| Agarwal, R; Mohan, V; Singh, RP | 1 |
| Dong, L; Guo, L; Li, L; Li, W; Li, Z; Lin, D; Ling, Y; Qiu, T; Yang, L; Yang, X; Ying, J | 1 |
| Choi, JW; Hua, TN; Jeong, Y; Kim, HW; Kim, KW; Kim, MK; Phan, AN; Rho, JK; Vo, VT | 1 |
| Amann, A; Gamerith, G; Huber, JM; Kelm, JM; Koeck, S; Lorenz, E; Obexer, P; Zwierzina, H | 1 |
| López-Brea, M | 1 |
| Álvarez-Fernández, C; Esteban-González, E | 1 |
| Diz Taín, P; García-Palomo, A; González, AL | 1 |
| Vidal, ÓJ | 1 |
| Alejandro, MÁ; Artal Cortés, Á; Gimeno Pelegrín, J | 1 |
| Cobo, M; Godoy, A; Gutiérrez, V; López, O; Rodelo, L; Ruiz, M | 1 |
| Taus, Á | 1 |
| Hai, P; Wang, YY; Xia, B; Zhang, CY; Zhao, R; Zhe, H; Zhou, S | 1 |
| Karachaliou, N; Rosell, R | 1 |
| Ballard, P; Box, M; Cantarini, M; Cross, D; Grist, M; Hickey, M; Jänne, PA; Johnström, P; Jordan, A; Kim, DW; Malmquist, J; Pickup, K; Thress, KS; Varnäs, K; Yang, JC; Yang, Z; Yates, JW | 1 |
| Burghuber, OC; Hochmair, M; Holzer, S | 1 |
| Huang, G; Jia, W; Li, J; Liu, J; Liu, L; Miao, P; Song, S; Sun, X; Yan, H; Yang, H; Zhao, L; Zhao, X; Zhou, X | 1 |
| Chang, GC; Close, S; Garrus, JE; Geater, SL; Han, M; Komarnitsky, P; Mok, TS; Park, K; Payumo, F; Su, WC; Tan, EH; Yang, JC | 1 |
| Creighton, CJ; Deng, B; Gibbons, DL; Guo, L; Lu, Q; Molina, JR; Sun, Z; Yang, P; Yang, Y; Yi, ES; Zhang, T | 1 |
| Huang, XX; Mao, SS; Wu, JS; Xiong, J; Yu, XN | 1 |
| Fukuhara, T; Maemondo, M; Morita, M; Nukiwa, T; Suzuki, A; Tanaka, N; Terasaki, H; Tsukita, Y; Watanabe, K | 1 |
| Lin, L; Qi, J; Ren, L; Wang, Y; Wen, L | 1 |
| Li, Y; Liu, W; Luo, E; Tian, L; Wang, Y; Wen, L; Wen, M; Wen, N; Yang, H; Yun, Y; Zhang, W; Zhao, L; Zhu, X | 1 |
| He, X; Hong, S; Huang, Y; Ma, Y; Sheng, J; Yang, Y; Zhang, J; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H; Zhou, T | 1 |
| Maeda, A; Nakata, M; Okita, R; Saisho, S; Shimizu, K; Yukawa, T | 1 |
| Bunn, PA; Chan, DC; Gao, D; Helfrich, BA; Kim, J; Tan, AC; Zhang, Z | 1 |
| Coghi, PS; Fan, XX; Law, BY; Leung, CH; Leung, EL; Liu, L; Ma, DL; Mok, SW; Wong, VK; Xu, SW; Zeng, W | 1 |
| Buck, A; Bundschuh, R; Dandekar, G; Fecher, D; Hofmann, E; Lückerath, K; Nietzer, S; Steinke, M; Walles, H; Walles, T | 1 |
| Harada, D; Harita, S; Hotta, K; Ichihara, E; Ichikawa, H; Inoue, K; Inoue, M; Kishino, D; Kiura, K; Kubo, T; Kuyama, S; Minami, D; Murakami, T; Ninomiya, K; Ninomiya, T; Oda, N; Shibayama, T; Takigawa, N; Tanimoto, M; Yokoyama, T | 1 |
| Cheng, Y; Enatsu, S; He, J; Kang, JH; Kim, JH; Murakami, H; Nakagawa, K; Orlando, M; Puri, T; Wang, X; Yang, JC; Yang, PC | 1 |
| He, J; Ma, J; Tan, W; Tang, X | 1 |
| Dietel, M; Eberhardt, W; Griesinger, F; Radke, S; Schirmacher, P; Schuette, W; Thomas, M; Zirrgiebel, U | 1 |
| Fan, S; Wang, W; Zang, H | 1 |
| Jin, Y; Lou, G; Shao, Y; Shi, X; Tong, X; Wu, X; Yu, X; Zhang, Y | 1 |
| Ichihara, E; Kiura, K; Kubo, T; Ohashi, K; Osawa, M; Takata, M; Takata, S; Takigawa, N; Tanimoto, M | 1 |
| Hayashi, H; Kudo, K; Nakagawa, K; Takeda, M; Ueda, H | 1 |
| Campo, M; Engelman, JA; Fidias, P; Gainor, JF; Gerber, D; Heist, RS; Muzikansky, A; Sequist, LV; Shaw, AT; Temel, JS | 1 |
| Goto, K; Kirita, K; Matsumoto, S; Niho, S; Ohmatsu, H; Sugiyama, E; Umemura, S; Yoh, K; Zenke, Y | 1 |
| Bidoli, P; Buosi, R; Burgio, MA; Cappuzzo, F; Cerea, G; Chiari, R; Cortinovis, D; De Marinis, F; Del Conte, A; Ferrari, S; Finocchiaro, G; Foltran, L; Giannetta, L; Mazzoni, F; Migliorino, MR; Montanino, A; Morabito, A; Normanno, N; Tiseo, M | 1 |
| Chang, CL; Chang, YW; Chen, SY; Chen, TH; Lin, SB | 1 |
| Baba, T; Futaki, M; Iwasawa, T; Kato, T; Ogura, T; Sakuranaka, H; Sekine, A; Suido, A | 1 |
| Guarino, M; Hanna, N; Jayaram, N; Masters, GA; Misleh, J; Patel, JD; Sanborn, RE; Stephens, A; Wu, J | 1 |
| Kowalski, DM; Krzakowski, M; Piórek, A; Szmit, S; Zaborowska-Szmit, M | 1 |
| Hotta, K; Ichihara, E; Kato, Y; Kiura, K; Kubo, T; Kudo, K; Minami, D; Ninomiya, K; Ninomiya, T; Oda, N; Ohashi, K; Sato, A; Tabata, M; Takigawa, N; Tanimoto, M; Yoshioka, H | 1 |
| Du, Z; Tang, X; Yang, M; Zhou, Y; Zhuang, J | 1 |
| Demuth, C; Meldgaard, P; Sorensen, BS; Sorensen, SF; Weber, B | 1 |
| Dickgreber, N; Feng, J; Geater, SL; Hirsh, V; Hu, CP; Huang, Y; Lu, S; Märten, A; Massey, D; Mok, T; O'Byrne, K; Okamoto, I; Schuler, M; Sebastian, M; Sequist, LV; Shah, R; Wind, S; Wu, YL; Yamamoto, N; Yang, JC; Zhou, C | 1 |
| Dietel, M; Eberhardt, WE; Radke, S; Schirmacher, P; Schuette, W; Thomas, M; Waller, C; Zirrgiebel, U | 1 |
| Arata, S; Hirose, T; Ishida, H; Kishino, Y; Kusumoto, S; Murata, Y; Ohba, M; Ohmori, T; Ohnishi, T; Sasaki, Y; Shirai, T; Yamaoka, T | 1 |
| Chen, DQ; Ding, J; Geng, MY; Liu, HC; Shen, AJ; Shen, JK; Sun, JY; Wang, X; Wang, YQ; Xiong, B; Zhang, MM; Zheng, M | 1 |
| Chen, HJ; Chen, ZH; Su, J; Tu, HY; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Arrieta, O; Barron, F; Cardona, AF; de la Torre-Vallejo, M; Luna-Palencia, RL | 1 |
| Dowlati, A; Fu, P; Pennell, NA; Sharma, N; Yi, Q | 1 |
| Aerts, HJ; Grossmann, P; Oxnard, GR; Rizvi, N; Schwartz, LH; Tan, Y; Zhao, B | 1 |
| Fukuoka, M; Hohjoh, H; Takahashi, M; Yoshioka, K | 1 |
| Chang, YH; Chien, KH; Hsu, CR; Tai, MC | 1 |
| Nakamura, H; Nishimura, T | 1 |
| Feng, X; Jiang, J; Wu, Y; Yang, Y; Zhou, W | 1 |
| Arai, D; Betsuyaku, T; Hamamoto, J; Hayashi, Y; Hirano, T; Ishioka, K; Kawada, I; Miyawaki, M; Naoki, K; Nukaga, S; Ohgino, K; Soejima, K; Tani, T; Yasuda, H | 1 |
| Aleksakhina, SN; Chubenko, VA; Imyanitov, EN; Ivantsov, AO; Iyevleva, AG; Kozyreva, KS; Kramchaninov, MM; Mitiushkina, NV; Moiseyenko, FV; Moiseyenko, VM; Preobrazhenskaya, EV; Shelekhova, KV; Venina, AR; Volkov, NM; Zhuravlev, AS | 1 |
| Cai, H; Miao, L; Qian, D; Tian, Y; Wang, Y; Yang, J; Yang, Z; Zhang, Z | 1 |
| Kataoka, K; Okamura, Y; Osaka, E; Shimizu, T; Tokuhashi, Y; Yoshida, Y | 1 |
| Du, Y; Liu, H; Ma, T; Pan, Y; Shen, Y; Zhu, Y | 1 |
| Chen, Z; Jiang, B; Su, J; Wu, YL; Xu, C; Yan, H; Yang, J; Zhang, Q; Zhang, X; Zhou, Q | 1 |
| Hosomi, Y; Kashima, J; Miwa, M; Okuma, Y | 1 |
| Adam, J; Artignan, X; Bardet, E; Lacas, B; Lacroix, L; Le Péchoux, C; Levy, A; Pignon, JP; Verrelle, P | 1 |
| Hu, M; Qian, K; Wang, R; Yao, S; Zhang, Y; Zhi, X | 1 |
| Bi, M; Chen, W; Ding, F; Tang, C; Tang, DJ; Wang, J; Yu, H | 1 |
| Chen, M; Gu, Y; Sun, Y; Wang, M; Xu, Y; Yang, Z; Ye, X; Zhao, J; Zhong, W; Zhu, G | 1 |
| Jeong, JH; Kwon, TK; Oh, YJ; Seo, YH | 1 |
| Chen, J; Ding, L; Hu, X; Liu, J; Shentu, J; Tan, F; Wang, Y; Wu, G; Wu, L; Xu, W; Zhou, H; Zhu, M | 1 |
| Banno, E; Hayashi, H; Kaneda, H; Nakagawa, K; Nishio, K; Sakai, K; Takeda, M; Tanizaki, J; Togashi, Y | 1 |
| Doki, Y; Fukuoka, J; Hori, T; Isobe, M; Kurose, K; Nakayama, E; Nishio, Y; Nozawa, R; Ohue, Y; Oka, M; Tanaka, T | 1 |
| Wu, YL; Xu, CR; Yang, JJ; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Ahn, JS; Ahn, MJ; Choi, YL; Heo, DS; Jeon, YK; Keam, B; Kim, DW; Kim, TM; Lee, JK; Lee, SH; Min, HS; Park, K; Sun, JM | 1 |
| Chai, Y; Zhu, Z | 1 |
| Han, B; Jin, B; Lou, Y; Wang, H; Wu, D; Xu, J; Yang, H; Zhang, X; Zhang, Y; Zhong, H | 1 |
| Li, B; Lin, D; Wan, Y; Yao, Z | 1 |
| Chai, Y; Yu, T; Zhu, Z | 1 |
| Ahn, MJ; Cho, BC; Jang, JS; Jung, I; Kim, DW; Kim, HR; Kim, JH; Kim, SW; Lee, DH; Lee, KH; Sun, JM | 1 |
| Chen, J; Li, Y; Liu, H; Liu, M; Wang, Y; Xu, S; Zhang, H | 1 |
| Goto, K; Ishii, G; Kohno, T; Matsumoto, S; Murakami, H; Nishio, M; Nogami, N; Nomura, S; Ohe, Y; Ohtsu, A; Sato, A; Satouchi, M; Seto, T; Tsuchihara, K; Tsuta, K; Yamamoto, N; Yoh, K | 1 |
| Hong, SE; Jang, YS; Jeong, W; Jo, YJ; Kim, H; Kim, J; Lee, GR; Lee, HI; Lee, HJ; Lee, J; Lee, JS; Oh, SH | 1 |
| Bonetti, A; Giuliani, J; Remo, A | 1 |
| Cheng, YD; Chung, JG; Hsia, TC; Hsiao, YT; Huang, AC; Kuo, CL; Lin, TS; Ma, YS; Peng, SF; Yang, MD | 1 |
| Chang, HY; Chang, YL; Chao, MW; Cheng, CC; Cheng, HC; Hsu, CC; Hsu, JT; Lin, SI; Liu, SJ; Liu, TW; Pan, SL; Tsai, HJ; Tseng, CP; Wang, HY | 1 |
| Fang, S; Han, X; Tang, N; Wang, Z; Zhang, Q | 1 |
| Chang, JC; Iqbal, A; Jakubowski, CD; Paik, PK; Plodkowski, AJ; Rekhtman, N; Yu, HA | 1 |
| Chow, LW; Fan, XX; Jiang, ZB; Leung, EL; Li, X; Liu, L; Loo, WT; Yao, XJ | 1 |
| Chen, G; Gao, Y; Huang, C; Lu, Z; Shi, L; Song, Z; Wang, B; Wang, Y; Xu, D; Zhang, H; Zhang, W; Zhang, Y; Zhuang, N | 1 |
| Chang, H; Kim, HS; Kim, JW; Lee, JS; Moon, SU; Sung, JH | 1 |
| Agatsuma, T; Gomi, D; Hachiya, T; Hanaoka, M; Koizumi, T; Koyama, S; Kuraishi, H; Miyahara, T; Ono, Y; Suzuki, T; Tateishi, K; Wada, Y; Yamamoto, R; Yoshiike, F | 1 |
| Fujii, S; Kashiwabara, K; Semba, H; Tsumura, S | 2 |
| Biaoxue, R; Hua, L; Shuanying, Y; Wenlong, G | 1 |
| Brückl, W; Huber, RM; Tufman, A | 1 |
| Asao, T; Hayashi, H; Iihara, H; Imai, H; Itoh, Y; Kaira, K; Kita, Y; Minato, K; Mizusaki, N; Naruse, I; Sugiyama, T; Yamada, M | 1 |
| Ali, SM; Bocharov, EV; Campregher, PV; Chung, J; Gitlitz, BJ; Haddad, CK; Johnson, M; Klempner, SJ; Miller, VA; Ou, SI; Ross, JS; Schrock, AB; Steinecker, G; Stephens, PJ; Suh, JH; Velcheti, V | 1 |
| Han, XC; Li, Y; Ma, XW; Xin, QZ | 1 |
| Asmat, A; Kumarakulasinghe, NB; Loy, EY; Pang, B; Soo, RA; Soon, YY; Syn, N; Zheng, H | 1 |
| Ang, MK; Chowbay, B; Jain, A; Kanesvaran, R; Lim, WT; Ng, QS; Sutiman, N; Tan, EH; Tan, SW; Tan, WL; Toh, CK | 1 |
| Pakkala, S; Ramalingam, SS | 2 |
| Azuma, K; Chiba, M; Kim, YH; Kobayashi, Y; Mitsudomi, T; Nagai, H; Nishio, K; Sato, K; Sesumi, Y; Shimoji, M; Takemoto, T; Togashi, Y; Tomizawa, K | 1 |
| Hong, ST; Lin, AM; Lin, KH; Lo, YL; Wang, HT; Yang, JC | 1 |
| Cao, XN; Deng, Y; Hu, FY; Hu, JB; Lai, SY; Ma, J; Xu, QZ | 1 |
| Ahn, MJ; Bai, Y; Chen, K; Cheng, Z; Guo, Q; Kim, DW; Rabbie, S; Wang, Y; Xu, Y; Yang, JC; Yang, Z; Yin, X; Zhang, L; Zhang, X | 1 |
| An, N; Cai, J; Li, Q; Li, Z; Niu, H; Zhang, Y; Zhao, Q | 1 |
| Adamo, V; Franchina, T; Ricciardi, GRR; Russo, A | 1 |
| Cai, W; Cao, TH; Chen, C; Li, Y; Lu, HL; Ning, ZQ; Shen, H; Shu, YQ; Wang, L; Zhu, J | 1 |
| Chen, Z; Deng, W; Ke, E; Niu, F; Su, J; Wu, Y; Xu, C; Yan, H; Yang, J; Zhang, Q; Zhang, X; Zhao, N; Zhou, Q | 1 |
| Song, Z; Wang, W; Zhang, Y | 1 |
| Hayama, M; Hirashima, T; Morishita, N; Nishida, T; Nishihara, T; Okamoto, N; Shiroyama, T; Suzuki, H; Tamiya, M; Tanaka, A | 1 |
| Feng, J; Gibson, N; Hirsh, V; Hou, M; Hu, CP; Huang, Y; Kim, M; Li, W; Lu, S; Massey, D; Mok, T; O'Byrne, K; Schuler, M; Sequist, LV; Wu, YL; Yamamoto, N; Yang, JC | 1 |
| Bray, V; Ding, PN; Gebski, V; Gralla, RJ; Lee, CK; Links, M; Lord, SJ; Yang, JC | 1 |
| Diebold, J; Froesch, P; Früh, M; Gautschi, O; Jochum, W; Klingbiel, D; Mark, M; Reichegger, H; Rothschild, S; Schmid, S | 1 |
| Bandoh, S; Chiba, Y; Ishii, T; Kadowaki, N; Kanaji, N; Kita, N; Sato, A; Tadokoro, A; Ueno, M; Watanabe, N | 1 |
| Bertolini, F; Bettelli, S; Longo, L; Manfredini, S; Mengoli, MC; Rossi, G | 1 |
| Bashir, ES; Chan, CY; Kwan, AK; Mun Keong, K | 1 |
| Ding, L; Fu, J; Lu, S; Tan, F; Wu, B; Ye, M | 1 |
| Han, L; He, J; Huang, Z; Li, W; Ma, P; Nie, F; Zhang, M | 1 |
| Bai, JP; Chen, X; Li, Y; Liu, LR; Liu, YH; Qu, X; Qu, YC; Zhang, FL; Zhang, HB; Zheng, GJ; Zhu, YJ; Zhu, YZ | 1 |
| Chen, HY; He, Y; Kang, J; Li, KL; Li, L; Wang, YB; Zhang, P | 1 |
| Jänne, PA; Saxon, JA; Sholl, LM | 1 |
| Ali, SM; Allen, JM; Erlich, RL; Miller, VA; Ou, SI; Ross, JS; Schrock, AB; Stephens, PJ; Vafai, D | 1 |
| Jiang, H; Li, J; Liu, X; Xu, H; Zheng, R | 1 |
| Al-Khafaji, AS; Davies, MP; Field, JK; Gosney, JR; Koffa, M; Liloglou, T; Marcus, MW; Risk, JM; Shaw, RJ | 1 |
| Bai, XY; Chen, HJ; Jiang, BY; Su, J; Tu, HY; Wang, BC; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Hagiwara, K; Iwai, Y; Kawamura, R; Koyama, N; Koyama, S; Miwa, C; Nagai, Y; Watanabe, Y | 1 |
| Go, YJ; Han, JY; Joo, J; Lee, GK; Lee, JS; Lee, KH; Lee, SH; Lee, Y; Lim, KY | 1 |
| Abazeed, ME; Khunger, M; Velcheti, V | 1 |
| Bae, E; Ikeda, N; Kato, M; Kuroda, M; Makino, Y; Mamura, M; Miyazawa, K; Ohira, T; Yoon, JH | 1 |
| Fukui, T; Ichinoe, M; Igawa, S; Katagiri, M; Kubota, M; Masuda, N; Murakumo, Y; Nakahara, Y; Nakashima, H; Otani, S; Ryuge, S; Sasaki, J; Sato, Y; Satoh, Y | 1 |
| Assi, T; El Rassy, E; Ghosn, M; Kattan, J; Moussa, T | 1 |
| Jiang, T; Qiao, M; Ren, S; Su, C; Zhou, C; Zhou, F | 1 |
| Lee, JK; Lee, SH | 1 |
| Di Maio, M; La Salvia, A; Rossi, A | 1 |
| Acquaviva, G; Brand, T; Brandes, AA; Cavallo, G; de Biase, D; Degli Esposti, R; Di Battista, M; Genestreti, G; Pession, A; Tallini, G; Visani, M | 1 |
| Gao, QL; Li, L; Li, QJ; Liu, HM; Ma, XH; Shi, B; Tian, TD | 1 |
| Chang, CH; Lee, CH; Wang, JY | 1 |
| Chuang, JC; Das, M; Diehn, M; Huang, J; Liang, Y; Neal, JW; Stehr, H; Wakelee, HA | 1 |
| Akamatsu, H; Azuma, K; Fukuhara, T; Goto, K; Harada, D; Harada, T; Hotta, K; Iwama, E; Kishimoto, J; Kurata, T; Nakanishi, Y; Nishio, K; Nosaki, K; Ohyanagi, F; Okamoto, I; Sakai, K; Shimose, T | 1 |
| Cao, H; Fan, F; Feng, J; Hu, Y; Liu, S; Ma, R; Ni, J; Qin, X; Sha, H; Wang, Z; Wu, J; Wu, Y; Xu, X; Yan, D; Yu, S; Zang, J; Zhou, L | 1 |
| Li, P; Ma, Z; Wang, H; Yan, X; Zhang, G; Zhang, M | 1 |
| Ellison, K; Hirsch, FR; Kim, J; Mitsudomi, T; Murakami, I; Rivard, CJ; Suda, K; Yu, H | 1 |
| Chewaskulyong, B; Fukuoka, M; Haddad, V; Han, B; Ichinose, Y; Margono, B; Mok, TS; Ohe, Y; Rukazenkov, Y; Saijo, N; Sunpaweravong, P; Thongprasert, S; Wu, YL; Yang, JC; Yang, JJ; Young, H | 1 |
| Pi, C; Xu, CR; Zhang, YC; Zhou, Q | 1 |
| Song, Y; Yuan, DM | 1 |
| Choi, SY; Kim, HR; Lee, SY; Ryu, PD | 1 |
| Aiuchi, T; Arakawa, K; Hamada, Y; Igarashi, K; Ikegami, D; Iwasawa, C; Kuzumaki, N; Nagasawa, A; Narita, M; Ochiya, T; Shimura, E; Suda, Y; Takeshima, H; Ushijima, T; Yoshioka, Y | 1 |
| Ajithkumar, T; Geropantas, K; Glenn, A; Kouroupis, M; Maskell, D | 1 |
| Fraser, A | 1 |
| Chen, Y; Fuller-Pace, FV; Gong, D; Huang, L; Huang, Z; Li, K; Li, Y; Lin, P; Mo, C; Wei, Y; Zhang, J | 1 |
| Hu, Y; Jin, X; Shi, L; Su, Y; Zhang, C; Zhu, X | 1 |
| Akashi, K; Harada, T; Ijichi, K; Iwama, E; Nakanishi, Y; Obara, T; Ogata, H; Okamoto, I; Yoshimoto, G | 1 |
| Cho, BC; Doherty, JP; Garon, EB; Gernhardt, D; Giri, N; Jatoi, A; Keefe, DM; Kim, DW; Lacouture, ME; Nadanaciva, S; O'Connell, J; Sbar, E; Sonis, S; Wang, T | 1 |
| Ando, K; Arata, S; Ishida, H; Kusumoto, S; Murata, Y; Ohba, M; Ohmori, T; Ohnishi, T; Sasaki, Y; Yamaoka, T | 1 |
| Chen, YJ; Choong, WK; Hong, TM; Hsu, YL; Kuo, TC; Liao, YC; Pan, SH; Sung, TY; Tsai, CF; Wang, YT; Wu, HY; Yang, PC; Yen, HY | 1 |
| Feng, Q; Fu, X; Hackshaw, A; Mao, C; Tang, J; Yang, Z; Zhang, Y | 1 |
| Giusti, R; Iacono, D; Lauro, S; Marchetti, P; Mazzotta, M | 1 |
| Gettinger, S | 1 |
| Colantuoni, G; Del Gaizo, F; Falanga, M; Ferrara, C; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Palazzolo, G; Rossi, A | 1 |
| Bean, J; Chang, YC; Chen, KY; Cheng, AL; Hu, FC; Huang, CJ; Huang, CL; Lin, ZZ; Pao, W; Shih, JY; Shun, CT; Tsai, MC; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Enderlein, E; Gerber, PA; Homey, B | 1 |
| Yang, CH | 2 |
| Jänne, PA | 4 |
| Riely, GJ | 2 |
| Natale, RB | 4 |
| Heymach, JV; Nikolinakos, P | 1 |
| Ding, K; Florescu, M; Hasan, B; Seymour, L; Shepherd, FA | 1 |
| Li, T; Ling, YH; Perez-Soler, R | 1 |
| Balleyguier, C; Besse, B; Soria, JC; Wagner, M | 1 |
| Belli, C; Giovannini, M; Gregorc, V; Villa, E | 1 |
| Khuri, FR; Roman, J | 1 |
| Lin, R; Ling, YH; Perez-Soler, R | 1 |
| Endo, K; Fujii, Y; Iuchi, K; Kawaguchi, T; Kawahara, M; Kawano, O; Kitahara, N; Matsumura, A; Okuda, K; Sasaki, H; Takada, M; Tanaka, H; Yano, M; Yokoyama, T; Yukiue, H | 2 |
| Cheng, CM; Ciou, SC; Hong, JH; Jheng, MY; Ko, JC; Lin, YW; Ling, ST; Wang, LH | 1 |
| Ahn, JS; Ahn, MJ; Cho, JY; Choi, JH; Holmes, AJ; Jänne, PA; Kang, JH; Ki, CS; Kim, HT; Kim, SW; Lee, JS; Park, BB; Park, CK; Park, K; Park, SH; Shin, SW; Sohn, CH; Song, HS | 1 |
| Baselga, J; Cedres, S; Felip, E; Foernzler, D; Gatzemeier, U; Heller, A; Klughammer, B; Maacke, H; Möcks, J; Parera, M; Peralta, S; Reck, M; Rojo, F; Sala, G; Saura, C | 1 |
| Herder, GJ; Lind, JS; Smit, EF | 1 |
| Fujiwara, Y; Hirano, S; Kiura, K; Kondo, E; Ohashi, K; Osawa, M; Rai, K; Takata, K; Takata, M; Tanimoto, M; Yoshino, T | 1 |
| Altavilla, G; Arrigo, C; Galletti, G; Marabello, G; Picone, G; Pitini, VV; Santarpia, MC; Tomasello, C | 1 |
| Fujisaki, K; Hirakata, H; Iida, M; Inoshima, I; Katafuchi, R; Maeda, H; Masutani, K; Takayama, K; Toyonaga, J; Tsuruya, K | 1 |
| Crinò, L; Reck, M | 1 |
| Chang, YC; Chiu, YH; Gow, CH; Hsu, YC; Shih, JY; Wei, PF; Wu, JY; Wu, SG; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Endoh, H; Ishibashi, Y; Kimura, H; Kosaka, T; Kuwano, H; Mitsudomi, T; Onozato, R; Tanaka, S; Yajima, T; Yamaki, E; Yoshida, T | 1 |
| Besse, B; Osio, A; Rajpar, S | 1 |
| Fukai, M; Fushitani, K; Kimura, H; Mori, M; Naka, N; Nakagawa, M; Nakazawa, Y; Namba, Y; Niinaka, M; Okada, T; Yano, Y; Yokota, S | 1 |
| Choi, YJ; Kim, CH; Lee, JC; Lee, JK; Na, II; Rho, JK; Ryoo, BY; Yang, SH | 1 |
| Ishikawa, H; Kikuchi, N; Ohara, G; Satoh, H; Sekizawa, K | 1 |
| Braiteh, F; Johnson, FM; Kurzrock, R | 1 |
| Aoe, K; Bessho, A; Fujiwara, Y; Gemba, K; Hotta, K; Kamei, H; Kiura, K; Kuyama, S; Matsuo, K; Moritaka, T; Segawa, Y; Shibayama, T; Sugimoto, K; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Hamada, H; Hamaguchi, N; Higaki, J; Ito, R; Kadowaki, T; Miyoshi, S | 1 |
| Cutz, JC; da Cunha Santos, G; Ding, K; Kamel-Reid, S; Liu, N; Marrano, P; Sakurada, A; Seymour, L; Shepherd, FA; Squire, JA; Tsao, MS; Whitehead, M; Zhang, T; Zhu, CQ | 1 |
| Brugarolas, A; Eugenieva, E; Farré, J; Fernández Morejón, FJ; González Manzano, R; Martínez Navarro, E | 1 |
| Altavilla, G; Arrigo, C; Pitini, V | 1 |
| Kim, SW; Lee, DH; Lee, JS; Suh, C; Yi, EJ; Yoon, DH | 1 |
| Sundermeyer, M; Veeraputhiran, M | 1 |
| Butts, C; Ciardiello, F; Feld, R; Gallo, C; Gridelli, C; Perrone, F | 1 |
| Ackman, JB; Iafrate, AJ; Sequist, LV; Settleman, JE | 1 |
| Chang, JW; Chen, CM; Cheung, YC; Hsieh, JJ; Hsu, T; Huang, SF; Lin, G | 1 |
| Bafaloukos, D; Dahabreh, IJ; Kosmidis, P; Linardou, H; Manoloukos, M; Murray, S | 1 |
| Arrieta, O; Castillo-Gonzalez, P; de la Cruz Vargas, J; De la Garza, J; Flores-Estrada, D; Gonzalez, C; Gonzalez-De la Rosa, CH; Guzman, E; Hernandez-Pedro, N; Martinez-Barrera, L; Morales-Barrera, R; Rios-Trejo, MA; Téllez, E; Treviño, S | 1 |
| Chella, A; Falcone, A; Tibaldi, C; Vasile, E | 1 |
| Han, HS; Han, JY; Hwang, SW; Lim, KY | 1 |
| Chang, YL; Gow, CH; Shih, JY; Wu, JY; Wu, SG; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Kawabe, J; Ohsaki, Y; Osanai, S; Sasaki, T; Shibukawa, K; Tanno, S | 1 |
| Epstein, D; Haley, JD; Petti, F; Sujka-Kwok, I; Thomson, S | 1 |
| Bianco, R; Del Vecchio, S; Fonti, R; Iommelli, F; Lettieri, A; Papaccioli, A; Pirozzi, G; Salvatore, M; Sommella, J; Tortora, G; Zannetti, A | 1 |
| Dacic, S; Dubey, S; Eickhoff, JC; Hoang, T; Kolesar, JM; Marcotte, SM; Schiller, JH; Siegfried, JM; Stabile, LP; Traynor, AM | 1 |
| Bachariou, A; Chasapi, V; Papadopoulos, R | 1 |
| Li, JR; Li, LY; Wang, MZ; Wang, SL; Zhang, L; Zhang, XT; Zhong, W | 2 |
| Burgers, JA; Haas, RL; Kappers, I; Klomp, HM; van Pel, R; Van Zandwijk, N | 1 |
| Choong, NW; Dancey, JE; Grushko, T; Haraf, DJ; Hoffman, PC; Kozloff, M; Lester, E; Lin, S; Mauer, AM; Olopade, OI; Salgia, R; Szeto, L; Vokes, EE | 1 |
| Chansky, K; Crowley, JJ; Franklin, WA; Gandara, DR; Hesketh, PJ; Hirsch, FR; Mack, PC; Marchello, BT; Moon, J; Spreafico, A; Wozniak, AJ | 1 |
| Grünberg, K; Lagerwaard, FJ; Lind, JS; Senan, S; Smit, EF | 1 |
| Chin, TM; Seto, KY; Soo, RA; Wong, AS | 1 |
| Bolshakov, S; Dicker, A; Korchin, B; Lahat, G; Lazar, A; Lev, D; Merritt, W; Nguyen, T; Pollock, RE; Ren, W; Sood, A; Wei, C | 1 |
| Barlési, F | 2 |
| Stewart, DJ | 2 |
| Bhutani, M; Mao, L; Pathak, AK | 1 |
| Dahlberg, SE; Gray, RJ; Johnson, BE | 1 |
| Eguchi, K; Fukuoka, M; Harada, M; Ichinose, Y; Imamura, F; Inoue, A; Itoh, Y; Jiang, H; Maruyama, R; Masuda, N; Nakagawa, K; Negoro, S; Nishiwaki, Y; Saijo, N; Shinkai, T; Takeda, K; Tamura, T; Tomii, K; Tsuboi, M; Yamamoto, N | 1 |
| Armour, AA; Cappuzzo, F; Crinò, L; Cullen, M; Duffield, EL; Ford, HE; Ghiorghiu, S; Hirsch, FR; Pesek, M; Reck, M; Speake, G; Thompson, JC; Varella-Garcia, M; Zatloukal, P | 1 |
| Socinski, MA; Stinchcombe, TE | 2 |
| Hayakawa, K; Jiang, SX; Katagiri, M; Masuda, N; Okayasu, I; Piao, CJ; Saegusa, M; Umezawa, A; Yamamoto, M; Yamashita, K; Yoshida, T | 1 |
| Fandi, A; Giaccone, G; Herbst, RS; Iacona, RB; Janas, M; Johnson, DH; Ochs, JS | 1 |
| Astoul, P; Barlési, F; Breen, D; Fina, F; Martin, PM; Nanni-Metellus, I | 1 |
| Giaccone, G; Gutierrez, M; Rajan, A | 1 |
| Fukui, T; Furuta, K; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Takano, T; Tamura, T; Tsuta, K; Yamamoto, N; Yamamoto, S | 1 |
| Tamura, K | 1 |
| Babur, M; Shannon, AM; Stratford, IJ; Telfer, BA; Wedge, SR; Williams, KJ | 2 |
| Dias-Santagata, DC; Lynch, TJ; Nanda, A; O'Hara, CJ; Stubbs, H; Willers, H; Zaner, KS | 1 |
| Eguchi, K; Ishizaka, A; Kawada, I; Kawamura, M; Kobayashi, K; Nakachi, I; Naoki, K; Soejima, K; Watanabe, H; Yasuda, H | 1 |
| Alfieri, RR; Ardizzoni, A; Boni, L; Bortesi, B; Bozzetti, C; Camisa, R; Capelletti, M; Cavazzoni, A; De Palma, G; Franciosi, V; Galetti, M; Goldoni, M; Loprevite, M; Mozzoni, P; Petronini, PG; Rindi, G; Tiseo, M | 1 |
| Akamine, SJ; Ebi, N; Kuraki, T; Nakanishi, Y; Okamoto, I; Semba, H; Takayama, K; Tokunaga, SJ; Wataya, H; Yamamoto, H | 1 |
| Bunn, PA; Dziadziuszko, R; Gajapathy, S; Hirsch, FR; Lin, M; O'Neill, V; Skokan, M; Varella-Garcia, M; Xiao, Y | 1 |
| Fu, L; Li, J; Li, L; Liu, H; Luo, X; Mei, C; Xiong, X | 1 |
| Alloisio, M; Cappuzzo, F; Destro, A; Finocchiaro, G; Incarbone, M; Jänne, PA; Ligorio, C; Roncalli, M; Rossi, E; Santoro, A; Skokan, M; Terracciano, L; Toschi, L; Varella-Garcia, M; Zucali, PA | 1 |
| Abidoye, O; Salgia, R; Sattler, M | 1 |
| Bianchi, F; Neri, I; Patrizi, A | 1 |
| Döme, B; Magyar, M | 1 |
| Ishihara, S; Minato, K; Mogi, A; Naito, Y; Saito, R; Shitara, Y; Suga, T; Takise, A; Tsuchiya, S; Yamabe, K | 1 |
| Hotta, K; Kiura, K; Shirahige, A; Tabata, M; Takata, S; Takigawa, N; Tanimoto, M; Watanabe, H | 1 |
| Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Merk, J; Rolff, J; Sommer, A; Soong, R | 1 |
| Bonomi, PD; Cohen, G; De Braud, F; Eberhardt, WE; Herbst, RS; Heymach, JV; Johnson, BE; Krebs, AD; Paz-Ares, L; Ranade, AA; Sandler, AB; Sebastian, M; Stewart, DJ; Trigo, JM; Vasselli, J | 1 |
| Amoroso, D; Ardizzoni, A; Bearz, A; Belvedere, O; Brandes, AA; Cascinu, S; Crinò, L; Gridelli, C; Grossi, F; Labianca, R; Piantedosi, FV; Siena, S; Tiseo, M; Valentino, B; Venturino, P | 1 |
| Chang, GC; Chen, JC; Hsu, SL; Tsai, CH; Tsai, JR; Wu, CC; Wu, WJ; Yu, CT | 1 |
| Endo, T; Funayama, Y; Furukawa, K; Hashimoto, T; Hayashibara, K; Ichimura, H; Inagaki, M; Ishikawa, H; Ishikawa, S; Kaburagi, T; Kagohashi, K; Kamiyama, K; Kishi, K; Kurishima, K; Matsumura, T; Nawa, T; Satoh, H; Shinohara, Y; Sumi, M | 1 |
| Dastane, AM; Gupta, R; Marchevsky, AM; McKenna, R | 1 |
| Bertran-Alamillo, J; Botia, M; Carrasco, E; Castellà, E; Costa, C; Llatjós, M; Mate, JL; Mayo, C; Molina-Vila, MA; Moran, T; Pérez-Cano, M; Pradas, A; Queralt, C; Reguart, N; Rosell, R; Taron, M; Tomàs, M | 1 |
| Buhl, R; Fischer, B; Makowski, J; Meier, S; Post, F; Schad, A; Schadmand-Fischer, S; Sebastian, M; Springer, E; Taube, C; Wiewrodt, R | 1 |
| Chin, TM; Haber, DA; Lynch, TJ; Quinlan, MP; Sequist, LV; Settleman, J; Sharma, SV; Singh, A | 1 |
| Homes, AJ; Jackman, DM; Jänne, PA; Johnson, BE; Lindeman, N; Rogers, AM; Yonesaka, K; Zejnullahu, K; Zhao, F | 1 |
| Cho, BC; Costa, DB; Halmos, B; Huberman, MS; Jackman, DM; Jänne, PA; Kim, JH; Kobayashi, S; Nguyen, KS; Pao, W; Riely, GJ; Sequist, LV; Tenen, DG; Yeap, BY | 1 |
| Copeman, M | 1 |
| Hanagiri, T; Ichiki, Y; Mizukami, M; Onitsuka, T; Oyama, T; Sugaya, M; Sugio, K; Takenoyama, M; Uramoto, H; Yasuda, M; Yasumoto, K | 1 |
| Chen, KY; Cheng, AL; Hu, FC; Huang, CL; Lin, ZZ; Shih, JY; Yang, CH; Yang, PC; Yeh, KH; Yu, CJ | 1 |
| Fukuyama, S; Ichinose, Y; Ikeda, J; Maruyama, R; Nishimura, M; Okamoto, T; Osoegawa, A; Seto, T; Tagawa, T; Wataya, H; Yamanaka, T; Yamazaki, K | 1 |
| Herbst, RS; Sandler, A | 1 |
| Owonikoko, TK; Ramalingam, S | 1 |
| Cheng, CM; Ciou, SC; Hong, JH; Jheng, MY; Ko, JC; Lin, ST; Lin, YW; Wang, LH | 1 |
| Im, KC; Kim, SW; Lee, DH; Lee, JS; Moon, DH; Oh, SJ; Ryu, JS; Sohn, HJ; Suh, C; Yang, YJ | 1 |
| Balak, M; Bean, J; Ladanyi, M; Marks, JL; Miller, VA; Pao, W; Riely, GJ | 1 |
| Hanibuchi, M; Kakiuchi, S; Li, Q; Matsumoto, K; Mitsudomi, T; Nakamura, T; Nishioka, Y; Ogino, H; Sakurama, H; Sone, S; Uehara, H; Wang, W; Yano, S; Yatabe, Y | 1 |
| Donovan, JC; Ghazarian, DM; Shaw, JC | 1 |
| Boggon, TJ; Chan, PS; Christensen, JG; Dietrich, S; Du, R; El-Telbany, A; Halmos, B; Hirashima, T; Iwasaki, T; Jiang, S; Kawahara, K; Kawase, I; Kern, JA; Kijima, T; Kobayashi, M; Ma, PC; Matsui, K; Nakagawa, K; Okamoto, N; Petri, ET; Salgia, R; Sasada, S; Suzuki, H; Tang, Z | 1 |
| Azzariti, A; Duan, HQ; Galetta, D; Gao, EM; Han, Y; Liu, XQ; Paradiso, A; Toschi, L; Xu, JM; Zhang, JS; Zhang, Y | 1 |
| Ahn, BM; Choi, DR; Choi, JS; Jung, JY; Kim, HJ; Kim, HS; Kim, HY; Kim, JH; Kwon, JH; Lee, KM; Park, S; Shin, YC; Song, HH; Zang, DY | 1 |
| Ren, SX; Yan, LH; Zhang, L; Zhou, CC; Zhou, SW | 1 |
| Cullen, M; Thatcher, N | 1 |
| Armour, AA; Douillard, JY; Gervais, R; Hirsh, V; Kim, ES; Li, LY; Liao, ML; Lippman, SM; Lowe, ES; Mok, T; Osterlind, K; Reck, M; Sellers, MV; Shepherd, FA; Socinski, MA; Sun, Y; Watkins, CL; Wu, YL | 1 |
| Balko, JM; Black, EP | 1 |
| Harichand-Herdt, S; Ramalingam, SS | 2 |
| Azzoli, CG; Brahmer, JR; Fogle, M; Ginsberg, M; Kris, MG; Miller, VA; Milton, DT; Riely, GJ; Rizvi, NA; Rosen, N; Rudin, CM; Senturk, E; Seshan, VE; Sirotnak, FM; Solit, DB | 1 |
| Fukuoka, M; Hida, T; Katakami, N; Kawahara, M; Kubota, K; Matsui, K; Nakagawa, K; Nishiwaki, Y; Noda, K; Saijo, N; Takeda, K; Tamura, T; Watanabe, K; Yokoyama, A | 1 |
| Bodenstein, H; Digel, W; Franke, A; Guschall, WR; Gütz, S; Heigener, D; Laack, E; Reck, M; Schmidtgen, C; Schneider, CP; Schott-von-Römer, K | 1 |
| Bang, YJ; Han, SW; Heo, DS; Im, SA; Kim, CS; Kim, DW; Kim, HJ; Kim, TY; Kim, YJ; Lee, SH; Oh, DY; Yi, HG | 1 |
| Chang, YL; Hsu, YC; Shih, JY; Tsai, MF; Wu, JY; Wu, SG; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Descourt, R; Misery, L; Roguedas, AM; Rouxel, AM | 1 |
| Pavlidis, N; Pentheroudakis, G; Vassou, A; Voulgaris, E | 1 |
| Backes, H; Borgman, CL; Jacobs, AH; Koker, M; Li, H; Neumaier, B; Shapiro, GI; Shimamura, T; Sos, ML; Tawadros, S; Thomas, RK; Ullrich, RT; Waerzeggers, Y; Winkeler, A; Wolf, J; Zander, T | 1 |
| Chu, DT; Sun, Y; Wang, B; Wang, HJ; Wang, Y; Zhang, XR | 1 |
| Jiang, H | 1 |
| de Boer, R; Godwood, A; Humblet, Y; Milenkova, T; Nogová, L; Ruffert, K; Smith, R; Vansteenkiste, J; Wolf, J | 1 |
| Deng, Q; Ma, S; Xu, Y; Yu, X | 1 |
| Chen, E; Feld, R; Gauthier, I; Goss, G; Laurie, S; Leighl, N; Powers, J; Seymour, L; Shepherd, FA | 1 |
| Catania, C; Curigliano, G; de Braud, F; De Carlis, L; De Pas, T; Locatelli, M; Lorizzo, K; Pelosi, G; Spitaleri, G; Toffalorio, F | 1 |
| Cardona, AF; Reguart, N; Reveiz, L | 1 |
| Acharya, J; Bottomley, DM; Lyon, C | 1 |
| Hida, T; Horio, Y; Ogawa, S; Park, JC; Park, JY; Shimizu, J; Yoshida, K | 1 |
| Bareschino, M; Colantuoni, G; Falanga, M; Ferrara, ML; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Palazzolo, G; Rossi, A; Rossi, E; Schettino, C | 1 |
| Chouaid, C; Coudray-Omnès, C; Moser, A; Vergnenègre, A | 1 |
| Angagaw, MH; Bettano, KA; Chenard, M; Haines, BB; Reilly, JF; Sevilla, RS; Sur, C; Tong, C; Ware, C; Winkelmann, CT; Zhang, W | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sim, SH | 1 |
| Boysen, M; Longson, C; Stevens, A | 1 |
| Borgman, CL; Brandstetter, KA; Bronson, RT; Chen, L; Chesa, PG; Chirieac, LR; Greulich, H; Guertler, U; Ji, H; Kubo, S; Li, D; Meyerson, M; Padera, RF; Perera, SA; Raso, MG; Shapiro, GI; Shimamura, T; Solca, F; Takahashi, M; Wistuba, II; Wong, KK; Zaghlul, S | 1 |
| Ailawadhi, S; Derby, L; Fetterly, G; Natarajan, R; Ramnath, N; Reid, M | 1 |
| Mehić, B; Smoljanović, V; Stanetić, M; Tinjić, L | 1 |
| Galvany, L; Herrera-Acosta, E; Iglesias, M; Márquez, G; Umbert, P; Vidal, I | 1 |
| Sakurada, A; Tsao, MS | 1 |
| Haigentz, M; Li, T; Ling, YH; Perez-Soler, R | 1 |
| Carloni, F; Lazzari Agli, L; Santelmo, C; Sartori, S; Tamburini, E; Tassinari, D; Tombesi, P | 1 |
| Bunn, PA; Dziadziuszko, R; Hedman, K; Hirsch, FR; Varella-Garcia, M; Witta, SE; Yoshida, K | 1 |
| Katayama, H; Kishino, D; Kiura, K; Kuyama, S; Ohashi, K; Okada, T; Sato, K; Takigawa, N; Tanimoto, M | 1 |
| Aoyagi, D; Kanda, S; Kobayashi, N; Koizumi, T; Kubo, K; Nakayama, J; Ushiki, A; Yamamoto, H; Yasuo, M | 1 |
| Dagnaes-Hansen, F; Jakobsen, S; Keiding, S; Memon, AA; Nexo, E; Sorensen, BS | 1 |
| Choi, Y; Kim, JE; Kim, SW; Lee, DH; Lee, JS; Suh, C; Yoon, DH | 1 |
| Ciou, SC; Hong, JH; Jhan, JY; Ko, JC; Lin, ST; Lin, YW; Wang, LH | 1 |
| Boinpally, R; Chick, JB; Dunlop, D; Hughes, AN; Nicolson, M; O'Brien, ME; Petty, WJ; Price, A; Rankin, E; Wolf, J; Woll, PJ | 1 |
| Fu, Z; Li, M; Li, X; Liu, N; Ma, L; Meng, X; Yang, G; Yang, Y; Yu, J; Zhao, S | 1 |
| Andrew, AS; Duell, EJ; Mason, RA; Memoli, V | 1 |
| Hanayama, K; Hirashima, T; Imamura, F; Kanazawa, S; Kinoshita, Y; Nomura, S; Sasada, S; Siomi, K; Tujimoto, M; Yamaguchi, K | 1 |
| Duchnowska, R; Grala, B; Siemiatkowska, A; Smoter, M | 1 |
| Deng, QF; Su, B; Zhao, YM; Zhou, CC | 1 |
| Xing, LN; Zhang, F | 1 |
| Ito, F; Nishio, K; Shin-ya, T; Takeuchi, K | 1 |
| Ahn, JS; Ahn, MJ; Choi, MK; Hong, JY; Jae Park, M; Lee, J; Lee, SJ; Oh, SJ; Park, K; Park, MJ; Yi, JH | 1 |
| Bradley, J; Feins, RH; Gewanter, RM; Gopal, RS; Komaki, RU; Kong, FM; Langer, CJ; Lee, HK; Movsas, B; Rosenzweig, KE | 1 |
| Frenkel, EP; Gazdar, AF; Minna, JD; Peyton, M; Soh, J; Xie, Y; Zhang, W | 1 |
| Akerley, W; Arbogast, K; Bentz, JS; Boucher, KM; Walters, T | 1 |
| Calabrò, E; De Marinis, F; Fabbri, A; Marchianò, A; Novello, S; Orsenigo, M; Pastorino, U; Sozzi, G; Tamborini, E | 1 |
| Kometani, T; Maehara, Y; Miura, N; Ohba, T; Okazaki, H; Shoji, F; Takenaka, T; Yano, T; Yoshino, I | 1 |
| Beau-Faller, M; Gaub, MP; Guerin, E; Jeung, MY; Legrain, M; Mennecier, B; Molard, A; Neuville, A; Oudet, P; Quoix, E; Ruppert, AM; Voegeli, AC | 1 |
| Adamo, B; Adamo, V; Caristi, N; Chiofalo, G; Denaro, N; Franchina, T; Gambadauro, P; Giordano, A; Russo, A; Scimone, A | 1 |
| O'Neill, ID | 1 |
| Date, H; Fujiwara, Y; Hosokawa, S; Hotta, K; Kiura, K; Soh, J; Takigawa, N; Tanimoto, M; Tokumo, M; Toyooka, S; Yoshino, T | 1 |
| Fukuoka, M; Hatashita, E; Jänne, PA; Nakagawa, K; Nishio, K; Okabe, T; Okamoto, I; Tsukioka, S; Uchida, J; Yamada, Y; Yoshida, T | 1 |
| Lin, SS; Tsai, TH; Yang, HH | 1 |
| Chu, D; Lin, D; Ma, F; Shi, Y; Sun, T; Sun, Y; Tan, W; Wu, C; Xu, B; Yang, M; Yu, D | 1 |
| Cappuzzo, F; Drabkin, H; Gajapathy, S; Gemmill, R; Rossi, E; Valente, M; Varella-Garcia, M | 1 |
| Costa, DB; Kobayashi, S | 2 |
| Aggarwal, AN; Singh, N | 1 |
| Bergot, E; Zalcman, G | 1 |
| Barletta, E; Cusano, F; Ferrara, G; Ingordo, V | 1 |
| Andreu, J; Baselga, J; Cedrés, S; del Campo, JM; Felip, E; Martínez, P; Pallisa, E; Prat, A; Quispe, I; Sala, G | 1 |
| Chang, JW; Hsieh, JJ; Hsu, T; Li, YY; Shen, YC; Wang, CH; Yeh, KY | 1 |
| Barkauskas, DS; Dowlati, A; Du, R; Flask, C; Gerson, S; Halmos, B; Jiang, S; Kern, JA; Lam, M; Lee, Z; Liu, L; Ma, PC; Molter, J; Richey, J; Tang, Z; Wang, Y; Wu, C | 1 |
| Evans, CP; Gandara, DR; Gautschi, O; Green, TP; Gumerlock, PH; Kung, HJ; Lara, PN; Mack, PC; Purnell, PR; Tepper, CG | 1 |
| Agarwal, S; Christensen, JG; Digiovanna, MP; Harris, LN; Kolmakova, J; Rimm, DL; Stern, DF; Zerillo, C | 1 |
| Deplanque, G; Deray, G; Dreno, B; Janus, N; Launay-Vacher, V; Mateus, C; Morere, JF; Robert, C; Souquet, PJ | 1 |
| Ahn, JS; Ahn, MJ; Jun, HJ; Kim, HS; Kim, S; Lee, J; Lee, S; Park, K; Park, YH; Yi, SY | 1 |
| Bunn, PA; Franklin, WA; Hirsch, FR; Kosaka, T; Mitsudomi, T; Nakajima, E; Skokan, M; Varella-Garcia, M; Xavier, AC; Yatabe, Y; Zeng, C | 1 |
| Atsou, K; Chouaid, C; Hejblum, G; Vergnenegre, A | 1 |
| Ginsberg, MS; Heelan, R; Hussain, S; Kris, MG; Ladanyi, M; Miller, VA; Pao, W; Rusch, VW; Zakowski, MF | 1 |
| Ikeda, K; Itoh, S; Matsumoto, F; Ohba, S | 1 |
| Fimognari, FL; Franco, A; Pastorelli, R; Pellegrinotti, M; Repetto, L | 1 |
| Falcone, A; Tibaldi, C; Vasile, E | 1 |
| Bayer-Zubek, V; Cordon-Cardo, C; Costa, J; Donovan, MJ; Greco, FA; Hainsworth, JD; Kotsianti, A; Parums, DV; Teverovskiy, M; Verbel, D | 1 |
| Hirai, Y; Kawago, M; Kiyoi, M; Naito, K; Ohta, F; Okamura, Y; Oura, S; Shimizu, Y; Tamaki, T; Yoshimasu, T | 1 |
| Eguchi, K; Fukuoka, M; Ichinose, Y; Imamura, F; Itoh, Y; Nakagawa, K; Negoro, S; Nishiwaki, Y; Saijo, N; Sekine, I; Shinkai, T; Takeda, K; Tamura, T; Tsuboi, M; Yamamoto, N | 1 |
| Ali, S; Gadgeel, SM; Philip, PA; Sarkar, FH; Wozniak, A | 1 |
| Lagerwaard, FJ; Lind, JS; Senan, S; Smit, EF | 1 |
| Armour, AA; Ataman, OU; Biesma, B; Duffield, E; Ferry, D; Goss, G; Hirsch, FR; Laurie, SA; Thompson, J; Varella-Garcia, M; Wierzbicki, R; Zarenda, M | 1 |
| Lu, MQ; Wang, J; Wei, Q; Wen, CH; Xu, XH; Zhou, ZT | 1 |
| Bodkin, D; Capó, A; Eberhardt, WE; Germonpré, P; Govindan, R; Kennedy, SJ; Natale, RB; Ranson, M; Rizvi, NA; Sleckman, BG; Stockman, PK | 1 |
| Li, L; Li, XQ; Liu, H; Liu, XJ; Zhen, YS | 1 |
| Lin, CC; Yang, CH | 1 |
| Aracil, M; Jimeno, J; Ling, YH; Perez-Soler, R; Zou, Y | 1 |
| Bryce, J; De Feo, G; De Maio, E; Del Giudice, A; Di Maio, M; Falasconi, F; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC | 1 |
| Distel, RJ; Jänne, PA; Kuang, Y; Makrigiorgos, M; Rogers, A; Thiede, S; Vetrand, K; Wang, L; Yeap, BY | 1 |
| Fischer, F; Frommolt, P; Garraway, LA; Gazdar, AF; Girard, L; Heynck, S; Kashkar, H; Koker, M; Mermel, C; Meyerson, M; Michel, K; Minna, JD; Pao, W; Peifer, M; Peyton, M; Rabinovsky, R; Seeger, JM; Sos, ML; Thomas, RK; Weir, BA; Weiss, J; Zander, T | 1 |
| Horn, L; Sandler, AB | 1 |
| Karapanagiotou, EM; Merikas, I; Saif, MW; Syrigos, KN; Tsimboukis, S | 1 |
| Reck, M | 4 |
| Ishigatsubo, Y; Kaneko, T; Kuroda, H; Miyazawa, N; Murakami, S; Takeno, M | 1 |
| Alexandrescu, DT; Dasanu, CA; Kauffman, CL | 1 |
| Fujii, Y; Kawano, O; Okuda, K; Sasaki, H; Yano, M; Yukiue, H | 1 |
| Chen, HJ; Chen, ZH; Guo, AL; Mok, TS; Su, J; Wu, YL; Zhang, XC | 1 |
| Kunitoh, H; Saijo, N; Takeuchi, M | 1 |
| Hawkins, N; Scott, DA; Thatcher, N; Woods, BS | 1 |
| Billheimer, D; Brahmer, J; Carbone, D; Chen, H; Chen, S; Dang, TP; Herbst, R; Lee, JW; Massion, P; Salmon, S; Sandler, A; Schiller, J; Shyr, Y; Tran, H; Tsao, A | 1 |
| Bousamra, M; Fan, TW; Higashi, RM; Kloecker, G; Lane, AN; Miller, DM | 1 |
| Engelman, JA; Lynch, TJ; Sequist, LV | 1 |
| An, TT; Bai, H; Duan, CJ; Guo, ZQ; Liu, HN; Liu, YX; Mao, L; Wang, HS; Wang, J; Wang, X; Wang, YY; Wu, NM; Yang, L; Zhao, J | 1 |
| Manegold, C | 2 |
| Filipits, M; Minar, W; Pirker, R | 1 |
| Alfieri, RR; Ardizzoni, A; Bonelli, M; Capelletti, M; Cavazzoni, A; Fumarola, C; Galetti, M; Generali, D; Goldoni, M; La Monica, S; Mutti, A; Petronini, PG; Tagliaferri, S; Tiseo, M | 1 |
| Ren, XB; Sun, J; Wang, CL; Wang, J; Wang, P; Yuan, ZY; Zhao, LJ; Zhuang, HQ | 1 |
| Chen, ZG; Huang, DH; Khuri, FR; Peng, XH; Shin, DM; Su, L; Zhang, H | 1 |
| Akslen, LA; Briggs, A; Byers, LA; Cascone, T; Engelman, J; Folkman, J; Halmos, B; Heymach, JV; Jänne, P; Johnson, BE; Kobayashi, S; Lifshits, E; Naumov, GN; Nilsson, MB; Straume, O; Tang, XM; Tenen, D; Wu, HK; Xu, L; Yeap, B | 1 |
| Hanrahan, EO; Herbst, RS; Heymach, JV; Johnson, BE; Kennedy, SJ; Langmuir, P; Mann, H; Natale, RB; Ryan, AJ | 1 |
| Aubry, MC; Rickman, OB; Sanyal, B; Thomas, CF; Vohra, PK; Vrana, JA; Wigle, DA | 1 |
| Hoeller, C; Kunstfeld, R; Loewe, R; Paulitschke, V; Pehamberger, H; Pilarski, P; Schicher, N; Swoboda, A | 1 |
| Doral Stefani, S; Giorgio Saggia, M; Vicino dos Santos, EA | 1 |
| Fujii, A; Fujita, F; Fujita, M; Koike, M; Nakamura, H; Ohya, J; Suzuki, T | 1 |
| Fujimoto, T; Ito, T; Kanda, S; Mori, S | 1 |
| Shih, JY; Wu, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Ardizzoni, A; Boni, L; Bozzetti, C; Camisa, R; Campanini, N; Capelletti, M; De Palma, G; Franciosi, V; Lagrasta, C; Marchioni, A; Rindi, G; Rossi, G; Sartori, G; Spiritelli, E; Tiseo, M | 1 |
| Dhruva, N; Socinski, MA | 1 |
| Chang, CP; Chao, HS; Chen, YM; Chiu, CH; Chu, LS; Tsai, CM | 1 |
| Han, JY; Kang, KW; Kim, HT; Kim, HY; Kim, SK; Lee, DH; Lee, HY; Lee, JS; Lee, SY; Park, SH | 1 |
| Cheng, LC; Chua, DT; Chung, LP; Ho, JC; Leung, EL; Sihoe, AD; Tam, IY; Tin, VP; Wong, MP | 1 |
| Ichihara, E; Kiura, K; Ogino, A; Ohashi, K; Osawa, M; Takigawa, N; Tanimoto, M | 1 |
| Kaji, A; Katayama, K; Kawahara, H; Mitsuhashi, J; Noguchi, K; Sugimoto, Y | 1 |
| Beckett, L; Davies, AM; Gandara, DR; Ho, C; Lara, PN; Lau, D; Perkins, N; Scudder, SA | 1 |
| Clynes, M; Collins, DM; Crown, J; Devery, A; O'Connor, R; O'Donovan, N; O'Driscoll, L; O'Sullivan, F | 1 |
| Becker, M; Fichtner, I; Leschber, G; Merk, J; Rolff, J | 1 |
| Mekhail, T; Pennell, NA | 1 |
| Chu, DS; Johnson, KS; Levin, F | 1 |
| Li, D; Shen, QJ; Wang, F; Xing, WH; Xu, J; Zhang, LN; Zhang, XH; Zhuo, RJ; Zou, ZQ | 1 |
| Ansari, J; Hussain, SA; Palmer, DH; Rea, DW | 1 |
| Demierre, MF; Goldberg, LJ; Pongpudpunth, M | 1 |
| Biasco, G; Boschi, S; Fanti, S; Lollini, PL; Nannini, M; Pantaleo, MA | 1 |
| Brower, SL; Bush, JE; Rice, SD | 1 |
| Adachii, M; Ando, K; Hirose, T; Hosaka, T; Inoue, F; Ishida, H; Kadofuku, T; Kanome, T; Kusumoto, S; Ohmori, T; Ohnishi, T; Okuda, K; Saijo, N; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| He, C; Liu, M; Ouyang, M; Xu, J; Zhang, J; Zhong, N; Zhou, C | 1 |
| Asahina, H; Fukuoka, M; Hagiwara, K; Hida, T; Hirashima, T; Inoue, A; Kobayashi, K; Mitsudomi, T; Morita, S; Nukiwa, T; Okamoto, I; Sugio, K; Sunaga, N; Yamazaki, K; Yanagitani, N; Yasumoto, K; Yoshida, K | 1 |
| Chen, KY; Ho, CC; Shih, JY; Wu, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Guan, ZZ; Huang, H; Wang, ZQ; Xu, F; Xu, GC; Zhang, L; Zhang, Y; Zhao, HY | 1 |
| Ayabe, E; Endo, M; Igawa, S; Kaira, K; Kaira, R; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shimoyama, R; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Cho, EK; Ha, SY; Hong, J; Kim, YS; Lee, H; Lee, JH; Lee, JI; Park, J; Park, SH; Shin, DB; Sim, H | 1 |
| Clément-Duchêne, C; Merritt, R; Wakelee, HA | 1 |
| Choo, SP; Leong, SS; Li, HH; Lim, WT; Tan, EH; Tan, SH; Tham, CK; Toh, CK | 1 |
| Benedetti, G; Colucci, G; Crinò, L; Galetta, D; Latini, L | 1 |
| Chikaishi, Y; Inoue, M; Nose, N; So, T; Sugio, K; Yasumoto, K | 1 |
| Bagust, A; Boland, A; Davis, H; Dickson, R; Dundar, Y; Green, J; Hockenhull, J; Macbeth, F; McLeod, C; Proudlove, C; Stevenson, J; Walley, T | 1 |
| de Castro, J; García-Campelo, R; Isla, D; Provencio, M | 1 |
| Baudrin, L; Cadranel, J; Milleron, B; Morere, JF; Morin, F; Moro-Sibilot, D; Mourlanette, P; Quoix, E; Soria, JC; Souquet, PJ | 1 |
| Choe, du H; Kim, CH; Koh, JS; Lee, JC; Na, II; Ryoo, BY; Yang, SH | 1 |
| Antoine, M; Baudrin, L; Cadranel, J; Isaac-Sibille, S; Lebitasy, MP; Longchampt, E; Neuville, A; Poulot, V; Pradere, M; Wislez, M | 1 |
| Dorans, K | 1 |
| Hanagiri, T; Nose, N; Onitsuka, T; Sugio, K; Takenoyama, M; Uramoto, H; Yasumoto, K | 1 |
| Dziadziusko, R; Fennell, D; Gridelli, C; Lacombe, D; Pallis, AG; Serfass, L; van Meerbeeck, JP; Welch, J | 1 |
| Endo, M; Igawa, S; Kaira, K; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tamiya, A; Tsuya, A; Yamamoto, N | 1 |
| Greer, J; Lynch, TJ; Pirl, WF; Sequist, L; Solis, J; Temel, JS | 1 |
| Bowman, ED; Croce, CM; Gemma, A; Goto, A; Harris, CC; Horikawa, I; Jen, J; Kudoh, S; Mathe, EA; Okano, T; Schetter, AJ; Seike, M; Sugimura, H; Yang, P | 1 |
| Ji, Y; Lu, YJ; Ma, SL; Tang, JJ; Wu, YM; Zhang, YP | 1 |
| Huh, K; Kim, MJ; Kim, SW; Oh, J | 1 |
| Costa, DB; Kobayashi, S; Nguyen, KS | 1 |
| Aono, N; Isa, S; Kawaguchi, T; Koh, Y; Kubo, A; Kurata, T; Nakao, K; Tachibana, K; Takada, M; Tsujino, K | 1 |
| Bodkin, D; Chiappori, A; Eton, O; Favis, R; Fenton, D; Halmos, B; Hirsh, V; Liu, H; Lynch, TJ; Middleman, EL; Shepherd, FA; Trepicchio, WL | 1 |
| Arrieta, O; Michel, RM; Rios Trejo, MA | 1 |
| Jiang, W; Wu, JX; Xue, C; Zhang, L; Zhang, Y; Zhao, HY; Zhao, YY | 1 |
| Fujita, S; Harada, Y; Hata, A; Imai, Y; Ishihara, K; Katakami, N; Nishimura, T; Seo, R; Takeshim, Y; Tomii, K | 1 |
| Bigelow, RL; Burke, P; Cardelli, JA; Carroll, JL; Coleman, DT; Milligan, SA; Steffan, JJ; Williams, BJ | 1 |
| Friedrich, MJ | 2 |
| Aizawa, H; Azuma, K; Basaki, Y; Hattori, S; Kage, M; Kashihara, M; Kawahara, A; Kuwano, M; Nakano, K; Ono, M; Shirouzu, K; Takamori, S; Terazaki, Y; Yanagawa, T | 1 |
| Date, H; Hotta, K; Jida, M; Kiura, K; Kubo, T; Matsuo, K; Mitsudomi, T; Miyoshi, S; Ohe, Y; Oto, T; Sano, Y; Takano, T; Toyooka, S; Tsukuda, K; Yamamoto, H; Yamane, M; Yatabe, Y | 1 |
| Goto, Y; Hojo, M; Kobayashi, N; Kudo, K; Takeda, Y | 1 |
| Ren, S; Tang, L; Yan, L; Zhang, J; Zhang, L; Zhou, C; Zhou, S | 1 |
| Fujita, Y; Fukai, S; Kawabata, T; Kawahra, M; Saito, R; Shibata, S; Shibayama, T; Shirai, M; Tamura, A; Tomizawa, Y | 1 |
| Chin, TM; Wong, AS; Zee, YK | 1 |
| Admane, S; Chirieac, LR; Costa, DB; Digumarthy, SR; Heist, RS; Iafrate, AJ; Kobayashi, S; Kwak, EL; Lynch, TJ; Mark, EJ; McDermott, U; Mino-Kenudson, M; Rodig, SJ; Settleman, J; Shaw, AT; Solomon, B; Stubbs, H; Yeap, BY | 1 |
| Chang, CC; Cheng, CM; Chuang, SM; Ciou, SC; Jhan, JY; Ko, JC; Lin, ST; Lin, YW; Su, YJ | 1 |
| Cheng, LC; Chua, DT; Chung, LP; Leung, EL; Sihoe, AD; Tam, IY; Tin, VP; Wong, MP | 1 |
| Cioffredi, LA; Giaccone, G; Jackman, DM; Jänne, PA; Johnson, BE; Miller, VA; Riely, GJ; Ruiz, MG; Sequist, LV; Yeap, BY | 1 |
| Hampton, T | 2 |
| Ding, J; Hu, G; Li, J; Qian, X; Wang, Z; Zhang, W | 1 |
| Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sun, JM | 1 |
| Gazdar, AF | 3 |
| Cappuzzo, F; Hirsch, FR; Varella-Garcia, M | 1 |
| Ho, JC; Ip, MS; Lam, B; Lam, WK; Lo, AI; Wong, MK | 1 |
| Ahn, JS; Ahn, MJ; Cho, JY; Choi, JH; Kang, JH; Kim, HT; Kim, SW; Lee, J; Lee, JS; Park, BB; Park, K; Park, SH; Shin, SW; Sohn, CH; Song, HS; Uhm, JE | 1 |
| Hirano, S; Ichihara, E; Kiura, K; Kubo, T; Ohashi, K; Osawa, M; Takata, M; Takeda, H; Takigawa, N; Tanimoto, M; Yoshino, T | 1 |
| Tsai, CC; Wang, HC; Wang, PH | 1 |
| Armour, AA; Chewaskulyong, B; Chu, DT; Duffield, EL; Fukuoka, M; Han, B; Ichinose, Y; Jiang, H; Margono, B; Mok, TS; Nishiwaki, Y; Ohe, Y; Saijo, N; Sunpaweravong, P; Thongprasert, S; Watkins, CL; Wu, YL; Yang, CH; Yang, JJ | 1 |
| Bastus, R; Bertran-Alamillo, J; Bover, I; Camps, C; Cardenal, F; Catot, S; Garcia-Campelo, R; Gonzalez-Larriba, JL; Insa, A; Isla, D; Lopez-Vivanco, G; Majem, M; Massuti, B; Mayo, C; Molina, MA; Moran, T; Moreno, MA; Palmero, R; Paz-Ares, L; Porta, R; Provencio, M; Queralt, C; Reguart, N; Rolfo, C; Rosell, R; Sanchez, JJ; Sánchez, JM; Taron, M | 1 |
| Murakami, H; Ohashi, Y; Sakurai, M; Shino, M; Suzuki, K; Takahashi, T; Yamamoto, N | 1 |
| Hirano, S; Kobayashi, N; Kudo, K; Morii, S; Morita, A; Sano, K; Sugiyama, H; Takeda, Y; Uruga, K | 1 |
| Fukui, T; Hatooka, S; Hida, T; Ito, S; Katayama, T; Mitsudomi, T; Onozato, R; Shimizu, J; Suda, K; Sueda, T; Yatabe, Y | 1 |
| Gold, KA; Kim, ES; William, WN | 1 |
| Garfield, DH; West, HL | 1 |
| Arai, S; Fukui, T; Hataishi, R; Iwasaki, M; Katagiri, M; Katono, K; Kobayashi, H; Kubota, M; Masuda, N; Mitsufuji, H; Nishii, Y; Onoda, S; Otani, S; Ryuge, S; Takakura, A; Wada, M; Yamamoto, M; Yanaihara, T; Yanase, N; Yokoba, M | 1 |
| Ikeda, S; Suzuki, K; Takabe, K | 1 |
| Lazzari-Agli, L; Sartori, S; Tassinari, D; Tombesi, P | 2 |
| Alì, G; Baldini, E; Boldrini, L; Camacci, T; Comin, CE; Fontanini, G; Gisfredi, S; Lucchi, M; Maddau, C; Melfi, F; Mussi, A; Servadio, A; Tibaldi, C; Ursino, S | 1 |
| Mendoza, L | 1 |
| Akerley, W; Compton, P; Huang, JE; Kolb, MM; Langer, CJ; Socinski, MA; Wang, L | 1 |
| Boyer, MJ; Chen, YM; Chua-Tan, M; Chui, W; Ignacio, J; Jin, K; Johnston, M; Lee, JS; Liao, M; Mok, TS; Srimuninnimit, V; Sriuranpong, V; Sudoyo, AW; Wu, YL; Yu, CJ; Zhang, L; Zhou, C | 1 |
| Hsu, JY; Wakelee, HA | 1 |
| Kim, YH; Mio, T; Mishima, M | 1 |
| de Stanchina, E; Goel, A; Gong, Y; Koutcher, JA; Mellinghoff, IK; Ouerfelli, O; Pao, W; Politi, KA; Regales, L; Shen, R; Spassova, M; Vivanco, I; Zakowski, MF | 1 |
| Han, JY; Jung, JI; Kim, JY; Park, IH | 1 |
| Miller, AA; Petty, WJ; Waller, LL | 1 |
| Auclair, PL; Battelli, C; Carrier, K; Emery, IF; Hayes, DM | 1 |
| Hida, T; Horio, Y; Matsuo, K; Mitsudomi, T; Ogawa, S; Park, J; Park, JY; Shimizu, J; Yatabe, Y; Yoshida, K | 1 |
| Herbst, RS | 4 |
| Boggon, TJ; Cappuzzo, F; Clifford, B; Eisenberg, R; Franklin, WA; Fu, P; Halmos, B; Hamdan, A; Hirsch, FR; Jin, C; Leidner, RS; Skokan, M; Varella-Garcia, M | 1 |
| Kondo, T; Murakami, S; Oshita, F; Saito, H; Yamada, K | 1 |
| Hughes, B | 1 |
| Buttitta, F; Cappuzzo, F; Carlone, D; Ceribelli, A; Cognetti, F; Del Grammastro, M; Felicioni, L; Finocchiaro, G; Gelibter, AJ; Iacobelli, S; Irtelli, L; Malatesta, S; Marchetti, A; Mezzetti, A; Milella, M; Nuzzo, C; Perrucci, B; Sciarrotta, M | 1 |
| Da Silva, S; Decaestecker, C; Demetter, P; Mathieu, A; Salmon, I; Verbeken, E; Weynand, B | 1 |
| Cameron, MD; Kamenecka, TM; Li, X | 1 |
| Fukuoka, M; Hatashita, E; Jänne, PA; Kuwata, K; Nakagawa, K; Nishio, K; Okamoto, I; Okamoto, W; Yamada, Y; Yoshida, T | 1 |
| Choi, YJ; Kim, CH; Lee, JC; Lee, JK; Lee, SS; Na, II; Rho, JK; Ryoo, BY; Yang, SH; Yoo, YD | 1 |
| Carlson, JJ | 1 |
| Goto, D; Hizawa, N; Kohno, M; Ohara, G; Satoh, H; Sumida, T | 1 |
| Cristofanilli, M; Esteva, FJ; Hortobagyi, GN; Hung, MC; Krishnamurthy, S; LaFortune, TA; Liu, P; Lucci, A; Singh, B; Ueno, NT; Zhang, D | 1 |
| Busser, B; Coll, JL; Favrot, MC; Hurbin, A; Josserand, V; Niang, C; Sancey, L | 1 |
| Busser, B; Coll, JL; Favrot, MC; Hurbin, A; Josserand, V; Khochbin, S; Niang, C; Sancey, L | 1 |
| Chen, F; Lu, Y; Luo, R; Luo, X; Zhang, J | 1 |
| Nagai, A; Shiroma, T; Yamaguchi, M | 1 |
| Gandara, DR; Lara, PN; Li, T; Mack, PC; Perez-Soler, R | 1 |
| Kayano, Y; Li, Q; Matsumoto, I; Matsumoto, K; Nishioka, Y; Oda, M; Sone, S; Wang, W; Watanabe, G; Yamada, T; Yano, S | 1 |
| Ichinose, Y; Maruyama, R; Seto, T; Wataya, H | 1 |
| Bronson, RT; Chen, Z; Engelman, JA; Faber, AC; García-Echeverría, C; Li, D; Liang, MC; Lifshits, E; Maira, SM; Song, Y; Wong, KK; Yeap, BY | 1 |
| Sanford, M; Scott, LJ | 1 |
| Bonnichon, A; Le Floch, H; Mairovitz, A; Margery, J; Rivière, F; Staub, E; Vaylet, F | 1 |
| Castaldo, V; Ferrara, ML; Gridelli, C; Maione, P; Mazzeo, N; Palazzolo, G; Rossi, A | 1 |
| Iizasa, T; Itakura, M; Kimura, H; Nakajima, T; Nishimura, H; Shingyoji, M | 1 |
| Boerner, S; Chung, CT; Joshua, AM; Lara-Guerra, H; Leighl, NB; Liu, G; Ludkovski, O; Ma, C; Paul, N; Sakurada, A; Salvarrey, MA; Shepherd, FA; Squire, J; Tsao, MS; Waddell, TK | 1 |
| Chen, JH; Chen, KY; Shih, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Beckett, LA; Burich, RA; Davies, AM; Gandara, DR; Holland, WS; Lara, PN; Li, Y; Mack, PC; Sangha, R; Solis, LJ | 1 |
| Kappers, I; Klomp, HM | 1 |
| Anisimov, VV; Imyanitov, EN; Ivantsov, AO; Iyevleva, AG; Levchenko, EV; Matsko, DE; Moiseyenko, VM; Semionov, II; Yargnian, SM | 1 |
| Cha, MY; Kim, JW; Kim, MS; Kim, YH; Lee, CG; Lee, GS; Lee, KO; Park, SB; Song, JY | 1 |
| Bai La, BL; Endo, J; Funaguchi, N; Ito, F; Minatoguchi, S; Mori, H; Nakano, M; Ohno, Y; Yanase, K | 1 |
| Bessho, A; Harita, S; Hayashi, H; Hotta, K; Kamei, H; Kiura, K; Kuyama, S; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Umemura, S; Yoshioka, H | 1 |
| Blakely, J; Houts, AC; Reyes, CM; Schwartzberg, LS; Stepanski, EJ; Walker, MS | 1 |
| Beganovic, S | 1 |
| Arnold, A; Ciuleanu, TE; Dediu, M; Ding, K; Ellis, PM; Fenton, D; Frymire, E; Gauthier, I; Goss, GD; Ho, C; Laberge, F; Laurie, SA; Lee, CW; Leighl, NB; Noble, J; Seymour, L; Shepherd, FA; Vincent, MD; Walde, D; Zukin, M | 1 |
| Dempoya, J; Hayashi, A; Mikuniya, M; Morimoto, T; Nakamura, K; Okudera, K; Okumura, K; Takanashi, S | 1 |
| Choi, SJ; Choi, YJ; Jeon, BS; Kim, CH; Kim, HR; Lee, JC; Lee, SS; Park, SC; Rho, JK | 1 |
| Ito, F; Takeuchi, K | 1 |
| Engelman, JA; Jackman, D; Jänne, PA; Johnson, BE; Kris, MG; Lynch, T; Miller, VA; Pao, W; Riely, GJ | 1 |
| Du, DZ; Hanrahan, EO; Heymach, JV; Johnson, BE; Kim, ES; Langmuir, P; Lee, JJ; Lin, HY; McKee, KS; Ryan, AJ; Tran, HT; Yan, S | 1 |
| Benlloch, S; Molina, MA; Rosell, R; Taron, M; Viteri, S | 1 |
| Afifi, Y; Benomar, S; Bouhllab, J; Boutayeb, S; Errihanni, H; Hamada, S; Hassam, B | 1 |
| Atoyan, R; Bao, R; Borek, M; Cai, X; DellaRocca, S; Forrester, J; Lai, CJ; Qian, C; Qu, H; Samson, M; Tao, X; Wang, DG; Wang, J; Xu, GX; Yin, L; Zhai, HX; Zifcak, B | 1 |
| Alessandro Fanti, P; Balestri, R; Dika, E; Misciali, C; Patrizi, A; Vaccari, S | 1 |
| Kawana, S; Mitsuishi, T; Motoki, T | 1 |
| Cattaneo, MT; Clementi, E; Ferrario, S; Filipazzi, V; Gambaro, A; Isabella, L; Oteri, A; Piazza, E; Radice, S; Tosca, N | 1 |
| Büttner, R; Heukamp, LC | 1 |
| Gao, W; Shen, H; Shu, YQ; Sun, J; Yuan, Y | 1 |
| Chen, HY; Lee, CN; Liu, HE | 1 |
| Inoue, F; Momosaki, N; Morizono, G; Takenaka, T; Tanaka, T; Tomisaki, S | 1 |
| Iwakawa, J; Kawamata, Y; Kumamoto, T; Suetsugu, T; Tanoue, A | 1 |
| Bekers, O; Heideman, DA; Lind, JS; Postmus, PE; Smit, EF; Thunnissen, EB | 1 |
| Broxterman, HJ; de Haas, RR; Lind, JS; Smit, EF; van Hinsbergh, VW; Verheul, HM; Vroling, L | 1 |
| Lyseng-Williamson, KA | 1 |
| Ballatori, E; Fatigoni, S; Roila, F | 1 |
| Hammersley, JR; Kanjwal, S; Taj, A | 1 |
| Asami, K; Fukuoka, M; Hirashima, T; Katakami, N; Kudoh, S; Mitsudomi, T; Morita, S; Nakagawa, K; Negoro, S; Okamoto, I; Saito, H; Satouchi, M; Seto, T; Shibata, K; Shimizu, E; Tada, H; Takada, M; Toyooka, S; Tsurutani, J; Yatabe, Y; Yoshioka, H | 1 |
| Bosenberg, M; Bressel, A; Chin, L; Chiu, MI; Clark, SC; Depinho, RA; Heyer, J; Horner, JW; Jacks, T; Rancourt, R; Reddypalli, S; Rideout, WM; Robinson, MO; Woo, JK; Zhou, Y; Zi, T | 1 |
| Baba, N; Fujio, K; Kimura, S; Kohno, M; Kosugi, M; Ozaki, K; Sakamoto, T; Tanimura, S | 1 |
| Eck, MJ; Yun, CH | 1 |
| Besse, B; Soria, JC; Vignot, S | 1 |
| Kris, MG; Ladanyi, M; Pao, W; Rizvi, NA; Rusch, VW; Solomon, SB; Thornton, RH; Zakowski, MF | 1 |
| Besse, B; Bidart, JM; Bosq, J; Lacroix, L | 1 |
| Ayala, D; Blackstock, AW; Capellari, J; Center, B; Hinson, WH; Lovato, J; Miller, AA; Oaks, T; Petty, WJ | 1 |
| Amann, JM; Brahmer, J; Carbone, DP; Gonzalez, A; Lee, JW; Roder, H; Schiller, JH | 1 |
| Fukui, T; Hataishi, R; Igawa, S; Jiang, SX; Katagiri, M; Kubota, M; Masuda, N; Mitsufuji, H; Nishii, Y; Otani, S | 1 |
| Abe, K; Akasaka, K; Imai, Y; Imura, J; Kaburagi, T; Nagao, K; Ohmori, K; Sagara, H; Ueda, Y; Yasuda, S | 1 |
| Billheimer, D; Carbone, DP; Chen, H; Dang, TP; Herbst, RS; Roder, H; Roder, J; Salmon, JS; Sandler, A; Tran, HT; Tsao, AS; Tsypin, M | 1 |
| Duan, HQ; Han, Y; Liu, XQ; Xu, JM; Zhang, JS; Zhang, Y | 1 |
| Armour, AA; Bischoff, H; Douillard, JY; Gervais, R; Hirsh, V; Kim, ES; Liao, ML; Mok, T; Reck, M; Sellers, MV; Shepherd, FA; Socinski, MA; Speake, G; Watkins, CL | 1 |
| Ando, M; Fukuoka, M; Hida, T; Ichinose, Y; Iwamoto, Y; Kashii, T; Katakami, N; Kudoh, S; Kurata, T; Matsui, K; Nakagawa, K; Okamoto, I; Sasaki, J; Sato, T; Satouchi, M; Sawa, T; Seto, T; Takayama, K; Takeda, K; Yamamoto, N | 1 |
| Huang, MS; Hung, HC; Hung, JY; Lai, CL; Lai, YF; Lin, MC; Shieh, JM; Yang, CT | 1 |
| Drevs, J; Esser, N; Jürgensmeier, JM; Medinger, M; Ryan, A; Zirrgiebel, U | 1 |
| Amir, E; Seruga, B; Tannock, I | 1 |
| Takano, T | 1 |
| Qiu, JH; Wang, J | 1 |
| Desai, RU; Rachakonda, LP; Saffra, NA | 1 |
| Ganti, AK | 1 |
| Freidlin, B; Korn, EL; McShane, LM | 1 |
| Beika, Y; Enomoto, T; Fujii, T; Kishi, K; Kurosaki, A; Miyamoto, A; Morokawa, N; Takaya, H; Uruga, H; Yoshimura, K | 1 |
| Ma, PC; Manson, GV | 1 |
| Argiris, A; Burtness, BA; Caprioli, RM; Carbone, DP; Chung, CH; Cohen, EE; Forastiere, AA; Gilbert, J; Grigorieva, J; Murphy, B; Roder, H; Roder, J; Seeley, EH; Tsypin, M | 1 |
| Neal, JW | 2 |
| Chang, SC; Kuo, LC; Lin, PC; Wang, KF; Yuan, MK | 1 |
| Bharthuar, A; Iyer, R | 1 |
| Araki, T; Baba, M; Hayashizaki, Y; Kaira, K; Kakegawa, S; Kawai, Y; Lezhava, A; Mitani, Y; Miyamae, Y; Shimizu, K; Sugano, M; Takeyoshi, I; Yamamoto, K | 1 |
| Blumenschein, GR; Herbst, RS; Kim, ES; Lu, C; Lum, BL; Malik, M; Oh, YW; Papadimitrakopoulou, VA; Tran, HT; Zinner, RG | 1 |
| Chen, L; Ma, X; Sun, C; Zhong, M | 1 |
| Aoe, K; Bessho, A; Fujiwara, K; Harita, S; Hotta, K; Kamei, H; Kato, K; Kawai, H; Kiura, K; Kuyama, S; Maeda, T; Moritaka, T; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Umemura, S; Yonei, T; Yoshioka, H | 1 |
| Chen, TH; Fischer, F; Getlik, M; Greulich, H; Heuckmann, JM; Heynck, S; Klüter, S; Koker, M; Pawar, VG; Peifer, M; Rabiller, M; Rauh, D; Reuter, C; Rode, HB; Ruddigkeit, L; Simard, JR; Sos, ML; Thomas, RK; Weiss, J; Yuza, Y | 1 |
| Chen, YM; Chou, KT; Fan, WC; Lee, YC; Perng, RP; Shih, JF; Tsai, CM; Wu, CH | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, GK; Lee, JS; Lee, YJ; Sung, JH; Yun, T | 1 |
| Ayabe, E; Endo, M; Horie, Y; Kaira, K; Kondo, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Carney, D; Forde, P; Murphy, C; O'Sullivan, C | 1 |
| Akimov, M; Au, JS; Baselga, J; Damyanov, D; Delmar, P; Essioux, L; Felip, E; Hillenbach, C; Klughammer, B; Kuo, HP; McLoughlin, P; Milanowski, J; Orlov, S; Pluzanska, A; Ramlau, R; Reck, M; Tan, EH; Yang, PC | 1 |
| Hudish, TM; Karoor, V; Keith, RL; Le, M; Miller, YE; Mozer, AB | 1 |
| Brown, A; Capelletti, M; Christensen, JG; Engelman, JA; Ercan, D; Jänne, PA; Kwiatkowski, DJ; Lee, C; Lifshits, E; Rogers, A; Xiao, Y; Yonesaka, K; Zejnullahu, K | 1 |
| Antonia, S; Bepler, G; Chiappori, A; Gray, J; Haura, EB; Litschauer, S; Neuger, A; Rawal, B; Schell, MJ; Simon, G; Song, L; Tanvetyanon, T; Tetteh, L; Williams, C | 1 |
| Ahn, JS; Ahn, MJ; Kang, JH; Kim, JH; Kim, SW; Lee, DH; Lee, JS; Park, K; Shin, SW; Suh, C | 1 |
| Hirte, H; Hotte, SJ; Kavsak, PA | 1 |
| Clarke, JL; Lassman, AB; Miller, VA; Pao, W; Wu, N | 1 |
| Alfieri, RR; Ardizzoni, A; Bordi, F; Carmi, C; Cavazzoni, A; Galetti, M; La Monica, S; Lodola, A; Mor, M; Petronini, PG; Rivara, S; Silva, C; Vacondio, F; Vezzosi, S | 1 |
| Fujimoto, H; Hashimoto, K; Ishizuka, H; Kameyama, Y; Oyama, T; Suito, T; Yasuda, H | 1 |
| Caicun, Z; Jian, G; Jie, Z; Liang, T; Ling, Z; Qinfang, D; Songwen, Z | 1 |
| Burgers, JA; Cortesi, F; D'Incecco, A; Danesi, R; Falcone, A; Giaccone, G; Giovannetti, E; Peters, GJ; Santoro, A; Smit, EF; Tibaldi, C; Zucali, PA | 1 |
| Ramsey, SD | 1 |
| Bradbury, PA; Evans, WK; Isogai, PK; Leighl, NB; Mittmann, N; Ng, R; Seymour, L; Shepherd, FA; Tsao, MS; Tu, D; Zhu, L | 1 |
| Hatsuse, M; Morihara, K; Murakami, S; Nagata, K; Okano, A; Shimazaki, C; Shiotsu, S; Yuba, T | 1 |
| Hilbe, W; Pircher, A; Ploner, F; Popper, H | 1 |
| Liao, XB; Liu, JQ; Sun, XL; Wang, YX; Yan, DF; Yan, SX; Yang, JS | 1 |
| Chen, Z; Ding, WB; Lou, YJ; Ye, ZQ; Yu, YP; Zhang, YD | 1 |
| Han, YH; Kim, SW; Lee, DH; Lee, JS; Suh, C | 1 |
| Ishida, T; Iwasaku, M; Kunimasa, K; Nishiyama, A; Ubukata, S; Yoshioka, H | 1 |
| Arao, T; Fujita, Y; Fukuoka, M; Ito, H; Nakagawa, K; Nishio, K; Okamoto, I; Takeda, M | 1 |
| Arakawa, M; Hasegawa, T; Honda, N; Nakamura, K; Rosser, CJ; Saito, H; Tobiume, M; Yamada, Y | 1 |
| Cadranel, J; De Fraipont, F; Faller, MB; Fraboulet, G; Lantuejoul, S; Legendre, A; Milleron, B; Moro-Sibilot, D; Oliveiro, G; Perol, M; Pluquet, E; Quoix, E; Souquet, PJ; Zalcman, G | 1 |
| Alzani, R; Ciomei, M; Degrassi, A; Fanti, S; Giusti, AM; Nanni, C; Patton, V; Pesenti, E; Russo, M; Texido, G | 1 |
| Fujimoto, N; Fujiwara, Y; Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M; Toyooka, S; Ueoka, H; Umemura, S | 1 |
| Aikou, T; Akiba, S; Baba, M; Castillo, A; Eizuru, Y; Higashi, M; Itoh, T; Khan, N; Koriyama, C; Matsumoto, H; Natsugoe, S; Shuyama, KY; Yanagi, M | 1 |
| Chen, L; Shi, YX; Wang, F; Zhang, L; Zhang, Y; Zhao, H | 1 |
| Butler, JS; Donahue, BR; Huang, Y; Olmez, I; Rubin, P; Xu, Y | 1 |
| Gao, ZQ; Gu, AQ; Han, BH; Shi, CL; Wang, HM; Xiong, LW | 1 |
| Aisner, J; Allen, KE; Blumenschein, GR; Damjanov, N; Dowlati, A; Garst, J; Hassani, H; Leopold, L; Rigas, JR; Ross, HJ; Shepherd, FA; Smylie, M; Zaks, TZ | 1 |
| Barabasz, A; Fadden, P; Foley, B; Hall, S; Huang, K; Rice, JW; Scott, A; Steed, P; Veal, JM | 1 |
| Funato, T; Takeda, M | 1 |
| Fujita, S; Fukudo, M; Ikemi, Y; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y | 1 |
| Aizawa, H; Akiba, J; Azuma, K; Basaki, Y; Hattori, S; Izumi, H; Kage, M; Kawahara, A; Kohno, K; Kono, S; Kuwano, M; Nakashima, K; Ono, M; Takamori, S; Yanagawa, T | 1 |
| Hang, J; Li, Z; Su, B; Su, C; Zhang, L; Zhao, Y; Zhou, C; Zhou, S | 1 |
| Gotoh, N; Higuchi, T; Imoto, S; Kojima, K; Miyano, S; Nagasaki, M; Shimamura, T; Ueno, K; Yamaguchi, R; Yamauchi, M; Yoshida, R | 1 |
| Choi, PJ; Kim, KN; Lee, KN; Lee, SK; Roh, MS; Son, C; Um, SJ; Yang, DK | 1 |
| Belani, CP | 3 |
| Hasegawa, S; Hashimoto, M; Kondo, N; Matsumoto, S; Okumura, Y; Takuwa, T; Tanaka, F; Torii, I; Yoneda, K | 1 |
| Eguchi, K; Fukuoka, M; Horai, T; Ichinose, Y; Masuda, N; Mitsudomi, T; Mori, K; Nukiwa, T; Saijo, N; Segawa, Y; Takahashi, T; Tsuboi, M; Yamamoto, N; Yokota, S | 1 |
| Hansen, O; Schytte, T | 1 |
| Borrill, J; Edwards, SJ | 1 |
| Chen, W; Chen, WC; Hsia, TC; Lai, HC; Shih, CM; Tseng, GC | 1 |
| Deng, X; Dewan, MZ; Kuroi, K; Saji, S; Takada, M; Terunuma, H; Toi, M; Yamamoto, N | 1 |
| Lind, JS; Postmus, PE; Smit, EF | 1 |
| Barchuk, AS; Ievleva, AG; Imianitov, EN; Ivantsov, AO; Levchenko, EV; Matsko, DE; Mitiushkina, NV; Moiseenko, FV; Moiseenko, VM; Protsenko, SA; Semenov, II; Togo, AV | 1 |
| Alfieri, RR; Andreoli, R; Ardizzoni, A; Bonelli, M; Cavazzoni, A; De Palma, G; Fumarola, C; Galetti, M; La Monica, S; Mor, M; Mozzoni, P; Mutti, A; Petronini, PG; Tiseo, M | 1 |
| Travers, J; Workman, P | 1 |
| Fukuoka, M; Nakagawa, K; Okamoto, I; Takeda, M | 1 |
| Belani, CP; Owonikoko, TK; Ramalingam, SS | 1 |
| Athanasiou, A; Bardi, G; Chandrinou, H; Stathopoulos, GP; Trafalis, D | 1 |
| Bekers, O; Dingemans, AM; Giovannetti, E; Groen, HJ; Heideman, DA; Honeywell, RJ; Lind, JS; Peters, GJ; Postmus, PE; Smit, EF; Thunnissen, FB; van Suylen, RJ | 1 |
| Barlési, F; Baudrin, L; Bréchot, JM; Debieuvre, D; Gounant, V; Lebeau, B; Milleron, B; Morère, JF; Morin, F; Moro-Sibilot, D; Souquet, PJ; Urban, T; Vaylet, F; Westeel, V; Zalcman, G | 1 |
| Doi, S; Fukuda, M; Hayashi, T; Kohno, S; Nagashima, S; Nakamura, Y; Nakano, H; Nakatomi, K; Soda, H; Takasu, M; Takatani, H; Tomonaga, N; Tsukamoto, K; Yamaguchi, H | 1 |
| Gao, HJ; Guo, WF; Li, JJ; Li, XY; Liu, B; Liu, XQ; Qu, LL; Tang, CH; Wang, WW; Wang, WX | 1 |
| Liao, ML; Qin, SK; Sun, Y; Wu, YL; Zhou, CC | 1 |
| Brekken, RA; Carney, DN; Korpanty, G; Smyth, E; Sullivan, LA | 1 |
| Chen, J; Liu, H; Xu, Y; Zhou, Q | 1 |
| Chan, R; Jacks, T; Jasper, PJ; Lane, K; Lauffenburger, DA; Lazzara, MJ; Neel, BG; Sorger, PK; Yaffe, MB | 1 |
| Hotta, K; Inoue, K; Kishino, D; Kiura, K; Okada, T; Suzuki, E; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Yoshioka, H | 1 |
| Cai, CJ; Deng, QH; He, JX; Huang, J; Li, HL; Wang, DY; Wang, W; Wen, DP; Xie, SM; Zhang, L; Zhong, NS | 1 |
| De Pas, TM; Delmonte, A; Gregorc, V; Spitaleri, G; Toffalorio, F | 1 |
| Dive, C; Harrison, LR; Mironov, A; Moreira-Leite, FF; Roberts, RA | 1 |
| Blackhall, F; Campbell, L; Thatcher, N | 1 |
| Arnold, A; Ciuleanu, T; Dediu, M; Ding, K; Ellis, PM; Fenton, D; Goodwin, R; Laberge, F; Laurie, SA; LeMaître, A; Seymour, L; Shepherd, FA; Vincent, M; Walde, D; Zukin, M | 1 |
| Heo, DS; Kang, JH; Kim, DW; Kim, HK; Kim, SY; Lee, JS; Lee, MA; Lee, SH; Shin, SW | 1 |
| Hsu, WH; Hung, JJ; Jeng, WJ; Liu, JS; Wu, YC | 1 |
| Cho, BC; Choi, SY; Kim, EM; Kim, HK; Kim, JH; Kim, JS; Kim, SM; Solca, F; Yun, CO | 1 |
| Anthoney, A; Blatter, J; Dean, E; Hanauske, AR; Kletzl, H; Klingelschmitt, G; Melezinek, I; Ranson, M; Reck, M; Twelves, C | 1 |
| Li, LY; Wang, MZ; Xu, LY; Zhang, L; Zhang, XT; Zhang, XY; Zhong, W | 1 |
| Fukuoka, M; Itoh, Y; Jiang, H; Negoro, S; Nishiwaki, Y; Saijo, N; Yamamoto, N | 1 |
| Guo, Y; Jiang, W; Li, S; Liao, H; Shi, YX; Xue, C; Zhang, L; Zhang, Y; Zhao, HY; Zhao, YY | 1 |
| Calvo, A; Catena, R; Collantes, M; Diaz, R; Díaz-González, JA; Manrique, I; Nguewa, PA; Parrondo, R; Peñuelas, I; Perez-Stable, C; Redrado, M | 1 |
| Fujita, S; Fukudo, M; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y | 1 |
| Miller, VA; Oxnard, GR | 1 |
| Camps, C; Carcereny, E; Gasco, A; Massuti, B; Moran, T; Quiroga, V; Rosell, R; Viteri, S; Wei, J | 1 |
| Ramalingam, SS; Stinchcombe, TE | 1 |
| Brugger, W; Cappuzzo, F; Cicenas, S; Ciuleanu, T; Esteban, E; Giaccone, G; Juhász, E; Klingelschmitt, G; Klughammer, B; Melezínek, I; Molinier, O; Stelmakh, L; Szczésna, A | 1 |
| Bou Reslan, H; Cao, TC; Carano, RA; Cheng, JH; Clermont, AC; Devasthali, V; Forrest, WF; Fuh, G; Hamilton, P; Ho, CC; Johnson, L; Koeppen, H; Lee, CV; Lima, A; Molina, R; Nannini, MA; Plowman, GD; Singh, M; Thompson, JD; Yu, RX | 1 |
| Bilici, A; Gumus, M; Kefeli, AU; Kefeli, U; Seker, M; Ustaalioglu, BB; Yildirim, ME | 1 |
| An, SJ; Chen, HJ; Chen, ZH; Cheng, H; Dong, S; Guo, AL; Lin, QX; Wu, YL; Zhang, XC; Zhang, YF | 1 |
| Besse, B; Buisine, MP; Copin, MC; Dansin, E; Ferté, C; Parent, F; Penel, N; Soria, JC | 1 |
| Barchuk, AS; Imyanitov, EN; Ivantsov, AO; Iyevleva, AG; Levchenko, EV; Matsko, DE; Mitiushkina, NV; Moiseyenko, FV; Moiseyenko, VM; Procenko, SA; Semionov, II; Togo, AV | 1 |
| Fukudo, M; Inui, K; Masago, K; Mishima, M; Togashi, Y | 1 |
| Bodio, K; Costa, DB; Huberman, MS; Kobayashi, S; Kris, MG; Lau, MW; Pao, W; Riely, GJ; Tenen, DG; Warner, JL; Yeap, BY; Yeo, WL | 1 |
| Fujita, S; Ichikawa, M; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M | 1 |
| Eckert, R; Faehling, M; Kamp, T; Kuom, S; Schumann, C; Stoiber, KM | 1 |
| Choi, YJ; Kim, CH; Kim, HR; Kim, HT; Kim, YM; Koh, JS; Kook, EH; Lee, JC; Rho, JK | 1 |
| Ambrosio, R; Barbato, V; Bareschino, MA; Falanga, M; Gridelli, C; Maione, P; Rossi, A; Sacco, PC; Schettino, C | 2 |
| Fukuoka, M; Kuwata, K; Nakagawa, K; Nishio, K; Okamoto, I; Takezawa, K; Tanizaki, J; Yamaguchi, H | 1 |
| Bartolotti, M; Bordi, P; Gelsomino, F; Tiseo, M | 1 |
| Guo, P; Kris, MG; Ladanyi, M; Moskowitz, CS; Oxnard, GR; Pao, W; Rizvi, NA; Rusch, VM; Schwartz, LH; Zhao, B | 1 |
| Ahmed, IS; Craven, RJ; Rohe, HJ; Twist, KE | 1 |
| Ahn, JS; Ahn, MJ; Choi, YL; Kim, JH; Kim, ST; Lee, J; Park, K; Park, YH; Sun, JM; Won, YW | 1 |
| Wörmann, B | 1 |
| Belani, CP; Gandara, DR; Govindan, R; Ivy, SP; Koczywas, M; Longmate, J; Mack, PC; Ramalingam, SS; Vokes, EE | 1 |
| Fujikura, Y; Hizawa, N; Homma, S; Kurishima, K; Morishima, Y; Ota, K; Otsuka, S | 1 |
| Ji, H | 1 |
| Ahn, JS; Ahn, MJ; Kim, JH; Kim, ST; Lee, J; Park, K; Park, YH; Sun, JM; Won, YW; Yun, J | 1 |
| Ge, XQ; Huang, JJ; Shen, H; Yuan, Y; Zhong, X | 1 |
| Biesma, B; Eberhardt, WE; Germonpré, P; Herbst, RS; Heymach, JV; Ichinose, Y; Johnson, BE; Kabbinavar, F; Kennedy, SJ; Langmuir, P; Li, L; Qin, S; Saijo, N; Sun, Y; Tada, H; Wang, J; Zhang, L; Zhou, C | 1 |
| Hosoda, W; Kitamura, A; Mitsudomi, T; Sasaki, E; Yatabe, Y | 1 |
| Hatch, H; Hirai, H; Kotani, H; Majumder, PK; Miyama, K; Nakatsuru, Y; Pan, BS; Sootome, H; Taguchi, S; Tsujioka, K; Ueno, Y | 1 |
| Ando, M; Fujita, Y; Gemma, A; Hagiwara, K; Harada, M; Harada, T; Hirano, H; Inoue, A; Isobe, H; Kinoshita, I; Kobayashi, K; Maemondo, M; Miyazawa, H; Morita, S; Nukiwa, T; Ogura, T; Oizumi, S; Okinaga, S; Saijo, Y; Sugawara, S; Tanaka, T; Yoshimori, K; Yoshizawa, H | 1 |
| Rudman, SM; Spicer, JF | 1 |
| Belsanova, B; Benesova, L; Minarik, M; Pesek, M; Sekerka, P | 1 |
| Döme, B; Ostoros, G; Strausz, J; Tímár, J | 1 |
| Brückl, WM; Ficker, JH; Wiest, GH | 1 |
| Fukuoka, M; Makimura, C; Nakagawa, K; Okamoto, I; Takeda, M | 1 |
| Chang, CY; Chang, SC; Chen, CY; Yu, CJ | 1 |
| Babineaux, S; Klein, R; Lawson, A; Liepa, AM; Muehlenbein, C; Schwartzberg, L; Wielage, R | 1 |
| Lin, CC; Shao, YY; Yang, CH | 1 |
| Muro, Y; Shimoyama, Y; Sugiura, K; Tomita, Y; Yamaki, M | 1 |
| Giaccone, G; Lopez-Chavez, A | 1 |
| Ackerman, J; Albain, KS; Barlesi, F; Berkowitz, L; Besse, B; Gabrail, N; Hart, LL; Herbst, RS; Leighl, NB; Massarelli, E; Melnyk, O; Miller, VA; Raez, LE; Rosen, PJ; Shepherd, FA; Shun, Z; Sternas, L | 1 |
| Catot, S; Colomer, R; de Castro, J; Guillem, V; Gúrpide, A; Isla, D; Lianes, P; Massutí, B; Mayo, C; Paz-Ares, L; Polo, E; Porta, R; Pradas, A; Puig, T; Queralt, C; Reguart, N; Rosell, R; Salinas, P; Sánchez-Torres, JM; Tarón, M | 1 |
| Ahn, JS; Ahn, MJ; Ahn, YC; Kim, JA; Lee, J; Lee, S; Park, HC; Park, K; Park, YH; Sun, JM | 1 |
| He, C; Li, P; Ma, J; Ma, Z; Wang, H; Wang, Q; Wei, B; Zhu, H | 1 |
| Breen, L; Clynes, M; Collins, DM; Dunne, G; O'Connor, R; Roche, S | 1 |
| Govindan, R; Stinchcombe, TE | 1 |
| Dahm-Daphi, J; Dikomey, E; Holst, K; Kasten-Pisula, U; Kriegs, M; Rieckmann, T; Saker, J | 1 |
| De Jonge, M; Guttman-Yassky, E; Iwata, KK; Krueger, JG; Matthews, L; McCarthy, S; Mita, A; Rowinsky, EK; Verweij, J | 1 |
| de Ruysscher, D; Dingemans, AM; Lind, JS; Meijerink, MR; Ollers, MC; Postmus, PE; Smit, EF; van Kuijk, C | 1 |
| English, JF; Erridge, SC; Ironside, JA; Kerr, GR; Little, FA; Mackean, MJ; Price, A | 1 |
| Chang, SH; Hsu, YC; Shih, JY; Wu, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Antoniou, C; Chasapi, V; Dilana, KD; Karapanagiotou, EM; Matekovits, AE; Stratigos, AJ; Syrigos, KN; Tsimboukis, S; Vergou, T | 1 |
| Ding, YM; Ju, LX; Li, W; Meng, SY; Su, B; Tang, L; Yan, LH; Yang, XJ; Zhao, YM; Zhou, CC | 1 |
| Bokemeyer, C; Laack, E; Sauter, G | 1 |
| Aebersold, DM; Bernier, J; Bucher, SE; Ciernik, IF; Glanzmann, C; Lippuner, T; Lombrieser, N; Lütolf, UM; Ries, G; Rothschild, S; Zouhair, A | 1 |
| Ikemura, S; Ishizaka, A; Kawada, I; Nakachi, I; Nakayama, S; Naoki, K; Sato, T; Satomi, R; Soejima, K; Terai, H; Watanabe, H; Yasuda, H; Yoda, S | 1 |
| Dempsey, EC; Karoor, V; Le, M; Merrick, D; Miller, YE | 1 |
| Inoue, A | 1 |
| Ishikawa, H; Kato, T; Naito, T; Nakagaki, S; Ohashi, Y; Onishi, T; Sakurai, M; Shino, M; Suzuki, K; Takahashi, T; Yamamoto, N | 1 |
| Fukuda, M; Hayashi, T; Kohno, S; Nagashima, S; Nakamura, Y; Oka, M; Sano, K; Soda, H; Takatani, H; Tsukamoto, K | 1 |
| Fujita, S; Hata, A; Imai, Y; Ishihara, K; Kaji, R; Katakami, N; Nishimura, T; Takahashi, Y; Tomii, K | 1 |
| Blackhall, FH; Kennedy, SJ; Milenkova, T; Nicolson, M; O'brien, M; Schmid, P; Taylor, P; Thatcher, N | 1 |
| Costa, DB; Hamada, A; Kobayashi, S; Yeo, WL | 1 |
| Byers, L; Cai, D; Gao, B; Gazdar, AF; Girard, L; Heymach, J; Kim, YH; Kodadek, T; Mills, G; Minna, JD; Nanjundan, M; Peyton, M; Pollack, JR; Raso, MG; Shames, DS; Sullivan, JP; Wistuba, I; Xie, Y | 1 |
| Lv, P; Zhou, T | 1 |
| Akiyama, H; Hishida, T; Horinouchi, H; Kondo, H; Mitsudomi, T; Nagai, K; Nagayasu, T; Tsuboi, M; Yokoi, K | 1 |
| Chen, J; Liu, H; Wang, Y | 1 |
| Eaton, KD; Martins, RG | 1 |
| Blum, RA; Cheng, CP; Hanifudin, A; Lim, LT | 1 |
| Hanagiri, T; Iwata, T; Onitsuka, T; Oyama, T; Shimokawa, H; Uramoto, H | 1 |
| Bago-Horvath, Z; Berger, W; Cejka, D; Filipits, M; Haitel, A; Hayden, H; Herberger, B; Schmid, K; Sieghart, W; Werzowa, J | 1 |
| Fujita, J; Furuta, J; Hizawa, N; Kikuchi, N; Miyazaki, K; Morishima, Y; Nozato, K; Ogawa, R; Sakamoto, T | 1 |
| Bogart, J; Dipetrillo, T; Garst, J; Graziano, S; Green, MR; Gu, L; Jänne, PA; Ready, N; Vokes, EE; Wang, X | 1 |
| Backes, WH; Brans, B; de Langen, AJ; Dingemans, AC; Groen, HJM; Hoekstra, OS; Marcus, JT; Pruim, J; Scholtens, HTGM; Smit, EF; Thunnissen, FB; van den Boogaart, V; van Tinteren, H | 1 |
| Kink, JA; Raines, RT; Rutkoski, TJ; Schilling, CI; Strong, LE | 1 |
| Huang, C; Jiang, K; Wu, B; Xu, Z; Zhang, J; Zhuang, W | 1 |
| Bertran-Alamillo, J; Cardenal, F; Cobo, M; Garrido, P; Isla, D; Lianes, P; Manegold, C; Massuti, B; Molina, MA; Moran, T; Ramirez, JL; Rosell, R; Salazar, F; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Stahel, R; Taron, M; Trigo, JM | 1 |
| Katayama, T; Kosaka, T; Matsuo, K; Mitsudomi, T; Sueda, T; Yatabe, Y | 1 |
| Chan, N; Lim, SW; Soo, RA; Teo, C; Wong, AS; Wong, E | 1 |
| Altorki, N; Camiolo, M; Fenoglio, S; Gao, DC; Johns, C; Kenner, L; Lindsted, T; Mittal, V; Schlederer, M; Sordella, R; Stiles, B; Yao, Z | 1 |
| Arao, T; Fukuoka, M; Hatashita, E; Jänne, PA; Kuwata, K; Nakagawa, K; Nishio, K; Okamoto, I; Okamoto, W; Tanaka, K; Yamada, Y; Yamaguchi, H | 1 |
| Aukema, TS; Codrington, HE; Kappers, I; Klomp, HM; Olmos, RA; van Pel, R; van Tinteren, H | 1 |
| Amarshi, N; Billingsley, A; Nair, BA; Thomas, KS | 1 |
| Ghosh, G; Kron, SJ; Lee, AG; Palecek, SP; Yan, X | 1 |
| Cioffredi, LA; Hatabu, H; Jackman, DM; Jänne, PA; Johnson, BE; Nishino, M; Van den Abbeele, AD; Yap, JT; Yeap, BY | 1 |
| Kim, YM; Park, SY; Pyo, H | 1 |
| Becker, A; Postmus, PE; Smit, EF; van Wijk, A | 1 |
| Allan, S; Baliko, Z; Gridelli, C; Heigener, D; Krzakowski, M; Reck, M; Rischin, D; van Zandwijk, N | 1 |
| Ahn, HK; Ahn, JS; Ahn, MJ; Chang, MH; Choi, YL; Jung, CK; Lee, J; Park, K; Park, YH | 1 |
| Matsuzaki, T; Miyauchi, J; Morishita, T; Naitou, A; Ogawa, R; Terashima, T | 1 |
| Fabian, P; Lakomý, R; Nemecek, R; Slabý, O; Stanková, M; Svoboda, M; Vyzula, R | 1 |
| Fujita, S; Hata, A; Imai, Y; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Kunimasa, K; Nishiyama, A; Tomii, K; Yoshioka, H | 1 |
| Au, JS; Mok, T; Park, K; Perng, RP; Wu, YL; Zhang, L; Zhou, C | 1 |
| Berrino, L; Capasso, A; Ciardiello, F; De Vita, F; Eckhardt, SG; Martinelli, E; Morelli, MP; Morgillo, F; Orditura, M; Rodolico, G; Santoro, M; Troiani, T; Tuccillo, C; Vecchione, L; Vitagliano, D | 1 |
| Chopra, A; Ku, GY; Lopes, Gde L | 1 |
| Chung, KP; Shih, JY; Yu, CJ | 1 |
| Bafaloukos, D; Dahabreh, IJ; Kosmidis, P; Linardou, H; Murray, S | 1 |
| Fukuoka, M; Nakagawa, K; Nakamatsu, K; Nishimura, Y; Okamoto, H; Okamoto, I; Takahashi, T; Watanabe, K; Yamamoto, N | 1 |
| Cho, EK; Hong, J; Jung, SH; Kyung, SY; Lee, JH; Lee, JI; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB; Sym, SJ | 1 |
| Chang, YC; Chang, YL; Hsu, YC; Shih, JY; Wu, JY; Wu, SG; Yang, CH; Yang, PC | 1 |
| Alam, N; Dudek, AZ; Gustafson, KS; Kapoor, A; Ladanyi, M; Truskinovsky, AM; Zakowski, MF | 1 |
| Iqbal, SA; Myerson, JS; O'Brien, ME; Popat, S | 1 |
| Andreuccetti, M; Borghi, F; Caparello, C; Caponi, S; D'Incecco, A; Falcone, A; Ginocchi, L; Lucchesi, M; Tibaldi, C; Vasile, E | 1 |
| Geng, YT; Li, XD; Shen, H; Shu, YQ; Sun, J; Wu, CP; Yin, YM | 1 |
| Fujiwara, K; Kudo, K; Matsuo, K; Mizuta, M; Sato, T; Tsushima, M; Yonei, T | 1 |
| Geng, YT; Hu, XL; Li, W; Shao, YF; Shu, YQ; Wang, ZX; Yin, YM | 1 |
| Fu, XY; Huang, Q; Li, DJ; Lu, MQ; Su, J; Xu, XH; Xue, F | 1 |
| Chang, CH; Chang, KC; Chu, CY; Kuo, TC; Lu, PH | 1 |
| Alauddin, MM; Balatoni, JA; Gelovani, JG; Gonzalez-Lepera, C; Mukhopadhyay, U; Ogawa, K; Pal, A; Shavrin, A; Tong, W; Volgin, A | 1 |
| Cheng, G; Li, L; Wu, XN; Zhang, P; Zhang, ZJ | 1 |
| Eberhardt, W | 1 |
| Arcila, ME; Azzoli, CG; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Pao, W; Pietanza, MC; Price, KA; Riely, GJ; Rizvi, NA | 1 |
| Altomare, G; Bidoli, P; Cazzaniga, ME; Cicchiello, F; Colombo, I; Cortinovis, DL; Crippa, A; Villa, F | 1 |
| Furugaki, K; Iwai, T; Kondoh, K; Mori, K; Moriya, Y; Shirane, M | 1 |
| Becker, A; Chiappori, A; Haura, EB; Sommers, E; Song, L | 1 |
| Fukuhara, A; Hatachi, Y; Kim, YH; Kubo, T; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Togashi, K; Togashi, Y | 1 |
| Alessandroni, P; Baldelli, AM; Casadei, V; Catalano, V; Dennetta, D; Giordani, P; Graziano, F; Luzi Fedeli, S; Rossi, D; Ugolini, M | 1 |
| Der, CJ; Roberts, PJ; Socinski, MA; Stinchcombe, TE | 1 |
| Albain, KS; Atkins, JN; Chansky, K; Crowley, JJ; Dakhil, SR; Franklin, WA; Gandara, DR; Herbst, RS; Hirsch, FR; Kelly, K; Kim, ES; Mack, PC; Redman, M | 1 |
| Chen, LC; Gitlitz, B; Jezior, D; Milne, G; Patel, R; Reckamp, K; Syto, M; Zaknoen, S | 1 |
| Aburatani, H; Fukayama, M; Ishikawa, S; Matsubara, D; Niki, T; Sachiko, O | 1 |
| Hojjati, M; Nguyen, S | 1 |
| Balemans, C; Mattijssen, V; Ruinemans, GM; Smit, HJ; Wiersma-van Tilburg, AJ | 1 |
| Murashige, N; Oshima, Y; Tanimoto, T | 1 |
| Hosomi, Y; Iguchi, M; Miyamoto, S; Ohkuma, Y; Okamura, T; Shibuya, M; Shimokawa, T; Takagi, Y | 1 |
| Chang, YH; Lim, KH | 1 |
| Armour, AA; Watkins, CL | 1 |
| Basaki, Y; Izumi, H; Kage, M; Kawahara, A; Kohno, K; Kuwano, M; Nakashima, K; Ono, M; Uramoto, H; Yamamoto, C; Yasumoto, K | 1 |
| Bryce, J; Carillio, G; Carotenuto, P; Costanzo, R; Daniele, G; Di Maio, M; Giordano, P; La Rocca, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Benlloch, S; Cardenal, F; Molina, MA; Moran, T; Porta, R; Rosell, R; Taron, M; Viteri, S | 1 |
| Chiba, M; Fujiwara, M; Goya, T; Kishino, T; Matsushima, S; Morii, T; Ogura, W; Ohnishi, H; Ohtsuka, K; Watanabe, T | 1 |
| Jones, SJ; Milenkova, T | 1 |
| Keane, MP; Kelly, E; McDonnell, TJ; Mhurchu, EN; Sukor, S; Tryfonopoulos, D | 1 |
| Saijo, N | 3 |
| Burtness, B; Psyrri, A | 1 |
| Britt, GJ; Costa, DB; Heon, S; Jackman, DM; Johnson, BE; Rabin, MS; Yeap, BY | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Chang, TH; Huang, CP; Lan, CC; Lin, SB; Shih, JY; Su, KY; Tsai, MF; Wu, CP; Wu, SG; Yang, CH; Yang, PC; Yu, SL; Yu, YL | 1 |
| Chalfant, CE; Goehe, RW; Hawkins, AJ; Minna, JD; Murudkar, C; Shay, JW; Shultz, JC; Wijesinghe, DS | 1 |
| Costanzo, R; Daniele, G; Di Maio, M; Giordano, P; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Riccardi, MG; Rocco, G | 1 |
| Bagust, A; Boland, A; Brown, T; Dickson, R; Dundar, Y; Hockenhull, J; Oyee, J; Proudlove, C; Ramani, VS | 1 |
| Grygárková, Y; Havel, L; Hrnciarik, M; Kolek, V; Koubková, L; Krejcí, J; Pesek, M; Salajka, F; Skalová, B; Skricková, J; Stícha, M; Tomísková, M; Zatloukal, P | 1 |
| Katayama, T; Maehara, Y; Mitsudomi, T; Murakami, I; Osada, H; Sekido, Y; Suda, K; Tomizawa, K; Yatabe, Y | 1 |
| Ahn, JS; Ahn, MJ; Kim, ST; Lee, J; Park, K; Park, YH; Sun, JM | 1 |
| Chen, Z; Ding, W; Gao, L; Huang, X; Lou, Y; Yang, H; Ye, Z; Yu, Y; Zhang, Y | 1 |
| Duchnowska, R | 1 |
| Addison, CL; Bradbury, PA; Ding, K; Goss, GD; Le Maître, A; Seymour, L; Shepherd, FA; Tsao, MS; Zhao, H | 1 |
| Altiok, S; Bai, Y; Eschrich, S; Fang, B; Haura, EB; Kinose, F; Koomen, J; Li, J; Lin, H; Liu, RZ; Oguz, U; Remily-Wood, ER; Zhang, G | 1 |
| Liu, F; Liu, H; Ning, K; Wang, F; Wang, Y; Yu, J; Yuan, S; Zhang, J | 1 |
| Chen, X; Dai, L; Fang, J; Han, J; Han, S; Hu, W; Liu, X; Nie, J; Tian, G | 1 |
| Aono, T; Iwase, K; Nakamura, Y; Nomura, M; Tanaka, Y | 1 |
| Ahn, JS; Ahn, MJ; Chung, MJ; Hwang, HS; Kim, TS; Lee, HY; Lee, JW; Lee, KS; Park, K; Yi, CA | 1 |
| Horger, M; Schulze, M; Spengler, W | 1 |
| Ho, CC; Kuo, YW; Shih, JY; Wu, SG | 1 |
| Chen, YM; Chou, KT; Fan, WC; Hsia, TC; Huang, MS; Huang, SF; Lai, CL; Lee, YC; Perng, RP; Tien, YJ; Tsai, CM; Wu, CH; Yu, CJ | 1 |
| Guan, ZZ; Guo, GF; Wan, DS; Wu, PH; Xia, JC; Xia, LP; Zeng, YX; Zhang, B | 1 |
| Dong, M; Lepler, S; Pampo, C; Rice, L; Siemann, DW | 1 |
| Dong, N; Guo, Y; Luan, HL; Sun, BC; Sun, LN; Wang, M; Zang, FL; Zhan, ZL | 1 |
| Bischoff, H; Kindermann, M; Reinmuth, N; Steins, MB; Thomas, M | 1 |
| Al-Khater, AM; Rasul, KI | 1 |
| Colucci, G; Galetta, D; Millaku, A; Pisconti, S; Rossi, A | 1 |
| Asamura, H; Furuta, K; Kohno, T; Kozu, Y; Sekine, I; Suzuki, K; Tamura, T; Tsuda, H; Tsuta, K; Watanabe, S; Yokota, J; Yoshida, A | 1 |
| Azzoli, CG; Brevet, M; Johnson, ML; Ladanyi, M | 1 |
| Heigener, D; Mok, T; Reck, M; Wolf, J; Wu, YL | 1 |
| Liu, D; Shentu, J; Tan, F; Wang, Y; Xu, N; Yang, G; Yao, Y; Zhao, Q; Zhou, J | 1 |
| Baak, JP; Guo, H; Liu, JX; Madebo, T; Xu, L | 1 |
| Chattopadhyay, S; Cohen, MH; Johnson, JR; Justice, R; Pazdur, R; Sridhara, R; Tang, S | 1 |
| Hui, RC; Ko, JH; Shih, YC; Yang, CH | 1 |
| Azzoli, CG; D'Angelo, SP; Janjigian, YY; Kris, MG; Ladanyi, M; Pao, W; Park, BJ; Shen, R; Zakowski, MF; Zheng, J | 1 |
| Doebele, RC; Heasley, LE; Heasley, LR; Helfrich, BA; Hercule, P; Hinz, TK; Marek, L; Marshall, ME; Ware, KE | 1 |
| Kuwata, K; Nakagawa, K; Nishio, K; Okamoto, I; Okamoto, K; Okamoto, W; Takezawa, K; Tanaka, K; Yamaguchi, H | 1 |
| Lee, P | 1 |
| Cortot, AB | 1 |
| Choi, YJ; Chung, JH; Kim, CH; Kim, HR; Lee, CT; Lee, JC; Lee, JS; Rho, JK; Xu, X; Yoon, HI | 1 |
| Ardizzoni, A; Bartolotti, M; Boggiani, D; Bortesi, B; Bozzetti, C; Gelsomino, F; Sammarelli, G; Thai, E; Tiseo, M | 1 |
| Lin, CC; Yang, JC | 1 |
| Beijnen, JH; Fanggiday, JC; Lankheet, NA; Malingré, MM; Staaks, GH; Ter Heine, R; Van Der Westerlaken, MM | 1 |
| Heigener, DF; Reck, M | 1 |
| Imai, H; Ishizuka, T; Kaira, K; Kanai, Y; Mori, M; Nagamori, S; Nakajima, T; Oriuchi, N; Promchan, K; Shimizu, K; Sunaga, N; Tominaga, H; Yamamoto, N; Yanagitani, N | 1 |
| Chu, Z; Huang, L; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Chang, HT; Chen, CA; Chen, CY; Chen, YJ; Chong, NS; Hsieh, CH; Hsieh, YP; Lin, SC; Lin, SL; Shueng, PW; Wang, LY | 1 |
| Baba, J; Ichikawa, K; Kagamu, H; Kondo, R; Koshio, J; Miyabayashi, T; Narita, I; Ota, T; Tanaka, H; Tanaka, J; Watanabe, S; Yoshizawa, H | 1 |
| Erdem, L; Giovannetti, E; Leon, LG; Olcay, E; Peters, GJ | 1 |
| Dobashi, Y; Kanai, Y; Koyama, S; Tetsuka, K | 1 |
| Longo, M; Merlo, V; Novello, S; Scagliotti, GV | 1 |
| Binns, DS; Callahan, J; Conti, P; Fine, BM; Hicks, RJ; Macfarlane, D; Mileshkin, L; Pirzkall, A; Scott, AM; Yu, W | 1 |
| Chen, B; Liu, S; Wang, D; Wang, Y; Wu, J; Zhao, W | 1 |
| Cerea, G; Chella, A; Ciardiello, F; de Marinis, F; Di Maio, M; Fasano, M; Favaretto, A; Gridelli, C; Maione, P; Mattioli, R; Morgillo, F; Pasello, G; Ricciardi, S; Rossi, A; Tortora, G | 1 |
| Chang, GC; Hsu, SL; Lai, JM; Wu, CC; Yu, CT | 1 |
| Cappuzzo, F; Cortinovis, D; De Marinis, F; Di Maio, M; Gridelli, C; Mok, T | 2 |
| Alauddin, MM; Balatoni, J; Flores, L; Gelovani, JG; Gonzalez-Lepera, C; Krasnykh, V; Mukhapadhyay, U; Najjar, AM; Ogawa, K; Pal, A; Shavrin, A; Soghomonyan, S; Tong, W; Volgin, AY; Yeh, HH; Young, D | 1 |
| Boss, DS; Britten, CD; Camidge, DR; Eckhardt, SG; Engelman, JA; Garon, EB; Guo, F; Jänne, PA; Letrent, S; Liang, J; Millham, R; Schellens, JH; Taylor, I; Wong, S | 1 |
| Donev, IS; Li, Q; Matsumoto, K; Nishioka, Y; Sone, S; Takeuchi, S; Wang, W; Yamada, T; Yamori, T; Yano, S | 1 |
| Honda, T; Kameda, Y; Kondo, T; Miyagi, Y; Murakami, S; Noda, K; Obata, M; Oshita, F; Saito, H; Sakuma, Y; Yamada, K; Yokose, T | 1 |
| Fan, Y; Huang, ZY; Luo, LH; Yu, HF | 1 |
| Coveney, PV; Wan, S | 1 |
| Ariza, A; Benlloch, S; Bertran-Alamillo, J; Bivona, TG; Carcereny, E; Cardenal, F; Cobo, M; Costa, C; de Aguirre, I; Garcia-Campelo, R; Gimenez-Capitan, A; Insa, A; Isla, D; Majem, M; Massuti, B; Mate, JL; Mayo, C; Mendez, P; Molina, MA; Moran, T; Porta, R; Provencio, M; Queralt, C; Reguart, N; Rosell, R; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Sawyers, CL; Simonetti, S; Taron, M; Viteri, S | 1 |
| Kowalski, DM; Krawczyk, P; Krzakowski, M; Kucharczyk, T; Milanowski, J; Mlak, R; Wojas-Krawczyk, K | 1 |
| Chang, CC; Chang, HJ; Chi, KH; Hsieh, YS; Hsu, PS; Jiang, JS; Kao, SJ; Tsang, YW; Yeh, YW | 1 |
| Azzoli, CG; Ginsberg, MS; Janjigian, YY; Kris, MG; Krug, LM; Miller, VA; Pao, W; Pereira, LK; Pietanza, MC; Riely, GJ; Rizvi, NA | 1 |
| An, SJ; Chen, ZH; Cheng, H; Dong, S; Wu, YL; Zhang, XC; Zhang, YF | 1 |
| Chang, KT; Chen, JT; Chen, YM; Chiu, CH; Hsiao, SY; Lai, CL; Stewart, DJ; Tsai, CM | 1 |
| Bar-Sela, G; Haim, N; Nasrallah, H | 1 |
| Ito, K; Kawano, D; Maehara, Y; Morodomi, Y; Shoji, F; Yano, T | 1 |
| Han, JH; Han, JY; Kim, HT; Lee, GK; Lee, JS; Lee, YJ; Park, JH; Yoon, KA; Yoon, SJ; Yun, T | 1 |
| Fridlyand, J; Fyfe, G; Kaiser, LD | 1 |
| Beck, JF; Kurtze, I; Sonnemann, J | 1 |
| Endo, M; Kaira, K; Kaira, R; Kenmotsu, H; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, K; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Asami, K; Atagi, S; Kawaguchi, T; Kawahara, M; Okishio, K | 1 |
| Fujita, S; Fukuhara, A; Hatachi, Y; Kim, YH; Masago, K; Mio, T; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y | 2 |
| de Marinis, F; Gridelli, C; Rossi, A; Venturino, P | 1 |
| Amir, E; Bradbury, PA; Douillard, JY; Horgan, AM; Kim, ES; Leighl, NB; Ng, R; Shepherd, FA | 1 |
| Anthoine, G; Berghmans, T; CsToth, I; Mascaux, C; Meert, AP; Paesmans, M; Sculier, JP | 1 |
| Fujitaka, K; Hamada, A; Haruta, Y; Hattori, N; Ishikawa, N; Iwamoto, H; Kanehara, M; Kohno, N; Masuda, T; Murai, H; Ohshimo, S | 1 |
| Barlesi, F; Tomasini, P | 1 |
| Abratt, RP; Arrieta, Ó; Blackhall, FH; Chan, V; de Boer, RH; de Marinis, F; Gottfried, M; Langmuir, P; Milenkova, T; Raats, J; Read, J; Vansteenkiste, JF; Wolf, J; Yang, CH | 1 |
| Barlesi, F; Ferry, D; Gogov, S; Goss, GD; Greco, FA; Langmuir, P; Mulatero, C; Natale, RB; Rowbottom, JA; Sunpaweravong, P; Thomas, M; Thompson, J; Thongprasert, S; Tsai, CM; Whorf, R | 1 |
| Carlson, JJ; Reyes, C; Veenstra, DL; Wong, WB | 1 |
| Blanchet, B; Goldwasser, F; Mir, O | 2 |
| Camidge, DR; Cappuzzo, F; Varella-Garcia, M | 1 |
| Farndon, PA; Kobayashi, S; Li-Wan-Po, A; Mitsudomi, T; Potter, VA | 1 |
| Abraham, J; Davis, C | 1 |
| Babu, VC; Harini, VV; Kumar, BS; Nargund, A; Patil Okaly, GV; Rao, R; Rao, S; Sahoo, R; Venkataswamy, E | 1 |
| Hanagiri, T; Kuwano, M; Ono, M; Shimokawa, H; Uramoto, H | 1 |
| Hureaux, J; Jeanfaivre, T; Le Maignan, L; Mirebeau-Prunier, D; Urban, T; Vervueren, L | 1 |
| Fujita, S; Hata, A; Kaji, R; Katakami, N | 1 |
| Morioka, T; Niikura, N; Okamura, T; Saito, Y; Suzuki, Y; Terada, M; Terao, M; Tokuda, Y; Tsuda, B | 1 |
| Hwang, J; Subramaniam, DS | 1 |
| Beinert, T; Binder, D; Buckendahl, AC; Hübner, RH; Schlattmann, P; Suttorp, N; Temmesfeld-Wollbrück, B | 1 |
| Ashton, S; Barry, ST; Blakey, D; Lewis, CE; Murdoch, C; Tazzyman, S; Wood, P | 1 |
| Mountzios, G; Syrigos, KN | 1 |
| Assaraf, YG; D'Incecco, A; Danesi, R; Falcone, A; Giaccone, G; Giovannetti, E; Guchelaar, HJ; Lemos, C; Peters, GJ; Santoro, A; Scheffer, GL; Tibaldi, C; van der Straaten, T; Zucali, PA | 1 |
| Gao, L; Liu, X; Ni, L | 1 |
| Behrens, RJ; Cannon, MW; Friedman, EL; Gross, GG; Hillman, SL; Jatoi, A; Mc Kean, H; Rowland, KM; Sborov, MD; Stella, PJ | 1 |
| Chang, DS; Di, YP; Li, HQ; Li, P; Liu, LY; Wang, J; Wang, JD; Wang, X; Wang, YJ; Wu, WZ; Xia, TY | 1 |
| Amler, LC; Charu, V; Fine, BM; Gitlitz, BJ; Hicks, RJ; Hughes, BG; Macfarlane, D; Mileshkin, L; Mitchell, PL; Pirzkall, A; Solomon, B; Yu, W | 1 |
| Chen, X; Guo, R; Shu, Y; Sun, J; Wang, T; Zhang, Z | 1 |
| Hibino, M; Kudo, S; Minamiya, Y; Nakamura, M; Ogawa, J; Okuyama, M; Sasaki, Y; Tenma, K | 1 |
| Morio, A; Ninomiya, H; Sunada, K | 1 |
| Kitamura, Y; Sakakura, N; Suyama, M; Uchida, T | 1 |
| Bergot, E; Creveuil, C; Lechapt, E; Levallet, G; Zalcman, G | 1 |
| De Marinis, F; Karapanagiotou, EM; Oikonomopoulos, G; Saif, MW; Syrigos, KN | 1 |
| Cataldo, VD; Gibbons, DL; Pérez-Soler, R; Quintás-Cardama, A | 1 |
| Abe, M; Hashimoto, O; Inoue, K; Iwamoto, H; Kerbel, RS; Koga, H; Kurogi, J; Kuwahara, R; Nakamura, T; Niizeki, T; Sata, M; Torimura, T; Ueno, T; Yano, H | 1 |
| Castel, M; Despas, F; Mazières, J; Pathak, A | 1 |
| Chen, J; Chu, BB; Deng, J; Fang, HM; Fang, WJ; Mou, HB; Qian, J; Teng, LS; Wu, DP; Xu, N; Zhang, XC | 1 |
| Hirano, S; Ishii, S; Kobayashi, N; Kudo, K; Naka, G; Sugiyama, H; Takeda, Y | 1 |
| Chiu, HC; Chou, DL; Hsu, JT; Huang, CT; Lien, TW; Lin, WH; Yen, KJ | 1 |
| Han, JY; Hyung, LS; Kim, HT; Lee, JS; Lee, SH; Moon, YJ; Yoo, NJ; Yun, T | 1 |
| Chen, YM; Chou, KT; Chou, TY; Fan, WC; Lee, YC; Liu, SH; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J; Wu, CH | 1 |
| Antoine, M; Cadranel, J; Gounant, V; Lavolé, A; Wislez, M | 1 |
| Chang, GC; Chen, KC; Hsu, KH; Lee, HM; Tsai, CR; Yang, TY | 1 |
| Boellaard, R; Buettner, R; Dietlein, M; Draube, A; Engel-Riedel, W; Hallek, M; Hellmich, M; Heukamp, L; Jacobs, AH; Ko, YD; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Papachristou, I; Querings, S; Scheffler, M; Schlesinger, A; Schulte, K; Smit, E; Stoelben, E; Thomas, RK; Toepelt, K; Ullrich, RT; Wolf, J; Zander, T | 1 |
| Akhavanfard, S; Bergethon, K; Christensen, JG; Cosper, AK; Dias-Santagata, D; Digumarthy, S; Engelman, JA; Fidias, P; Gettinger, S; Heist, RS; Iafrate, AJ; Lanuti, M; Lynch, TJ; Mark, EJ; Mino-Kenudson, M; Sequist, LV; Shaw, AT; Temel, J; Turke, AB; Vernovsky, K; Wain, JC; Waltman, BA | 1 |
| Fujita, S; Fukuhara, A; Hatachi, Y; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Nagai, H; Okuda, C; Sakamori, Y; Togashi, Y | 1 |
| Bivona, TG; Chang, K; Costa, C; Dahlman, K; Hannon, G; Hieronymus, H; Miller, VA; Moonsamy, P; Parker, J; Rosell, R; Sawyers, CL; Taron, M | 1 |
| Murphy, M; Stordal, B | 1 |
| Heigener, DF; Horwood, K; Mali, P; Reck, M; van Zandwijk, N; Wu, YL | 1 |
| de Marinis, F; Di Maio, M; Gridelli, C; Ricciardi, S; Rossi, A | 1 |
| Döme, B; Fehniger, TE; Laurell, T; Marko-Varga, G; Rezeli, M; Végvári, A | 1 |
| Choi, BG; Han, JY; Kim, JY; Lee, SH; Yoo, NJ | 1 |
| Nishizawa, S; Saito, T; Soejima, Y; Takahashi, M; Yamamoto, J | 1 |
| Abe, H; Aikawa, E; Akiba, J; Azuma, K; Kage, M; Kawahara, A; Nakashima, K; Sumi, A; Taira, T; Takamori, S; Yamaguchi, T | 1 |
| Fukuoka, J; Isa, S; Kawaguchi, T; Kitaichi, M; Koh, Y; Kubo, A; Kusunoki, Y; Nakagawa, K; Okamoto, I; Takada, M | 1 |
| Asahina, H; Dosaka-Akita, H; Fujita, Y; Harada, M; Inoue, A; Ishida, T; Isobe, H; Kinoshita, I; Maemondo, M; Nishimura, M; Nukiwa, T; Oizumi, S; Saijo, Y; Sukoh, N | 1 |
| Cabodi, S; Camacho-Leal, MP; Defilippi, P; Morello, V; Papotti, M; Repetto, D; Sigismund, S; Turco, E; Volante, M | 1 |
| Guo, J; Ma, B; Wang, Y; Zhang, Y; Zhou, H | 1 |
| Anadkat, MJ; Hepper, DM; Wu, P | 1 |
| Früh, M | 1 |
| Tuder, RM; Winn, RA | 1 |
| Bae, JH; Chung, JS; Kang, CD; Kim, H; Kim, MJ; Kim, SH; Kim, SJ; Park, SJ | 1 |
| Azuma, J; Fujio, Y; Furukawa, M; Goya, S; Hirata, H; Kawase, I; Kida, H; Kijima, T; Minami, T; Nagatomo, I; Nonen, S; Otani, Y; Shimizu, T; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Chung, WC; Gold, KA; Hittelman, WN; Kang, SM; Ki Hong, W; Kim, ES; Koo, JS; Lee, J; Ryu, SH | 1 |
| Chen, KY; Shih, JY; Wu, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Dhillon, S; Muir, VJ | 1 |
| Kimura, H; Nakagawara, A; Nakajima, T; Yasufuku, K; Yoshino, I | 1 |
| Fujita, S; Hata, A; Hayashi, H; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Kunimasa, K; Morita, S; Nanjo, S; Nishiyama, A; Otsuka, K; Tomii, K; Yoshioka, H | 1 |
| Chang, YC; Shih, JY; Wu, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Abbate, I; Bongarzone, I; Cremona, M; De Bortoli, M; Galetta, D; Garrisi, VM; Mangia, A; Paradiso, A; Pastorino, U; Quaranta, M; Vaghi, E | 1 |
| Kern, I; Kovac, V; Rajer, M; Smrdel, U; Vrankar, M; Zwitter, M | 1 |
| Antoine, M; Cadranel, J; Lacave, R; Poulot, V; Ruppert, AM; Wislez, M | 1 |
| Chang, HC; Chao, TY; Chung, YH; Lie, CH; Lin, MC; Wang, CC; Wang, JL | 1 |
| Ardizzoia, A; Bertolini, A; Cortesi, E; Fagnani, D; Farina, G; Farris, A; Garassino, MC; Labianca, R; Locatelli, MC; Longo, F; Mancuso, A; Martelli, O; Moscetti, L; Pavese, I; Rulli, E; Scanni, A; Tomirotti, M; Valmadre, G | 1 |
| Crinò, L; Metro, G | 1 |
| Bagai, R; Fan, W; Flask, CA; Fu, P; Hafez-Khayyata, S; Halmos, B; Howell, S; Huang, H; Jiang, S; Koon, H; Kresak, A; Ma, PC; Morrison, B; Tang, Z; Vasanji, A; Yin, L | 1 |
| Dyckhoff, G; Gottschling, S; Herpel, E; Kuhnt, T; Pelz, T; Penzel, R; Schnabel, PA; Thomas, M | 1 |
| Fujita, Y; Hiroshima, K; Niijima, M; Nishio, K; Saitoh, M; Takiguchi, Y; Tatsumi, K | 1 |
| Azzoli, CG; Bains, M; Chaft, JE; Downey, R; Flores, R; Heelan, RT; Kris, MG; Krug, LM; Ladanyi, M; Miller, VA; Pao, W; Park, B; Rizvi, NA; Rusch, V; Shen, R; Singh, B; Zakowski, M | 1 |
| Bosquée, L; Corhay, JL; Thonnard, AS | 1 |
| de Lima Lopes, G; Haaland, BA; Ku, GY | 1 |
| Hazama, M; Kim, YH; Niimi, M; Sakamori, Y; Tanaka, S; Yanagihara, K | 1 |
| Wang, L; Xiao, F; Zhang, W; Zheng, J | 1 |
| Abdiche, S; Bonnabau, H; Chouaïd, C; Cumin, I; Decroisette, Ch; Ejnaini, CN; Hureaux, J; Lombard, JN; Mazières, J; Monnet, I; Quéré, G; Vergnenègre, A | 1 |
| Cui, CX; Hao, XZ; Li, JL; Shi, YK; Wang, B; Wang, HY; Wang, Y; Zhang, XR; Zhao, LD | 1 |
| Bass, JD; Burris, HA; Daniel, DB; Friedman, EK; Greco, FA; Hainsworth, JD; Mitchell, RB; Shipley, DL; Spigel, DR; Waterhouse, DM; Whorf, RC; Zangmeister, J | 1 |
| Horai, T; Horiike, A; Kudo, K; Nishio, M; Ohyanagi, F; Yanagitani, N | 1 |
| Goya, S; Hirata, H; Kawase, I; Kida, H; Kijima, T; Kuhara, H; Minami, T; Nagatomo, I; Osa, A; Tachibana, I; Takahashi, R; Takeda, Y; Tetsumoto, S | 1 |
| Fujii, M; Maehara, Y; Mitsudomi, T; Murakami, H; Osada, H; Sekido, Y; Suda, K; Tomizawa, K; Yatabe, Y | 1 |
| Antoine, M; Brambilla, E; Busser, B; Cadranel, J; Coll, JL; de Fraipont, F; Dufort, S; Hurbin, A; Moro-Sibilot, D; Rabbe, N; Tenaud, C; Wislez, M | 1 |
| Gruber-Mösenbacher, U; Hilbe, W; Hulla, W; Mohn-Staudner, A; Pirker, R; Ploner, F; Popper, H; Studnicka, M; Wrba, F | 1 |
| Bhattacharyya, A; Kundu, S; Sengupta, S | 1 |
| Ji, Y; Lu, YJ; Ma, SL; Wang, CR; Wu, YM; Zhao, YF | 1 |
| Berghmans, T; Meert, AP; Sculier, JP | 1 |
| Ansari, R; Bustin, F; Flynn, P; Hainsworth, J; Hart, L; Herbst, RS; O'Connor, P; Otterson, GA; Soh, CH; Vlahovic, G | 1 |
| Campbell, TC; Hoang, T; Kim, K; Larson, MM; LoConte, NK; Marcotte, SM; O'Mahar, SE; Seo, S; Traynor, AM | 1 |
| Berg, A; Brustugun, OT; Helland, Å; Lund-Iversen, M | 1 |
| Dallas, JL; Jantz, MA; Kaye, FJ; Lightsey, JL; Sonntag, C | 1 |
| Azzoli, CG; Ginsberg, MS; Johnson, ML; Kris, MG; Miller, VA; Pao, W; Riely, GJ; Rizvi, NA; Sima, CS | 1 |
| Garrido, P; Longo, F; Olmedo, ME; Riquelme, A; Rodríguez, M | 1 |
| Date, H; Mishima, M; Nagai, H; Niimi, M; Sasaki, T; Seo, N; Tanaka, S; Yanagihara, K; Yasuda, H | 1 |
| Haro, A; Ito, K; Kawano, D; Maehara, Y; Miura, N; Morodomi, Y; Shoji, F; Takenaka, T; Yano, T; Yoshino, I | 1 |
| Katzumata, A; Kawauchi, M; Kuramoto, S; Matsumoto, Y; Ono, Y; Toyoshima, A; Toyota, Y | 1 |
| Busch, AM; Cyrus, J; Dmitrovsky, E; Dragnev, KH; Erkmen, CP; Freemantle, SJ; Galimberti, F; Johnstone, D; Kurie, JM; Liu, X; Ma, T; Memoli, V; Nugent, W; Rigas, JR; Seltzer, M; Tsongalis, GJ; Waxman, S | 1 |
| Ma, S; Xu, Y; Zhang, Y | 1 |
| Heneberg, P | 1 |
| Li, Y; Liu, B; Qin, X; You, J; Zhou, Q | 1 |
| Gu, A; Han, B; Shen, J; Shi, C; Xiong, L | 1 |
| Horinouchi, H; Izumi, Y; Kamiya, K; Kawamura, M; Kohno, M; Nomori, H; Shimada, N; Watanabe, M | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, GK; Lee, JS; Lee, YJ; Yoon, KA; Yun, T | 1 |
| Chen, Y; Feng, L; Ge, W; Han, W; Jin, H; Li, J; Lin, X; Pan, H; Sun, J; Wang, X; Wang, Y | 1 |
| Baselga, J; Felip, E; Hermes, A; Klughammer, B; Reck, M; Tan, EH | 1 |
| Borget, I; Cadranel, J; Chouaid, C; Coudert, B; Daniel, C; Dansin, E; Friard, S; Madelaine, J; Madroszyk, A; Morin, F; Pignon, JP; Quoix, E; Westeel, V | 1 |
| Bryce, J; Carillio, G; Costanzo, R; Daniele, G; De Feo, G; Di Maio, M; Giordano, P; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Agustoni, F; Buzzoni, R; Ducceschi, M; Formisano, B; Gelsomino, F; Pietrantonio, F; Platania, M; Pusceddu, S; Vitali, M; Zilembo, N | 1 |
| Shepherd, FA | 2 |
| Armour, AA; Chao, TY; Chu, DT; Duffield, EL; Fukuoka, M; Jiang, H; Leong, SS; Mok, TS; Nakagawa, K; Rukazenkov, Y; Saijo, N; Speake, G; Sriuranpong, V; Sunpaweravong, P; Thongprasert, S; To, KF; Wu, YL; Yang, JC | 1 |
| Dallas, J; Jantz, MA; Kaye, FJ | 1 |
| Durand, JB; Kim, P; Yusuf, SW | 1 |
| Okamoto, I; Takeda, M | 1 |
| Gemma, A; Hagiwara, K; Inoue, A; Isobe, H; Kobayashi, K; Maemondo, M; Nukiwa, T; Oizumi, S; Saijo, Y; Satoh, H; Yoshizawa, H | 1 |
| Fukudo, M; Ikemi, Y; Katsura, T; Kim, YH; Masago, K; Mio, T; Mishima, M; Okuda, C; Sakamori, Y; Togashi, Y; Tsuchido, Y | 1 |
| Chen, YY; Kiura, K; Noujima, D; Ochi, N; Takigawa, N; Tanimoto, M; Tanimoto, Y; Zhang, D | 1 |
| Ahn, JS; Ahn, MJ; Jung, SH; Kim, ST; Kim, SW; Lee, J; Park, K; Park, YH; Sohn, I; Sun, JM; Uhm, JE | 1 |
| Kosaka, T; Kuwano, H; Mogi, A; Yamaki, E | 1 |
| Ishida, T; Katsuura, Y; Minemura, H; Misa, K; Munakata, M; Tachihara, M; Uematsu, M | 1 |
| Chanprapaph, K; Pongcharoen, P; Vachiramon, V | 1 |
| Altavilla, G; Benecchi, S; Magri, I; Pettineo, G; Rosell, R; Salazar, MF; Santarpia, M | 1 |
| Bennouna, J; de Castro, J; Dingemans, AM; Gridelli, C; Griesinger, F; Grossi, F; Langer, C; Rossi, A; Thatcher, N; Wong, EK | 1 |
| Asano, H; Harada, M; Kagawa, S; Kanazawa, S; Katsui, K; Maki, Y; Masuda, H; Miyoshi, S; Muraoka, T; Naito, M; Naomoto, Y; Takemoto, M; Toyooka, S; Tsukuda, K | 1 |
| Hashimoto, K; Komune, S; Nakano, T; Nakashima, T; Oda, Y; Oyama, M; Shiratsuchi, H; Tamiya, S; Yamamoto, H | 1 |
| Belani, CP; Blumenschein, G; Goss, G | 1 |
| Chida, K; Inui, N; Matsuura, S; Nakamura, Y; Ozawa, Y; Shirai, T; Suda, T; Suganuma, H; Toyoshima, M; Yamada, T; Yasuda, K; Yokomura, K | 1 |
| Iwamoto, Y; Katakami, N; Kobayashi, M; Matsui, K; Moriyama, A; Nakagawa, K; Sueoka-Aragane, N; Takada, M; Takeda, K; Yoshioka, H | 1 |
| Bakri, K; Beaumont, JL; Bradford, DS; Crane, JM; Harper, HD; Hensing, TA; Lee, CB; McElroy, E; Moore, DT; Niell, HB; Pal, S; Peterman, AH; Schwartz, G; Socinski, MA; Stinchcombe, TE; Taylor, M | 1 |
| Correa, PD; Rizwanullah, M; Shrimali, RK | 1 |
| He, W; Jiang, G; Liu, M; Song, N; Zhang, P | 1 |
| Chang, YL; Jan, IS; Luo, SC; Shih, JY; Su, KY; Tsai, TH; Wu, SG; Yang, PC; Yu, CJ; Yu, SL | 1 |
| Boons, CC; Boven, E; Hugtenburg, JG; Mangnus, D; Moes, JE; Smit, EF; Swart, EL; Timmers, L | 1 |
| Han, JY; Kim, HT; Lee, GK; Lee, JS; Lim, KY; Park, SY; Won, YW; Yoon, KA; Yun, T | 1 |
| Chang, SC; Hsu, SY; Kuo, LC; Lai, JI; Lai, YC; Lin, PC; Wang, WS | 1 |
| Ameshima, S; Asami, K; Atagi, S; Hirai, K; Kawahara, M; Koizumi, T; Morikawa, A; Morozumi, N; Tsukadaira, A | 1 |
| Cha, MY; Chae, YJ; Kim, M; Kim, MS; Kim, YH; Lee, GS; Lee, KH; Lee, KO; Park, J; Park, SB; Song, JY; Suh, KH | 1 |
| Kagohashi, K; Kawaguchi, M; Kurishima, K; Nakayama, H; Ohara, G; Satoh, H | 1 |
| Blanchet, B; Dauphin, A; Dusser, D; Faivre, L; Goldwasser, F; Gomo, C; Mir, O; Ropert, S; Schoemann-Thomas, A; Taieb, F; Vidal, M | 1 |
| Berrino, L; Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; Heymach, JV; Martinelli, E; Morgillo, F; Saintigny, P; Troiani, T; Tuccillo, C | 1 |
| Han, SY; Li, PP; Zhao, MB; Zhuang, GB | 1 |
| Ando, M; Dote, H; Jida, M; Kawasaki, K; Kiura, K; Kobayashi, N; Kubo, T; Miyoshi, S; Ogino, A; Otani, H; Soh, J; Toyooka, S; Ueno, T; Yamamoto, H | 1 |
| Akerley, WL; Arthur, S; Brugger, W; Chen, Y; Costa, DB; Ferrari, D; Garmey, EG; Gerber, DE; Gorbachevsky, I; Orlov, S; Ramlau, R; Schiller, JH; Schwartz, B; Sequist, LV; von Pawel, J | 1 |
| Fukudo, M; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y | 1 |
| Moro-Sibilot, D | 1 |
| Douillard, JY; Lokiec, F | 1 |
| Besse, B; Zalcman, G | 1 |
| Giroux Leprieur, E; Planchard, D | 1 |
| Chew, HK; Christensen, S; Davies, AM; Gandour-Edwards, R; Gitlitz, B; Linden, H; Mack, PC; Solis, LJ; Somlo, G; Yang, X | 1 |
| Fujita, S; Kim, YH; Masago, K; Mio, T; Mishima, M; Okuda, C; Sakamori, Y; Togashi, Y | 1 |
| Chen, G; Chen, L; Feng, J; Hu, C; Huang, J; Liu, XQ; Lu, S; Luo, Y; Ma, J; Ren, S; Wang, C; Wang, J; Wu, YL; Xiu, Q; Ye, M; You, C; Zhang, L; Zhang, S; Zhang, Y; Zhi, X; Zhou, C; Zhou, S | 1 |
| Becker, A; Crombag, L; Heideman, DA; Postmus, PE; Smit, EF; Thunnissen, FB; van Wijk, AW | 1 |
| Barratt, BJ; Fukuoka, M; Hada, S; Jawaid, A; Kamatani, N; Kato, H; Kudoh, S; March, R; Mushiroda, T; Nakamura, Y; Nakata, K; Nyberg, F; Ohe, Y; Takahashi, A; Umemura, T | 1 |
| An, SJ; Chen, HJ; Chen, ZH; Huang, YS; Su, J; Wang, BC; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Yin, XL; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Houwing, RH; Koster, ME; Lips, IM; Vonk, EJ | 1 |
| de Lima Lopes, G; Do, YK; Finkelstein, EA; Mok, T; Segel, JE; Tan, DS | 1 |
| Akimoto, S; Clausen, IG; Dobashi, T; Fukuoka, M; Harbron, CG; Higenbottam, T; Kato, H; Kawakami, T; Kihara, M; Komatsu, Y; Kudoh, S; Kyono, Y; Marko-Varga, G; Nagasaka, K; Nakata, K; Nishimura, T; Nyberg, F; Ogiwara, A; Ohe, Y; Otsuji, M; Peers, IS; South, MC; Takami, S; Tu, HK; Wada, K | 1 |
| Gaafar, RM; Hasan, B; Papamichael, D; Scagliotti, GV; Surmont, VF; Torri, V; Van Klaveren, RJ; van Meerbeeck, JP; Welch, JJ | 1 |
| Fujita, S; Fukuhara, A; Hatachi, Y; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
| Hotta, K; Kiura, K | 1 |
| Amihai, D; Gilad, Y; Gorzalczany, Y; Hammel, I; Merimsky, O; Sagi-Eisenberg, R | 1 |
| Aziz, F; Cheng, P; Ding, X; Gao, H; Liu, H; Su, X; Wang, D; Wei, D; Zhang, T | 1 |
| de Boer, RH; Wong, HL | 1 |
| Bunn, PA; Camidge, DR; Camidge, R; Dziadziuszko, R; Eisen, T; Franklin, WA; Hirsch, FR; Kabbinavar, F; Martins, R; Richardson, F; Richardson, K; Rusk, J; Schnell, FM; Sternberg, DW; Varella-Garcia, M; Wacker, B | 1 |
| Arcila, ME; Azzoli, CG; Janjigian, YY; Kass, SL; Kris, MG; Ladanyi, M; Miller, VA; Oxnard, GR; Pao, W; Riely, GJ; Sima, CS | 1 |
| Fujiwara, K; Kiura, K; Kudo, K; Matsuo, K; Mizuta, M; Rai, K; Sato, T; Tsushima, M; Yamadori, I; Yonei, T | 1 |
| Bellevicine, C; Malapelle, U; Palombini, L; Troncone, G; Zeppa, P | 1 |
| Chen, X; Geng, Y; Hu, X; Li, W; Shu, Y; Wang, R; Yin, Y | 1 |
| Barberis, M; Catania, C; de Braud, F; De Pas, T; Delmonte, A; Fumagalli, C; Giovannini, M; Manzotti, M; Spaggiari, L; Spitaleri, G; Toffalorio, F | 1 |
| Kawano, Y; Kawasaki, M; Kitasato, Y; Mizuta, Y; Sakoda, Y; Takata, S | 1 |
| Keiding, S; Meldgaard, P; Memon, A; Nexo, E; Sorensen, BS; Sorensen, L; Weber, B; Winterdahl, M | 1 |
| Jou, YS; Ko, JY; Lin, KT; Lin, SC; Tu, PH; Wang, YW | 1 |
| Baumann, M; Benes, C; Dahm-Daphi, J; Dikomey, E; Gheorghiu, L; Krause, M; Kriegs, M; Morsbach, F; Nanda, A; Sander, D; Settleman, J; Wang, M; Willers, H | 1 |
| Chaft, JE; Kris, MG; Miller, VA; Oxnard, GR; Riely, GJ; Sima, CS | 1 |
| Chang, GC; Chen, HW; Chen, JJ; Hsieh, WY; Lee, JY; Lee, YM; Yang, PC; Yu, SL | 1 |
| Lin, D; Ma, F; Shi, Y; Sun, T; Xu, B | 1 |
| Colomer, R; Quintela-Fandino, M | 1 |
| Clarke, JL; Grommes, C; Holodny, AI; Kris, MG; Lassman, AB; Miller, VA; Oxnard, GR; Pao, W | 1 |
| Aoki, T; Hanagiri, T; Korogi, Y; Mukae, H; Uramoto, H; Yamashita, Y; Yoshii, C | 1 |
| Fiegl, M; Hack, R; Hilbe, W; Jamnig, H; Pall, G; Pircher, A; Sterlacci, W; Ulsperger, E; Zelger, B | 1 |
| Douillard, JY; Jiang, GL; Kim, ES; Li, LY; Liao, ML; Milenkova, T; Sun, Y; Wu, YL | 1 |
| Hao, XZ; Hu, XS; Li, B; Li, JL; Shi, YK; Wang, B; Wang, L; Wang, Y; Zhang, XR; Zhu, HX | 1 |
| Li, L; Liu, JL; Su, H; Xu, CA; Zou, HW | 1 |
| Chu, QS; de Jonge, MJ; Hamilton, M; Iwata, K; McCarthy, S; Mita, AC; Mita, MM; Papadopoulos, K; Ricart, A; Rowinsky, EK; Schwartz, G; Tolcher, AW; Verweij, J; Wacker, B; Witt, K; Wood, L | 1 |
| Asahina, H; Horinouchi, H; Kubota, K; Nokihara, H; Sekine, I; Tamura, T; Yamamoto, N | 1 |
| Azuma, K; Hattori, S; Kage, M; Kawahara, A; Kinoshita, T; Kuwano, M; Nakagawa, K; Nakashima, K; Okamoto, I; Ono, M; Taira, T; Takamori, S; Takeda, M | 1 |
| Beckett, LA; Davies, AM; Gandara, DR; Hesketh, PJ; Lara, PN; Lau, D; Li, T; Mack, PC; Perkins, N; Sangha, R | 1 |
| Duffield, E; Fukuoka, M; Goto, K; Ichinose, Y; Itoh, Y; Jiang, H; McCormack, R; Mok, T; Negoro, S; Nishio, K; Ohe, Y; Saijo, N; Yamamoto, N | 1 |
| Loo, BW; Ma, L; Meng, X; Murphy, JD; Sun, X; Yu, J | 1 |
| Cappuzzo, F; D'Incecco, A | 1 |
| Chin, A; Depinho, RA; Dinulescu, DM; Faça, VM; Gazdar, AF; Goodman, G; Hanash, SM; Kelly-Spratt, K; Kemp, CJ; Kucherlapati, R; Lockwood, WW; Park, KS; Pitteri, SJ; Politi, K; Sage, J; Taguchi, A; Varmus, HE; Wong, CH; Zhang, Q | 1 |
| Custodio, A; de Castro, J | 1 |
| Horai, T; Horiike, A; Kasahara, K; Kudo, K; Miyauchi, E; Nishio, M; Ohyanagi, F | 1 |
| Chua, KT; Lai, NL; Lee, CH; Liam, CK; Lim, BK; Pang, YK | 1 |
| Abe, T; Hayashi, S; Hirai, M; Hosomi, T; Iwanaga, K; Kimura, S; Komiya, K; Nakamura, T; Sato, A; Sueoka, E; Sueoka-Aragane, N; Ureshino, N | 1 |
| Guo, J; Liu, Y; Wang, Y; Wang, Z; Yang, J | 2 |
| Carloni, F; Castellani, C; Drudi, F; Lazzari-Agli, L; Sartori, S; Scarpi, E; Tassinari, D; Tombesi, P | 1 |
| Arakawa, H; Hataji, O; Johkoh, T; Kusumoto, M; Sakai, F; Taguchi, O | 1 |
| Clark, P; George, E; Rinaldi, F | 1 |
| Barlesi, F; Bota, S; Chouaid, C; Corre, R; Delhoume, JY; Dujon, C; Falchero, L; Jullian, H; LeCaer, H; Vergnenegre, A | 1 |
| Guo, ZZ; Huang, JJ; Huang, Y; Lin, TY; Tian, Y; Xu, F; Zhang, LL | 1 |
| Kani, K; Mallick, P; Sordella, R | 1 |
| Chang, CY; Chang, SC; Chang, SJ; Chen, CY; Liu, YC; Tang, GJ; Wei, YF; Yu, CJ; Yuan, MK | 1 |
| Arao, T; Horiike, A; Ikeda, N; Kasahara, K; Kimura, H; Koizumi, F; Matsumoto, K; Nishio, K; Nishio, M; Ohira, T; Saijo, N; Sakai, A; Sakai, K; Sone, T; Yamanaka, T | 1 |
| Bachi, A; Bergamaschi, L; Bulotta, A; Cattaneo, A; Floriani, I; Garavaglia, D; Ghio, D; Gregorc, V; Grigorieva, J; Lazzari, C; Roder, H; Sorlini, C; Spreafico, A; Tsypin, M; Viganò, MG | 1 |
| Choi, CM; Choi, DR; Kim, SW; Lee, DH; Lee, JS; Suh, C | 1 |
| Bagust, A; Blundell, M; Boland, A; Davis, H; Dickson, R; Dundar, Y; Hockenhull, J; Martin Saborido, C; Oyee, J; Ramani, VS | 1 |
| Blasinska-Morawiec, M; Brugger, W; Cappuzzo, F; Curescu, S; Manikhas, GM; Mayne, K; Mazieres, J; Sakalauskas, R; Triller, N; Trunzer, K; Ward, C; Whittom, R | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Petrelli, F | 1 |
| Bendapudi, PK; Chen, J; Choi, P; Felsher, DW; Horng, G; Hughes, NP; Kawashima, T; Kitamura, T; Koh, S; Lin, HJ; Miller, VA; Paik, D; Schwartz, LH; Tran, PT | 1 |
| Ahn, J; Hyon, JY; Lee, JH; Wee, WR | 1 |
| Imyanitov, EN; Ivantsov, AO; Levchenko, EV; Matsko, DE; Moiseyenko, FV; Moiseyenko, VM; Radzhabova, SA; Suspitsin, EN | 1 |
| Asuncion, BR; Gaire, F; Gustavson, M; Hirsch, FR; Ikeda, N; Kato, Y; Mascaux, C; Matsubayashi, J; Nagao, T; Ohira, T; Ranger-Moore, J; Tran, C; Wynes, MW; Yoshida, K; Zhao, JM | 1 |
| Lanuti, M; Mino-Kenudson, M; Sequist, LV; Sharma, A | 1 |
| Eshuis, SA; Gemmel, F; Gemmel, P; van Vollenhoven, F | 1 |
| Agelaki, S; Georgoulias, V; Giassas, S; Kentepozidis, N; Kotsakis, A; Pallis, AG; Papakotoulas, P; Tryfonidis, K; Vamvakas, L; Vardakis, N; Voutsina, A | 1 |
| Doheny, S; Hughes, D | 1 |
| Chen, C; Fujioka, N; Gupta, K; Gupta, V; Johnson, KN; Kratzke, RA; Li, Y; Nguyen, J; Niehans, G; Pasrija, T | 1 |
| Knap, MM; Madsen, HH; Meldgaard, P; Nexo, E; Sorensen, BS; Weber, B | 1 |
| Dainton, M; Lim, E; Min, T; Nicholson, AG; O'Brien, ME; Popat, S; Swansbury, J; Vieira de Araújo, A; Wotherspoon, A | 1 |
| Chen, W; Qiao, J | 1 |
| Armour, A; Chen, YM; Chu, DT; Duffield, E; Fukuoka, M; Kuo, HP; Lam, KC; Liao, M; Magill, P; Negoro, S; Saijo, N; Thongprasert, S; Wu, YL; Yang, JC | 1 |
| Cho, J; Chowhan, NM; Funke, R; Gadgeel, SM; Lara, PN; Lynch, TJ; Miller, VA; Mitchell, B; Pennell, NA; Pietanza, MC; Vrindavanam, N; Wakelee, HA; Yanagihara, RH | 1 |
| Li, B; Sheng, ZX; Wang, F; Wang, LD | 1 |
| Goya, S; Hatazawa, J; Hirata, H; Inoue, A; Kawase, I; Kida, H; Kijima, T; Kumagai, T; Kumanogoh, A; Nagatomo, I; Okumura, M; Shimosegawa, E; Tachibana, I; Takahashi, R; Takeda, Y; Yoshida, M | 1 |
| Brownstein, CM; Chen, D; Crino, L; Eberhardt, WE; Engelman, JA; Habben, K; Jänne, PA; Liu, L; Novello, S; Ramalingam, SS; Reck, M; Schneider, CP; Spigel, DR; Steins, MB | 1 |
| Li, H; Schmid-Bindert, G; Su, B; Wang, D; Yang, X; Zhao, Y; Zhou, C | 1 |
| Levêque, D | 1 |
| Barberis, M; Catania, C; De Pas, TM; Giovannini, M; Labianca, R; Manzotti, M; Spaggiari, L; Toffalorio, F; Trifirò, G | 1 |
| Allen-Auerbach, MS; Benz, MR; Czernin, J; Figlin, R; Garon, EB; Herrmann, K; Phelps, ME; Reckamp, KL; Walter, F; Weber, WA | 1 |
| Benz, G; Brutsche, M; Früh, M; Putora, PM; Rodriguez, R | 1 |
| Cromwell, I; Melosky, B; Peacock, S; van der Hoek, K | 1 |
| Higashiyama, M; Kimura, T; Kiura, K; Kondoh, K; Kudoh, S; Minami, Y; Mitsudomi, T; Noguchi, M; Nokihara, H; Oda, M; Ohe, Y; Saito, H; Tachibana, K; Takeuchi, S; Tanaka, H; Uramoto, H; Yamada, T; Yano, S; Yasumoto, K; Yatabe, Y; Yokota, J; Yoshida, J | 1 |
| Chang, JW; Chen, YR; Chen, YT; Chiu, YT; Hsieh, JJ; Huang, SF; Liu, HP; Wu, HD; Yu, TF | 1 |
| Fujita, S; Hata, A; Imai, Y; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Kunimasa, K; Tachikawa, R; Tomii, K; Yoshioka, H | 1 |
| Boellaard, R; Dietlein, M; Holstein, A; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Scheffler, M; Ullrich, RT; Wolf, J; Zander, T | 2 |
| Murakami, H; Naito, T; Nakamura, Y; Nishio, K; Nokihara, H; Sarashina, A; Seki, Y; Shahidi, M; Takahashi, T; Tamura, T; Yamamoto, N | 1 |
| Brugarolas, A; Evgenyeva, E; Fernández, FJ; Forteza, J; González-Manzano, R; Martínez-Navarro, EM; Rebollo, J; Sureda, M; Valenzuela, B | 1 |
| Groen, HJ; Hiltermann, TJ; Schuuring, E; Timens, W | 1 |
| Chan, AB; Lam, KC; Lee, KW; Lo, AW | 1 |
| Anchisi, S; Bernhard, J; Bodis, S; Caspar, CB; Cathomas, R; D'Addario, G; Fischer, N; Klingbiel, D; Kotrubczik, NM; Mayer, M; Pesce, GA; Peters, S; Pilop, C; Pless, M; Ribi, K; Schlaeppi, M; Stupp, R; von Moos, R; Weber, DC; Zouhair, A | 1 |
| Basu, S; Batus, M; Bonomi, PD; Buckingham, L; Coon, J; Fidler, MJ; Jacobson, KK; Jewell, SS; Morrison, LE; Walters, K | 1 |
| Cohen, EE; Faoro, L; Gao, F; Govindan, R; Karrison, T; Kozloff, M; Salgia, R; Subramanian, J; Szeto, L; Vokes, EE | 1 |
| Beijnen, JH; Lankheet, NA; Malingré, MM; Schaefer-Prokop, CM; Staaks, GH; ter Heine, R; van den Bosch, RT; van den Brand, JJ; van der Westerlaken, MM | 1 |
| Cole, PA; Head, S; Kim, K; Leahy, DJ; Longo, PA; Tarrant, MK; Wang, Z | 1 |
| Chen, Y; Deng, J; Zhuang, L | 1 |
| Alfieri, RR; Andreoli, R; Ardizzoni, A; Bonelli, M; Cavazzoni, A; De Palma, G; Fumarola, C; Galetti, M; Galvani, E; La Monica, S; Mari, E; Mor, M; Mozzoni, P; Mutti, A; Petronini, PG; Tiseo, M; Tramonti, S | 1 |
| Chung, CT; Hwang, DM; Lara-Guerra, H; Leighl, NB; Pintilie, M; Schwock, J; Tsao, MS; Waddell, TK | 1 |
| Fang, W; Gu, XY; Jiang, Z | 1 |
| Ashley, S; Chua, S; Cook, G; Coward, JI; Gunapala, R; Myerson, JS; O'Brien, ME; Popat, S; Puglisi, M; Sharma, B; Trani, L; Wotherspoon, A | 1 |
| Cappuzzo, F; Jänne, PA; Mok, TS; Soria, JC | 1 |
| Forsyth, M; Nadler, E; Reyes, C; Satram-Hoang, S | 1 |
| Chang, YL; Chen, YH; Kuo, YW; Shih, JY; Tsai, MF; Wu, SG; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Düwel, P; Gehl, HB; Görner, M; Hirnle, P; Müller, F; Riesenberg, H | 1 |
| Jirillo, A; Trojniak, MP | 1 |
| Arpin, D; Ernesto, S; Nesme, P; Pérol, M | 1 |
| Alam, S; Layman, R; Lustberg, M; Reinbolt, RE; Shapiro, C | 1 |
| Guo, H; Kang, Y; Li, Y; Lin, D; Liu, Q; Tian, G; Wan, Y; Yao, Z | 1 |
| Bischoff, H; Chouaid, C; de Castro Carpeño, J; Grossi, F; Heigener, D; Nuijten, MJ; Vergnenègre, A; Walzer, S | 1 |
| Bar, J; Onn, A | 1 |
| Aleknavičius, E; Cicėnienė, A; Drobnienė, M; Grigienė, R; Lachej, N; Steponavičienė, L; Zelvienė, TP | 1 |
| Chen, YM; Chou, TY; Fan, WC; Lee, YC; Liu, SH; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J; Wu, CH | 1 |
| Alder, H; Cascione, L; Condorelli, G; Croce, CM; Di Leva, G; Engelman, JA; Garofalo, M; Jeon, YJ; Lovat, F; Nephew, KP; Ngankeu, A; Nuovo, G; Ono, M; Rho, JK; Romano, G; Sun, J; Volinia, S | 1 |
| Kameda, Y; Koizume, S; Matsukuma, S; Miyagi, Y; Nakamura, Y; Nakayama, H; Sakuma, Y; Yamazaki, Y; Yokose, T; Yoshihara, M | 1 |
| Cheng, H; De Luo, B; Liu, ZG; Ren, Y; Zhang, YF; Zhu, H | 1 |
| Ren, SX; Zhang, L; Zhou, CC; Zhou, SW | 1 |
| Gabr, AG; Goto, H; Hanibuchi, M; Kakiuchi, S; Kuramoto, T; Moriya, Y; Nishioka, Y; Ogawa, H; Saijo, A; Sakaguchi, S; Sone, S; Suzuki, M; Trung, VT | 1 |
| Ishida, T; Iwasaku, M; Korogi, Y; Kunimasa, K; Nagai, H; Nishiyama, A; Yoshioka, H | 1 |
| Aftab, D; Chen, X; Chmielecki, J; Hutchinson, K; Kris, MG; Miller, V; Pao, W; Pietanza, MC; Rizvi, N; Shen, R; Stout, T; Viale, A; Zhao, Z | 1 |
| He, CS; Hu, ZH; Liu, JL; Tian, Y; Xie, M; Xu, F; Zhang, L; Zhao, LP | 1 |
| Funada, Y; Hatakeyama, Y; Hori, S; Kasai, D; Kobayashi, K; Kondoh, T; Kotani, Y; Nagano, T; Nishimura, H; Nishimura, Y | 1 |
| Arcila, ME; Capelletti, M; Eck, MJ; Ginsberg, MS; He, M; Jänne, PA; Kris, MG; Ladanyi, M; Miller, VA; Nafa, K; Oxnard, GR; Yun, CH; Zhao, B | 1 |
| Goishi, K; Higashiyama, S; Ise, N; Nambara, D; Omi, K | 1 |
| Endo, M; Harada, H; Inomata, M; Kenmotsu, H; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Fujimoto-Ouchi, K; Iwai, T; Mori, K; Moriya, Y; Shirane, M | 1 |
| Chang, CY; Chang, TY; Chao, YS; Chen, CH; Chen, YR; Chu, CY; Fang, MY; Hsieh, HP; Hsu, JT; Huang, YW; Lien, TW; Lin, WH; Song, JS; Wu, SH; Yen, KJ | 1 |
| Goozner, M | 1 |
| Cromwell, I; Malfair Taylor, SC; Melosky, B; Peacock, S; van der Hoek, K | 1 |
| Abolhoda, A; Ahn, JS; Ahn, MJ; Cui, Z; Kim, Y; Ko, J; Ou, SH; Park, K | 1 |
| Chen, ZG; Fan, S; Khuri, FR; Koo, J; Li, Y; Owonikoko, TK; Ramalingam, SS; Sun, SY; Yue, P | 1 |
| Hao, X; Li, J; Shi, Y; Wang, Y; Zhang, X | 1 |
| Chen, Z; Cheng, D; Ding, K; Le Maitre, A; Liu, G; Liu, N; Patel, D; Seymour, L; Shepherd, FA; Tsao, MS | 1 |
| Adjei, A; Brown, A; Camidge, DR; Doebele, R; Dy, G; Fetterly, G; Franklin, W; Hirsch, FR; Jackson, MK; Lettieri, J; Lu, X; Maxson, D; Oton, A; Reynolds, M; Varella-Garcia, M; Weickhardt, A; Wynes, MW; Youssoufian, H | 1 |
| Chachoua, A; Cohen, DE; de Souza, A; Wnorowski, AM | 1 |
| Ou, SH | 1 |
| Gubish, CT; Henry, C; Rothstein, ME; Siegfried, JM; Stabile, LP | 1 |
| Bekele, BN; Biernacka, A; Erez, B; Herbst, RS; Hosho, K; Jacoby, JJ; Jürgensmeier, JM; Komaki, R; Korshunova, MV; O'Reilly, MS; Ryan, A; Smith, PD; Takahashi, O; Wistuba, II | 1 |
| Paz-Ares, L | 1 |
| Cicenas, S; Ciuleanu, T; Gonzalez, EE; Grigorescu, AC; Hillenbach, C; Johannsdottir, HK; Klughammer, B; Miliauskas, S; Stelmakh, L | 1 |
| Agatsuma, T; Eda, S; Hachiya, T; Kobayashi, T; Koizumi, T; Koyama, S; Kubo, K; Kuraishi, H; Ohura, N; Tsushima, K; Yasuo, M | 1 |
| Govindan, R; Subramanian, J | 1 |
| Altavilla, G; Artal, A; Baize, N; Bearz, A; Bernabe, R; Bombaron, P; Bover, I; Carcereny, E; Cobo, M; Corre, R; Cortesi, E; Dansin, E; de Aguirre, I; de Castro, J; De Marinis, F; Domine, M; Drozdowskyj, A; Felip, E; Ferrera-Delgado, L; Garcia-Campelo, R; Garcia-Gomez, R; Garrido, P; Gebbia, V; Gervais, R; Illiano, A; Insa, A; Isla, D; Jimenez, U; Longo, F; Lopez-Vivanco, G; Massuti, B; Mazieres, J; Milella, M; Molina, MA; Molinier, O; Moran, T; Moreno, MA; Muñoz-Langa, J; Pallares, C; Palmero, R; Paz-Ares, L; Porta, R; Provencio, M; Queralt, C; Ramirez, JL; Reguart, N; Robinet, G; Rodriguez-Abreu, D; Rolfo, C; Rosell, R; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Taron, M; Terrasa, J; Valdivia, J; Vergnenegre, A | 1 |
| Argast, GM; Davies, A; Epstein, DM; Mercado, P; Richardson, F; Sennello, R; Wacker, B; Wolf, J; Young, GD | 1 |
| Abe, T; Aoki, T; Furuya, N; Hayama, N; Hisata, J; Igawa, S; Katagiri, M; Masuda, N; Mineshita, M; Miyazawa, T; Tajiri, S; Urano, T | 1 |
| Kaira, K; Yamamoto, N | 1 |
| Kondo, T; Murakami, S; Noda, K; Oshita, F; Saito, H; Yamada, K | 1 |
| Wu, YL; Zhou, Q | 1 |
| Adachi, K; Burioka, N; Chikumi, H; Igishi, T; Kanamori, Y; Miyake, N; Nanba, E; Shimizu, E; Takata, M; Yamasaki, A | 1 |
| McIvor, RA; Popat, N; Raghavan, N | 1 |
| Koizumi, H; Li, Q; Matsumoto, K; Mukaida, N; Nakagawa, T; Nakamura, T; Nishioka, Y; Sone, S; Takeuchi, S; Uenaka, T; Wang, W; Yamada, T; Yano, S | 1 |
| Han, R; He, JK; Qin, ZH; Reid, PF; Wang, JH; Wu, JC; Xie, Y | 1 |
| De Grève, J; De Mey, J; Decoster, L; Everaert, H; Galdermans, D; Geers, C; In't Veld, P; Schallier, D; Teugels, E; Umelo, I | 1 |
| Asaka, R; Hamanaka, W; Hatano, S; Ishikawa, Y; Lim Choi, Y; Mano, H; Nakagawa, K; Ninomiya, H; Okumura, S; Sakata, S; Satoh, Y; Soda, M; Suzuki, R; Takeuchi, K; Togashi, Y; Uehara, H | 1 |
| Arai, Y; Chiku, S; Enari, M; Furuta, K; Harris, CC; Haugen, A; Hiramoto, M; Ichikawa, H; Iwakawa, R; Kohno, T; Nammo, T; Ogawa, S; Ogiwara, H; Oike, T; Okayama, H; Sakamoto, H; Schetter, AJ; Sekine, I; Shibata, T; Shimada, Y; Skaug, V; Totoki, Y; Tsuda, H; Tsuta, K; Watanabe, S; Yamanaka, I; Yasuda, K; Yokota, J; Yoshida, T | 1 |
| Ansén, S; Bass, AJ; Beer, DG; Brace, LE; Brambilla, C; Brambilla, E; Brustugun, OT; Cho, J; Clement, JH; Deng, X; Dutt, A; Eck, MJ; Gabler, F; Gray, NS; Greulich, H; Groen, H; Hammerman, PS; Hanna, M; Hatton, C; Haura, EB; Helland, A; Heuckmann, JM; Heynck, S; Janne, PA; Johnson, BE; Koker, M; Lawrence, MS; Leenders, F; Lim, SM; Lin, W; Lorimier, P; Meyerson, M; Moch, H; Onofrio, RC; Peifer, M; Petersen, I; Querings, S; Ramos, AH; Rauh, D; Salvesen, HB; Seidel, D; Sietsma, H; Simard, JR; Soltermann, A; Sos, ML; Stoelben, E; Thomas, RK; Timens, W; Tsao, MS; Winckler, W; Wolf, J; Wong, KK; Woods, BA; Xu, C; Zander, T; Zhang, J; Zhou, W | 1 |
| Akazawa, Y; Imamura, F; Kumagai, T; Nishino, K; Okyuama, T; Uchida, J | 1 |
| Del Vecchio, S; Iommelli, F; Salvatore, M; Speranza, A; Zannetti, A | 1 |
| Chen, W; Hu, CP; Liu, JK; Lu, RL; Xiong, Z; Zhou, H; Zhou, ML | 1 |
| Ban, HJ; Kim, KS; Kim, YC; Oh, IJ | 1 |
| Higashino, M; Hiraishi, Y; Hirano, S; Iikura, M; Ishii, S; Izumi, S; Kobayashi, N; Naka, G; Nakamichi, S; Sugiyama, H; Takeda, Y | 1 |
| Fujiu, K; Kobayashi, N; Miyamoto, H; Suzuki, H | 1 |
| Guo, L; Liu, Z; Meng, Q; Shi, H; Tang, J; Xu, L; Zhu, Y | 1 |
| Böker, B; Grohé, C; Lüders, H | 1 |
| Jaśkiewicz, P; Kowalski, DM; Krawczyk, P; Krzakowski, M; Kucharczyk, T; Milanowski, J; Mlak, R; Winiarczyk, K; Wojas-Krawczyk, K | 1 |
| Chang, S; Ding, J; Ding, K; Geng, M; Liu, Y; Lu, X; Luo, J; Pei, D; Ren, X; Tu, Z; Xu, S; Xu, T; Xu, Y; Zhang, L; Zhang, Z | 1 |
| Huang, B; Huang, YS; Wu, YL | 1 |
| Chen, L; Fujimoto, T; Handa, N; Kawa, S; Kobayashi, T; Kukimoto-Niino, M; Liu, ZJ; Parker, L; Sano, S; Sato, M; Semba, K; Shirouzu, M; Tanaka, T; Terada, T; Terazawa, Y; Wakiyama, M; Wang, BC; Yamamoto, T; Yokoyama, S; Yoshikawa, S | 1 |
| Barletta, G; Boldrini, L; Brianti, A; Cosso, M; Dal Bello, MG; Defferrari, C; Fontanini, G; Genova, C; Grossi, F; Murolo, C; Pronzato, P; Rijavec, E; Truini, M | 1 |
| Atagi, S; Fukuoka, M; Ichinose, Y; Ishikura, S; Niho, S; Ohe, Y; Okamoto, H; Saijo, N; Shibata, T; Takeda, K; Tamura, T; Yokoyama, A | 1 |
| Permsuwan, U; Thongprasert, S; Tinmanee, S | 1 |
| Ahn, JS; Ahn, MJ; Han, JH; Han, JY; Jo, SJ; Kim, HT; Kim, HY; Kim, SW; Lee, DH; Lee, JS; Lee, JW; Park, K; Suh, C; Yoon, SJ; Yun, T | 1 |
| Blajman, CR; Chen, YM; Emerson, L; Hirsh, V; Langmuir, P; Lee, JS; Manegold, C; Park, K; Perng, RP; Qin, S | 1 |
| Lin, TC; Wu, PY | 1 |
| Byun, JY; Cha, MY; Choi, KJ; Jung, YH; Kang, SJ; Kim, MS; Lee, GS; Lee, HJ; Lee, KO; Park, SB; Song, JY | 1 |
| Bago-Horvath, Z; Berger, W; Filipits, M; Grusch, M; Haitel, A; Hayden, H; Komina, O; Lackner, A; Pirker, C; Schmid, K; Sieghart, W; Węsierska-Gądek, J | 1 |
| Damse, A; Lacouture, ME; Rosen, AC; Sherman, E; Wu, S | 1 |
| Eberhardt, WE; Groneberg, M; Kübler, D; Pöttgen, C; Sak, A; Stuschke, M | 1 |
| Hirata, H; Inoue, K; Kida, H; Kijima, T; Kohmo, S; Kumanogoh, A; Minami, T; Nagatomo, I; Otani, Y; Suzuki, M; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Bai, H; Han, B | 1 |
| Fan, Q; Li, P; Ma, Z; Qi, G; Wang, H; Wang, Q; Yan, X; Zhang, G; Zhu, H | 1 |
| Bai, C; He, J; Li, H; Qin, Y; Song, H; Wang, C; Wei, L; Wu, C; Wu, M; Xu, J; Zhang, X; Zhu, T | 1 |
| Chang, JW; Chang, NJ; Chen, CH; Cheng, HY; Chung, FT; Hou, MM; Hsieh, JJ; Hsu, T; Huang, SF; Kuo, HP; Lin, HC; Lin, YC; Ou, LY; Tsai, YH; Wang, CL; Wang, HM; Yang, CT; Yu, CT | 1 |
| Agatsuma, T; Ameshima, S; Hayasaka, M; Ikegami, K; Kanda, S; Kobayashi, T; Koizumi, T; Kubo, K; Matsuo, A; Morikawa, M; Shiina, T; Suzuki, T; Takasuna, K; Yoshikawa, S | 1 |
| Choi, YH; Han, HS; Kim, ST; Lee, JY; Lee, KH; Lee, OJ; Lim, SN; Shim, YK | 1 |
| Berard, H; Chouaid, C; Corre, R; Crequit, J; Dujon, C; Falchero, L; Greillier, L; Jullian, H; LeCaer, H; Vergnenegre, A | 1 |
| Jeong, SH; Kim, J; Kim, S; Ku, B; Lee, DW | 1 |
| He, AN; Lin, F; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Bengtsson, T; Hicks, RJ; Peterson, A; Port, RE | 1 |
| Chang, GC; Chen, HY; Chen, KC; Hsu, KH; Tseng, JS; Yang, TY | 1 |
| Egawa, K; Matsushita, H; Miura, H; Osawa, T; Takahashi, T; Tsubouchi, Y; Yuyama, K | 1 |
| Ashai, A; Avital, I; Hassan, R; Kalra, N; Raffeld, M; Xi, L; Zhang, J | 1 |
| Liu, G; Wang, W; Zhang, X; Zhu, X | 1 |
| Tao, L; Yang, F; Zhu, B; Zhuo, W | 1 |
| Ghosh, G; Kron, SJ; Lian, X; Palecek, SP | 1 |
| Chen, G; De Grève, J; Kronenberger, P; Teugels, E; Umelo, IA | 2 |
| Hirsh, V; Novello, S; Sandler, AB; Scagliotti, GV; Schiller, JH; Schwartz, B; Sequist, LV; Soria, JC; von Pawel, J; Von Roemeling, R | 1 |
| Yang, G; Yao, Y; Zhao, Q; Zhou, J | 1 |
| Bai, CX; Garfield, D; Ge, HY; Song, YL; Wang, X; Wang, XY; Xu, N; Yang, P; Zhang, X | 1 |
| Fujita, S; Hata, A; Imai, Y; Kaji, R; Katakami, N; Kida, Y; Tanaka, K | 1 |
| Bunn, PA; Hirsch, FR | 2 |
| Cadranel, J; Chao, TY; Chen, YM; Cong, XJ; Crino, L; Heo, DS; Hirsh, V; Kim, SW; Lorence, RM; Miller, VA; Park, K; Shahidi, M; Su, WC; Sun, Y; Tan, EH; Wang, M; Yang, JC; Zhou, C | 1 |
| Chang, GC; Cong, XJ; Dudek, AZ; Ho, CL; Hsia, TC; Lorence, RM; Miller, VA; Ou, SH; Sequist, LV; Shahidi, M; Shih, JY; Su, WC; Tsai, CM; Yang, JC; Yang, PC; Yu, CJ | 1 |
| Kawada, A; Nakagawa, K; Oiso, N; Okamoto, I; Takeda, M; Tsurutani, J | 1 |
| Fujii, S; Hamada, A; Inaba, M; Isobe, T; Iwamoto, N; Kai, Y; Kashiwabara, K; Kishi, H; Kohrogi, H; Saeki, S; Saito, H; Sasaki, J; Semba, H; Tsubata, Y; Urata, M; Ushijima, S | 1 |
| Cinieri, S; Lorusso, V | 1 |
| Hansen, KH; Hansen, NC; Hansen, O; Kristiansen, C; Olsen, KE | 1 |
| Bischoff, HG; Eberhardt, WE; Fischer, JR; Gottschling, S; Heigener, DF; Herpel, E; Klein, P; Köhne, CH; Kortsik, C; Kuhnt, T; Meister, M; Moldenhauer, I; Muley, T; Penzel, R; Schnabel, PA; Thomas, M | 1 |
| Fujiwara, K; Hamada, N; Horita, N; Hotta, K; Kamei, H; Kiura, K; Segawa, Y; Takata, I; Takigawa, N; Tanimoto, M; Tsubouchi, K; Umemura, S; Yamane, H; Yoshioka, H | 1 |
| Chang, X; Chatterjee, A; Horii, A; Kobayashi, T; Koch, WM; Kusuke, D; Levenson, VV; Liggett, TE; Melnikov, AA; Monitto, CL; Ogawa, T; Shiga, K; Sidransky, D | 1 |
| Fu, H; Hu, YD; Liu, XJ; Long, C; Xiao, Y; Zhang, XL | 1 |
| Amler, LC; Atwal, S; Fine, BM; Hampton, GM; Hicks, RJ; Hughes, BG; Lackner, MR; Liu, W; Pirzkall, A; Punnoose, EA; Raja, R | 1 |
| Kim, JH; Klingelschmitt, G; Ng, C; Park, K; Wu, YL; Zaatar, A | 1 |
| Schmid-Bindert, G; Wang, YH; Wang, YS; Xia, HP; Zhou, CC; Zhou, SW | 1 |
| Chien, CR; Hsia, TC; Lin, CC | 1 |
| Furukawa, M; Kiura, K; Kubo, T; Maki, Y; Mitsudomi, T; Miyoshi, S; Muraoka, T; Shien, K; Soh, J; Suda, K; Tanaka, N; Toyooka, S; Tsukuda, K; Ueno, T; Yamamoto, H | 1 |
| Hirata, K; Kimura, T; Kudoh, S; Manabe, M; Mitsuoka, S; Takeda, A; Tanaka, H; Umekawa, K; Yoshimura, N | 1 |
| Bunn, PA; Hirsch, FR; Jotte, RM; Konduri, K; Neubauer, MA; Ruxer, RL; Spira, AI; Varella-Garcia, M; Witta, SE | 1 |
| Ando, M; Hasegawa, Y; Horio, M; Horio, Y; Kondo, M; Saito, H; Tamura, M; Yamamoto, M | 1 |
| Dittmann, K; Huber, SM; Mayer, C; Misovic, M; Rodemann, HP | 1 |
| Chang, YC; Chang, YL; Hu, FC; Lee, YC; Shih, JY; Wu, JY; Wu, SG; Yang, PC; Yu, CJ | 1 |
| Dong, M; Pampo, C; Shi, W; Siemann, DW | 1 |
| Ahn, MJ; Blair, JM; Chen, YM; Kang, JH; Liang, J; Linn, C; Orlando, M; Peng, G; Xiu, Q; Yang, JC | 1 |
| Arango, N; Bonilla, C; Cuello, J; Llinás, N; Rivas, G; Rubiano, J | 1 |
| Albert, I; Azzoli, CG; Bodkin, D; Iannotti, NO; Jiang, PY; Juhász, E; Kelly, K; Koutsoukos, T; Patel, JD; Pereira, JR; Weems, G; Zatloukal, P | 1 |
| Ikari, A; Sato, T; Sugatani, J; Watanabe, R; Yamazaki, Y | 1 |
| Juergens, R; Levine, MN | 1 |
| Capelletti, M; Crawford, J; Edelman, MJ; Gu, L; Jänne, PA; Kratzke, R; Miller, VA; Socinski, MA; Stinchcombe, TE; Villalona-Calero, MA; Vokes, EE; Wang, X | 1 |
| Kita, K; Mano, H; Matsumoto, K; Nakade, J; Nakagawa, T; Nakamura, T; Nanjo, S; Soda, M; Takeuchi, S; Uenaka, T; Yamada, T; Yano, S | 1 |
| Gao, W; Guo, R; Shen, H; Shu, Y; Sun, J; Xu, R | 1 |
| Ariansen, S; Berg, T; Bremnes, R; Brustugun, OT; Dai, HY; Dønnem, T; Fjellbirkeland, L; Grønberg, BH; Helgeland, L; Helland, Å; Jebsen, P; Kleinberg, L; Mangseth, K; Scott, H; Wahl, SG | 1 |
| Albert, I; Chao, RC; Govindan, R; Karaseva, N; Krzakowski, M; Makhson, A; Miziara, JE; Papai, ZS; Portulas, ED; Reck, M; Scagliotti, GV; Selaru, P; Strausz, J; Szczesna, A; Thomas, M; Thongprasert, S; Tye, L; von Pawel, J; Wierzbicki, RF; Zhang, K | 1 |
| Ayoola, A; Barochia, A; Belani, CP; Belani, K | 1 |
| Hamatani, Y; Kim, YH; Masago, K; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
| Gemma, A; Hagiwara, K; Harada, M; Harada, T; Inoue, A; Isobe, H; Kato, T; Kinoshita, I; Kobayashi, K; Maemondo, M; Morita, S; Nukiwa, T; Oizumi, S; Okinaga, S; Saijo, Y; Sugawara, S; Yokomizo, Y; Yoshizawa, H | 1 |
| Kaneko, F; Oyama, N; Togashi, A; Yamamoto, T | 1 |
| Molina, JJ; Molina-Prat, N; Morral, M; Quintana, R; Saint-Jean, A; Sainz de la Maza, M; Torras, J | 1 |
| Boehm, JS; Butaney, M; Cheung, HW; Du, J; Engelman, JA; Golub, TR; Hahn, WC; He, F; Jänne, PA; Luo, B; Meyerson, M; Root, DE; Sequist, LV; Wang, X; Weir, BA | 1 |
| Baldotto, CS; da Silveira, JS; de Lima Araújo, LH; Ferreira, CG; Zukin, M | 1 |
| Antoine, M; Belmont, L; Cadranel, J; Fallet, V; Lacave, R; Lavolé, A; Poulot, V; Ruppert, AM; Wislez, M | 1 |
| Lemmon, MA; Park, JH | 1 |
| Barkovich, KJ; Blair, JA; Fan, QW; Garske, AL; Hariono, S; Nicolaides, T; Shokat, KM; Weiss, WA; Zhang, J | 1 |
| Brennan, CW; Campos, C; Chang, SM; Chheda, MG; Cloughesy, TF; Dang, J; DeAngelis, LM; Drappatz, J; Fine, HA; Gilbert, MR; Grommes, C; Heguy, A; Horvath, S; Iwanami, A; Kubek, S; Kuga, D; Kuhn, JG; Lamborn, KR; Lassman, AB; Liau, LM; Lieberman, F; Mehta, MP; Mellinghoff, IK; Mischel, PS; Nghiemphu, PL; Oldrini, B; Pedraza, A; Prados, MD; Reardon, DA; Robins, HI; Rohle, D; Tao, H; Vivanco, I; Wen, PY; Wu, N; Yannuzzi, N; Yong, WH; Yung, WK; Zhu, S | 1 |
| Basu, S; Batus, M; Bonomi, P; Buckingham, L; Coon, J; Fidler, MJ; McCormack, S; Walters, K | 1 |
| Bertran-Alamillo, J; Costa, C; Giménez-Capitán, A; Mayo, C; Molina-Vila, MÁ; Rosell, R | 1 |
| Chauhan, S; Gupta, M; Gupta, MK; Kesari, AA; Madabhavi, I; Rastogi, M; Revannasiddaiah, S; Seam, RK | 1 |
| Chai, F; Ferrari, D; Garmey, EG; Goldman, JW; Just, RG; Laux, I; Rosen, LS; Savage, RE | 1 |
| Chang, CY; Chang, SC; Chang, SJ; Chen, CY; Kuo, LC; Lai, YC; Liu, YC; Yu, CJ; Yuan, MK | 1 |
| Brewster, M; Cedrés, S; Dean, E; Felip, E; Galdermans, D; Martínez, P; McNally, V; Ranson, M; Ross, G | 1 |
| Ando, M; Fukuoka, M; Johkoh, T; Kudoh, S; Nakagawa, K; Ohe, Y; Seki, A; Takemoto, S; Yamazaki, N | 1 |
| Baird, RD; Barton, DP; Kaye, SB; Khan, AZ; Moreno, V; Vitfell-Pedersen, J; Yap, TA | 1 |
| Gao, H; Guo, W; Li, J; Liu, X; Qin, H; Qu, L; Tang, C; Wang, H; Wang, W; Wei, X | 1 |
| Guo, Z; Li, J | 1 |
| Au, JS; Cheng, CK; Merimsky, O; Reck, M; von Pawel, J | 1 |
| Mason, DP | 1 |
| Gasol-Cudós, A; Llombart-Cussac, A; Márquez-Medina, D; Salud-Salvia, A; Samamé Pérez-Vargas, JC; Taberner-Bonastre, MT | 1 |
| Nakamura-Wakatsuki, T; Yamamoto, T | 1 |
| Chen, LK; Dinglin, XX; Liang, Y; Liao, H; Liu, JL; Xu, F; Zeng, YD; Zhang, L | 1 |
| Gerber, DE; Hamann, HA; Lee, SJ; Rasco, DW; Woodruff, S | 1 |
| Asrani, K; Bremner, R; Cheng, E; Hostetter, G; Inge, L; Jameson, NM; Kingsley, CB; Loftus, JC; Tran, NL; Weiss, GJ; Whitsett, TG; Winkles, JA | 1 |
| Harada, H; Mitsuya, K; Mizokami, Y; Nakamura, Y; Nakasu, Y; Nishimura, T; Ono, A; Takahashi, T; Toda, Y; Yamamoto, N | 1 |
| Albano, T; Arnovitz, P; Burstein, D; Dhawan, NS; Difeo, A; Farrington, C; Galsky, M; Izadmehr, S; Katz, S; Mazhar, S; Melville, H; Narla, G; Ohlmeyer, M; Okrent, R; Politi, K; Rana, H; Sangodkar, J; Singh, VJ; Yuan, E; Zhang, D | 1 |
| Anderson, KS; Apetri, M; Kim, Y; Li, Z; Luo, B; Settleman, JE | 1 |
| Chang, KT; Chen, JT; Chen, YM; Chiu, CH; Hsiao, SY; Lai, CL; Tsai, CM | 1 |
| Chu, CT; Kim, ES; Sada, YH | 1 |
| Ahn, JS; Ahn, MJ; Hwang, IG; Jo, SJ; Kim, BS; Kim, HK; Kim, SW; Kim, YH; Lee, DH; Lee, JW; Lee, K; Lee, KH; Min, YJ; Park, K; Song, HS; Sun, JM; Yun, HJ | 1 |
| Kim, HT; Kim, KP; Kim, SW; Lee, DH; Lee, JS; Park, SJ; Suh, C | 1 |
| Fukuda, A; Sonoda, T; Takenaka, T; Yamagata, M | 1 |
| Chen, Y; Gao, Z; Zhuang, L | 1 |
| Chen, J; Chen, L; Guan, Z; Han, B; Jiang, G; Li, L; Li, W; Liao, M; Liu, X; Luo, R; Tao, M; Wang, M; Wu, Y; Xu, J; Xu, N; Yu, S; Zhao, X; Zhong, W | 1 |
| Berard, H; Chouaid, C; Corre, R; Crequit, J; Dujon, C; Falchero, L; Le Caer, H; Locher, C; Monnet, I; Vergnenegre, A | 1 |
| El-Modir, A; Stevenson, R | 1 |
| Hashimoto, K; Hayashi, Y; Horinouchi, H; Izumi, Y; Kohno, M; Nomori, H; Ohtsuka, T | 1 |
| Chen, YG; Chian, CF; Lin, CS; Shen, CH | 1 |
| Ashizawa, J; Deguchi, Y; Hashimoto, R; Hitani, K; Hori, Y; Maeno, T; Shiba, T; Ubuka, M | 1 |
| Chen, J; Cui, IH; Gong, Y; Jin, Y; Tang, C; Wu, X; Xu, Z; Zhang, X; Zhang, Y | 1 |
| Dempsey, EC; Fagan, KA; Karoor, V; Le, M; Merrick, D; Miller, YE | 1 |
| Assiddiq, BF; Chan, SP; Chong, PK; Lim, YP; Tan, KY; Toy, W | 1 |
| Keshtgarpour, M; Ma, PC; Pennell, NA; Yin, L | 1 |
| Clarke, S; Clingan, P; De Boer, R; Johnston, M; Michael, M; Pavlakis, N | 1 |
| Harada, D; Ichihara, E; Kiura, K; Kubo, T; Ninomiya, T; Ochi, N; Ohashi, K; Takata, S; Takeda, H; Takigawa, N; Tanimoto, M; Yasugi, M | 1 |
| Cappuzzo, F | 3 |
| Perez-Soler, R; Piperdi, B | 1 |
| Califano, R; D'arcangelo, M; Mok, TS | 1 |
| Jett, JR; Pao, W; Yatabe, Y | 1 |
| Azzoli, CG; Beumer, JH; Dowlati, A; Gadgeel, SM; Kris, MG; Krug, LM; Lynch, TJ; Miller, VA; Mitchell, B; Pietanza, MC; Price, KA; Riely, GJ; Rizvi, NA; Rowland, KM; Salgia, R; Tonda, M; Wertheim, MS | 1 |
| Brown, MP; Cheetham, G; Scott, HS; Sharma, A; Tan, TH | 1 |
| Fujimura, M; Kasahara, K; Kimura, H; Nakao, S; Ohmori, T; Sakai, A; Sone, T | 1 |
| Aide, N; Bardet, S; Crouzeix, G; Michels, JJ; Sevin, E; Vaur, D | 1 |
| Dietlein, M; Kahraman, D; Kobe, C; Neumaier, B; Nogova, L; Scheffler, M; Thomas, R; Wolf, J; Zander, T | 1 |
| Hsu, CP; Hsu, PY; Lin, JJ; Wu, YL | 1 |
| Cheng, YP; Chiu, HY; Jee, SH; Tsai, TF | 1 |
| Britt, GJ; Butaney, M; Costa, DB; Heon, S; Jackman, DM; Johnson, BE; Joshi, VA; Lindeman, NI; Rabin, MS; Yeap, BY | 1 |
| Bepler, G; Chen, W; Ghosh, D; Norkin, M; Raghunathan, TE; Sargent, DJ | 1 |
| Bunn, PA; Casás-Selves, M; Chan, DC; DeGregori, J; Gao, D; Helfrich, BA; Kim, J; Porter, CC; Scarborough, HA; Tan, AC; Zhang, Z | 1 |
| Blumenschein, GR; Chao, RC; Ciuleanu, T; Groen, HJ; Juhasz, E; Robert, F; Ruiz-Garcia, A; Tye, L; Usari, T | 1 |
| Abdel-Rahman, M; Arcila, M; Au, V; Bivona, TG; Boggon, TJ; Choi, CM; Choi, YJ; Costa, C; Halmos, B; Jang, SJ; Kim, SW; Kim, WS; Ladanyi, M; LaFramboise, T; Lee, DH; Lee, JC; Lee, JS; Levine, AD; Lin, L; Ma, PC; Miller, VA; Moonsamy, P; Olivas, V; Park, YS; Rho, JK; Rosell, R; Sawyers, C; Taron, M; Wang, X; Zhang, Z | 1 |
| Cai, L; Cao, M; Gemma, A; Kitamura, K; Minegishi, Y; Mizutani, H; Noro, R; Seike, M; Soeno, C; Yoshimura, A | 1 |
| Hu, X; Huang, Y; Lee, RJ; Li, H; Xiang, G; Yung, B; Zhou, X | 1 |
| Burgers, JA; Codrington, HE; Kappers, I; Klomp, HM; Schaake, EE; Teertstra, HJ; Valdés Olmos, RA; van Pel, R; van Tinteren, H | 1 |
| Barrios, CH; Blackhall, F; Bover, I; Boyer, M; Campbell, AK; Frank, R; Krzakowski, M; Letrent, SP; Liang, JQ; O'Connell, J; Park, K; Ramalingam, SS; Rosell, R; Ruiz-Garcia, A; Seog Heo, D; Talbot, DC; Taylor, I | 1 |
| Ahn, JS; Ahn, MJ; Cho, SH; Choi, YL; Han, JH; Hwang, DW; Ji, JH; Lee, JY; Park, K; Park, LC; Park, S; Sun, JM | 1 |
| Gu, H; Li, X; Liu, S; Wang, D | 1 |
| Baudrin, L; Cadranel, J; Coëtmeur, D; Duruisseaux, M; Monnet, I; Morère, JF; Morin, F; Moro-Sibilot, D; Mourlanette, P; Quoix, E; Soria, JC; Westeel, V; Wislez, M | 1 |
| Anand, S; Bachi, A; Floriani, I; Gregorc, V; Lazzari, C; Milan, E; Sorlini, C; Torri, V | 1 |
| Han, JY; Kim, HT; Kim, SH; Lee, JS; Lee, Y; Yun, T | 1 |
| Furcht, CM; Lazzara, MJ; Muñoz Rojas, AR; Nihalani, D | 1 |
| Alam, Y; Butts, C; Cantile, F; Ciardiello, F; Cinieri, S; da Cunha Santos, G; Di Maio, M; Favaretto, A; Feld, R; Felletti, R; Gallo, C; Gebbia, V; Genestreti, G; Gridelli, C; Leighl, N; Maione, P; Mancuso, G; Morabito, A; Morgillo, F; Perrone, F; Piccirillo, MC; Riccardi, F; Rossi, A; Saieg, M; Siena, S; Tortora, G; Tsao, MS; Wierzbicki, R | 1 |
| Cai, DY; Hong, TT; Hua, D; Wu, XH; Zhang, RX | 1 |
| Donev, IS; Kita, K; Li, Q; Matsumoto, K; Nakagawa, T; Nakamura, T; Nishioka, Y; Shimizu, E; Sone, S; Takeuchi, S; Uenaka, T; Wang, W; Yamada, T; Yano, S | 1 |
| A't Hart, N; Stigt, JA; van der Wekken, AJ | 1 |
| Huang, JA; Min, DL; Shen, Z; Tang, LN; Yang, Y; Yue, L; Zhou, XH | 1 |
| Fukudo, M; Ikemi, Y; Katsura, T; Kim, YH; Masago, K; Masuda, S; Mishima, M; Mizuno, T; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
| Botteman, MF; Carter, JA; Ganguli, A; Gao, X; Ray, S; Wiegand, P | 1 |
| Girard, L; Heymach, JV; Johnson, FM; Lippman, SM; Minna, JD; Peng, S; Saintigny, P; Sen, B; Wistuba, II; Zhang, L | 1 |
| Dong, XR; Huang, J; Liu, L; Lu, HD | 1 |
| Hamaguchi, M; Kawase, I; Kida, H; Kijima, T; Komuta, K; Minami, S; Nagatomo, I; Nakatani, T; Tachibana, I; Takahashi, R; Takeuchi, Y; Yamamoto, S | 1 |
| Bernstein, ED; Clément-Duchêne, C; Dudek, AZ; Jahan, T; Krupitskaya, Y; Latz, JE; Natale, RB; Osarogiagbon, R; Sanborn, RE; Shi, P; Wakelee, HA | 1 |
| Abe, H; Arao, T; Azuma, K; Hayashi, K; Kage, M; Kanda, R; Kawahara, A; Kubo, T; Kuwano, M; Murakami, Y; Nishio, K; Ono, M; Rosell, R; Sonoda, K; Tabara, K; Tahira, T; Yoshinaga, A | 1 |
| Bill, A; Famulok, M; Hannam, JS; Heukamp, LC; König, K; Schmitz, A | 1 |
| Auliac, JB; Chouaid, C; Dujon, C; Le Caer, H; Locher, C; Monnet, I; Thomas, P; Vergnenegre, A | 1 |
| Li, H; Ren, XB; Wang, CL; Wang, M; Yu, JP; Zhang, LM; Zhao, J | 1 |
| Abdul Razak, M; Chan, LC; Ong, CK; Tan, WC | 1 |
| Caparelli, F; Hoff, PM; Sahade, M | 1 |
| Chen, Y; Han, B; Jia, J; Jiang, Y; Ma, X; Tan, C; Wei, X; Zhang, J; Zhu, F | 1 |
| Horn, L; Lovly, CM | 1 |
| Ishikawa, D; Kita, K; Matsumoto, K; Mitsudomi, T; Nakagawa, T; Nakamura, T; Nanjo, S; Sano, T; Sekido, Y; Suda, K; Takeuchi, S; Uenaka, T; Yamada, T; Yano, S | 1 |
| Chen, M; Hu, P; Li, L; Nie, L; Wang, M; Xiao, Y; Zhang, L; Zhao, J; Zhong, W | 1 |
| Koma, Y; Matsuoka, H; Suzuki, Y; Yoshimatsu, H | 1 |
| Chen, RC; Halle, J; Higginson, DS; Marks, LB; Morris, DE; Pham, E; Rosenman, JG; Socinski, MA; Stefanescu, M; Tracton, G | 1 |
| Hashimoto, M; Koizumi, F; Minakata, K; Moriyama, H; Murakami, A; Nara, T; Nishio, K; Nurwidya, F; Seyama, K; Tajima, K; Takahashi, F; Takahashi, K; Yae, S | 1 |
| Jänne, PA; Oxnard, GR | 1 |
| Shi, YK | 1 |
| Gao, W; Huang, P; Liu, L; Liu, P; Shao, X; Shu, Y; Wang, R; Yin, Y; Zhang, Z | 1 |
| An, TT; Bai, H; Duan, JC; Wang, J; Wang, SH; Wang, YY; Wang, ZJ; Wu, MN; Yang, L; Zhao, J; Zhuo, ML | 1 |
| Ievleva, AG; Imianitov, EN; Ivantsov, AO; Levchenko, EV; Matsko, DE; Mitiushkina, NV; Moiseenko, FV; Moiseenko, VM; Novik, AV; Protsenko, SA; Rudakova, AV; Semënov, II; Togo, AV | 1 |
| Jin, C; Li, W; Li, Y; Ren, S; Zhang, D; Zhao, Z | 1 |
| Cho, BC; Christensen, JG; Ha, SJ; Hong, YK; Kim, JH; Kim, SM; Kwon, OJ; Lee, JH; Solca, F; Soo, RA | 1 |
| Ali, K; Kumar, I; Saeed, MU; Usman-Saeed, M | 1 |
| Gemma, A; Gemmah, A; Hagiwara, K; Harada, M; Inoue, A; Isobe, H; Kobayashi, K; Kudoh, S; Maemondo, M; Minegishi, Y; Morikawa, N; Nukiwa, T; Oizumi, S; Okinaga, S; Tanaka, T | 1 |
| Kris, MG; Ladanyi, M; Moreira, AL; Paik, PK; Rekhtman, N; Sima, CS; Varghese, AM | 1 |
| Chua, KT; Lee, CH; Liam, CK; Lim, BK; Pang, YK; Ruthranesan, M | 1 |
| Chu, DT; Duffield, E; Fukuoka, M; Han, B; Jiang, H; Liao, M; Liu, X; Mok, T; Wu, YL; Zhang, L; Zhou, C | 1 |
| Chen, HM; Kuo, R; Lai, MS; Lin, ZZ; Shao, YY; Shau, WY; Yang, JC | 1 |
| Abell, F; Boyer, M; De Souza, P; Horwood, K; Johnston, M; Millward, M; Pavlakis, N; Rischin, D; Stein, B | 1 |
| Awada, A; Bastholt, L; Bonichon, F; de la Fouchardiere, C; Gómez, JM; Krause, T; Leboulleux, S; Leenhardt, L; Licour, M; Schlumberger, MJ; Soufflet, C; Tennvall, J | 1 |
| Gao, G; Ren, S; Wu, X; Zhou, C | 1 |
| Beculic, H; Dervisevic, S; Imsirovic, B; Mekic-Abazovic, A | 1 |
| Benešová, L; Bortlíček, Z; Brůha, F; Fiala, O; Fínek, J; Krejčí, J; Minárik, M; Pešek, M | 1 |
| Fujii, N; Fujimoto, N; Kato, T; Nagao, T; Nakanishi, G; Tanaka, T; Toda, N | 1 |
| Badurak, P; Janowicz-Żebrowska, A; Jaśkiewicz, P; Knetki-Wróblewska, M; Kowalski, DM; Krzakowski, M; Płużański, A; Zajda, K | 1 |
| Cei, M; Mumoli, N; Vitale, J | 1 |
| Daw, H; Haddad, A; Petrosyan, F; Spiro, T | 1 |
| Chen, ZH; Cheng, H; Dong, S; Wu, YL; Xie, Z; Zhang, XC; Zhang, YF; Zhu, JQ | 1 |
| Kimura, Y; Morikawa, N; Murakami, K; Nagano, Y; Tabata, T; Yanagisawa, S | 1 |
| Chisholm, JW; Igal, RA; Nashed, M | 1 |
| Cai, J; Chen, T; Chen, Y; Deng, J; Du, Z; Li, Q; Lu, J; Shan, B; Song, X; Wery, JP; Yang, M; Zhang, L | 1 |
| Barlési, F; Chouaid, C; Crequit, J; Devouassoux-Shisheboran, M; Falchero, L; Fournel, P; Gervais, R; Le Caer, H; Léna, H; Milleron, B; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Ségura-Ferlay, C; Taron, M; Vaylet, F; Vergnenègre, A; Westeel, V; Zalcman, G | 1 |
| Chen, X; Duvvuri, U; Fung, C; Grandis, JR | 1 |
| Arcila, ME; de Stanchina, E; Janjigian, YY; Kris, MG; Ladanyi, M; Melnick, MA; Miller, VA; Nebhan, CA; Ohashi, K; Pao, W; Pirazzoli, V; Politi, K; Riely, GJ; Song, X; Spitzler, PJ; Takezawa, K | 1 |
| Jain, A; Ryan, PD; Seiden, MV | 1 |
| Butaney, M; Capelletti, M; Ercan, D; Garraway, LA; Goetz, EM; Gray, NS; Ivanova, EV; Jänne, PA; Lazzara, MJ; Letai, A; Maertens, O; Monast, CS; Montero, J; Pratilas, CA; Repellin, C; Rogers, A; Rosen, N; Shimamura, T; Sholl, L; Tadi, M; Wong, KK; Xu, C; Yanagita, M | 1 |
| Fujita, Y; Gemma, A; Hagiwara, K; Harada, M; Harada, T; Hirano, H; Inoue, A; Isobe, H; Kinoshita, I; Kobayashi, K; Maemondo, M; Morita, S; Nukiwa, T; Oizumi, S; Okinaga, S; Saijo, Y; Sugawara, S; Yoshimori, K; Yoshizawa, H | 1 |
| Jappe, A; Jehl, V; Johnson, BE; Klimovsky, J; Papadimitrakopoulou, VA; Soria, JC | 1 |
| Al-Shahrour, F; Alexander, D; Baran, M; Carretero, J; Difilippantonio, S; El Meskini, R; Guerin, T; Gumprecht, M; Iacovelli, AJ; Kozlov, S; Kulaga, A; Martin, PL; McCann, T; Mena, S; Schlomer, J; Van Dyke, T; Weaver, Z; Wong, KK | 1 |
| Carlson, JJ; Yeung, K | 1 |
| Hashemi-Sadraei, N; Pennell, NA | 1 |
| Dekker, H; Galvani, E; Giovannetti, E; Honeywell, R; Labots, M; Lind, JS; Peters, GJ; Sciarrillo, R; Smit, EF; Verheul, HM | 1 |
| Biaoxue, R; Shuanying, Y; Wei, L; Wei, Z; Zongjuan, M | 1 |
| Antoine, M; Blons, H; Buisine, MP; Cadranel, J; Chetaille, B; Chouaid, C; Coudert, B; Daniel, C; Danton, G; De Fraipont, F; Faller, M; Foucher, P; Lacroix, L; Longchampt, E; Mauguen, A; Michiels, S; Morin, F; Pignon, JP; Poulot, V; Quoix, E; Solassol, J; Urban, T; Westeel, V; Wislez, M; Zalcman, G | 1 |
| Chmielecki, J; Foo, J; Michor, F; Pao, W | 1 |
| Ackerman, A; Costa, DB; Goldstein, MA; Kobayashi, S | 1 |
| Chen, Z; Li, Z; Liao, M; Lu, S; Niu, X; Shen, L; Shen, S; Yu, Y | 1 |
| Busch, TM; Cengel, KA; Edmonds, C; Gallagher-Colombo, SM; Hagan, S | 1 |
| Byun, SY; Choi, JW; Hong, JS; Huh, CH; Kwon, SH; Na, JI; Park, KC; Youn, SW | 1 |
| Ahn, JH; Kim, EJ; Kim, SW; Kim, SY; Lee, HJ; Lee, SJ; Moon, DH; Oh, SJ; Ryu, JS | 1 |
| Chen, M; Li, L; Wang, M; Xia, Y; Zhang, L; Zhao, J; Zhong, W | 1 |
| Hasegawa, S; Kondo, N; Tanaka, F; Uramoto, H; Yamada, T; Yano, S | 1 |
| Jiang, SJ; Ma, XB; Zhang, QC; Zhang, S | 1 |
| Maemondo, M | 1 |
| Katsura, Y; Ko, R; Koyama, R; Minakata, K; Murakami, A; Muraki, K; Namba, Y; Ohashi, R; Sakuraba, S; Shukuya, T; Takahashi, F; Takahashi, K; Yagishita, S | 1 |
| Cho, BC; Lee, JH; Park, JH; Shin, JU | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| Betticher, D; Brauchli, P; Bubendorf, L; Crowe, S; Droege, C; Froesch, P; Gautschi, O; Hess, T; Mayer, M; Ochsenbein, A; Oppliger Leibundgut, E; Pless, M; Rauch, D; Ribi, K; Schmid, P; Stahel, R; von Moos, R; Zappa, F | 1 |
| Berry, DA; Gong, J; Janku, F; Kurzrock, R; Parsons, HA; Stewart, DJ | 1 |
| Jan, IS; Liao, WY; Shih, JY; Tsai, MF; Wu, SG; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Chohnabayashi, N; Inoue, A; Mochizuki, S; Murakami, K; Nishimura, N; Nukiwa, T | 1 |
| Chang, PM; Chen, CC; Chen, KY; Chiou, JF; Ho, CC; Hsiao, M; Huang, CY; Kuo, YL; Lai, JM; Lee, PY; Liu, YW; Lu, PJ; Wang, LS; Wu, AT; Wu, CH; Yang, CN; Yang, PC; Yang, SC; Yeh, CT; Yen, CC | 1 |
| Clark, P; Dillon, B; Knight, H; Naidoo, B | 1 |
| Boellaard, R; Dietlein, M; Holstein, A; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Scheffler, M; Wolf, J; Zander, T | 1 |
| Beer, DG; Gotoh, N; Hatanaka, Y; Higuchi, T; Imoto, S; Kohno, T; Miyano, S; Nagasaki, M; Nakata, A; Nomura, M; Saito, A; Shimamura, T; Ueno, K; Yamaguchi, R; Yamauchi, M; Yokota, J; Yoshida, R | 1 |
| Hashisako, M; Ikegame, S; Kajiki, A; Kumazoe, H; Nagata, N; Wakamatsu, K | 1 |
| Iwanaga, K; Kimura, S; Mori, D; Nakamura, T; Sueoka-Aragane, N | 1 |
| Dang, NH; Hayashi, Y; Hosono, O; Ichihara, H; Inoue, Y; Iwata, S; Kamiya, K; Katayose, T; Kawasaki, H; Kichikawa, Y; Kondo, S; Morimoto, C; Sakamoto, M; Souta-Kuribara, A; Tanaka, H; Yamada, T; Yamazaki, H | 1 |
| Blackstock, AW; Decker, RH; Gettinger, SN; Khandani, A; Lankford, S; Moore, DT; Morris, DE; Petty, WJ; Schwartz, G; Socinski, MA; Stinchcombe, TE | 1 |
| Chen, YM; Chiang, CL; Chiu, CH; Chou, TY; Lai, SL; Lee, YC; Shih, JF; Tsai, CM | 1 |
| Hallek, M; Ullrich, RT; Wolf, J; Zander, T | 1 |
| Alden, C; Blumenschein, G; Davis, SE; Herbst, R; Hong, WK; Kim, E; Lee, JJ; Lippman, S; Liu, S; Stewart, D; Tang, XM; Tsao, AS; Wistuba, I | 1 |
| Carbone, DP; Ding, K; Grigorieva, J; Roder, H; Roder, J; Seymour, L; Shepherd, FA; Tsao, MS | 1 |
| Bianchi, L; Lisi, P; Minotti, V; Stingeni, L | 1 |
| Edelman, MJ; Mok, T; O'Byrne, K; Paz-Ares, L; Rittweger, K; Spigel, DR; Thurm, H; Yu, W | 1 |
| Hirano, S; Hojo, M; Iikura, M; Ishii, S; Izumi, S; Kobayashi, N; Kudo, K; Naka, G; Sano, K; Sugiyama, H; Takeda, Y | 1 |
| Jiao, W; Luo, Y; Shen, Y; Sui, A; Tang, D; Wang, M; Wang, Y; Wang, Z; Yang, R | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Krejci, J; Minarik, M; Pesek, M; Ricar, J | 1 |
| Bevilacqua, S; Botti, G; Caraco, C; Caronna, A; Costanzo, R; De Lutio, E; Montanino, A; Morabito, A; Normanno, N; Pasquale, R; Rocco, G; Sandomenico, C | 1 |
| Brandão, EP; Cruz, M; Pantarotto, MG | 1 |
| Bivona, TG; Blakely, CM | 1 |
| Riely, GJ; Yu, HA | 1 |
| Boshoff, C; Bulley, S; Chao, D; Falk, S; Hackshaw, A; Hatton, M; Jones, R; Khan, I; Lal, R; Lee, SM; Lewanski, C; Marshall, E; Middleton, G; Ngai, Y; Rudd, R; Skailes, G; Toy, E; Upadhyay, S; Woll, PJ | 1 |
| Chen, HJ; Dong, S; Huang, YS; Jiang, BY; Liao, RQ; Nie, Q; Su, J; Wang, BC; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Cho, YW; Choi, HW; Choi, IS; Choi, JH; Lee, HW; Lee, JY; Lee, KT; Park, JY; Rim, HK | 1 |
| Dingemans, AM; Grigorieva, J; Groen, HJ; Kuiper, JL; Lind, JS; Roder, H; Roder, J; Smit, EF | 1 |
| Biesma, B; Heideman, D; Smit, EF; Thunnissen, E; van Riel, S | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Mitsuoka, S; Nagata, M; Suzumura, T; Tanaka, H; Umekawa, K; Yoshimura, N | 1 |
| Abe, K; Ebina, M; Endo, C; Inoue, A; Kobayashi, M; Kondo, T; Kumamoto, H; Maemondo, M; Miki, Y; Mori, K; Narumi, S; Nukiwa, T; Sasano, H; Sato, I; Suzuki, T; Yamada-Okabe, H | 1 |
| Bortlíček, Z; Coupková, H; Grygárková, Y; Havel, L; Hejduk, K; Hrnčiarik, M; Kolek, V; Košatová, K; Koubková, L; Pešek, M; Roubec, J; Salajka, F; Sixtová, D; Skřičková, J; Spelda, S; Tomíšková, M; Zatloukal, P; Zemanová, M | 1 |
| Chang, YJ; Huang, MH; Lee, JH; Lin, AM; Lin, YL; Tsai, HH; Yang, JC | 1 |
| Baghdadi, TA; Bhatia, S; Hanna, N; Harb, W; Jalal, SI; Johnson, C; McClean, J; Riggs, H; Taber, D; Yu, M | 1 |
| Baty, F; Brutsche, M; Bubendorf, L; Carbone, D; Crowe, S; Dingemans, AM; Gautschi, O; Grigorieva, J; Hsu Schmitz, SF; Na, KJ; Peters, S; Pless, M; Roder, H; Roder, J; Smit, E; Stahel, R; Zappa, F | 1 |
| Chen, MS; Chi, CW; Hsu, CC; Huang, YC; Kuo, CD; Lee, HC; Lee, LM; Lee, YC; Liao, JF; Lin, AM; Yang, CH; Yin, PH | 1 |
| Bidkhori, G; Masoudi-Nejad, A; Moeini, A | 1 |
| Fang, X; Hu, Y; Li, M; Ma, S; Shen, H; Tan, C; Yuan, Y | 1 |
| Amler, LC; Brachmann, RK; Fridlyand, J; Friedman, LS; Hampton, GM; Haverty, PM; Huw, L; Koeppen, H; Lackner, MR; Mohan, S; O'Brien, C; Pandita, A; Ross, L; Sampath, D; Shames, DS; Spoerke, JM | 1 |
| Bahce, I; Heideman, DA; Hendrikse, NH; Lammertsma, AA; Lubberink, M; Postmus, PE; Schuit, RC; Smit, EF; Thunnissen, E; van der Veldt, AA; Windhorst, AD; Yaqub, M | 1 |
| Chen, SS; Falchook, GS; Fok, JY; Fu, S; Hong, DS; Janku, F; Kurzrock, R; Naing, A; Piha-Paul, SA; Stephen, B; Tsimberidou, AM; Wheler, JJ | 1 |
| Alesini, D; Cortesi, E; Passaro, A; Pochesci, A | 1 |
| Hosoya, T; Imai, S; Kuzumaki, N; Morita, H; Nagasawa, A; Narita, M; Okada, Y; Okano, H; Okano, HJ; Suzuki, A; Suzuki, T; Yamamizu, K; Yamashita, JK | 1 |
| Ahye, N; Azzoli, CG; Chaft, JE; D'Angelo, SP; Dycoco, J; Janjigian, YY; Kris, MG; Ladanyi, M; Riely, GJ; Rusch, V; Shen, R; Sima, CS; Zakowski, MF; Zheng, J | 1 |
| Aisner, DL; Bunn, PA; Burke, JM; Camidge, DR; Doebele, RC; Gan, G; Gaspar, LE; Kavanagh, BD; Lu, X; Scheier, B; Weickhardt, AJ | 1 |
| Alam, Y; Bianco, R; Butts, C; Ciardiello, F; Cinieri, S; Di Maio, M; Fasano, M; Favaretto, A; Feld, R; Felletti, R; Fregoni, V; Gallo, C; Gebbia, V; Genestreti, G; Gridelli, C; Leighl, NB; Maione, P; Mancuso, G; Morabito, A; Morgillo, F; Perrone, F; Ravaioli, A; Riccardi, F; Rossi, A; Siena, S; Signoriello, S; Spatafora, M; Tsao, MS; Wierzbicki, R | 1 |
| Aburatani, H; Endo, S; Fukayama, M; Ishikawa, S; Kanai, Y; Kataoka, H; Matsubara, D; Murakami, Y; Niki, T; Oguni, S; Ohara, S; Sakatani, T; Tamura, T; Yoshimoto, T | 1 |
| Ebara, T; Nakano, T; Sato, Y; Sunaga, N; Takahashi, T | 1 |
| Teh, BW; Worth, LJ | 1 |
| Li, X; Lü, JL; Qin, N; Sun, YF; Wu, YH; Yang, XJ; Zhang, H; Zhang, Q; Zhang, SC | 1 |
| Printz, C | 1 |
| Chiu, NT; Chung, WP; Ho, CL; Song, HL; Su, WC | 1 |
| Amler, LC; Armstrong, EA; Harari, PM; Huang, S; Li, C; Peet, CR; Saker, J; Sliwkowski, MX | 1 |
| Beijnen, JH; Burgers, JA; Huitema, AD; Lankheet, NA; Rosing, H; Schaake, EE; Schellens, JH | 1 |
| Chambers, CR; Sheikh, N | 1 |
| Liu, HB; Lv, TF; Shi, Y; Song, Y; Xiao, YY; Yuan, DM; Zhan, P | 1 |
| Guirgis, HM | 1 |
| Guo, LX; Jiao, J; Li, GQ; Liu, Y; Yao, ZJ; Zhang, B; Zhou, B; Zhou, GB | 1 |
| Boursier, C; Bylicki, O; Dot, JM; Peloni, JM | 1 |
| Kobayashi, K | 3 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Matsuura, K; Mitsuoka, S; Nagata, M; Nakai, T; Suzumura, T; Tanaka, H; Umekawa, K; Yoshimura, N | 1 |
| Arakawa, K; Fukatsu, M; Kataoka, K; Katsuno, S; Kimura, T; Kondoh, Y; Nakamura, N; Nishiyama, O; Takashima, N; Taniguchi, H; Umemura, T; Watanabe, N | 1 |
| Daga, H; Hirashima, T; Hirata, K; Kawaguchi, T; Kimura, T; Kobayashi, M; Kudoh, S; Mitsuoka, S; Okishio, K; Takeda, K; Yoshimura, N | 1 |
| Hou, B; Jiang, WR; Kong, QT; Li, B; Li, J; Liu, ZB; Shen, TZ; Wang, Y; Wang, Z; Wu, XH; Zhu, XX | 1 |
| Hirami, Y; Maeda, A; Nakata, M; Okita, R; Saisho, S; Shimizu, K; Yasuda, K; Yukawa, T | 1 |
| Cioffi, P; Fanizza, C; Giglioni, A; Grappasonni, I; Marotta, V; Natoli, C; Petrelli, F | 1 |
| Horiguchi, N; Kakizaki, S; Mori, M; Nakajima, Y; Sato, K; Sunaga, N; Takagi, H | 1 |
| Jeon, WI; Lee, SY; Ryu, PD | 1 |
| Chan, E; Heffron, TP; La, H; Lee, HJ; Malek, S; Merchant, M; Pirazzoli, V; Politi, K; Schaefer, G; Settleman, J; Shao, L; Sideris, S; Ubhayakar, S; Yauch, RL; Ye, X | 1 |
| Baqir, W; Husband, A; Mahony, M; Todd, A; Williamson, S | 1 |
| Adjei, AA; Ansari, RH; Dy, GK; Lyss, AP; Mandrekar, SJ; Meyers, JP; Molina, JR; Nelson, GD; Ross, HJ; Schild, SE; Stella, PJ | 1 |
| Alfieri, RR; Ampollini, L; Ardizzoni, A; Barocelli, E; Bonelli, M; Carbognani, P; Cavazzoni, A; Cretella, D; Fumarola, C; Galetti, M; Galvani, E; Graiani, G; La Monica, S; Madeddu, D; Mozzoni, P; Mutti, A; Petronini, PG; Quaini, F; Saccani, F; Tiseo, M | 1 |
| Hirashima, T; Kawase, I; Kitai, K; Morishita, N; Okamoto, N; Otsuka, T; Shiroyama, T; Suzuki, H; Tamiya, M; Yamadori, T | 1 |
| Bailey, AS; Canepa, HM; Costa, DB; Goldstein, MA; Huberman, MS; Kobayashi, S; Nakayama, S; Yamaguchi, N | 1 |
| Fujita, S; Hata, A; Imai, Y; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Korogi, Y; Kunimasa, K; Nishiyama, A; Notohara, K; Tachikawa, R; Tomii, K; Yoshioka, H | 1 |
| Baik, CS; Chow, LQ; Eaton, KD; Pritchard, CC | 1 |
| Bartolotti, M; Brandes, AA; Franceschi, E | 1 |
| Chen, Z; Han, R; Sun, L; Wang, J; Wang, X; Zhang, J; Zhao, J; Zhong, D | 1 |
| Gridelli, C; Maione, P; Rossi, A | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Krejci, J; Minarik, M; Pesek, M | 1 |
| Chang, H; Cho, BC; Cho, J; Ha, SJ; Hong, YK; Jeong, JH; Kim, HR; Kim, JH; Kim, SH; Kim, SM; Shim, HS; Sung, JH; Tania, C | 1 |
| Asami, K; Atagi, S; Hirashima, T; Kawaguchi, T; Kawahara, M; Okishio, K; Okuma, T; Omachi, N; Takeuchi, N | 1 |
| Abe, H; Azuma, K; Hattori, S; Hoshino, T; Kage, M; Kawahara, A; Yamada, K; Yamashita, F; Yoshida, T; Zaizen, Y | 1 |
| Wang, B; Wang, YN; Zhao, Q | 1 |
| Chen, Y; Sun, C; Zhang, X | 1 |
| Li, H; Li, X; Schmid-Bindert, G; Wang, D; Wang, Y; Zhou, C; Zhou, S | 1 |
| Cai, Y; Chen, G; Jia, J; Liu, B; Liu, H; Liu, JY; Zhang, JL; Zhang, W; Zhao, YF; Zhong, HY | 1 |
| Brodsky, O; Feng, J; Ferre, R; Gajiwala, KS; Kath, JC; Ryan, K; Stewart, A; Weinrich, S | 1 |
| Akerley, W; Boucher, K; Bylund, J; Egbert, L; Harker, G; Reddy, C; Rich, N; Van Duren, T | 1 |
| Ichihara, E; Kataoka, I; Kiura, K; Minami, D; Ochi, N; Ohashi, K; Takeda, H; Takigawa, N; Tanimoto, M | 1 |
| Higami, Y; Kato, M; Kobayashi, T; Koshimo, Y; Marumo, S; Takeda, M; Teranishi, T | 1 |
| Hao, XZ; Li, JL; Shi, YK; Wang, B; Wang, Y; Wang, ZP; Zhang, XR | 1 |
| Cai, DY; Hua, D; Wu, XH; Zhang, RX | 1 |
| Hokkoku, K; Igarashi, S; Kitade, H; Mori, M; Nakai, M; Sagawa, M; Shintaku, K; Yamada, T; Yano, S | 1 |
| Boellaard, R; Büttner, R; Dietlein, M; Engel-Riedel, W; Heukamp, L; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Papachristou, I; Querings, S; Scheffler, M; Stoelben, E; Wolf, J; Zander, T | 1 |
| Gonzalez, D; Nicholson, AG; Nutting, CM; O'Brien, M; Popat, S; Wotherspoon, A | 1 |
| Chung, DH; Heo, DS; Jeon, YK; Keam, B; Kim, DW; Kim, TM; Kim, YT; Kim, YW; Lee, SH; Park, JH | 1 |
| Banna, GL; Bellavia, M; Borsellino, N; Ferraù, F; Gebbia, V; Russo, P; Tralongo, P | 1 |
| Chen, Y; Du, XJ; Yang, M; Yu, S; Yuan, X; Zhang, L | 1 |
| Angelini, F; Bianchetti, S; Gamucci, T; Gemma, D; Grande, R; Mansueto, G; Narducci, F; Sperduti, I; Trombetta, G | 1 |
| Agatsuma, T; Hachiya, T; Hirai, K; Ichiyama, T; Koizumi, T; Koyama, S; Morozumi, N; Shiina, T; Tateishi, K | 1 |
| Ishikawa, D; Matsumoto, K; Nakagawa, T; Nakamura, T; Nanjo, S; Sano, T; Takeuchi, S; Yamada, T; Yano, S | 1 |
| An, C; Xuan, X; Zhou, C | 1 |
| Ji, L; Pei, Y | 1 |
| Endo, H; Higashiyama, M; Imamura, F; Inoue, M; Kondo, J; Kumagai, T; Nishizawa, Y; Okami, J; Okuyama, H; Takehara, T; Uchida, J | 1 |
| Cadranel, J; Cong, XJ; Fairclough, D; Finnern, HW; Hirsh, V; Lorence, RM; Miller, VA; Palmer, M; Yang, JC | 1 |
| Bastida, CC; Falchook, GS; Janku, F; Kurzrock, R; Stewart, DJ; Tsao, AS | 1 |
| Bridge, S; Dharamshi, K; Jäkel, A; Johns, A; Modha, R; Plested, M | 1 |
| Azuma, K; Daga, H; Hayashi, H; Kiyota, H; Miyazaki, M; Murakami, H; Naito, T; Nakagawa, K; Okada, H; Okamoto, I; Takeda, K; Takeda, M; Tanaka, K; Terashima, M; Yamamoto, N | 1 |
| Allen, PK; Amini, A; Brown, P; Chang, JY; Chen, SS; Garland, LL; Heymach, JV; Holt, J; Kim, ES; Komaki, R; Liao, Z; McGovern, SL; Munsell, MF; Stea, B; Sulman, E; Unger, W; Wefel, JS; Welsh, JW | 1 |
| Cheng, X; Li, H; Li, L; Li, M; Lu, W; Wang, X; Zhou, T | 1 |
| Broggini, M; De Braud, F; Garassino, MC; Platania, M; Torri, V | 1 |
| Duyster, J; Kancha, RK; Kunst, PW; Reinten, RJ; van der Ven, WH; van Noesel, CJ; van Noesel, J; van Os, TA; Weegenaar, J | 1 |
| Alfieri, R; Ardizzoni, A; Carmi, C; Cavazzoni, A; Dekker, H; Galvani, E; Giovannetti, E; Leon, LG; Mor, M; Peters, GJ; Petronini, PG; Saccani, F | 1 |
| Majem, M; Pallarès, C | 1 |
| Cai, J; Li, T; Wang, X; Wu, B; Xu, Y; Ye, M; Zhu, J | 1 |
| Fujita, H; Kashihara, M; Kuwano, M; Nakagawa, K; Ogi, S; Ohdo, S; Okamoto, I; Ono, M; Sonoda, K; Tanaka, Y; Yamamoto, C | 1 |
| Crawford, M; Fabbri, M; Friedman, A; Garofalo, M; Kang, HW; Nana-Sinkam, SP; Nuovo, G | 1 |
| Buechner, SA; Erne, P; Iezzi, G; Kyriakakis, E; Pfaff, D; Philippova, M; Resink, TJ; Schoenenberger, AW; Spagnoli, GC | 1 |
| Grigorieva, J; Lee, CB; Moore, DT; Peterman, AH; Roder, J; Socinski, MA; Stinchcombe, TE | 1 |
| Augustin, A; Avila, DW; Duchateau-Nguyen, G; Essioux, L; Golling, S; Hermann, JC; Klughammer, B; Lamerz, J; Langen, H; Meistermann, H; Scheiblich, S; Tzouros, M | 1 |
| Kuiper, JL; Smit, EF | 1 |
| Besse, B; Chaubet-Houdu, M | 1 |
| Ebi, H; Hasegawa, Y; Ishikawa, D; Nakagawa, T; Nanjo, S; Sano, T; Sato, M; Sekido, Y; Takeuchi, S; Yamada, T; Yano, S | 1 |
| Goyal, A; Singh, N | 1 |
| Buyyounouski, MK; Demas, W; Khuntia, D; Komaki, R; Mehta, MP; Nedzi, LA; Perry, G; Robins, HI; Schell, MC; Shah, SA; Souhami, L; Sperduto, PW; Suh, JH; Wang, M; Werner-Wasik, M | 1 |
| Fang, Z; Li, B; Zang, YS | 1 |
| Good, JA; Kaan, HY; Kozielski, F; MacKay, SP; Podgórski, D; Rath, O; Talapatra, SK; Wang, F | 1 |
| Khan, I; Sarker, SJ; Whitehead, A | 1 |
| Dering, J; Desai, AJ; Dubinett, SM; Finn, RS; Garon, EB; Hosmer, W; Kamranpour, N; Márquez-Garbán, DC; Pietras, RJ; Pitts, S; Slamon, DJ; von Euw, EM | 1 |
| Sánchez De Cos Escuín, J | 1 |
| Herbst, RS; Kies, MS | 1 |
| Natale, RB; Zaretsky, SL | 1 |
| Averbuch, SD; Baselga, J; Herbst, RS; Hong, WK; LoRusso, PM; Maddox, AM; Ochs, J; Rojo, F; Rothenberg, ML; Rubin, EH; Small, EJ; Swaisland, H | 1 |
| Jänne, PA; Johnson, BE; Salgia, R; Taffaro, ML | 1 |
| Elomaa, I; Joensuu, H; Orpana, A; Osterlund, P; Repo, H | 1 |
| Coll, JL; Dubrez, L; Favrot, MC; Hurbin, A | 1 |
| Wilkinson, E | 1 |
| Culy, CR; Faulds, D | 1 |
| Couzin, J | 2 |
| Albanell, J; Averbuch, SD; Baselga, J; Bjork, T; Calvert, H; Feyereislova, A; Gianni, L; Harris, A; Kaye, SB; Kieback, DG; Ranson, M; Raymond, E; Rischin, D; Rojo, F; Swaisland, H | 1 |
| Koty, PP; Lei, W; Levitt, ML | 1 |
| Twombly, R | 3 |
| Baselga, J; Hammond, LA | 1 |
| Bunn, PA; Franklin, W | 1 |
| Baldwin, J | 1 |
| Burton, A | 1 |
| Ebina, M; Gomi, K; Inoue, A; Kikuchi, T; Kimura, Y; Maemondo, M; Moriya, T; Nukiwa, T; Saijo, Y; Tokue, Y | 1 |
| Thomas, M | 2 |
| Aherne, GW; Hobbs, S; Welsh, SJ | 1 |
| Dummer, R; Follath, F; Jacky, E; Trojan, A | 1 |
| Tamura, T | 2 |
| Glisson, BS | 1 |
| Binetti, P; La Cesa, A; Massacesi, C; Picardi, A; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Lorusso, PM | 1 |
| Cella, D | 1 |
| Schiller, JH | 2 |
| Mauer, AM; Villano, JL; Vokes, EE | 1 |
| Muguruma, H; Sone, S; Yano, S | 2 |
| Fujiwara, K; Hamasaki, S; Kiura, K; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Ranson, M; Thatcher, N | 1 |
| Lavelle, F | 1 |
| Nakamura, M; Nakano, J | 1 |
| Dyer, O | 1 |
| Arteaga, CL; Johnson, DH | 2 |
| Averbuch, S; Baselga, J; Dong, RP; Douillard, JY; Eek, R; Feyereislova, A; Fukuoka, M; Giaccone, G; Horai, T; Kudoh, S; Macleod, A; Nakagawa, K; Nishiwaki, Y; Noda, K; Rischin, D; Smit, E; Takata, I; Tamura, T; Vansteenkiste, J; Yano, S | 1 |
| Cyranoski, D | 1 |
| Carbone, D; Heelan, RT; Johnson, DH; Kris, MG; Krozely, P; Krug, LM; Miller, VA; Ochs, J; Perez, W; Pizzo, B; Sandler, A; Smith, R; Tyson, L | 1 |
| Androulakis, N; Bozionelou, V; Georgoulias, V; Kouroussis, C; Mavroudis, D; Pallis, AG; Souglakos, J; Vlachonikolis, IG | 1 |
| Fujii, K; Kihara, N; Kohrogi, H; Matsumoto, M; Okamoto, I; Suga, M; Terasaki, Y | 1 |
| Daigo, Y; Hirata, K; Kakiuchi, S; Katagiri, T; Kikuchi, T; Nakamura, Y; Nishime, C; Ohnishi, Y; Zembutsu, H | 1 |
| Patrick-Miller, LJ | 1 |
| Averbuch, SD; Baselga, J; Bjork, T; Calvert, H; Feyereislova, A; Gianni, L; Harris, A; Herbst, RS; Heyes, A; Kaye, S; Kieback, D; LoRusso, PM; Maddox, AM; Ochs, J; Ranson, M; Raymond, E; Rischin, D; Rothenberg, ML; Rubin, EH; Small, EJ | 1 |
| Giaccone, G; Janmaat, ML; Kruyt, FA; Rodriguez, JA | 1 |
| Ouchi, Y; Teramoto, S; Yamamoto, H | 1 |
| Hanajiri, K; Maruyama, T; Mitsui, H; Nakajima, J; Omata, M | 1 |
| Aono, Y; Azuma, M; Kanematsu, T; Miki, T; Sone, S; Uehara, H; Yamamoto, A; Yano, S | 1 |
| Graham, J; Kirkpatrick, P; Muhsin, M | 1 |
| Seymour, L; Shepherd, FA; Sridhar, SS | 1 |
| Dancey, JE; Freidlin, B | 1 |
| Bartolini, S; Calandri, C; Cancellieri, A; Cappuzzo, F; Ceresoli, G; Crino, L; de Rosa, M; Gregorc, V; Lombardo, L; Magrini, E; Paties, CT; Rossi, E; Villa, E | 1 |
| Bartolini, S; Calandri, C; Cappuzzo, F; Crinò, L | 1 |
| Bunn, PA; Ciardiello, F; Helfrich, B; Raben, D | 1 |
| Johnson, DH | 1 |
| Bonomi, P | 2 |
| Ardizzoni, A; Bartolini, S; Calandri, C; Cappuzzo, F; Crinò, L; Gridelli, C; Maione, P; Santoro, A; Soto-Parra, H; Tiseo, M | 1 |
| Behnken, D; Govindan, R; McLeod, H; Read, W | 1 |
| Ieki, R; Saitoh, E; Shibuya, M | 1 |
| Kelly, K | 1 |
| Goto, H; Hashimoto, E; Ieki, R; Iguchi, M; Moriyama, S; Ohta, T; Okamura, T; Saitoh, E; Shibuya, M; Yuasa, K | 1 |
| Chen, G; Cohen, MH; Pazdur, R; Sridhara, R; Williams, GA | 1 |
| Chang, GC; Chiang, CD; Huang, CM; Wang, NS; Yang, TY | 1 |
| Genma, A; Kudo, S; Yoshimura, A | 1 |
| Gemma, A; Kudoh, S; Yoshimura, A | 1 |
| George, SL | 1 |
| Herchenhorn, D; Rabinowits, G; Rabinowits, M; Torres, W; Weatge, D | 1 |
| Goya, T; Koshiishi, Y; Miya, T; Ono, Y; Tanaka, H | 1 |
| Endo, H; Hida, T; Masuda, A; Mitsudomi, T; Nakagawa, T; Sugiura, T; Suzuki, T; Takahashi, T; Yatabe, Y | 1 |
| Liu, CY; Seen, S | 1 |
| Albain, KS; Averbuch, SD; Belani, CP; Cella, D; Herbst, RS; Kay, AC; Kelly, K; Kris, MG; Lynch, TJ; Natale, RB; Ochs, JJ; Prager, D; Sandler, A; Schiller, JH; Spiridonidis, H; Wolf, MK | 1 |
| Dainichi, T; Furue, M; Noda, K; Tanaka, M; Tsuruta, N | 1 |
| Ceribelli, A; Cognetti, F; Gelibter, A; Milella, M; Mottolese, M; Vocaturo, A | 1 |
| DeGrendele, H | 1 |
| Okamoto, I; Suga, M | 1 |
| Castaldo, V; Gridelli, C; Maione, P; Rossi, A | 1 |
| Averbuch, SD | 1 |
| Sandler, AB | 3 |
| Khuri, FR | 1 |
| Goldman, B | 1 |
| Cortes-Funes, H; Soto Parra, H | 1 |
| van Zandwijk, N | 1 |
| Katz, A; Zalewski, P | 1 |
| Bernardo, MM; de Braud, F; Gridelli, C; Kosimidis, P; Parra, HS; Petruzelka, L; Rossi, A; Souquet, PJ; Stahel, R | 1 |
| Miller, VA; Shah, NT | 1 |
| Bunn, PA; Herbst, RS | 1 |
| Alloisio, M; Campagnoli, E; Cavina, R; Ferrari, B; Ginanni, V; Latteri, F; Morenghi, E; Pedicini, V; Ravasi, G; Roncalli, M; Santoro, A; Soto Parra, HJ; Zucali, PA | 1 |
| Asai Go, Go; Fukuoka, M; Kaneda, H; Kurata, T; Nakagawa, K; Nogami, T; Tamura, K; Uejima, H | 1 |
| Gatzemeier, U | 1 |
| Hidalgo, M | 1 |
| Sandler, A | 2 |
| Soulières, D | 1 |
| Pérez-Soler, R | 5 |
| Bartolini, S; Calandri, C; Cappuzzo, F; Ceresoli, GL; Crinò, L; Gregorc, V; Lombardo, L; Spreafico, A; Tamberi, S; Toschi, L; Villa, E | 1 |
| Jones, S | 1 |
| Bonomi, PD | 1 |
| Vansteenkiste, J | 2 |
| Nakata, H; Ohsaki, Y; Tuji, T | 1 |
| Kris, MG; Miller, VA; Pao, W | 1 |
| Hussar, DA | 1 |
| Averbuch, S; Blackledge, G | 1 |
| Fayette, J; Le Chevalier, T; Soria, JC | 1 |
| Fujimura, M; Kasahara, K; Kimura, H; Kita, T; Nakao, S; Yoshimoto, A | 1 |
| Haraguchi, N; Kikuchi, N; Kodama, T; Satoh, H; Sekizawa, K | 1 |
| Belani, CP; Ramalingam, S | 2 |
| Ochs, JS | 1 |
| Abraham, S; Baird, A; Chen, G; Cohen, MH; Liang, C; Lostritto, R; McGuinn, WD; Morse, D; Pazdur, R; Rahman, A; Sridhara, R; Williams, GA | 1 |
| Glover, KY; Papadimitradopoulou, VA; Perez-Soler, R | 1 |
| Averbuch, S; Kelly, K | 1 |
| España, A; Fernandez-Galar, M; López-Picazo, JM | 1 |
| Baselga, J | 2 |
| Averbuch, SD; Fandi, A; Gatzemeier, U; Giaccone, G; Grous, J; Herbst, RS; Johnson, DH; Manegold, C; Miller, V; Natale, RB; Ochs, JS; Pluzanska, A; Rennie, P; Rosell, R; Scagliotti, G; Schiller, JH; Von Pawel, J; Wolf, MK | 1 |
| Averbuch, SD; Fandi, A; Giaccone, G; Grous, J; Herbst, RS; Johnson, DH; Krebs, AD; Manegold, C; Miller, V; Natale, RB; Ochs, JS; Oliff, I; Reeves, JA; Rosell, R; Scagliotti, G; Schiller, JH; Wolf, MK | 1 |
| Hasegawa, S; Ishibashi, O; Kambayashi, T; Tanaka, F; Wada, H; Yanagihara, K | 1 |
| Azzoli, C; Ben-Porat, L; Gomez, J; Heelan, RT; Kris, MG; Krug, LM; Memoli, N; Miller, VA; Pao, W; Patel, J; Pizzo, B; Rizvi, N; Rusch, V; Shah, N; Tyson, L; Venkatraman, E; Zakowski, M | 1 |
| Choi, JH; Kim, SW; Koh, JK; Lee, HW; Lee, MW; Moon, KC; Seo, CW; Yang, HJ | 1 |
| Shimizu, E | 1 |
| Ranson, M; Wardell, S | 1 |
| Ardizzoni, A; Tiseo, M | 2 |
| Fidias, P; Gurubhagavatula, S; Jänne, PA; Johnson, BE; Lucca, J; Lynch, TJ; Ostler, P; Skarin, AT; Yeap, BY | 1 |
| Perras, C | 1 |
| Krozely, P | 1 |
| Baas, P; Haringhuizen, A; Vaessen, HF; van Tinteren, H; van Zandwijk, N | 1 |
| Ono, M | 1 |
| Fukuoka, M; Horai, T; Imamura, F; Katakami, N; Kiura, K; Kudoh, S; Matsui, K; Nakagawa, K; Nishiwaki, Y; Noda, K; Saka, H; Sawa, Y; Sugiura, T; Takada, M; Takata, I; Takeda, K; Tamura, T; Uchida, H; Watanabe, K; Yano, S; Yokoyama, A | 1 |
| Akaza, H; Blackledge, G; Carmichael, J; Isonishi, S; Kakeji, Y; Kurebayashi, J; Nakagawa, M; Nakamura, S; Ohashi, Y; Saijo, N; Sone, S; Tsuruo, T; Yamamoto, N | 1 |
| Green, MR | 1 |
| Bell, DW; Brannigan, BW; Christiani, DC; Gurubhagavatula, S; Haber, DA; Haluska, FG; Harris, PL; Haserlat, SM; Louis, DN; Lynch, TJ; Okimoto, RA; Settleman, J; Sordella, R; Supko, JG | 1 |
| Boggon, TJ; Eck, MJ; Fujii, Y; Gabriel, S; Greulich, H; Herman, P; Jänne, PA; Johnson, BE; Kaye, FJ; Lee, JC; Lindeman, N; Meyerson, M; Naoki, K; Paez, JG; Sasaki, H; Sellers, WR; Tracy, S | 1 |
| Marx, J | 1 |
| Choy, H; Kim, DW | 1 |
| Campiglio, M; Di Maio, M; Normanno, N; Perrone, F | 1 |
| Dancey, JE | 2 |
| Marmé, D | 1 |
| Cersosimo, RJ | 2 |
| Siegfried, JM; Stabile, LP | 1 |
| Fischman, J | 1 |
| Argiris, A; Mittal, N | 1 |
| Congleton, J; Harper-Wynne, C; O'Brien, M; Sumpter, K | 1 |
| Ebihara, S; Ohrui, T; Sasaki, H; Takahashi, H; Yamada, M | 1 |
| Abe, S; Inomata, S; Nagata, M; Saitoh, T; Sato, T; Satoh, M; Shiratori, M; Takahashi, H; Tanaka, H; Yamada, G | 1 |
| Adames, V; Beck, G; Birnboeck, H; Gand, L; Higgins, B; Hoffmann, G; Kolinsky, K; Linn, M; Rashed, M; Smith, M; Wheeldon, E | 1 |
| Chabner, BA | 1 |
| Arteaga, CL | 2 |
| Gazdar, AF; Herz, J; Minna, JD; Sprang, SR | 1 |
| Campagnoli, E; Cavina, R; Grimaldi, GC; Latteri, F; Morenghi, E; Parra, HS; Roncalli, M; Santoro, A; Zucali, PA | 1 |
| Kodama, T; Kunitoh, H; Kusumoto, M; Nokihara, H; Ohe, Y; Saijo, N; Sekine, I; Takano, T; Tamura, T; Tateishi, U; Yamamoto, N; Yamamoto, S | 1 |
| Igarashi, T; Imamura, F; Nakamura, S; Ueno, K; Yamamoto, S; Yoshimura, M | 1 |
| Hasegawa, Y; Kumasaka, R; Nakamura, M; Nakamura, N; Okumura, K; Osawa, H; Shirato, K; Takanashi, S; Tamura, M; Yamabe, H | 1 |
| Bartolini, S; Cappuzzo, F; Ceresoli, GL; Crinò, L; Gregorc, V; Villa, E | 1 |
| Purdom, M | 1 |
| Chansky, K; Crowley, J; Davies, AM; Franklin, WA; Gandara, DR; Gumerlock, PH; Hirsch, FR; Lau, DH; West, H | 1 |
| Giaccone, G | 4 |
| Hirano, A; Kawata, N; Kimura, G; Okada, C; Shibayama, T; Soda, R; Tada, A; Takahashi, K; Takigawa, N; Yamadori, I | 1 |
| Futreal, PA; Stratton, MR | 1 |
| Golsteyn, RM | 2 |
| Im, YH; Jung, CW; Kang, WK; Kim, HY; Kim, JH; Kim, JY; Kim, K; Lee, KE; Lee, MH; Lee, SH; Lee, SI; Park, BB; Park, J; Park, JO; Park, K; Park, SH; Park, YS | 1 |
| Behnken, D; Coplin, MA; Gao, F; Govindan, R; Kommareddy, A; Read, W; Romvari, E | 1 |
| Figg, WD; Price, DK | 1 |
| Bayle, S; Daniel, C; Descourt, R; Gouva, S; Robinet, G | 1 |
| McNeil, C | 1 |
| Cheng, ZW; Gao, JM; Zhang, L | 1 |
| Li, LY; Wang, SL; Zhang, XT | 1 |
| Averbuch, S; Swaisland, H; Wolf, M | 1 |
| Eccles, SA; Harrington, KJ; Nutting, CM; Rogers, SJ | 1 |
| Nakagawa, K | 2 |
| Bell, DW; Haber, DA; Settleman, J; Sordella, R | 1 |
| Armstrong, EA; Benavente, S; Chinnaiyan, P; Harari, PM; Huang, S | 1 |
| Fujiwara, M; Ishikawa, H; Nakayama, M; Ohtsuka, M; Satoh, H; Sekizawa, K | 1 |
| Kris, MG; Miller, VA; Pao, W; Venkatraman, E | 1 |
| Bartolini, S; Bellezza, G; Calandri, C; Cancellieri, A; Cappuzzo, F; Ceresoli, GL; Crinò, L; Damiani, S; Gregorc, V; Ligorio, C; Lombardo, L; Ludovini, V; Magrini, E; Paties, CT; Rossi, E; Spreafico, A; Tonato, M | 1 |
| Bianco, AR; Bianco, C; Bianco, R; Bunn, P; Ciardiello, F; Cionini, L; D'Armiento, FP; Damiano, V; Melisi, D; Mignogna, C; Raben, D; Tortora, G | 1 |
| Price, N; Reddy, GK | 1 |
| Bonomi, P; Chachoua, A; Clark, GM; Hammond, LA; Huberman, M; Karp, D; Pérez-Soler, R; Rigas, J; Rowinsky, EK; Santabárbara, P | 1 |
| Chocholska, S; Krawczyk, P; Milanowski, J | 1 |
| Li, LY; Mu, XL; Wang, MZ; Wang, SL; Zhang, XT | 2 |
| Doherty, J; Fulton, L; Heelan, R; Kris, M; Kupfer, D; Mardis, E; Miller, V; Pao, W; Politi, K; Rusch, V; Sarkaria, I; Singh, B; Varmus, H; Wilson, R; Zakowski, M | 1 |
| Amano, H; Hoshi, S; Kono, C; Yamada, Y; Yamaguchi, T | 1 |
| Bamias, A; Efstathiou, E; Stratigos, A; Zorzou, MP | 1 |
| Camus, P; Ebina, M; Kudoh, S | 1 |
| Chang, GC; Chen, CY; Hsu, SL; Liang, FP; Lin, SY; Sheu, GT; Tsai, JR | 1 |
| Pizzo, B | 1 |
| Chau, I; Cunningham, D; Hill, M; Katopodis, R; Middleton, G; Norman, AR; Oates, JR; Ross, PJ; Stewart, G; Topham, C; Waters, JS | 1 |
| Vastag, B | 1 |
| Sorscher, SM | 1 |
| Longo, L; Marchioni, A; Rossi, G | 1 |
| Rasheed, BK; Rich, JN; Yan, H | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Kim, DW; Kim, NK; Kim, TY; Kim, YT | 1 |
| Zhang, L | 1 |
| Bencardino, KB; Cappuzzo, F; Ceresoli, GL; Crinò, L; Ferraldeschi, M; Floriani, I; Gregorc, V; Ludovini, V; Mihaylova, Z; Pistola, L; Spreafico, A; Tofanetti, FR; Tonato, M; Torri, V; Villa, E | 1 |
| del Giglio, A; Ito, C | 1 |
| Barthorpe, A; Bignell, G; Blow, M; Brackenbury, L; Brasseur, F; Butler, A; Chenevix-Trench, G; Clarke, O; Cole, J; Cooper, CS; Davies, H; Dicks, E; Dike, A; Drozd, A; Edkins, S; Edwards, K; Flanagan, AM; Forbes, S; Foster, R; Futreal, PA; Goldstraw, P; Gray, K; Greenman, C; Halliday, K; Harris, G; Hills, K; Hunter, C; Knowles, M; Kosmidou, V; Leung, SY; Looijenga, LH; Louis, DN; Lugg, R; Malkowicz, B; Menzies, A; Nicholson, AG; O'Meara, S; Parker, A; Perry, J; Petty, R; Pierotti, MA; Raine, K; Ratford, L; Shepherd, R; Small, A; Smith, R; Stephens, P; Stephens, Y; Stevens, C; Stratton, MR; Teague, J; Teh, B; Tofts, C; Varian, J; Weber, BL; West, S; Widaa, S; Wooster, R; Yates, A; Yuen, ST | 1 |
| Ishida, A; Iwamoto, Y; Kanoh, K; Kohno, N; Miyazawa, T; Miyazu, Y; Nishisaka, T | 1 |
| Fukuoka, M; Kaneda, H; Kurata, T; Nakagawa, K; Tamura, K; Uejima, H | 1 |
| Fujiwara, K; Hisamoto, A; Hotta, K; Kiura, K; Kozuki, T; Okada, T; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Ito, M; Iwasaki, T; Kawamura, S; Kijima, T; Kimura, H; Maeda, H; Nakagawa, M; Namba, Y; Niinaka, M; Okada, T; Okumura, Y; Takeda, Y; Yamaguchi, T; Yokota, S | 1 |
| Easthope, SE; Frampton, JE | 2 |
| Hansen, M; Jänne, PA; Johnson, BE; Meyerson, M; Mukohara, T; Tracy, S | 1 |
| Kikuchi, K; Nakanishi, K; Ohsaki, Y; Tanno, S; Toyoshima, E | 1 |
| Bando, M; Hosono, T; Nakazawa, S; Ohno, S; Oshikawa, K; Sohara, Y; Sugiyama, Y | 1 |
| Lyle, J | 1 |
| Saeed, M | 1 |
| Bjarnason, GA; Charpentier, D; Dent, S; Douglas, L; Goel, R; Matthews, S; Seymour, L; Walsh, W; Winquist, E; Wong, R | 1 |
| Chang, GC; Chen, KC; Hsu, JY; Kuo, BI; Lin, CP; Yang, TY; Yin, MC | 1 |
| Goto, K; Ishii, G; Kim, YH; Kodama, T; Nagai, K; Nishiwaki, Y; Nitadori, J; Ochiai, A; Shiono, S; Tsuta, K | 1 |
| Senior, K | 1 |
| Fujimoto, N; Fujiwara, K; Hamazaki, S; Kiura, K; Kozuki, T; Mizobuchi, K; Shiomi, K; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Ho, SS; Mok, TS; Poon, AN; Yeo, W | 1 |
| Settleman, J | 1 |
| Chang, GC; Chen, KC; Lin, YC; Wang, RC; Yang, TY; Yin, MC | 1 |
| Ando, Y; Nagashima, F; Narabayashi, M; Ohyanagi, F; Sasaki, Y | 1 |
| Faulkner, K; Forsythe, B | 1 |
| Adjei, A; Belani, CP | 1 |
| Ben-Porat, L; Heelan, RT; Heinemann, MH; Kris, MG; Miller, VA; Pao, W; Pizzo, BM; Sachs, DL; Shah, NT; Tyson, LB | 1 |
| Feinstein, MB; Gomez, JE; Kris, MG; Milton, DT | 1 |
| Dennis, PA; Tsurutani, J | 1 |
| Baselga, J; Fukuoka, M; Herbst, RS | 1 |
| Von Pawel, J | 1 |
| Koh, Y; Koizumi, F; Nishio, K; Saijo, N; Taguchi, F; Tamura, T | 1 |
| Astoul, P; Barlési, F; Doddoli, C; Kleisbauer, JP; Tchouhadjian, C; Torre, JP | 1 |
| Chen, YM; Chiang, SC; Chiu, CH; Liou, JL; Perng, RP; Tsai, CM | 1 |
| Alfaro, V; Tanović, A | 1 |
| Birnbaum, A; Ready, N | 1 |
| Bowman, R; Fong, KM | 1 |
| Cadranel, J; Madelaine, J; Zalcman, G | 1 |
| Chang, WC; Chen, YR; Chen, YT; Fu, YN; Huang, SF; Ku, YC; Kuo, HP; Li, LH; Lin, YF; Liu, HP; Tsai, HY; Tsai, SF; Wu, YC | 1 |
| Brave, S; Kendrew, J; Stratford, IJ; Telfer, BA; Wedge, SR; Whittaker, L; Williams, KJ | 1 |
| Arnheim, K | 1 |
| Cho, D; Halmos, B; Janne, PA; Kocher, O; Lee, JC; Meyerson, ML; Tenen, DG | 1 |
| Isoe, T; Kamishohara, M; Kubo, K; Miura, T; Nakamura, K; Shibuya, M; Taguchi, E; Takahashi, K; Yamamoto, A | 1 |
| Fuster, LM; Sandler, AB | 1 |
| Patel, JD | 1 |
| Bakoyannis, C; Briasoulis, E; Dimopoulos, M; Efstathiou, H; Fountzilas, G; Kopterides, P; Kosmidis, P; Lambropoulos, S; Makatsoris, T; Papadopoulos, S; Pectasides, D; Razis, E; Rigatos, S; Skarlos, D; Tzamakou, E; Varthalitis, G | 1 |
| Akita, H | 1 |
| Aikawa, A; Hanawa, Y; Hashizume, M; Itou, S; Katou, K; Kidokoro, T; Kimura, B; Okano, Y; Takano, T; Takaoka, K; Tokimitsu, S; Uchikado, M; Yagi, M; Yamagishi, M | 1 |
| Curigliano, G; De Braud, F; De Pas, T; Dodaro, L; Manzoni, S; Noberasco, C; Pelosi, G; Spaggiari, L | 1 |
| Normanno, N | 1 |
| Singer, E | 1 |
| Belani, C; Price, N | 1 |
| Heelan, RT; Kris, MG; Ladanyi, M; Miller, VA; Pan, Q; Pao, W; Riely, GJ; Varmus, HE; Wang, TY; Zakowski, MF | 1 |
| Belani, CP; Cella, D; Herbst, RS; Heyes, A; Kay, AC; Kris, MG; Lynch, TJ; Natale, RB; Ochs, JS; Prager, D; Schiller, JH; Wolf, MK | 1 |
| Ishii, T; Masuda, M; Matsuse, T; Teramoto, S | 1 |
| Boyer, M; Clarke, S; Millward, M; Sharma, R | 1 |
| Aoe, M; Date, H; Gazdar, AF; Ichimura, K; Kiura, K; Shigematsu, H; Shimizu, N; Tabata, M; Tanimoto, M; Tokumo, M; Tomii, K; Toyooka, S; Tsuda, T; Tsukuda, K; Ueoka, H; Yano, M | 1 |
| Bang, YJ; Choi, IS; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Jeong, S; Kim, DW; Kim, J; Kim, JH; Kim, NK; Kim, TY; Kim, YT; Lee, JS; Oh, DY | 1 |
| Castaldo, V; Del Gaizo, F; Gridelli, C; Guerriero, C; Maione, P; Rossi, A | 1 |
| Belani, CP; Gooding, W; Lin, Y; Mohamed, MK; Ramalingam, S | 1 |
| Boggon, TJ; Dayaram, T; Eck, MJ; Halmos, B; Jänne, PA; Johnson, BE; Kobayashi, S; Kocher, O; Meyerson, M; Tenen, DG | 1 |
| Dowell, JE; Minna, JD | 3 |
| Matsuo, K; Tanimoto, M; Uchida, A | 1 |
| Cantley, LC; Cichowski, K; Engelman, JA; Fleet, C; Jänne, PA; Johnson, BE; Mermel, C; Mukohara, T; Pearlberg, J | 1 |
| Chang, KL; Lau, SK | 1 |
| Chu, DT; Wang, B; Zhang, XR | 2 |
| Gatzemeier, U; Reck, M | 3 |
| Grandis, JR; Gubish, CT; Lyker, JS; Siegfried, JM; Stabile, LP; Zhang, W | 1 |
| Doi, S; Ikegami, Y; Itoh, A; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M | 1 |
| Antonella, P; Augusto, P; Busi, G; Giancarla, B; Palumbo, A; Pedrazzini, A; Roggero, E | 1 |
| Kris, MG; Miller, VA; Pao, W; Politi, KA; Riely, GJ; Somwar, R; Varmus, H; Zakowski, MF | 1 |
| Endoh, H; Hatooka, S; Hida, T; Horio, Y; Kosaka, T; Mitsudomi, T; Mori, S; Shinoda, M; Takahashi, T; Yatabe, Y | 1 |
| Apáti, A; Buday, L; Elkind, NB; Homolya, L; Kéri, G; Német, K; Ozvegy-Laczka, C; Sarkadi, B; Szabó, K; Szentpétery, Z; Ujhelly, O; Váradi, A; Várady, G | 1 |
| Blumenschein, G; Carbone, DP; Eberhard, DA; Henderson, T; Herbst, RS; Hong, WK; Johnson, DH; Kelley, SK; Kim, ES; Lee, JJ; Liu, DD; Mass, R; Mininberg, E; Ramies, DA; Sandler, A; Seshagiri, S; Tran, H; Truong, MT; Tsao, A; Xie, D | 1 |
| Coppola, D; Cress, D; Haura, EB; Livingston, S; Song, L | 1 |
| Burdak-Rothkamm, S; Feldmann, K; Ludwig, D; Nguyen, TP; Rübe, C; Rübe, CE; Wiegel, T | 1 |
| Koizumi, F; Nishio, K; Saijo, N; Shimoyama, T; Taguchi, F | 1 |
| del Valle, ML; Sanz, A | 1 |
| Miller, VA; Pao, W | 1 |
| Curigliano, G; de Braud, F; De Pas, T; Noberasco, C; Pelosi, G; Spaggiari, L; Veronesi, G | 1 |
| Yatabe, Y | 1 |
| Araki, J; Ichikawa, Y; Okamoto, I; Sasaki, J; Suto, R | 1 |
| Karjalainen, EM; Knuuttila, A; Mali, P; Rouhos, A | 1 |
| Ahn, SJ; Baek, SM; Jeong, JY; Kim, KS; Kim, YC; Kim, YH; Kim, YI; Lim, SC; Na, KJ; Park, CM; Park, CS; Park, KO | 1 |
| Dimitroulakos, J; Goss, G; Hanson, JE; Lagarde, AE; Lorimer, IA; Mantha, AJ | 1 |
| Choe, JK; Cogswell, J; Kasimis, B; Nagaria, NC | 1 |
| Desai, AA; Ratain, MJ | 1 |
| Barnett, S; Bichat, F; Giles, PB; Guilbaud, N; Kemp, JV; Kendrew, J; McKillop, D; Partridge, EA; Patterson, AB; Spence, MP; Stephens, TC; Wood, PG | 1 |
| Armstrong, E; Chinnaiyan, AM; Chinnaiyan, P; Harari, PM; Huang, S; Tomlins, SA; Vallabhaneni, G; Varambally, S | 1 |
| Endo, K; Fujii, Y; Fukai, I; Iuchi, K; Kawaguchi, T; Kawahara, M; Konishi, A; Matsumura, A; Okumura, M; Sasaki, H; Shimizu, T; Takada, M; Takeuchi, H; Tanaka, H; Yano, M | 1 |
| Han, JY; Hong, EK; Kim, HK; Kim, HY; Lee, DH; Lee, EK; Lee, HG; Lee, JJ; Lee, JS | 1 |
| Blankenburg, T; Brust, D; Nagel, S; Schaedlich, S; Schütte, W | 1 |
| Bell, DW; Haber, DA; Louis, DN; Riemenschneider, MJ | 1 |
| Abrey, LE; Franceschi, E; Kris, MG; Miller, VA; Milton, DT; Omuro, AM; Shah, N | 1 |
| Coulon, C; Gandara, D; Geraghty, E; Laptalo, L; Lau, D; Seibert, A | 1 |
| Chiu, CH; Perng, RP; Shih, YN; Tsai, CM | 1 |
| Alberola, V; Camps, C; Cardenal, F; Castellanos, D; Cortes-Funes, H; Diz, P; Garcia-Giron, C; Gomez, C; Gonzalez-Larriba, JL; Izquierdo, A; Maeztu, I; Mayo, C; Mendez, P; Moran, T; Queralt, C; Rosell, R; Sanchez, JJ; Taron, M; Valero, P; Velasco, A; Vieitez, JM | 1 |
| Carpentier, AF; Delattre, JY; Hoang-Xuan, K; Marie, Y; Omuro, AM; Sanson, M; Thillet, J | 1 |
| Carbone, DP; Dang, TP; Eichenberger, S; Gonzalez, A; Haruki, N; Kawaguchi, KS; Massion, PP; Olson, S | 1 |
| Kaye, FJ | 1 |
| Bartolini, S; Bemis, L; Bunn, PA; Cappuzzo, F; Ceresoli, GL; Crino, L; Danenberg, K; Doglioni, C; Domenichini, I; Franklin, WA; Gregorc, V; Haney, J; Hirsch, FR; Ludovini, V; Magrini, E; Rossi, E; Sidoni, A; Tonato, M; Varella-Garcia, M; Witta, S | 1 |
| Horai, T; Horiike, A; Ishikawa, Y; Nakagawa, K; Nishio, K; Nishio, M; Ohyanagi, F; Okumura, S; Satoh, Y | 1 |
| Gemma, A; Kataoka, K; Kokubo, Y; Kudoh, S; Matsuda, K; Minegishi, Y; Noro, R; Okano, T; Seike, M; Shibuya, M; Yoshimura, A | 1 |
| Edelman, MJ | 2 |
| Fujimura, M; Hourai, T; Kasahara, K; Kimura, H; Nakao, S; Nishio, M; Sone, T; Yoshimoto, A | 1 |
| Herbst, RS; Onn, A; Sandler, A | 1 |
| Ciardiello, F; Di Maio, M; Gridelli, C; Normanno, N; Perrone, F | 1 |
| Bell, DW; Brannigan, BW; Driscoll, DR; Fidias, P; Godin-Heymann, N; Haber, DA; Harris, PL; Isselbacher, KJ; Kwak, EL; Lynch, TJ; McGinnis, JP; Okimoto, RA; Rabindran, SK; Settleman, J; Sharma, SV; Sordella, R; Wissner, A | 1 |
| Fujii, T; Hirata, A; Hosoi, F; Kuwano, M; Miyagawa, M; Naito, S; Ono, M; Ueda, S | 1 |
| Kiura, K; Mitsudomi, T; Toyooka, S | 1 |
| Dietrich, GM; Fischer, JR; Geiger, D; Haffner, U; Lahm, H; Spahlinger, B | 1 |
| Astoul, P; Barlési, F; Doddoli, C; Greillier, L; Kleisbauer, JP; Tchouhadjian, C; Thomas, P; Villani, P | 1 |
| Hsu, HS; Huang, BS; Huang, MJ; Lim, KH; Tzen, CY; Yen, Y | 1 |
| Kanazawa, S; Kinoshita, Y; Muramatsu, M; Nomura, S; Yamaguchi, K | 2 |
| Anderson, H; Bebb, G; Ho, C; Laskin, J; Melosky, B; Murray, N | 1 |
| Heymach, JV | 1 |
| Campagnoli, E; Cavina, R; De Vincenzo, F; Latteri, F; Santoro, A; Soto Parra, HJ; Zucali, PA | 1 |
| Ichinose, Y; Ikeda, J; Maruyama, R; Miyake, T; Nakamura, T; Okamoto, T; Shoji, F; Wataya, H | 1 |
| Chuah, KL; Leong, SS; Lim, ST; Lim, WT; Tan, EH; Tay, MH; Toh, CK; Wong, EH | 1 |
| Reddy, GK | 2 |
| Tyagi, P | 1 |
| Buchholz, E; Fandi, A; Gatzemeier, U; Manegold, C; Smith, RP | 1 |
| Byrne, BJ; Garst, J | 1 |
| Fukuda, M; Kitazaki, T; Kohno, S; Soda, H | 1 |
| Costello, G; Holloway, B; Speake, G | 1 |
| Fukuoka, M; Tamura, K | 1 |
| Blackhall, FH; Rehman, S; Thatcher, N | 1 |
| Doi, S; Kitazaki, T; Kohno, S; Nakamura, Y; Oka, M; Soda, H; Takemura, M; Tsurutani, J; Yabuuchi, H; Yasunaga, M | 1 |
| Chang, XY; Cui, QC; Li, LY; Mu, XL; Song, W; Wang, MZ; Wang, SL; Zhang, L; Zhang, XT; Zhong, W | 1 |
| Blackhall, F; Danson, S; Papakotoulas, PI; Thatcher, N | 1 |
| Buter, J; Giaccone, G | 2 |
| Cui, QC; Feng, RE; Guo, BQ; Li, LY; Mu, XL; Wang, MZ; Zhang, XT; Zhou, HS | 1 |
| Lilenbaum, R; Lopes, G; Raez, LE | 1 |
| Dowell, J; Minna, JD | 1 |
| Gooding, WE; Grandis, JR; Lui, VW; Siegfried, JM; Thomas, SM; Wentzel, AL | 1 |
| Haber, DA; Settleman, J | 1 |
| Endoh, H; Kosaka, T; Mitsudomi, T; Yatabe, Y | 1 |
| Masuda, N; Yanase, N; Yokoba, M | 1 |
| Bunn, PA; Crowley, J; Franklin, WA; Gandara, DR; Gumerlock, P; Hirsch, FR; McCoy, J; Varella-Garcia, M; West, H; Xavier, AC | 1 |
| Kunitoh, H; Matsuno, Y; Nokihara, H; Ohe, Y; Sakamoto, H; Sakiyama, T; Sekine, I; Shibata, T; Takano, T; Tamura, T; Tateishi, U; Tsuta, K; Yamamoto, N; Yamamoto, S; Yoshida, T | 1 |
| Gallegos-Ruiz, M; Giaccone, G; Janmaat, ML; Kruyt, FA; Rodriguez, JA | 1 |
| Abe, T; Hagiri, S; Ishii, K; Katagiri, M; Kato, E; Kobayashi, H; Kuboto, M; Masuda, N; Mitsufuji, H; Onoda, S; Ryuge, S; Takada, N; Tanaka, N; Wada, M; Yamamoto, M; Yanaihara, T; Yanase, N; Yokoba, M | 1 |
| Brom, R; Candelaria, M; Duenas-Gonzalez, A; Meza, F; Taja-Chayeb, L; Trejo-Becerril, C | 1 |
| Doi, S; Kitazaki, T; Kohno, S; Nakamura, Y; Nakano, H; Soda, H | 1 |
| Besse, B; Cirauqui, B; Ichinose, Y; Mate, JL; Mendez, P; Moran, T; Nishiyama, K; Perez, M; Queralt, C; Reguart, N; Rosell, R; Sanchez, JJ; Sanchez, JM; Sarries, C; Taron, M | 1 |
| Bezjak, A; Campos, D; Ciuleanu, T; Clark, G; Dediu, M; Findlay, B; Hirsh, V; Johnston, D; Maoleekoonpiroj, S; Martins, R; Rodrigues Pereira, J; Santabárbara, P; Seymour, L; Shepherd, FA; Smylie, M; Tan, EH; Thongprasert, S; Tu, D; van Kooten, M | 1 |
| Doroshow, JH | 1 |
| Gow, CH; Shih, JY; Yang, PC | 1 |
| Cutz, JC; da Cunha Santos, G; Daneshmand, M; Ding, K; Kamel-Reid, S; Lagarde, A; Liu, N; Lorimer, I; Marrano, P; Pater, J; Richardson, F; Sakurada, A; Seymour, L; Shepherd, FA; Squire, J; Tsao, MS; Whitehead, M; Zhang, T; Zhu, CQ | 1 |
| Ready, N | 1 |
| Ettinger, DS | 1 |
| Choi, JH; Hyun, MS; Kim, MK; Lee, JK; Lee, KH | 1 |
| Cheng, AL; Shen, YC; Wan, JP; Yeh, KH; Yeh, SH | 1 |
| Hiddemann, W; Krych, M; Ostermann, H; Schoenberg, SO; Stemmler, HJ; Weigert, O | 1 |
| Friess, T; Hasmann, M; Scheuer, W | 1 |
| Gandara, DR; Gumerlock, PH | 1 |
| Amler, LC; Eberhard, DA; Goddard, AD; Heldens, SL; Herbst, RS; Hillan, KJ; Ince, WL; Jänne, PA; Januario, T; Johnson, BE; Johnson, DH; Klein, P; Miller, VA; Ostland, MA; Ramies, DA; Sebisanovic, D; Seshagiri, S; Stinson, JA; Zhang, YR | 1 |
| Fehrenbacher, L; Herbst, RS; Hermann, R; Johnson, BE; Johnson, DH; Klein, P; Kris, MG; Li, X; Miller, VA; Prager, D; Ramies, D; Sandler, A; Tran, HT | 1 |
| Bartolini, S; Bunn, PA; Cappuzzo, F; Ceresoli, GL; Crino, L; Domenichini, I; Franklin, WA; Gazdar, AF; Gregorc, V; Hirsch, FR; Ludovini, V; Rossi, E; Shigematsu, H; Toschi, L; Varella-Garcia, M | 1 |
| Engelman, JA; Jänne, PA | 1 |
| Cortese, JF; Eliason, JF; Everson, RB; Gowda, AL; Pass, HI; Wali, A | 1 |
| Cheng, AL; Chu, YC; Huang, CJ; Whang-Peng, J; Yang, CH; Yang, CS; Yang, PC | 1 |
| Chen, YF; Cohen, MH; Johnson, JR; Pazdur, R; Sridhara, R | 1 |
| Comis, RL | 1 |
| Chu, DT; Guan, ZZ; Jiang, GL; Li, LY; Li, W; Liu, XY; Zhang, L; Zhao, HY | 1 |
| Bradley, J; Govindan, R; Hope, A; Kreisel, D; Krupnick, AS; Meyers, B | 1 |
| Alavi, J; Algazy, K; Bearn, L; Eaby, B; Evans, T; Shults, J; Stevenson, JP; Veronese, ML | 1 |
| Bearz, A; Berretta, M; Spazzapan, S; Tirelli, U; Vaccher, E | 1 |
| Altundag, K; Altundag, O; Boruban, C; Silay, YS | 1 |
| Fukuyama, S; Hagiwara, K; Kanazawa, M; Kato, M; Kobayashi, K; Miyazawa, H; Nagai, Y; Tanaka, T; Udagawa, K; Yokote, A | 1 |
| Gazdar, AF; Minna, JD; Peyton, MJ | 1 |
| Cantley, LC; Engelman, JA; Halmos, B; Hanna, NH; Jänne, PA; Johnson, BE; Kobayashi, S; Lindeman, N; Mukohara, T; Pearlberg, J; Tenen, DG; Tsuchihashi, Z; Yeap, BY | 1 |
| Blanke, CD | 1 |
| Harper, P; Spicer, J | 1 |
| Haber, DA; Lynch, TJ; Sequist, LV | 1 |
| Hsue, V; Ichinose, Y; Jablons, D; Jahan, T; Manegold, C; Massuti, B; Mate, JL; Mok, T; Moran, T; Ono, M; Queralt, C; Rosell, R; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Taron, M; Zamora, L | 1 |
| Edakuni, N; Inayama, M; Kakiuchi, S; Muguruma, H; Nakataki, E; Nishikubo, N; Ohtsuka, S; Sone, S; Tomimoto, H; Yano, S | 1 |
| Ganti, AK; Potti, A | 1 |
| Govindan, R; Pillot, G; Viswanathan, A | 1 |
| Bartolini, S; Cappuzzo, F; Crinò, L; Finocchiaro, G; Metro, G; Toschi, L; Trisolini, R | 1 |
| Hasegawa, Y; Imaizumi, K; Kataoka, K; Kawabe, T; Kimura, T; Kondoh, Y; Kume, H; Nishiyama, O; Shimokata, K; Taniguchi, H | 1 |
| Fukui, T; Hasegawa, Y; Imaizumi, K; Kondo, M; Kume, H; Nagasaka, T; Sekido, Y; Shimokata, K; Yokoi, K; Yokoyama, T; Yoshioka, H | 1 |
| Burt, PA; Lee, LW | 1 |
| Fox, JL | 1 |
| Chang, YL; Chen, KY; Gow, CH; Hsu, YC; Shih, JY; Su, WP; Tsai, MF; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Kasahara, K; Kimura, H; Nishio, K; Sekijima, M; Tamura, T | 1 |
| Hotta, K; Inoue, A; Kiura, K; Nukiwa, T; Tanimoto, M; Ueoka, H | 1 |
| Bessho, A; Gemba, K; Harita, S; Hotta, K; Kiura, K; Matsuo, K; Tabata, M; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Fujikawa, T; Ito, M; Iwasaki, T; Kawamura, T; Kimura, H; Mori, M; Naka, N; Nakagawa, M; Namba, Y; Niinaka, M; Okada, T; Takeda, Y; Yamaguchi, T; Yokota, S | 1 |
| Matsumori, Y; Muguruma, H; Nakataki, E; Sone, S; Yano, S; Yoshizumi, M; Zheng, R | 1 |
| Benson, K; Booth, B; Chen, YF; Chidambaram, N; Cohen, M; Duan, J; Gobburu, J; Hsieh, LS; Johnson, JR; Leighton, J; Pazdur, R; Sridhara, R; Williams, GM; Zimmerman, P | 1 |
| Abraham, RT; Baker, A; Berggren, MI; Ihle, NT; Kirkpatrick, DL; Paine-Murrieta, G; Powis, G; Tate, WR; Wipf, P | 1 |
| Binns, D; Cullinane, C; Hicks, RJ; McArthur, GA; Roselt, P; Solomon, B; Weibe, LI | 1 |
| Chang, YL; Gow, CH; Shih, JY; Yu, CJ | 1 |
| Beijnen, JH; Schellens, JH; Siegel-Lakhai, WS | 1 |
| Lee, D | 1 |
| Bradof, JE; Brierre, JE; Burkett, ER; Burris, HA; Dickson, NR; Greco, FA; Hainsworth, JD; Jones, SF; Rubinsak, JR; Scullin, DC; Spigel, DR; Thomas, M; Yardley, DA | 1 |
| Garcia-Foncillas, J; Gurpide, A; Lopez-Picazo, JM; Martin-Algarra, S; Moreno, M; Perez-Gracia, JL; Zubieta, JL | 1 |
| Ceribelli, A; Cognetti, F; Gelibter, A; Milella, M; Moscetti, L; Pollera, CF; Sperduti, I | 1 |
| Leighl, NB; Nematollahi, M; Shepherd, FA; Tsao, WS; Zawisza, DL | 1 |
| Hsu, C; Shih, JY; Su, WP; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Hanagiri, T; Morita, M; Ono, K; Oyama, T; Sugaya, M; Sugio, K; Uramoto, H; Yasumoto, K; Yoshimatsu, T | 1 |
| Endo, K; Fujii, Y; Fukai, I; Haneda, H; Iuchi, K; Kawahara, M; Kobayashi, Y; Konishi, A; Kuwabara, Y; Matsumura, A; Mizuno, K; Okumura, M; Sasaki, H; Sugiura, H; Suzuki, E; Takada, M; Tanaka, H; Yano, M | 1 |
| Dobashi, K; Iijima, H; Ishizuka, T; Minna, JD; Mori, M; Nakajima, T; Otani, Y; Saito, R; Sato, K; Suga, T; Sunaga, N; Takise, A; Tanaka, S; Tomizawa, Y | 1 |
| Baselga, J; Bell, DW; Brannigan, BW; Fukuoka, M; Giaccone, G; Haber, DA; Harris, PL; Haserlat, SM; Herbst, RS; Iacona, RB; Johnson, DH; Krebs, AD; Kris, MG; Lynch, TJ; Manegold, C; Muir, B; Ochs, JS; Okimoto, RA; Riemenschneider, MJ; Sgroi, DC | 1 |
| Chen, YR; Chen, YT; Fu, YN; Hu, SF; Huang, SF; Lin, CH; Tsai, SF; Yang, ST | 1 |
| Brown, ER; Shepherd, FA | 1 |
| Fukuoka, M; Ichinose, Y; Jiang, H; Kato, H; Nagai, K; Tada, H; Tsuboi, M; Tsuchiya, R; Wada, H | 1 |
| Kakiuchi, S; Sone, S; Yano, S | 1 |
| Bessho, A; Gemba, K; Harita, S; Hotta, K; Kiura, K; Maeda, T; Ogino, A; Tabata, M; Tanimoto, M; Ueoka, H; Umemura, S; Yonei, T | 1 |
| Daigo, Y; Hayama, S; Inai, K; Ishikawa, N; Kato, T; Kohno, N; Murakami, H; Nakamura, Y; Nishimura, H; Takano, A; Takeshima, Y; Taniwaki, M; Tsuchiya, E | 1 |
| Brown, E; Buck, E; Gibson, N; Griffin, G; Haley, JD; Iwata, KK; Petti, F; Ramnarine, N; Thomson, S | 1 |
| Li, LY; Mu, XL; Song, W; Wang, MZ; Wang, SL; Zhang, XT | 1 |
| Garfield, DH | 2 |
| Bitran, JD; Nabhan, C | 1 |
| Ladanyi, M; Miller, VA; Pao, W | 1 |
| Ohe, Y; Takano, T | 1 |
| Kanazawa, S; Kinoshita, Y; Komiyama, Y; Muramatsu, M; Nomura, S; Yamaguchi, K | 3 |
| Fujii, T; Kuwano, M; Nakamura, H; Ono, M; Shirouzu, K; Takamori, S; Yamana, H | 1 |
| D'Amico, TA | 1 |
| Hotta, K; Kanehiro, A; Kishino, D; Kiura, K; Nishii, K; Notohara, K; Tabata, M; Tanimoto, M; Tanimoto, Y; Ueoka, H; Umemura, S | 1 |
| Carbone, DP | 1 |
| Berdel, WE; Hoffknecht, P; Lange, T; Müller-Tidow, C; Serve, H; Thomas, M | 1 |
| Abrey, LE; Chang, S; Cowell, JK; DeAngelis, LM; Gilbert, MR; Grefe, CN; Holland, EC; Kuhn, JG; Lamborn, K; Lassman, AB; Lieberman, FS; Nowak, NJ; Pao, W; Prados, M; Raizer, JJ; Razier, JR; Rossi, MR; Shih, AH; Wen, P; Wilson, R; Yung, WA | 1 |
| Kris, M | 1 |
| Horio, Y; Mitsudomi, T; Shimizu, J | 1 |
| Hirashima, T; Kawahara, K; Kawase, I; Kobayashi, M; Matsui, K; Nakamura, Y; Nitta, T; Sasada, S; Takimoto, T | 1 |
| Kabasawa, K; Kawasaki, N; Nakamura, H; Taguchi, M | 1 |
| Macarulla, T; Tabernero, J | 1 |
| Bartolini, S; Bemis, L; Bunn, PA; Cancellieri, A; Cappuzzo, F; Ceresoli, GL; Crino, L; Domenichini, I; Franklin, WA; Hirsch, FR; Ludovini, V; Magrini, E; Rossi, E; Toschi, L; Varella-Garcia, M | 1 |
| Dudek, AZ; Keshtgarpour, M; Kmak, KL; Koopmeiners, J | 1 |
| Anderson, F; Bebb, G; Davis, J; Ho, C; Murray, N | 1 |
| Belinchón, I; Pascual, JC; Sivera, F; Yuste, A | 1 |
| Endo, K; Fujii, Y; Fukai, I; Mizuno, K; Sasaki, H; Yamakawa, Y; Yano, M | 1 |
| Biddle, A; Desai, NB; Dmitrovsky, E; Dragnev, KH; Memoli, V; Petty, WJ; Rigas, JR; Shah, S | 1 |
| Bepler, G; Cantor, A; Haura, EB; Song, L; Zheng, Z | 1 |
| Apolone, G; Garattini, S; La Vecchia, C | 1 |
| Smith, J | 1 |
| Jacobson, JW; Lively, TG; Taube, SE | 1 |
| Rivera, MP; Silvestri, GA | 1 |
| Araki, J; Fukuoka, M; Nakagawa, K; Okamoto, I; Shimada, M; Suto, R | 1 |
| Cody, DD; Dackor, J; Fujimoto, N; Hanna, AE; Herbst, R; Iwanaga, K; Kalyankrishna, S; Kurie, JM; Massarelli, E; Minna, JD; Peyton, M; Price, RE; Sato, M; Shay, JW; Tang, X; Threadgill, DW; Wislez, M; Wistuba, II; Zhang, J | 1 |
| Bavetsias, V; Forster, MD; Gibbs, DD; Green, M; Henderson, E; Jackman, AL; Mitchell, F; Raynaud, F; Theti, DS; Valenti, M; Wood, N | 1 |
| Garfield, D; Kashef, G | 1 |
| Cardiff, RD | 1 |
| Amler, LC; Cavet, G; Eberhard, DA; Fu, L; Januario, T; Lin, CY; Modrusan, Z; O'Neill, V; Pham, TQ; Seshagiri, S; Soriano, R; Stinson, J; Yauch, RL; Zhu, W | 1 |
| Edakuni, N; Goto, H; Kakiuchi, S; Matsumori, Y; Muguruma, H; Nakataki, E; Ryan, A; Sone, S; Tomimoto, H; Uehara, H; Yamamoto, A; Yano, S | 1 |
| Adachi, M; Ando, K; Hirose, T; Horichi, N; Hosaka, T; Inoue, F; Ishida, H; Kadofuku, T; Kuroki, T; Nishio, K; Ohmori, T; Okuda, K; Saijo, N; Shirai, T | 1 |
| Fukuoka, M; Hirata, K; Kimura, T; Kudoh, S; Matsui, K; Matsuura, K; Mitsuoka, S; Nakagawa, K; Negoro, S; Yoshimura, N | 1 |
| Chan, SK; Gullick, WJ; Hill, ME | 1 |
| Goto, H; Imao, M; Kato, T; Nakashima, M; Sano, K; Yasuda, S; Yoshimura, K | 1 |
| Goto, K; Kakinuma, R; Kubota, K; Niho, S; Nishiwaki, Y; Ohmatsu, H; Saijo, N; Yoh, K | 1 |
| Hur, GY; In, KH; Jung, HC; Jung, KH; Kang, KH; Kim, JH; Lee, SY; Shim, JJ; Shin, C; Yoo, SH | 1 |
| Baldwin, PD; Lundberg, AS; Tammaro, KA | 1 |
| Boshoff, C; Falzon, M; Lai, CS; Lee, SM | 1 |
| Eguchi, K; Koboyashi, T; Seki, N; Seto, T; Shioya, S; Tanigaki, T; Uematsu, K; Umemura, S | 1 |
| Baron, A; Bunn, PA; Chan, DC; Chan, Z; Coldren, CD; Drabkin, HA; Dziadziuszko, R; Franklin, W; Gazdar, AF; Gemmill, RM; Girard, L; Hedman, K; Helfrich, B; Hirsch, FR; Minna, JD; Ravdel, L; Sugita, M; Witta, SE | 1 |
| Chen, YM; Perng, RP; Tsai, CM | 1 |
| Song, ST; Wang, Y; Xu, JM | 1 |
| Li, Zi; Lu, S; Yu, YF | 1 |
| Kim, TY; Moriguchi, H; Sato, C | 1 |
| Ballas, M; Dennis, PA; Egilsson, V; Steinberg, SM; Tsurutani, J | 1 |
| Journagan, S; Obadiah, J | 1 |
| Hur, GY; In, KH; Jung, HC; Jung, KH; Kang, EJ; Kang, KH; Kim, JH; Lee, SY; Shim, JJ; Shin, C; Yoo, SH | 1 |
| Buttitta, F; Felicioni, L; Marchetti, A | 1 |
| Gatzemeier, U; Kranich, AL; Reck, M; Steinbach, AK | 1 |
| Li, LY; Wang, MZ; Wang, SL; Zhang, L; Zhang, XT; Zhong, W | 1 |
| Cascone, T; Ciardiello, F; Gridelli, C; Morelli, MP; Troiani, T | 1 |
| Polk, B | 1 |
| Borras, AM; Distel, RJ; Halmos, B; Jänne, PA; Johnson, BE; Joshi, VA; Kuang, Y; Lee, JC; Lindeman, N; Liyanage, H; Maher, EA; Meyerson, M; Rogers, AM | 1 |
| Kris, MG; Ladanyi, M; Li, AR; Miller, VA; Pao, W; Pham, D; Riely, GJ; Rizvi, N; Venkatraman, ES; Zakowski, MF | 1 |
| Axelson, J; Breen, TE; Einhorn, LH; Estes, D; Govindan, R; Hanna, NH; Moore, AM; Vinson, J; Yu, M | 1 |
| Gazdar, AF; Girard, L; Lee, W; Minna, JD; Peyton, M; Ramirez, RD; Sato, M; Shames, DS; Shay, JW; Sunaga, N; Vaughan, MB | 1 |
| Aoe, M; Date, H; Fujiwara, Y; Hotta, K; Kiura, K; Matsuo, K; Tabata, M; Takigawa, N; Tanimoto, M; Tokumo, M; Toyooka, S | 1 |
| Chuai, S; Kris, MG; Ladanyi, M; McDonough, T; Miller, VA; Pao, W; Pham, D; Riely, GJ; Rusch, VW; Sarkaria, IS; Singh, B; Venkatraman, ES; Wilson, RK | 1 |
| Shepherd, FA; Tsao, MS | 1 |
| Hatano, H; Ishii, D; Kosaka, T; Mitsudomi, T; Mizuno, M; Nakahara, N; Natsume, A; Shimato, S; Wakabayashi, T; Yatabe, Y; Yoshida, J | 1 |
| Fukuda, M; Kitazaki, T; Kohno, S; Nagashima, S; Nakamura, Y; Oka, M; Shiozawa, K; Soda, H; Takemura, M; Tsukamoto, K; Yabuuchi, H | 1 |
| He, YM; Lai, RS; Shen, LS; Xie, L; Zhu, CL | 1 |
| Schwartz, LM; Woloshin, S | 1 |
| Iwashige, A; Kagami, S; Tsukada, J; Uramoto, H | 1 |
| Abe, S; Harada, K; Inomata, S; Kanai, A; Kitajima, H; Saikai, T; Takahashi, H; Taniguchi, H | 1 |
| Cufer, T; Erensoy, I; Gaafar, R; Pemberton, K; Vrdoljak, E | 1 |
| Kris, MG; Moryl, N; Obbens, EA; Ozigbo, OH | 1 |
| Hayashi, T; Kitazaki, T; Kohno, S; Nakamura, Y; Nakano, H; Nakatomi, K; Soda, H; Tsukamoto, K; Uchida, K; Urabe, S | 1 |
| Chen, YM; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
| Febbo, PG; Riedel, RF | 1 |
| Khuri, FR; Saba, NF; Shin, DM | 1 |
| Al-Dayel, F; Al-Jommah, N; Al-Kuraya, K; Amr, S; Bavi, P; Ezzat, A; Guido, S; Sheikh, S; Simon, R; Siraj, AK | 1 |
| Goto, K; Park, K | 1 |
| Endo, M; Johkoh, T; Kimura, K; Yamamoto, N | 1 |
| Bartralot, R; Bodet, D; García-Patos, V; Heras, C; Mollet, J | 1 |
| Bartolini, S; Bunn, PA; Cancellieri, A; Cappuzzo, F; Ceresoli, GL; Crino, L; Domenichini, I; Finocchiaro, G; Franklin, WA; Hirsch, FR; Magrini, E; Metro, G; Santoro, A; Tallini, G; Toschi, L; Trisolini, R; Varella-Garcia, M | 1 |
| Ardizzoni, A; Franciosi, V; Tiseo, M | 1 |
| Hashizume, T; Kobayashi, N; Kozawa, S; Miyazawa, N; Ogura, T; Tagawa, A; Takahashi, H; Watanuki, Y | 1 |
| Fujii, Y; Kuga, T; Matsuoka, T; Morikage, N; Nakayama, T | 1 |
| Govindan, R; Morgensztern, D | 1 |
| Fish-Steagall, A; Searcy, P; Sipples, R | 1 |
| Garfield, D | 2 |
| Chansky, K; Crowley, JJ; Franklin, WA; Gandara, DR; Gumerlock, PH; Lau, DH; McCoy, J; Vance, R; West, HL | 1 |
| Fujiwara, Y; Hotta, K; Ishimaru, F; Kiura, K; Kubonishi, S; Matsuo, K; Nakajima, H; Niiya, D; Ogino, A; Shinagawa, K; Tabata, M; Tanimoto, M; Uchida, A; Ueoka, H | 1 |
| Altavilla, G; Rosell, R; Salazar, F; Santarpia, M; Tarón, M | 1 |
| Leow, CH; Liam, CK; Pang, YK | 1 |
| Bakri, K; Bůzková, P; Choksi, J; Gillenwater, H; Jones, PE; Mears, A; Socinski, MA; Stinchcombe, TE; Taylor, M; Tynan, M | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Jeon, YK; Kim, DW; Kim, JH; Kim, NK; Kim, TY; Lee, KH | 1 |
| Kawase, I | 1 |
| Blumenschein, GR; Fossella, FV; Glisson, BS; Herbst, RS; Kies, MS; Lee, JJ; Liu, D; Pisters, KM; Schaerer, R; Thomas, SK; Tsao, AS; Zinner, RG | 1 |
| Baba, K; Hasegawa, Y; Imaizumi, K; Kato, K; Matsumoto, S; Oishi, T; Saito, H; Saka, H; Shimokata, K; Suzuki, R; Taniguchi, H; Yamamoto, M | 1 |
| Al-Hashem, R; Bronson, RT; Discafani, CM; Eck, M; Glatt, KA; Horner, JW; Ji, H; Jung, BL; Li, D; Maher, E; McNamara, K; Meyerson, M; Mitchell, A; Protopopov, A; Rabindran, SK; Sasaki, H; Shapiro, GI; Shimamura, T; Sun, Y; Thomas, RK; Wong, KK; Xia, H; Yuza, Y; Zhao, X | 1 |
| Adams, D; Fernanadez, EM; Seiverling, EV | 1 |
| Cho, CD; Fisher, GA; Halsey, J; Sikic, BI | 1 |
| Goto, K; Kim, YH; Kubota, K; Niho, S; Nishiwaki, Y; Ohmatsu, H; Saijo, N; Yoh, K | 1 |
| Goodin, S | 1 |
| Barón, AE; Bunn, PA; Cappuzzo, F; Crino, L; Danenberg, KD; Danenberg, PV; Dziadziuszko, R; Franklin, WA; Hirsch, FR; Park, S; Tanaka, K; Varella-Garcia, M; Witta, SE | 1 |
| Fukumoto, H; Kiura, K; Koizumi, F; Nishio, K; Saijo, N; Shimoyama, T; Tanimoto, M | 1 |
| Pérol, M | 1 |
| Le Chevalier, T; Tsuboi, M | 1 |
| Costa, DB; Schumer, ST | 1 |
| Brink, C; Carter, CA; Chen, C; Gilbert, KS; Maxuitenko, YY; Vincent, P; Waud, WR; Zhang, X | 1 |
| Basti, S; Benson, A; Lacouture, ME; Patel, J | 1 |
| Al-Hashem, R; Bronson, RT; Chen, L; Chirieac, LR; Jänne, PA; Ji, H; Johnson, BE; Kim, W; Kobayashi, S; Li, D; Mahmood, U; McNamara, K; Mitchell, A; Padera, R; Shapiro, GI; Sharpless, NE; Shimamura, T; Sun, Y; Tenen, D; Weissleder, R; Wong, KK | 1 |
| Aoe, M; Date, H; Ichihara, S; Ichimura, K; Kiura, K; Ohashi, K; Sano, Y; Shimizu, N; Tabata, M; Tokumo, M; Toyooka, S; Tsukuda, K | 1 |
| Johnston, PG; Karaiskou-McCaul, A; Kelly, DM; Kyula, J; Longley, DB; Stokesberry, SA; Van Cutsem, E; Van Schaeybroeck, S | 1 |
| Mitra, SS; Simcock, R | 1 |
| Ando, M; Ariyoshi, Y; Fukuoka, M; Okamoto, I; Seto, T; Takeda, K; Tamura, K; Yamamoto, N | 1 |
| Dubinett, SM; Elashoff, RM; Figlin, RA; Krysan, K; Milne, GL; Morrow, JD; Newman, RA; Reckamp, KL; Tucker, C | 1 |
| Blackhall, F; Ranson, M; Thatcher, N | 1 |
| Bièche, I; Blanc, JF; Dugot-Senant, N; Laurendeau, I; Pines, M; Rosenbaum, J; Rullier, A; Taras, D | 1 |
| Aksoy, S; Altundag, K; Dincer, M; Kilickap, S | 1 |
| Cecere, F; Reguart, N; Rosell, R; Santarpia, M; Taron, M | 1 |
| von Eyben, FE | 1 |
| Goto, H; Matsumori, Y; Nakataki, E; Ryan, AJ; Sone, S; Wedge, SR; Yano, S | 1 |
| Fukuhara, T; Inoue, A; Kimura, Y; Maemondo, M; Morikawa, N; Nukiwa, T; Saijo, Y; Suzuki, T; Watanabe, H | 1 |
| Bang, SI; Choi, YJ; Kim, DK; Kim, JH; Kim, MH; Nam, DH; Nam, SJ; Son, MJ; Song, HS; Yang, JH | 1 |
| Kim, CH; Koh, JS; Lee, JC; Na, II; Ryoo, BY; Yang, SH | 1 |
| Breau, JL; Brechot, JM; Chouahnia, K; Des-Guetz, G; Morere, JF; Saintigny, P | 1 |
| Bogeschdorfer, F; Gronau, S; Riechelmann, H | 1 |
| Ramalingam, S; Sandler, AB | 1 |
| Aldanondo, I; Fernández-Guarino, M; Garrido, P; González-García, C; Jaén, P; Marquet, A; Pérez-García, B | 1 |
| Belani, CP; Govindan, R; Hensing, T; Herbst, R; Kelly, K; Krebs, A; Natale, R; Ochs, J; Reiling, R; Wade, J; Wozniak, A | 1 |
| Gadgeel, SM | 1 |
| Gautschi, O; Lee, D | 1 |
| Davies, AM; Gandara, DR; Gumerlock, PH; Ho, C; Lara, PN; Mack, P | 1 |
| Clark, GM; Ding, K; Santabarbara, P; Seymour, L; Shepherd, FA; Whitehead, M; Zborowski, DM | 1 |
| Buchholz, E; Gatzemeier, U; Krutzfeldt, K; Manegold, C; Reck, M; Romer, KS | 1 |
| Costa, DB; Huberman, MS | 1 |
| Chang, JW; Cheung, YC; Chou, WC; Hsieh, JJ; Huang, SF; Liu, MY; Wang, HM; Yeh, KY | 1 |
| Eguchi, K; Seki, N; Shibakuki, R; Uematsu, K | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Kim, DW; Kim, TY; Lee, KH; Oh, DY | 1 |
| Glatt, KA; Greulich, H; Ji, H; Lowell, AM; Meyerson, M; Minami, Y; Shah, K; Shapiro, GI; Shimamura, T; Thomas, RK; Wong, KK | 1 |
| Bell, DW; Haber, DA; Halmos, B; Holmes, AJ; Huberman, MS; Jackman, DM; Jänne, PA; Johnson, BE; Joshi, VA; Lindeman, N; Lynch, TJ; Meyerson, M; Rabin, MS; Sequist, LV; Yeap, BY | 1 |
| Holloway, B; Kasahara, K; Kawaishi, M; Kimura, H; Kunitoh, H; Nishio, K; Tamura, T | 1 |
| Pedersen, MW; Poulsen, HS | 1 |
| Hasegawa, Y; Hashimoto, N; Honda, T; Imaizumi, K; Kawabe, T; Nagasaka, T; Shimokata, K | 1 |
| Han, JY; Kim, HT; Lee, DH; Lee, JS | 1 |
| Hida, T; Horio, Y; Kosaka, T; Mitsudomi, T; Takahashi, T; Yatabe, Y | 1 |
| Graves, JE; Heffernan, MP; Jones, BF; Lind, AC | 1 |
| High, WA | 1 |
| Auberger, J; Hilbe, W; Loeffler-Ragg, J; Wurzer, W | 1 |
| Kosaka, T; Mitsudomi, T; Yatabe, Y | 1 |
| Ishikawa, S; Ito, H; Onizuka, M; Ozawa, Y; Sakai, M; Sakakibara, Y; Yamamoto, T | 1 |
| Cozzani, E; Parodi, A; Santoro, F | 1 |
| Herbst, R; Sandler, A | 1 |
| Endo, K; Fujii, Y; Haneda, H; Kawano, O; Kobayashi, Y; Sasaki, H; Suzuki, E; Yano, M; Yukiue, H | 1 |
| Bell, DW; Godin-Heymann, N; Haber, DA; Kwak, EL; Lynch, TJ; Settleman, J; Sharma, SV; Sordella, R | 1 |
| Amler, LC; Goddard, AD; Hillan, KJ | 1 |
| Hirsch, FR | 2 |
| Chang, WC; Chang, YH; Chen, HC; Chen, YT; Fang, YF; Hsi, BL; Hsieh, MH; Huang, SF; Ku, YC; Kuo, HP; Lin, SY; Liu, CL; Liu, HP; Tsai, SF | 1 |
| Bach, JP; Faoro, C; Gorg, C; Kiessling, AM; Kleinhans, A; Neubauer, A; Riera-Knorrenschild, J; Schwella, N; Wagner, HJ | 1 |
| Barón, A; Bunn, PA; Coldren, CD; Franklin, WA; Geraci, MW; Helfrich, BA; Hirsch, FR; Lapadat, R; Sugita, M; Witta, SE; Zeng, C | 1 |
| Azzoli, CG; Dunne, M; Gomez, JE; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Milton, DT; Pao, W; Rizvi, NA; Venkatraman, E | 1 |
| Endo, K; Fujii, Y; Iuchi, K; Kawaguchi, T; Kawahara, M; Kitahara, N; Kobayashi, Y; Matsumura, A; Okumura, M; Sasaki, H; Takada, M; Tanaka, H; Yano, M; Yukiue, H | 1 |
| Bruno, R; Eppler, SM; Hamilton, M; Lu, JF; Lum, BL; Rakhit, A; Wolf, J | 1 |
| Borrás, AM; Cantley, LC; Engelman, JA; Gale, CM; Heymach, JV; Jänne, PA; Jarrell, E; Johnson, BE; Lifshits, E; Mukohara, T; Naumov, GN; Sun, J; Tracy, S; Yeap, BY; Zejnullahu, K; Zhao, X | 1 |
| Iijima, M; Kitami, A; Nakada, T; Sagara, R | 1 |
| Aoe, K; Aoe, M; Asano, H; Date, H; Ichihara, S; Inukai, M; Ito, S; Kiura, K; Ouchida, M; Shimizu, N; Soh, J; Suehisa, H; Toyooka, S | 1 |
| Katakami, N | 1 |
| Cho, KH; Cho, MJ; Jun, HJ; Lee, JS; Park, JS; Pyo, H; Zo, JI | 1 |
| Ayoub, J; Bezjak, A; Chan, RT; Clark, G; Cyjon, A; de Albuquerque Ribeiro, R; Fenton, D; Gerogianni, A; Laberge, F; Lago, S; Noble, J; Reck, M; Seymour, L; Shepherd, FA; Trajkovic, A; Tu, D; von Pawel, J; Zukin, M | 1 |
| Nieder, C | 1 |
| Aoe, K; Aoe, M; Asano, H; Date, H; Hiraki, A; Ichihara, S; Katayama, H; Kiura, K; Sano, Y; Shimizu, N; Soh, J; Sugi, K; Toyooka, S | 1 |
| Funk, G; Kornek, GV; Oehler, L; Scheithauer, W; Schwarz, C; Urbauer, E; Wenzel, C | 1 |
| Buck, E; Cagnoni, P; Eyzaguirre, A; Gibson, NW; Haley, JD; Iwata, KK | 1 |
| Attoub, S; Bruyneel, E; Emami, S; Gespach, C; Grijelmo, C; Nguyen, QD; Rivat, C; Rodrigue, CM; Rodrigues, S | 1 |
| Choi, SH; Lemmon, MA; Mendrola, JM | 1 |
| Ali, MA; Cao, C; Choy, H; Kim, JC; Mukhopadhyay, P; Nandi, A; Saha, D | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Jeon, YK; Kim, DW; Kim, TY; Lee, KH; Lee, SH; Oh, DY | 1 |
| Fujiwara, Y; Hotta, K; Kiura, K; Segawa, Y; Shinkai, T; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Umemura, S | 1 |
| Asada, K; Chida, K; Hasegawa, H; Naito, T; Suda, T | 1 |
| Bailey, C; Borras, AM; de Jong, F; Holmes, AJ; Jackman, DM; Jänne, PA; Johnson, BE; Kesari, S; Lindeman, N; Wen, PY | 1 |
| Hirata, K; Iwao, H; Kimura, T; Kudoh, S; Matsuura, K; Mitsuoka, S; Yoshikawa, J; Yoshimura, N | 1 |
| Chang, GC; Chen, KC; Gow, CH; Hsu, C; Lin, CP; Shih, JY; Su, WP; Yang, CH; Yang, PC; Yang, TY; Yu, CJ | 1 |
| Chen, YM; Chiu, CH; Lin, WC; Liou, JL; Perng, RP; Tsai, CM | 1 |
| Azerad, MA; Bosquée, L; Canon, JL; Collard, P; De Greve, J; Duplaquet, F; Galdermans, D; Germonpré, P; Goeminne, JC; Meert, AP; Nackaerts, K; Schallier, D; Tits, G; van Puijenbroek, R; Vandenhoven, G; Vansteenkiste, J | 1 |
| Gerdes, S; Mrowietz, U | 1 |
| Das, AK; Gazdar, AF; Girard, L; Graves, R; Minna, JD; Nirodi, CS; Peyton, M; Redpath, S; Sato, M; Shay, JW; Story, MD | 1 |
| Ennishi, D; Hatake, K; Hino, N; Senoo, T; Sezaki, N; Terui, Y | 1 |
| Krohn, KA; Linden, HM; Livingston, RB; Mankoff, DA | 1 |
| Bodenstein, C; Czernin, J; Dubinett, S; Dumont, RA; Herschman, H; Phelps, ME; Seimbille, Y; Su, H; Weber, W | 1 |
| Endoh, H; Hida, T; Kosaka, T; Kuwano, H; Mitsudomi, T; Tada, H; Tsuboi, M; Yatabe, Y; Yoshida, K | 1 |
| Fujiwara, M; Ito, M; Kakemizu, N; Kido, Y; Kusano, N; Momiyama, M; Nishikawa, M; Nozaki, M; Yoshimoto, N | 1 |
| Hsiao, YP; Shih, HC; Wu, MF; Yang, JH | 1 |
| Azim, HA; Ganti, AK | 1 |
| Arimura, K; Higashimoto, I; Machida, K; Matsuyama, W; Mitsuyama, H; Osame, M; Watanabe, M; Yamamoto, M | 1 |
| Asahina, H; Dosaka-Akita, H; Kinoshita, I; Nishimura, M; Yamazaki, K; Yokouchi, H | 1 |
| Hong, WK; Kim, ES; Lee, HY; Morgillo, F; Woo, JK | 1 |
| Asahina, H; Dosaka-Akita, H; Fujita, Y; Harada, M; Ishida, T; Isobe, H; Kinoshita, I; Kojima, T; Nishimura, M; Ogura, S; Okamoto, Y; Sukoh, N; Yamazaki, K; Yokouchi, H | 1 |
| Kameda, Y; Matsukuma, S; Miyagi, Y; Ohgane, N; Oshita, F; Saito, H; Sakuma, Y; Tsuchiya, E; Yamada, K; Yoshihara, M | 1 |
| Agelaki, S; Argiraki, A; Christofillakis, Ch; Georgoulias, V; Kalykaki, A; Kotsakis, A; Mavroudis, D; Pallis, AG; Souglakos, J; Tselepatiotis, E; Vamvakas, L; Vardakis, N | 1 |
| Heelan, RT; Kris, MG; Miller, VA; Milton, DT; Pao, W; Riely, GJ | 1 |
| Ahmed, SM; Salgia, R | 1 |
| Kato, T; Nishio, K | 1 |
| Kagohashi, K; Ohtsuka, M; Satoh, H | 1 |
| Baas, P; Boerrigter, L; Burgers, S; de Jong, D; Mathy, A; Nederlof, P; Ruijter, H; Tielen, I; van Zandwijk, N | 1 |
| Fujiwara, Y; Kasahara, K; Kimura, H; Kunitoh, H; Nishio, K; Sone, T; Tamura, T | 1 |
| Bunn, PA | 2 |
| Gallegos Ruiz, M; Giaccone, G; Janne, P; Le Chevalier, T; Oulid-Aissa, D; Rodriguez, JA; Smit, E; Soria, JC; Thatcher, N | 1 |
| Adamoli, L; Catania, C; De Pas, TM; Goldhirsch, A; Manzotti, M; Nolè, F; Pelosi, G | 1 |
| Fujimoto, K; Kawai, S; Masui, K; Nishi, N; Yonezawa, T | 1 |
| Bearz, A; Berretta, M; Fratino, L; Giacalone, A; Simonelli, C; Spazzapan, S; Tirelli, U | 1 |
| Botwood, N; Bunn, PA; Chang, A; Ciuleanu, T; Donald, E; Dziadziuszko, R; Ellison, G; Flannery, A; Franklin, WA; Hirsch, FR; Holloway, B; Knight, L; Parikh, P; Parums, D; Pereira, JR; Thatcher, N; Varella-Garcia, M; von Pawel, J; Watkins, C | 1 |
| Balak, MN; Chiang, A; Gong, Y; Kris, MG; Ladanyi, M; Li, AR; Miller, VA; Ouerfelli, O; Pao, W; Riely, GJ; Somwar, R; Yang, G; Zakowski, MF | 1 |
| Pao, W | 1 |
| Balko, JM; Black, EP; Haura, EB; Potti, A; Saunders, C; Stromberg, A | 1 |
| Döme, B; Ostoros, G | 1 |
| Hagiwara, K; Kanazawa, M; Kobayashi, K; Koyama, N; Miyazawa, H; Murayama, Y; Nagai, Y; Nagata, M; Sutani, A; Tanaka, T; Uchida, Y; Udagawa, K | 1 |
| Ahmad, B; Anuar, D; Chin, TM; Goh, BC; Iacopetta, B; Kawakami, K; Lee, SC; Li, WQ; Salto-Tellez, M; Segal, A; Soo, R; Soong, R | 1 |
| Emdad, L; Fisher, PB; Gupta, P; Lebedeva, IV; Sarkar, D; Settleman, J; Su, ZZ | 1 |
| Brown, E; Buck, E; Eyzaguirre, A; Gibson, NW; Griffin, G; Haley, JD; Iwata, KK; McCormack, S; Petti, F | 1 |
| Giaccone, G; Oudejans, JJ; Rodriguez, JA; Vischioni, B; Vos, W | 1 |
| Pujol, JL | 1 |
| Herbst, R; Sandler, A; Vokes, E | 1 |
| Honmura, Y; Komagata, H; Kurimoto, F; Sakai, H; Sudo, J; Yoneda, S | 1 |
| Barón, A; Bemis, L; Bunn, PA; Chan, DC; Coldren, C; Franklin, WA; Gazdar, A; Gustafson, D; Helfrich, BA; Hirsch, FR; Minna, J; Raben, D; Varella-Garcia, M; Zeng, C | 1 |
| Albert, JM; Cao, C; Geng, L; Ivy, PS; Johnson, DH; Lu, B; Sandler, A | 1 |
| Golub, T; Halmos, B; Hetherington, CJ; Kobayashi, S; Lowell, AM; Meyerson, M; Monti, S; Shapiro, GI; Shimamura, T; Steidl, U; Tenen, DG | 1 |
| Yu, SY; Zhang, L | 1 |
| Chen, M; Gemma, A; Kataoka, K; Kokubo, Y; Kosaihira, S; Kudoh, S; Matsuda, K; Minegishi, Y; Noro, R; Okano, T; Seike, M; Yoshimura, A | 1 |
| An, TT; Fang, J; Liu, XY; Wu, MN; Yang, L | 1 |
| Hughes, S; Meehan, L; Moore, S; Norton, A; O'Brien, M; Papadopoulos, P; Popat, S; Priest, K; Wilkins, A | 1 |
| Chang, A; Zhang, X | 1 |
| Guan, ZZ; Pan, ZK; Wang, ZQ; Xu, F; Xu, GC; Zhang, L; Zhang, Y; Zhao, HY | 1 |
| Han, Y; Li, YM; Paradiso, A; Wang, Y; Xu, JM; Zhao, CH | 1 |
| Hanagiri, T; Oyama, T; Sugaya, M; Sugio, K; Uramoto, H; Yasumoto, K | 1 |
| Beck, S; Benson, R; Beusmans, JM; de Graaf, D; Griffiths, GJ; Hendriks, BS; Hickinson, M; Kenyon, D; Lauffenburger, D; Lazzara, M; Swinton, J | 1 |
| Lu, Y; Lubet, RA; Vikis, H; Wang, M; Wang, Y; Yan, Y; Yao, R; You, M | 1 |
| Aoe, K; Aoe, M; Asano, H; Date, H; Fujiwara, Y; Hotta, K; Ichihara, S; Ichimura, K; Kiura, K; Shigematsu, H; Shimizu, K; Shimizu, N; Soh, J; Tokumo, M; Toyooka, S | 1 |
| Cohen, AF; Dubois, EA; van Bronswijk, H | 1 |
| Chen, G; Huang, YJ; Liao, RQ; Lin, JY; Wang, K; Wang, Z; Wu, YL; Xu, CR; Yang, JJ; Yang, XN; Zhang, GC; Zhou, Q | 1 |
| Fujimoto, N; Fujiwara, K; Hisamoto, A; Hotta, K; Katayama, H; Kiura, K; Kozuki, T; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H | 1 |
| Boye, K; Bras-Gonçalves, RA; Chapelier, A; de Cremoux, P; Defrance, R; Judde, JG; Livartowski, A; Poupon, MF; Rebucci, M; Tran-Perennou, C; Vogt, N | 1 |
| Hanada, M; Noguchi, T; Yamaoka, T | 1 |
| Borras, AM; Fidias, P; Freidlin, B; Holmes, AJ; Jackman, DM; Jänne, PA; Johnson, BE; Lindeman, NI; Lucca, J; Lynch, TJ; Meyerson, M; Ostler, PA; Rabin, MS; Skarin, AT; Temel, J; Yeap, BY | 1 |
| Abe, T; Haraguchi, M; Hayashi, M; Ito, K; Tsutsui, N | 1 |
| Grenier, J; Soria, JC | 1 |
| Chou, LS; Garey, J; Kim, E; Oishi, K | 1 |
| Achille, M; Gallegos-Ruiz, M; Giaccone, G; Soria, JC | 1 |
| Guitart, J; Lacouture, ME; Lai, SE; Luu, M; Patel, J | 1 |
| Scagliotti, GV; Selvaggi, G | 1 |
| Hirano, S; Kitao, H; Kiura, K; Ogino, A; Rai, K; Tabata, M; Takata, M; Takigawa, N; Tanimoto, M; Toyooka, S; Uchida, A | 1 |
| Choi, YJ; Kim, CH; Lee, JC; Na, II; Rho, JK; Ryoo, BY; Yang, SH | 1 |
| Akita, RW; Schaefer, G; Shao, L; Totpal, K | 1 |
| Gong, SJ; Gong, YF; Hu, XH; Jiang, B; Liu, F; Wang, ML; Yao, BD; Zhang, WY; Zhu, GS; Zhu, ZZ | 1 |
| Fidias, P; Haber, DA; Jänne, PA; Johnson, BE; Joshi, VA; Kucherlapati, R; Lynch, TJ; Meyerson, M; Muzikansky, A; Sequist, LV | 1 |
| Fujii, K; Gemma, A; Hirohashi, S; Kato, H; Kondo, T; Kudoh, S; Matsuno, Y; Nishimura, T; Ohe, Y; Okano, T; Takano, T; Tsuta, K | 1 |
| Bell, DW; Haber, DA; Lynch, TJ; Sequist, LV | 1 |
| Fidler, IJ; Herbst, RS; Isobe, T; Itasaka, S; Komaki, R; Langley, RR; O'Reilly, MS; Onn, A; Ryan, AJ; Shibuya, K; Shitani, T; Wu, W | 1 |
| Ashitani, J; Imai, K; Kodama, T; Kyoraku, Y; Matsumoto, N; Nakazato, M; Sano, A; Yanagi, S | 1 |
| Bemis, L; Bunn, PA; Cappuzzo, F; Chansky, K; Crino, L; Dziadziuszko, R; Franklin, WA; Gandara, DR; Gazdar, AF; Gumerlock, P; Hirsch, FR; McCoy, J; Varella-Garcia, M; West, H; Xavier, AC | 1 |
| Duster, T | 1 |
| van de Vijver, MJ; van Zandwijk, N | 1 |
| Fukuoka, M; Nakagawa, K; Okabe, T; Okamoto, I; Satoh, T; Takada, M; Tamura, K; Terashima, M; Yoshida, T | 1 |
| Anderson, KS; Bell, DW; Ferrand, A; Haber, DA; Kim, Y; Mulloy, R; Settleman, J; Sordella, R | 1 |
| Serke, M | 1 |
| Boggon, TJ; Eck, MJ; Greulich, H; Li, Y; Meyerson, M; Woo, MS; Yun, CH | 1 |
| Carlisle, DL; Gaither-Davis, A; Grandis, JR; Liu, X; Siegfried, JM; Swick, MC | 1 |
| Aoki, H; Iijima, H; Imai, H; Ishihara, S; Iwasaki, Y; Mori, M; Saito, R; Sunaga, N; Tomizawa, Y; Watanabe, S | 1 |
| Blaukat, A; Funk, JO; Irmer, D | 1 |
| de Waal, RM; Kats, G; Küsters, B; Leenders, WP; Roodink, I; Ruiter, DJ; Verrijp, K; Wesseling, P | 1 |
| Dobashi, K; Hisada, T; Iijima, H; Ishizuka, T; Kaira, K; Mori, M; Saito, R; Shimizu, K; Suga, T; Sunaga, N; Tanaka, S; Tomizawa, Y; Yanagitani, N | 1 |
| Akie, K; Asahina, H; Dosaka-Akita, H; Harada, M; Ishida, T; Isobe, H; Kinoshita, I; Konishi, J; Munakata, M; Nishimura, M; Ogura, S; Sukoh, N; Yamazaki, K; Yokouchi, H | 1 |
| Asomaning, K; Christiani, DC; Gurubhagavatula, S; Heist, R; Liu, G; Lynch, TJ; Su, L; Wang, Z; Yeap, BY; Zhou, W | 1 |
| Gabizon, A; Gipps, M; Grenader, T; Shavit, L | 1 |
| Adachi, S; Funada, Y; Kotani, Y; Mitsudomi, T; Negoro, S; Sakuma, T; Satouchi, M; Shimada, T; Takada, Y; Urata, Y; Watanabe, H; Yatabe, Y; Yoshimura, S | 1 |
| Fujimura, M; Kasahara, K; Kimura, H; Mizuguchi, M; Nakao, S; Nakatsumi, Y; Nishio, K; Shibata, K; Sone, T; Waseda, Y | 1 |
| Cho, BK; Choi, HJ; Kim, SY; Lee, JY; Park, HJ | 1 |
| Fujiwara, Y; Hisamoto, A; Hotta, K; Ichihara, E; Kiura, K; Kozuki, T; Ohashi, K; Osawa, M; Shibayama, T; Tabata, M; Tada, A; Takahashi, K; Takata, S; Takeyama, M; Takigawa, N; Tanimoto, M; Umemura, S | 1 |
| Sequist, LV | 1 |
| Armando, E; Bertetto, O; Bonello, L; Bussolati, G; Ciuffreda, L; Daniele, L; Dongiovanni, D; Macrì, L; Sapino, A; Schena, M | 1 |
| Gadgeel, SM; Heath, EI; Heilbrun, LK; Ruckdeschel, JC; Venkatramanamoorthy, R; Wozniak, A | 1 |
| Aoe, M; Date, H; Kiura, K; Kosaka, T; Mitsudomi, T; Ogino, A; Ouchida, M; Shigematsu, H; Soh, J; Takata, M; Toyooka, S; Uchida, A | 1 |
| Argiris, A; Gooding, W; Hensing, T; Kolesar, J; Masters, G; Patel, S; Pins, M; Raji, A; Sturgis, C; Yeldandi, A | 1 |
| Fujimura, M; Ichikawa, Y; Ishiura, Y; Kasahara, K; Kashii, T; Kimura, H; Kita, T; Kobayashi, M; Kunitoh, H; Mizuguchi, M; Nakao, S; Nakatsumi, Y; Nishio, K; Shiarasaki, H; Shibata, K; Sone, T; Tamura, T; Waseda, Y; Watanabe, K; Yoshimoto, A | 1 |
| Evans, WK; Feld, R; Mackay, JA; Shepherd, FA; Sridhar, SS | 1 |
| Nokihara, H; Sekine, I; Takada, M; Tamura, T; Yamamoto, S | 1 |
| Deneulin, A; Fandi, A; Feld, R; Laurie, SA; Pujol, JL; Rebattu, P; Viens, P | 1 |
| Chang, GC; Chen, KC; Chiu, CH; Hsu, JY; Lin, CP; Perng, RP; Shih, JY; Tsai, CM; Yang, CH; Yang, PC; Yang, TY; Yu, CJ | 1 |
| Chen, YM; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J | 1 |
| Bedano, PM; Hanna, NH | 1 |
| Endoh, H; Kosaka, T; Kuwano, H; Mitsudomi, T; Yatabe, Y | 1 |
| Grandis, JR; Keohavong, P; Romkes, M; Siegfried, JM; Stabile, LP; Traynor, AM; Zhang, W | 1 |
| Kishi, K; Nakata, K; Yoshimura, K | 1 |
| Furuyashiki, G; Goya, T; Koshiishi, Y; Matsushima, S; Nogami, H; Ohnishi, H; Ohtsuka, K; Ooide, A; Watanabe, T | 1 |
| Clark, GM; Culbertson, JL; Savoie, M; Seymour, L; Shepherd, FA; Whitehead, M; Zborowski, DM | 1 |
| Botwood, N; Chang, A; Ganzon, D; Parikh, P; Perng, RP; Tan, EH; Thatcher, N; Thongprasert, S; Tsao, CJ; Watkins, C; Yang, CH | 1 |
| Hanna, N | 1 |
| Han, JY; Hong, EK; Kim, HT; Kim, HY; Lee, DH; Lee, JS; Nam, BH; Yu, SY | 1 |
| Carser, JE; Summers, YJ | 1 |
| Davies, A; Fukuoka, M; Garfield, DH; Giaccone, G; Jassem, J; Kris, MG; Quoix, EA; Sandler, AB; Scagliotti, GV; Van Meerbeeck, JP; West, H | 1 |
| Hida, T; Horio, Y; Kosaka, T; Matsuo, K; Mitsudomi, T; Park, JY; Shimizu, J; Yatabe, Y; Yoshida, K | 1 |
| Bunn, PA; Dziadziuszko, R; Hirsch, FR; Jassem, J; Limon, J; Rzyman, W; Siemiatkowska, A; Varella-Garcia, M | 1 |
| Galetta, D; Gridelli, C; Maione, P; Rossi, A | 1 |
| Aburatani, H; Fukayama, M; Goto, A; Ishikawa, S; Morikawa, T; Nakajima, J; Nakamura, Y; Niki, T; Ohara, E; Ota, S; Wang, T | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Jeon, YK; Keam, B; Kim, DW; Kim, TY; Lee, KH; Lee, SH; Oh, DY | 1 |
| Chen, XQ; Rong, TH; Wei, WD; Wen, ZS; Wu, HY | 1 |
| Yoneda, S | 1 |
| Sugio, K; Uramoto, H; Yasumoto, K | 1 |
| Li, YL; Li, Z; Wang, ZM; Wei, Z; Wu, C; Zhang, TX | 1 |
| Inuzuka, K; Kasahara, K; Kawashima, A; Kita, T; Yoshimoto, A | 1 |
| Beckett, LA; Davies, AM; Gandara, DR; Hesketh, PJ; Ho, C; Lara, PN; Lau, DH | 1 |
| De Rosa, F; Gatzemeier, U; Janaskova, T; Karnicka-Mlodkowski, H; Kaukel, E; Manikhas, GM; Milanowski, J; Pesek, M; Pluzanska, A; Ramlau, R; Roubec, J; Serwatowski, P; Strausz, J; Szczesna, A; Vansteenkiste, J; Von Pawel, J | 1 |
| Huang, YJ; Huang, YS; Liao, RQ; Lin, JY; Wang, Z; Wu, YL; Xu, CR; Yang, JJ; Zhou, Q | 1 |
| Chen, YM; Chiu, CH; Liou, JL; Perng, RP; Shih, YN; Tsai, CM | 1 |
| Kohno, H; Maehara, Y; Mori, D; Shoji, F; Yamasaki, F; Yano, T; Yoshino, I | 1 |
| Chowbay, B; Goh, JW; Lee, P; Mancer, K; Tan, PH; Toh, CK | 1 |
| Fischer, JR; Geiger, D; Haffner, UJ; Lahm, H | 1 |
| Haigentz, M; Li, T; Ling, YH; Perez-Soler, R; Weber, TK; Yuan, Z | 1 |
| Bergot, E; Richard, N; Zalcman, G | 1 |
| Amadori, D; Brigliadori, G; Fabbri, F; Granato, AM; Rosetti, M; Silvestrini, R; Tesei, A; Ulivi, P; Vannini, I; Zoli, W | 1 |
| Cantley, LC; Cappuzzo, F; Christensen, J; Engelman, JA; Gale, CM; Holmes, AJ; Hyland, C; Jänne, PA; Johnson, BE; Kosaka, T; Lee, C; Lindeman, N; Mitsudomi, T; Mok, T; Park, JO; Rogers, AM; Song, Y; Zejnullahu, K; Zhao, X | 1 |
| Esmaili, A; Vahid, B | 1 |
| Adjei, AA; Croghan, G; Hanson, LJ; Jett, JR; Lathia, C; Mandrekar, SJ; Marks, R; Molina, JR; Reid, JR; Simantov, R; Xia, C | 1 |
| Ciardiello, F; Hong, WK; Kim, ES; Kim, WY; Lee, HY; Morgillo, F | 1 |
| Basu, S; Bonomi, P; Buckingham, LE; Coon, JS; Gale, M; Jacobson, KK; Jewell, SS; Kaiser, KA; Mauer, AM; Morrison, LE; Muzzafar, T; Polowy, C; Villaflor, VM | 1 |
| Jiang, B; Li, LY; Lin, JY; Liu, W; Mok, T; Mu, XL; Wang, Z; Wu, YL; Xu, CR; Zhang, GC; Zhang, L; Zhang, XT; Zhong, WZ; Zhou, CC; Zhou, Q | 1 |
| Fujisaka, Y; Horiike, A; Murakami, H; Shimoyama, T; Tamura, T; Yamada, Y; Yamamoto, N | 1 |
| Aoe, K; Aoe, M; Date, H; Fujiwara, Y; Hotta, K; Ichihara, S; Ichimura, K; Kiura, K; Kobayashi, N; Soh, J; Suehisa, H; Toyooka, S | 1 |
| Chen, TH; Feng, W; Glatt, KA; Greulich, H; Ji, H; Jiang, J; Lee, JC; Meyerson, M; Minami, Y; Shapiro, G; Shimamura, T; Wong, KK; Woo, MS; Yanagisawa, H; Yuza, Y | 1 |
| Hanibuchi, M; Sone, S; Tomimoto, H; Yano, S | 1 |
| Bekele, BN; Herbst, RS; Liu, DD; Massarelli, E; Ozburn, NC; Tang, X; Varella-Garcia, M; Wistuba, II; Xavier, AC | 1 |
| Hayashi, A; Nakatani, K; Nishioka, J; Nobori, T; Noma, K; Takao, M; Wada, H; Yasuda, K | 1 |
| Bragg, J; Pomeranz, MK | 1 |
| Hwang, C; Lacouture, ME; Marymont, MH; Patel, J | 1 |
| Jablons, DM; Raz, DJ | 1 |
| Foley, J; Gilmore, JL; Gonterman, RM; Koltz, PF; Konger, RL; Laughner, R; Lewis, DA; Lorch, G; Nadella, KS; Rosol, TJ; Toribio, RE | 1 |
| De Tursi, M; Grassadonia, A; Iacobelli, S; Innominato, PF; Irtelli, L; Iurisci, I; Lévi, F; Rich, T; Tinari, N | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Ciardiello, F; Crino, L; Finocchiaro, G; Holmes, AJ; Jänne, PA; Ligorio, C; Magrini, E; Paioli, D; Patelli, M; Rossi, E; Toschi, L; Trisolini, R; Varella-Garcia, M | 1 |
| Bunn, PA; Chan, D; Coldren, CD; Frederick, BA; Helfrich, BA; Raben, D; Zheng, D | 1 |
| Goldman, ID; Li, T; Ling, YH; Perez-Soler, R | 1 |
| Date, H; Kiura, K; Takata, M; Toyooka, S; Uchida, A | 1 |
| Beckett, LA; Gandara, DR; Shelton, DK; Yoneda, KY | 1 |
| Paz-Ares, L; Rosell, R; Sanchez, JJ; Taron, M | 1 |
| Bashar, AH; Funai, K; Kazui, T; Mori, H; Sugimura, H; Suzuki, K; Takamochi, K | 1 |
| Liu, G; Shepherd, FA; Tsao, MS | 1 |
| Brahmer, J; Bunn, PA; Caprioli, R; Carbone, DP; Duncan, MW; Dziadziuszko, R; Gray, R; Gregorc, V; Grigorieva, J; Hirsch, FR; Hunsucker, SW; Kasahara, K; Ludovini, V; Massion, PP; Nishio, M; Roder, H; Schiller, J; Solomon, B; Spreafico, A; Taguchi, F; Tsypin, M | 1 |
| Chouaid, C; Fournel, P; Monnet, I; Perol, M; Robinet, G; Vergnenegre, A | 1 |
| Eguchi, K; Hisamoto, A; Kiura, K; Kozuki, T; Mandai, K; Nakata, M; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H | 1 |
| Bareschino, M; Ciardiello, F; Gridelli, C; Maione, P; Mongillo, F; Rossi, A | 1 |
| Di Todaro, F; Gaudenzi, P; Manfredini, R; Morandi, P; Nielsen, I; Salmi, R | 1 |
| Okamoto, H; Watanabe, K | 1 |
| Costa, DB | 1 |
| Han, Y; Li, YM; Liu, XQ; Song, ST; Xu, JM; Yang, WW; Zhang, Y | 1 |
| Chang, J; Cho, BC; Choi, HJ; Im, CK; Kim, H; Kim, JH; Kim, SK; Kim, YJ; Park, JP; Park, MS; Shin, SJ; Sohn, JH | 1 |
| Azzoli, CG; Gomez, JE; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Milton, DT; Pao, W; Pizzo, B; Riely, GJ; Rizvi, NA | 1 |
| Brahmer, J; Juergens, R | 1 |
| An, SJ; Gan, B; Guo, AL; Huang, Y; Li, R; Lin, JY; Mok, TS; Nie, Q; Wang, Z; Wu, YL; Zhang, GC | 1 |
| Calhoun, R; Gandara, DR; Jablons, D; Wakelee, H | 1 |
| Cagnoni, PJ; Clark, G; Nagrani, T; Wacker, B; Weinberg, J; Witt, K | 1 |
| Date, H; Fujiwara, Y; Hotta, K; Kiura, K; Soh, J; Tabata, M; Takigawa, N; Tanimoto, M; Toyooka, S | 1 |
| Bolognesi, A; Dell'Oca, I; Ghio, D; Giovannini, M; Gregorc, V; Spreafico, A; Viganò, MG; Villa, E | 1 |
| Kubota, K | 1 |
| Argiris, A; Grandis, JR; Karamouzis, MV | 1 |
| Costa, DB; Huberman, MS; Kobayashi, S; Tenen, DG | 1 |
| Araujo, N; Armand, JP; de La Motte Rouge, T; Dessen, P; Galluzzi, L; Harel-Belan, A; Harper, F; Kroemer, G; Lazar, V; Olaussen, KA; Pierron, G; Pinna, G; Ripoche, H; Robert, T; Soria, JC; Tasdemir, E; Wong, TW; Zermati, Y | 1 |
| Chang, JW; Cheung, YC; Chou, CL; Hsieh, JJ; Hsu, T; Huang, SF; Wang, HM | 1 |
| Furukawa, K; Ichinose, S; Imai, K; Inoue, T; Kato, H; Kubota, M; Maehara, S; Ohira, T; Ohtani, K; Oikawa, T; Okunaka, T; Suga, Y; Sugimoto, Y; Tsunoda, Y; Tsutsui, H; Usuda, J | 1 |
| Jänne, PA; Liu, W; Makrauer, FL; Odze, RD; Qamar, AA | 1 |
| Barclay, L; Bebb, G; English, J; Fee, J; Ho, C; Horsman, D; Laskin, JJ; Marra, MA; Melosky, B; Murray, N; O'Connor, R; Pugh, TJ; Salski, C; Sutcliffe, M; Vielkind, J | 1 |
| Mu, D; Song, X; Sun, X; Wang, H; Yang, G; Yu, J; Zhao, S | 1 |
| Brahmer, JR; Hann, CL | 1 |
| Cabebe, E; Wakelee, H | 1 |
| Akimoto, S; Anyoji, H; Fujii, K; Fukuoka, M; Hada, S; Harbron, CG; Higenbottam, T; Hirano, T; Jiang, H; Kanazawa, M; Kato, H; Kawakami, T; Kawamura, T; Kudoh, S; Kunito, H; Kyono, Y; Marko-Varga, G; Nakata, K; Nishimura, T; Nishio, K; Nishiwaki, Y; Nyberg, F; Ogiwara, A; Peers, IS; South, MC; Tsuboi, M; Tu, HK | 1 |
| Li, LY; Wang, MZ; Wang, SL; Zhang, L; Zhang, XT | 1 |
| Agata, J; Asahina, H; Itoh, T; Nishimura, M; Shinagawa, N; Yamazaki, K | 1 |
| Chan, G; Pilichowska, M | 1 |
| Chen, YR; Cheng, HH; Fu, YN; Huang, SF; Tsai, SF; Yang, CH; Yeh, CL | 1 |
| Jones, DV; Klementich, FJ; Ravindranathan, M | 1 |
| Botwood, N; Carbone, D; Danson, S; Dunlop, D; O'Byrne, KJ; Ranson, M; Taguchi, F | 1 |
| Basti, S; Jampol, LM; Zhang, G | 1 |
| Hanrahan, EO; Heymach, JV | 1 |
| Jackman, D; Jänne, PA; Johnson, BE | 1 |
| Bareschino, MA; Ciardiello, F; Gridelli, C; Maione, P; Rossi, A; Schettino, C | 1 |
| Antoine, M; Cadranel, J; Gounant, V; Lavolé, A; Milleron, B; Wislez, M | 1 |
| Davies, AM; Lara, PN | 1 |
| Davies, A; Gandara, D; Ho, C; Mack, P | 1 |
| Carrión, RP; Gracián, AC; Hernandez, PS | 1 |
| Brun, L; Colin, G; Copin, MC; Lafitte, JJ; Makris, D; Marquette, CH; Scherpereel, A | 1 |
| Thatcher, N | 1 |
| Endo, K; Fujii, Y; Iuchi, K; Kawaguchi, T; Kawahara, M; Kawano, O; Kitahara, N; Matsumura, A; Okumura, M; Sasaki, H; Takada, M; Tanaka, H; Yano, M; Yokoyama, T; Yukiue, H | 1 |
| Fukui, T; Mitsudomi, T | 1 |
| Barry, ST; Copley, C; James, NH; Jürgensmeier, JM; Kendrew, J; Oakley, I; Smith, NR; Wainwright, A; Wedge, SR; Womersley, LM | 1 |
| Hirano, S; Ishiai, M; Kitao, H; Kiura, K; Kozuki, T; Ogino, A; Takata, M; Takigawa, N; Tanimoto, M; Uchida, A | 1 |
| Abe, S; Chiba, H; Hasegawa, T; Igarashi, Y; Inokuchi, J; Iseki, K; Ishii, A; Kabayama, K; Kaneko, M; Noguchi, M; Saitoh, M; Satoh, M; Shiratori, M; Suzuki, T; Tagami, S; Takahashi, H; Watanabe, A | 1 |
| Baker, SD; Cusatis, G; Ghio, D; Gregorc, V; Hidalgo, M; Ingersoll, RG; Ludovini, V; Marsh, S; Sparreboom, A; Spreafico, A; Steinberg, SM; Viganò, MG; Villa, E | 1 |
| Al Hammadi, A; Gerstein, W; Tangri, N | 1 |
| Hao, HJ; Li, Q; Li, XH; Zhao, YL | 1 |
| Duan, HQ; Han, Y; Liu, XQ; Song, ST; Xu, JM; Zhang, JS; Zhang, Y | 1 |
| Ling, YH; Perez-Soler, R; Piperdi, B | 1 |
| Colantuoni, G; Del Gaizo, F; Ferrara, C; Galetta, D; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A | 1 |
| Date, H; Fujiwara, Y; Hotta, K; Kanehiro, A; Kato, K; Kiura, K; Soh, J; Tabata, M; Takigawa, N; Tanimoto, M; Tanimoto, Y; Toyooka, S | 1 |
| Akhurst, T; Kris, MG; Miller, VA; Milton, DT; Moore, E; Pao, W; Riely, GJ; Rizvi, NA; Schwartz, LH; Tyson, L; Zhao, B | 1 |
| Huang, MY; Huang, YJ; Liu, SF; Wang, CJ | 1 |
| Long, J; Thotathil, Z | 1 |
| Arpin, D; Balme, B; Becuwe, C; Dalle, S; Thomas, L | 1 |
| Araya, T; Fujimura, M; Kasahara, K; Kimura, H; Koizumi, F; Miyamoto, K; Nakao, S; Nishio, K; Sone, T; Suminoe, M; Tamori, S | 1 |
| Azzoli, CG; Ginsberg, MS; Kris, MG; Liu, V; Miller, VA; Travis, W; White, DA; Zakowski, MF | 1 |
| Fukui, T; Furuta, K; Kunitoh, H; Matsuno, Y; Nokihara, H; Ohe, Y; Sakamoto, H; Sekine, I; Takano, T; Tamura, T; Tateishi, U; Tsuta, K; Yamamoto, N; Yoshida, T | 1 |
| de Gunst, MM; Gallegos-Ruiz, MI; Giaccone, G; Rodriguez, JA | 1 |
| Belani, CP; Bodrogi, I; Csada, E; Gadgeel, S; Herbst, RS; Heymach, JV; Hou, J; Johnson, BE; Kennedy, SJ; Pesek, M; Prager, D; Roubec, J; Spásová, I | 1 |
| Alam, Y; Arnold, AM; Butts, C; Chan, A; Ding, K; Djurfeldt, M; Ellis, P; Findlay, B; Goss, G; Gregg, R; Langmuir, P; Lee, CW; Meharchand, J; Seymour, L; Shepherd, F; Smylie, M; Ung, Y; Whitehead, M | 1 |
| Ang, K; Herbst, RS; Itasaka, S; Jürgensmeier, JM; Komaki, R; Milas, L; O'Reilly, MS; Ryan, A; Shibuya, K; Shintani, T | 1 |
| Karrison, TG; Maitland, ML; Ratain, MJ; Stadler, WM | 1 |
| Pan, M; Santamaria, M; Wollman, DB | 1 |
| Barrow, D; Gee, JM; Hutcheson, IR; Jones, HE; Knowlden, JM; Nicholson, RI | 1 |
| Belani, CP; Bonomi, PD; Fehrenbacher, L; Hart, L; Herbst, RS; Lin, M; Melnyk, O; O'Neill, VJ; Ramies, D; Sandler, A | 1 |
| Gemma, A; Kataoka, K; Kokubo, Y; Kosaihira, S; Kudoh, S; Matsuda, K; Minegishi, Y; Miyanaga, A; Nara, M; Noro, R; Okano, T; Seike, M; Yoshimura, A | 1 |
| Endo, K; Hisada, T; Ishizuka, T; Kaira, K; Mori, M; Oriuchi, N; Sunaga, N; Tomizawa, Y; Yanagitani, N | 1 |
| Baker, CH; Bekele, N; Fidler, IJ; Herbst, RS; Langley, RR; O'Reilly, MS; Onn, A; Tang, XM; Tsan, RZ; Wu, W | 1 |
| Ashley, S; Barbachano, Y; Norton, A; O'Brien, M; Popat, S | 1 |
| Moldvay, J | 1 |
| Boelke, E; Budach, W; Enderlein, E; Gerber, PA; Homey, B; Muller, A | 1 |
| Balak, M; Chmielecki, J; Gong, Y; Jiang, X; Pao, W; Politi, K; Somwar, R | 1 |
| Colantuoni, G; Del Gaizo, F; Ferrara, C; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A | 1 |
| Fan, Z; Li, X; Liang, K; Lu, Y | 1 |
| Alexandru, A; Dediu, M; Gal, C; Median, D; Vremes, G | 1 |
| Hanaoka, T; Hayano, T; Okada, M; Sone, S; Yamaguchi, S | 1 |
| Cadranel, J; Gounant, V; Khalil, A; Lavole, A; Milleron, B; Poulot, V; Wislez, M | 1 |
| Ahmed, F; Ali, S; Gadgeel, SM; Philip, PA; Sarkar, FH; Wozniak, A | 1 |
| Noda, K; Oshita, F; Saito, H; Yamada, K | 1 |
| Besse, B; Italiano, A; Planchard, D; Soria, JC | 1 |
| Fekrazad, MH; Jones, DV; Ravindranathan, M | 1 |
| Boggon, TJ; Costa, DB; Halmos, B; Huberman, MS; Kobayashi, S; Kumar, A; Schumer, ST; Tenen, DG | 1 |
| Cragg, MS; Huang, DC; Kuroda, J; Puthalakath, H; Strasser, A | 1 |
| Boggon, TJ; Dowlati, A; Halmos, B; Jin, C; Kern, JA; Kobayashi, S; Ma, PC; Tenen, DG; Yu, Z | 1 |
| Ardizzoni, A; Bortesi, B; Bozzetti, C; Camisa, R; Campanini, N; Capelletti, M; Chiaramondia, M; Dadati, P; Franciosi, V; Grossi, F; Kunkl, A; Lagrasta, C; Loprevite, M; Naldi, N; Nizzoli, R; Rindi, G; Spiritelli, E; Tiseo, M; Zennaro, D | 1 |
| Gemma, A; Kudoh, S; Matsuda, K; Minegishi, Y; Nara, M; Noro, R; Okano, T; Shibuya, M; Takemura, A; Yoshimura, A | 1 |
| Briasoulis, E; Georgoulias, V; Kalikaki, A; Koutsopoulos, A; Mavroudis, D; Murray, S; Pallis, AG; Souglakos, J; Stathopoulos, E; Tripaki, M; Voutsina, A | 1 |
| Hizawa, N; Ishikawa, H; Kurishima, K; Ohara, G; Satoh, H | 1 |
| Schalock, PC; Zug, KA | 1 |
| Okagawa, T; Suyama, M; Uchida, T | 1 |
| Conklin, E; Dwyer-Nield, LD; Eckhardt, SG; Fritz, JM; Gustafson, DL; Iwata, KK; Kane, S; Malkinson, AM; Redente, EF; Shroyer, RJ; Tucker, C; Zerbe, LK | 1 |
| Burkitt, V | 1 |
| Fregoni, V; Pavesi, L; Ponchio, L; Prada, GA; Sagrada, P; Zambelli, A | 1 |
| Ge, FJ; Luo, WD; Wang, Y; Xu, JM; Yuan, SJ; Zhao, CH | 1 |
| Miyazaki, M; Nakagawa, K | 1 |
| Bell, DW; Brannigan, BW; Morabito, A; Moscato, M; Normanno, N; Zampa, G | 1 |
| Amoroso, D; Baldari, M; Bearz, A; Bettoli, V; Cammilluzzi, E; Crinò, L; De Marinis, F; Di Pietro, FA; Gridelli, C; Grossi, F; Innocenzi, D; Maione, P; Micali, G; Piantedosi, FV; Scartozzi, M | 1 |
| Cai, D; Carlson, NE; Deng, J; Letai, A; Perera, S; Shapiro, GI; Shimamura, T; Wong, KK | 1 |
| Althaus, IW; Bradner, JE; Engelman, JA; Gale, CM; Gandhi, L; Gonzales, AJ; Heymach, JV; Jänne, PA; Lifshits, E; Meyerson, M; Naumov, GN; Nelson, JM; Shapiro, GI; Shimamura, T; Vincent, PW; Wong, KK; Zejnullahu, K; Zhao, F | 1 |
| Costa, DB; Kobayashi, S; Schumer, ST | 1 |
| Balak, M; Bean, J; Brennan, C; Broderick, S; Chang, WC; Chitale, D; Gazdar, A; Gerald, W; Huang, SF; Ladanyi, M; Miller, V; Motoi, N; Pao, W; Pass, H; Riely, G; Rusch, V; Shih, JY; Szoke, J; Viale, A; Wang, L; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Betticher, DC; Bihl, M; Bubendorf, L; D'Addario, G; Jost, L; Lerch, S; Mach, N; Mayer, M; Pless, M; Rauch, D; Ribi, K; Stahel, R; Stupp, R; Tapia, C; Widmer, L | 1 |
| Knabl, A | 1 |
| Dizdar, O; Gököz, O; Yalçin, B; Yalçin, S | 1 |
| Chen, L; He, Y; Huang, H; Liao, H; Wei, W | 1 |
| Higashiyama, M; Kato, K; Kodama, K; Koizumi, K; Maeda, J; Oda, K; Okami, J; Orita, N; Taniguchi, K | 1 |
| Comb, MJ; Guo, A; Gygi, SP; Innocenti, G; Kornhauser, J; Lee, KA; MacNeill, J; Mitchell, J; Nardone, J; Polakiewicz, RD; Possemato, A; Rikova, K; Rush, J; Stokes, MP; Villén, J; Wang, Y; Wetzel, R | 1 |
| Arai, Y; Kojima, A | 1 |
| Hanagiri, T; Sugio, K; Takenoyama, M; Uramoto, H; Yasumoto, K | 1 |
| Davies, AM; Gandara, DR; Gumerlock, PH; Holland, W; Lara, PN; Mack, PC; Mahaffey, CM; Pryde, B | 1 |
| Danesi, R; Giaccone, G; Giovannetti, E; Lemos, C; Nannizzi, S; Peters, GJ; Ricciardi, S; Rodriguez, JA; Smid, K; Tekle, C | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Im, SA; Jeon, YK; Kim, DW; Kim, HP; Kim, TY; Lee, SH; Oh, DY | 1 |
| Hida, T; Mitsudomi, T; Sugiura, H; Sugiura, T; Yamada, K | 1 |
| Goya, S; Kawase, I; Kijima, T; Kumagai, T; Matsuoka, H; Minami, S; Osaki, T; Suzuki, M; Tachibana, I; Takeda, Y; Ueda, K; Yokota, S; Yoshida, M | 1 |
| Alligood, K; Cable, L; Carter, HL; Gallagher, KT; Gilmer, TM; Rusnak, D; Shewchuk, L; Spehar, G; Truesdale, AT; Woldu, E; Wood, ER | 1 |
| Ando, M; Gemma, A; Hagiwara, K; Iwanami, H; Kataoka, K; Kobayashi, K; Kosaihira, S; Kudoh, S; Minegishi, Y; Miyanaga, A; Miyazawa, H; Nara, M; Noro, R; Okano, T; Tanaka, T; Tsuboi, E; Yoshimura, A | 1 |
| Chen, L; Zhang, PL | 1 |
| Bunn, PA; Dziadziuszko, R; Franklin, WA; Hirsch, FR; Holloway, B; Mann, H; Parums, DV; Speake, G; Thatcher, N; Watkins, C | 1 |
| Miller, VA | 1 |
| Ano, T; Miyazaki, K; Nakazawa, K; Ohtsuka, M; Satoh, H | 1 |
| Lindsley, CW; Thomas, AL | 1 |
| Addeo, A; Barone, C; Birocco, N; Buffoni, L; Bussolati, G; Ciuffreda, L; Daniele, L; Dongiovanni, D; Dongiovanni, V; Fissore, C; Gaspari, F; Grillo, R; Macrì, L; Sapino, A; Schena, M | 1 |
| Fang, Z; Li, B; Xia, TB; Xiu, QY; Zang, YS | 1 |
| Almasi, A; Conte, P; Dominici, M; Eckhardt, S; Jori, B; Kanya, M; Keri, G; Kopper, L; Moldvay, J; Papay, J; Petak, I; Pinter, F; Sapi, Z; Schwab, R; Szabo, E; Szondy, K; Tamasi, A; Varkondi, E | 1 |
| Sun, Y; Wang, B; Wang, Y; Xu, NZ; Zhang, XR; Zhu, HX | 1 |
| Akamine, S; Akizuki, S; Hijiya, N; Kadota, J; Kawahara, K; Matsuura, K; Miyawaki, M; Moriyama, M; Tsuji, K; Tsukamoto, Y; Uchida, T | 1 |
| Belani, C; Ramalingam, S | 1 |
| de Marinis, F; Grossi, F | 1 |
| Curiel, DT; Dent, P; Emdad, L; Fisher, PB; Gupta, P; Lebedeva, IV; Sarkar, D; Settleman, J | 1 |
| Hagiwara, K; Hirama, T; Ikebuchi, K; Kanazawa, M; Kobayashi, K; Koyama, N; Matsuoka, M; Miyazawa, H; Murayama, Y; Nagai, Y; Nagata, M; Nukiwa, T; Sutani, A; Takenoshita, S; Tanaka, T; Udagawa, K; Zhang, J | 1 |
| Aoe, K; Date, H; Fujiwara, Y; Hotta, K; Ichihara, S; Kiura, K; Kosaka, T; Matsuo, K; Mitsudomi, T; Ohe, Y; Otani, H; Soh, J; Takano, T; Toyooka, S; Yatabe, Y | 1 |
| Ding, K; Pater, J; Seymour, L; Shepherd, FA; Whitehead, M | 1 |
| Alfieri, RR; Bonelli, M; Bordi, F; Carmi, C; Cavazzoni, A; Frazzi, R; Fumarola, C; Galetti, M; Lodola, A; Mor, M; Petronini, PG; Zuliani, V | 1 |
| Brooks, C; Hobbs, ML; Liu, J; Meyn, RE; Munshi, A; Tanaka, T | 1 |
| Albert, D; Axelrod, R; Botkin, D; Dowlati, A; Lilenbaum, R; Seigel, L; Thomas, S; Witt, K | 1 |
| Gipps, M; Goldberg, A; Grenader, T | 1 |
| Chu, CY; Hsiao, CH; Sheen, YS | 1 |
| Ebi, N; Fukuoka, J; Fukuoka, M; Hirashima, T; Ichinose, Y; Kashii, T; Katakami, N; Kudoh, S; Negoro, S; Nishimura, T; Okamoto, I; Satoh, T; Sawa, T; Shibata, K; Shimizu, E; Tamura, K | 1 |
| Epstein, RJ; Leung, TW | 1 |
| Banville, M; Bourget, L; Collins, C; Jaramillo, ML; O'Connor-McCourt, M; Paul-Roc, B | 1 |
| Antonia, SJ; Begum, M; Bepler, G; Chiappori, A; Extermann, M; Haura, EB; Ismail-Khan, R; Kapoor, R; Schell, MJ; Simon, GR; Williams, CC | 1 |
| Dohadwala, M; Dubinett, SM; Elashoff, D; Figlin, RA; Gardner, BK; Inge, L; Krysan, K; Mao, J; Rajasekaran, A; Reckamp, KL; Sharma, S | 1 |
| Claasen, J; Sos, ML; Staratschek-Jox, A; Thomas, RK; Wolf, J; Zander, T | 1 |
| Chang, JW; Chen, YH; Chen, YR; Chen, YT; Chiu, YT; Fang, YF; Hsi, BL; Hsieh, JJ; Hsieh, MH; Hsieh, MS; Hsu, HY; Huang, SF; Liu, HP; Tsai, HY; Tsai, SF | 1 |
| Bemis, LT; Birks, DK; Bunn, PA; Franklin, WA; Haney, J; Helfrich, BA; Hirsch, FR; Kato, H; Nakajima, E; Robinson, WA; Sugita, M; Varella-Garcia, M; Weiss, GJ | 1 |
| Armstrong, DK; Brahmer, JR; Carducci, MA; Chen, P; Das, S; Desai, A; Fackenthal, DL; Fleming, GF; Janisch, L; Jiang, X; Karrison, T; Liu, W; Poonkuzhali, B; Ramirez, J; Ratain, MJ; Rudin, CM; Schuetz, E; Vokes, EE | 1 |
| Costa, DB; Kobayashi, S; Schumer, ST; Tenen, DG | 1 |
| Halle, JS; Hayes, DN; Lee, CB; Moore, DT; Morris, DE; Rivera, MP; Rosenman, JG; Socinski, MA; Stinchcombe, TE | 1 |
| Belani, CP; Evans, T; Forster, J; Lu, H; Naret, C; Ramalingam, S; Sulecki, M; Teegarden, P; Weber, MR | 1 |
| Fong, T; Govindan, R; Morgensztern, D | 1 |
| Brueckl, WM; Hahn, EG; Murray, S; Schoeberl, A; Wiest, GH; Wirtz, RM | 1 |
| Chang, AY | 1 |
| Higashiyama, M; Kato, K; Kodama, K; Okami, J; Taniguchi, K | 1 |
| Fujisaki, R; Gu, Z; Horii, A; Inomata, K; Inoue, A; Kondo, T; Nukiwa, T; Sakurada, A; Sato, M; Yamanaka, S | 1 |
| Armour, A; Fukuoka, M; Higenbottam, T; Ichinose, Y; Itoh, Y; Jiang, H; Kato, H; Kudoh, S; Nakagawa, K; Nakata, K; Nishiwaki, Y; Nyberg, F; Suga, M; Tsuboi, M; Watkins, C; Yokota, S | 1 |
| Gerber, PA; Homey, B | 1 |
| Asahina, H; Konishi, J; Nishimura, M; Suzuki, M; Yamazaki, K | 1 |
| Fukuoka, M; Hatashita, E; Iwasa, T; Nakagawa, K; Okabe, T; Okamoto, I; Satoh, T; Tamura, K; Tsukioka, S; Uchida, J; Yamada, Y; Yoshida, T | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, HP; Kim, SH; Kim, TY; Oh, DY | 1 |
| Carbone, DP; Heelan, RT; Heller, G; Herbst, RS; Johnson, DH; Kris, MG; Ladanyi, M; Li, AR; Miller, VA; Pao, W; Patel, JD; Riely, GJ; Sandler, AB; Tsao, A; Zakowski, MF | 1 |
| Blumenfeld, M; Farrar, W; Landon, MB; Pant, S; Shapiro, CL | 1 |
| Hong, JH; Ko, JC; Lin, YW; Wang, LH | 1 |
| Arteaga, CL; Johnson, DH; Keedy, VL | 1 |
| Albain, KS; Chansky, K; Crowley, JJ; Gandara, DR; Gaspar, LE; Jett, J; Kelly, K; Lau, DH; Ung, YC | 1 |
| Nishio, M; Okano, Y | 1 |
| Agarwala, A; Breen, T; Bruetman, D; Einhorn, LH; Fisher, W; Hanna, N; Juliar, B; McClean, J; Taber, D; Titzer, M; Yu, M | 1 |
| Advani, S; Aggarwal, S; Babu, G; Bhattacharyya, GS; Chacko, RT; Chang, AY; Digumarti, R; Doval, DC; Hargreaves, L; Jagannathan, R; Nag, S; Parikh, P; Ranade, A; Thatcher, N | 1 |
| Eguchi, K; Fukuoka, M; Jiang, H; Kiura, K; Nakagawa, K; Nishio, K; Ohe, Y; Saijo, N; Seto, T; Shinkai, T; Tsuboi, M; Yamamoto, N; Yokota, S | 1 |
| Chin, TM; Chuah, KL; Lim, SW; Nga, ME; Seah, SB; Soo, RA; Soong, R; Wong, AS | 1 |
| Ardizzoni, A; Ciardiello, F; De Marinis, F; De Petris, L; Di Maio, M; Gridelli, C; Hanna, N; Heymach, JV; Perrone, F; Rosell, R; Shepherd, FA; Thatcher, N; Vansteenkiste, J | 1 |
| Shih, JY; Wu, SG; Yang, PC; Yu, CJ | 1 |
| Byun, BH; Cheon, GJ; Choe, DH; Kang, HJ; Kim, CH; Koh, JS; Lee, JC; Lim, SM; Na, II; Ryoo, BY; Yang, SH | 1 |
| Argiris, A; Basu, S; Bonomi, P; Buckingham, L; Coon, J; Fidler, MJ; Johnson, DH; Kaiser, K; Patel, JD; Sandler, A; Villaflor, VM | 1 |
| Chalfe, N; Plestina, S; Samarzija, M; Zuljević, E | 1 |
| De Grève, J; Decoster, L; Schallier, D; Teugels, E; Van Meerbeek, J; Vermeij, J | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Castaldini, L; Crino, L; Finocchiaro, G; Magrini, E; Metro, G; Tallini, G; Toschi, L; Trisolini, R | 1 |
| Arnold, A; Chen, E; Ellis, PM; Gauthier, I; Goss, G; Laurie, SA; Powers, J; Puchalski, TA; Robertson, J; Seymour, L; Shepherd, FA; Tu, D; Walsh, W | 1 |
| Perng, RP; Su, HT; Tsai, CM | 1 |
| An, SJ; Guo, AL; Li, R; Mok, TS; Wu, YL; Zhang, GC; Zhang, XC; Zhang, YF; Zhong, WZ; Zhu, JQ | 1 |
| Ambrogio, L; Baum, A; Chirieac, LR; Greulich, H; Himmelsbach, F; Kubo, S; Li, D; Meyerson, M; Padera, RF; Rettig, WJ; Shapiro, GI; Shimamura, T; Solca, F; Takahashi, M; Wong, KK | 1 |
| Clack, G; Dixon, JM; Elvin, P; Fennell, M; Green, TP; Jacobs, V; Jones, RJ; Marshall, A; Renshaw, L; Womack, C; Young, O | 1 |
| Iwasaki, T; Kimura, H; Kitada, S; Maekura, R; Mori, M; Naka, N; Nakagawa, M; Nakazawa, Y; Namba, Y; Niinaka, M; Okada, T; Yano, Y; Yokota, S | 1 |
| McDermott, U; Settleman, J; Sharma, SV | 1 |
| Chang, GD; Chen, CS; Hung, JH; Kashida, Y; Kulp, SK; Sargeant, AM; Wang, D; Wang, YC; Yamaguchi, M; Yang, CC | 1 |
| Brannigan, BW; Godin-Heymann, N; Haber, DA; Lamb, J; Maheswaran, S; McDermott, U; Settleman, J; Ulkus, L | 1 |
| Guo, AL; Wang, Z; Wu, YL; Xu, CR; Zhang, GC; Zhou, Q | 1 |
| Chen, LK; Huang, H; Xu, GC; Zhang, L; Zhang, Y; Zhao, HY | 1 |
| Chan, KA; Chang, CH; Chen, KY; Kurth, T; Orav, EJ; Yang, PC; Young-Xu, Y | 1 |
| Chang, GC; Chang, WC; Chen, CH; Chen, HC; Chen, YM; Chu, NM; Chung, CY; Ho, ML; Hsia, TC; Hsieh, RK; Huang, MS; Kao, WY; Kuo, HP; Lai, RS; Lin, MC; Lin, ZZ; Perng, RP; Su, WC; Tsao, CJ; Wang, JL; Yang, CH; Yu, CJ; Yu, CT | 1 |
| Hainsworth, JD; Lin, M; O'Neill, V; Spigel, DR | 1 |
| Fukuhara, T; Inoue, A; Kanamori, M; Morikawa, N; Nakashima, I; Nukiwa, T; Saijo, Y; Sakakibara, T | 1 |
| Lazzari, G; Lovecchio, M; Palazzo, C; Silvano, G | 1 |
| Cadranel, J; de Prost, N; Lavolé, A; Taillade, L; Wislez, M | 1 |
| Adjei, AA; Cassivi, SD; Molina, JR; Schild, SE; Yang, P | 1 |
| Cruz Hernández, JJ; Delgado Fernández, C; Mezquita Pérez, L; Navarro Martín, M; Rodríguez Sánchez, C | 1 |
| Engelman, JA; Evans, TL; Goldberg, JS; Grunberg, SM; Haber, DA; Han, M; Iafrate, AJ; Jänne, PA; Johnson, BE; Joshi, VA; Kuhlmann, GL; Lynch, TJ; Martins, RG; McCollum, D; Muzikansky, A; Sequist, LV; Settleman, J; Spigel, D; Spira, A | 1 |
| Ceresoli, GL; Comoglio, P; Destro, A; Floor, K; Garassino, I; Giaccone, G; Giovannetti, E; Rodriguez, JA; Roncalli, M; Ruiz, MG; Santoro, A; Varella-Garcia, M; Zucali, PA | 1 |
| Clark, GM; Ding, K; Seymour, L; Shepherd, FA; Wheatley-Price, P | 1 |
| Black, JD; Iyer, RV; Javle, MM; Levea, CM; Maddipatla, S; Nwogu, CE; Pande, AU; Rani, A; Yang, GY | 1 |
| Li, AW; Xu, JF; Zhou, CC | 1 |
| Li, LY; Wang, HZ; Wang, MZ; Wang, SL; Wu, C; Zhang, L; Zhang, XT; Zhong, W | 1 |
| Black, CC; Dmitrovsky, E; Gribble, GW; Honda, T; Lamph, WW; Liby, K; Liu, X; Risingsong, R; Royce, DB; Sporn, MB; Sporn, TA; Williams, CR; Yore, MM | 1 |
| Buhl, R; Fischer, B | 1 |
| Fujiwara, Y; Hotta, K; Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H | 1 |
| Buchler, T; Joseph, T; Lai, C; Lee, SM | 1 |
| Akita, H; Kinoshita, I | 1 |
| Bereczky, B; Itoh, K; Nishimura, Y; Yoshioka, K | 1 |
| Cai, H; Duan, W; Fu, L; Jiang, H; Li, L; Mei, C; Wang, L; Xiong, X | 1 |
| Atassi, G; Brassinne, C; Coune, A; Frühling, J; Ghanem, G; Hildebrand, J; Laduron, C; Ruysschaert, JM; Sculier, JP; Stryckmans, P | 1 |
| Brassinne, C; Coune, A; Frühling, J; Ghanem, G; Hildebrand, J; Laduron, C; Sculier, JP; Verbist, A | 1 |
| Peters, GJ; Pinedo, HM; Telleman, F; van der Wilt, CL; van Triest, B | 1 |
| Baccanari, DP; Boytos, CM; Caddell, JM; Comley, JC; Friedman, HS; Hunter, RN; Jones, ML; Joyner, SS; Knick, V; Kuyper, LF; Rudolph, SK; Stables, JN; Tansik, RL; Wilson, HR | 1 |
| Böhmer, FD; Fernández, LE; Greiser, U; Lage, A; Perez, R; Sánchez, B; Suarez Pestana, E | 1 |
| Klein, JM; McCarthy, TA | 1 |
| Adenis, A; Basser, R; Drings, P; Le Chevalier, T; Perez Manga, G; Seymour, L; Smith, F; Thatcher, N; Woll, PJ | 1 |
| Bauer, B; Benter, T; Daniel, PT; Dietz, R; Dörken, B; Friedrich, M; Köhne, CH; Kretzschmar, A; Thuss-Patience, P | 1 |
| Aiba, K; Akazawa, S; Fukuoka, M; Furue, H; Furuse, K; Horikoshi, N; Kanamaru, R; Konishi, T; Kotake, T; Kudoh, S; Kurihara, M; Niitani, H; Ota, K; Sakata, Y; Taguchi, T; Tsukagoshi, S; Wakui, A; Yoshida, S | 1 |
| Navarro-Blasco, FJ | 1 |
| Calvert, AH; Curtin, NJ; Delaney, CA; Durkacz, BW; Hostomsky, Z; Kyle, S; Newell, DR; Wang, LZ; White, AW | 1 |
| Aherne, GW; Hardcastle, A; Jackman, AL; Ladner, RD; Webley, SD | 1 |
| Averbuch, SD; Baselga, J | 1 |
| Kris, MG; Miller, VA; Scher, HI; Sirotnak, FM; Zakowski, MF | 1 |
| Solignac, M | 1 |
| Baguley, BC; Bu, X; Deady, LW; Denny, WA; Finlay, GJ | 1 |
| Klar, U; Lichtner, RB; Menrad, A; Schneider, MR; Sommer, A | 1 |
| Matsubara, T; Ogasawara, M; Suzuki, H | 1 |
| Norman, P | 1 |
| Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M | 1 |
| Bunn, PA; Chan, D; Helfrich, BA; Johnson, G; Raben, D | 1 |
| Buchholz, E; Kloeppel, R; Kreisel, C; Manegold, C; Smith, M | 1 |
| Fukuoka, M | 1 |
| Bunn, PA; Chan, DC; Chan, KK; Covey, JM; Feng, WY; Gera, L; Helfrich, B; Stewart, JM; Zhao, TL | 1 |
| Albanell, J; Baselga, J | 1 |
| Sobel, RK | 1 |
| Kubota, K; Yoh, K | 1 |
| Kawate, N | 1 |
| Kudoh, S; Yamauchi, S | 1 |
| Ariyoshi, H; Furue, H; Hasegawa, K; Majima, H; Nakao, I; Niitani, H; Ohta, K; Taguchi, T; Tsukagoshi, S; Yasutomi, M | 1 |
| Aherne, GW; Curtin, NJ; Harris, AL | 1 |
| Osada, Y; Tanaka, NG; Tohgo, A | 1 |
| Kajanti, M; Kinnula, V; Maasilta, P; Mattson, K; Niiranen, A | 1 |
| Maasilta, PK; Mattson, KV; Mattson, MT; Rautonen, JK | 1 |
| Burke, MT; D'Acquisto, RW; Fanucchi, MP; Gralla, RJ; Heelan, RT; Kris, MG; Marks, LD | 1 |
| Aherne, GW; Curtin, NJ; Harris, AL; Marks, V; Piall, EM | 1 |
| Maroun, J | 1 |
| Grove, W; Holsti, LR; Maasilta, P; Mattson, K; Tammilehto, L | 1 |
| Maroun, JA; Natale, RB; Robert, F | 1 |
| Cassidy, C; Chou, TC; Fanucchi, MP; Fleisher, M; Lokos, G; Niedzwiecki, D; Vidal, P; Walsh, TD; Williams, L; Young, CW | 1 |
| Curtin, NJ; Harris, AL | 1 |
566 review(s) available for quinazolines and Lung Neoplasms
| Article | Year |
|---|---|
An appraisal of anticancer activity with structure-activity relationship of quinazoline and quinazolinone analogues through EGFR and VEGFR inhibition: A review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Quinazolines; Quinazolinones; Receptors, Vascular Endothelial Growth Factor; Structure-Activity Relationship; Vascular Endothelial Growth Factor A | 2022 |
Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Gefitinib: An Updated Review of its Role in the Cancer Management, its Nanotechnological Interventions, Recent Patents and Clinical Trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patents as Topic; Quinazolines | 2023 |
Icotinib: efficacy in different solid tumors and gene mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Neoplasms; Quinazolines | 2020 |
Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Oxaliplatin; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2020 |
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Topics: Afatinib; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bias; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Pemetrexed; Progression-Free Survival; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2021 |
Insight into Discovery of Next Generation Reversible TMLR Inhibitors Targeting EGFR Activating and Drug Resistant T790M Mutants.
Topics: Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Purines; Pyridones; Pyrimidines; Quinazolines; Structure-Activity Relationship | 2017 |
Prognostic value of early response assessment using (18F)FDG-PET in patients with advanced non-small cell lung cancer treated with tyrosine-kinase inhibitors.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome | 2017 |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Retreatment; Sequence Deletion | 2017 |
Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis.
Topics: Alleles; Amino Acid Substitution; Antineoplastic Agents; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Odds Ratio; Publication Bias; Quinazolines; Treatment Outcome | 2017 |
Recent Management of Patients with Advanced Epidermal Growth Factor Receptor Mutation Non-small Cell Lung Cancer: Role of Afatinib and Lesson Learned for Developing Countries.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Developing Countries; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Indonesia; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2017 |
Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Crown Ethers; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Network Meta-Analysis; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.
Topics: Afatinib; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Humans; Lung Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Ramucirumab; Retreatment; Taxoids | 2017 |
Antimetabolites in the treatment of advanced pleural mesothelioma: a network meta-analysis of randomized clinical trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Network Meta-Analysis; Pemetrexed; Pleural Neoplasms; Quinazolines; Thiophenes; Treatment Outcome | 2017 |
Targeted Therapy and Imaging Findings.
Topics: Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Crizotinib; Diagnostic Imaging; Gefitinib; Humans; Lung; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines | 2017 |
Angiogenesis Inhibitors in NSCLC.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids | 2017 |
Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines | 2017 |
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2017 |
Gefitinib for advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Treatment Failure | 2018 |
Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Comparative Effectiveness Research; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2018 |
Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Prognosis; Quinazolines; Radiation-Sensitizing Agents | 2018 |
Ethnic differences in idiopathic pulmonary fibrosis: The Japanese perspective.
Topics: Asian People; Cause of Death; Disease Progression; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Idiopathic Pulmonary Fibrosis; Japan; Lung Neoplasms; Male; Pneumonectomy; Prevalence; Prognosis; Protein Kinase Inhibitors; Quinazolines; Sex Factors; Survival Rate | 2018 |
Fruquintinib: First Global Approval.
Topics: Antineoplastic Agents; Benzofurans; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-1 | 2018 |
Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Network Meta-Analysis; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic | 2019 |
Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an
Topics: Adenocarcinoma of Lung; Adult; Chemotherapy, Adjuvant; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Male; Oncogene Proteins, Fusion; Pneumonectomy; Precision Medicine; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Rad51 Recombinase; Thoracoscopy; Treatment Outcome | 2019 |
Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
Topics: Asbestos; Bevacizumab; Carcinogenesis; Humans; Indoles; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Neovascularization, Pathologic; Pleural Neoplasms; Quinazolines | 2019 |
Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemoradiotherapy; Clinical Trials as Topic; Combined Modality Therapy; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Humans; Immunotherapy; Lung Neoplasms; Pyrazoles; Pyridines; Quinazolines | 2013 |
Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma.
Topics: Alanine; Antineoplastic Agents; Benzimidazoles; Carcinoma, Squamous Cell; Gene Amplification; Humans; Lung Neoplasms; Molecular Targeted Therapy; Quinazolines; Quinolones; Receptors, Fibroblast Growth Factor; Signal Transduction; Triazines | 2013 |
Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2013 |
[Lung adenocarcinoma with intramedullary spinal cord metastasis: a case report and review of the literature].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Disease Progression; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Quinazolines; Radiography; Spinal Cord Neoplasms | 2013 |
Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405).
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Protein Kinase Inhibitors; Quinazolines; Smoking | 2013 |
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2013 |
Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
Topics: Acneiform Eruptions; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Patient Education as Topic; Pruritus; Quinazolines | 2013 |
Erlotinib in the first-line treatment of non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2013 |
Clinical perspective of afatinib in non-small cell lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2013 |
How and when to use genetic markers for nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Oncogene Proteins, Fusion; Quinazolines; Receptor Protein-Tyrosine Kinases | 2013 |
The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Brain Neoplasms; Chemoradiotherapy; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Targeted therapy for non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pyrazoles; Pyridines; Quinazolines | 2013 |
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2013 |
Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors | 2013 |
Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Databases, Bibliographic; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2013 |
Afatinib: first global approval.
Topics: Afatinib; Animals; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Drug Approval; European Union; Humans; Lung; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Grading; Neoplasm Proteins; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2; Taiwan; United States; United States Food and Drug Administration | 2013 |
The role of afatinib in the management of non-small cell lung carcinoma.
Topics: Afatinib; Antineoplastic Agents; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2013 |
Chemotherapy with or without gefitinib in patients with advanced non-small-cell lung cancer: a meta-analysis of 6,844 patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Polymorphism, Single Nucleotide; Quinazolines | 2013 |
Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Evaluation, Preclinical; Drug Interactions; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2013 |
A severe dermatologic adverse effect related with gefitinib: case report and review of the literature.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Edema; Erythema; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2013 |
[Hemolytic anemia under erlotinib treatment].
Topics: Aged, 80 and over; Anemia, Hemolytic; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
[New developments in treatment of non-small cell lung cancer].
Topics: Antineoplastic Agents; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Imaging; Quinazolines | 2013 |
Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Incidence; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Risk; Survival Analysis | 2014 |
Epidermal growth factor receptor mutations in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Kinase 1; Models, Biological; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2014 |
Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population: review of patient profile.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Taxoids | 2014 |
Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Neoplasm Grading; Protein Kinase Inhibitors; Quinazolines | 2014 |
Subsequent treatment choices for patients with acquired resistance to EGFR-TKIs in non-small cell lung cancer: restore after a drug holiday or switch to another EGFR-TKI?
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Retreatment | 2014 |
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Crown Ethers; Data Collection; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Markov Chains; Mutation; Probability; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Icotinib: activity and clinical application in Chinese patients with lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; China; Clinical Trials, Phase III as Topic; Crown Ethers; Drug Interactions; ErbB Receptors; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines; Randomized Controlled Trials as Topic | 2014 |
Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.
Topics: Afatinib; Animals; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2014 |
Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; PTEN Phosphohydrolase; Quinazolines; Signal Transduction | 2014 |
Afatinib for the treatment of advanced non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Factors | 2015 |
Erlotinib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Lung Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
[Adverse events of afatinib as first-line treatment for five cases of advanced lung adenocarcinoma and review of literature].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Stomatitis | 2014 |
Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Incidence; Lung Neoplasms; Molecular Targeted Therapy; Prognosis; Quinazolines; Radiosurgery; Treatment Outcome | 2014 |
Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
Gefitinib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemistry, Pharmaceutical; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Solubility | 2014 |
[Programs for continuing medical education: B session; 4. Progress in lung cancer therapy].
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Crizotinib; Drug Discovery; Education, Medical, Continuing; Erlotinib Hydrochloride; Etoposide; Gefitinib; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Small Cell Lung Carcinoma | 2014 |
The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2014 |
Second-line therapy in non-small-cell lung cancer: the DELTA between different genotypes widens.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA-Binding Proteins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Genotype; Glutamates; Guanine; Humans; Keratin-7; Lung Neoplasms; Middle Aged; Palliative Care; Pemetrexed; Pleural Effusion, Malignant; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Taxoids; Transcription Factors; Treatment Failure | 2014 |
Next generation tyrosine kinase inhibitor (TKI): afatinib.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Patents as Topic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic | 2014 |
Management and future directions in non-small cell lung cancer with known activating mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Mutation Rate; Neoplasms, Squamous Cell; Oncogenes; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2014 |
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
[Afatinib (BIBW 2992)].
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Approval; ErbB Receptors; France; Humans; Lung Neoplasms; Quinazolines | 2014 |
Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer.
Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Deoxycytidine; Docetaxel; Enzyme Induction; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Nicotine; Paclitaxel; Polycyclic Aromatic Hydrocarbons; Quinazolines; Smoking; Taxoids | 2014 |
Predictive value of a serum-based proteomic test in non-small-cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors: a meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Predictive Value of Tests; Proteomics; Quinazolines | 2014 |
Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Efficacy and safety of gefitinib during pregnancy: case report and literature review.
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Mutation; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Protein Kinase Inhibitors; Quinazolines; Radiography, Thoracic; Tomography Scanners, X-Ray Computed | 2014 |
Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence.
Topics: Asian People; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Protein Kinase Inhibitors; Quinazolines | 2014 |
Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Area Under Curve; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines; ROC Curve | 2014 |
Ocular side effects and trichomegaly of eyelashes induced by erlotinib: a case report and review of the literature.
Topics: Adenocarcinoma; Aged; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Eyelid Diseases; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2015 |
Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2014 |
Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2015 |
Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Models, Biological; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2015 |
Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines | 2014 |
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Hemorrhage; Humans; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Ramucirumab; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Afatinib and lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Lung Neoplasms; Quinazolines | 2014 |
Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Molecular Targeted Therapy; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Small Cell Lung Carcinoma | 2014 |
A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC).
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines | 2014 |
Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fatigue; Humans; Lung Neoplasms; Outcome Assessment, Health Care; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Vascular Endothelial Growth Factor A | 2015 |
EGFR-TKIs combined with chemotherapy versus EGFR-TKIs single agent as first-line treatment for molecularly selected patients with non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2015 |
EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer.
Topics: Antineoplastic Agents; Bombesin; Cell Proliferation; Cholecystokinin; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neurotensin; Protein Kinase Inhibitors; Quinazolines; Receptors, G-Protein-Coupled | 2016 |
Treatment on advanced NSCLC: platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Platinum Compounds; Quinazolines | 2015 |
First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Multicenter Studies as Topic; Mutation; Quality of Life; Quinazolines; Retrospective Studies | 2015 |
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2015 |
Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.
Topics: Afatinib; Base Sequence; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Signal Transduction; Survival Rate | 2015 |
Gefitinib: a review of its use in adults with advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2015 |
Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crown Ethers; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
Management of EGFR mutated nonsmall cell lung carcinoma patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2015 |
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2015 |
[Pharmacological and clinical profile of afatinib (Giotrif®)].
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Dose-Response Relationship, Drug; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quinazolines | 2015 |
Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Hypertension; Long QT Syndrome; Lung Neoplasms; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Risk | 2015 |
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Publication Bias; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk | 2015 |
The comparisons of the efficacy and toxicity between gefitinib and docetaxel for patients with advanced nonsmall-cell lung cancer: a meta-analysis from randomized controlled clinical trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2014 |
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Pharmacogenetics; Quinazolines | 2015 |
EGFR mutations in lung cancer: from tissue testing to liquid biopsy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genotyping Techniques; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2015 |
Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2015 |
Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic | 2015 |
Pathological complete response to gefitinib in a 10-year-old boy with EGFR-negative pulmonary mucoepidermoid carcinoma: a case report and literature review.
Topics: Carcinoma, Mucoepidermoid; Child; DNA-Binding Proteins; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Transcription Factors; Treatment Outcome | 2017 |
[Radiotherapy concomitant with first-generation epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of brain metastases from non small cell lung cancer: a meta-analysis].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2015 |
Practical Value of Molecular Pathology in Stage I-III Lung Cancer: Implications for the Clinical Surgeon.
Topics: Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2015 |
Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2015 |
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Medical Oncology; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2015 |
Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2016 |
Managing acquired resistance in EGFR-mutated non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2015 |
Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2015 |
Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis.
Topics: Afatinib; Alanine Transaminase; Antineoplastic Agents; Aspartate Aminotransferases; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2016 |
Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Smoking | 2015 |
Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.
Topics: Afatinib; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Genotype; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2016 |
Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature.
Topics: Afatinib; Animals; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2016 |
Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Platinum; Quinazolines; Small Cell Lung Carcinoma | 2016 |
Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Rate | 2016 |
Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Incidence; Lung Diseases; Lung Neoplasms; Models, Statistical; Odds Ratio; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment | 2016 |
FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Drug Discovery; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Research Design; Treatment Outcome; United States; United States Food and Drug Administration | 2016 |
[Companion Diagnostics for Solid Tumors].
Topics: Anaplastic Lymphoma Kinase; Biomarkers, Tumor; Breast Neoplasms; Cetuximab; Colonic Neoplasms; Crizotinib; Diagnostic Uses of Chemicals; Drug Discovery; ErbB Receptors; Gefitinib; Gene Fusion; Guidelines as Topic; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Molecular Targeted Therapy; Pharmacogenetics; Precision Medicine; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Trastuzumab | 2015 |
Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines | 2016 |
[Living with incurable cancer].
Topics: Aged; Anxiety; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Depression; Emotions; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Psychotherapy; Quality of Life; Quinazolines | 2016 |
Molecular Understanding of the Acquisition of Resistance to Anti-cancer Drugs Associated with the Exacerbation of Cancer.
Topics: Adenosine Triphosphate; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein-Tyrosine Kinases; Quinazolines; Receptor Cross-Talk; Receptor, Adenosine A2A; Receptors, G-Protein-Coupled | 2016 |
Safety of gefitinib in non-small cell lung cancer treatment.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2016 |
Kinases inhibitors in lung cancer: From benchside to bedside.
Topics: Afatinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines | 2016 |
[Current status of EGFR/ErbB inhibitors in non-small cell lung carcinoma].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-2; Genetic Markers; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2016 |
[Mechanism of action and preclinical development of afatinib].
Topics: Afatinib; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Rats; Treatment Outcome | 2016 |
[Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].
Topics: Afatinib; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Genes, erbB; Genetic Markers; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
[Evidence on afatinib in patients progressing on a first-line treatment].
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Administration Schedule; ErbB Receptors; Genes, erbB; Genetic Markers; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
[Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].
Topics: Administration, Oral; Afatinib; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Genes, erbB; Genetic Markers; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
[Toxicity associated with EGRF inhibition: review and key aspects in the management of afatinib].
Topics: Afatinib; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Genes, erbB; Genetic Markers; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
The role of microRNAs in resistance to targeted treatments of non-small cell lung cancer.
Topics: Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MicroRNAs; Molecular Targeted Therapy; Quinazolines; Receptor Protein-Tyrosine Kinases | 2017 |
The safety of afatinib for the treatment of non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quality of Life; Quinazolines; Risk Factors | 2016 |
Rapid onset of radiation maculopathy after whole-brain radiation therapy: A case report.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; Dose-Response Relationship, Radiation; Female; Gefitinib; Humans; Lung Neoplasms; Macular Degeneration; Middle Aged; Quinazolines; Radiation Injuries; Visual Acuity | 2016 |
Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Quinazolines; Reagent Kits, Diagnostic; Real-Time Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Analysis, DNA | 2016 |
EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Platinum Compounds; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Afatinib: A Review in Advanced Non-Small Cell Lung Cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2016 |
Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diarrhea; Disease-Free Survival; ErbB Receptors; Exanthema; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pruritus; Quinazolines; Treatment Outcome | 2016 |
Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm.
Topics: Acrylamides; Adenocarcinoma; Afatinib; Amino Acid Substitution; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2017 |
EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Survival Analysis; Taxoids | 2016 |
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Rate | 2017 |
Effect of Combined Therapy Inhibiting EGFR and VEGFR Pathways in Non-Small-cell Lung Cancer on Progression-free and Overall Survival.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2017 |
Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prospective Studies; Quinazolines | 2017 |
Treatment of choice for patients with EGFR mutation-positive non-small cell lung carcinoma presenting with choroidal metastases: radiotherapy or TKIs?
Topics: Carcinoma, Non-Small-Cell Lung; Choroid Neoplasms; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Humans; Lung Neoplasms; Mutation; Outcome Assessment, Health Care; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2017 |
Targeted therapy in advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
New insights in drug development for the non-small cell lung cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future.
Topics: Antineoplastic Agents; Asia, Eastern; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2008 |
Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.
Topics: Alleles; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Quinazolines | 2008 |
The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Neovascularization, Pathologic; Piperidines; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Disease Models, Animal; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Risk Assessment; Survival Analysis; Thoracic Neoplasms | 2008 |
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Prognosis; Quinazolines; Quinolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
[New therapies for the treatment of advanced non-small cell lung cancer: inhibitors of the epidermal growth factor receptor and angiogenesis].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neovascularization, Pathologic; Quinazolines | 2008 |
Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Medical Oncology; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
[Management of targeted molecular therapies toxicities in thoracic cancerology].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Drug Delivery Systems; Erlotinib Hydrochloride; France; Humans; Lung Neoplasms; Palliative Care; Protein Kinase Inhibitors; Quality of Life; Quinazolines | 2008 |
[Case of bilateral pneumothorax observed during the administration of gefitinib for lung adenocarcinoma with multiple pulmonary metastases].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Pneumothorax; Quinazolines | 2008 |
[Targeted therapies for lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Gene Targeting; Humans; Lung Neoplasms; Patient Selection; Protein-Tyrosine Kinases; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2008 |
[Tumor vasculature as a therapeutic target in non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Imidazoles; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Xanthones | 2008 |
The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current "best evidence" with meta-analysis.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Double-Blind Method; ErbB Receptors; Evidence-Based Medicine; Gefitinib; Humans; Lung Neoplasms; Predictive Value of Tests; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction | 2009 |
Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2008 |
Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome | 2008 |
Overview of gefitinib in non-small cell lung cancer: an Asian perspective.
Topics: Antineoplastic Agents; Asia, Eastern; Asian People; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2009 |
Gefitinib for the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2009 |
New avenues for second-line treatment of metastatic non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Metastasis; Pemetrexed; Quinazolines; Taxoids | 2009 |
Predictive biomarkers for EGFR therapy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Predictive Value of Tests; Quinazolines | 2009 |
Second line treatments in advanced platinum-resistant non small cell lung cancer. A critical review of literature.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2009 |
Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Signal Transduction | 2009 |
Economics of treatments for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cost-Benefit Analysis; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Taxoids | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aging; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2009 |
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Therapy; ErbB Receptors; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2009 |
Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2009 |
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2009 |
Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Gefitinib in the treatment of advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Reasons for response differences seen in the V15-32, INTEREST and IPASS trials.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Docetaxel; ErbB Receptors; Europe; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; North America; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Recurrence; South America; Survival Analysis; Taxoids; Tumor Burden | 2009 |
No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bias; Carcinoma, Non-Small-Cell Lung; Data Interpretation, Statistical; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Taxoids; Young Adult | 2009 |
New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Platinum Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2008 |
Investigational agents in the management of non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A | 2009 |
Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Survival Analysis; Treatment Outcome | 2009 |
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines | 2010 |
Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymphoma; Male; Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2009 |
Targeted therapies in the treatment of advanced/metastatic NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Quinazolinones | 2009 |
Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Databases, Factual; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; ROC Curve; Survival Rate | 2009 |
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptors, Growth Factor; Sequence Deletion; Treatment Outcome | 2009 |
Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Gene Expression; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2009 |
Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kidney Neoplasms; Lung Neoplasms; Neoplasms; Neovascularization, Pathologic; Quinazolines; Ramucirumab; Vascular Endothelial Growth Factor A | 2009 |
Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Smoking; Smoking Cessation | 2010 |
EGFR inhibition in NSCLC: the emerging role of cetuximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Taxoids | 2004 |
Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines | 2010 |
Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines | 2009 |
Treatment of advanced non-small-cell lung cancer in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cardiovascular Diseases; Cisplatin; Clinical Trials as Topic; Comorbidity; Contraindications; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Vascular Endothelial Growth Factor A | 2009 |
EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; bcl-Associated Death Protein; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Membrane Proteins; Models, Biological; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2010 |
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Sex Factors; Smoking; Survival Analysis; Vascular Endothelial Growth Factor A | 2009 |
[Molecular diagnostics in lung carcinoma for therapy stratification].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Molecular Diagnostic Techniques; Neoplasm Staging; Prognosis; Protein-Tyrosine Kinases; Quinazolines | 2010 |
Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.
Topics: Animals; Catalytic Domain; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Small Cell Lung Carcinoma; Structure-Activity Relationship | 2010 |
[KRAS status versus EGFR status in lung cancer therapy].
Topics: DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Genetic Markers; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; ras Proteins | 2009 |
Erlotinib.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review.
Topics: Acute Disease; Adenocarcinoma; Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Review Literature as Topic; Treatment Outcome | 2011 |
A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Early Detection of Cancer; ErbB Receptors; Europe; Gefitinib; Humans; Lung Neoplasms; Mutation; Patient Selection; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; United States; White People | 2010 |
Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Gefitinib; Hemorrhage; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Medical Oncology; Middle Aged; Neoplasm Metastasis; Quinazolines; Tomography, X-Ray Computed | 2010 |
[Current update and testing procedures for genetic diagnosis in malignant neoplasm: additional information on pathological tests].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Cetuximab; Colonic Neoplasms; ErbB Receptors; Gefitinib; Genes, ras; Genetic Testing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Mutation; Pharmacogenetics; Quality Control; Quinazolines | 2010 |
The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Morpholines; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Quinolines | 2010 |
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Lung Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2010 |
Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib.
Topics: Adenocarcinoma; Animals; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2010 |
Gefitinib for the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2010 |
Use of erlotinib or gefitinib as initial therapy in advanced NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2010 |
Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer.
Topics: BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Clinical Trials, Phase II as Topic; DNA-Binding Proteins; ErbB Receptors; Erlotinib Hydrochloride; Histone Chaperones; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Neoplasm Staging; Nuclear Proteins; Quinazolines; RNA, Messenger | 2010 |
Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Remission Induction; Time Factors | 2010 |
Erlotinib in the treatment of non-small cell lung cancer: current status and future developments.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond.
Topics: Asia; Clinical Trials, Phase III as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
[Oncology 2010].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2010 |
Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer therapy.
Topics: Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2010 |
EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
[Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Pemetrexed; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2010 |
[Current status of erlotinib and gefitinib in palliative therapy for NSCLC--does the EGF-R mutation state have any significance?].
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Long-Term Care; Lung Neoplasms; Palliative Care; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2010 |
Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2010 |
Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Discovery; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2010 |
[Molecular factors related to gefitinib efficacy in advanced non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2010 |
[The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs].
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
Maintenance chemotherapy in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Taxoids | 2010 |
Targeted therapy: an evolving world of lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2011 |
[EGFR tyrosine kinase inhibitors as a targeted therapy for bronchioloalveolar carcinoma of the lung: a case report of a clinically prompt and intensive response and literature review].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2010 |
EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genetic Markers; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Odds Ratio; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; White People | 2011 |
Second-line treatment for non-small-cell lung cancer: one size does not fit all.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Prognosis; Quinazolines; Taxoids | 2010 |
Factors driving the choice of the best second-line treatment of advanced NSCLC.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Decision Making; Docetaxel; ErbB Receptors; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Taxoids; Thymidylate Synthase | 2011 |
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cetuximab; Cisplatin; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Signal Transduction; Survival Analysis; Translocation, Genetic | 2010 |
Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy.
Topics: Aged; Antineoplastic Agents; Diphosphonates; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Octreotide; Osteoarthropathy, Secondary Hypertrophic; Pain; Quinazolines; Rheumatology; Treatment Outcome; Vagotomy | 2011 |
The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Precision Medicine; Quinazolines | 2010 |
Vandetanib: An overview of its clinical development in NSCLC and other tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Neoplasms; Piperidines; Quinazolines | 2010 |
New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Drug Discovery; Humans; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Quinazolines; Randomized Controlled Trials as Topic | 2010 |
Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Gefitinib; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic | 2010 |
[Consolidation therapy in advanced non-small cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Lung Neoplasms; Medical Oncology; Neoplasm Staging; Prognosis; Quinazolines; Risk Assessment | 2010 |
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2010 |
Maintenance or non-maintenance therapy in the treatment of advanced non-small cell lung cancer: that is the question.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Pemetrexed; Prognosis; Quinazolines; Vascular Endothelial Growth Factor A | 2010 |
Reviewing the safety of erlotinib in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Product Surveillance, Postmarketing; Quinazolines | 2011 |
[EGFR inhibitors in non-small cell lung cancer: more than yesterday (but less than tomorrow)].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Controlled Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Quinazolines; Survival Rate | 2010 |
Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Exanthema; Gefitinib; Humans; Lung Neoplasms; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2011 |
Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor; TOR Serine-Threonine Kinases | 2011 |
EGFR pathway in advanced non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2011 |
The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2011 |
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Prognosis; Quality of Life; Quinazolines | 2011 |
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Quinazolines | 2011 |
The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Prospective Studies; Quinazolines; Retrospective Studies; Risk Assessment; Technology Transfer | 2011 |
BIBW 2992 in non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2011 |
A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk Assessment | 2011 |
[Gefitinib-induced acute lung injury: a case report and review of the literature].
Topics: Acute Lung Injury; Aged; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Tomography, X-Ray Computed | 2011 |
[Prognostic and predictive biomarkers in non-small cell lung cancers. From conditioned registrations to routine molecular mapping of lung cancers: Methodological issues].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Mutational Analysis; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
The need for third-line treatment in non-small cell lung cancer: an overview of new options.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Quinazolines; Salvage Therapy | 2011 |
Treatment of non-small-cell lung cancer with erlotinib or gefitinib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2011 |
[Adverse effects of new biological therapies for non-small-cell bronchial cancer].
Topics: Angiogenesis Inhibitors; Biological Products; Carcinoma, Non-Small-Cell Lung; Cooperative Behavior; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Interdisciplinary Communication; Lung Neoplasms; Neoplasm Staging; Patient Care Team; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
[Bronchiolar-alveolar carcinoma: From concept to innovative therapeutic strategies].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pneumonectomy; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Gene Expression; Humans; Lung Neoplasms; Mutation; Ovarian Neoplasms; Platinum; Protein Kinase Inhibitors; Quinazolines; Recurrence; Survival Rate; Treatment Outcome | 2011 |
[Gefitinib for non-small cell lung cancer: a meta analysis].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quality Control; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
The search for improved systemic therapy of non-small cell lung cancer--what are today's options?
Topics: Afatinib; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Precision Medicine; Protein-Tyrosine Kinases; Quinazolines; Quinolines | 2011 |
Erlotinib: as maintenance monotherapy in non-small-cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quality of Life; Quinazolines | 2011 |
[A simple view on lung cancer biology: The EGFR pathway].
Topics: Adenocarcinoma; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
KRAS-mutation positive, metastatic tonsil carcinoma with cancer stem-like cell features and long-term response to gefitinib: a case report and review of the literature.
Topics: Antineoplastic Agents; Biopsy; Carcinoma, Squamous Cell; ErbB Receptors; Fatal Outcome; Female; Gefitinib; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Time Factors; Tomography, X-Ray Computed; Tonsillar Neoplasms; Treatment Outcome | 2011 |
Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Therapy; ErbB Receptors; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Smoking; Survival Analysis | 2011 |
EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Quinazolines; Radiation Tolerance | 2011 |
[Indication of EGFR kinase inhibitors should be refined].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2011 |
Tissue sampling in lung cancer: a review in light of the MERIT experience.
Topics: Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Genetic Testing; Humans; Lung Neoplasms; Practice Guidelines as Topic; Precision Medicine; Quinazolines; Tissue and Organ Harvesting; Tissue Array Analysis | 2011 |
Gefitinib in non small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptors, Growth Factor | 2011 |
Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Patient Selection; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2011 |
Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoglobulins, Intravenous; Lung Neoplasms; Quinazolines; Receptor, IGF Type 1; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction | 2012 |
Problems involved in the clinical trials for non-small cell lung carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Mutation; Patient Selection; Pemetrexed; Platinum; Quinazolines | 2012 |
Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2011 |
Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2011 |
Vandetanib for the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Humans; Lung Neoplasms; Molecular Structure; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction | 2011 |
Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Neoplasm Metastasis; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2011 |
Gefitinib for non-small-cell lung cancer treatment.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2011 |
Strategies for maintenance therapy in advanced non-small cell lung cancer: current status, unanswered questions and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Immunotherapy; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Quality of Life; Quinazolines; Survival Rate; Treatment Outcome | 2012 |
Noninferiority trials in second-line treatments of nonsmall cell lung cancer: a systematic review of literature with meta-analysis of phase III randomized clinical trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Topotecan | 2012 |
Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines; Randomized Controlled Trials as Topic; Smoking | 2011 |
The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Middle Aged; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2011 |
[Resistant mechanism and treatment strategy of tyrosine kinase inhibitors].
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Gefitinib compared with systemic chemotherapy as first-line treatment for chemotherapy-naive patients with advanced non-small cell lung cancer: a meta-analysis of randomised controlled trials.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Myocardial Infarction; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
Long-term outcome after multidisciplinary approach for leptomeningeal carcinomatosis in a non-small cell lung cancer patient with poor performance status.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Quinazolines; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome; Ventriculoperitoneal Shunt | 2011 |
Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2012 |
Clinical trials and biomarker research on lung cancer in China.
Topics: Biomarkers, Tumor; China; Clinical Trials as Topic; Cytochrome P-450 CYP1A1; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Translational Research, Biomedical | 2012 |
[Vandetanib treatment in refractory advanced lung adenocarcinoma patients: five cases and review of literature].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Piperidines; Quinazolines | 2012 |
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Eruptions; ErbB Receptors; Female; Humans; Incidence; Lung Neoplasms; Male; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk; Severity of Illness Index; Small Cell Lung Carcinoma; Thyroid Neoplasms | 2012 |
Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2011 |
Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Databases, Factual; Disease-Free Survival; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate | 2012 |
[Vandetanib for advanced non-small cell lung cancer: a meta-analysis].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Quinazolines; Treatment Outcome; Young Adult | 2012 |
Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2012 |
Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Meningeal Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications.
Topics: Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Pharmacogenetics; Protein Kinase Inhibitors; Quinazolines | 2012 |
The role of surgery for locally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Multimodal Imaging; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tomography, X-Ray Computed | 2012 |
Vandetanib for the treatment of lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Vascular Endothelial Growth Factor A | 2012 |
Addition of vandetanib to chemotherapy in advanced solid cancers: a meta-analysis.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Humans; Lung Neoplasms; Neoplasms; Piperidines; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2012 |
Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2012 |
The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Gefitinib; Health Status; Humans; Lung Neoplasms; Practice Guidelines as Topic; Quality of Life; Quinazolines; Sickness Impact Profile; Taxoids; Time Factors; Treatment Outcome | 2013 |
Cediranib: a VEGF receptor tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Glioblastoma; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Ovarian Neoplasms; Prostatic Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Sarcoma | 2012 |
Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.
Topics: Adenocarcinoma; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Erosive pustular dermatosis of the scalp-like eruption due to gefitinib: case report and review of the literature of alopecia associated with EGFR inhibitors.
Topics: Aged; Alopecia; Antineoplastic Agents; Asian People; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Scalp Dermatoses | 2012 |
Targeted therapy for lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Crizotinib; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines | 2012 |
Clinical and economic review of erlotinib in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; China; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; MEDLINE; Mutation; Quinazolines | 2012 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2014 |
Chemotherapy plus Vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Survival Rate | 2013 |
EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2012 |
A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Docetaxel; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Taxoids | 2013 |
An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents.
Topics: Afatinib; Aminoquinolines; Angiogenesis Inhibitors; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lapatinib; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Quinolines | 2013 |
[Brain metastases of non small cell lung cancers: systemic treatments].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crizotinib; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Pyridines; Quinazolines | 2013 |
[New therapeutic targets and strategies in lung cancer].
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Benzodiazepines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Endothelial Growth Factors; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Metalloendopeptidases; Multicenter Studies as Topic; Piperazines; Polyisoprenyl Phosphates; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinolones; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sesquiterpenes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
ZD1839 (Iressa) in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic | 2002 |
ZD1839 (Iressa): what's in it for the patient?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Patients; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Research Design; Treatment Outcome | 2002 |
Gefitinib.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Lung Neoplasms; Quinazolines; Signal Transduction; Treatment Outcome; Tumor Cells, Cultured | 2002 |
HER-targeted tyrosine-kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Morpholines; Ovarian Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2002 |
Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Cetuximab; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Precancerous Conditions; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2002 |
Overview of clinical trials with epidermal growth factor receptor inhibitors in advanced non-small cell lung cancer.
Topics: Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Oncology Nursing; Quinazolines; Survival Analysis; Treatment Outcome | 2002 |
[Molecular-targeted therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Endothelial Growth Factors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Recurrent small cell lung cancer: update.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Gefitinib; Humans; Immunotoxins; Lung Neoplasms; Neoplasm Recurrence, Local; Oligonucleotides, Antisense; Prognosis; Quinazolines; Thionucleotides | 2003 |
Phase I studies of ZD1839 in patients with common solid tumors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic | 2003 |
New directions for ZD1839 in the treatment of solid tumors.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
[Molecular targetting therapy for non-small-cell lung neoplasms with EGF-R inhibitors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Small Cell; Cetuximab; Clinical Trials as Topic; Depression, Chemical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Quinazolines | 2003 |
Erlotinib (Tarceva): an update on the clinical trial program.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2003 |
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Survival Rate | 2003 |
Targeting epidermal growth factor receptor--are we missing the mark?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Research Design; Treatment Failure | 2003 |
Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Research Design; Treatment Outcome | 2003 |
Gefitinib (Iressa) trials in non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis; Treatment Outcome | 2003 |
Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.
Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; Lung Neoplasms; Organic Chemicals; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Treatment Outcome | 2003 |
Erlotinib: a new therapeutic approach for non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Screening Assays, Antitumor; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Tumor Cells, Cultured | 2003 |
The benefits of achieving stable disease in advanced lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Gefitinib; Humans; Lung Neoplasms; Outcome Assessment, Health Care; Quality of Life; Quinazolines; Survivors | 2003 |
Gefitinib (Iressa, ZD 1839) for non-small cell lung cancer (NSCLC): recents results and further strategies.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Random Allocation; Treatment Outcome | 2003 |
[Non-small cell lung cancer: 1) Molecular-target therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2003 |
[Non-small cell lung cancer: 2) Epidermal growth factor receptor inhibitor and severe adverse phenomena].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines | 2003 |
[Iressa (gefitinib)].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2003 |
Gefitinib therapy for advanced non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2003 |
Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Treatment Outcome | 2003 |
The impact of gefitinib on epidermal growth factor receptor signaling pathways in cancer.
Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2003 |
Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Ligands; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Molecular targeted agents in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase C; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2003 |
Adjuvant systemic therapies in early-stage non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoprevention; Chemotherapy, Adjuvant; Drug Resistance; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant; Selenium; Survival Analysis | 2003 |
Primary and secondary prevention of non-small-cell lung cancer: the SPORE Trials of Lung Cancer Prevention.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemoprevention; Clinical Trials as Topic; Disease Progression; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Precancerous Conditions; Protein-Tyrosine Kinases; Quinazolines; Quinolones | 2003 |
Tolerability of gefitinib in patients receiving treatment in everyday clinical practice.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Quinazolines; Treatment Outcome | 2003 |
Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Quality of Life; Quinazolines | 2003 |
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2003 |
Targeting the HER1/EGFR receptor to improve outcomes in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prognosis; Quinazolines; Treatment Outcome | 2003 |
Erlotinib: preclinical investigations.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Transplantation, Heterologous | 2003 |
Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Survival Analysis; Treatment Outcome | 2003 |
Identifying predictive and surrogate markers of erlotinib antitumor activity other than rash.
Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Patient Selection; Predictive Value of Tests; Quinazolines | 2003 |
Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Quinazolines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2003 |
Gefitinib (Iressa): a novel treatment for non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC).
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
[Therapeutic implications of epidermal growth factor receptor in lung cancer].
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioblastoma; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasm Proteins; Neoplasms; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents | 2004 |
Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cisplatin; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Proteins; Quinazolines | 2004 |
A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Gefitinib: phase II and III results in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
[Molecular pathogenesis of lung cancers and the preservative therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Cycle Proteins; Cisplatin; Enzyme Inhibitors; Etoposide; Gefitinib; Gene Targeting; Genes, bcl-2; Genes, p53; Genetic Therapy; Humans; Lung Neoplasms; Mass Screening; Mutation; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant | 2004 |
Gefitinib, a novel, orally administered agent for the treatment of cancer.
Topics: Administration, Oral; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2004 |
Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Quinazolines | 2004 |
[Anti angiogenesis].
Topics: Angiogenesis Inhibitors; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclooxygenase 2; Female; Humans; Isoenzymes; Lung Neoplasms; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase Inhibitors; Membrane Proteins; Neoplasms; Neovascularization, Pathologic; Piperidines; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Quinazolines; Research Design; Thalidomide; Vascular Endothelial Growth Factor A | 2004 |
Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiation-Sensitizing Agents | 2004 |
Epidermal growth factor receptor-targeted therapy with ZD1839: symptom improvement in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2004 |
Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2004 |
Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States | 2004 |
Estrogen receptor pathways in lung cancer.
Topics: Age Factors; Animals; Antineoplastic Agents; Epidermal Growth Factor; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Receptors, Estrogen; Risk Factors; Sex Distribution; Sex Factors; Signal Transduction; Smoking; Survival Rate; United States | 2004 |
[Lung cancer: molecular targeting therapy].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gene Targeting; Genetic Therapy; Humans; Imatinib Mesylate; Indoles; Lung Neoplasms; Piperazines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Trastuzumab | 2004 |
Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Severity of Illness Index; Sickness Impact Profile; Survival Analysis | 2004 |
Management of acneiform rashes related to gefitinib therapy.
Topics: Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dermatologic Agents; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mouth Neoplasms; Prognosis; Quinazolines; Skin Care | 2004 |
Current data and ongoing trials in patients with recurrent non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cytotoxins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Glutathione; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Prodrugs; Prognosis; Quinazolines; Taxoids | 2004 |
Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Quinazolines; Signal Transduction | 2004 |
The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2004 |
The role of gefitinib in lung cancer treatment.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Disease Progression; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2004 |
Mutations in the EGFR: the importance of genotyping.
Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Genotype; Humans; Lung Neoplasms; Mutation; Quinazolines | 2004 |
[New advance of the molecular targeting agents in advanced non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Keratinocytes; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Quinazolines; Tissue Distribution; Treatment Outcome | 2004 |
Combination epidermal growth factor receptor inhibition and radical radiotherapy for NSCLC.
Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Prognosis; Protein-Tyrosine Kinases; Quinazolines | 2004 |
[Gefitinib in non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
Anti-HER therapeutic agents in the treatment of non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Genes, erbB-2; Humans; Lung Neoplasms; Quinazolines; Receptor, ErbB-3; Receptor, ErbB-4; Trastuzumab | 2003 |
Interstitial lung disease associated with drug therapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Quinazolines; Respiratory Distress Syndrome; Risk Factors | 2004 |
New directions in oncology nursing care: focus on gefitinib in patients with lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Patient Education as Topic; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2004 |
Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Biological Availability; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Half-Life; Humans; Intestinal Absorption; Lung Neoplasms; Metabolic Clearance Rate; Middle Aged; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2004 |
Brain metastasis responding to gefitinib alone.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gingival Neoplasms; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2004 |
Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Product Surveillance, Postmarketing; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Gefitinib--a novel targeted approach to treating cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Quinazolines | 2004 |
[Does molecular targeted therapy change the treatment for lung cancer?].
Topics: Antineoplastic Agents; Cell Cycle; Gefitinib; Genes, erbB-1; Genetic Therapy; Lung Neoplasms; Neovascularization, Pathologic; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tumor Suppressor Protein p53; Vaccines, Synthetic | 2004 |
Gefitinib: current status in the treatment of non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Therapy, Combination; Gefitinib; Humans; Lung Neoplasms; Molecular Structure; Quinazolines | 2004 |
Gefitinib therapy for non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis | 2005 |
A molecular chink in the lung cancer armour.
Topics: ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Pharmacogenetics; Quinazolines; Treatment Outcome | 2004 |
[Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting].
Topics: Adenocarcinoma; Antineoplastic Agents; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-raf; Quinazolines | 2004 |
Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2004 |
Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
[Second-line treatment for advanced non-small-cell lung cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2005 |
Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis | 2005 |
Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Treatment Outcome | 2005 |
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2005 |
[Molecular diagnosis of solid tumors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gastrointestinal Neoplasms; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Trastuzumab | 2005 |
[Gefitinib as targeted treatment for non-small-cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Female; Finland; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2005 |
Spotlight on gefitinib in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2005 |
Computer-assisted image analysis of bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Gefitinib; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Quinazolines; Remission Induction; Tomography, X-Ray Computed | 2005 |
Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2005 |
Angiogenesis and lung cancer: prognostic and therapeutic implications.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Lung; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib | 2005 |
Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Metaphor; Mutation; Protein Kinase Inhibitors; Quinazolines | 2005 |
ZD6474--clinical experience to date.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A | 2005 |
Role of epidermal growth factor receptor mutations in predicting sensitivity or resistance to targeted agents in non-small-cell lung cancer.
Topics: Amino Acid Substitution; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Methionine; Mutation; Quinazolines; Sex Factors; Threonine | 2005 |
Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
Recent developments related to the EGFR as a target for cancer chemotherapy.
Topics: Aminoquinolines; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Structure; Organic Chemicals; Protein Kinase Inhibitors; Quinazolines | 2005 |
Gefitinib in non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2005 |
Erlotinib in non-small cell lung cancer: a review.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2005 |
Perspectives on novel therapies for bronchial carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Patient Selection; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Vascular Endothelial Growth Factor A | 2005 |
Medical treatment of non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Erlotinib hydrochloride.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2005 |
[Translational research on lung cancer--EGFR gene mutation].
Topics: Adenocarcinoma; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sequence Deletion; Smoking; Transcription, Genetic | 2005 |
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine | 2005 |
Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Factors predicting response to EGFR tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Patient Selection; Quinazolines | 2005 |
The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2005 |
Recent advances and future perspectives in the management of lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Forecasting; Gefitinib; Humans; Interleukin-2; Lung Neoplasms; Lung Transplantation; Mass Screening; Neoadjuvant Therapy; Neoplasm Staging; Pneumonectomy; Quinazolines; Radiotherapy, Adjuvant; Sentinel Lymph Node Biopsy; Smoking | 2005 |
Targeted therapies for non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Lung Neoplasms; Mutation; Oligonucleotides, Antisense; Protein Kinase Inhibitors; Quinazolines | 2005 |
Epidermal growth factor inhibition in solid tumours.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; Drug Delivery Systems; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic | 2005 |
Perspectives on salvage therapy for non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Second-line chemotherapy and beyond for non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Forecasting; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed; Pneumonectomy; Quinazolines; Salvage Therapy; Survival Rate; Taxoids; Time Factors | 2004 |
Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Forecasting; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2005 |
Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Taxoids | 2005 |
Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung cancer: two case reports and a review of the literature.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Quinazolines; Radiography | 2005 |
Erlotinib in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2005 |
[Development of individualized therapy of non-small cell lung cancer targeted at the EGF receptor].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2005 |
Adjuvant chemotherapy for non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Oncogene Proteins; Protein Kinase Inhibitors; Quinazolines | 2005 |
The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2004 |
[Molecular targeted therapy--non-small-cell lung cancer and gefitinib].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Female; Gefitinib; Gemcitabine; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Paclitaxel; Quinazolines; Survival Rate | 2005 |
Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Survival Analysis | 2006 |
Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis | 2005 |
Cancer diagnostics: decision criteria for marker utilization in the clinic.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow Examination; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Genetic Testing; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Neoplasm, Residual; Neoplasms; Neoplastic Cells, Circulating; Patient Selection; Practice Guidelines as Topic; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Technology Assessment, Biomedical; Trastuzumab | 2005 |
Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genes, erbB-1; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Patient Selection; Prognosis; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genetic Therapy; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
EGFR inhibitors in lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Controlled Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Patient Selection; Quinazolines; Treatment Failure | 2005 |
[EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Quinazolines; Survival Rate | 2005 |
Antiangiogenic drugs in non-small cell lung cancer treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Humans; Lung Neoplasms; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2006 |
[Erlotinib. A new option for non-small cell lung cancer].
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2006 |
[Chemotherapy for lung cancer patients].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Etoposide; Evidence-Based Medicine; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2006 |
Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2005 |
Targeting HER1/EGFR in cancer therapy: experience with erlotinib.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Mice; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Asia; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis | 2006 |
Multi-target inhibitors in non-small cell lung cancer (NSCLC).
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Medical Oncology; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2006 |
Gefitinib: an adverse effects profile.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2006 |
Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Piperidines; Quinazolines; Randomized Controlled Trials as Topic | 2006 |
Clinical experience with anti-EGFR therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Safety; Survival Rate; Treatment Outcome | 2006 |
From the bench to the bed: individualizing treatment in non-small-cell lung cancer.
Topics: 14-3-3 Proteins; Adenocarcinoma; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; DNA Damage; DNA Repair; Epistasis, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Genes, BRCA1; Genes, cdc; Genes, erbB-1; Genes, ras; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Piperazines; Polymorphism, Genetic; Pyrimidines; Quinazolines | 2006 |
[Present status of and new trends in therapy for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Pneumonectomy; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2006 |
Nondermatologic adverse events associated with anti-EGFR therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Irinotecan; Lung Diseases, Interstitial; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Where next for gefitinib in patients with lung cancer?
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2006 |
Predicting the outcome of chemotherapy for lung cancer.
Topics: 14-3-3 Proteins; Antineoplastic Agents; Cell Transformation, Neoplastic; Clinical Trials as Topic; DNA Repair Enzymes; DNA-Binding Proteins; Drug Resistance, Neoplasm; Epigenesis, Genetic; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mesoderm; Mutation; Nuclear Proteins; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Smoking; Thioredoxins; Treatment Outcome; Y-Box-Binding Protein 1 | 2006 |
EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinolines; Signal Transduction | 2006 |
Epidermal growth factor receptor inhibition and non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Denmark; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Structure, Tertiary; Quinazolines; Signal Transduction | 2006 |
Advanced non-small-cell lung cancer: new data, therapy choices, and challenging decisions.
Topics: Antineoplastic Agents; Biological Products; Biomedical Research; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Medical Oncology; Protein Kinase Inhibitors; Quinazolines | 2006 |
[New substances in the therapy of head and neck cancer].
Topics: Administration, Oral; Aminoquinolines; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Double-Blind Method; Erlotinib Hydrochloride; Fibroblast Growth Factor 7; Gefitinib; Head and Neck Neoplasms; Humans; Imiquimod; Infusions, Intravenous; Iodine Radioisotopes; Lung Neoplasms; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Ointments; Protein Kinase Inhibitors; Quinazolines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Skin Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2006 |
Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Taxoids | 2006 |
Clinical development of SRC tyrosine kinase inhibitors in lung cancer.
Topics: Benzodioxoles; Clinical Trials, Phase I as Topic; Dasatinib; Drug Evaluation, Preclinical; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; src-Family Kinases; Thiazoles | 2006 |
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2006 |
[Mutations in the epidermal growth factor receptor: structure and biological function in human tumors].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Lung Neoplasms; Mutation; Neoplasms; Prognosis; Quinazolines; Receptor Protein-Tyrosine Kinases | 2006 |
Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neovascularization, Pathologic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2006 |
Biological and clinical implications of EGFR mutations in lung cancer.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2006 |
Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Synergism; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines; Vascular Endothelial Growth Factor A | 2006 |
Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Amplification; Humans; In Vitro Techniques; Lung Neoplasms; Male; Models, Molecular; Mutation; Oncogenes; Quinazolines | 2005 |
Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genes, ras; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Smoking | 2005 |
Targeted therapy in advanced non-small cell lung cancer (NSCLC): where do we stand?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
Topics: Antineoplastic Agents; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Second-line therapeutic options in non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2006 |
Defining clinically relevant molecular subsets of lung cancer.
Topics: Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2006 |
[Erlotinib in the treatment of non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
[Is it possible to treat bronchial carcinoma without chemotherapy?].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meta-Analysis as Topic; Neoadjuvant Therapy; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Risk Factors; Sex Factors; Smoking | 2006 |
Angiogenesis inhibition in the treatment of lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Erlotinib Hydrochloride; Hemorrhage; Humans; Lung Neoplasms; Neovascularization, Pathologic; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Vascular Endothelial Growth Factor A | 2006 |
Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Clinical Trials, Phase II as Topic; DNA Mutational Analysis; DNA, Neoplasm; Double-Blind Method; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Ethnicity; Exons; Female; Gefitinib; Genes, erbB-1; Genes, p53; Genes, ras; Genotype; Humans; Lung Neoplasms; Male; Mutagenesis, Insertional; Mutation; Mutation, Missense; Protein Structure, Tertiary; Quinazolines; Randomized Controlled Trials as Topic; Sequence Deletion; Smoking | 2007 |
[Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2007 |
Managing dermatologic toxicities of epidermal growth factor receptor inhibitors.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors | 2006 |
Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2006 |
The place of targeted therapies in the management of non-small cell bronchial carcinoma. Target therapies in lung cancer management.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2006 |
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Amplification; Gene Expression Profiling; Genetic Testing; Humans; Lung Neoplasms; Male; Mutation; Patient Selection; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2007 |
Medicalisation of race.
Topics: Age Distribution; Aged; Antineoplastic Agents; Black or African American; Clinical Trials as Topic; Drug Approval; Drug Combinations; Gefitinib; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Lung Neoplasms; Middle Aged; Patents as Topic; Quinazolines; United States; United States Food and Drug Administration | 2007 |
EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines | 2007 |
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Morpholines; Organic Chemicals; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines | 2007 |
Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2006 |
Salvage therapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids | 2006 |
[Prediction of effectiveness of EGFR tyrosine kinase inhibitors for the patients with by EGFR mutations].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Paclitaxel; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Smoking | 2007 |
Combination of target agents: challenges and opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Drug Resistance, Neoplasm; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2007 |
[New biological treatments for lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biopsy; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Forecasting; Gefitinib; Humans; Lung; Lung Neoplasms; Male; Mutation; Patient Selection; Polymerase Chain Reaction; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.
Topics: Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; China; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Analysis | 2007 |
Epidermal growth factor receptor inhibitors in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis | 2007 |
Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors.
Topics: Bronchoscopy; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Ultrasonography | 2007 |
Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2007 |
[What is drug-epidemiology?].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cohort Studies; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Quinazolines | 2007 |
Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mutation; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2007 |
"Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?".
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Medical Oncology; Mutation; Quinazolines; ras Proteins; Smoking | 2007 |
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2007 |
Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Bevacizumab in non small cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Vascular Endothelial Growth Factor A | 2007 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2007 |
Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases | 2007 |
Erlotinib in non-small cell lung cancer treatment: current status and future development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Analysis; Treatment Outcome | 2007 |
[Therapeutic management of extensive bronchiolo-alveolar adenocarcinoma: chemotherapy or inhibitors of epidermal growth factor receptor tyrosine kinase?].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2007 |
Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2007 |
Erlotinib as a single agent in select subsets of patients with advanced non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Karnofsky Performance Status; Lung Neoplasms; Quinazolines; Treatment Outcome | 2007 |
The place of targeted therapy in the patient management of non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2007 |
[Gefitinib and epidermal growth factor receptor gene mutation].
Topics: Adenocarcinoma; Antineoplastic Agents; Enzyme Inhibitors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines; Respiratory Distress Syndrome; Smoking | 2007 |
Erlotinib in non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Testing; Humans; Lung Neoplasms; Mutation; Pancreatic Neoplasms; Patient Selection; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2007 |
[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Proteins; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2007 |
EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2008 |
Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Platinum; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Taxoids; Treatment Outcome | 2008 |
Considerations for second-line therapy of non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2008 |
The role of gefitinib in the management of Asian patients with non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2008 |
[Efficacy of gefitinib in treatment of lung cancer patients with bone metastasis].
Topics: Alkaline Phosphatase; Antineoplastic Agents; Biomarkers; Bone Neoplasms; Bone Resorption; Collagen Type I; Female; Fractures, Spontaneous; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Osteogenesis; Peptide Fragments; Peptides; Procollagen; Quinazolines | 2008 |
[Targeted therapies in the treatment of non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-1 | 2008 |
Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Quinazolines; Trastuzumab; Treatment Outcome | 2006 |
The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis.
Topics: Antineoplastic Agents; Asia, Eastern; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Gefitinib; Humans; Lung Neoplasms; Male; Platinum Compounds; Quinazolines | 2008 |
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Diet; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Lymph Node Excision; Neoplasm Staging; Pharmacogenetics; Quinazolines; Radiotherapy Dosage; Risk Factors; Smoking; Survival Analysis; Survivors; Tobacco Smoke Pollution; Treatment Outcome | 2008 |
Epidermal growth factor receptor-directed therapy in esophageal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Gefitinib; Humans; Incidence; Lung Neoplasms; Quinazolines; Survival Analysis | 2007 |
[Lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drugs, Investigational; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Pneumonectomy; Pyridines; Pyrroles; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib | 2008 |
[Non-small-cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2008 |
Advances in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2008 |
ZD1839 ('Iressa') as an anticancer agent.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Division; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Mice; Quinazolines; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
Tyrosine kinase inhibitors-ZD1839 (Iressa).
Topics: Animals; Antibodies; Carcinoma, Non-Small-Cell Lung; Cell Division; Clinical Trials as Topic; Disease Progression; Dogs; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Ligands; Lung Neoplasms; Neoplasms; Quinazolines; Rats | 2001 |
ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Chemoprevention; Clinical Trials as Topic; Combined Modality Therapy; Disease Models, Animal; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Quinazolines; Signal Transduction; Transplantation, Heterologous; Up-Regulation | 2002 |
[Non surgical new treatment modalities for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Delivery Systems; Enzyme Inhibitors; Gefitinib; Genetic Therapy; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy | 2002 |
[Molecular target-based cancer therapy: epidermal growth factor receptor inhibitors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2002 |
[Progress in diagnosis and treatment of lung cancer].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Endothelial Growth Factors; Enzyme Inhibitors; Gefitinib; Genetic Therapy; Humans; Hydroxamic Acids; Lung Neoplasms; Lymphokines; Mass Screening; Metalloendopeptidases; Quinazolines; Receptor Protein-Tyrosine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Targeting epidermal growth factor receptor in lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2002 |
[ZD1839].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Treatment Outcome | 2002 |
[New treatment strategy for stage III non-small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quinazolines; Radiotherapy; Taxoids; Treatment Outcome; Vinblastine | 2002 |
[Latest therapeutic strategy for stage IV non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; Gefitinib; Humans; Hyperthermia, Induced; Immunotherapy; Lung Neoplasms; Neoplasm Staging; Quinazolines; Radiotherapy; Stents | 2002 |
[Future trends in anticancer chemotherapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Design; Drug Therapy; Drugs, Investigational; Endothelial Growth Factors; Forecasting; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Quinazolines; Recombinant Proteins; Trastuzumab; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
667 trial(s) available for quinazolines and Lung Neoplasms
| Article | Year |
|---|---|
Poziotinib for Patients With
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate | 2022 |
In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial.
Topics: Animals; Humans; Lung; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Quinazolines | 2021 |
Poziotinib in Non-Small-Cell Lung Cancer Harboring
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Prognosis; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Survival Rate | 2022 |
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With
Topics: Acrylamides; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Gefitinib; Humans; Indoles; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Small Cell Lung Carcinoma | 2022 |
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Tyrosine | 2022 |
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2022 |
Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Circulating Tumor DNA; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2022 |
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study.
Topics: Carcinoma, Non-Small-Cell Lung; Central Nervous System; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
Topics: Adenocarcinoma of Lung; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2023 |
Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Central Nervous System; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2023 |
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2020 |
Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Pyridines; Quinazolines; Research Design; Young Adult | 2020 |
Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial.
Topics: Adult; Aged; Alleles; Amino Acid Substitution; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Young Adult | 2020 |
Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601).
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Japan; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2020 |
A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; Double-Blind Method; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2020 |
Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quinazolines; Treatment Outcome | 2020 |
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Goals; Humans; Lung Neoplasms; Mexico; Mutation; Phthalazines; Piperazines; Protein Kinase Inhibitors; Quinazolines; Spain | 2020 |
Drug interaction of ningetinib and gefitinib involving CYP1A1 and efflux transporters in non-small cell lung cancer patients.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Drug Interactions; Gefitinib; Humans; Lung Neoplasms; Mice; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines | 2021 |
Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Humans; Lung Neoplasms; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines | 2021 |
Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706).
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyridines; Quality of Life; Quinazolines; Vascular Endothelial Growth Factor A | 2021 |
Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Radiosurgery | 2017 |
The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; DNA, Neoplasm; Drug Substitution; ErbB Receptors; Feasibility Studies; Gefitinib; Humans; Liquid Biopsy; Lung Neoplasms; Mutation; Piperazines; Quinazolines; Research Design; Response Evaluation Criteria in Solid Tumors | 2017 |
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Quinazolines; Treatment Outcome | 2017 |
Analyzing epidermal growth factor receptor mutation status changes in advanced non-small-cell lung cancer at different sampling time-points of blood within one day.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Mutation Rate; Neoplasm Staging; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2017 |
Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2017 |
Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Point Mutation; Quinazolines | 2017 |
Evaluation of the VeriStrat
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Hematologic Tests; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Quinazolines; Retrospective Studies; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Analysis; Treatment Outcome | 2017 |
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Female; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Quinazolines | 2017 |
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Monitoring; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retreatment; Sirolimus; Treatment Outcome | 2017 |
Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Female; Follow-Up Studies; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2017 |
Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Quinazolines; Treatment Outcome | 2017 |
Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome | 2017 |
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Crown Ethers; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Quinazolines | 2017 |
Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Deletion; Humans; Hydroxamic Acids; Lung Neoplasms; Mutation; Quinazolines; Vorinostat | 2017 |
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Prognosis; Quinazolines; Quinazolinones; Survival Analysis; Treatment Outcome | 2017 |
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Australia; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Piperazines; Quinazolines; Republic of Korea; Taiwan; Treatment Outcome; United States | 2017 |
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cohort Studies; Diarrhea; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2017 |
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2018 |
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6).
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Health Status; Humans; Lung Neoplasms; Male; Patient Reported Outcome Measures; Polymorphism, Single Nucleotide; Quality of Life; Quinazolines; Survival Analysis | 2018 |
Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Grading; Quinazolines; Reproducibility of Results; Retrospective Studies; Statistics, Nonparametric; Time Factors; Treatment Outcome | 2017 |
Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Economics, Pharmaceutical; ErbB Receptors; Exanthema; Female; Gefitinib; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Outcome Assessment, Health Care; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2018 |
A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations.
Topics: Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Mutation; Prognosis; Quinazolines; Survival Rate | 2018 |
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non‒Small-Cell Lung Cancer.
Topics: Aged; Asian People; Benzofurans; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Placebos; Progression-Free Survival; Quinazolines | 2018 |
Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Gefitinib; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2018 |
OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Massachusetts; Protein Kinase Inhibitors; Quinazolines | 2018 |
Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs.
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Young Adult | 2018 |
Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Crown Ethers; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Survival Analysis | 2019 |
Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Pleural Neoplasms; Progression-Free Survival; Quinazolines | 2019 |
Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Exanthema; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Time Factors; Treatment Outcome | 2013 |
Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661).
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proteomics; Quinazolines; Tandem Mass Spectrometry | 2013 |
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Triazines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Carboplatin; Carcinoma, Non-Small-Cell Lung; Costs and Cost Analysis; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Models, Economic; Quinazolines; Time Factors | 2013 |
N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines.
Topics: Adenocarcinoma; Adult; Aged; Antigens, CD; Cadherins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Up-Regulation | 2013 |
Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Models, Biological; Neoplasm Proteins; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines | 2013 |
HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neoplastic Cells, Circulating; Proto-Oncogene Proteins c-met; Quinazolines | 2013 |
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Paclitaxel; Quality of Life; Quinazolines | 2013 |
Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tetrahydronaphthalenes; Treatment Outcome | 2013 |
Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Quinazolines; Treatment Outcome | 2013 |
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.
Topics: Acute-Phase Proteins; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gene Amplification; Genes, erbB-1; Humans; Interleukin-9; Kaplan-Meier Estimate; Lipocalin-2; Lipocalins; Lung Neoplasms; Male; Middle Aged; Mutation; Piperidines; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; TNF-Related Apoptosis-Inducing Ligand | 2013 |
Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2013 |
Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803).
Topics: Aged; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2013 |
Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Folic Acid Antagonists; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2013 |
Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2013 |
Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prospective Studies; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Survival; Treatment Outcome | 2013 |
Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oligodeoxyribonucleotides; Protein Kinase Inhibitors; Quinazolines; Toll-Like Receptor 9 | 2013 |
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Quinazolines; Retrospective Studies; Sirolimus; Survival; Thiazoles; Treatment Outcome | 2013 |
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; ErbB Receptors; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pemetrexed; Quinazolines | 2013 |
LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2013 |
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; ErbB Receptors; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Pemetrexed; Quality of Life; Quinazolines; Treatment Outcome | 2013 |
Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids | 2013 |
Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Proportional Hazards Models; Quinazolines | 2013 |
A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Quinazolines; Treatment Outcome | 2013 |
[A randomized clinical study of Gefitinib and pemetrexed as second line therapy for advanced non-squamous non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quality of Life; Quinazolines; Treatment Outcome | 2013 |
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2013 |
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Placebos; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2013 |
A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Risk Factors; Treatment Outcome | 2013 |
Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Quinazolines; Retreatment; Risk Factors; Treatment Outcome | 2013 |
Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Asian People; Brain Neoplasms; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2013 |
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Exanthema; Female; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Piperidines; Platinum Compounds; Quinazolines; Vascular Endothelial Growth Factor A | 2013 |
Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclin D1; Cyclin D3; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Polyethylene Glycols; Protein Kinase Inhibitors; Quinazolines; Recombinant Proteins; Survival; Taxoids; Treatment Outcome | 2013 |
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Proto-Oncogene Proteins c-met; Quinazolines; Treatment Outcome | 2013 |
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Proportional Hazards Models; Quinazolines; Treatment Outcome | 2013 |
Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2013 |
Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Pemetrexed; Prospective Studies; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study).
Topics: Adenocarcinoma; Aged; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2014 |
A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium.
Topics: Adenocarcinoma; Adult; Aged; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Survival Rate | 2014 |
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Asian People; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2C19; Disease Progression; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines | 2013 |
A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Paclitaxel; Platinum Compounds; Population Groups; Quinazolines | 2014 |
Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Vinblastine | 2014 |
Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Time Factors; Treatment Outcome | 2014 |
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Treatment Outcome | 2014 |
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; White People; Young Adult | 2014 |
A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Quinazolines; Survival Analysis; Young Adult | 2014 |
Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; DNA Mutational Analysis; Early Detection of Cancer; ErbB Receptors; Gefitinib; Histological Techniques; Humans; Lung Neoplasms; Mutation; Precision Medicine; Quinazolines; Treatment Outcome; Tumor Burden | 2014 |
Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Sirolimus; Treatment Outcome | 2014 |
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cyclic N-Oxides; Cyclin-Dependent Kinases; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Indolizines; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pyridinium Compounds; Quinazolines | 2014 |
Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean in silico model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Culture Techniques; Cell Line, Tumor; Gefitinib; Humans; Lung Neoplasms; Models, Biological; Neoplasm Invasiveness; Neoplasm Proteins; Quinazolines; Signal Transduction; Swine; Tumor Microenvironment | 2014 |
Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Prognosis; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Rate | 2014 |
A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Panobinostat; Quinazolines; Treatment Outcome | 2014 |
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Risk Factors; Thailand; Time Factors; Treatment Outcome | 2014 |
Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Multimodal Imaging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Recurrence; Tomography, X-Ray Computed | 2014 |
A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antimetabolites, Antineoplastic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Dosage; Glutamates; Guanine; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2014 |
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Quinazolinones; Treatment Failure | 2014 |
[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Radiography; Radiopharmaceuticals; Survival Rate; Time Factors | 2014 |
Early pharmacodynamic assessment using ¹⁸F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Treatment Outcome | 2014 |
Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines; Risk Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2014 |
Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Pneumonectomy; Prospective Studies; Quinazolines; Survival Rate | 2014 |
Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Quinazolines; Treatment Outcome; Vorinostat | 2014 |
Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2014 |
A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Quinazolines; Treatment Outcome | 2014 |
Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Piperidines; Placebos; Quinazolines; Survival Rate | 2014 |
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibitors; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostaglandins; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sulfonamides; Survival Rate | 2014 |
[Prospective study of biotin treatment in patients with erythema due to gefitinib or erlotinib].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biotin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Erythema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2014 |
LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Quinazolines; Treatment Outcome | 2014 |
A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2014 |
[Association between GNAS1 T393C polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated advanced non-small cell lung cancer with unknown EGFR mutation status].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chromogranins; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; GTP-Binding Protein alpha Subunits, Gs; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Oligonucleotides; Protein Kinase Inhibitors; Quinazolines; Toll-Like Receptor 9; Treatment Outcome | 2014 |
Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.
Topics: Adult; Aged; Aged, 80 and over; Black or African American; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pharmacogenetics; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2014 |
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indazoles; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Sulfonamides; Treatment Outcome | 2014 |
Timing of metabolic response monitoring during erlotinib treatment in non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Quinazolines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Furans; Humans; Ketones; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2014 |
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.
Topics: Biomarkers, Tumor; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Proteomics; Quinazolines | 2014 |
Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Proportional Hazards Models; Quinazolines; Taxoids; Treatment Outcome | 2014 |
(18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Remission Induction; ROC Curve; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
O02.03 Value of adding erlotinib to thoracic radiation therapy with chemotherapy for stage III non-small cell lung cancer: a prospective phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Erlotinib Hydrochloride; Esophagitis; Genes, erbB-1; Humans; Lung Neoplasms; Paclitaxel; Prospective Studies; Quinazolines; Radiation Injuries; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Analysis; Taxoids | 2014 |
MO06.03 Bevacizumab and erlotinib or bevacizumab, cisplatin and pemetrexed in patients with metastatic non-small cell lung cancer: EGFR mutation based treatment allocation and repeat biopsy at progression in the SAKK19/09 (BIOPRO) trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Genes, erbB-1; Genes, ras; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Mutation; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2014 |
Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Contrast Media; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Iohexol; Lung Neoplasms; Male; Multidetector Computed Tomography; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiographic Image Enhancement; Reproducibility of Results; Treatment Outcome; Tumor Burden | 2014 |
Phase II study of Afatinib as third-line treatment for patients in Korea with stage IIIB/IV non-small cell lung cancer harboring wild-type EGFR.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Republic of Korea | 2014 |
Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catheters, Indwelling; Humans; Lung Neoplasms; Middle Aged; Piperidines; Pleural Effusion, Malignant; Pleurodesis; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recurrence; Survival Rate; Time Factors; Treatment Outcome | 2014 |
SNPs in the transforming growth factor-β pathway as predictors of outcome in advanced lung adenocarcinoma with EGFR mutations treated with gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Prognosis; Quinazolines; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta; Treatment Outcome | 2014 |
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2014 |
A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Disease Progression; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retreatment; Small Cell Lung Carcinoma; src-Family Kinases; Treatment Outcome | 2014 |
Second- and further-line therapy with erlotinib in patients with advanced non-small-cell lung cancer in daily clinical practice.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cranial Irradiation; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Recovery of Function; Treatment Outcome | 2014 |
Phase II study of pemetrexed and erlotinib in pretreated nonsquamous, non-small-cell lung cancer patients without an EGFR mutation.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neutropenia; Pemetrexed; Quinazolines; Thrombocytopenia; Treatment Outcome | 2013 |
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retreatment; Risk Factors; Taxoids; Treatment Failure; Treatment Outcome | 2014 |
First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Monitoring; Drug Screening Assays, Antitumor; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Japan; Liver Function Tests; Lung Neoplasms; Male; Neoplasm Staging; Quality of Life; Quinazolines | 2014 |
Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Monitoring, Physiologic; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Single-Blind Method; Treatment Outcome | 2014 |
Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; United States; Vascular Endothelial Growth Factor A; Young Adult | 2014 |
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.
Topics: Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Expression; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity | 2014 |
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2014 |
Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Asia, Southeastern; Carcinoma, Non-Small-Cell Lung; Cooking; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Inhalation Exposure; Life Style; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Surveys and Questionnaires | 2014 |
Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Dideoxynucleosides; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Survival Analysis | 2015 |
A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Protocols; Disease-Free Survival; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Quinazolines; Research Design; Treatment Outcome; Young Adult | 2015 |
Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment.
Topics: Antineoplastic Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Research Design; Survival Analysis; Withholding Treatment | 2015 |
A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Hepatocyte Growth Factor; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Retreatment; Treatment Outcome | 2014 |
Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Quinazolines; Risk Factors; Taxoids; Treatment Outcome | 2014 |
Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2014 |
Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Quinazolines | 2014 |
Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Quinazolines; Treatment Outcome | 2014 |
Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Colorado; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Risk Factors; Texas; Time Factors; Treatment Outcome | 2014 |
Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib.
Topics: Adenocarcinoma; Afatinib; Disease-Free Survival; Health Status; Humans; Longitudinal Studies; Lung Neoplasms; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2014 |
Erlotinib plus bevacizumab is effective in EGFR-mutant NSCLC.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quinazolines; Radiotherapy Dosage; Radiotherapy, Adjuvant | 2015 |
[Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Asian People; Carboplatin; Disease-Free Survival; Gefitinib; Hospitals, General; Humans; Lung Neoplasms; Paclitaxel; Platinum; Quinazolines; Smoking | 2014 |
Personalized biomarkers to monitor disease progression in advanced non-small-cell lung cancer patients treated with icotinib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Drug Monitoring; Electrophoresis, Polyacrylamide Gel; Female; Humans; Immunity, Humoral; Inflammation; Lung Neoplasms; Male; Middle Aged; Precision Medicine; Quinazolines; Time Factors | 2015 |
Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Brain; Brain Neoplasms; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis | 2014 |
Prospective assessment of pemetrexed or pemetrexed plus platinum in combination with gefitinib or erlotinib in patients with acquired resistance to gefitinib or erlotinib: a phase II exploratory and preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2015 |
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Health Care Costs; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Prospective Studies; Quality-Adjusted Life Years; Quinazolines; Survival Analysis | 2014 |
Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Genes, erbB-1; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2015 |
Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins; Republic of Korea; Treatment Outcome | 2014 |
Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804).
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2015 |
Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Quinazolines; Survival Rate; Treatment Outcome; Vorinostat | 2015 |
Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Asian People; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Prospective Studies; Quinazolines | 2015 |
Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Oxonic Acid; Quinazolines; Retrospective Studies; Tegafur; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Prognosis; Quinazolines; Survival Rate | 2015 |
Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biomarkers; Capecitabine; China; Deoxycytidine; Disease-Free Survival; Drug Synergism; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Fluorouracil; Genes, erbB-1; Genes, ras; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines; Thymidine Phosphorylase; Treatment Outcome | 2015 |
Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Combinations; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Oxonic Acid; Quinazolines; Tegafur; Treatment Outcome | 2015 |
A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Female; Genetic Variation; Genotype; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pharmacogenetics; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2015 |
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
Topics: Adolescent; Adult; Aged; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Indoles; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Pyrroles; Quinazolines; ras Proteins; Reproducibility of Results; Small Cell Lung Carcinoma; Sunitinib; Thymus Neoplasms; Treatment Outcome; Young Adult | 2015 |
Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Quinoxalines; Sulfonamides; Treatment Outcome | 2015 |
Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Incidence; Kaplan-Meier Estimate; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2015 |
Potential therapeutic benefit of combining gefitinib and tamoxifen for treating advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; ErbB Receptors; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Tamoxifen | 2015 |
Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Prospective Studies; Quinazolines; Survival Rate | 2015 |
Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2015 |
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Quinazolines; Thymidylate Synthase; Treatment Outcome | 2015 |
Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Pemetrexed; Quinazolines | 2016 |
A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Meningeal Neoplasms; Middle Aged; Quinazolines | 2015 |
[Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2015 |
Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; International Cooperation; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Molecular Chaperones; Mutation; Quinazolines; Resorcinols; Treatment Outcome | 2015 |
Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; China; Clinical Protocols; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Drugs, Chinese Herbal; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Research Design; Surveys and Questionnaires; Time Factors; Treatment Outcome; Young Adult | 2015 |
Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Quinazolines; Retrospective Studies; Time-to-Treatment; Treatment Failure | 2015 |
Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; ErbB Receptors; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quinazolines; Sequence Deletion; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Prevalence; Proto-Oncogene Proteins c-ret; Quinazolines; Retrospective Studies; Translocation, Genetic; Treatment Outcome | 2015 |
Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pre-Exposure Prophylaxis; Quinazolines; Risk Factors; Skin Diseases; Tetracycline | 2015 |
A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines | 2015 |
Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer.
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quality of Life; Quinazolines; Treatment Outcome | 2015 |
A randomized phase II study of erlotinib plus nab-paclitaxel versus erlotinib alone as second-line therapy for Chinese patients with advanced EGFR wild-type non-small-cell lung cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Quinazolines | 2015 |
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Intensity-Modulated; Time Factors | 2015 |
Comparison of the pharmacokinetics of erlotinib administered in complete fasting and 2 h after a meal in patients with lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Cross-Over Studies; Erlotinib Hydrochloride; Fasting; Female; Food-Drug Interactions; Humans; Lung Neoplasms; Male; Middle Aged; Postprandial Period; Protein Kinase Inhibitors; Quinazolines | 2015 |
Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gene Deletion; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Staging; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.
Topics: Aldosterone; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Canada; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Peptidyl-Dipeptidase A; Predictive Value of Tests; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
[Experience with the use of gefitinib in patients with inoperable non-squamous cell lung cancer with activating EGFR mutations].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Quinazolines | 2015 |
[Oligoprogression].
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Quinazolines; Radiosurgery; Radiotherapy Dosage; Retreatment; Survival Rate; Treatment Failure | 2015 |
QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Proportional Hazards Models; Quality of Life; Quinazolines; Treatment Outcome; Young Adult | 2015 |
A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Crown Ethers; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines | 2015 |
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome; Tumor Burden | 2015 |
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Europe; Female; Gefitinib; Genetic Predisposition to Disease; Glutamates; Guanine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Phenotype; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Crown Ethers; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Risk Factors; Treatment Outcome | 2015 |
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pyrrolidinones; Quinazolines; Quinolines; Young Adult | 2015 |
Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer.
Topics: Afatinib; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Female; Gastrointestinal Diseases; Humans; Lung Neoplasms; Male; Nutritional Status; Quinazolines | 2015 |
A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Erysipelas; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Treatment Outcome | 2015 |
Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib Treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2015 |
Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Follow-Up Studies; Gefitinib; Half-Life; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Staging; Neutropenia; Patient Dropouts; Quinazolines; Taxoids | 2015 |
Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines | 2015 |
Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Quinazolines; Survival Rate; Taxoids | 2016 |
Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Febrile Neutropenia; Female; Gemcitabine; Humans; International Cooperation; Lapatinib; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Renal Insufficiency; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Consolidation Chemotherapy; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2015 |
Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcino
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Quinazolines | 2015 |
Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours.
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2015 |
Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Gefitinib; Lung Neoplasms; Mutation; Paclitaxel; Quinazolines; Retrospective Studies; Sequence Deletion | 2015 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2016 |
A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib.
Topics: Adult; Afatinib; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents | 2016 |
[Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies | 2015 |
First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Quinazolines | 2016 |
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Quinazolines; Treatment Outcome | 2016 |
Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erloti
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2016 |
Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Case-Control Studies; Contrast Media; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Tomography, Spiral Computed; Tumor Burden; Young Adult | 2016 |
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Disease-Free Survival; Female; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Radiation-Sensitizing Agents; Treatment Outcome | 2016 |
Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cranial Irradiation; Crown Ethers; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies | 2016 |
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retreatment | 2017 |
Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Half-Life; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Survival Rate | 2016 |
A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines | 2016 |
Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Young Adult | 2017 |
Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2016 |
[Exon-dependent Subgroup-analysis of the Non-interventional REASON-Study: PFS and OS in EGFR-mutated NSCLC Patients Treated with Gefitinib or Chemotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Genetic Markers; Genetic Predisposition to Disease; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Pharmacogenomic Testing; Point Mutation; Prevalence; Quinazolines; Radiation Injuries; Reproducibility of Results; Risk Factors; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2016 |
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Retreatment; Treatment Outcome | 2016 |
A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease Progression; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Piperidines; Quinazolines; Small Cell Lung Carcinoma | 2017 |
Prediction of biomarkers of therapeutic effects of patients with lung adenocarcinoma treated with gefitinib based on progression-free-survival by metabolomic fingerprinting.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Disease-Free Survival; Female; Gefitinib; Humans; Least-Squares Analysis; Lung Neoplasms; Male; Mass Spectrometry; Metabolomics; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Republic of Korea | 2016 |
[Subgroup Analysis of the Non-interventional REASON Study: PFS and OS According to Age, Smoking History, Gender, and Histology in NSCLC Patients Treated with Gefitinib or Chemotherapy].
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Prevalence; Quinazolines; Risk Factors; Sex Distribution; Smoking; Survival Analysis; Treatment Outcome | 2016 |
Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; Disease-Free Survival; DNA; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2016 |
Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pemetrexed; Proportional Hazards Models; Quinazolines; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2017 |
Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoadjuvant Therapy; Pilot Projects; Quinazolines; Tomography, X-Ray Computed | 2016 |
Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prevalence; Quinazolines; Risk Factors; Russia; Treatment Outcome | 2016 |
Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Prognosis; Quinazolines; Treatment Outcome | 2016 |
Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2016 |
A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2017 |
A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Quinazolines | 2016 |
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Treatment Outcome; Tumor Burden | 2017 |
A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Quinazolines | 2017 |
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gene Order; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Treatment Outcome | 2017 |
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Chemical Analysis; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Quinazolines | 2017 |
A Multicenter Double-blind Phase II Study of Metformin With Gefitinib as First-line Therapy of Locally Advanced Non-Small-cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Double-Blind Method; Female; Gefitinib; Humans; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Quinazolines; Research Design; Survival Analysis; Young Adult | 2017 |
A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Survival Analysis; Treatment Outcome | 2017 |
Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Retreatment; Simvastatin; Survival Analysis; Treatment Outcome | 2017 |
Efficacy and influence factors of icotinib hydrochloride in treating advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2017 |
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Smoking | 2017 |
Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).
Topics: Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Quinazolinones; Republic of Korea; Treatment Outcome | 2017 |
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Gene Deletion; Genes, erbB-1; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Quinazolines; Survival Analysis | 2008 |
A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21.
Topics: Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Ontario; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Time Factors | 2008 |
Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Erlotinib Hydrochloride; Ethnicity; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Time Factors; Treatment Outcome | 2008 |
A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Erlotinib Hydrochloride; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Quinazolines; Survival Analysis; Treatment Outcome | 2008 |
Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2008 |
An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rat
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Research Design | 2008 |
Wood-smoke exposure as a response and survival predictor in erlotinib-treated non-small cell lung cancer patients: an open label phase II study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Environmental Exposure; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Particulate Matter; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Smoke; Survival Rate; Wood | 2008 |
[Efficacy and safety of gefitinib in maintenance therapy for patients with advanced non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Exanthema; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Remission Induction; Smoking; Survival Rate | 2008 |
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate; Taxoids | 2008 |
Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Quinazolines; Survival Analysis; Taxoids | 2008 |
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Survival Analysis; Vinblastine; Vinorelbine | 2008 |
A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Health Surveys; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quinazolines | 2008 |
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Italy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prospective Studies; Quinazolines; Treatment Outcome | 2009 |
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Survival Analysis; Taxoids | 2008 |
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quinazolines; Smoking; Treatment Outcome | 2009 |
Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Dosage; Germany; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate; Treatment Outcome | 2008 |
An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Piperidines; Quinazolines | 2009 |
Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines | 2009 |
A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National C
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Treatment Outcome | 2009 |
Our experiences with erlotinib in second and third line treatment patients with advanced stage IIIB/ IV non-small cell lung cancer.
Topics: Aged; Bosnia and Herzegovina; Carcinoma, Non-Small-Cell Lung; Drug Tolerance; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Salvage Therapy | 2008 |
Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Smoking | 2009 |
A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2009 |
Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Docetaxel; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Surveys and Questionnaires; Taxoids; Treatment Outcome | 2009 |
Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Dose Fractionation, Radiation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2009 |
Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines | 2009 |
Erlotinib in advanced non-small-cell lung cancer after gefitinib failure.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Failure; Treatment Outcome | 2009 |
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Piperidines; Quinazolines | 2009 |
Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pleural Effusion, Malignant; Prognosis; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate; Treatment Outcome | 2009 |
Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Asian People; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; DNA; DNA, Neoplasm; ErbB Receptors; Exons; Feasibility Studies; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Odds Ratio; Patient Selection; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Risk Assessment; Time Factors; Treatment Outcome | 2009 |
Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2009 |
IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Disease Progression; DNA Mutational Analysis; DNA-Binding Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Transcription Factors | 2010 |
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Transforming Growth Factor alpha; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Treatment Failure | 2010 |
Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2009 |
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines | 2009 |
Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Quinazolines | 2009 |
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Response to gefitinib and erlotinib in Non-small cell lung cancer: a restrospective study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; STAT3 Transcription Factor | 2009 |
Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2010 |
Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Preoperative Period; Protein Kinase Inhibitors; Quinazolines | 2009 |
EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Treatment Outcome | 2009 |
A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Quinazolines | 2010 |
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cytokines; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Taxoids | 2010 |
A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Gefitinib; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Rate; Taxoids | 2010 |
Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Analysis | 2010 |
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Neoplasm Recurrence, Local; Precision Medicine; Predictive Value of Tests; Proteome; Quinazolines | 2010 |
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Logistic Models; Lung Neoplasms; Male; Mutation; Odds Ratio; Patient Selection; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Risk Assessment; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2010 |
Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (W
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Selection; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Risk Assessment; Time Factors; Treatment Outcome | 2010 |
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Quinazolines; Time Factors | 2011 |
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Prognosis; Quinazolines | 2010 |
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Dasatinib; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Fibroblast Growth Factor 2; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; Vascular Endothelial Growth Factor A | 2010 |
Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Quinazolines; Retreatment; Taxoids; Time Factors | 2010 |
Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Survival; Treatment Outcome | 2011 |
[Clinical observation of gefitinib for the treatment of 125 cases with advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Disease-Free Survival; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Rate | 2010 |
Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome; Young Adult | 2010 |
[Effectiveness of gefitinib (Iressa) as first-line therapy for inoperable non-small-cell lung cancer with mutated EGFR gene (phase II study)].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Eruptions; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Quinazolines; ras Proteins; Sorafenib; Vascular Endothelial Growth Factors | 2010 |
Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Taxoids | 2010 |
Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Protein Kinase Inhibitors; Pulmonary Surfactant-Associated Protein A; Pulmonary Surfactant-Associated Protein D; Quinazolines; Treatment Outcome | 2011 |
[Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Smoking; Survival Rate | 2010 |
[Efficacy and safety of Erlotinib in the treatment for advanced non-small cell lung cancer in Chinese patients].
Topics: Asian People; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate | 2010 |
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Placebos; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
Topics: Adenocarcinoma; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2011 |
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate; Time Factors; Tissue Distribution; Treatment Outcome | 2010 |
[Efficacy and safety of erlotinib as monotherapy for advanced non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Quinazolines; Regression Analysis; Retrospective Studies; Treatment Outcome | 2010 |
Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V-15-32) in advanced non-small cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2010 |
The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tandem Mass Spectrometry; Treatment Outcome | 2011 |
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2010 |
Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Sex Factors; Smoking; Treatment Outcome | 2010 |
A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Gefitinib; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Pilot Projects; Prognosis; Quinazolines; Sensitivity and Specificity; Tomography, X-Ray Computed; Tumor Burden | 2010 |
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; National Cancer Institute (U.S.); Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; United States | 2010 |
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Proportional Hazards Models; Quinazolines; Survival Analysis; Taxoids | 2010 |
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2010 |
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Dendrites; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Skin | 2010 |
Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Contrast Media; Erlotinib Hydrochloride; Female; Humans; Iohexol; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Radiographic Image Enhancement; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Feasibility Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2011 |
Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate; Treatment Outcome | 2010 |
A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Piperidines; Quinazolines; Survival Rate; Tissue Distribution; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiotherapy; ras Proteins; Survival Rate; Treatment Outcome | 2010 |
First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Tomography, Emission-Computed; Treatment Outcome | 2011 |
[Clinical investigation of efficacy of pemetrexed in 32 patients with pulmonary adenocarcinoma after failure to chemotherapy and gefitinib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quinazolines; Survival Rate; Treatment Failure; Treatment Outcome | 2010 |
Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer?
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Quinazolines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; International Agencies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2010 |
Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Sex Characteristics; Survival Rate; Treatment Outcome | 2011 |
Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Cohort Studies; ErbB Receptors; Everolimus; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Salvage Therapy; Sirolimus; Survival Rate; Treatment Outcome | 2010 |
Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines; Sex Factors; Smoking; Tumor Stem Cell Assay | 2010 |
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Patient Selection; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Research Design; Southwestern United States; Treatment Outcome | 2010 |
Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Selection; Prostaglandins; Pyrroles; Quinazolines; Sulfonamides | 2011 |
The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Quinazolines | 2010 |
Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Folliculitis; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Proto-Oncogene Proteins p21(ras); Quinazolines; Treatment Outcome | 2011 |
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; United States; United States Food and Drug Administration | 2010 |
Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.
Topics: Biological Transport; Blood Glucose; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Erlotinib Hydrochloride; Feasibility Studies; Fluorodeoxyglucose F18; Guideline Adherence; Humans; Internationality; Lung Neoplasms; Positron-Emission Tomography; Quality Control; Quinazolines; Treatment Outcome | 2011 |
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Heptanoic Acids; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Protein-Tyrosine Kinases; Pyrazoles; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4; Signal Transduction; Treatment Outcome | 2011 |
[Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pemetrexed; Platinum; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Salvage Therapy; Taxoids; Treatment Failure | 2010 |
Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Heart Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2011 |
Treatment, rationale, and study design of TALISMAN study: a randomized phase II open-label study of second-line erlotinib versus intermittent erlotinib dosing with docetaxel in the treatment of former-smoker men affected by recurrent squamous non-small-ce
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Recurrence; Research Design; Smoking; Taxoids | 2011 |
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Australia; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Mexico; Middle Aged; Pemetrexed; Piperidines; Proportional Hazards Models; Quinazolines; Risk Assessment; Risk Factors; South Africa; Time Factors; Treatment Outcome | 2011 |
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Europe; Female; Humans; Lung Neoplasms; Male; Middle Aged; North America; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2011 |
Exploring therapeutic decisions in elderly patients with non-small cell lung cancer: results and conclusions from North Central Cancer Treatment Group Study N0222.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Paclitaxel; Patient Selection; Practice Patterns, Physicians'; Quinazolines; Surveys and Questionnaires; Survival Analysis; Time Factors; Treatment Outcome; United States | 2011 |
Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Survival Analysis; Thymidine | 2011 |
Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Simvastatin; Treatment Outcome | 2011 |
A phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Salvage Therapy; Taiwan; Tegafur; Treatment Failure; Uracil | 2011 |
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Prognosis; Quinazolines | 2011 |
Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum Compounds; Quinazolines | 2011 |
Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance; Female; Gefitinib; Genes, erbB-1; Hepatocyte Growth Factor; Humans; Insulin-Like Growth Factor Binding Protein 3; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Quinazolines; Risk Factors; Sex Factors; Smoking; Survival Analysis; Treatment Outcome | 2011 |
Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2010 |
Intermittent chemotherapy and erlotinib for nonsmokers or light smokers with advanced adenocarcinoma of the lung: a phase II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Demography; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Quinazolines; Radiography; Radionuclide Imaging; Smoking; Time Factors; Treatment Outcome | 2011 |
Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mu
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Genes, ras; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Research Design; Survival Rate; Taxoids; Treatment Outcome | 2011 |
The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Catalytic Domain; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome; Tyrosine | 2011 |
Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST).
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Japan; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Research Design; Salvage Therapy; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2011 |
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Erlotinib Hydrochloride; Female; Gastrointestinal Diseases; Genes, erbB-1; Genes, ras; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Quinazolines; Salvage Therapy; Sorafenib; Treatment Outcome | 2011 |
Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Amphiregulin; Antineoplastic Agents; Biomarkers, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; EGF Family of Proteins; ErbB Receptors; Female; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; MAP Kinase Signaling System; Middle Aged; Mutation; Neoplasm Proteins; Quinazolines; Receptor, IGF Type 1; Transcription Factors; Treatment Outcome; Tumor Cells, Cultured | 2011 |
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Vascular Endothelial Growth Factor A | 2011 |
Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pyrroles; Quinazolines; Sunitinib; Survival Rate; Treatment Outcome | 2011 |
Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; Treatment Outcome | 2011 |
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cyclin D1; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoblotting; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice, Transgenic; Middle Aged; Mouth Mucosa; Mutation; Necrosis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Salvage Therapy; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 2011 |
[Role of erlotinib 100 mg/d in the treatment of advanced adenocarcinoma lung cancer failed to previous chemotherapy].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2011 |
Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell-Free System; DNA; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Smoking; Treatment Outcome | 2011 |
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; DNA, Neoplasm; Dose-Response Relationship, Drug; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines | 2012 |
Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rat
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glutamates; Guanine; Humans; International Agencies; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Platinum; Quality of Life; Quinazolines; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2011 |
Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: West Japan Thoracic Oncology Group Study 0402.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Agents; Diarrhea; Disease-Free Survival; Drug Eruptions; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Smoking; Treatment Outcome | 2011 |
A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Longitudinal Studies; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Placebos; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines; Receptors, Growth Factor; Survival Analysis | 2011 |
Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion.
Topics: Aged; Aged, 80 and over; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2011 |
Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Lung Neoplasms; Male; Middle Aged; Prostatic Neoplasms; PTEN Phosphohydrolase; Quinazolines; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Deletion; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2011 |
Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cetuximab; Cost-Benefit Analysis; ErbB Receptors; Gefitinib; Genetic Testing; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Pemetrexed; Pharmacogenetics; Quality-Adjusted Life Years; Quinazolines; Singapore; Treatment Outcome | 2012 |
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Double-Blind Method; Early Termination of Clinical Trials; ErbB Receptors; Europe; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Cadherins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Analysis; Vimentin | 2011 |
Effect of gefitinib challenge to initial treatment with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Remission Induction; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2011 |
Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mucositis; Neutropenia; Quinazolines; Taxoids | 2011 |
Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.
Topics: Acrylic Resins; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; False Negative Reactions; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Polyvinyls; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Quinazolines; Treatment Outcome | 2011 |
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFP
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Quinazolines; Taxoids | 2011 |
Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines; Treatment Outcome | 2011 |
Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Guidelines as Topic; Health Care Costs; Humans; Lung Neoplasms; Models, Economic; Platinum; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome; United Kingdom | 2011 |
Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA, Neoplasm; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Polymorphism, Genetic; Predictive Value of Tests; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sequence Analysis, DNA | 2011 |
A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2012 |
Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Treatment Outcome | 2011 |
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Azabicyclo Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2012 |
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Placebos; Quinazolines; Receptor, IGF Type 1 | 2011 |
(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Topics: Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Time Factors; Treatment Outcome | 2011 |
Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Brief Psychiatric Rating Scale; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cognition; Cranial Irradiation; Dacarbazine; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Outcome Assessment, Health Care; Quality of Life; Quinazolines; Survival Analysis; Temozolomide | 2012 |
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Survival Rate | 2012 |
Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Ki-67 Antigen; Lung Neoplasms; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2012 |
Cryoablation combined with molecular target therapy improves the curative effect in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cryosurgery; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Quinazolines; Treatment Outcome | 2011 |
A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Phenotype; Positron-Emission Tomography; Quinazolines; Time Factors; Tomography, Emission-Computed; Treatment Outcome | 2012 |
Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Quality of Life; Quinazolines; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pharmacogenetics; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines | 2012 |
A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; Retrospective Studies; Treatment Outcome | 2012 |
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Docetaxel; Early Termination of Clinical Trials; ErbB Receptors; Erlotinib Hydrochloride; Europe; Female; Glutamates; Guanine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome | 2012 |
A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2012 |
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Europe; Exons; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Patient Selection; Precision Medicine; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Treatment Outcome | 2012 |
Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retreatment; Sequence Deletion; Treatment Outcome | 2012 |
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2012 |
Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Feasibility Studies; Female; Gefitinib; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Compliance; Pneumonia; Quinazolines; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Treatment Failure | 2012 |
Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Smoking; Treatment Outcome | 2012 |
Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Retreatment; Salvage Therapy; Survival Rate; Treatment Outcome | 2012 |
A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Geriatric Assessment; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Treatment Outcome | 2012 |
18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value.
Topics: Biological Transport; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Likelihood Functions; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Quinazolines; Survival Analysis; Time Factors | 2012 |
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines; Research Design; Salvage Therapy; Survival Rate | 2012 |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.
Topics: Adenocarcinoma; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2012 |
Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2012 |
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA, Neoplasm; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Female; Genotype; Humans; Lung Neoplasms; Male; Mutation; Neoplastic Cells, Circulating; Positron-Emission Tomography; Quinazolines | 2012 |
Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Analysis; Treatment Outcome | 2012 |
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Male; Middle Aged; Pyridines; Quinazolines | 2012 |
Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quinazolines; Treatment Outcome | 2012 |
Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminopterin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Folic Acid Antagonists; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Failure; United States | 2012 |
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Placebos; Quinazolines; Smoking | 2012 |
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Placebos; Proportional Hazards Models; Pyrroles; Quinazolines; Smoking; Sunitinib; Treatment Outcome | 2012 |
Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Endpoint Determination; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Quality of Life; Quinazolines; Treatment Outcome | 2012 |
Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines | 2012 |
A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Treatment Outcome | 2012 |
[Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Stomatitis; Treatment Outcome | 2012 |
Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2012 |
Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Follow-Up Studies; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Pemetrexed; Prognosis; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Point Mutation; Quinazolines; Sequence Deletion; Treatment Outcome | 2012 |
Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505).
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Costs and Cost Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Frail Elderly; Humans; Lung Neoplasms; Male; Prospective Studies; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines | 2013 |
A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Early Termination of Clinical Trials; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2012 |
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Azabicyclo Compounds; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, ErbB-2; Survival Rate; Tissue Distribution | 2012 |
Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrroles; Quinazolines; Sunitinib; Survival Rate; Tissue Distribution | 2012 |
Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2012 |
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins | 2012 |
Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors.
Topics: Algorithms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Proteomics; Quinazolines; Serum Amyloid A Protein; Survival Rate | 2012 |
Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Early Detection of Cancer; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Prospective Studies; Quinazolines; Treatment Outcome; Young Adult | 2012 |
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2012 |
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Chromatography, High Pressure Liquid; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Quinazolines; Tandem Mass Spectrometry; Treatment Outcome | 2012 |
Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quinazolines; Risk Factors; Treatment Outcome | 2012 |
A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Risk Factors; Treatment Outcome | 2012 |
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Erlotinib Hydrochloride; France; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms; Monte Carlo Method; Multivariate Analysis; Prospective Studies; Quinazolines; Taxoids | 2012 |
First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Feasibility Studies; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate | 2012 |
Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; China; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Quality of Life; Quinazolines | 2012 |
Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Australia; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2012 |
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Topics: Adenocarcinoma, Follicular; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Papillary; Diarrhea; Disease-Free Survival; Double-Blind Method; Electrocardiography; ErbB Receptors; Female; Heart Conduction System; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Survival Analysis; Thyroid Cancer, Papillary; Thyroid Neoplasms; Young Adult | 2012 |
Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Paclitaxel; Quinazolines; Survival Analysis | 2013 |
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Erlotinib Hydrochloride; Everolimus; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Sirolimus; Tissue Distribution | 2012 |
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; Quinazolines; ras Proteins; Treatment Outcome | 2012 |
Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Quinazolines; Treatment Outcome | 2012 |
Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Esophagitis; Esophagus; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Radiotherapy, Conformal; Remission Induction; Tracheoesophageal Fistula; Treatment Failure | 2012 |
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Rate; Tetrahydronaphthalenes | 2012 |
Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.
Topics: Adenocarcinoma; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate | 2012 |
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Po
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Research Design; Survival Analysis | 2012 |
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2012 |
Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2013 |
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Research Design; Salvage Therapy; Surveys and Questionnaires | 2012 |
Efficacy vs. effectiveness: erlotinib in previously treated non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Young Adult | 2013 |
Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatigue; Female; Gefitinib; Glutamates; Guanine; Humans; Infections; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2013 |
Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radiosurgery; Treatment Outcome | 2014 |
A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Dyspnea; Fatigue; Female; Gemcitabine; Humans; Hypothyroidism; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Proportional Hazards Models; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Stomatitis; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Skin Diseases; Treatment Outcome | 2013 |
[Therapeutic effect of erlotinib in elderly patients with advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines | 2012 |
A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Proteins; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Proteomics; Quinazolines; Survival Analysis | 2013 |
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; Drug Eruptions; Emollients; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymecycline; Male; Middle Aged; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Skin; Sunscreening Agents; Treatment Outcome | 2013 |
[Prospective study on surface-enhanced laser desorption/ionization protein fingerprinting for diagnosing gene polymorphism leading to drug resistance drift: sequential therapy with a platinum-based regimen and gefitinib for non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Genetic; Prospective Studies; Proteomics; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome | 2013 |
Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Fatigue; Female; Follow-Up Studies; Gefitinib; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pain; Prognosis; Quality of Life; Quinazolines; Salvage Therapy | 2013 |
Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Quinazolines; Tegafur | 2013 |
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cranial Irradiation; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines; Treatment Outcome | 2013 |
A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Predictive Value of Tests; Proteomics; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Radiotherapy Dosage; Temozolomide | 2013 |
OSI Pharmaceuticals, Genentech and Roche announce data from clinical studies of Tarceva.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2001 |
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Skin Diseases | 2002 |
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Prostatic Neoplasms; Quinazolines; Skin; Treatment Outcome | 2002 |
Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic | 2003 |
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Epidermal Growth Factor; Female; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Survival Rate; Treatment Outcome | 2003 |
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Protein-Tyrosine Kinases; Quinazolines; Survival Rate; United States | 2003 |
ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Salvage Therapy; Treatment Outcome | 2003 |
Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease Progression; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Preoperative Care; Probability; Prognosis; Prospective Studies; Quinazolines; Receptor, ErbB-2; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2003 |
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC).
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.
Topics: Administration, Oral; Adolescent; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Approval; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Probability; Quinazolines; Reference Values; Survival Analysis; Tablets; Treatment Outcome; United States; United States Food and Drug Administration | 2003 |
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radiography; Survival Analysis; Treatment Outcome | 2003 |
Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Frail Elderly; Gefitinib; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2003 |
Adjuvant systemic therapies in early-stage non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoprevention; Chemotherapy, Adjuvant; Drug Resistance; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant; Selenium; Survival Analysis | 2003 |
Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC).
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Skin Diseases | 2004 |
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Probability; Prognosis; Quinazolines; Reference Values; Survival Analysis; Treatment Outcome | 2004 |
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Quinazolines; Reference Values; Risk Assessment; Survival Analysis; Treatment Outcome | 2004 |
Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Epidermal Growth Factor; Female; Gefitinib; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Sex Factors; Survival Analysis | 2004 |
Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Analysis | 2004 |
[Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Rate | 2004 |
Acute lung injury as an adverse event of gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Respiratory Distress Syndrome | 2004 |
Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Sex Factors; Smoking; Survival Analysis | 2004 |
Severe myelotoxicity in a combination of gefitinib and vinorelbine.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pilot Projects; Quinazolines; Thrombocytopenia; Vinblastine; Vinorelbine | 2004 |
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial.
Topics: Adult; Aged; Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Radiography; Skin Diseases; Survival Analysis; Treatment Outcome | 2004 |
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Enzyme Inhibitors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasm Staging; Phosphorylation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Survival Analysis; Treatment Outcome | 2004 |
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Analysis; Treatment Outcome | 2004 |
Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
Topics: Acne Vulgaris; Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Remission Induction; Stomatitis; Treatment Outcome | 2004 |
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate; Thiophenes; Thymidylate Synthase; Treatment Outcome | 2004 |
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Quinazolines; Survival Analysis | 2005 |
Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Sex Factors | 2004 |
Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Female; Head and Neck Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Salvage Therapy; Stomach Neoplasms; Thiophenes | 2005 |
Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2005 |
Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis; Treatment Outcome | 2004 |
Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Double-Blind Method; Endpoint Determination; Female; Gefitinib; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Sensitivity and Specificity; Survival Analysis | 2005 |
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Quinazolines; Sensitivity and Specificity; Sequence Analysis, DNA; Signal Transduction; Survival Analysis | 2005 |
Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Predictive Value of Tests; Probability; Prognosis; Prospective Studies; Quinazolines; Risk Assessment; Salvage Therapy; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2005 |
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
Topics: Adult; Aged; Amino Acid Sequence; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Neoplasm Recurrence, Local; Point Mutation; Predictive Value of Tests; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; RNA; Sensitivity and Specificity; Sex Factors; Survival Analysis | 2005 |
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung canc
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease Progression; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Skin Diseases; Smoking; Survival Analysis; Treatment Outcome | 2005 |
Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the 'Iressa' expanded access program.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quinazolines; Risk Assessment; Risk Factors; Survival Analysis; Terminal Care; Treatment Outcome | 2005 |
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Research Design; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Survival Analysis | 2005 |
Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Sex Factors; Smoking; Testosterone | 2005 |
Non-small-cell lung cancer patients unsuitable for first-line chemotherapy: a new category of patients for clinical studies?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patient Selection; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Quinazolines; Survival Analysis; Taxoids | 2005 |
Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Dyspnea; Female; Follow-Up Studies; Gefitinib; Health Status; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Quinazolines; Respiratory Function Tests; Retrospective Studies; Sex Factors; Survival Analysis; Treatment Outcome | 2005 |
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Dosage; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Erlotinib in previously treated non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Analysis | 2005 |
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Predictive Value of Tests; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
FDA drug approval summary: erlotinib (Tarceva) tablets.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Double-Blind Method; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Salvage Therapy; Survival Rate; Treatment Outcome; United States; United States Food and Drug Administration | 2005 |
[Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pruritus; Quinazolines; Survival Rate | 2005 |
Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Smoking; Survival Analysis | 2005 |
Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: results from a prospective feasibility study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Contraindications; Cystitis; Feasibility Studies; Female; Gastrointestinal Diseases; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Pneumonia; Quinazolines; Vomiting | 2005 |
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Topics: Adolescent; Adult; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Analysis; Treatment Failure; Treatment Outcome; United States; United States Food and Drug Administration | 2005 |
Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Psychomotor Performance; Quality of Life; Quinazolines; Treatment Outcome | 2005 |
Impact of gefitinib ('Iressa') treatment on the quality of life of patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Constipation; Disease Progression; Dyspnea; Fatigue; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires; Survival Analysis; Treatment Outcome | 2005 |
A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cost of Illness; ErbB Receptors; Erlotinib Hydrochloride; Fees, Pharmaceutical; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Compliance; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2006 |
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Survival Rate | 2005 |
Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Postoperative Complications; Postoperative Period; Quinazolines | 2005 |
Gefitinib affects functions of platelets and blood vessels via changes in prostanoids balance.
Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Blood Vessels; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Platelet Aggregation; Prostaglandins; Quinazolines | 2005 |
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.
Topics: Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Clinical Trials as Topic; Cluster Analysis; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Gene Deletion; Gene Expression Regulation, Neoplastic; Genome; Glioma; Humans; Lung Neoplasms; Models, Biological; Mutation; Nucleic Acid Hybridization; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Time Factors | 2005 |
Bexarotene and erlotinib for aerodigestive tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cyclin D1; Digestive System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 2005 |
EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib.
Topics: Administration, Oral; Aminoquinolines; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Organic Chemicals; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Radiography, Thoracic; Tomography, X-Ray Computed | 2006 |
Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan: a prospective phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Taiwan; Treatment Failure | 2005 |
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2006 |
Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Survival Rate; Treatment Outcome | 2006 |
Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Taxoids | 2006 |
Aspirin reduces adverse effects of gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Quinazolines; Thromboxane B2 | 2006 |
A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Fatigue; Female; Gefitinib; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Salvage Therapy; Survival Rate; Tegafur | 2006 |
Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Smoking; Survival; Treatment Outcome; Up-Regulation | 2006 |
Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Survival Analysis; Treatment Outcome | 2006 |
A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Survival Rate; Taxoids | 2006 |
A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Time Factors; Treatment Outcome | 2006 |
Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2006 |
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cohort Studies; Cyclooxygenase 2; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Pyrazoles; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Treatment Outcome | 2006 |
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Arginine; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Glutamic Acid; Humans; Leucine; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Quinazolines; Treatment Outcome | 2006 |
Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Health Services Accessibility; Humans; Lung Neoplasms; Male; Middle Aged; Outcome Assessment, Health Care; Quinazolines; Retrospective Studies; Time Factors; Treatment Outcome | 2006 |
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21.
Topics: Aged; Canada; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Smoking; Survival Analysis | 2006 |
Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2006 |
Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Point Mutation; Predictive Value of Tests; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Deletion; Survival Rate; Treatment Outcome | 2006 |
A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2006 |
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.
Topics: Adult; Aged; Algorithms; Analysis of Variance; Area Under Curve; Biotransformation; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasms; Population; Protein Kinases; Quinazolines | 2006 |
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Topics: Adult; Aged; Antineoplastic Agents; Canada; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Pain; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Surveys and Questionnaires; Survival Analysis; Treatment Outcome | 2006 |
Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate | 2006 |
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pruritus; Quinazolines; Treatment Outcome | 2006 |
Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Smoking; Survival Analysis; Taxoids | 2007 |
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; DNA Primers; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; In Situ Hybridization; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Tablets | 2006 |
Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines | 2007 |
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphorylation; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Analysis; Treatment Outcome | 2006 |
Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Peptide Nucleic Acids; Polymerase Chain Reaction; Prognosis; Quinazolines; Survival Analysis | 2006 |
[Gefitinib in the treatment of advanced non-small-cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Quinazolines; Remission Induction; Survival Analysis | 2006 |
Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Patient Selection; Quinazolines; Survival Analysis | 2006 |
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2007 |
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA, Neoplasm; Drug Administration Schedule; ErbB Receptors; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prospective Studies; Quinazolines; Severity of Illness Index; Treatment Outcome | 2007 |
Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Diarrhea; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Homozygote; Humans; Introns; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Polymorphism, Genetic; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Treatment Outcome | 2008 |
Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Confidence Intervals; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Platinum; Probability; Pyrazoles; Quinazolines; Risk Assessment; Sulfonamides; Survival Analysis | 2007 |
EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA; ErbB Receptors; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines | 2006 |
Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Vinblastine; Vinorelbine | 2006 |
Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2006 |
Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Niacinamide; Pemetrexed; Phenylurea Compounds; Piperidines; Probability; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; Korea; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Probability; Prognosis; Proportional Hazards Models; Prospective Studies; Quality of Life; Quinazolines; Risk Assessment; Single-Blind Method; Smoking; Survival Rate; Treatment Outcome | 2006 |
Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Mutation, Missense; Patient Selection; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2007 |
[Efficacy of gefitinib on advanced non-small cell lung cancer of bilateral diffuse or unilateral giant mass type].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Disease-Free Survival; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pruritus; Quality of Life; Quinazolines; Remission Induction | 2007 |
Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quality of Life; Quinazolines; Survival Analysis | 2007 |
Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quinazolines; Vinblastine; Vinorelbine | 2007 |
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Probability; Prognosis; Quinazolines; Risk Assessment; Statistics, Nonparametric; Survival Analysis | 2007 |
[Gefitinib target treatment in non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Rate | 2007 |
Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib | 2007 |
Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.
Topics: Adult; Aged; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Half-Life; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasms; Quinazolines | 2008 |
Association of epidermal growth factor receptor mutations in lung cancer with chemosensitivity to gefitinib in isolated cancer cells from Japanese patients.
Topics: Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Tumor Cells, Cultured | 2007 |
Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphorylation; Prospective Studies; Proto-Oncogene Proteins c-akt; Quinazolines; Smoking | 2007 |
Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2007 |
A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate | 2007 |
[Safety and efficacy of gefitinib for treatment of advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Disease Progression; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Remission Induction; Sex Factors; Treatment Outcome | 2007 |
Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2007 |
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Everolimus; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Sirolimus; Survival Rate; United States | 2007 |
The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Microsatellite Repeats; Middle Aged; Mutation; Polymorphism, Genetic; Quinazolines; Treatment Outcome | 2007 |
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2007 |
Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Gefitinib; Humans; Lactones; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Proteomics; Quinazolines; Sulfones; Survival Rate; Treatment Outcome | 2007 |
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Placebos; Quinazolines; Taxoids | 2007 |
Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20.
Topics: Adult; Aged; Carcinoma, Small Cell; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Placebos; Quality of Life; Quinazolines; Treatment Outcome | 2007 |
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Organoplatinum Compounds; Quinazolines | 2008 |
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; Quinazolines; Radiography; ras Proteins; Risk Assessment; Risk Factors; Smoking; Surveys and Questionnaires; Switzerland; Treatment Outcome | 2008 |
Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer.
Topics: Antibodies, Monoclonal; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Placebos; Predictive Value of Tests; Quinazolines | 2008 |
Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Quinazolines; Treatment Outcome | 2008 |
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Paclitaxel; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Surveys and Questionnaires | 2008 |
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines | 2008 |
Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Comorbidity; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Taxoids | 2008 |
Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Celecoxib; Chemokines, CC; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Macrophage Inflammatory Proteins; Matrix Metalloproteinase 9; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Sulfonamides; Tissue Inhibitor of Metalloproteinase-1 | 2008 |
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small ce
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Contraindications; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin G; Immunohistochemistry; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA; Treatment Outcome | 2008 |
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Suppressor of Cytokine Signaling Proteins; Treatment Outcome | 2008 |
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Etoposide; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Taxoids | 2008 |
Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Celecoxib; Disease-Free Survival; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrazoles; Quinazolines; Sulfonamides; Survival Rate | 2008 |
Clinical experience with gefitinib in Indian patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Humans; India; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2008 |
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; ErbB Receptors; Female; Humans; Japan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Recurrence, Local; Piperidines; Prognosis; Quinazolines | 2008 |
Second-line treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2008 |
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastrointestinal Hemorrhage; Humans; Immunohistochemistry; In Situ Hybridization; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mutation; Peptic Ulcer; Predictive Value of Tests; Pyrazoles; Quinazolines; Sulfonamides | 2008 |
[Erlotinib in non-small cell lung cancer: experience of clinical hospital for lung diseases Jordanovac].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2007 |
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institut
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Salvage Therapy; Sex Factors; Smoking; Taiwan | 2008 |
Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Ethnicity; Female; Humans; In Vitro Techniques; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Sex Factors; Smoking; Survival Analysis | 2008 |
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Retrospective Studies | 2008 |
[Gefitinib in the treatment of refractory non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Quality of Life; Quinazolines; Remission Induction; Survival Rate | 2007 |
[Gefitinib in the treatment of advanced non-small cell lung cancer with brain metastasis].
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Survival Rate | 2007 |
Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Small Cell; Disease Progression; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Rate; Thiophenes; Thymidylate Synthase; Treatment Outcome | 1997 |
[Phase I study of raltitrexed (ZD-1694)].
Topics: Adult; Aged; Alanine Transaminase; Anorexia; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Colonic Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Quinazolines; Thiophenes; Thymidylate Synthase | 1998 |
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Peritoneal Neoplasms; Quinazolines; Salvage Therapy; Secondary Prevention; Thiophenes; Treatment Outcome | 2002 |
Phase I dose-escalating study of raltitrexed ('Tomudex') and cisplatin in metastatic non-small cell lung cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Quinazolines; Thiophenes; Thrombocytopenia | 2002 |
[Phase I study of CI-898. CI-898 Study Group].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Digestive System Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Quinazolines; Trimetrexate | 1991 |
2909 other study(ies) available for quinazolines and Lung Neoplasms
| Article | Year |
|---|---|
Quinazoline-tethered hydrazone: A versatile scaffold toward dual anti-TB and EGFR inhibition activities in NSCLC.
Topics: A549 Cells; Antineoplastic Agents; Antitubercular Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Fibroblasts; Humans; Hydrazones; Lung Neoplasms; Models, Molecular; Mycobacterium tuberculosis; Quinazolines; Structure-Activity Relationship; Tuberculosis | 2021 |
A novel EGFR inhibitor suppresses survivin expression and tumor growth in human gefitinib-resistant EGFR-wild type and -T790M non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Piperazines; Protein-Tyrosine Kinases; Quinazolines; Small Cell Lung Carcinoma; Survivin; Xenograft Model Antitumor Assays | 2021 |
A multidimensional biosensor system to guide LUAD individualized treatment.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biosensing Techniques; Biphenyl Compounds; Cell Culture Techniques; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Lignans; Lung Neoplasms; Male; Mice; Mice, Nude; Piperidines; Precision Medicine; Quinazolines; Tumor Cells, Cultured | 2021 |
EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition.
Topics: Animals; Antineoplastic Agents; Benzamides; Biphenyl Compounds; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Humans; Lung Neoplasms; Mice; Morpholines; Mutation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridones; Pyrimidines; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2022 |
Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Crown Ethers; Dose-Response Relationship, Drug; ErbB Receptors; Exons; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2021 |
Chemical Enhancement Effect of Icotinib-Au Complex Studied by Combined Density Functional Theory and Surface-Enhanced Raman Scattering.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; Density Functional Theory; Gold; Humans; Lung Neoplasms; Metal Nanoparticles; Quinazolines; Spectrum Analysis, Raman | 2021 |
Rhabdomyolysis Caused by Gefitinib Overdose.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Rhabdomyolysis | 2022 |
Selective therapeutic benefit of X-rays and inhibitors of EGFR, PI3K/mTOR, and Bcl-2 in breast, lung, and cervical cancer cells.
Topics: Aniline Compounds; Breast Neoplasms; Cell Line; Cell Survival; ErbB Receptors; Female; Humans; Imidazoles; Lung Neoplasms; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Quinolines; Radiation Tolerance; Sulfonamides; TOR Serine-Threonine Kinases; Tyrphostins; Uterine Cervical Neoplasms; X-Rays | 2021 |
AZD3759 enhances radiation effects in non-small-cell lung cancer by a synergistic blockade of epidermal growth factor receptor and Janus kinase-1.
Topics: Acrylamides; Aniline Compounds; Animals; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 1; Lung Neoplasms; Mice; Mice, Nude; Piperazines; Quinazolines; Xenograft Model Antitumor Assays | 2022 |
Synergistic inhibitory effect of berberine and icotinib on non-small cell lung cancer cells via inducing autophagic cell death and apoptosis.
Topics: Animals; Apoptosis; Autophagic Cell Death; Berberine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Mice; Quinazolines; Signal Transduction | 2021 |
Combination treatment with bevacizumab plus erlotinib for meningeal carcinomatosis of afatinib-resistant EGFR mutated lung cancer without T790M mutation: a case report.
Topics: Afatinib; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Inhibitory effects of icotinib combined with antiangiogenic drugs in human non-small cell lung cancer xenograft models are better than single target drugs.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crown Ethers; Drug Therapy, Combination; Endostatins; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2022 |
Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor protein.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Boron Compounds; Cell Line, Tumor; Enhancer of Zeste Homolog 2 Protein; Gene Knockdown Techniques; Gene Knockout Techniques; Glycine; GTPase-Activating Proteins; HEK293 Cells; Heterocyclic Compounds, 3-Ring; Humans; Lung Neoplasms; Mice; Mutagenesis, Site-Directed; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein Stability; Proto-Oncogene Proteins p21(ras); Quinazolines; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2021 |
RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging.
Topics: Albumins; Amiloride; Animals; Antineoplastic Agents; Cell Line, Tumor; Dextrans; Humans; Lung Neoplasms; Mice; Mutation; Optical Imaging; Pancreatic Neoplasms; Piperazines; Proto-Oncogene Proteins p21(ras); Quinazolines | 2022 |
Successful erlotinib rechallenge in an EGFR-mutant metastatic non-small cell lung cancer patient with afatinib-induced drug rash with eosinophilia and systemic symptoms: A case report.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Eosinophilia; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Crown Ethers; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry | 2022 |
Primary Erlotinib Resistance in a Patient with Non-Small Cell Lung Cancer Carrying Simultaneous Compound EGFR L718A, Q849H, and L858R Mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Quinazolines | 2021 |
Uncovering Molecular Mechanisms of Drug Resistance via Network-Constrained Common Structure Identification.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Black phosphorus nanoparticles for dual therapy of non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Nanoparticles; Phosphorus; Protein Kinase Inhibitors; Quinazolines | 2022 |
Sulforaphane overcomes T790M-mediated gefitinib resistance in vitro through epithelial-mesenchymal transition.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Isothiocyanates; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Sulfoxides | 2021 |
Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Drugs, Investigational; Female; Humans; Lung Neoplasms; Oxazoles; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2022 |
EGFR-mutated advanced lung cancer. Data from a single institution, the Hospital of Leon, in Spain.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Hospitals; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Spain | 2023 |
Exploring binding stability of hydroxy-3-(4-hydroxyphenyl)-5-(4-nitrophenyl)-5,5a,7,8,9,9a-hexahydrothiazolo[2,3-b] quinazolin-6-one with T790M/L858R EGFR-TKD.
Topics: ErbB Receptors; Humans; Ligands; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2023 |
EGFR Inhibitor CL-387785 Suppresses the Progression of Lung Adenocarcinoma.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Quinazolines | 2023 |
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2023 |
Poziotinib-induced cutaneous adverse reactions in the treatment of non-small cell lung cancer: A case report.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2022 |
Analysis to determine the effect of mutations on binding to small chemical molecules.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quinazolines | 2022 |
Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRAS
Topics: Antineoplastic Agents; Drug Design; Humans; Lung Neoplasms; Mutation; Proto-Oncogene Proteins p21(ras); Quinazolines; Structure-Activity Relationship | 2022 |
Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Histamine H2 Antagonists; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines | 2022 |
In Silico Screening of Synthetic and Natural Compounds to Inhibit the Binding Capacity of Heavy Metal Compounds against EGFR Protein of Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Early Detection of Cancer; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Essential role for STAT3/FOXM1/ATG7 signaling-dependent autophagy in resistance to Icotinib.
Topics: Autophagy; Autophagy-Related Protein 7; Beclin-1; Cell Line, Tumor; Crown Ethers; ErbB Receptors; Forkhead Box Protein M1; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; STAT3 Transcription Factor | 2022 |
Dual-responsive nanoparticles loading bevacizumab and gefitinib for molecular targeted therapy against non-small cell lung cancer.
Topics: Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2023 |
Uncovering the Molecular Basis for the Better Gefitinib Sensitivity of EGFR with Complex Mutations over Single Rare Mutation: Insights from Molecular Simulations.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Evodiamine inhibits stemness and metastasis by altering the SOX9-β-catenin axis in non-small-cell lung cancer.
Topics: Alkaloids; Apoptosis; beta Catenin; Cadherins; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cysteine; Humans; Lung Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Reactive Oxygen Species; SOX9 Transcription Factor; Vimentin | 2022 |
Discovery of novel 4-arylamino-quinazoline derivatives as EGFR
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Lung Neoplasms; Molecular Structure; Mutation; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2022 |
Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhibitors; Hydrogen-Ion Concentration; Lung Neoplasms; Mice; Nanoparticle Drug Delivery System; Quinazolines; Quinazolinones | 2022 |
Targeted Co-Delivery of Gefitinib and Rapamycin by Aptamer-Modified Nanoparticles Overcomes EGFR-TKI Resistance in NSCLC via Promoting Autophagy.
Topics: Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Nanoparticles; Protein Kinase Inhibitors; Quinazolines; Sirolimus | 2022 |
Extracellular Vesicles from
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Vesicles; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Optimization of the 4-anilinoquin(az)oline scaffold as epidermal growth factor receptor (EGFR) inhibitors for chordoma utilizing a toxicology profiling assay platform.
Topics: Aniline Compounds; Chordoma; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HSP27 Heat-Shock Proteins; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines | 2022 |
Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Nucleotides; Polymorphism, Single Nucleotide; Quinazolines; Retrospective Studies | 2022 |
Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report.
Topics: Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Quinazolines | 2022 |
Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chlorpromazine; Drug Resistance, Neoplasm; ErbB Receptors; Everolimus; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Plasma exosomal DOK3 reflects immunological states in lung tumor and predicts prognosis of gefitinib treatment.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; CD8-Positive T-Lymphocytes; ErbB Receptors; Exosomes; Gefitinib; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Proteomics; Quinazolines | 2022 |
SH005S7 Overcomes Primary and Acquired Resistance of Non-Small Cell Lung Cancer by Combined MET/EGFR/HER3 Inhibition.
Topics: Animals; Apoptosis; Bromodeoxyuridine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Ki-67 Antigen; Lung Neoplasms; Matrix Metalloproteinase 9; Mice; Mice, Nude; Proliferating Cell Nuclear Antigen; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Tumor Necrosis Factor-alpha; Vimentin | 2022 |
Role of allogeneic natural killer T cells in the treatment of a patient with gefitinib-sensitive lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Hematopoietic Stem Cell Transplantation; Humans; Lung Neoplasms; Mutation; Natural Killer T-Cells; Protein Kinase Inhibitors; Quinazolines | 2022 |
A case of crescentic glomerulonephritis induced by afatinib for lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; ErbB Receptors; Glomerulonephritis; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Renal Dialysis | 2023 |
Gefitinib enhances the anti‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Immunity; Leukocytes, Mononuclear; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; T-Lymphocytes | 2022 |
The therapeutic inhibition of topoisomerase inhibitor and crizotinib combination in EGFR wild and mutant lung cancer cells.
Topics: Animals; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Reactive Oxygen Species; Topoisomerase Inhibitors; Topotecan | 2022 |
Down-regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; NF-E2-Related Factor 2; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species | 2022 |
Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors.
Topics: Adenosine Triphosphate; Allosteric Site; Aniline Compounds; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2022 |
Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study.
Topics: Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2023 |
Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Proof of Concept Study; Quinazolines | 2022 |
Second generation Spautin-1 analogues targeting EGFR-mutant non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Quinazolines | 2023 |
Non-small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib.
Topics: Afatinib; Aged; beta Catenin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2023 |
Computational Prediction of Resistance Induced Alanine-Mutation in ATP Site of Epidermal Growth Factor Receptor.
Topics: Adenosine Triphosphate; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Macrophage renewal modes affect acquired resistance to gefitinib in EGFR‑mutant lung cancer PC‑9 cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Macrophages; Protein Kinase Inhibitors; Quinazolines; Tumor Microenvironment | 2023 |
Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Ultrasound-mediated mesoporous silica nanoparticles loaded with PDLIM5 siRNA inhibit gefitinib resistance in NSCLC cells by attenuating EMT.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; LIM Domain Proteins; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Ultrasonography | 2023 |
Study on the hepatotoxicity and potential mechanism of gefitinib based on CYP450 in mice and AML12 cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP1A1; Drug-Related Side Effects and Adverse Reactions; Gefitinib; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Quinazolines; RNA, Messenger | 2023 |
Clinical impact of tetracyclines and/or proton pump inhibitors on the efficacy of epidermal growth factor receptor inhibitors in non-small cell lung cancer: a retrospective cohort study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies; Tetracyclines | 2023 |
[Gefitinib Monotherapy Afforded Long-Term Survival of an Octogenarian Patient with a Postoperative Recurrence of a Pulmonary Adenocarcinoma-A Case Report].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Octogenarians; Quinazolines | 2023 |
In silico target specific design of potential quinazoline-based anti-NSCLC agents.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Ligands; Lung Neoplasms; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Quinazolines | 2023 |
Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS-dependent apoptosis and ferroptosis.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Ferroptosis; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species | 2023 |
A multiparametric fluorescent visualization approach for detecting drug resistance in living cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2023 |
Identification and exploration of quinazoline-1,2,3-triazole inhibitors targeting EGFR in lung cancer.
Topics: ErbB Receptors; Humans; Ligands; Lung Neoplasms; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Kinase Inhibitors; Quinazolines | 2023 |
LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Methyltransferases; NLR Family, Pyrin Domain-Containing 3 Protein; Protein Kinase Inhibitors; Pyroptosis; Quinazolines; RNA, Long Noncoding | 2023 |
The Underlying Mechanism Involved in Gefitinib Resistance and Corresponding Experiment Validation in Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; TOR Serine-Threonine Kinases; Tumor Microenvironment | 2023 |
Pemetrexed induces ROS generation and cellular senescence by attenuating TS-mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cellular Senescence; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species | 2023 |
Poziotinib for HER2 Exon 20-Mutated NSCLC: Addition or Burden to the Therapeutic Arsenal?
Topics: Carcinoma, Non-Small-Cell Lung; Exons; Humans; Lung Neoplasms; Mutation; Quinazolines; Receptor, ErbB-2 | 2023 |
Methylseleninic acid overcomes gefitinib resistance through asparagine-MET-TOPK signaling axis in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Asparagine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2023 |
BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines | 2023 |
Coevolution-based computational approach to detect resistance mechanism of epidermal growth factor receptor.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2024 |
RAGE potentiates EGFR signaling and interferes with the anticancer effect of gefitinib on NSCLC cells.
Topics: Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Ligands; Lung Neoplasms; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor for Advanced Glycation End Products | 2023 |
Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2023 |
Targeting MET endocytosis or degradation to overcome HGF-induced gefitinib resistance in EGFR-sensitive mutant lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Endocytosis; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2023 |
Novel quinazoline-based dual EGFR/c-Met inhibitors overcoming drug resistance for the treatment of NSCLC: Design, synthesis and anti-tumor activity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; G2 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2024 |
Design, synthesis and biological evaluation of small molecule fluorescent probes targeting EGFR for tumor detection and treatment.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Fluorescent Dyes; Gefitinib; Humans; Lung Neoplasms; Mice; Neoplasms; Quinazolines | 2023 |
Design, synthesis and biological evaluation of structurally new 4-indolyl quinazoline derivatives as highly potent, selective and orally bioavailable EGFR inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2024 |
Yiqi Chutan Tang Reduces Gefitinib-Induced Drug Resistance in Non-Small-Cell Lung Cancer by Targeting Apoptosis and Autophagy.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2020 |
Primary resistance to icotinib in a patient with lung adenocarcinoma harboring EGFR L858R and Q787k mutations.
Topics: Adenocarcinoma of Lung; Aged; Amino Acid Substitution; Antineoplastic Agents; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Quinazolines; Structure-Activity Relationship; Treatment Outcome | 2019 |
Targeting an EGFR Water Network with 4-Anilinoquin(az)oline Inhibitors for Chordoma.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chordoma; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Lung Neoplasms; Models, Molecular; Molecular Targeted Therapy; Protein Binding; Protein Kinase Inhibitors; Quinazolines | 2019 |
Evaluation of EGFR-TK Expression with a
Topics: Animals; Cell Line, Tumor; Drug Stability; ErbB Receptors; Hepatobiliary Elimination; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred ICR; Quinazolines; Radiopharmaceuticals; Technetium; Tissue Distribution | 2019 |
Successful Treatment of a Miliary Metastatic NSCLC Patient With Activating EGFR Exon 20 Insertion Mutation with Response to Poziotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Quinazolines | 2019 |
Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2019 |
STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway.
Topics: Aminosalicylic Acids; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins p21(ras); Quinazolines; raf Kinases; STAT3 Transcription Factor; Sulfonamides | 2019 |
Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.
Topics: Acrylamides; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Receptor, Fibroblast Growth Factor, Type 4; Survival Analysis | 2019 |
FTIR spectra signatures reveal different cellular effects of EGFR inhibitors on nonsmall cell lung cancer cells.
Topics: A549 Cells; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Quinazolines; Spectroscopy, Fourier Transform Infrared | 2020 |
Icotinib-resistant HCC827 cells produce exosomes with mRNA MET oncogenes and mediate the migration and invasion of NSCLC.
Topics: Antineoplastic Agents, Immunological; Bronchoalveolar Lavage Fluid; Cell Line, Tumor; Cell Movement; Crown Ethers; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Exosomes; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Invasiveness; Oncogenes; Proto-Oncogene Proteins c-met; Quinazolines; RNA, Messenger | 2019 |
Sequence, Treat, Repeat: Addressing Resistance in EGFR-Mutant NSCLC.
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; ErbB Receptors; Exons; Humans; Lung Neoplasms; Mutation; Quinazolines; Quinolines | 2019 |
Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study.
Topics: Aged; Asian People; Carcinoma, Non-Small-Cell Lung; China; Circulating Tumor DNA; Crown Ethers; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2020 |
Dual inhibition of EGFR and MET by Echinatin retards cell growth and induces apoptosis of lung cancer cells sensitive or resistant to gefitinib.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chalcones; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; ErbB Receptors; Gefitinib; Glycyrrhiza; Humans; Lung Neoplasms; Molecular Docking Simulation; Plant Roots; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2020 |
Icotinib inhibits proliferation and epithelial-mesenchymal transition of non-small cell lung cancer A549 cells.
Topics: A549 Cells; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Crown Ethers; Drug Screening Assays, Antitumor; Epithelial-Mesenchymal Transition; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Neoplasm Invasiveness; Quinazolines | 2019 |
A high-throughput screen identifies that CDK7 activates glucose consumption in lung cancer cells.
Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Glucose; Glucose Transporter Type 1; High-Throughput Screening Assays; Humans; Lung Neoplasms; Phenylenediamines; Phosphorylation; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; RNA Polymerase II; RNA, Messenger; Signal Transduction; Triazines | 2019 |
Efficacy of early combination of local radiotherapy and GM-CSF for advanced non-small cell lung cancer treated with icotinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Young Adult | 2020 |
Can marine-derived fungus Neosartorya siamensis KUFA 0017 extract and its secondary metabolites enhance antitumor activity of doxorubicin? An in vitro survey unveils interactions against lung cancer cells.
Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; Doxorubicin; Humans; Indoles; Lung Neoplasms; Neosartorya; Quinazolines | 2020 |
RET-rearranged non-small-cell lung cancer and therapeutic implications.
Topics: Australia; Carcinoma, Non-Small-Cell Lung; Female; Gene Rearrangement; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Middle Aged; Mutation; Piperidines; Precision Medicine; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines | 2019 |
Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.
Topics: Carcinoma, Non-Small-Cell Lung; China; Circulating Tumor DNA; Crown Ethers; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Regulatory Networks; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Retrospective Studies; Sequence Analysis, DNA | 2020 |
Cost-effectiveness of icotinib versus whole-brain irradiation with or without chemotherapy in EGFR-mutant NSCLC patients with brain metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Cranial Irradiation; Crown Ethers; Disease Progression; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Quality of Life; Quinazolines | 2021 |
Aurora B induces epithelial-mesenchymal transition by stabilizing Snail1 to promote basal-like breast cancer metastasis.
Topics: Animals; Aurora Kinase B; Breast Neoplasms; Carcinoma, Ductal; Cell Line, Tumor; Down-Regulation; Epithelial-Mesenchymal Transition; Female; Glycogen Synthase Kinase 3 beta; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Neoplasm Invasiveness; Neoplasm Metastasis; Octamer Transcription Factor-3; Organophosphates; Phosphorylation; Protein Kinase Inhibitors; Protein Stability; Quinazolines; Signal Transduction; Snail Family Transcription Factors; Triple Negative Breast Neoplasms | 2020 |
Purpuric drug eruptions induced by EGFR tyrosine kinase inhibitors are associated with IQGAP1-mediated increase in vascular permeability.
Topics: Capillary Permeability; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Eruptions; Drug Resistance, Neoplasm; Endothelial Cells; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; ras GTPase-Activating Proteins | 2020 |
Evodiamine suppresses Notch3 signaling in lung tumorigenesis via direct binding to γ-secretases.
Topics: A549 Cells; Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Survival; Evodia; Female; Humans; Lung Neoplasms; Mice, Inbred Strains; Molecular Docking Simulation; Quinazolines; Receptor, Notch3; Signal Transduction; Urethane | 2020 |
Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gene Rearrangement; Genome, Human; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Republic of Korea; Treatment Outcome | 2020 |
Hybrids of Quinoline and Anilinopyrimidine: Novel EGFRT790M Inhibitors with Antiproliferative Activity against Non-Small Cell Lung Cancer Cell Lines.
Topics: Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Lung Neoplasms; Molecular Docking Simulation; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2020 |
Dual Loading of Nanoparticles with Doxorubicin and Icotinib for the Synergistic Suppression of Non-Small Cell Lung Cancer.
Topics: A549 Cells; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crown Ethers; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Synergism; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Nanoparticles; Quinazolines | 2020 |
Growth inhibitory role of the p53 activator SCH 529074 in non‑small cell lung cancer cells expressing mutant p53.
Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chloroquine; Dose-Response Relationship, Drug; Drug Synergism; Humans; Lung Neoplasms; Mutation; Piperazines; Quinazolines; Signal Transduction; Tumor Suppressor Protein p53 | 2020 |
Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; DNA-Activated Protein Kinase; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Pyridazines; Quinazolines; Radiation, Ionizing; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Bisdemethoxycurcumin Enhances the Sensitivity of Non-small Cell Lung Cancer Cells to Icotinib via Dual Induction of Autophagy and Apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Crown Ethers; Diarylheptanoids; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Quinazolines; Reactive Oxygen Species; Sp Transcription Factors; Voltage-Dependent Anion Channel 1 | 2020 |
Novel anilino quinazoline-based EGFR tyrosine kinase inhibitors for treatment of non-small cell lung cancer.
Topics: Aniline Compounds; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2021 |
Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Interrupted Time Series Analysis; Lung Neoplasms; Quinazolines; Taiwan | 2020 |
Reduced expression of CYLD promotes cell survival and inflammation in gefitinib-treated NSCLC PC-9 cells: Targeting CYLD may be beneficial for acquired resistance to gefitinib therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deubiquitinating Enzyme CYLD; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, Tumor Suppressor; Humans; Inflammation; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2020 |
A first case report of clinical response to targeted therapy in a patient with primary myoepithelial carcinoma of the lung harboring EGFR exon 19 deletion.
Topics: Aged; Antineoplastic Agents; Crown Ethers; Disease-Free Survival; ErbB Receptors; Exons; Gene Deletion; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Myoepithelioma; Quinazolines; Smoking | 2020 |
G9a regulates tumorigenicity and stemness through genome-wide DNA methylation reprogramming in non-small cell lung cancer.
Topics: Animals; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Forkhead Transcription Factors; Heterografts; Histone-Lysine N-Methyltransferase; Histones; Humans; Lung Neoplasms; Mice; Neoplastic Stem Cells; Quinazolines; Repressor Proteins; RNA, Small Interfering; Sequence Analysis, RNA; Up-Regulation | 2020 |
Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; GRB2 Adaptor Protein; Humans; Lung Neoplasms; Lymecycline; Male; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinase; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2020 |
Mechanistic Study of Potent Fluorinated EGFR Kinase Inhibitors with a Quinazoline Scaffold against L858R/T790M/C797S Resistance Mutation: Unveiling the Fluorine Substituent Cooperativity Effect on the Inhibitory Activity.
Topics: Drug Resistance, Neoplasm; ErbB Receptors; Fluorine; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2020 |
Combination treatment of Src inhibitor Saracatinib with GMI, a Ganoderma microsporum immunomodulatory protein, induce synthetic lethality via autophagy and apoptosis in lung cancer cells.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Autophagy-Related Protein 5; Benzodioxoles; Caspase 7; Cell Proliferation; Enzyme Inhibitors; Fungal Proteins; Ganoderma; Humans; Immunologic Factors; Lung Neoplasms; Mice; Quinazolines; src-Family Kinases; Synthetic Lethal Mutations; Xenograft Model Antitumor Assays | 2021 |
Gefitinib induced severe hyponatremia: A case report.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Hyponatremia; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2021 |
Detection of genes mutations in cerebrospinal fluid circulating tumor DNA from neoplastic meningitis patients using next generation sequencing.
Topics: Acrylamides; Adult; Aged; Aniline Compounds; Antineoplastic Agents; Circulating Tumor DNA; Class I Phosphatidylinositol 3-Kinases; Crown Ethers; DNA Copy Number Variations; Female; Genes, erbB-1; High-Throughput Nucleotide Sequencing; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Mutation Rate; Proto-Oncogene Proteins c-akt; Quinazolines; Young Adult | 2020 |
Survival analysis of afatinib versus erlotinib for individuals with advanced del19 lung adenocarcinoma with asymptomatic brain metastasis after pemetrexed-cisplatin chemotherapy: a retrospective study.
Topics: Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Pemetrexed; Quinazolines; Retrospective Studies; Survival Analysis | 2020 |
The PI3Kα inhibitor DFX24 suppresses tumor growth and metastasis in non-small cell lung cancer via ERK inhibition and EPHB6 reactivation.
Topics: Antineoplastic Agents; Apoptosis; Benzene Derivatives; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Movement; Cell Survival; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mitochondria; Morpholines; Neoplasm Metastasis; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Eph Family; Sulfonamides; Xenograft Model Antitumor Assays | 2020 |
An Activatable Nano-Prodrug for Treating Tyrosine-Kinase-Inhibitor-Resistant Non-Small Cell Lung Cancer and for Optoacoustic and Fluorescent Imaging.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Lung Neoplasms; Mice; Prodrugs; Protein Kinase Inhibitors; Quinazolines; Tyrosine | 2020 |
When EGFR inhibitor meets autoimmune disease: Severe corneal complications in a patient with Sjögren syndrome after erlotinib treatment.
Topics: Cornea; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Sjogren's Syndrome | 2022 |
Absolute Configurations and Chitinase Inhibitions of Quinazoline-Containing Diketopiperazines from the Marine-Derived Fungus
Topics: Cell Line, Tumor; Chitinases; Circular Dichroism; Diketopiperazines; Enzyme Inhibitors; Humans; Lung Neoplasms; Magnetic Resonance Spectroscopy; Penicillium; Prazosin; Quinazolines; Stomach Neoplasms; Urinary Bladder Neoplasms | 2020 |
Continued gefitinib retreatment beyond progression in patients with advanced non-small cell lung cancer harboring sensitive
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retreatment; Retrospective Studies | 2020 |
Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Renal Insufficiency | 2021 |
Long-term response to second-line afatinib treatment for advanced squamous cell carcinoma non-small cell lung cancer: a rare case report.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2020 |
Evodiamine suppresses non-small cell lung cancer by elevating CD8
Topics: Animals; Carcinoma, Non-Small-Cell Lung; CD8-Positive T-Lymphocytes; Down-Regulation; Female; Humans; Lung Neoplasms; Mice; Mucin-1; Plant Extracts; Programmed Cell Death 1 Receptor; Quinazolines; Transfection | 2020 |
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Biomarkers, Tumor; China; Crown Ethers; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines | 2020 |
Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer.
Topics: Animals; Autophagosomes; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crown Ethers; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mice, Nude; Microtubule-Associated Proteins; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Protein Kinase Inhibitors; Quinazolines; Sequestosome-1 Protein; Signal Transduction | 2020 |
Dynamic contrast-enhanced MRI for response evaluation of non-small cell lung cancer in therapy with epidermal growth factor receptor tyrosine kinase inhibitors: a pilot study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Pilot Projects; Protein Kinase Inhibitors; Quinazolines | 2021 |
HER2 amplification as a potential mechanism of acquired resistance to afatinib in an advanced non-small-cell lung cancer patient.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2021 |
Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Drug Administration Schedule; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Progression-Free Survival; Quinazolines | 2021 |
Structure-Activity Relationship (SAR) Study of Spautin-1 to Entail the Discovery of Novel NEK4 Inhibitors.
Topics: Antineoplastic Agents; Benzylamines; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; NIMA-Related Kinases; Quinazolines; Structure-Activity Relationship | 2021 |
Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer.
Topics: Acrylamides; Aged; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Female; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2021 |
Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Caffeic Acids; Computational Biology; Computer Simulation; Dimerization; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Indolizines; Ligands; Lung Neoplasms; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Phenylethyl Alcohol; Quinazolines; Withanolides | 2021 |
Proteasome regulation by reversible tyrosine phosphorylation at the membrane.
Topics: Acetylation; Animals; Benzodioxoles; Cell Membrane; Cytoplasm; Heterografts; Humans; Lung Neoplasms; Mice; Mutation; Phosphorylation; Proteasome Endopeptidase Complex; Protein Processing, Post-Translational; Protein Tyrosine Phosphatase, Non-Receptor Type 2; Quinazolines; Tyrosine | 2021 |
Differential effects of epidermal growth factor receptor inhibitors in a single patient with neuropathic pain.
Topics: Afatinib; ErbB Receptors; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neuralgia; Protein Kinase Inhibitors; Quinazolines | 2021 |
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Compassionate Use Trials; Disease Progression; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Time Factors | 2021 |
Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2021 |
[Establishment of animal models of epidermal growth factor receptor inhibitor-related rashes].
Topics: Animals; ErbB Receptors; Erlotinib Hydrochloride; Female; Lung Neoplasms; Mice; Mice, SCID; Models, Animal; Quinazolines; Rats | 2021 |
Cediranib Induces Apoptosis, G1 Phase Cell Cycle Arrest, and Autophagy in Non-Small-Cell Lung Cancer Cell A549 In Vitro.
Topics: A549 Cells; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; G1 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; MAP Kinase Signaling System; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Vascular Endothelial Growth Factor; TOR Serine-Threonine Kinases; Tumor Stem Cell Assay | 2021 |
Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report.
Topics: Adenocarcinoma of Lung; Carcinoma, Adenosquamous; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2021 |
Survival analysis for older patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after progression of first-line gefitinib.
Topics: Age Factors; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis | 2022 |
Bevacizumab Combined with Icotinib Overcomes Osimertinib Resistance in a Patient of Non-Small Cell Lung Cancer.
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crown Ethers; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
The Pharmacokinetics of Gefitinib in a Chinese Cancer Population Group: A Virtual Clinical Trials Population Study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Gefitinib; Humans; Lung Neoplasms; Mutation; Population Groups; Quinazolines | 2021 |
KPNB1 Inhibitor Importazole Reduces Ionizing Radiation-Increased Cell Surface PD-L1 Expression by Modulating Expression and Nuclear Import of IRF1.
Topics: Active Transport, Cell Nucleus; B7-H1 Antigen; beta Karyopherins; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy; Interferon Regulatory Factor-1; Lung Neoplasms; Quinazolines; Radiation, Ionizing | 2021 |
Combination Treatment of OSI-906 with Aurora B Inhibitor Reduces Cell Viability via Cyclin B1 Degradation-Induced Mitotic Slippage.
Topics: Aurora Kinase B; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin B1; Dose-Response Relationship, Drug; Humans; Imidazoles; Lung Neoplasms; Mitosis; Protein Kinase Inhibitors; Proteolysis; Pyrazines; Quinazolines; Receptor, IGF Type 1 | 2021 |
A novel evodiamine amino derivative as a PI3K/AKT signaling pathway modulator that induces apoptosis in small cell lung cancer cells.
Topics: Administration, Oral; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Male; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Signal Transduction; Small Cell Lung Carcinoma | 2021 |
Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L.
Topics: Aged; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Japan; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2021 |
HER2 exon 20 insertion mutations in lung adenocarcinoma with leptomeningeal metastasis: a case report and response to poziotinib.
Topics: Adenocarcinoma of Lung; Bevacizumab; Exons; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Mutagenesis, Insertional; Quinazolines | 2022 |
Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Bevacizumab; Carcinoma, Non-Small-Cell Lung; China; Crown Ethers; Drug Therapy, Combination; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies | 2021 |
Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC).
Topics: Acrylamide; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2021 |
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Biomarkers, Tumor; Cell Line, Tumor; Cluster Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Isotope Labeling; Lung Neoplasms; Mass Spectrometry; Mutation; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Proteomics; Quinazolines; Reproducibility of Results; Signal Transduction; Tyrosine | 2017 |
Clinical Response to Everolimus of EGFR-Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Gefitinib; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Oligonucleotide Array Sequence Analysis; Quinazolines; Real-Time Polymerase Chain Reaction | 2017 |
Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
Topics: A549 Cells; Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HT29 Cells; Humans; Lung Neoplasms; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Structure-Activity Relationship | 2017 |
Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.
Topics: Adenocarcinoma; Afatinib; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Platelet Endothelial Cell Adhesion Molecule-1; Quinazolines; Remission Induction; Xenograft Model Antitumor Assays | 2017 |
Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed | 2017 |
Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung; Lung Neoplasms; Mice; Models, Molecular; Morpholines; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Xenograft Model Antitumor Assays | 2017 |
Acquired
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Mutation; NIH 3T3 Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Combined bevacizumab and erlotinib treatment in patients with lung cancer with the T790M resistance mutation.
Topics: Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hedgehog Proteins; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing.
Topics: Amino Acid Substitution; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; CRISPR-Cas Systems; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Editing; Gene Expression; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cellular Senescence; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Glucose; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Phloretin; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Withanolides; Xenograft Model Antitumor Assays | 2017 |
[Cabozantinib: Mechanism of action, efficacy and indications].
Topics: Anilides; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Everolimus; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Piperidines; Prostatic Neoplasms; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Selective targeting of point-mutated KRAS through artificial microRNAs.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gefitinib; HEK293 Cells; Humans; Lung Neoplasms; Mice; Mice, Nude; MicroRNAs; Neoplasm Transplantation; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins p21(ras); Quinazolines; RNA Interference; RNA, Small Interfering; Transplantation, Heterologous | 2017 |
The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2017 |
Evaluation of 99mTc-HYNIC-MPG as a novel SPECT radiotracer to detect EGFR-activating mutations in NSCLC.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Female; Heterografts; Humans; Lung Neoplasms; Mice; Mutation; Organotechnetium Compounds; Quinazolines; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 2017 |
Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Gene Fusion; Humans; Lung Neoplasms; Male; Middle Aged; Neuregulin-1; Quinazolines | 2017 |
Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gain of Function Mutation; Gefitinib; Hepatitis C, Chronic; Humans; Liver Neoplasms; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Smoking; Taiwan | 2017 |
Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC).
Topics: Afatinib; Amides; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Models, Biological; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Thiophenes | 2017 |
Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.
Topics: Acrylamides; Aged; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Piperazines; Prognosis; Quinazolines; Remission Induction | 2017 |
Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Filaggrin Proteins; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines | 2017 |
Corneal edema with a systemic epidermal growth factor receptor inhibitor.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Corneal Edema; Dose-Response Relationship, Drug; Drug Substitution; Epithelium, Corneal; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2017 |
Cigarette smoke extract induces EGFR-TKI resistance via promoting EGFR signaling pathway and ROS generation in NSCLC cell lines.
Topics: A549 Cells; Acetylcysteine; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cigarette Smoking; Drug Resistance, Neoplasm; ErbB Receptors; Free Radical Scavengers; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; Signal Transduction | 2017 |
Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non-small-cell Lung Cancer.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Gefitinib; Genotype; Histamine H2 Antagonists; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Proton Pump Inhibitors; Quinazolines; Retrospective Studies | 2017 |
Afatinib Decreases P-Glycoprotein Expression to Promote Adriamycin Toxicity of A549T Cells.
Topics: A549 Cells; Afatinib; ATP Binding Cassette Transporter, Subfamily B; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Proteins; Quinazolines | 2018 |
Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
Droplet digital PCR improved the EGFR mutation diagnosis with pleural fluid samples in non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Particle Size; Pleural Effusion; Polymerase Chain Reaction; Quinazolines | 2017 |
Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Imidazoles; Lung Neoplasms; Molecular Docking Simulation; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2017 |
EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; ErbB Receptors; Exons; Female; Humans; INDEL Mutation; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2017 |
Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Comorbidity; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Prognosis; Propensity Score; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Registries; Retreatment; Severity of Illness Index; Taiwan; Treatment Outcome | 2017 |
Matrine increases the inhibitory effects of afatinib on H1975 cells via the IL‑6/JAK1/STAT3 signaling pathway.
Topics: Afatinib; Alkaloids; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Humans; Interleukin-6; Janus Kinase 1; Lung Neoplasms; Matrines; Protein Kinase Inhibitors; Quinazolines; Quinolizines; Signal Transduction; STAT3 Transcription Factor | 2017 |
Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome | 2017 |
The Effect of Afatinib Treatment in Non-small Cell Lung Cancer Cells.
Topics: A549 Cells; Afatinib; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Endoplasmic Reticulum Chaperone BiP; ErbB Receptors; Heat-Shock Proteins; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Signal Transduction | 2017 |
HB-EGF Is a Promising Therapeutic Target for Lung Cancer with Secondary Mutation of
Topics: Animals; Antineoplastic Agents; Apoptosis; Bacterial Proteins; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Heparin-binding EGF-like Growth Factor; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines; Tumor Burden | 2017 |
Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
Liposomal honokiol induced lysosomal degradation of Hsp90 client proteins and protective autophagy in both gefitinib-sensitive and gefitinib-resistant NSCLC cells.
Topics: Animals; Antineoplastic Agents; Autophagy; Biphenyl Compounds; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lignans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Signal Transduction | 2017 |
The EGFR/miR-338-3p/EYA2 axis controls breast tumor growth and lung metastasis.
Topics: Adult; Aged; Aged, 80 and over; Animals; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Inbred BALB C; MicroRNAs; Middle Aged; Nuclear Proteins; Protein Tyrosine Phosphatases; Quinazolines; Signal Transduction; Transplantation, Homologous | 2017 |
Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway.
Topics: Apoptosis; Artemisinins; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclin B1; Down-Regulation; Drug Synergism; Gefitinib; Humans; Lung Neoplasms; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor; TOR Serine-Threonine Kinases; Up-Regulation | 2017 |
Case series on the association between blood levels and side effects of afatinib maleate.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Quinazolines | 2017 |
A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2017 |
Therapeutic Role of MiR-140-5p for the Treatment of Non-small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Disease Progression; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; MicroRNAs; Pyrazoles; Quinazolines; Quinolines; Signal Transduction; Up-Regulation | 2017 |
Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiation-Sensitizing Agents | 2017 |
Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase; Gefitinib; Humans; Lung Neoplasms; Phytotherapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Saponins; Signal Transduction | 2017 |
Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Crown Ethers; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy | 2018 |
YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells.
Topics: Afatinib; Antineoplastic Agents; Cell Line, Tumor; Drug Evaluation, Preclinical; ErbB Receptors; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Imidazoles; Lung Neoplasms; Methylation; Naphthoquinones; Octamer Transcription Factor-3; Phosphorylation; Quinazolines; RNA, Messenger | 2017 |
[A Case of Lung Adenocarcinoma Presenting with Leptomeningeal Carcinomatosis Successfully Treated with Afatinib after Erlotinib-Induced Hepatotoxicity].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Quinazolines; Treatment Outcome | 2017 |
Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Duodenal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Pyrimidines; Quinazolines; Treatment Outcome | 2017 |
Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; ErbB Receptors; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Pemetrexed; Protein-Tyrosine Kinases; Quinazolines | 2017 |
Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Pyridines; Quinazolines; Retrospective Studies; Signal Transduction; Time Factors; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2017 |
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Indoles; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Sulfones | 2017 |
Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer.
Topics: Acrylamides; Adult; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Piperazines; Quinazolines | 2017 |
Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Forkhead Box Protein M1; Gefitinib; Gene Silencing; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Niacinamide; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Quinazolines; RNA, Neoplasm; Signal Transduction; Sorafenib; Stathmin; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
Topics: ADAMTS Proteins; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium-Binding Proteins; Calponins; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exome; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Lung Neoplasms; Male; Microfilament Proteins; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Suppressor Protein p53; Wnt Proteins | 2017 |
Gefitinib-loaded DSPE-PEG2000 nanomicelles with CD133 aptamers target lung cancer stem cells.
Topics: A549 Cells; AC133 Antigen; Animals; Antineoplastic Agents; Aptamers, Peptide; Drug Carriers; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, SCID; Nanoparticles; Neoplastic Stem Cells; Phosphatidylethanolamines; Polyethylene Glycols; Quinazolines; Xenograft Model Antitumor Assays | 2017 |
Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells.
Topics: Acetophenones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2017 |
Gefitinib Enhances Mitochondrial Biological Functions in NSCLCs with
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Aggregation; Cell Count; Cell Line, Tumor; Doxorubicin; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Mutation; Quinazolines; Succinate Dehydrogenase | 2017 |
Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydrogen-Ion Concentration; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Quinazolines; Urine | 2017 |
Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Medical Oncology; Neoplasm Metastasis; Nivolumab; Quinazolines; Ramucirumab; Taxoids | 2017 |
An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Topics: A549 Cells; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; CCAAT-Enhancer-Binding Protein-beta; Cell Movement; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Protein Kinase Inhibitors; Protein Stability; Quinazolines; RNA Interference; Signal Transduction; Time Factors; Transcription Factors; Transcription, Genetic; Transfection; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
Dual effects of a CpG-DNAzyme targeting mutant EGFR transcripts in lung cancer cells: TLR9 activation and EGFR downregulation.
Topics: Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; CpG Islands; DNA, Catalytic; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Quinazolines; RNA, Messenger; Toll-Like Receptor 9 | 2018 |
Novel Mutation Pair L858M/L861Q Caused Resistance to Both First- and Third-Generation EGFR Inhibitors, but Was Found to Be Sensitive to the Combination of Lapatinib and Erbitux.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lapatinib; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells.
Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Cycle Checkpoints; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Fatty Acids, Unsaturated; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Survivin; Time Factors | 2017 |
Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged, 80 and over; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines | 2017 |
Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Bile Duct Neoplasms; Cholangiocarcinoma; Female; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Neuregulin-1; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Quinazolines; Syndecan-4 | 2017 |
In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer.
Topics: Cell Line, Tumor; Gefitinib; Humans; Lung Neoplasms; Nanoparticles; Quinazolines | 2017 |
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
Topics: Acrylamides; Afatinib; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Imidazoles; Lung Neoplasms; Male; Mice; Mice, Nude; Pemetrexed; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Random Allocation; Triazines; Xenograft Model Antitumor Assays | 2017 |
Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab.
Topics: Afatinib; Aged; Antibodies, Monoclonal; Carcinoma, Squamous Cell; Disease Progression; Humans; Lung Neoplasms; Male; Nivolumab; Quinazolines | 2018 |
AZD3759 for CNS metastases in EGFR-mutant lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2017 |
Murine breast cancer mastectomy model that predicts patient outcomes for drug development.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Luminescent Measurements; Lung; Lung Neoplasms; Mammary Neoplasms, Experimental; Mastectomy, Radical; Mice, Inbred BALB C; Neoplasm Metastasis; Quinazolines | 2017 |
PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; PPAR gamma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Survival Analysis; Thiazolidinediones | 2017 |
Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Membrane; Electrophoresis, Polyacrylamide Gel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neuraminidase; Protein-Tyrosine Kinases; Quinazolines; Real-Time Polymerase Chain Reaction; Signal Transduction | 2017 |
Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pleural Effusion; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2018 |
Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Interleukin-6; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Prevalence; Quinazolines; Risk Factors; Survival Rate; Treatment Outcome | 2018 |
Targeting tumor cells based on Phosphodiesterase 3A expression.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carrier Proteins; Cell Line, Tumor; Colonic Neoplasms; Cyclic Nucleotide Phosphodiesterases, Type 3; Female; Gastrointestinal Stromal Tumors; Gene Expression; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Molecular Targeted Therapy; Neoplasm Proteins; Organ Specificity; Organoplatinum Compounds; Oxaliplatin; Phosphodiesterase Inhibitors; Pyridazines; Quinazolines; RNA, Messenger; Skin Neoplasms | 2017 |
Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; China; Crown Ethers; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Pneumonectomy; Point Mutation; Postoperative Period; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion | 2017 |
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers.
Topics: Adrenergic beta-Antagonists; Afatinib; AMP-Activated Protein Kinase Kinases; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclic AMP Response Element-Binding Protein; Drug Resistance, Neoplasm; Epinephrine; ErbB Receptors; Humans; Interleukin-6; Lung Neoplasms; Mutation; Norepinephrine; Protein Kinase C; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Receptors, Adrenergic, beta; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2017 |
A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Female; Humans; Lung Neoplasms; Middle Aged; Neuregulin-1; Quinazolines; Radiation-Sensitizing Agents | 2017 |
Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2018 |
Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Exons; Female; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2; Sequence Analysis, DNA; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Up-regulation of YPEL1 and YPEL5 and down-regulation of ITGA2 in erlotinib-treated EGFR-mutant non-small cell lung cancer: A bioinformatic analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; China; Computational Biology; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Nuclear Proteins; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transcriptional Activation; Up-Regulation | 2018 |
The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Mutation; Quinazolines; Treatment Outcome | 2018 |
The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2017 |
Elevation of sensitivity to anticancer agents of human lung adenocarcinoma A549 cells by knockdown of claudin-2 expression in monolayer and spheroid culture models.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Cell Nucleus; Cell Proliferation; Cisplatin; Claudin-2; Doxorubicin; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Quinazolines; Spheroids, Cellular | 2018 |
Metabolic Pathway of Icotinib In Vitro: The Differential Roles of CYP3A4, CYP3A5, and CYP1A2 on Potential Pharmacokinetic Drug-Drug Interaction.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Lung Neoplasms; Metabolic Networks and Pathways; Microsomes, Liver; Quinazolines | 2018 |
MiR-181a contributes gefitinib resistance in non-small cell lung cancer cells by targeting GAS7.
Topics: Biomarkers, Tumor; China; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Male; MicroRNAs; Nerve Tissue Proteins; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Rate | 2018 |
Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Diagnostic Techniques; Netherlands; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2018 |
Lung Cancer with Concomitant Double Gene Mutation.
Topics: Adenocarcinoma; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Biopsy; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Nivolumab; Pemetrexed; Positron Emission Tomography Computed Tomography; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2018 |
Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer to Gefitinib by Targeting TRIM16.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; Transcription Factors; Tripartite Motif Proteins; Tumor Cells, Cultured; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2018 |
A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2018 |
[Clinical Observation of Gefitinib with Pericardial Perfusion for
Advanced Non-small Cell Lung Cancer].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Perfusion; Pericardial Effusion; Pericardium; Quinazolines; Retrospective Studies; Treatment Outcome | 2018 |
Multiple single cell screening and DNA MDA amplification chip for oncogenic mutation profiling.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Mutational Analysis; DNA, Neoplasm; Drug Screening Assays, Antitumor; Gefitinib; HEK293 Cells; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Microfluidic Analytical Techniques; Mutation; Nucleic Acid Amplification Techniques; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Quinazolines; Single-Cell Analysis | 2018 |
Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression.
Topics: Aged; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis | 2018 |
Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Selection; Program Evaluation; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Failure | 2018 |
PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; PPAR gamma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Rosiglitazone; Thiazolidinediones | 2018 |
Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization.
Topics: Adaptor Proteins, Signal Transducing; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclopropanes; Drug Resistance, Neoplasm; Enzyme Activation; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mice; p38 Mitogen-Activated Protein Kinases; Phosphoproteins; Phosphorylation; Pyridines; Quinazolines; Tetraploidy; Transcription Factors; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2018 |
Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non-small cell lung cancer.
Topics: Animals; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; DNA Repair; ErbB Receptors; Female; G2 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Mice; Mutation; Piperazines; Quinazolines; Radiation-Sensitizing Agents; Xenograft Model Antitumor Assays | 2018 |
A secondary RET mutation in the activation loop conferring resistance to vandetanib.
Topics: Adenocarcinoma; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Middle Aged; Mutation, Missense; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines | 2018 |
Discovery of 2-(4-Substituted-piperidin/piperazine-1-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-quinazoline-2,4-diamines as PAK4 Inhibitors with Potent A549 Cell Proliferation, Migration, and Invasion Inhibition Activity.
Topics: A549 Cells; Cell Movement; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Neoplasm Invasiveness; p21-Activated Kinases; Quinazolines | 2018 |
The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Treatment Outcome | 2018 |
New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers.
Topics: Acrylamide; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Lung Neoplasms; Molecular Structure; Mutation; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2018 |
Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Biopsy; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutagenesis, Insertional; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Tomography, X-Ray Computed | 2017 |
Skin Rash Can Be a Useful Marker for Afatinib Efficacy.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paronychia; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Stomatitis; Treatment Outcome | 2018 |
Molecular Modeling, Docking, Dynamics and Simulation of Gefitinib and its Derivatives with EGFR in Non-small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Computer-Aided Design; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Kinase Inhibitors; Quinazolines; Software | 2018 |
Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancer.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Quinazolines; Radiation-Sensitizing Agents | 2018 |
Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months' survival.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Exons; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Quinazolines; Survival Analysis; Time Factors | 2018 |
Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Computer Simulation; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Principal Component Analysis; Protein Kinase Inhibitors; Quinazolines | 2018 |
Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Neoplasm Proteins; Quinazolines; Topotecan; Up-Regulation; Xenograft Model Antitumor Assays | 2018 |
Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Amplification; Humans; Lung Neoplasms; Mice; Neoplastic Stem Cells; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Taxoids; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors.
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cardiotonic Agents; Cardiovascular Diseases; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Nebivolol; Piperazines; Protein Kinase Inhibitors; Quinazolines; Ramipril | 2018 |
Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib.
Topics: Acrylamides; Adenocarcinoma of Lung; Adult; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Cohort Studies; Crizotinib; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Amplification; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis | 2018 |
Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Count; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Humans; Lactic Acid; Lung Neoplasms; Male; Microarray Analysis; Middle Aged; Mutation; Nanofibers; Neoplastic Cells, Circulating; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Quinazolines; Reproducibility of Results | 2018 |
Phenethyl Isothiocyanate Induces Apoptotic Cell Death Through the Mitochondria-dependent Pathway in Gefitinib-resistant NCI-H460 Human Lung Cancer Cells
Topics: Apoptosis; Calcium Signaling; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Humans; Isothiocyanates; Lung Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Quinazolines; Reactive Oxygen Species; Signal Transduction | 2018 |
Krüppel-like factor 4 promotes c-Met amplification-mediated gefitinib resistance in non-small-cell lung cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Gene Amplification; Humans; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lung Neoplasms; Male; Mice, Nude; Proto-Oncogene Proteins c-met; Quinazolines; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Mandibular metastasis as the first clinical indication of occult lung adenocarcinoma with multiple metastases: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Biopsy; Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Female; Gefitinib; Humans; Imidazoles; Immunohistochemistry; Lung; Lung Neoplasms; Mandible; Mandibular Neoplasms; Neoplasm Grading; Neoplasm Staging; Quinazolines; Thyroid Neoplasms; Treatment Outcome; Zoledronic Acid | 2018 |
Icotinib and whole-brain radiotherapy for the treatment in patients with brain metastases from EGFR-mutant nonsmall cell lung cancer: A retrospective study.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; China; Combined Modality Therapy; Cranial Irradiation; Crown Ethers; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radiotherapy Dosage; Retrospective Studies | 2018 |
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Topics: Afatinib; Animals; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Exons; Humans; Lung Neoplasms; Mice; Mutagenesis, Insertional; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Tumor Burden | 2018 |
A blood biomarker for monitoring response to anti-EGFR therapy.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Peroxiredoxin VI; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Treatment Outcome | 2018 |
Histologic transformation from adenocarcinoma to both small cell lung cancer and squamous cell carcinoma after treatment with gefitinib: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2018 |
Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cell Line, Tumor; Cell Survival; Cyclin D1; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Membrane Proteins; Mice; Mice, Nude; Naphthoquinones; Quinazolines; Signal Transduction; Sincalide; STAT3 Transcription Factor; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2018 |
Poziotinib for uncommon ERBB mutations.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Humans; Lung Neoplasms; Mutation; Quinazolines | 2018 |
Systematic bioinformatic approaches reveal novel gene expression signatures associated with acquired resistance to EGFR targeted therapy in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Computational Biology; Databases, Genetic; Drug Resistance, Neoplasm; ELAV-Like Protein 1; ErbB Receptors; Erlotinib Hydrochloride; Estrogen Receptor alpha; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines | 2018 |
Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Crown Ethers; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Thalidomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Apoptosis; B7-H1 Antigen; Bcl-2-Like Protein 11; Biomarkers, Tumor; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Proteins; Neoplasm Recurrence, Local; Quinazolines; Vascular Endothelial Growth Factor A | 2018 |
Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Remission Induction | 2018 |
Knockdown of annexin A5 restores gefitinib sensitivity by promoting G2/M cell cycle arrest.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Annexin A5; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; M Phase Cell Cycle Checkpoints; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines | 2018 |
Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan.
Topics: Adult; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Budgets; Carcinoma, Non-Small-Cell Lung; Decision Making, Organizational; Disease-Free Survival; ErbB Receptors; Exons; Health Planning; Humans; Lung Neoplasms; Models, Biological; Models, Economic; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; United States; Young Adult | 2018 |
Marked Response to Icotinib in Lung Squamous Cell Carcinoma with EGFR Wild-Type.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Male; Quinazolines; Treatment Outcome | 2018 |
Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Prospective Studies; Quinazolines; Survival Rate | 2018 |
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung canc
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Crizotinib; Drug Monitoring; Drug Stability; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Limit of Detection; Lung Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
Tyrosine kinase inhibitor-induced IL-6/STAT3 activation decreases sensitivity of EGFR-mutant non-small cell lung cancer to icotinib.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Interleukin-6; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; STAT3 Transcription Factor | 2018 |
Improved delivery of natural alkaloids into lung cancer through woody oil-based emulsive nanosystems.
Topics: A549 Cells; Alkaloids; Animals; Antineoplastic Agents; Biological Availability; Brucea javanica; Cell Line, Tumor; Drug Delivery Systems; Drugs, Chinese Herbal; Emulsions; Excipients; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Nanoparticles; Plant Oils; Quinazolines; Rats; Rats, Sprague-Dawley; Solubility; Wool | 2018 |
Preliminary mechanisms of regulating PD‑L1 expression in non‑small cell lung cancer during the EMT process.
Topics: A549 Cells; Animals; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Female; Fibroblast Growth Factor 2; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Transforming Growth Factor beta1 | 2018 |
Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2018 |
A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation.
Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2018 |
[The efficacy of TKIs in treatment of human primary small cell lung cancer xenograft model in vivo].
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
[Expression of Acetaldehyde Dehydrogenase in Gefitinib-resistant Human Lung Adenocarcinoma HCC-827/GR Cells].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aldehyde Oxidoreductases; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Quinazolines | 2018 |
PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Male; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Urokinase Plasminogen Activator; Signal Transduction; Survivin | 2018 |
Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; NF-kappa B; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Quinazolines; RNA Interference; RNA, Small Interfering; Up-Regulation | 2019 |
Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab.
Topics: Antibodies, Monoclonal; Autopsy; Carcinoma, Squamous Cell; Fatal Outcome; Female; Humans; Lung; Lung Neoplasms; Middle Aged; Neoplastic Cells, Circulating; Pulmonary Veno-Occlusive Disease; Quinazolines; Thrombotic Microangiopathies; Uterine Cervical Neoplasms | 2018 |
An exosomal- and interfacial-biosensing based strategy for remote monitoring of aberrantly phosphorylated proteins in lung cancer cells.
Topics: Adsorption; Cell Line, Tumor; ErbB Receptors; Exosomes; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gold; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines | 2018 |
HOTAIR, a long noncoding RNA, is a marker of abnormal cell cycle regulation in lung cancer.
Topics: Animals; Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; E2F Transcription Factors; Epithelial-Mesenchymal Transition; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Quinazolines; Retinoblastoma Protein; RNA, Long Noncoding; Transplantation, Heterologous | 2018 |
Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Topics: Anilides; Animals; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Heparin-binding EGF-like Growth Factor; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Sodium-Phosphate Cotransporter Proteins, Type IIb; Up-Regulation; Xenograft Model Antitumor Assays | 2018 |
Pharmacodynamic modelling of resistance to epidermal growth factor receptor inhibition in brain metastasis mouse models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Luminescent Measurements; Lung Neoplasms; Mice; Neoplasm Staging; Piperazines; Quinazolines; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Calpain 2 knockdown promotes cell apoptosis and restores gefitinib sensitivity through epidermal growth factor receptor/protein kinase B/survivin signaling.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Calpain; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Survivin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Efficacy of icotinib in advanced lung squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Crown Ethers; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome | 2018 |
Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis.
Topics: Aged; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Pneumatosis Cystoides Intestinalis; Protein Kinase Inhibitors; Quinazolines | 2018 |
Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib.
Topics: Afatinib; Aged; Algorithms; Antineoplastic Agents; Canada; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies | 2019 |
Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Cell Proliferation; ErbB Receptors; Humans; Lung Neoplasms; Proto-Oncogene Proteins p21(ras); Quinazolines; RNA, Small Interfering; RNAi Therapeutics; Signal Transduction | 2019 |
Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Rate | 2018 |
Erlotinib as adjuvant therapy in EGFR-mutant NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Quinazolines; Vinorelbine | 2018 |
[112th Scientific Meeting of the Japanese Society of Internal Medicine: Presidential Lecture: Panel discussion: Preemptive Medicine from the Perspective of Physicians: Lung Cancer].
Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2015 |
Benzyl Isothiocyanate Induces Apoptotic Cell Death Through Mitochondria-dependent Pathway in Gefitinib-resistant NCI-H460 Human Lung Cancer Cells
Topics: Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Isothiocyanates; Lung Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Quinazolines; Reactive Oxygen Species; Signal Transduction | 2018 |
Fluoxetine Inhibits DNA Repair and NF-ĸB-modulated Metastatic Potential in Non-small Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; DNA Repair; Fluoxetine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Metastasis; NF-kappa B; Phenyl Ethers; Quinazolines; Signal Transduction | 2018 |
Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Databases, Factual; ErbB Receptors; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2018 |
[Formulation and Efficacy of Liposome-encapsulated Afatinib for Therapy of Non-small Cell Lung Cancer].
Topics: Afatinib; Capsules; Carcinoma, Non-Small-Cell Lung; Drug Compounding; Liposomes; Lung Neoplasms; Quinazolines | 2018 |
Osimertinib Treats CNS Metastases in NSCLC.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quinazolines | 2018 |
Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay.
Topics: Adult; Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Male; Mutation; Precision Medicine; Quinazolines; Treatment Outcome | 2018 |
Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biomarkers, Pharmacological; Cohort Studies; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression; Humans; Leukocytes; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Telomere | 2018 |
An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Proteomics; Quinazolines; Research Design | 2018 |
Clinicopathologic characteristics and outcome of patients with different EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2019 |
Vandetanib Tumor Shrinkage in Metastatic Medullary Thyroid Cancer Allowing Surgical Resection of the Primary Site: A Case Report.
Topics: Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Child; Humans; Lung Neoplasms; Male; Piperidines; Quinazolines; Thyroid Neoplasms; Treatment Outcome; Tumor Burden | 2019 |
Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Consolidation Chemotherapy; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Retrospective Studies; Survival Analysis | 2019 |
Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1α and APC2 gene expression in non-small cell lung cancer.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromobox Protein Homolog 5; Chromosomal Proteins, Non-Histone; Cytoskeletal Proteins; Disease Models, Animal; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Lung Neoplasms; Mice; Quinazolines; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2018 |
Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines | 2018 |
Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Exons; Humans; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2018 |
Nonsmall cell lung cancer with rare exon 7 p.A289V mutation in the EGFR gene responds to Icotinib treatment: A case report.
Topics: Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Tomography, X-Ray Computed | 2018 |
Straightforward synthesis, characterization, and cytotoxicity evaluation of hybrids of natural alkaloid evodiamine/rutaecarpine and thieno[2,3-
Topics: Alkaloids; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Indole Alkaloids; Lung Neoplasms; Molecular Structure; Pyrimidinones; Quinazolines; Structure-Activity Relationship | 2020 |
Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib.
Topics: Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Mutagenesis, Insertional; Quinazolines; Sequence Deletion | 2019 |
[Effect of Fuzheng Kang'ai Recipe Combined Gefitinib on Lung Cancer A549 Cells and Its Mecha- nism Research].
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drugs, Chinese Herbal; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2016 |
Sialidase Attenuates Epidermal Growth Factor Response and Abolishes Antiproliferative Effects of Erlotinib in A549Alveolar Epithelial Cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epidermal Growth Factor; Epithelial Cells; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neuraminidase; Protein Kinase Inhibitors; Quinazolines | 2019 |
[Efficacy and Safety of Gefitinib as First-Line Chemotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer(NSCLC)].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2019 |
20(S)-ginsenoside Rg3 sensitizes human non-small cell lung cancer cells to icotinib through inhibition of autophagy.
Topics: Animals; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Crown Ethers; Drug Synergism; Female; Ginsenosides; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Quinazolines; Xenograft Model Antitumor Assays | 2019 |
Evodiamine inhibits migration and invasion by Sirt1-mediated post-translational modulations in colorectal cancer.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; NF-kappa B; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; Sirtuin 1; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Glycerol Kinase; Humans; Lung Neoplasms; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Signal Transduction; Stearoyl-CoA Desaturase; Sterol Regulatory Element Binding Protein 1; Up-Regulation | 2019 |
Synergistic Effect of Novel EGFR Inhibitor AZD8931 and p38α siRNA in Lung Adenocarcinoma Cancer Cells.
Topics: A549 Cells; Adenocarcinoma; Apoptosis; Cell Proliferation; ErbB Receptors; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 14; Quinazolines; RNA, Small Interfering | 2019 |
Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2019 |
Secondary polycythemia in a sarcoma patient: a commentary about cediranib.
Topics: Antineoplastic Agents; Humans; Lung Neoplasms; Male; Middle Aged; Polycythemia; Protein Kinase Inhibitors; Quinazolines; Sarcoma, Alveolar Soft Part | 2019 |
[Clinical effect of icotinib in treatment of elderly advanced non-small cell lung cancer patients with EGFR mutations].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quinazolines | 2019 |
Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Young Adult | 2019 |
Tyrosine kinase inhibitor conjugated quantum dots for non-small cell lung cancer (NSCLC) treatment.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Survival; Drug Liberation; Esterases; Humans; Lung Neoplasms; Lysosomes; Protein Kinase Inhibitors; Quantum Dots; Quinazolines | 2019 |
Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Crown Ethers; Drug Synergism; Humans; Lung Neoplasms; Mice; Mice, Nude; Pemetrexed; Quinazolines | 2019 |
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Aurora Kinase B; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; G1 Phase Cell Cycle Checkpoints; Histones; Humans; Lung Neoplasms; Male; Mice; Middle Aged; Organophosphates; Phosphorylation; Polyploidy; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Icotinib plus osimertinib overcome epidermal growth factor receptor 19del/T790 M/C797S/V834L quadruplet resistance mutation in a patient with non-small cell lung cancer.
Topics: Acrylamides; Aged; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Quinazolines | 2019 |
Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines | 2019 |
Angio-associated migratory cell protein interacts with epidermal growth factor receptor and enhances proliferation and drug resistance in human non-small cell lung cancer cells.
Topics: A549 Cells; Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Crown Ethers; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Knockdown Techniques; HEK293 Cells; Heterografts; Humans; Lung Neoplasms; Mice; Phosphorylation; Quinazolines; Transfection; Tumor Burden | 2019 |
Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines.
Topics: Adenocarcinoma of Lung; Anthraquinones; Antineoplastic Agents; Apoptosis; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Crown Ethers; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2019 |
Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
Topics: Adenocarcinoma of Lung; Afatinib; Aged; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.
Topics: Acrylamides; Adenocarcinoma of Lung; Aged; Aniline Compounds; Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Quinazolines; Quinolines; Tumor Stem Cell Assay | 2019 |
Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase B; Cell Line, Tumor; Drug Discovery; Humans; Lung Neoplasms; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Organophosphates; Polypharmacology; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Quinolines; Systems Analysis | 2019 |
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
Topics: Acrylamides; Afatinib; Aged; Aniline Compounds; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Fatal Outcome; Female; Follow-Up Studies; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Mutation; Protein Kinase Inhibitors; Quinazolines | 2019 |
Knockout of glucosidase II beta subunit inhibits growth and metastatic potential of lung cancer cells by inhibiting receptor tyrosine kinase activities.
Topics: alpha-Glucosidases; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; ErbB Receptors; Humans; Lung; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2019 |
Identification of a Novel Icotinib-Sensitive EGFR-SEPTIN14 Fusion Variant in Lung Adenocarcinoma by Next-Generation Sequencing.
Topics: Adenocarcinoma of Lung; Crown Ethers; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2019 |
Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; Crown Ethers; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; G2 Phase Cell Cycle Checkpoints; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; RNA, Small Interfering | 2019 |
[Fatal interstitial lung disease associated with erlotinib use].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; BRCA1 Protein; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Endodeoxyribonucleases; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Expression Profiling; Humans; LIM Domain Proteins; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Young Adult | 2013 |
Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease.
Topics: Adenocarcinoma; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cranial Nerve Diseases; Cytarabine; Erlotinib Hydrochloride; Female; Gefitinib; Headache; Humans; Hydrocortisone; Infusions, Intraventricular; Intracranial Pressure; Karnofsky Performance Status; Lung Neoplasms; Male; Meningeal Carcinomatosis; Mental Disorders; Methotrexate; Middle Aged; Nausea; Palliative Care; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Vomiting | 2013 |
Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.
Topics: Aged; Algorithms; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Mutation; Pemetrexed; Proportional Hazards Models; Quinazolines; Retrospective Studies; Smoking; Treatment Outcome | 2013 |
Erlotinib-induced hair repigmentation.
Topics: Adenocarcinoma; Aged; Erlotinib Hydrochloride; Female; Hair Color; Humans; Lung Neoplasms; Pigmentation; Protein Kinase Inhibitors; Quinazolines | 2014 |
[About new treatments in thoracic oncology].
Topics: Afatinib; Antineoplastic Agents; Crizotinib; DNA Mutational Analysis; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Oncogene Proteins, Fusion; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines | 2013 |
Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; CpG Islands; Decitabine; DNA Methylation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines | 2013 |
Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model.
Topics: Afatinib; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; ErbB Receptors; Exons; Female; Gefitinib; Heterografts; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2013 |
Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung cancer.
Topics: Animals; Benzamides; beta Karyopherins; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; Genes, Essential; Genome-Wide Association Study; Head and Neck Neoplasms; Humans; Kinesins; Lung Neoplasms; Mice; Microtubule-Associated Proteins; Nuclear Proteins; Quinazolines; ran GTP-Binding Protein; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Neoplasm Proteins; Protein Kinase Inhibitors; Proteome; Proteomics; Quinazolines; Retrospective Studies | 2013 |
Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research?
Topics: Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2013 |
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Transformation, Neoplastic; Diphenylamine; Feedback, Physiological; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Point: should epidermal growth factor receptor mutations be routinely tested for in patients with lung cancer? Yes.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Diagnostic Tests, Routine; DNA Mutational Analysis; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Quinazolines; Treatment Outcome | 2013 |
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biopsy; CD56 Antigen; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Ki-67 Antigen; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2 | 2013 |
Two rare exon 21 EGFR mutations in patients treated with gefitinib.
Topics: Adenocarcinoma; Aged, 80 and over; ErbB Receptors; Exons; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2013 |
Erlotinib in the treatment of patients with multiple metastases from non-small cell lung cancer: clinical case selection for optimal response.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines | 2013 |
[Primary lateral sclerosis and lung adenocarcinoma].
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Causality; Diagnosis, Differential; Dysarthria; Electromyography; Fatal Outcome; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Motor Neuron Disease; Motor Neurons; Multimodal Imaging; Paraneoplastic Syndromes, Nervous System; Pemetrexed; Pleural Effusion, Malignant; Positron-Emission Tomography; Quadriplegia; Quinazolines; Tomography, X-Ray Computed | 2013 |
Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
α-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells.
Topics: Antioxidants; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; G1 Phase Cell Cycle Checkpoints; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Reactive Oxygen Species; Receptor, ErbB-2; Thioctic Acid | 2013 |
[A case of lung adenocarcinoma with coexisting G719X and T790M EGFR mutations in which erlotinib was effective for the treatment of leptomeningeal carcinomatosis].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Biopsy; Brain Neoplasms; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
[Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Safety; Survival Analysis | 2013 |
Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Sulfonamides; Xenograft Model Antitumor Assays | 2013 |
Pressure sore-like ulcers on acneiform papules caused by EGFR inhibitors.
Topics: Acneiform Eruptions; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Pressure Ulcer; Quinazolines; Wound Healing | 2014 |
Skin rash as a surrogate marker of clinical response of targeted therapy using gefitinib in advanced or metastatic non-small-cell lung cancer--a retrospective study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Eruptions; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Prognosis; Quinazolines; Retreatment; Retrospective Studies; Sex Factors; Treatment Outcome | 2012 |
Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Everolimus; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
[Erlotinib-induced acneiform eruption].
Topics: Acneiform Eruptions; Adenocarcinoma; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Ciprofloxacin; Doxycycline; Drug Therapy, Combination; Erlotinib Hydrochloride; Fluoroquinolones; Humans; Lung Neoplasms; Male; Methylprednisolone; Quinazolines; Quinolizines; Treatment Outcome | 2013 |
Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor?
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies | 2013 |
Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC.
Topics: Apoptosis; Autocrine Communication; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Clone Cells; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Humans; Lung Neoplasms; Models, Biological; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; RNA, Small Interfering; Signal Transduction | 2013 |
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Patho
Topics: Adenocarcinoma; Anaplastic Lymphoma Kinase; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Molecular Targeted Therapy; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Systematic Reviews as Topic | 2013 |
Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis Regulatory Proteins; Base Sequence; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Transdifferentiation; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Sequence Analysis, DNA; Sequence Deletion | 2013 |
Influence of gefitinib and erlotinib on apoptosis and c-MYC expression in H23 lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2013 |
Cisplatin influences acquisition of resistance to molecular-targeted agents through epithelial-mesenchymal transition-like changes.
Topics: Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases | 2013 |
Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemokine CCL5; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Inflammation; Interleukin-10; Interleukin-8; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome | 2013 |
Update: NCCN non-small cell lung cancer clinical practice guidelines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Gefitinib; Humans; Lung Neoplasms; Neoplasm Micrometastasis; Neoplasm Staging; Positron-Emission Tomography; Practice Guidelines as Topic; Quinazolines | 2004 |
[Analysis of drug therapy of lung cancer in Hungary].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan | 2013 |
The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.
Topics: Animals; Antimalarials; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Chloroquine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytoskeletal Proteins; Down-Regulation; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Nude; Mutation; Phosphorylation; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Quinazolines; RNA, Messenger; Signal Transduction; Transcriptome | 2013 |
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
Topics: Adenocarcinoma; Antineoplastic Agents; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Oncogene Proteins, Fusion; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2013 |
Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Crown Ethers; ErbB Receptors; G1 Phase; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-cbl; Quinazolines; Signal Transduction | 2013 |
Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Genes, bcl-2; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinazolines; RNA Interference; RNA, Small Interfering | 2013 |
Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Keratin-19; Luminescent Measurements; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Letter to the editor. Probing gender-specific change in IgG1 Fc-galactosylation in non-small cell lung cancer patients treated with epidermal growth factor receptor inhibitor.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Galactose; Humans; Immunoglobulin Fc Fragments; Immunoglobulin G; Lung Neoplasms; Male; Mass Spectrometry; Quinazolines; Sex Factors | 2013 |
mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mutation, Missense; PTEN Phosphohydrolase; Quinazolines; Radiation Tolerance; RNA, Small Interfering; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
[The cost-effectiveness analysis of gefitinib or erlotinib in the treatment of advanced EGFR mutant non-small cell lung cancer patients].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cost-Benefit Analysis; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Insurance, Health; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Outcome Assessment; Protein Kinase Inhibitors; Quinazolines | 2013 |
Spontaneous hemothorax as a presenting form of bronchogenic carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Large Cell; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Hemothorax; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Pleural Effusion, Malignant; Pulmonary Atelectasis; Quinazolines; Rupture, Spontaneous; Solitary Pulmonary Nodule; Tomography, X-Ray Computed | 2013 |
Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; France; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutagenesis, Insertional; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Spain; Switzerland; Trastuzumab; Treatment Outcome | 2013 |
Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphate; Amino Acid Substitution; Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; Female; Humans; Lapatinib; Lung Neoplasms; Mice; Mice, Nude; Mice, Transgenic; Mutation, Missense; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Quinazolines; Receptor, ErbB-2; Signal Transduction; Substrate Specificity | 2013 |
Reply to N. Singh et al.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
Reply to M.C. Garassino et al.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2013 |
Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; HEK293 Cells; Humans; Immunoblotting; Immunohistochemistry; Inhibitory Concentration 50; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; RNA Interference; Signal Transduction; Tissue Array Analysis | 2013 |
Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crown Ethers; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prognosis; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2013 |
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2013 |
Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Patient Selection; Pemetrexed; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines | 2013 |
Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cytochrome P-450 CYP2D6; Female; Follow-Up Studies; Gefitinib; Humans; Liver Diseases; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
Hand-foot syndrome induced by erlotinib (Tarceva(Ⓡ) ).
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Hand-Foot Syndrome; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin.
Topics: Acute Kidney Injury; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Hypertension; Lung Neoplasms; Middle Aged; Oxonic Acid; Pemetrexed; Plasma; Purpura, Thrombotic Thrombocytopenic; Pyridines; Quinazolines; Recombinant Proteins; Solubility; Taxoids; Tegafur; Thrombomodulin | 2013 |
[Clinical effects for patients with recurrent advanced non-small cell lung cancer treated with icotinib hydrochloride].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Recurrence; Retrospective Studies; Survival Analysis; Treatment Failure | 2013 |
Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Middle Aged; Mutation; Quinazolines; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases | 2013 |
A swollen knee in a 77-year-old lung cancer patient receiving antimicrobial therapy for pneumonia.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Erlotinib Hydrochloride; Fatal Outcome; Humans; Knee; Knee Injuries; Lung Neoplasms; Male; Pneumonia; Quinazolines | 2013 |
Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Metformin; Mice; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction; Tumor Burden; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2013 |
β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; beta Catenin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Quinazolines; Signal Transduction | 2014 |
[Small molecule inhibitor SB203580 enhances the antitumor effect of gefitinib in PC-9 and A549 lung cancer cell lines].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; Gefitinib; Humans; Imidazoles; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Quinazolines; Signal Transduction | 2013 |
Severe refractory scarring alopecia associated with combinational use of ficlatuzumab (AV-299) and gefitinib.
Topics: Aged; Alopecia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cicatrix; Female; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Quinazolines; Risk Assessment; Severity of Illness Index | 2013 |
Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridazines; Quinazolines; Signal Transduction; Small Cell Lung Carcinoma; Triazoles; Xenograft Model Antitumor Assays | 2013 |
Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Adult; Aged; Alleles; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity | 2013 |
USP8 is a novel target for overcoming gefitinib resistance in lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Endopeptidases; Endosomal Sorting Complexes Required for Transport; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Protease Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Ubiquitin Thiolesterase; Xenograft Model Antitumor Assays | 2013 |
Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exons; Feasibility Studies; Female; France; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA; Survival Rate; Treatment Outcome | 2013 |
Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor requires E-cadherin in esophageal cancer and malignant pleural mesothelioma.
Topics: Biomarkers, Tumor; Cadherins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; ErbB Receptors; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Quinazolines; Signal Transduction | 2013 |
Antitumor impact of p14ARF on gefitinib-resistant non-small cell lung cancers.
Topics: Amino Acid Sequence; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Intracellular Space; Lung Neoplasms; Molecular Sequence Data; Mutation; Peptides; Protein Kinase Inhibitors; Protein Transport; Quinazolines; Tumor Suppressor Protein p14ARF | 2013 |
Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Humans; Lung Neoplasms; Membrane Proteins; Microtubule-Associated Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2013 |
[A case report of patient with advanced non-small cell lung cancer by five times EGFR-TKIs therapy].
Topics: Carcinoma, Non-Small-Cell Lung; Drug Therapy; ErbB Receptors; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2013 |
Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Adenosquamous; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome | 2013 |
Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations.
Topics: Aged; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
Epidermal growth factor receptor in lung cancer: the amazing interplay of molecular testing and cytopathology.
Topics: Carcinoma, Non-Small-Cell Lung; Cytodiagnosis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2013 |
EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cytodiagnosis; ErbB Receptors; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
Recurrence patterns of advanced non-small cell lung cancer treated with gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2013 |
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Anaplastic Lymphoma Kinase; Antigens, Differentiation, B-Lymphocyte; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Crizotinib; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Frequency; Gene Rearrangement; Glutamates; Guanine; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Pyrimidines; Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Smoking; Treatment Outcome | 2013 |
RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Statistics, Nonparametric; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Individualized treatment of NSCLC: from research to clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Transcriptome | 2013 |
IL-33/IL-31 axis: a new pathological mechanisms for EGFR tyrosine kinase inhibitors-associated skin toxicity.
Topics: Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Interleukin-33; Interleukins; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Skin | 2013 |
Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; ErbB Receptors; Ethnicity; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2013 |
Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown EGFR mutational status.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.
Topics: Adult; Aged; Blood-Brain Barrier; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2013 |
DISSECT Method Using PNA-LNA Clamp Improves Detection of EGFR T790m Mutation.
Topics: Alleles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Oligonucleotides; Peptide Nucleic Acids; Polymerase Chain Reaction; Quinazolines; Sequence Analysis, DNA | 2013 |
Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Body Size; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2013 |
RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Hypoxia; Cell Line, Tumor; Computational Biology; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Lung Neoplasms; Mice; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Sequence Analysis, RNA; Species Specificity; Xenograft Model Antitumor Assays | 2013 |
Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Genes, ras; Genetic Variation; Humans; Lung Neoplasms; Mice; Mice, Nude; Mice, SCID; Mutation; Neoplasm Transplantation; Proto-Oncogene Proteins c-met; Quinazolines; ras Proteins; Receptor, Fibroblast Growth Factor, Type 1; Xenograft Model Antitumor Assays | 2013 |
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT & SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320: in regard to Sperduto
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; Dacarbazine; Humans; Lung Neoplasms; Quinazolines; Radiosurgery | 2013 |
In reply to Robins et al.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; Dacarbazine; Humans; Lung Neoplasms; Quinazolines; Radiosurgery | 2013 |
Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
Topics: Animals; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; HSP90 Heat-Shock Proteins; Humans; Janus Kinase 1; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2013 |
[How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI?].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Choice Behavior; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retreatment; Retrospective Studies; Treatment Outcome | 2013 |
[Clinical observation of icotinib hydrochloride in first-line therapy for pulmonary adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Crown Ethers; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Treatment Outcome | 2013 |
5-aminolaevulinic acid/photo-dynamic therapy and gefitinib in non-small cell lung cancer cell lines: a potential strategy to improve gefitinib therapeutic efficacy.
Topics: Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; NF-kappa B; Photochemotherapy; Photosensitizing Agents; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Quinazolines; Transcription, Genetic | 2013 |
Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling.
Topics: Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Humans; Integrin beta1; Lung Neoplasms; Oncogene Protein v-akt; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; src-Family Kinases | 2013 |
Personalised cancer management: closer, but not here yet.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Molecular Targeted Therapy; Precision Medicine; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
[EGFR-ERK signaling pathway down-regulates miRNA-145 in lung cancer cells].
Topics: Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Down-Regulation; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Humans; Lung; Lung Neoplasms; MAP Kinase Signaling System; MicroRNAs; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nitriles; Phosphorylation; Quinazolines; Tyrphostins | 2013 |
Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Eukaryotic Initiation Factor-4F; Humans; Immunoblotting; Lung Neoplasms; Mutation; Phosphorylation; Protein Biosynthesis; Protein Kinase Inhibitors; Quinazolines; RNA Caps; Signal Transduction; Tumor Cells, Cultured | 2013 |
EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2013 |
Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA | 2013 |
Challenges to implementation of an epidermal growth factor receptor testing strategy for non-small-cell lung cancer in a publicly funded health care system.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Canada; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Financing, Government; Follow-Up Studies; Gefitinib; Health Plan Implementation; Health Services; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Oncogene Protein v-akt; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Receptor, ErbB-3; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Brain metastasis in patients with non-small-cell lung cancer and epidermal growth factor receptor mutations.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2013 |
Should erlotinib be coadministered with whole-brain radiotherapy in patients with brain metastases and non-small-cell lung cancer?
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2013 |
Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quinazolines | 2013 |
New kinase inhibitor approved for metastatic lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Approval; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Erlotinib in the treatment of advanced squamous cell NSCLC.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Reaction of plasma adiponectin level in non-small cell lung cancer patients treated with EGFR-TKIs.
Topics: Adiponectin; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Insulin; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib.
Topics: Anti-Ulcer Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Ranitidine; Retrospective Studies; Stomach Ulcer; Treatment Outcome | 2013 |
The role of epithelial-mesenchymal transition and IGF-1R expression in prediction of gefitinib activity as the second-line treatment for advanced nonsmall-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Epithelial-Mesenchymal Transition; Female; Gefitinib; Genes, erbB-1; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Receptor, IGF Type 1; Treatment Outcome | 2013 |
Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dipeptides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Protein Kinase Inhibitors; Quinazolines; Receptor, Notch1; RNA Interference; Signal Transduction; Time Factors; Transfection; Xenograft Model Antitumor Assays | 2013 |
[Long survival case of resected lung cancer after chemotherapy with gefitinib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Gefitinib; Humans; Lung Neoplasms; Male; Mediastinum; Pneumonectomy; Quinazolines; Time Factors | 2013 |
RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Kinase 1; MAP Kinase Signaling System; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Quinazolines; Real-Time Polymerase Chain Reaction; Transcriptome | 2013 |
The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.
Topics: Adaptor Proteins, Signal Transducing; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoblotting; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Mice; Middle Aged; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; Signal Transduction; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2013 |
Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation.
Topics: Autophagy; Cell Communication; Cell Degranulation; Cell Line, Tumor; Cytotoxicity, Immunologic; ErbB Receptors; Gefitinib; Histocompatibility Antigens Class I; Humans; Immunomodulation; Interferon-gamma; Killer Cells, Natural; Ligands; Lung Neoplasms; Mutation; NK Cell Lectin-Like Receptor Subfamily K; Quinazolines; Receptor, IGF Type 2; STAT3 Transcription Factor | 2013 |
Coadministration of erlotinib and curcumin augmentatively reduces cell viability in lung cancer cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Curcumin; Erlotinib Hydrochloride; Humans; I-kappa B Proteins; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Quinazolines; RNA Interference | 2014 |
Reply to v.R. Bhatt et Al and m.C. Chamberlain.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2013 |
Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
Icotinib: kick-starting the Chinese anticancer drug industry.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2013 |
Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Quinazolines | 2013 |
Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Mutation; Pyrazoles; Pyridines; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Treatment Outcome | 2013 |
Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Humans; Immunoassay; Lung Neoplasms; Lymphatic Metastasis; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasms, Experimental; Oncogene Proteins; Phosphorylation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2013 |
Erlotinib and concurrent chemoradiation in pretreated NSCLC patients: radiobiological basis and clinical results.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2013 |
[A case of lung adenocarcinoma wtih exon19 and T790M mutations in EGFR having good response to erlotinib after gefitinib treatment failure].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Salvage Therapy | 2013 |
Suppression of respiratory papillomatosis with malignant transformation by erlotinib in a kidney transplant recipient.
Topics: Bronchoscopy; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Erlotinib Hydrochloride; Humans; Kidney Transplantation; Lung Neoplasms; Male; Middle Aged; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Respiratory Tract Infections; Thoracic Surgery, Video-Assisted | 2013 |
In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Computer Simulation; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Quinazolines; Quinolines; Small Molecule Libraries | 2013 |
Serum CEA level change and its significance before and after Gefitinib therapy on patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate | 2013 |
Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; SOXB1 Transcription Factors; Survival Analysis; Taxoids; Treatment Outcome; Tumor Suppressor Protein p53 | 2013 |
Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Quinazolines | 2013 |
A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Treatment Outcome; Young Adult | 2013 |
Scalp pustules in a patient receiving chemotherapy.
Topics: Acneiform Eruptions; Aged; Aged, 80 and over; Biopsy; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Scalp | 2013 |
EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines | 2013 |
Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, Nude; Mice, Transgenic; Mutation, Missense; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
[Biological diagnosis of resistance to erlotinib in a malignant pleural effusion].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Pleural Effusion, Malignant; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; ROC Curve; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A | 2013 |
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.
Topics: Aldehyde Oxidoreductases; Antineoplastic Agents; Antioxidants; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Genotype; Humans; Lung Neoplasms; Mutation; Neoplastic Stem Cells; Phenotype; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Silybin; Silymarin; Spheroids, Cellular; Tumor Cells, Cultured | 2013 |
The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.
Topics: Acetylation; Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Indoles; Lung Neoplasms; Mice; Mice, Nude; Propidium; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Computational Biology; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Mice, SCID; Models, Chemical; Molecular Structure; Mutation; Protein Kinase Inhibitors; Pteridines; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Afatinib monotherapy in EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Afatinib; Clinical Trials, Phase III as Topic; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cause of Death; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies | 2013 |
Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lapatinib; Lung Neoplasms; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyridones; Quinazolines; Sulfonamides | 2013 |
Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Heptanoic Acids; Humans; Lung Neoplasms; Mice; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins p21(ras); Pyrroles; Quinazolines; ras Proteins; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2013 |
Synthesis and biological evaluation of novel pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction | 2013 |
Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatography, Liquid; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Inbred BALB C; Models, Biological; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Tandem Mass Spectrometry; Xenograft Model Antitumor Assays | 2013 |
The economic evaluation of personalised oncology medicines: ethical challenges.
Topics: Antineoplastic Agents; Australia; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Precision Medicine; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Lung Neoplasms; Mice; Molecular Structure; Quinazolines; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2013 |
Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line.
Topics: AC133 Antigen; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; CD24 Antigen; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Glycoproteins; Humans; Hyaluronan Receptors; Hypoglycemic Agents; Lung Neoplasms; Metformin; Mice; Mice, SCID; Neoplasm Transplantation; Peptides; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
Second-line therapy in elderly patients with advanced nonsmall cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Treatment Failure; Treatment Outcome | 2014 |
In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Aurora Kinase A; Aurora Kinase B; Carcinoma, Non-Small-Cell Lung; Caspases; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Line, Tumor; Cell Proliferation; Cyclin B; Cyclin B1; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; G2 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Microtubules; Myeloid Cell Leukemia Sequence 1 Protein; Phosphorylation; Quinazolines; Quinolines; RNA Interference; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Successful treatment with a combination of electrocautery using wire snares and gefitinib in patients with EGFR-mutant lung cancer and central airway obstruction.
Topics: Aged; Aged, 80 and over; Airway Obstruction; Antineoplastic Agents; Combined Modality Therapy; Electrocoagulation; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Treatment Outcome | 2013 |
IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dasatinib; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Female; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression; Humans; Inhibitory Concentration 50; Insulin-Like Growth Factor Binding Protein 2; Lung Neoplasms; Mice; Mutation; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Signal Transduction; Thiazoles; Xenograft Model Antitumor Assays | 2013 |
Experimental models to study drug distributions in tissue using MALDI mass spectrometry imaging.
Topics: Adenocarcinoma; Animals; Biological Transport; Cholinergic Antagonists; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Microtomy; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinazolines; Scopolamine Derivatives; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tiotropium Bromide; Tissue Culture Techniques; Tumor Microenvironment | 2013 |
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Indazoles; Interleukin-6; Kidney Neoplasms; Lung Neoplasms; Methylation; Molecular Targeted Therapy; Mutation; Neoplasms; Precision Medicine; Predictive Value of Tests; Pyrimidines; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sample Size; Sulfonamides; Temozolomide; Tumor Suppressor Proteins | 2013 |
Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotherapy, Adjuvant; Drug Synergism; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lung Neoplasms; MAP Kinase Kinase 3; MAP Kinase Kinase 6; Metformin; Mutation; MutS Homolog 2 Protein; p38 Mitogen-Activated Protein Kinases; Pyridines; Quinazolines; RNA, Small Interfering; Signal Transduction; Transgenes | 2013 |
Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with clinical outcome of erlotinib treatment.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cytokines; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Invasiveness; Proto-Oncogene Proteins c-met; Quinazolines | 2013 |
A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platform
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; False Positive Reactions; Gefitinib; Genotype; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Nucleic Acid Amplification Techniques; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sequence Analysis, DNA | 2014 |
Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 7; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Humans; Lung Neoplasms; Mutation; Quinazolines | 2014 |
[Assessing the usefulness of erlotinib in patients with unknown or negative epidermal growth factor receptor mutation status].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Analysis | 2013 |
Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.
Topics: Afatinib; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Gene Amplification; Gene Rearrangement; Humans; Lung Neoplasms; Microarray Analysis; Mutation; Oncogene Proteins, Fusion; Phosphorylation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2014 |
Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Hedgehog Proteins; Humans; Lung Neoplasms; MicroRNAs; Pyridines; Quinazolines; RNA, Small Interfering; Signal Transduction; Transfection | 2013 |
Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation.
Topics: Aged; Amino Acid Sequence; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epitopes, T-Lymphocyte; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; HLA-A2 Antigen; Humans; Immunotherapy; Leukocytes, Mononuclear; Lung Neoplasms; Lymphocyte Activation; Male; Middle Aged; Molecular Sequence Data; Mutation; Peptides; Protein Kinase Inhibitors; Quinazolines | 2013 |
Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Indoles; Lung Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases; Wnt Proteins | 2013 |
[Effect of Wnt signaling suppression on gefitinib in non small cell lung cancer cell lines].
Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Quinazolines; Wnt Signaling Pathway | 2013 |
Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Treatment Failure | 2014 |
MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Guanylate Kinases; Humans; Lung Neoplasms; Membrane Proteins; MicroRNAs; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor beta1 | 2014 |
Post-progression survival in patients with non-small cell lung cancer with clinically acquired resistance to gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival; Treatment Outcome | 2013 |
Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carcinoma, Non-Small-Cell Lung; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Estradiol; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; Transfection; Up-Regulation | 2014 |
Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor | 2013 |
Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
miR-30b and miR-30c expression predicted response to tyrosine kinase inhibitors as first line treatment in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; MicroRNAs; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
Evidence that depletion of the sorting nexin 1 by siRNA promotes HGF-induced MET endocytosis and MET phosphorylation in a gefitinib-resistant human lung cancer cell line.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Endocytosis; Endosomes; Gefitinib; Gene Silencing; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Microscopy, Fluorescence; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-met; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Sorting Nexins; Tumor Cells, Cultured | 2014 |
Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Young Adult | 2014 |
VeriStrat: a prognostic and/or predictive biomarker for advanced lung cancer patients?
Topics: Algorithms; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Predictive Value of Tests; Prognosis; Proteomics; Quinazolines; Severity of Illness Index; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome | 2014 |
Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Risk Factors; Sex Factors; Survival Analysis | 2014 |
[Effects of AG1478 on the expression of FOXM1 gene via FOXO3a in non-small cell lung cancer cells].
Topics: Adenocarcinoma; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; ErbB Receptors; Forkhead Box Protein M1; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Lung Neoplasms; Quinazolines; RNA, Messenger; RNA, Small Interfering; Transfection; Tyrphostins | 2013 |
Reversion of erlotinib-acquired resistance twice by chemotherapy: a case report.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Endothelial Cells; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quinazolines; Retrospective Studies; Stem Cells | 2013 |
Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Gene Knockdown Techniques; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Neoplasm Recurrence, Local; Quinazolines; RNA, Small Interfering; src-Family Kinases; Xenograft Model Antitumor Assays | 2014 |
Genomic aberrations associated with erlotinib resistance in non-small cell lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Chromosome Aberrations; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Real-Time Polymerase Chain Reaction | 2013 |
[Effect of bufalin combined gefitinib on lung cancer H1975 cells and its mechanisms research].
Topics: Bufanolides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2013 |
Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck.
Topics: Afatinib; Animals; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Oncogene Proteins v-erbB; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2014 |
MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; RNA Interference; RNA-Binding Proteins; Transgenes; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells.
Topics: Adenocarcinoma; Aminopyridines; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Matrix Metalloproteinase 9; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; RNA, Messenger; Vascular Endothelial Growth Factor A | 2013 |
Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Regression Analysis; Retrospective Studies; Treatment Outcome | 2014 |
Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2013 |
ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Clone Cells; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Furans; Head and Neck Neoplasms; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Pyrimidines; Quinazolines; ras Proteins; Signal Transduction | 2014 |
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Topics: Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crystallography, X-Ray; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Models, Molecular; Molecular Sequence Data; Mutagenesis, Insertional; Mutation; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Structural Homology, Protein; Translational Research, Biomedical | 2013 |
Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Prognosis; Quinazolines; Republic of Korea; Retrospective Studies; Sequence Deletion; Survival Analysis; Treatment Outcome | 2013 |
Dramatic response to high-dose icotinib in a lung adenocarcinoma patient after erlotinib failure.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Crown Ethers; Docetaxel; Drug Dosage Calculations; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Remission Induction; Salvage Therapy; Taxoids; Treatment Failure | 2014 |
The current state of molecularly targeted drugs targeting HGF/Met.
Topics: Acrylamides; Afatinib; Aminopyridines; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drugs, Investigational; ErbB Receptors; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrrolidinones; Quinazolines; Quinolines; Signal Transduction; Up-Regulation; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
Topics: Acetylation; Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antigens, Nuclear; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Proliferation; DNA-Binding Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Histone Deacetylase 1; Humans; Immunoenzyme Techniques; Immunoprecipitation; Ku Autoantigen; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Neoplasm Metastasis; Phosphatidylinositol 3-Kinase; Phosphorylation; Prognosis; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, IGF Type 1; Tumor Cells, Cultured | 2014 |
[Tumor microenvironment elicits primary resistance to afatinib through HGF secretion].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Coculture Techniques; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Fibroblasts; Hepatocyte Growth Factor; Humans; Lung; Lung Neoplasms; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Transforming Growth Factor alpha; Tumor Microenvironment; Vimentin | 2013 |
Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.
Topics: Acrylamides; Afatinib; Amino Acid Substitution; Animals; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, SCID; Mutation, Missense; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Denmark; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Prospective Studies; Quinazolines; Survival Analysis; Treatment Outcome | 2014 |
Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Aged; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Hydrocortisone; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Skin; Survival Analysis; Treatment Outcome | 2014 |
Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Giant Cell Tumors; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Sarcoma; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
An uncommon insertion mutation in exon 19 of EGFR showed stable disease after TKI treatment.
Topics: Adenocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Middle Aged; Mutagenesis, Insertional; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
Topics: Adenocarcinoma; Aged; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Salvage Therapy | 2013 |
Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Community Networks; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Medical Oncology; Neoplasm Staging; Pemetrexed; Practice Patterns, Physicians'; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; United States | 2013 |
Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retreatment; Retrospective Studies; Smoking; Treatment Outcome | 2014 |
Complete metabolic remission with Gefitinib in a hemodialysis patient with bone metastases from non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Gefitinib; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Positron-Emission Tomography; Prognosis; Quinazolines; Remission Induction; Renal Dialysis; Tomography, X-Ray Computed | 2014 |
Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Vinblastine; Vinorelbine | 2014 |
A limited sampling strategy for estimation of the area under the plasma concentration-time curve of gefitinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Diarrhea; Drug Monitoring; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; ROC Curve; Sensitivity and Specificity; Specimen Handling; Time Factors | 2014 |
Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Crizotinib; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome | 2014 |
Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
EGFR exon 19 insertions show good response to gefitinib, but short time to progression in Japanese patients.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2014 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2014 |
The presence of EGFR mutations predicts the response in Chinese non-small cell lung cancer patients treated with erlotinib.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2014 |
Gefitinib and non-small cell lunt cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Taxoids | 2013 |
American Society of Clinical Oncology Annual Meeting 2013.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States | 2013 |
Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Quinazolines; Retrospective Studies | 2014 |
Afatinib for lung cancer: let there be light?
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Lung Neoplasms; Nitrosamines; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Quinazolines | 2014 |
Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Integrin beta1; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
[Radiosensitizing effect of erlotinib on human lung adenocarcinoma cell line A549].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Particle Accelerators; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents | 2013 |
Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Enzymologic; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Tamoxifen; Thymidine Phosphorylase; Time Factors | 2014 |
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Phosphatidylinositol 3-Kinases; Precision Medicine; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome | 2014 |
Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation, Missense; Proportional Hazards Models; Quinazolines; Retrospective Studies; Treatment Outcome | 2014 |
Gefitinib enhances the antitumor activity of CPT-11 in vitro and in vivo by inhibiting ABCG2 but not ABCB1: a new clue to circumvent gastrointestinal toxicity risk.
Topics: Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Cell Survival; Diarrhea; Drug Synergism; Drug Therapy, Combination; Female; Gefitinib; HEK293 Cells; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Quinazolines; RNA, Messenger; Transplantation, Heterologous | 2013 |
The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Phosphorylation; Quinazolines; Receptor, IGF Type 1; RNA, Small Interfering | 2014 |
Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Luteolin; Male; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Frequency; Genetic Association Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Quinazolines; Retrospective Studies; Treatment Outcome | 2014 |
Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.
Topics: AC133 Antigen; Animals; Antigens, CD; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Cell Separation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glycoproteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin-Like Growth Factor I; Lung Neoplasms; Mice, Inbred NOD; Mutation; Neoplasm Transplantation; Neoplastic Stem Cells; Octamer Transcription Factor-3; Peptides; Quinazolines; Receptor, IGF Type 1; Spheroids, Cellular; Up-Regulation | 2014 |
Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2014 |
Afatinib-related nonhematologic adverse events: is common evaluation enough for now?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2014 |
Reply to F. De Marinis et al.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2014 |
Reply to E.R. Haspinger et al.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2014 |
SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Pyrazoles; Quinazolines; Quinolines; Receptors, Neurotensin; RNA, Small Interfering; Transcriptional Activation; Transforming Growth Factor alpha | 2014 |
Humoral immune responses to EGFR-derived peptides predict progression-free and overall survival of non-small cell lung cancer patients receiving gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Humans; Immunity, Humoral; Immunoglobulin G; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Oligopeptides; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Quinazolines | 2014 |
Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Curcumin; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Mice; Mice, Nude; Mutation; Quinazolines; Random Allocation; Survivin; Xenograft Model Antitumor Assays | 2013 |
Simultaneous blockage of epidermal growth factor receptor and cyclooxygenase-2 in a human xenotransplanted lung cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Quinazolines; Sulfonamides; Transplantation, Heterologous | 2014 |
Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Apoptosis; Calcium Channel Blockers; Calcium Channels, T-Type; Cell Cycle Checkpoints; Cell Line, Tumor; Humans; Lung Neoplasms; Piperazines; Quinazolines | 2014 |
In-depth analysis shows synergy between erlotinib and miR-34a.
Topics: Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Lung Neoplasms; MicroRNAs; Quinazolines | 2014 |
Pneumonectomy after response to gefitinib treatment for lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biopsy; Chemotherapy, Adjuvant; Empyema, Pleural; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Lymph Node Excision; Mutation; Neoadjuvant Therapy; Neoplasm, Residual; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2013 |
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines | 2013 |
EGFR gene mutations in patients with adenosquamous lung carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Adenosquamous; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Poland; Polymerase Chain Reaction; Quinazolines; Remission Induction; Smoking | 2014 |
miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; Receptors, G-Protein-Coupled; RNA, Messenger; RNA, Neoplasm | 2014 |
High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Meningeal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Monitoring of gefitinib sensitivity with radioiodinated PHY based on EGFR expression.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, Emission-Computed, Single-Photon | 2014 |
Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA | 2014 |
MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MicroRNAs; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2014 |
Short-course treatment with gefitinib enhances curative potential of radiation therapy in a mouse model of human non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; ErbB Receptors; Gefitinib; Genes, erbB-1; Heterografts; Histones; Humans; Lung Neoplasms; Mice; Mitogen-Activated Protein Kinase Kinases; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2014 |
Erlotinib induced target-like purpura.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Purpura; Quinazolines | 2014 |
Synergistic anti-tumor effects of a novel phosphatidyl inositol-3 kinase/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Gefitinib; Humans; Imidazoles; Lung Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
A case of residual non-small cell lung cancer cells coexisting with newly developed small cell lung cancer cells in ascitic fluid after chemotherapy for non-small cell lung cancer.
Topics: Antineoplastic Agents; Ascitic Fluid; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2014 |
Successful gefitinib treatment administration via gastrostomy tube in a patient with non-small cell lung cancer with dysphagia.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deglutition Disorders; Drug Administration Routes; Female; Gastrostomy; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2014 |
Autocrine signaling via release of ATP and activation of P2X7 receptor influences motile activity of human lung cancer cells.
Topics: Adenosine Triphosphate; Autocrine Communication; Cell Line, Tumor; Cell Movement; Humans; Lung Neoplasms; Quinazolines; Receptors, Purinergic P2X7; Tyrphostins | 2014 |
Regulatory mechanisms of betacellulin in CXCL8 production from lung cancer cells.
Topics: Apoptosis; Betacellulin; Cell Count; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cycloheximide; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Lipopolysaccharides; Lung Neoplasms; Models, Biological; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Tumor Necrosis Factor-alpha | 2014 |
Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation, Missense; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Smoking; Treatment Outcome | 2014 |
Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Autophagy; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2014 |
Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Pemetrexed; Quinazolines; Radiography; Treatment Outcome | 2014 |
Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Interleukin-6; Kaplan-Meier Estimate; Lung Neoplasms; Metformin; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation.
Topics: Animals; Apoptosis; Aurora Kinase B; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cellular Senescence; Chromatin; DNA Breaks, Double-Stranded; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mutation; Protein Kinase C-alpha; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiation Tolerance; ras Proteins; Xenograft Model Antitumor Assays | 2014 |
Learning from errors: response to gefitinib in kidney urothelial carcinoma with EGFR mutations.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Kidney; Kidney Neoplasms; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Urothelium | 2014 |
EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Dynamins; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Knockdown Techniques; Humans; Hydrazones; Lung Neoplasms; Male; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; rab GTP-Binding Proteins; Signal Transduction | 2014 |
Celastrol induces apoptosis in gefitinib-resistant non-small cell lung cancer cells via caspases-dependent pathways and Hsp90 client protein degradation.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mitochondria; Pentacyclic Triterpenes; Protein Kinase Inhibitors; Proteolysis; Quinazolines; Signal Transduction; Triterpenes | 2014 |
Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mass Spectrometry; Mice; Mice, Nude; Multimodal Imaging; Phthalazines; Piperidines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2014 |
Changes in symptom severity in Taiwanese lung cancer patients after gefitinib treatment: a pilot study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Quinazolines; Severity of Illness Index; Symptom Assessment; Taiwan; Treatment Outcome | 2014 |
Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Brain Neoplasms; Cranial Irradiation; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Retrospective Studies; Survival Analysis | 2014 |
Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Taxoids | 2014 |
T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines | 2014 |
Second line treatment for EGFR wild-type advanced NSCLC: the jury is still out.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Salvage Therapy; Taxoids | 2014 |
Reossification of osteolytic metastases at the acetabulum following gefitinib and multidisciplinary treatment for lung cancer: a case report with autopsy findings.
Topics: Acetabulum; Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Autopsy; Biopsy; Bone Neoplasms; Disease Progression; ErbB Receptors; Fatal Outcome; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Ossification, Heterotopic; Quinazolines; Tomography, X-Ray Computed | 2015 |
An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Afatinib in NSCLC harbouring EGFR mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; PPAR gamma; Protein Kinase Inhibitors; Quinazolines; Smad2 Protein; Thiazolidinediones; Transforming Growth Factor beta2; Wound Healing | 2014 |
Efficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dendritic Cells; Erlotinib Hydrochloride; Female; Humans; Immunotherapy, Adoptive; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2014 |
Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Quinazolines | 2014 |
Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Death; Cell Proliferation; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice, Nude; Microtubules; Mitosis; Niacinamide; Paclitaxel; Phosphorylation; Polymerization; Quinazolines; STAT3 Transcription Factor; Sulfonamides; Tubulin; Tumor Suppressor Protein p53; Vincristine | 2014 |
Suppression of Dicer increases sensitivity to gefitinib in human lung cancer cells.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression; Gene Knockdown Techniques; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Quinazolines; Retrospective Studies; Ribonuclease III; RNA, Messenger | 2014 |
Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Time Factors; Treatment Outcome; United Kingdom | 2014 |
Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Tumor Cells, Cultured | 2014 |
Combined therapeutic potential of nuclear receptors with receptor tyrosine kinase inhibitors in lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cyclin B; Cyclin D1; ErbB Receptors; Gefitinib; Humans; Hydrocarbons, Fluorinated; Indoles; Liver X Receptors; Lung Neoplasms; Orphan Nuclear Receptors; Protein Kinase Inhibitors; Quinazolines; Receptors, Cytoplasmic and Nuclear; Sulfonamides; Sulfones | 2014 |
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2014 |
Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment.
Topics: Adenocarcinoma; Amino Acid Sequence; Base Sequence; Carcinoma, Large Cell; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Molecular Sequence Data; Mutagenesis, Insertional; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2014 |
Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Methionine; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Republic of Korea; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Threonine; Treatment Outcome; Tumor Cells, Cultured | 2014 |
SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Humans; Lung Neoplasms; Mice, Transgenic; Mutation; Neoplasms, Experimental; Quinazolines; SOXB1 Transcription Factors | 2014 |
An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Integrin alphaVbeta3; Integrin beta3; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Molecular Targeted Therapy; Neoplastic Stem Cells; Phenotype; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-rel; Proto-Oncogene Proteins p21(ras); Quinazolines; ral GTP-Binding Proteins; Randomized Controlled Trials as Topic; ras Proteins; RNA Interference; Signal Transduction; Spheroids, Cellular; Time Factors; Transfection; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Erlotinib or gefitinib as first-choice therapy for bronchorrhea in bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Bronchi; Bronchial Diseases; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Radiography, Thoracic | 2014 |
RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Silencing; Humans; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; rac1 GTP-Binding Protein; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
The TAILOR study: to agree or to disagree?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Research Design; Salvage Therapy; Taxoids | 2014 |
Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Everolimus; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutant Proteins; Mutation; Neovascularization, Pathologic; Phosphorylation; Quinazolines; Ribosomal Protein S6; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
Cytoplasmic YAP expression is associated with prolonged survival in patients with lung adenocarcinomas and epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Cytoplasm; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphoproteins; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Response Evaluation Criteria in Solid Tumors; Survival Rate; Transcription Factors; YAP-Signaling Proteins; Young Adult | 2014 |
Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Phenotype; Quinazolines; Retrospective Studies | 2014 |
Case of erlotinib-induced photosensitivity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Dermatitis, Photoallergic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Patch Tests; Protein Kinase Inhibitors; Quinazolines | 2014 |
Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Computational Biology; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Nitriles; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Quinolines; Sequence Analysis, RNA | 2014 |
Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Mice, Transgenic; Multiprotein Complexes; Mutation; Quinazolines; Random Allocation; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Cell Proliferation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Quinolines; Thiourea; Vascular Endothelial Growth Factor A | 2014 |
Radiation pneumonitis in patients with non--small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radiation Pneumonitis; Radiography; Severity of Illness Index | 2014 |
Small-cell lung cancers in patients who never smoked cigarettes.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Chromogranins; Class I Phosphatidylinositol 3-Kinases; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Rearrangement; GTP-Binding Protein alpha Subunits, Gs; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Second Primary; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-cbl; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Retinoblastoma Protein; Retrospective Studies; Small Cell Lung Carcinoma; Smoking; Survival Rate; Telomerase; Tumor Suppressor Protein p53 | 2014 |
A complex deletion/insertion on exon 19 of the EGFR gene predicts response to gefitinib.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Exons; Female; Gefitinib; Humans; INDEL Mutation; Lung Neoplasms; Quinazolines | 2014 |
VeriStrat validated in patients with non-small-cell lung cancer.
Topics: Blood Proteins; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Proteomics; Quinazolines | 2014 |
Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cyclin B1; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; HEK293 Cells; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; RNA Interference; Time Factors; Transfection; Tumor Burden; Wnt Proteins; Wnt-5a Protein; Xenograft Model Antitumor Assays | 2014 |
Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; ErbB Receptors; Female; Humans; Li-Fraumeni Syndrome; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2 | 2014 |
Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; G1 Phase Cell Cycle Checkpoints; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2014 |
Development of a new colorimetric and red-emitting fluorescent dual probe for G-quadruplex nucleic acids.
Topics: Alkaloids; Colorimetry; DNA; DNA, Ribosomal; Fluorescent Dyes; G-Quadruplexes; HeLa Cells; Humans; Indicators and Reagents; Lung Neoplasms; Molecular Structure; Nucleolin; Phosphoproteins; Quinazolines; RNA-Binding Proteins; Spectrometry, Fluorescence | 2014 |
Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Indoles; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines | 2014 |
Commentary: highlights in NSCLC from the 15th World Conference on Lung Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Paclitaxel; Quinazolines | 2014 |
Ten lessons from EGFR.
Topics: Afatinib; Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines | 2014 |
Afatinib with concurrent radiotherapy in a patient with metastatic non-small cell lung cancer.
Topics: Afatinib; Aged; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Humans; Lung Neoplasms; Quinazolines; Radiotherapy, Conformal; Treatment Outcome | 2014 |
[Joint serum tumor markers serve as survival predictive model of erlotinib in the treatment of recurrent non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Rate | 2014 |
[Efficacy of gefitinib for young patients with unknown EGFR gene mutation
in advanced lung adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2014 |
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome; United States; United States Food and Drug Administration; Young Adult | 2014 |
Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
Topics: Animals; Antineoplastic Agents; Cell Line; DNA Repair; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Enzymologic; Humans; Isoquinolines; Lung Neoplasms; Lymphangioleiomyomatosis; Mice, Inbred C57BL; Mice, SCID; Molecular Targeted Therapy; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolines; Rats; Sirolimus; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Marsdenia; Phosphatidylinositol 3-Kinases; Phytotherapy; Plant Extracts; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Transplantation, Heterologous | 2014 |
Fibroblasts weaken the anti-tumor effect of gefitinib on co-cultured non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Epithelial-Mesenchymal Transition; Fibroblasts; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2014 |
EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: clinical correlations and response to therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Cognition Disorders; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Treatment Outcome | 2014 |
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression; Humans; Immunoconjugates; Lung Neoplasms; Maytansine; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Humans; Lung Neoplasms; Multidrug Resistance-Associated Protein 2; Neoplasm Proteins; Quinazolines | 2014 |
A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Amino Acid Substitution; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Codon; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; GPI-Linked Proteins; Homeodomain Proteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Nude; MicroRNAs; Mutation; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Transcription Factors; Xenograft Model Antitumor Assays; Zinc Finger E-box-Binding Homeobox 1 | 2014 |
Comparison is beyond IPASS and OPTIMAL.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
[Long-term survival with complete response by gefitinib treatment followed by noncurative operation for lung cancer].
Topics: Antineoplastic Agents; Combined Modality Therapy; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Time Factors; Vena Cava, Superior | 2014 |
Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Disease Models, Animal; Erlotinib Hydrochloride; Female; Fibroblasts; Humans; Interleukin-6; Lung Neoplasms; Mice; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Serine; STAT3 Transcription Factor; Tyrosine | 2014 |
Identification of metabolic signatures associated with erlotinib resistance of non-small cell lung cancer cells.
Topics: Adenocarcinoma; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Copy Number Variations; Drug Resistance, Neoplasm; Electrophoresis, Capillary; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Metabolome; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2014 |
Primary and secondary resistance to tyrosine kinase inhibitors in lung cancer.
Topics: Apoptosis; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2014 |
Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Quinazolines; Renal Dialysis | 2014 |
Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Keratin-19; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2014 |
Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Italy; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases | 2014 |
Coexistence of tyrosine kinase inhibitor-sensitizing and resistant EGFR mutations in an untreated lung adenocarcinoma patient and response to erlotinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Palliative Care; Protein Kinase Inhibitors; Quinazolines | 2014 |
Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Erlotinib Hydrochloride; Female; Gene Expression; Gene Expression Profiling; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Platinum; Prognosis; Prospective Studies; Quinazolines; Reproducibility of Results; Risk Factors | 2014 |
Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
Topics: Animals; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Gefitinib; Humans; Imidazoles; Ki-67 Antigen; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Quinolines; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
ARRY-334543 reverses multidrug resistance by antagonizing the activity of ATP-binding cassette subfamily G member 2.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Neoplasm Proteins; Oncogene Proteins v-erbB; Paclitaxel; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Thiazoles | 2014 |
Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Matrix; Gefitinib; Humans; Lung; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Microenvironment | 2014 |
Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chloroquine; Drug Synergism; ErbB Receptors; Female; Gefitinib; Heterocyclic Compounds, 3-Ring; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; Xenograft Model Antitumor Assays | 2014 |
management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis.
Topics: Afatinib; Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Feeding Behavior; Gefitinib; Humans; Incidence; Lung Neoplasms; Mucositis; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Withholding Treatment | 2014 |
CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
Topics: Animals; Apoptosis; Autoantigens; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Membrane Proteins; Mice; Protein Kinase Inhibitors; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Transcription, Genetic | 2014 |
AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2014 |
Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chalcones; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung; Lung Neoplasms; Mice, Nude; Molecular Docking Simulation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2015 |
[A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Consensus; Drug Administration Schedule; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4 | 2014 |
MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Proto-Oncogene Proteins c-met; Quinazolines; Random Allocation; Transfection; Xenograft Model Antitumor Assays | 2014 |
Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, Liquid; Cisplatin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Pemetrexed; Quinazolines; Retrospective Studies; Tandem Mass Spectrometry | 2015 |
Increased INR after gefitinib and acenocoumarol co-administration.
Topics: Acenocoumarol; Adenocarcinoma; Aged; Anticoagulants; Antineoplastic Agents; Atrial Fibrillation; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Gefitinib; Heart Failure; Humans; International Normalized Ratio; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2014 |
Development of bilateral acquired toxoplasmic retinochoroiditis during erlotinib therapy.
Topics: Adenocarcinoma; Anti-Infective Agents; Atovaquone; Chorioretinitis; ErbB Receptors; Erlotinib Hydrochloride; Female; Food Parasitology; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Toxoplasma; Toxoplasmosis, Ocular | 2014 |
Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain; Cetuximab; ErbB Receptors; Fatal Outcome; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Meningeal Neoplasms; Mutation; Neoplasms, Second Primary; Quinazolines | 2014 |
Chronopharmacology and mechanism of antitumor effect of erlotinib in Lewis tumor-bearing mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Phosphoproteins; Proto-Oncogene Proteins c-akt; Quinazolines; Time Factors; Xenograft Model Antitumor Assays | 2014 |
The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2014 |
The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Vimentin; X-Rays | 2014 |
Reversible nyctalopia and retinopathy in a patient with metastatic cancer treated with anti-heat shock protein 90 therapy.
Topics: Adenocarcinoma; Aged; Autoantibodies; Autoantigens; Electroretinography; Erlotinib Hydrochloride; HSP90 Heat-Shock Proteins; Humans; Infusions, Intravenous; Isoxazoles; Lung Neoplasms; Male; Night Blindness; Paraneoplastic Syndromes, Ocular; Phosphopyruvate Hydratase; Quinazolines; Resorcinols; Retina; Tomography, Optical Coherence; Visual Acuity | 2014 |
EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Repetitive Sequences, Nucleic Acid; Risk Factors; Treatment Outcome | 2014 |
Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA; DNA-Binding Proteins; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; High Mobility Group Proteins; Humans; Luciferases; Lung Neoplasms; Mice; Mice, Nude; NF-kappa B p50 Subunit; Quinacrine; Quinazolines; RNA, Small Interfering; Transcriptional Elongation Factors; Xenograft Model Antitumor Assays | 2014 |
Network-based modeling and intelligent data mining of social media for improving care.
Topics: Antineoplastic Agents; Artificial Intelligence; Computer Simulation; Data Mining; Erlotinib Hydrochloride; Health Literacy; Humans; Lung Neoplasms; Meaningful Use; Models, Statistical; Natural Language Processing; Needs Assessment; Patient Education as Topic; Patient Satisfaction; Quality Improvement; Quinazolines; Social Media; Treatment Outcome; Vocabulary, Controlled | 2015 |
Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Point Mutation; Quinazolines; Retrospective Studies; Sequence Deletion; Treatment Outcome | 2014 |
Detection of mutations by fill-in ligation reaction with enzyme-linked immunosorbent assay for rapid medical diagnosis.
Topics: Base Sequence; DNA Mutational Analysis; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Exons; Gefitinib; Genotyping Techniques; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Plasmids; Polymorphism, Single Nucleotide; Quinazolines; Time Factors; Treatment Outcome | 2014 |
Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib--a cohort study.
Topics: Carcinoma, Non-Small-Cell Lung; Cohort Studies; Erlotinib Hydrochloride; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Tomography, X-Ray Computed | 2014 |
EGFR-mutated lung cancer in Li-Fraumeni syndrome.
Topics: Adult; Breast Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Li-Fraumeni Syndrome; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Tumor Suppressor Protein p53; Young Adult | 2014 |
Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorine Radioisotopes; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Radiopharmaceuticals; RNA Interference; Xenograft Model Antitumor Assays | 2014 |
Assay of lapatinib in murine models of cigarette smoke carcinogenesis.
Topics: Animals; Antineoplastic Agents; Body Weight; Disease Models, Animal; DNA Adducts; DNA Damage; Erythrocytes; Gene Expression Regulation; Lapatinib; Lung; Lung Neoplasms; Mice; MicroRNAs; Protein Kinase Inhibitors; Quinazolines; Tobacco Smoke Pollution; Toxicity Tests, Subchronic | 2014 |
Effective ultra-low doses of erlotinib in patients with EGFR sensitising mutation.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; DNA, Neoplasm; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Erlotinib treatment of meningeal carcinomatosis in lung cancer: more is better.
Topics: ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Neoplasm Metastasis; Quinazolines | 2014 |
Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Lung Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, Nude; MicroRNAs; Neoplasm Transplantation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Survival Analysis | 2014 |
A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Carcinogenesis; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Oncogene Proteins, Fusion; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2014 |
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Interleukin-6; Janus Kinase 1; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mice, SCID; Mutation; Nitriles; Oncogenes; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridazines; Pyrimidines; Quinazolines; ras Proteins; Receptors, Fibroblast Growth Factor; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2014 |
Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression; Humans; Ligands; Lung Neoplasms; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Neoplasm Proteins; Principal Component Analysis; Protein Kinase Inhibitors; Protein Structure, Secondary; Protein Structure, Tertiary; Quinazolines | 2014 |
Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Erlotinib Hydrochloride; Female; Humans; Intensive Care Units; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Respiration, Artificial; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Monitoring cancer through the blood.
Topics: Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Monitoring, Physiologic; Protein Kinase Inhibitors; Quinazolines | 2014 |
Hinokitiol induces DNA damage and autophagy followed by cell cycle arrest and senescence in gefitinib-resistant lung adenocarcinoma cells.
Topics: Acridine Orange; Adenocarcinoma; Adenocarcinoma of Lung; Annexin A5; Antineoplastic Agents, Phytogenic; Autophagy; Blotting, Western; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Cupressaceae; DNA Damage; Drug Resistance, Neoplasm; ErbB Receptors; Gas Chromatography-Mass Spectrometry; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Monoterpenes; Oils, Volatile; Quinazolines; Real-Time Polymerase Chain Reaction; Taiwan; Tropolone; Tumor Stem Cell Assay | 2014 |
FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mutation; Nuclear Proteins; Oncogene Protein v-akt; Protein Kinase Inhibitors; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Transfection; Twist-Related Protein 1 | 2014 |
Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Gene Amplification; Humans; Lactams, Macrocyclic; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-3 | 2014 |
Effective treatment with icotinib in primary adenoid cystic carcinoma of the lung with liver metastasis.
Topics: Adult; Biopsy; Carcinoma, Adenoid Cystic; Crown Ethers; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Quinazolines; Tomography, X-Ray Computed | 2014 |
3,6,2',4',5'-Pentahydroxyflavone, an orally bioavailable multiple protein kinase inhibitor, overcomes gefitinib resistance in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Aurora Kinase B; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Flavonoids; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Burden | 2014 |
High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling.
Topics: Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoplastic Stem Cells; Quinazolines; Receptor, Notch3; Receptors, Notch; Signal Transduction; Transcription, Genetic | 2014 |
Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Cohort Studies; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2014 |
Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2014 |
Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non-small-cell lung cancer: a 10-year retrospective population-based review.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; British Columbia; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Therapy; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum Compounds; Quinazolines; Retrospective Studies; Sex Factors; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2014 |
Spatiotemporal T790M heterogeneity in a patient with EGFR-mutant non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Genetic Heterogeneity; Humans; Lung Neoplasms; Mutation; Quinazolines; Spatio-Temporal Analysis | 2014 |
β-catenin contributes to lung tumor development induced by EGFR mutations.
Topics: Afatinib; Animals; Antineoplastic Agents; beta Catenin; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Doxycycline; ErbB Receptors; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Lung Neoplasms; Mice, Transgenic; Mutation, Missense; Protein Stability; Quinazolines; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation.
Topics: Adult; Aged; Aged, 80 and over; Body Surface Area; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Time Factors; Treatment Outcome | 2014 |
What new therapeutic targets exist for EGFR-mutant NSCLC?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2014 |
Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; Cell Surface Extensions; Chick Embryo; Cortactin; Female; Humans; Lung Neoplasms; Matrix Metalloproteinase 14; Mice; Mice, Nude; Neoplasm Metastasis; Neoplastic Stem Cells; Phosphate-Binding Proteins; Phosphoproteins; Protein Kinase Inhibitors; Quinazolines; Transcellular Cell Migration | 2014 |
TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway.
Topics: Animals; Apoptosis; Autoantigens; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 9; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Membrane Proteins; Mice; Mice, Nude; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines | 2014 |
Prognostic significance of microRNA expression in completely resected lung adenocarcinoma and the associated response to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Retrospective Studies; Survival Analysis | 2014 |
Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dasatinib; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Focal Adhesion Kinase 1; Genes, erbB-1; Humans; Immunoblotting; Lung Neoplasms; Mice; Mice, Nude; Mutation; Pyrimidines; Quinazolines; Signal Transduction; src-Family Kinases; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
Induced IGF-1R activation contributes to gefitinib resistance following combined treatment with paclitaxel, cisplatin and gefitinib in A549 lung cancer cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Treatment Failure; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Melatonin; Mutation; Phosphorylation; Quinazolines | 2014 |
Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Drug Substitution; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2014 |
Pulmonary embolism with haemorrhagic pericardial effusion and tamponade: a clinical dilemma.
Topics: Anticoagulants; Carcinoma, Non-Small-Cell Lung; Cardiac Tamponade; Diagnosis, Differential; Drainage; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Multiple Organ Failure; Pericardial Effusion; Protein Kinase Inhibitors; Pulmonary Embolism; Quinazolines; Treatment Outcome; Vena Cava Filters | 2014 |
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.
Topics: Adenine; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Methionine; Mice; Mutation; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Threonine | 2014 |
Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Cohort Studies; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Treatment Outcome | 2014 |
Distribution of EGFR mutations commonly observed in primary lung adenocarcinomas in Pakistan as predictors for targeted therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Asian People; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pakistan; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction | 2014 |
Therapeutic effects and adverse drug reactions are affected by icotinib exposure and CYP2C19 and EGFR genotypes in Chinese non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; China; Chromatography, High Pressure Liquid; Crown Ethers; Cytochrome P-450 CYP2C19; Disease-Free Survival; Drug Eruptions; Female; Genes, erbB-1; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Tandem Mass Spectrometry | 2014 |
Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Caspase 8; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Cytoplasm; Dose-Response Relationship, Drug; Enzyme Activation; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Microscopy, Confocal; Mutation; Protein Binding; Protein Kinase Inhibitors; Protein Transport; Quinazolines | 2014 |
Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Compassionate Use Trials; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2014 |
Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; MCF-7 Cells; Mutagenesis, Site-Directed; Mutation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transcription Factors | 2014 |
[Safety of reintroduction of erlotinib at low doses following hand-foot syndrome induced by erlotinib treatment for a Pancoast-Tobias tumour].
Topics: Aged, 80 and over; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Hand-Foot Syndrome; Humans; Lung Neoplasms; Male; Pancoast Syndrome; Protein Kinase Inhibitors; Quinazolines; Retreatment | 2014 |
Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Enzyme Activation; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Pyrones; Quinazolines; Signal Transduction; Thiophenes; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome | 2014 |
Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Interactions; Erlotinib Hydrochloride; Female; Gastric Acid; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lung Neoplasms; Male; Middle Aged; Omeprazole; Population Groups; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.
Topics: Adult; Afatinib; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Animals; Autocrine Communication; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Female; Heparin-binding EGF-like Growth Factor; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Matrix Metalloproteinase 1; Mice, Nude; Middle Aged; Neoplasm Staging; Neuregulin-1; Neurotensin; Paracrine Communication; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Neurotensin; Signal Transduction; Time Factors; Treatment Outcome; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retreatment; Retrospective Studies; Risk Factors; Treatment Outcome; Young Adult | 2014 |
Erlotinib-induced cutaneous toxicity: findings on 18F-FDG PET/CT imaging.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Skin Diseases; Tomography, X-Ray Computed | 2015 |
The role of BIM-EL and BCL2-α on the efficacy of erlotinib and gefitinib in lung cancer.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Membrane Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Real-Time Polymerase Chain Reaction; RNA, Messenger | 2015 |
Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Cysts; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Neoplasm Metastasis; Pneumothorax; Protein Kinase Inhibitors; Quinazolines; Rupture, Spontaneous | 2014 |
Cost-effectiveness of epidermal growth factor receptor-targeting tyrosine kinase inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Crotoxin suppresses the tumorigenic properties and enhances the antitumor activity of Iressa® (gefinitib) in human lung adenocarcinoma SPCA‑1 cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinogenesis; Cell Line, Tumor; Crotoxin; ErbB Receptors; G1 Phase Cell Cycle Checkpoints; Gefitinib; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Neovascularization, Pathologic; Quinazolines | 2014 |
Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications.
Topics: Animals; Cell Culture Techniques; Cell Line, Tumor; Disease Models, Animal; Erlotinib Hydrochloride; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Membrane Proteins; Mice; Myristoylated Alanine-Rich C Kinase Substrate; Phosphatidylinositol 3-Kinase; Phosphatidylinositol Phosphates; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2014 |
Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines.
Topics: Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphenylamine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Hepatocyte Growth Factor; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; ras Proteins | 2015 |
Estrogen adversely affects the prognosis of patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; ErbB Receptors; Estradiol; Estrogen Receptor beta; Estrogens; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; MAP Kinase Signaling System; Middle Aged; Osteopontin; Pleural Effusion, Malignant; Prognosis; Prospective Studies; Quinazolines; Transcriptional Activation | 2015 |
MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Computational Biology; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results | 2015 |
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Comparative Genomic Hybridization; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Variation; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Phosphatidylinositol 3-Kinases; Polymerase Chain Reaction; Proteomics; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2015 |
Pim-1 kinase is a target of miR-486-5p and eukaryotic translation initiation factor 4E, and plays a critical role in lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Eukaryotic Initiation Factor-4E; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Protein Biosynthesis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-pim-1; Quinazolines; Transcription, Genetic | 2014 |
The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies | 2015 |
Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Are we expanding oligometastatic non-small-cell lung cancer using advanced radiotherapeutic modalities?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Radiosurgery | 2014 |
Long‑term exposure to gefitinib induces acquired resistance through DNA methylation changes in the EGFR‑mutant PC9 lung cancer cell line.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Methylation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Microarray Analysis; Mutation; Quinazolines; Time Factors | 2015 |
Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphocytes; Male; Neutrophils; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2017 |
Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Cytoskeletal Proteins; Female; Humans; Lung Neoplasms; Neoplasm Metastasis; Oncogene Proteins, Fusion; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Treatment Outcome | 2016 |
Long-term survival of non-small-cell lung cancer patients with EGFR inhibitor treatment.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2014 |
In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Crown Ethers; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Humans; Inhibitory Concentration 50; Lung Neoplasms; Paclitaxel; Quinazolines; Resting Phase, Cell Cycle; Signal Transduction | 2015 |
Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer.
Topics: Acrylamides; Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Caspases; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Lung Neoplasms; Mice; Mutation; Neoplasm Transplantation; Pyrimidines; Quinazolines; Vorinostat; Xenograft Model Antitumor Assays | 2015 |
Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Fibroblasts; Gefitinib; Gene Expression; Humans; Lung Neoplasms; Male; Membrane Glycoproteins; Middle Aged; Mutation; Phosphorylation; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines; Risk Factors; Treatment Outcome; Tumor Microenvironment | 2015 |
The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.
Topics: Antigens, CD; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor Protein-Tyrosine Kinases; RNA Interference; Signal Transduction; Time Factors; Transfection; Vimentin | 2014 |
Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Time Factors; Transfection; Tumor Suppressor Proteins | 2014 |
Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; DNA Mutational Analysis; Female; Gefitinib; Genes, erbB-1; High-Throughput Nucleotide Sequencing; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor Protein-Tyrosine Kinases; Sensitivity and Specificity; Sulfones; Translocation, Genetic | 2015 |
Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Autophagy; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung; Lung Neoplasms; Mass Spectrometry; Phosphopeptides; Phosphorylation; Point Mutation; Protein Kinase Inhibitors; Proteomics; Quinazolines; Signal Transduction | 2015 |
Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mucin-1; Mutation; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Risk Factors; RNA, Messenger; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
CUL4A overexpression enhances lung tumor growth and sensitizes lung cancer cells to erlotinib via transcriptional regulation of EGFR.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cullin Proteins; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Transcription, Genetic | 2014 |
Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic non-small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Metastasis; Pemetrexed; Quinazolines; Stevens-Johnson Syndrome | 2015 |
Is the evidence of the Supreme Court Ruling of gefitinib litigation in Japan scientific?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Labeling; Drug Packaging; Gefitinib; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Product Surveillance, Postmarketing; Quinazolines | 2014 |
New therapy targets resistant non-small-cell lung cancers.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Drug Combinations; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; National Cancer Institute (U.S.); Quinazolines; United States | 2014 |
Current status and study activity of lung cancer in Japan.
Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Japan; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Research | 2014 |
Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: a retrospective case-control study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Disease-Free Survival; Drugs, Chinese Herbal; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies | 2014 |
P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
Topics: Activin Receptors, Type II; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; HeLa Cells; Humans; Imidazoles; Lung Neoplasms; Male; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Nude; Multiprotein Complexes; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinolines; ras Proteins; TOR Serine-Threonine Kinases | 2014 |
Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanism.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Administration Schedule; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; MAP Kinase Signaling System; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2014 |
Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.
Topics: Acrylamides; Afatinib; Aged; Aniline Compounds; Animals; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Male; Mice, Nude; Molecular Targeted Therapy; Mutation; Quinazolines | 2015 |
The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Membrane; Chromones; Cytoplasm; Diketopiperazines; ErbB Receptors; Erlotinib Hydrochloride; Heterocyclic Compounds, 4 or More Rings; Humans; Lung Neoplasms; Morpholines; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2014 |
Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.
Topics: Apoptosis; Autophagy; Casein Kinase II; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Naphthyridines; Phagosomes; Phenazines; Protein Kinase Inhibitors; Quinazolines | 2014 |
Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cluster Analysis; CpG Islands; DNA Methylation; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Lung; Lung Neoplasms; Phenotype; Prognosis; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results | 2014 |
Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Enoxaparin; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; rac GTP-Binding Proteins; Vimentin; Xenograft Model Antitumor Assays | 2015 |
Predictive and prognostic significance of sodium levels in patients with NSCLC treated by erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hyponatremia; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sodium; Treatment Outcome | 2014 |
Evodiamine induces G2/M arrest and apoptosis via mitochondrial and endoplasmic reticulum pathways in H446 and H1688 human small-cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Endoplasmic Reticulum; Humans; Lung Neoplasms; M Phase Cell Cycle Checkpoints; Mitochondria; Quinazolines; Small Cell Lung Carcinoma | 2014 |
Acquired resistance to EGFR tyrosine kinase inhibitor in A431 squamous cell carcinoma xenografts is mediated by c-Kit pathway transduction.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
Long-term outcome of surgical resection for residual or regrown advanced non-small cell lung carcinomas following EGFR-TKI treatment: report of four cases.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Pneumonectomy; Quinazolines | 2016 |
[Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Disease-Free Survival; ErbB Receptors; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Pemetrexed; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Computer Simulation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Molecular; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice, Nude; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; RNA, Messenger; Xenograft Model Antitumor Assays | 2015 |
Nit-picking around second line in EGFRwt NSCLC: just an academic effort.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Quinazolines | 2015 |
Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Quinazolines; RNA, Small Interfering; Signal Transduction | 2015 |
Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A.
Topics: Afatinib; Aged; Animals; Apoptosis; Autoantigens; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; ets-Domain Protein Elk-1; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Lung Neoplasms; Male; Membrane Proteins; Mice, Nude; Middle Aged; Mutation; Promoter Regions, Genetic; Protein Binding; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Xenograft Model Antitumor Assays | 2015 |
[Effect of EGFR-TKI on lymphangiogenesis of lung cancer with EGFR mutation].
Topics: Afatinib; Animals; Cell Line, Tumor; ErbB Receptors; Female; Humans; Lung Neoplasms; Lymphangiogenesis; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Kinomic profiling of electromagnetic navigational bronchoscopy specimens: a new approach for personalized medicine.
Topics: Aged; Aged, 80 and over; Bronchoscopy; Crizotinib; Electromagnetic Phenomena; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Phosphotransferases; Precision Medicine; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines | 2014 |
Interstitial lung disease arising from erlotinib treatment in a Caucasian patient.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; White People | 2015 |
Histologic evolution from adenocarcinoma to squamous cell carcinoma after gefitinib treatment.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2015 |
Can EGFR mutation status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Preoperative Care; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA | 2015 |
Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; ras Proteins; Receptor, Notch1; Tumor Suppressor Protein p53 | 2014 |
γ Secretase inhibitor BMS-708163 reverses resistance to EGFR inhibitor via the PI3K/Akt pathway in lung cancer.
Topics: Amyloid Precursor Protein Secretases; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; ErbB Receptors; Female; Gefitinib; Immunohistochemistry; Lung Neoplasms; Mice; Mice, Inbred BALB C; Oxadiazoles; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Sulfonamides | 2015 |
[Cetuximab in combination with icotinib overcomes the acquired resistance caused by EGFR T790M mutation in non-small cell lung cancer].
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cetuximab; Crown Ethers; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Genes, erbB-1; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Quinazolines; Signal Transduction | 2014 |
Prognostic potential of initial CT changes for progression-free survival in gefitinib-treated patients with advanced adenocarcinoma of the lung: a preliminary analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Epidemiologic Methods; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer in the era of personalized medicine.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Quinazolines; Taxoids | 2015 |
Alternative strategy to achieve increased overall survival and better quality of life in patients with second-line advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Palliative Care; Quinazolines; Taxoids | 2015 |
Reply to G. Spitzer and M.A. Socinski, F. Zhou et al, and B. Biswas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Palliative Care; Quinazolines; Taxoids | 2015 |
Epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR wild-type lung cancer: when there is a target, there is a targeted drug.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Quinazolines; Taxoids | 2015 |
Reply to G. Spitzer and M.A. Socinski.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Palliative Care; Quinazolines; Taxoids | 2015 |
LUX-Lung: determining the best EGFR inhibitor in NSCLC?
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2015 |
DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Dual Specificity Phosphatase 1; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Quinazolines; Xenograft Model Antitumor Assays | 2015 |
ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction | 2015 |
Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Central Nervous System Neoplasms; Disease Progression; Female; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Time Factors; Trastuzumab; Treatment Outcome | 2015 |
Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Young Adult | 2014 |
A case of new onset keratosis pilaris after discontinuation of erlotinib.
Topics: Abnormalities, Multiple; Antineoplastic Agents; Darier Disease; ErbB Receptors; Erlotinib Hydrochloride; Eyebrows; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2014 |
Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA End-Joining Repair; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; M Phase Cell Cycle Checkpoints; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Resorcinols | 2015 |
Erlotinib efficacy in NSCLC patients with high polysomy of chromosome 7 and EGFR/KRas wild-type tumors.
Topics: Aneuploidy; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chromosomes, Human, Pair 7; Cohort Studies; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2015 |
Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study.
Topics: Alleles; Amino Acid Substitution; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Lapatinib; Lung Neoplasms; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2015 |
Targeted therapies: LUX-Lung trials-not all mutations are created equal.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2015 |
Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dose Fractionation, Radiation; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Myelitis; Palliative Care; Quinazolines; Radiation Injuries; Spinal Neoplasms; Thoracic Vertebrae | 2015 |
AURKA upregulation plays a role in fibroblast-reduced gefitinib sensitivity in the NSCLC cell line HCC827.
Topics: Antineoplastic Agents; Aurora Kinase A; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Coculture Techniques; Drug Resistance, Neoplasm; Enzyme Induction; ErbB Receptors; Fibroblasts; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genes, erbB-1; Humans; Lung Neoplasms; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-mdm2; Quinazolines; Recombinant Fusion Proteins; RNA Interference; RNA, Small Interfering; Signal Transduction; Stromal Cells; Tumor Suppressor Protein p53; Up-Regulation | 2015 |
Gender-based impact of epidermal growth factor receptor mutation in patients with nonsmall cell lung cancer and previous tuberculosis.
Topics: Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sex Factors; Taiwan; Tuberculosis, Pulmonary | 2015 |
CpG hypermethylation contributes to decreased expression of PTEN during acquired resistance to gefitinib in human lung cancer cell lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; CpG Islands; Cyclin D1; DNA Methylation; Drug Resistance, Neoplasm; Early Growth Response Protein 1; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Intercellular Adhesion Molecule-1; Lung Neoplasms; Phosphorylation; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines | 2015 |
Ets1 identified as a novel molecular target of RNA aptamer selected against metastatic cells for targeted delivery of nano-formulation.
Topics: Animals; Antineoplastic Agents; Aptamers, Nucleotide; Cell Line, Tumor; Cell Membrane Permeability; Drug Carriers; Female; Gefitinib; Humans; Lactic Acid; Lung Neoplasms; Mice, Nude; Nanoparticles; Neoplasm Metastasis; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Proto-Oncogene Protein c-ets-1; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
EGF‑stimulated AKT activation is mediated by EGFR recycling via an early endocytic pathway in a gefitinib‑resistant human lung cancer cell line.
Topics: Cell Line, Tumor; Cell Membrane; Drug Resistance, Neoplasm; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Monensin; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sorting Nexins | 2015 |
SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer.
Topics: Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; DNA-Binding Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Polycomb Repressive Complex 1; Proto-Oncogene Proteins c-met; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2015 |
Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib-induced cytotoxicity in human lung cancer cells.
Topics: Antineoplastic Agents; Cell Proliferation; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Drug Screening Assays, Antitumor; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Messenger; Signal Transduction; Structure-Activity Relationship; Tumor Cells, Cultured; X-ray Repair Cross Complementing Protein 1 | 2015 |
A 'shock-ing' endoscopic finding on esophagogastroduodenoscopy.
Topics: Adenocarcinoma; Antineoplastic Agents; Endoscopy, Digestive System; Erlotinib Hydrochloride; Esophagus; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Multiple Organ Failure; Necrosis; Quinazolines | 2015 |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2015 |
Oncologists push beyond new lung cancer genomic testing guidelines.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Genomics; Humans; Lung Neoplasms; Medical Oncology; Molecular Targeted Therapy; Mutation; Practice Guidelines as Topic; Precision Medicine; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Societies, Medical; Sulfones; Translocation, Genetic | 2015 |
CD133-Positive Cells from Non-Small Cell Lung Cancer Show Distinct Sensitivity to Cisplatin and Afatinib.
Topics: AC133 Antigen; Afatinib; Antigens, CD; Antigens, Neoplasm; Carcinoma, Non-Small-Cell Lung; Cell Adhesion Molecules; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Therapy, Combination; Epithelial Cell Adhesion Molecule; ErbB Receptors; Glycoproteins; Humans; Lung Neoplasms; Neoplastic Stem Cells; Peptides; Quinazolines | 2015 |
Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; CpG Islands; DNA Methylation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung; Lung Neoplasms; Male; MCF-7 Cells; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA | 2015 |
Long progression-free survival with afatinib in a patient with EGFR-unknown lung adenocarcinoma after erlotinib failure: a case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines; Treatment Failure; Treatment Outcome | 2015 |
Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Nicotine; Quinazolines; Receptors, Nicotinic; Signal Transduction; Smoking | 2015 |
Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; G1 Phase; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyridones; Pyrimidinones; Quinazolines; Sulfonamides; Up-Regulation; Vemurafenib | 2015 |
Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation.
Topics: Afatinib; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Quinazolines; Radiation-Sensitizing Agents; Random Allocation; Xenograft Model Antitumor Assays | 2015 |
The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells.
Topics: Actin Cytoskeleton; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Shape; Cell Survival; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; MAP Kinase Signaling System; Piperidines; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; rho GTP-Binding Proteins | 2015 |
Protein kinase Cα mediates erlotinib resistance in lung cancer cells.
Topics: Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase C-alpha; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transforming Growth Factor beta; Up-Regulation | 2015 |
Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Smoking; Treatment Outcome | 2015 |
Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carbolines; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; G2 Phase Cell Cycle Checkpoints; Gefitinib; Humans; Lung Neoplasms; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Docking Simulation; Molecular Targeted Therapy; Mutation; Phosphorylation; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Attitude to Health; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Quinazolines | 2015 |
Disease flare after gefitinib discontinuation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Withholding Treatment | 2015 |
Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorescent Antibody Technique, Indirect; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Mice; Mice, Nude; Mutation; Neovascularization, Pathologic; Proto-Oncogene Proteins c-myc; Quinazolines | 2015 |
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aniline Compounds; Antineoplastic Agents; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Recurrence; Retinoblastoma Protein; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides | 2015 |
Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Random Allocation; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays | 2015 |
Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Retrospective Studies; Seoul | 2016 |
CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dipeptides; ErbB Receptors; Gastrins; Gefitinib; Hormone Antagonists; Humans; Indoles; Lung Neoplasms; Meglumine; Pyrimidines; Quinazolines | 2015 |
AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.
Topics: Animals; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Mice, SCID; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptor Protein-Tyrosine Kinases; Resorcinols; Xenograft Model Antitumor Assays | 2015 |
Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy.
Topics: Adult; Aged; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Quinazolines; Young Adult | 2015 |
[Brain metastases in pulmonary adenocarcinoma with EGFR mutation: how important is therapy with erlotinib compared to radiotherapy?].
Topics: Adenocarcinoma; Brain Neoplasms; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2015 |
Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Radiation Tolerance; RNA, Small Interfering; Signal Transduction; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.
Topics: Adenine; Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chloroquine; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2015 |
Aflatoxin B1 induces Src phosphorylation and stimulates lung cancer cell migration.
Topics: Aflatoxin B1; Benzodioxoles; Cell Line, Tumor; Cell Movement; Gene Expression Regulation, Neoplastic; Humans; Insulin Receptor Substrate Proteins; Lung Neoplasms; Phosphorylation; Quinazolines; Signal Transduction; src-Family Kinases | 2015 |
Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Drug Substitution; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nephrosis, Lipoid; Protein Kinase Inhibitors; Quinazolines | 2015 |
Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor--Mutated Non--Small-Cell Lung Cancer With T790M Mutations.
Topics: Afatinib; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Panitumumab; Quinazolines | 2015 |
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Line, Tumor; Crizotinib; DNA; DNA Barcoding, Taxonomic; DNA, Complementary; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gene Dosage; Gene Library; Humans; Lung Neoplasms; Models, Theoretical; Neoplasms; Oligonucleotides; Polymerase Chain Reaction; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Sequence Analysis, RNA | 2015 |
Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Fetus; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Maternal-Fetal Exchange; Mutation; Perfusion; Placenta; Pregnancy; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2015 |
Discovery of 2',4'-dimethoxychalcone as a Hsp90 inhibitor and its effect on iressa-resistant non-small cell lung cancer (NSCLC).
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chalcones; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mutation; Proto-Oncogene Proteins c-met; Quinazolines | 2015 |
EGFR-independent autophagy induction with gefitinib and enhancement of its cytotoxic effect by targeting autophagy with clarithromycin in non-small cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Clarithromycin; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2015 |
Importance of ethnicity and smoking status in EGFR gene testing in lung cancers.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Quinazolines | 2015 |
Importance of ethnicity and smoking status in EGFR gene testing in lung cancers.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Quinazolines | 2015 |
An Integrative Analysis of the Putative Gefitinib-resistance Related Genes in a Lung Cancer Cell Line Model System.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromosome Mapping; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Signal Transduction | 2015 |
Current two EGFR mutations in lung adenocarcinoma - case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography | 2015 |
10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2015 |
MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Proto-Oncogene Proteins c-met; Quinazolines | 2015 |
EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Databases, Protein; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Quinazolines | 2015 |
Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cell Line, Tumor; Cytoskeletal Proteins; Drug Delivery Systems; ErbB Receptors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Essential; Humans; Lung Neoplasms; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; RNA; Sequence Analysis, RNA; Single-Cell Analysis; Transcriptome | 2015 |
Monitoring response to gefitinib in nude mouse tumor xenografts by (18)F-FDG microPET-CT: correlation between (18)F-FDG uptake and pathological response.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; ROC Curve; Tissue Distribution; Tomography, X-Ray Computed; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of (18)F-FDG Uptake at PET-Association with Treatment Response and Prognosis.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Treatment Outcome | 2015 |
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gefitinib; Genes, erbB-1; High-Throughput Nucleotide Sequencing; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multiplex Polymerase Chain Reaction; Mutation; Proportional Hazards Models; Quinazolines; Sequence Analysis, DNA | 2015 |
High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Down-Regulation; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; RNA, Long Noncoding; Transfection; Xenograft Model Antitumor Assays | 2015 |
Non small cell carcinoma of lung with metachronous breast metastasis and cardiac tamponade: Unusual presentation of a common cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Non-Small-Cell Lung; Cardiac Tamponade; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Neoplasms, Second Primary; Quinazolines; Radiography | 2015 |
[Relationship between EGFR Promoter Region Methylation and Secondary Resistance Which may be Induced by Gefitinib].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Methylation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Promoter Regions, Genetic; Quinazolines | 2015 |
Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Tomography, X-Ray Computed | 2015 |
Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Postoperative Period; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Proteomics; Quinazolines; Receptor, EphA2 | 2015 |
Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chloroquine; Cisplatin; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2015 |
Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lapatinib; Lung Neoplasms; Macrolides; Membrane Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; RNA Interference; Transfection; Vacuolar Proton-Translocating ATPases | 2015 |
[Hange-Shashin-to for preventing diarrhea during afatinib therapy].
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drugs, Chinese Herbal; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2015 |
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Everolimus; Female; Gene Amplification; Gene Rearrangement; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Neuroimaging; Oncogene Proteins, Fusion; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines | 2015 |
Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2015 |
Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Dynamics Simulation; Mutant Proteins; Mutation; Protein Binding; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-3; Regression Analysis; Signal Transduction; Structural Homology, Protein; Thermodynamics | 2015 |
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
Topics: Aged; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Polymorphism, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Retrospective Studies | 2015 |
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation, Missense; Quinazolines | 2015 |
Case records of the Massachusetts General Hospital. Case 17-2015. A 44-year-old woman with intractable pain due to metastatic lung cancer.
Topics: Adult; Analgesics; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Conscious Sedation; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Frameshift Mutation; Genes, erbB-1; Humans; Lung; Lung Neoplasms; Lymphatic Metastasis; Pain Management; Pain, Intractable; Palliative Care; Quinazolines; Radiography | 2015 |
An important role for peroxiredoxin II in survival of A549 lung cancer cells resistant to gefitinib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Oxidative Stress; Peroxiredoxins; Quinazolines; Reactive Oxygen Species | 2015 |
Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Body Surface Area; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines; Survival Rate | 2015 |
Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Glycolysis; Humans; Lung Neoplasms; Male; Quinazolines; Radionuclide Imaging | 2015 |
Renin-Angiotensin system blockers may prolong survival of metastatic non-small cell lung cancer patients receiving erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Afatinib (Gilotrif) for advanced non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; United States; United States Food and Drug Administration | 2015 |
Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Rate | 2015 |
Successful Afatinib Therapy after Resistance to EGFR-TKI in a Patient with Advanced Adenosquamous Cell Lung Cancer.
Topics: Afatinib; Aged; Carcinoma, Adenosquamous; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2015 |
Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Comorbidity; Female; Gefitinib; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Quinazolines; Radiosurgery; Retrospective Studies; Taiwan; Treatment Outcome | 2015 |
EGFR mutations and EGFR tyrosine kinase inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2015 |
Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
Topics: Afatinib; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lung Neoplasms; Mice; Mutation; Pyrazines; Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Erlotinib Pretreatment Improves Photodynamic Therapy of Non-Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice, Nude; Photochemotherapy; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Heterografts; Humans; Lung Neoplasms; Mice, SCID; Mutation; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction | 2015 |
Modern Treatments in Advanced Non-Small-Cell Lung Cancer: Temporal Trends and Effect on Survival. A French Population-Based Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Follow-Up Studies; France; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Platinum Compounds; Population Groups; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Radionuclide Imaging; Radiopharmaceuticals; Signal Transduction; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2015 |
TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Focal Adhesion Protein-Tyrosine Kinases; Gefitinib; Humans; Lung Neoplasms; Mice; Morpholines; Mutation; Protein Binding; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; Xenograft Model Antitumor Assays | 2015 |
ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations.
Topics: 3T3 Cells; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; China; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Estrogen Receptor Antagonists; Estrogen Receptor beta; Female; Fulvestrant; Gefitinib; HeLa Cells; Humans; Lung Neoplasms; Male; MCF-7 Cells; Mice; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2015 |
Decision to adopt medical technology under the National Health Insurance System in Taiwan: case study of new molecular targeted drugs among non-small cell lung cancer patients.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Databases, Factual; Decision Making; Drug Utilization; Erlotinib Hydrochloride; Female; Gefitinib; Hospital Administration; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; National Health Programs; Ownership; Quinazolines; Residence Characteristics; Taiwan | 2015 |
[Comparison of the Efficacy and Safety of Icotinib with Standard Second-line
Chemotherapy in Previously Treated Advanced Non-small Cell Lung Cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
[Molecular targeted therapies and cytotoxics: Friends or foes?].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Molecular Targeted Therapy; Quinazolines | 2015 |
[Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].
Topics: Adenocarcinoma; Afatinib; Anaplastic Lymphoma Kinase; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2015 |
Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Sequence Deletion | 2015 |
Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Quinazolinones; Signal Transduction; Up-Regulation | 2015 |
Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Exons; Female; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Pemetrexed; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vinblastine; Vinorelbine | 2015 |
Afatinib for Erlotinib Refractory Brain Metastases in a Patient with EGFR-Mutant Non-Small-Cell Lung Cancer: Can High-Affinity TKI Substitute for High-Dose TKI?
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2015 |
Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Quinazolines; Retreatment; Treatment Outcome | 2015 |
Assessment of Proliferation and Cytotoxicity in a Biomimetic Three-Dimensional Model of Lung Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomimetics; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cisplatin; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Biological; Protein Kinase Inhibitors; Quinazolines | 2015 |
EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Topics: Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cyclins; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Signaling System; Membrane Proteins; Models, Biological; Mutation; Neoplasm Proteins; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Protein c-ets-1; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; ras Proteins; RNA, Messenger; src-Family Kinases | 2015 |
EGFR tyrosine kinase inhibitors in squamous cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2015 |
Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Lung Neoplasms; Male; Mice; Mice, Inbred ICR; Protein Serine-Threonine Kinases; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2015 |
Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Harringtonines; Homoharringtonine; Humans; Interleukin-6; Janus Kinase 1; Lung Neoplasms; Male; Mice; Mice, Nude; Mitochondria; Phosphorylation; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Taxoids; Transplantation, Heterologous | 2015 |
Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Outcome Assessment, Health Care; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2015 |
Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer.
Topics: Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Consensus; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Quinazolines | 2015 |
MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Base Sequence; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Neoplasm Invasiveness; Proto-Oncogene Proteins c-met; Quinazolines; RNA Interference | 2015 |
Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report.
Topics: Afatinib; Carcinoma, Large Cell; Cell Differentiation; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Quinazolines | 2015 |
Bidirectional signaling between TM4SF5 and IGF1R promotes resistance to EGFR kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Spheroids, Cellular | 2015 |
[A Case of Pneumatosis Cystoides Intestinalis Secondary to Gefitinib Therapy for Lung Adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Diarrhea; Gefitinib; Humans; Lung Neoplasms; Male; Pneumatosis Cystoides Intestinalis; Quinazolines; Tomography, X-Ray Computed; Vomiting | 2015 |
FDG-PET/CT as a Predictor of Outcome in EGFR-Mutant Non-Small-Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Glycolysis; Humans; Lung Neoplasms; Male; Quinazolines; Radionuclide Imaging | 2015 |
Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Predictive Value of Tests; Quinazolines; Survival Rate | 2015 |
Maintenance Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor after First-Line Chemotherapy in Mutation-Positive Non-Small-Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2015 |
Reply: To PMID 25546556.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2015 |
Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib.
Topics: Afatinib; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Crizotinib; DNA Methylation; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Mutation; Neoplastic Stem Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Retinal Dehydrogenase; Sequence Analysis, DNA; Taxoids | 2015 |
Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Communication; Cell Line, Tumor; Chromones; Connexin 26; Connexins; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gap Junctions; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
First Reported Case of Unexpected Response to an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the I744M Uncommon EGFR Mutation.
Topics: Aged; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Diarrhea; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Respiratory Sounds; Treatment Outcome | 2015 |
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.
Topics: Afatinib; Animals; Cell Line, Tumor; Databases, Genetic; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gene Expression; Gene Frequency; Humans; Lung Neoplasms; Male; Mice; Middle Aged; Models, Molecular; Molecular Conformation; Mutation; Mutation Rate; Protein Kinase Inhibitors; Quinazolines; Quinolines; Structure-Activity Relationship; Transfection; Treatment Outcome | 2015 |
An unusual bowel complication during molecularly-targeted therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Emphysema; Female; Gefitinib; Humans; Intestinal Diseases; Lung Neoplasms; Pneumoperitoneum; Quinazolines; Tomography, X-Ray Computed | 2015 |
Systematic Analysis of Icotinib Treatment for Patients with Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Humans; Lung Neoplasms; Meta-Analysis as Topic; Neoplasm Staging; Prognosis; Quinazolines | 2015 |
The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Tandem Mass Spectrometry; Treatment Outcome | 2015 |
Can the Lung Cancer Pie Be Divided into Angiogenic Slices?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neovascularization, Pathologic; Quinazolines | 2015 |
Invited Commentary.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomimetics; Cell Culture Techniques; Cisplatin; Humans; Lung Neoplasms; Models, Biological; Protein Kinase Inhibitors; Quinazolines | 2015 |
Gefitinib Approved for EGFR-Mutated NSCLC.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; United States; United States Food and Drug Administration | 2015 |
First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Drug Monitoring; ErbB Receptors; Feasibility Studies; Female; Follow-Up Studies; Gefitinib; Humans; Incidence; Japan; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Severity of Illness Index; Survival Analysis | 2015 |
Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
Topics: Administration, Intravenous; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Decision Support Techniques; DNA Mutational Analysis; Economics, Pharmaceutical; ErbB Receptors; Gefitinib; Humans; Japan; Lung Neoplasms; Markov Chains; Mutation; Paclitaxel; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2015 |
Antitumoral activity of tyrosine kinase inhibitors in patients with non-small cell lung cancer harbouring rare epidermal growth factor receptor mutations.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Treatment Outcome | 2015 |
Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs.
Topics: Adenocarcinoma; Antineoplastic Agents; Base Sequence; beta Catenin; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Molecular Sequence Data; Molecular Targeted Therapy; Mutation, Missense; Protein Transport; Quinazolines; Transcription, Genetic; Transcriptional Activation; Up-Regulation; Wnt Signaling Pathway | 2015 |
Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Membrane Permeability; Crystallography, X-Ray; Databases, Chemical; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Kinetics; Lung Neoplasms; Models, Molecular; Molecular Conformation; Mutation; Pyrazoles; Pyrimidines; Quinazolines; Small Molecule Libraries; Solubility; src-Family Kinases; Structure-Activity Relationship | 2015 |
[Targeted therapy for solid tumors in the elderly].
Topics: Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Cetuximab; Colonic Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Trastuzumab | 2015 |
Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cluster Analysis; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Mice; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad Proteins; Transforming Growth Factor beta1 | 2015 |
EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.
Topics: Adult; Afatinib; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Gene Duplication; Gene Frequency; Humans; Lung Neoplasms; Male; Models, Molecular; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Protein Conformation; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Gli1-Mediated Regulation of Sox2 Facilitates Self-Renewal of Stem-Like Cells and Confers Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hedgehog Proteins; Humans; Lung Neoplasms; Promoter Regions, Genetic; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; SOXB1 Transcription Factors; Spheroids, Cellular; Stem Cells; Transcription Factors; Tumor Cells, Cultured; Zinc Finger Protein GLI1 | 2015 |
Identification of protein expression alterations in gefitinib-resistant human lung adenocarcinoma: PCNT and mPR play key roles in the development of gefitinib-associated resistance.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antigens; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Silencing; Humans; Lung Neoplasms; Membrane Proteins; Proteomics; Quinazolines; Receptors, Progesterone; RNA, Small Interfering; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2015 |
Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms; Capillary Permeability; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neurons; Pilot Projects; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2015 |
Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Computer-Aided Design; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Lung Neoplasms; Mice, SCID; Molecular Docking Simulation; Molecular Structure; Molecular Targeted Therapy; Neoplasm Invasiveness; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; src-Family Kinases; Structure-Activity Relationship; Time Factors; Xenograft Model Antitumor Assays | 2015 |
[Retrospective Analysis of the Afatinib Clinical Pathway during the 28-Day Introductory Period-The Japanese Style of Collaborative Drug Therapy Management(J-CDTM)].
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Exanthema; Female; Humans; Lung Neoplasms; Male; Medication Therapy Management; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Young Adult | 2015 |
Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Female; Heterografts; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2015 |
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; ras Proteins; RNA Interference; src-Family Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Heterografts; Humans; Immunohistochemistry; Lung Neoplasms; Mice; Mice, Nude; Multimodal Imaging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2016 |
Impact of Smoking History on the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Smoking; Treatment Outcome | 2015 |
Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Female; Gefitinib; Genes, erbB-1; Humans; Latin America; Lung Neoplasms; Male; Mexico; Models, Econometric; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines | 2016 |
EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Biopsy; Chemotherapy, Adjuvant; China; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Genetic Predisposition to Disease; Humans; Immunohistochemistry; Liver Neoplasms; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diabetes Mellitus, Type 2; Disease-Free Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Cell Line, Tumor; Cetuximab; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Lung Neoplasms; Mice; Mice, Nude; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins p21(ras); Quinazolines | 2016 |
Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Insulin; Lung Neoplasms; Mutation; Nuclear Proteins; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, IGF Type 1; RNA, Messenger; Signal Transduction | 2015 |
EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Amino Acid Substitution; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis | 2015 |
Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Compassionate Use Trials; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2015 |
Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.
Topics: Animals; Benzamides; Benzodioxoles; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Diphenylamine; Dose-Response Relationship, Drug; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Humans; Immunoblotting; Lung Neoplasms; MAP Kinase Kinase 1; Mice, Inbred BALB C; Mice, Nude; Microscopy, Confocal; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
[Clinical Experience of Gefitinib in the Treatment of 32 Lung Adenocarcinoma Patients with Brain Metastases].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Brain Neoplasms; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Disease-Free Survival; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Markov Chains; Models, Economic; Molecular Targeted Therapy; Mutation; Patient Selection; Pemetrexed; Protein Kinase Inhibitors; Quality of Life; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Uncertainty; United States | 2015 |
Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; NF-E2-Related Factor 2; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Quinazolines; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Voltage-Dependent Anion Channel 1; Vorinostat | 2015 |
Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.
Topics: Angiogenesis Inducing Agents; Antineoplastic Agents; Biomarkers, Tumor; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2015 |
The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
Topics: Afatinib; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Ligands; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neuregulin-1; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cytotoxicity, Immunologic; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Killer Cells, Natural; Lung Neoplasms; NK Cell Lectin-Like Receptor Subfamily K; Protein Kinase Inhibitors; Quinazolines | 2015 |
[Bufalin reverses hepatocyte growth factor-induced resistance to afatinib in H1975 lung cancer cells].
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bufanolides; Cadherins; Cell Line, Tumor; Cell Proliferation; Coloring Agents; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Hepatocyte Growth Factor; Humans; Lung Neoplasms; MAP Kinase Signaling System; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Quinazolines; Signal Transduction; Tetrazolium Salts; Thiazoles | 2015 |
Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2015 |
[An Elderly Patient with Non-Small Cell Lung Cancer Who Responded to Salvage S-1 Monotherapy after Gefitinib Therapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Combinations; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Oxonic Acid; Quinazolines; Salvage Therapy; Tegafur | 2015 |
Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series.
Topics: Adenocarcinoma; Afatinib; Brain Neoplasms; Diagnostic Imaging; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
LXR ligands sensitize EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt activation.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; In Vitro Techniques; Ligands; Liver X Receptors; Lung Neoplasms; Mutation; Orphan Nuclear Receptors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines | 2015 |
Overexpression of Cathepsin L is associated with gefitinib resistance in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cathepsin L; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Quinazolines; Real-Time Polymerase Chain Reaction | 2016 |
[Sequence-dependent Effect of Triptolide with Gefitinib on the Proliferation
and Apoptosis of Lung Adenocarcinoma Cell H1975].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Diterpenes; Epoxy Compounds; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phenanthrenes; Protein Kinase Inhibitors; Quinazolines | 2015 |
Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Cell Line, Tumor; Cell Proliferation; Cetuximab; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2015 |
Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study.
Topics: Adult; Aged; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; DNA Mutational Analysis; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genes, erbB-1; Hospitals; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Smoking | 2015 |
244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; HEK293 Cells; Humans; Lung Neoplasms; Mice, Nude; Mice, SCID; Molecular Dynamics Simulation; Mutation; Phenols; Phosphorylation; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Quinazolines; Signal Transduction; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Crystallography, X-Ray; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Binding; Protein Kinase Inhibitors; Quinazolines | 2015 |
Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer.
Topics: Afatinib; Calibration; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Erlotinib Hydrochloride; Gefitinib; Humans; Limit of Detection; Lung Neoplasms; Quinazolines; Tandem Mass Spectrometry | 2016 |
Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation.
Topics: Animals; Apoptosis; Benzophenanthridines; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression; Humans; Isoquinolines; Lung Neoplasms; Membrane Glycoproteins; Membrane Proteins; Methionine; Mice; Models, Biological; Models, Molecular; Molecular Conformation; NADPH Oxidase 2; NADPH Oxidases; Oxidation-Reduction; Protein Binding; Protein Kinase Inhibitors; Proteolysis; Quinazolines; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2016 |
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Clonal Evolution; Deoxycytidine; DNA, Neoplasm; Female; Gemcitabine; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Mutation; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Sequence Analysis, DNA; Spinal Neoplasms; Tamoxifen; Trastuzumab | 2015 |
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatography, High Pressure Liquid; ErbB Receptors; Gefitinib; Gene Expression Regulation; HEK293 Cells; Humans; Indoles; Lung Neoplasms; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; RNA Interference; RNA, Small Interfering; Tandem Mass Spectrometry | 2015 |
Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Prospective Studies; Quality of Life; Quinazolines; Sickness Impact Profile; Surveys and Questionnaires; World Health Organization | 2016 |
Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.
Topics: Afatinib; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Genes, erbB-2; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Transfection; Xenograft Model Antitumor Assays | 2016 |
Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hospitals, University; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Retrospective Studies; Risk Factors; Salvage Therapy; Time Factors; Treatment Failure | 2015 |
HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.
Topics: Afatinib; Antineoplastic Agents; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
[Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Retrospective Studies; Russia; Treatment Outcome | 2015 |
Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
Topics: Afatinib; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines | 2016 |
SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease-Free Survival; DNA-Binding Proteins; Drug Synergism; Enzyme Activation; Female; Histone Chaperones; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mice, Nude; Middle Aged; Paclitaxel; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcription Factors; Xenograft Model Antitumor Assays | 2016 |
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Small Molecule T315 Promotes Casitas B-Lineage Lymphoma-Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Enzyme Assays; ErbB Receptors; Humans; Lung Neoplasms; Mass Spectrometry; Mice; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Quinazolines; Real-Time Polymerase Chain Reaction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease-Free Survival; ErbB Receptors; Europe; Female; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2016 |
Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy.
Topics: Adult; Age Distribution; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Genetic Markers; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prevalence; Quinazolines; Retrospective Studies; Risk Factors; Sex Distribution; Smoking; Switzerland; Treatment Outcome | 2015 |
RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Treatment Outcome | 2015 |
Evaluation of melanoma antigen gene A3 expression in drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced nonsmall cell lung cancer treatment.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2015 |
Novel Quinazoline Derivatives Bearing Various 4-Aniline Moieties as Potent EGFR Inhibitors with Enhanced Activity Against NSCLC Cell Lines.
Topics: Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Humans; Lung Neoplasms; Magnetic Resonance Spectroscopy; Quinazolines; Spectrometry, Mass, Electrospray Ionization | 2016 |
Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diphosphonates; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pamidronate; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2016 |
Observation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Time Factors | 2016 |
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Topics: Aged; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Mutation; Proto-Oncogene Proteins; Quinazolines; RNA, Messenger; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Gemcitabine; Gene Deletion; Genetic Markers; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Pemetrexed; Prognosis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Taxoids | 2016 |
Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer.
Topics: Acneiform Eruptions; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Compassionate Use Trials; Cross-Sectional Studies; Drug Eruptions; Erlotinib Hydrochloride; Gefitinib; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Pruritus; Quinazolines; Retrospective Studies | 2016 |
Anti-Tumor Activity of Yuanhuacine by Regulating AMPK/mTOR Signaling Pathway and Actin Cytoskeleton Organization in Non-Small Cell Lung Cancer Cells.
Topics: Actin Cytoskeleton; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diterpenes; Female; Gefitinib; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2015 |
Effects of cetuximab combined with afatinib on the expression of KDR and AQP1 in lung cancer.
Topics: Afatinib; Antineoplastic Agents; Aquaporin 1; Cell Line, Tumor; Cetuximab; Drug Synergism; Humans; Lung Neoplasms; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Afatinib and chemotherapy in non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Humans; Lung Neoplasms; Paclitaxel; Quinazolines | 2016 |
Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Dosage; Genes, erbB-1; Genetic Heterogeneity; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis; Time-to-Treatment; Treatment Failure | 2016 |
[Combination of lapatinib with chlorogenic acid inhibits breast cancer metastasis by suppressing macrophage M2 polarization].
Topics: Animals; Chlorogenic Acid; Female; Lapatinib; Lung Neoplasms; Macrophages; Mammary Neoplasms, Experimental; Mice; Neoplasm Metastasis; Quinazolines | 2015 |
Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Real-Time Polymerase Chain Reaction; Retrospective Studies; Time Factors; Treatment Failure; Treatment Outcome | 2016 |
Overexpression of BRCA1 attenuates the sensitivity of PC9 cells to gefitinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; BRCA1 Protein; Cell Line, Tumor; Cell Proliferation; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Quinazolines; Signal Transduction | 2015 |
5-Aza-CdR can reverse gefitinib resistance caused by DAPK gene promoter methylation in lung adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Azacitidine; Blotting, Western; Cell Line, Tumor; Death-Associated Protein Kinases; DNA Methylation; Drug Resistance, Neoplasm; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Polymerase Chain Reaction; Promoter Regions, Genetic; Quinazolines | 2015 |
Total regression of brain metastases in non-small cell lung cancer patients harboring EGFR mutations treated with gefitinib without radiotherapy: two case reports.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Mutation; Quinazolines; Radiography, Thoracic; Remission Induction | 2016 |
Quinalizarin, a specific CK2 inhibitor, reduces cell viability and suppresses migration and accelerates apoptosis in different human lung cancer cell lines.
Topics: Adenocarcinoma; Apoptosis; Carcinoma, Large Cell; Casein Kinase II; Cell Movement; Cell Proliferation; Flow Cytometry; Humans; Lung Neoplasms; Quinazolines; Small Cell Lung Carcinoma; Tumor Cells, Cultured | 2015 |
TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; ErbB Receptors; Gefitinib; Heterografts; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Models, Molecular; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Transfection | 2016 |
Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung adenocarcinoma cells with an epithelial-mesenchymal transition phenotype.
Topics: Acrylamides; Adenocarcinoma; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Lung Neoplasms; Mutation; NIMA-Interacting Peptidylprolyl Isomerase; Peptidylprolyl Isomerase; Phenotype; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference | 2016 |
The apoptotic effect of simvastatin via the upregulation of BIM in nonsmall cell lung cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Quinazolines; Simvastatin; Up-Regulation | 2016 |
Evodiamine induces apoptosis and enhances apoptotic effects of erlotinib in wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Quinazolines; Ribosomal Protein S6 Kinases, 70-kDa; TOR Serine-Threonine Kinases | 2016 |
Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Crizotinib; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Maintenance Chemotherapy; Pemetrexed; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Singapore; Taxoids; Translocation, Genetic | 2015 |
Case Report: Bazex Syndrome Associated With Pulmonary Adenocarcinoma.
Topics: Acitretin; Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Biopsy, Needle; Bone Neoplasms; Carcinoma, Basal Cell; Dexamethasone; Drug Therapy, Combination; Follow-Up Studies; Gefitinib; Humans; Hypotrichosis; Immunohistochemistry; Lung Neoplasms; Lymph Nodes; Male; Paraneoplastic Syndromes; Quinazolines; Radiography; Rare Diseases; Risk Assessment; Skin Neoplasms; Treatment Outcome | 2016 |
Sarcopenia Is a Condition With Increasing Importance in Medical Oncology.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Gastrointestinal Diseases; Humans; Lung Neoplasms; Male; Quinazolines | 2016 |
In Reply.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Gastrointestinal Diseases; Humans; Lung Neoplasms; Male; Quinazolines | 2016 |
Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Tumor Burden; Young Adult | 2016 |
miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; Gene Expression Profiling; Humans; Indoles; Inhibitory Concentration 50; Lung Neoplasms; MicroRNAs; Phenotype; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Fibroblast Growth Factor; Receptors, Vascular Endothelial Growth Factor; Zinc Finger E-box-Binding Homeobox 1 | 2016 |
An unusual cause of early aortic bioprosthetic valve failure.
Topics: Adenocarcinoma; Antineoplastic Agents; Aortic Valve; Aortic Valve Stenosis; Bioprosthesis; Echocardiography; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prosthesis Failure; Quinazolines | 2016 |
[Mechanism of TRIM24 to Regulate Resistance of Gefitinib in NSCLC cells].
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines | 2016 |
[Successful Treatment of Non-Small Cell Lung Cancer with Afatinib after Gefitinib-Induced Hepatotoxicity].
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Gefitinib; Humans; Liver Diseases; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2016 |
The P21-activated kinase expression pattern is different in non-small cell lung cancer and affects lung cancer cell sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; p21-Activated Kinases; Protein Kinase Inhibitors; Quinazolines | 2016 |
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2016 |
Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines.
Topics: Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Lung; Lung Neoplasms; Molecular Docking Simulation; Point Mutation; Quinazolines | 2016 |
Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.
Topics: Acrylamides; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Oncogenes; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines | 2016 |
Paris Saponins enhance radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line by inducing apoptosis and G2/M cell cycle phase arrest.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Diosgenin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; G2 Phase Cell Cycle Checkpoints; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Saponins | 2016 |
Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts.
Topics: Acrylamides; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Signal Transduction | 2016 |
Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Topics: Adenine Nucleotide Translocator 2; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Molecular Targeted Therapy; Promoter Regions, Genetic; Quinazolines; RNA, Small Interfering; Up-Regulation | 2016 |
therascreen® EGFR RGQ PCR Kit: A Companion Diagnostic for Afatinib and Gefitinib in Non-Small Cell Lung Cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Reagent Kits, Diagnostic; Sensitivity and Specificity | 2016 |
Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; ErbB Receptors; Female; Gefitinib; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Pharmacogenetics; Protein Kinase Inhibitors; Quinazolines; Retreatment; Treatment Outcome | 2016 |
[The CK2 inhibitor quninalizarin enhances the anti-proliferative effect of icotinib on EGFR-TKIs-resistant cell lines and its underlying mechanisms].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Analysis of Variance; Anthraquinones; Apoptosis; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crown Ethers; Down-Regulation; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Lung Neoplasms; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2016 |
Resistance: Following different paths.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger | 2016 |
Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2016 |
The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Dasatinib; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Mice, Nude; Mutation; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-3; RNA Interference; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays | 2016 |
What is the clinical impact of the LUX-Lung 5 trial?
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Quinazolines | 2016 |
Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines.
Topics: Antigens, CD; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Cadherins; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Immunohistochemistry; Inhibitory Concentration 50; Lung Neoplasms; Neoplasm Proteins; Neoplastic Stem Cells; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Snail Family Transcription Factors; Transcription Factors; Up-Regulation | 2016 |
Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastric Acid; Gefitinib; Histamine H2 Antagonists; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2016 |
Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Models, Molecular; Molecular Conformation; Molecular Structure; Mutation; Prognosis; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.
Topics: Adenocarcinoma; Afatinib; Aged; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Mutagenesis, Insertional; Neoplasm Staging; Prognosis; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Tumor Cells, Cultured | 2016 |
Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2016 |
Ephedrae herba stimulates hepatocyte growth factor-induced MET endocytosis and downregulation via early/late endocytic pathways in gefitinib-resistant human lung cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Endocytosis; Ephedra; Gefitinib; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Phosphorylation; Plant Extracts; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction | 2016 |
Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; B7-H1 Antigen; Cell Line, Tumor; Cell Survival; Cisplatin; Dimethyl Sulfoxide; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Indoles; Lung Neoplasms; Metformin; Mutation; Purines; Quinazolines; Transforming Growth Factor beta | 2016 |
Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; China; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Treatment Outcome | 2016 |
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2016 |
Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Gene Deletion; Glycoproteins; Humans; Hypoxia; Immunohistochemistry; Lung Neoplasms; Mice; Mice, Inbred NOD; Microscopy, Fluorescence; Mutation; Neoplasm Transplantation; Neoplastic Stem Cells; Octamer Transcription Factor-3; Peptides; Phenotype; Quinazolines; Real-Time Polymerase Chain Reaction | 2016 |
Partial Remission of Hepatic Metastatic Lesion but Complicated with Secondary and Refractory Fever Lead by Nivolumab in a Patient with Lung Adenocarcinoma Presenting Gefitinib Acquired Resistance.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal; Drug Resistance, Neoplasm; Female; Fever; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nivolumab; Quinazolines | 2016 |
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2016 |
Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Mutation; Nutrition Assessment; Nutritional Status; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy.
Topics: Antineoplastic Agents; Autophagy; Cisplatin; ErbB Receptors; Exosomes; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Up-Regulation | 2016 |
Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Cancer Care Facilities; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Time Factors | 2016 |
Inequalities in lung cancer: a world of EGFR.
Topics: Afatinib; Crown Ethers; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Geography; Global Health; Health Care Costs; Health Equity; Health Services Accessibility; Healthcare Disparities; Humans; Lung Neoplasms; Medical Oncology; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Surveys and Questionnaires; United States | 2016 |
Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2016 |
Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2016 |
Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient.
Topics: Adrenal Cortex Hormones; Afatinib; Aged; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Skin; Stevens-Johnson Syndrome; Treatment Outcome | 2016 |
Analysis of a single-codon E746 deletion in exon 19 of the epidermal growth factor receptor.
Topics: Animals; Cell Line, Tumor; Codon; ErbB Receptors; Exons; Gefitinib; Gene Deletion; Lung Neoplasms; Mice; Molecular Docking Simulation; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Treatment Outcome | 2016 |
Choroidal metastasis as a presenting manifestation of a lung adenocarcinoma with response to afatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Choroid Neoplasms; ErbB Receptors; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Signal Transduction | 2016 |
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins p21(ras); Quinazolines; Swine; Tissue Engineering; Transforming Growth Factor beta1 | 2016 |
Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways.
Topics: A549 Cells; Animals; Autoantigens; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diterpenes, Kaurane; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; MAP Kinase Signaling System; Matrix Metalloproteinase 12; Membrane Proteins; Mice; Phosphorylation; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Membrane Transport Proteins; Middle Aged; Mutation; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines | 2017 |
NF-κB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Forkhead Box Protein O3; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplastic Stem Cells; NF-kappa B; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Tumor Cells, Cultured | 2016 |
Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression.
Topics: Adenocarcinoma; Aged; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Cadherins; Down-Regulation; ErbB Receptors; Female; Gefitinib; Humans; Hyaluronan Receptors; Immunohistochemistry; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Multivariate Analysis; Mutation; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor Protein-Tyrosine Kinases | 2016 |
Zoledronic acid increases the antitumor effect of gefitinib treatment for non-small cell lung cancer with EGFR mutations.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mutation; Quinazolines; STAT3 Transcription Factor; Zoledronic Acid | 2016 |
[Clinical Analysis of Icotinib on Beneficiary of
Advanced Non-small Cell Lung Cancer with EGFR Common Mutation].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies | 2016 |
Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Treatment Outcome | 2016 |
Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Inhibitory Concentration 50; Liliaceae; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Saponins; Signal Transduction | 2016 |
Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2016 |
A Triple Rare E709K and L833V/H835L EGFR Mutation Responsive to an Irreversible Pan-HER Inhibitor: A Case Report of Lung Adenocarcinoma Treated with Afatinib.
Topics: Adenocarcinoma; Afatinib; Aged; ErbB Receptors; Humans; Lung Neoplasms; Male; Mutation; Prognosis; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2 | 2016 |
Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.
Topics: Adenocarcinoma; Animals; Cell Line; Cell Survival; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Middle Aged; NIH 3T3 Cells; Oncogene Proteins, Fusion; Piperidines; Protein Isoforms; Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Transplantation, Heterologous | 2016 |
A platinum-based hybrid drug design approach to circumvent acquired resistance to molecular targeted tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Brain Chemistry; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; K562 Cells; Lung Neoplasms; Mice; Molecular Targeted Therapy; Mutation; Piperidines; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance.
Topics: Animals; Antineoplastic Agents, Immunological; Cell Line, Tumor; Cetuximab; Disease Models, Animal; Doxorubicin; Drug Carriers; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Heterografts; Humans; Lung Neoplasms; Nanomedicine; Quinazolines; Silicon Dioxide; Treatment Outcome | 2016 |
Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib.
Topics: Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multivariate Analysis; Neoplasm Proteins; Polymorphism, Single Nucleotide; Prospective Studies; Quinazolines | 2016 |
Overexpression of PAD4 suppresses drug resistance of NSCLC cell lines to gefitinib through inhibiting Elk1-mediated epithelial-mesenchymal transition.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ets-Domain Protein Elk-1; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hydrolases; Lung Neoplasms; Protein-Arginine Deiminase Type 4; Protein-Arginine Deiminases; Quinazolines; Signal Transduction; Up-Regulation | 2016 |
Are TKIs favourable for the elderly with non-small-cell lung cancer?
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Retrospective Studies; Treatment Outcome | 2016 |
Stevens-Johnson syndrome-like erosive dermatitis possibly related to afatinib.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Agents; Drug Eruptions; Female; Humans; Lung Neoplasms; Quinazolines | 2016 |
HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2016 |
Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant.
Topics: A549 Cells; Antineoplastic Agents; Cell Proliferation; Drug Discovery; ErbB Receptors; Humans; Inhibitory Concentration 50; Lung Neoplasms; Molecular Structure; Mutation; Protein Binding; Quinazolines | 2016 |
Necrolytic Migratory Erythema-like Skin Lesion During Gefitinib Treatment: A Rare Cutaneous Adverse Reaction.
Topics: Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Necrolytic Migratory Erythema; Protein Kinase Inhibitors; Quinazolines; Rare Diseases; Risk Assessment; Withholding Treatment | 2016 |
IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.
Topics: A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Interleukin-8; Lung Neoplasms; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; p38 Mitogen-Activated Protein Kinases; Phenotype; Quinazolines; Signal Transduction; Up-Regulation | 2016 |
Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cyclosporine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; NFATC Transcription Factors; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Signal Transduction; STAT3 Transcription Factor; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dihydrouracil Dehydrogenase (NADP); Drug Resistance, Neoplasm; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Plicamycin; Quinazolines; Signal Transduction; Sp1 Transcription Factor | 2016 |
The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Culture Techniques; Cell Line, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Gain of Function Mutation; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2016 |
PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells.
Topics: A549 Cells; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fimbriae Proteins; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction | 2016 |
miR-26a desensitizes non-small cell lung cancer cells to tyrosine kinase inhibitors by targeting PTPN13.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 13; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Adenoid Cystic Carcinoma of the Lung with an EGFR Mutation.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2016 |
Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Hydroxychloroquine; Lung Neoplasms; Lymphatic Metastasis; Mice; MicroRNAs; Neoplastic Stem Cells; Oligonucleotides; Quinazolines; Signal Transduction; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment
(2016 version)].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Consensus; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quinazolines | 2016 |
[Metastatic medullary thyroid carcinoma in a child with multiple endocrine neoplasia 2B. Efficiency of medium-term treatment with vandetanib without thyroid surgery].
Topics: Carcinoma, Neuroendocrine; Child; Female; Humans; Lung Neoplasms; Multiple Endocrine Neoplasia Type 2b; Piperidines; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms | 2016 |
TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proteolysis; Proto-Oncogene Proteins c-met; Quinazolines; Tumor Stem Cell Assay; Ubiquitin; Ubiquitination | 2016 |
MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Autophagy; Autophagy-Related Protein-1 Homolog; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Survival; Dasatinib; Down-Regulation; Humans; Intracellular Signaling Peptides and Proteins; Lung; Lung Neoplasms; MicroRNAs; Microtubule-Associated Proteins; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Signal Transduction; src-Family Kinases | 2017 |
LUX-Lung 7: is there enough data for a final conclusion?
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Quinazolines | 2016 |
LUX-Lung 7: is there enough data for a final conclusion?
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Quinazolines | 2016 |
LUX-Lung 7: is there enough data for a final conclusion?
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Quinazolines | 2016 |
A novel alkaloid, evodiamine causes nuclear localization of cytochrome-c and induces apoptosis independent of p53 in human lung cancer cells.
Topics: A549 Cells; Alkaloids; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cytochromes c; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Nuclear Localization Signals; Quinazolines; Tissue Distribution; Treatment Outcome; Tumor Suppressor Protein p53 | 2016 |
Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Outcome Assessment, Health Care; Protein Kinase Inhibitors; Quinazolines | 2016 |
Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gallic Acid; Gefitinib; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2016 |
Evaluation of assays for drug efficacy in a three-dimensional model of the lung.
Topics: Afatinib; Cell Cycle; Cell Proliferation; Cisplatin; Drug Screening Assays, Antitumor; Humans; Lung; Lung Neoplasms; Quinazolines; Spheroids, Cellular; Tissue Culture Techniques; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2016 |
[Not Available].
Topics: Afatinib; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; ErbB Receptors; Female; Gefitinib; Gossypol; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines | 2016 |
Implications of Blood-Based T790M Genotyping and Beyond in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Genotype; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Topics: Acrylamides; Afatinib; Aniline Compounds; Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Brain Neoplasms; Caco-2 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Dogs; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Madin Darby Canine Kidney Cells; Male; Mice; Mice, SCID; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Xenograft Model Antitumor Assays | 2016 |
Complete remissions in afatinib-treated non-small-cell lung cancer patients with symptomatic brain metastases.
Topics: Afatinib; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2016 |
Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Hydroxycholesterols; Lung Neoplasms; Membrane Proteins; Mice; Mice, Nude; Microtubule-Associated Proteins; Protein Kinase Inhibitors; Pyridines; Quinazolines; Signal Transduction; Sterol Regulatory Element Binding Protein 1; Thiazoles; Triterpenes; Xenograft Model Antitumor Assays | 2016 |
A genetic cell context-dependent role for ZEB1 in lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Male; Mice, Nude; MicroRNAs; Promoter Regions, Genetic; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, ErbB-3; Receptor, Notch1; Reproducibility of Results; Smoking; Xenograft Model Antitumor Assays; Zinc Finger E-box-Binding Homeobox 1 | 2016 |
Effect of saracatinib on pulmonary metastases from hepatocellular carcinoma.
Topics: Animals; Benzodioxoles; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Phosphorylation; Quinazolines; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays | 2016 |
EGFR Mutation Analysis of Circulating Tumor DNA Using an Improved PNA-LNA PCR Clamp Method.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Prospective Studies; Quinazolines | 2016 |
Effect of evodiamine on the proliferation and apoptosis of A549 human lung cancer cells.
Topics: A549 Cells; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspase 8; Cell Cycle; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glutathione; Hedgehog Proteins; Humans; Lung Neoplasms; Plant Extracts; Quinazolines; Reactive Oxygen Species; RNA, Messenger; Signal Transduction; Telomerase | 2016 |
FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive feedback loop.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Chromones; Drug Resistance, Neoplasm; Feedback, Physiological; Forkhead Box Protein M1; Gefitinib; Humans; Indoles; Lung Neoplasms; Morpholines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; RNA, Small Interfering; Signal Transduction; Sulfones | 2016 |
Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Staging; Predictive Value of Tests; Quinazolines; Response Evaluation Criteria in Solid Tumors; ROC Curve; Survival Analysis; Time Factors; Treatment Outcome | 2016 |
Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Pneumatosis Cystoides Intestinalis; Quinazolines; Tomography, X-Ray Computed | 2016 |
Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
Topics: Animals; Antineoplastic Agents; Aurora Kinase B; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Amplification; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, myc; Histones; Humans; Lung Neoplasms; Mice; Organophosphates; Phosphorylation; Polyploidy; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Transcriptome; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Autophagic degradation of epidermal growth factor receptor in gefitinib-resistant lung cancer by celastrol.
Topics: Antineoplastic Agents; Autophagy; Blotting, Western; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Pentacyclic Triterpenes; Proteolysis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Triterpenes; Tumor Cells, Cultured | 2016 |
Human Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-Imaging.
Topics: Animals; Antineoplastic Agents; Drug Evaluation, Preclinical; Fluorodeoxyglucose F18; Gefitinib; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Lung; Lung Neoplasms; Organ Culture Techniques; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Rats; Rats, Inbred Lew | 2016 |
Variations in EGFR ctDNA Correlates to the Clinical Efficacy of Afatinib in Non Small Cell Lung Cancer with Acquired Resistance.
Topics: Afatinib; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Crown Ethers; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Gene Library; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2016 |
Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation.
Topics: Animals; Antineoplastic Agents; Carcinogenesis; Carcinoma; ErbB Receptors; Gene Expression Regulation; Hyperplasia; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Piperidines; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2016 |
Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Prognosis; Quinazolines; Radiation-Sensitizing Agents | 2016 |
Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Biopsy; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Middle Aged; Mutation; Pilot Projects; Prospective Studies; Quinazolines; Radiation-Sensitizing Agents | 2016 |
Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Proteins; Plasminogen Activator Inhibitor 2; Pseudopodia; Quinazolines | 2016 |
Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP3A; ErbB Receptors; Gefitinib; Glucuronosyltransferase; Humans; Lung Neoplasms; Middle Aged; Mutation; Pharmacogenetics; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Retreatment; Treatment Outcome | 2016 |
Colossolactone H, a new Ganoderma triterpenoid exhibits cytotoxicity and potentiates drug efficacy of gefitinib in lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; DNA Damage; Down-Regulation; Ganoderma; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Molecular Structure; Quinazolines; Reactive Oxygen Species; Triterpenes; Tumor Suppressor Protein p53; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Biopsy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Fibrin Fibrinogen Degradation Products; Gefitinib; Humans; Iatrogenic Disease; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2016 |
Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; ErbB Receptors; Female; Gefitinib; Humans; Liver Function Tests; Lung Neoplasms; Male; Middle Aged; Mutation; Overweight; Quinazolines; Retrospective Studies; Risk Factors | 2016 |
Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Programmed Cell Death 1 Receptor; Quinazolines; Survival Analysis; Tumor Escape | 2016 |
Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Protein 4; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, IGF Type 1; Receptors, Death Domain; Receptors, Somatomedin; Signal Transduction; Smad2 Protein; Smad3 Protein; Somatomedins | 2016 |
Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Heterografts; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Neoplasm Transplantation; Oxazoles; Quinazolines; Resorcinols | 2016 |
Neighbors' death is required for surviving human adenocarcinoma PC-9 cells in an early stage of gefitinib treatment.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Quinazolines; Receptors, Fibroblast Growth Factor; Signal Transduction; Treatment Outcome | 2016 |
Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Asian People; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Lung Neoplasms; Mass Spectrometry; Molecular Targeted Therapy; Mutation; Oncogene Proteins, Fusion; Precision Medicine; Protein Interaction Mapping; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Receptor, ErbB-2; White People | 2016 |
MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; MicroRNAs; Models, Biological; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; RNA Interference; Signal Transduction | 2016 |
Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer.
Topics: Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Ligands; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sulfones; Translocation, Genetic | 2017 |
Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells.
Topics: Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor Protein-Tyrosine Kinases; Transfection | 2016 |
Lung squamous cell carcinoma with brachial soft tissue metastasis responsive to gefitinib: Report of a rare case.
Topics: Arm; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Soft Tissue Neoplasms; Treatment Outcome | 2016 |
Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome | 2016 |
miR-543 is up-regulated in gefitinib-resistant non-small cell lung cancer and promotes cell proliferation and invasion via phosphatase and tensin homolog.
Topics: A549 Cells; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Activation; Female; Gefitinib; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Invasiveness; PTEN Phosphohydrolase; Quinazolines | 2016 |
EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Quinazolines | 2016 |
Chalcone-templated Hsp90 inhibitors and their effects on gefitinib resistance in non-small cell lung cancer (NSCLC).
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Survival; Chalcone; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Molecular Docking Simulation; Protein Structure, Secondary; Quinazolines | 2017 |
Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Male; Mutation; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiation-Sensitizing Agents; Treatment Outcome | 2016 |
Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antigens, Neoplasm; B7-H1 Antigen; Biomarkers, Tumor; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; ErbB Receptors; Galectins; Humans; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Quinazolines; Receptor, ErbB-2; Survival Analysis | 2016 |
Heterogeneity of the resistance to gefitinib treatment in a non-small cell lung cancer patient with active epidermal growth factor receptor mutation.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genetic Heterogeneity; Humans; Liver Neoplasms; Lung Neoplasms; Male; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Treatment Outcome | 2017 |
Complete remission of liver metastasis in a lung cancer patient with epidermal growth factor mutation achieved with Icotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Male; Mutation; Pulmonary Surgical Procedures; Quinazolines; Remission Induction; Treatment Outcome | 2016 |
Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Octamer Transcription Factor-3; Protein Kinase Inhibitors; Quinazolines; RNA Interference; RNA, Small Interfering | 2016 |
Multiple primary lung cancer displaying different EGFR and PTEN molecular profiles.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Chemotherapy, Adjuvant; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Phenotype; Pneumonectomy; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Piperazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Effective killing of cancer cells and regression of tumor growth by K27 targeting sulfiredoxin.
Topics: A549 Cells; Acetylcysteine; Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Antioxidants; Apoptosis; beta-Alanine; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Epithelial Cells; Female; Gene Expression; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mitochondria; Molecular Targeted Therapy; Oxidative Stress; Oxidoreductases Acting on Sulfur Group Donors; Quinazolines; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2016 |
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epiderm
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Costs; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Bufalin inhibits gefitinib resistant NCI-H460 human lung cancer cell migration and invasion in vitro.
Topics: Antineoplastic Agents; Bufanolides; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Quinazolines; rhoA GTP-Binding Protein; Signal Transduction; SOS1 Protein | 2016 |
Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Glucocorticoids; Humans; Lung Neoplasms; Male; Mice; Middle Aged; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
Topics: A549 Cells; Angiogenesis Inhibitors; Animals; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Docetaxel; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice, Nude; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Quinazolines; Remission Induction; Tomography, X-Ray Computed; Withholding Treatment | 2017 |
Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; High-Throughput Screening Assays; Humans; Lung Neoplasms; Mutation; Naphthoquinones; Neoplasm Recurrence, Local; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Thioredoxin-Disulfide Reductase | 2017 |
miR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop.
Topics: 3' Untranslated Regions; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Movement; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Models, Biological; Neoplastic Stem Cells; NF-kappa B; Quinazolines; RNA Interference; Signal Transduction; Tumor Necrosis Factor alpha-Induced Protein 3 | 2017 |
EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Topics: Adenocarcinoma; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; fms-Like Tyrosine Kinase 3; Gefitinib; Gene Rearrangement; Hepatocyte Growth Factor; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; RNA, Small Interfering; Signal Transduction; Sorafenib; Sunitinib | 2017 |
Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Body Surface Area; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Feasibility Studies; Female; Gene Expression Regulation; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Radiation-Sensitizing Agents; Retrospective Studies | 2016 |
Tolerability and efficacy of afatinib at a low starting dosage in 10 elderly or low performance status patients with advanced refractory non-small-cell lung cancer.
Topics: Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; ErbB Receptors; Female; Humans; Intra-Abdominal Fat; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Radiation-Sensitizing Agents; Retrospective Studies; Salvage Therapy; Survival Rate | 2016 |
Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Renal Dialysis | 2017 |
HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.
Topics: Adult; Afatinib; Aged; Amino Acid Sequence; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Conformation; Protein Domains; Protein Multimerization; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2; Retrospective Studies; Sequence Alignment | 2017 |
The effect of low dosage of procaine on lung cancer cell proliferation.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mice; Procaine; Quinazolines | 2016 |
EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Databases, Factual; Disease Progression; Disease-Free Survival; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies; Risk Assessment; Risk Factors; Singapore; Time Factors; Treatment Outcome | 2016 |
EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Asian People; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2017 |
Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.
Topics: Afatinib; Alleles; Amino Acid Substitution; Animals; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Codon; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mice; Models, Molecular; Molecular Conformation; Mutagenesis; Mutation; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Structure-Activity Relationship | 2017 |
Enhancing Anticancer Effect of Gefitinib across the Blood-Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80.
Topics: Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Cell-Penetrating Peptides; Gefitinib; Glutathione; Humans; Liposomes; Lung Neoplasms; Microscopy, Confocal; Microscopy, Electron, Transmission; Polysorbates; Quinazolines | 2016 |
miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; HEK293 Cells; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; Snail Family Transcription Factors; STAT3 Transcription Factor | 2016 |
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.
Topics: Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Central Nervous System Neoplasms; Disease Models, Animal; ErbB Receptors; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Quinazolines; Spinal Cord | 2016 |
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
MicroRNA-30e reduces cell growth and enhances drug sensitivity to gefitinib in lung carcinoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Lung Neoplasms; Mice; MicroRNAs; Neoplasm Transplantation; Quinazolines; Transcription Factors | 2017 |
The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Precision Medicine; Prognosis; Quinazolines; Reagent Kits, Diagnostic; Sensitivity and Specificity; Treatment Outcome | 2017 |
Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFR-mutant (Exon18:G719S) lung adenocarcinoma as a second-line chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Quinazolines; Radiation-Sensitizing Agents | 2017 |
Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gene Rearrangement; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Survival Rate | 2017 |
An autopsy case of bronchiolitis obliterans as a previously unrecognized adverse event of afatinib treatment.
Topics: Adenocarcinoma; Afatinib; Autopsy; Bronchiolitis Obliterans; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2017 |
Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Remarkable bone formation following gefitinib for extensive lytic bone metastasis: a report of two cases.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Osteogenesis; Pelvic Bones; Quinazolines; Spine | 2016 |
Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Computer Simulation; Cost-Benefit Analysis; Crown Ethers; Disease-Free Survival; Drug Costs; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Models, Economic; Molecular Targeted Therapy; Mutation; Pemetrexed; Precision Medicine; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines; Time Factors; Treatment Outcome | 2017 |
Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA, Long Noncoding | 2017 |
Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2017 |
EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.
Topics: Acrylamides; Adenocarcinoma; Afatinib; Alleles; Aniline Compounds; Animals; Antineoplastic Agents; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Middle Aged; NIH 3T3 Cells; Phosphorylation; Piperazines; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2017 |
Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Circulating Tumor DNA; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Profiling; Genome; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Neoplasm Metastasis; Oncogene Proteins, Fusion; Quinazolines; Receptor, Fibroblast Growth Factor, Type 3; Recurrence | 2017 |
Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Saponins; Steroids; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
Aurora B expression modulates paclitaxel response in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Aurora Kinase B; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Organophosphates; Paclitaxel; Quinazolines; Up-Regulation | 2017 |
Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Odds Ratio; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion | 2017 |
Novel EGFR Exon 18 (G721R) Mutation in a Patient with Non-Small Cell Lung Carcinoma with Lack of Response to Afatinib.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2017 |
Repression of Smad3 by Stat3 and c-Ski/SnoN induces gefitinib resistance in lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Interleukin-6; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mutation; Proto-Oncogene Proteins; Quinazolines; Signal Transduction; Smad3 Protein; STAT3 Transcription Factor | 2017 |
Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Postoperative Period; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agents.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Quinazolines | 2017 |
Two recent phase 2 trials of vandetanib in RET-rearranged NSCLC.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-ret; Quinazolines | 2017 |
Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma.
Topics: Adenocarcinoma; Aged; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Dyspnea; ErbB Receptors; Exons; Gefitinib; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Mutation; Pleural Effusion; Protein Kinase Inhibitors; Quinazolines | 2017 |
Gefitinib or Erlotinib for Previously Treated Lung Adenocarcinoma: Which Is Superior?
Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2017 |
ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
Topics: Adenocarcinoma; Ado-Trastuzumab Emtansine; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Dosage; Genes, erbB-2; Humans; Lung Neoplasms; Male; Maytansine; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Quinazolines; Retrospective Studies; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2017 |
Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Circulating Tumor DNA; ErbB Receptors; Female; High-Throughput Nucleotide Sequencing; Humans; Liquid Biopsy; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prospective Studies; Quinazolines | 2017 |
Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro.
Topics: Antineoplastic Agents; Apoptosis; Benzoates; Benzylamines; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Liver X Receptors; Lung Neoplasms; NF-kappa B; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2017 |
Retrospective Analysis of Different Treatment Schemes After Gefitinib Resistance in Advanced Non-small Cell Lung Cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Rate | 2017 |
Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation.
Topics: Adenocarcinoma; Aged; Biomarkers; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2017 |
[Precision treatment after resistance to first-generation EGFR-TKI in patients with non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
[Precision first-line therapy for advanced non-small-cell lung cancer patients harboring EGFR mutation].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Regulation of voltage-gated potassium channels attenuates resistance of side-population cells to gefitinib in the human lung cancer cell line NCI-H460.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Potassium Channels, Voltage-Gated; Quinazolines; Side-Population Cells | 2017 |
Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Quinazolines | 2017 |
Patient response to use of tyrosine kinase inhibitors in lung cancer: a retrospective audit during funding changes.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Financing, Government; Gefitinib; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Medical Audit; Middle Aged; New Zealand; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2017 |
Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Prednisolone; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
DDX17 nucleocytoplasmic shuttling promotes acquired gefitinib resistance in non-small cell lung cancer cells via activation of β-catenin.
Topics: A549 Cells; Active Transport, Cell Nucleus; Antigens, CD; Antineoplastic Agents; beta Catenin; Cadherins; Carcinoma, Non-Small-Cell Lung; DEAD-box RNA Helicases; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Nuclear Export Signals; Nuclear Localization Signals; Protein Binding; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Signal Transduction; Time Factors; Transfection | 2017 |
A fluorescent light-up aggregation-induced emission probe for screening gefitinib-sensitive non-small cell lung carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Screening Assays, Antitumor; Fluorescent Dyes; Gefitinib; Humans; Lung Neoplasms; Optical Imaging; Peptides; Protein Kinase Inhibitors; Quinazolines; Stilbenes | 2017 |
Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Topics: Afatinib; Agranulocytosis; Blast Crisis; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Genes, erbB-1; Humans; Leukemia, Myelomonocytic, Chronic; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Efficacy of icotinib in lung squamous-cell cancer: A real-world experience from single institution.
Topics: Aged; Antineoplastic Agents; Crown Ethers; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Squamous Cell; Quinazolines; Retrospective Studies | 2017 |
Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Phosphoproteomics Reveals HMGA1, a CK2 Substrate, as a Drug-Resistant Target in Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HMGA1a Protein; Humans; Lung Neoplasms; Phosphorylation; Protein Interaction Maps; Protein Kinase Inhibitors; Proteomics; Quinazolines | 2017 |
Complete Tumor Response with Afatinib 20 mg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2008 |
RETRACTED: Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA, Neoplasm; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Immunoblotting; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2008 |
Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma.
Topics: Adenocarcinoma; Cerebrospinal Fluid; Diagnosis, Differential; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2008 |
Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: not just a case?
Topics: Adenocarcinoma; Antineoplastic Agents; Diagnosis, Differential; Drug Therapy, Combination; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Letrozole; Lung Neoplasms; Middle Aged; Nitriles; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Skin Neoplasms; Triazoles | 2008 |
From nihilism to individualism: the evolution of lung cancer therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK.
Topics: Amino Acid Substitution; Apoptosis; Arginine; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Caspase Inhibitors; Cell Line, Tumor; Down-Regulation; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Leucine; Lung Neoplasms; Mitochondria; Mutation; Oxidative Phosphorylation; Protein Structure, Quaternary; Protein Transport; Quinazolines; Reactive Oxygen Species; RNA, Small Interfering | 2008 |
EGFR polymorphism of the kinase domain in Japanese lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Polymorphism, Genetic; Prognosis; Quinazolines | 2008 |
Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitomycin; Phosphorylation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Quinazolines; Rad51 Recombinase; RNA, Messenger; Transfection | 2008 |
Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter.
Topics: Adenocarcinoma; Animals; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Peptides; Protein Kinase Inhibitors; Pulmonary Surfactant-Associated Protein C; Quinazolines | 2008 |
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines | 2008 |
Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Biopsy; Dose-Response Relationship, Drug; Female; Gefitinib; Glomerulonephritis, IGA; Humans; Kidney; Lung Neoplasms; Middle Aged; Nephritis, Interstitial; Quinazolines | 2008 |
First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Taiwan | 2008 |
Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelium; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mesoderm; Neoplasm Invasiveness; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Transforming Growth Factor beta1 | 2009 |
Prolonged response to gefitinib in bone metastasis.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Back Pain; Carboplatin; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Spinal Neoplasms; Time Factors | 2009 |
Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Brain Neoplasms; Carcinoma, Bronchogenic; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Follow-Up Studies; Humans; Hypertrichosis; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Quinazolines; Risk Assessment | 2008 |
Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Sex Factors; Smoking; Survival Rate; Treatment Outcome | 2009 |
[Successful treatment of non-small cell lung cancer by gefitinib in an elderly patient with poor performance status].
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Karnofsky Performance Status; Lung Neoplasms; Quinazolines | 2008 |
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Topics: Antineoplastic Agents; Canada; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Genes, erbB-1; Genotype; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Analysis | 2008 |
A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carcinoma, Non-Small-Cell Lung; Codon, Nonsense; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2008 |
Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Quinazolines; Smoking; Tomography, X-Ray Computed | 2008 |
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Azetidines; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Drug Interactions; Erlotinib Hydrochloride; Ezetimibe; Female; Humans; Hyperlipidemias; Hypertension; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rhabdomyolysis; Simvastatin; Tomography, X-Ray Computed | 2008 |
Case records of the Massachusetts General Hospital. Case 23-2008. A 26-year-old man with back pain and a mass in the lung.
Topics: Adenocarcinoma; Adult; Back Pain; Diagnosis, Differential; Drug Resistance, Neoplasm; Fractures, Compression; Gefitinib; Genes, erbB-1; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Male; Protein Kinase Inhibitors; Quinazolines; Radiography; Sequence Deletion; Spinal Fractures; Thoracic Vertebrae | 2008 |
Computed tomography-guided core-needle biopsy specimens demonstrate epidermal growth factor receptor mutations in patients with non-small-cell lung cancer.
Topics: Adult; Aged; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Tomography, X-Ray Computed | 2008 |
Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database.
Topics: Carcinoma, Non-Small-Cell Lung; Databases, Factual; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2008 |
Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Drug interaction between complementary herbal medicines and gefitinib.
Topics: Adenocarcinoma; Adult; ErbB Receptors; Female; Gefitinib; Herb-Drug Interactions; Herbal Medicine; Humans; Lung Neoplasms; Plants, Medicinal; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome | 2008 |
Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts.
Topics: Animals; Apoptosis; Carcinoma, Small Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; In Situ Nick-End Labeling; Lung Neoplasms; Mice; Necrosis; Neovascularization, Pathologic; Piperidines; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2008 |
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Topics: Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Chromatography, Liquid; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoblotting; Lung Neoplasms; Mesoderm; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Respiratory Mucosa; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Spectrometry, Mass, Electrospray Ionization; Thiophenes; Transforming Growth Factor beta; Tumor Cells, Cultured | 2008 |
Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3.
Topics: Aged; Animals; Apoptosis; bcl-X Protein; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoprecipitation; Inositol 1,4,5-Trisphosphate Receptors; Lung Neoplasms; Male; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Middle Aged; Mitochondria; Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Radiopharmaceuticals; Signal Transduction; Technetium Tc 99m Sestamibi | 2008 |
Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pilot Projects; Postmenopause; Prognosis; Quinazolines; Safety; Survival Rate; Treatment Outcome | 2009 |
Trichomegaly induced by erlotinib.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Humans; Hypertrichosis; Lung Neoplasms; Lymphatic Metastasis; Protein Kinase Inhibitors; Quinazolines | 2008 |
Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoadjuvant Therapy; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Pulmonary Alveoli; Quinazolines; Tomography, X-Ray Computed | 2008 |
Lung cancer response to gefitinib, then erlotinib, then gefitinib again.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography; Treatment Outcome | 2008 |
Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Muscle Neoplasms; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Tumor Cells, Cultured; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2008 |
[Targeted therapies. New hopes, new challenges].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Time Factors; Vascular Endothelial Growth Factor A | 2008 |
Gefitinib maintenance in stage III non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis | 2008 |
SWOG S0023: what meets the eye may be only half the truth.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2008 |
Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2008 |
Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survival Rate | 2008 |
EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance.
Topics: Aged; Base Sequence; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Genetic Heterogeneity; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2008 |
Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Non-Small-Cell Lung; Cell Division; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; Neoplasm Staging; Placebos; Platinum Compounds; Prognosis; Quinazolines; Survival Analysis | 2009 |
Non-small cell lung cancer-smokers or non-smokers, does it matter?
Topics: Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2009 |
Newer opportunities in systemic therapy of lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Treatment Outcome | 2008 |
Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts.
Topics: Animals; Apoptosis; Carcinoma; Combined Modality Therapy; Female; Lung Neoplasms; Mice; Mice, Nude; Necrosis; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Humans; Lung; Lung Neoplasms; Middle Aged; Quinazolines; Radiation Pneumonitis; Radiotherapy; Treatment Outcome | 2008 |
An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Quinazolines | 2008 |
Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dinucleotide Repeats; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunoenzyme Techniques; Introns; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Gefitinib first or gefitinib second: is timing everything in the treatment of EGFR mutant non-small cell lung cancer?
Topics: Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2008 |
Antitumor activity of a new N-substituted thiourea derivative, an EGFR signaling-targeted inhibitor against a panel of human lung cancer cell lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colony-Forming Units Assay; DNA; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Thiourea | 2008 |
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Cohort Studies; Disease Progression; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptors, Growth Factor; Survival Analysis | 2009 |
Rosaceiform eruption induced by erlotinib.
Topics: Acneiform Eruptions; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2008 |
[Evaluation of efficacy and safety of ZD1839 as monotherapy in Chinese patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Treatment Outcome | 2008 |
Impact of preexisting pulmonary fibrosis detected on chest radiograph and CT on the development of gefitinib-related interstitial lung disease.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; Radiography, Thoracic; Retrospective Studies; Risk Factors; Survival Rate; Tomography, X-Ray Computed | 2008 |
A case of advanced non-small-cell lung cancer who responded slowly to gefitinib monotherapy after long-term disease stabilization.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gemcitabine; Gene Expression Profiling; Genes, ras; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2008 |
An epidermal growth factor inhibitor, Gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Down-Regulation; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphorylation; Quinazolines; Signal Transduction; Tumor Suppressor Protein p53; Up-Regulation | 2008 |
A population-based study of gefitinib in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Demography; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Quinazolines; Smoking | 2009 |
A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity; Survival Rate | 2008 |
[Hemorrhagic pericardial effusion and multiple pulmonary nodules in a 37 year old male who has "never smoked"].
Topics: Adult; Erlotinib Hydrochloride; Hemorrhage; Humans; Lung Neoplasms; Male; Multiple Pulmonary Nodules; Pericardial Effusion; Protein Kinase Inhibitors; Quinazolines; Smoking; Treatment Outcome | 2009 |
Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Oncogene Protein v-akt; Quinazolines; Time Factors; Tumor Cells, Cultured | 2008 |
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
Topics: Amphiregulin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; EGF Family of Proteins; Gefitinib; Genes, erbB-1; Glycoproteins; Head and Neck Neoplasms; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Prolonged response to first-line erlotinib for advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2008 |
EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dinucleotide Repeats; Exanthema; Female; Gefitinib; Genes, erbB-1; Humans; Inteins; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pharmacogenetics; Polymorphism, Genetic; Quinazolines; Treatment Outcome | 2009 |
Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Treatment Outcome | 2009 |
The role of targeted agents in the treatment of elderly patients with non-small cell lung cancer (NSCLC).
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2008 |
Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Kinase 1; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Proteasome Endopeptidase Complex; Quinazolines; Rad51 Recombinase; Signal Transduction; Transfection | 2008 |
[18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorine Radioisotopes; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Quinazolines; Radiopharmaceuticals; ROC Curve; Thymidine; Time; Tomography, X-Ray Computed | 2008 |
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Afatinib; Aged; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Protein Structure, Quaternary; Quinazolines; Sequence Alignment | 2008 |
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.
Topics: Adenocarcinoma; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-3; Receptors, Growth Factor | 2008 |
Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib.
Topics: Aged; Alopecia; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Cicatrix; Disease Progression; ErbB Receptors; Fatal Outcome; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Quinazolines; Risk Assessment | 2008 |
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
Topics: Amino Acid Substitution; AMP-Activated Protein Kinase Kinases; Animals; Chlorocebus aethiops; COS Cells; ErbB Receptors; Erlotinib Hydrochloride; Focal Adhesion Kinase 1; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation, Missense; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Growth Factor; Sulfonamides | 2009 |
EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Treatment Outcome | 2009 |
Bilateral subdural hemorrhage as a possible adverse event of gefitinib in a patient with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Hematoma, Subdural; Humans; Lung Neoplasms; Quinazolines; Tomography, X-Ray Computed | 2009 |
[Impact of erlotinib treatment on symptoms and quality of life in patients with advanced non-small-cell lung cancer].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Quinazolines; Remission Induction; Salvage Therapy; Treatment Failure | 2008 |
Gefitinib or docetaxel in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2008 |
Ovarian carcinoma as a surrogate tumor for lung adenocarcinomas in evaluating the chemo-stability of a gene expression signature.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasms; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Regression Analysis; Reproducibility of Results; Tumor Cells, Cultured | 2009 |
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2009 |
Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
[Hand-foot syndrome: A new side effect of erlotinib].
Topics: Aged; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Erythema; Foot Dermatoses; Foot Diseases; Hand Dermatoses; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Syndrome | 2008 |
Disseminated intravascular coagulation (DIC) and non-small cell lung cancer (NSCLC): report of a case and review of the literature.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disseminated Intravascular Coagulation; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Thrombocytopenia | 2009 |
Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Dideoxynucleosides; Down-Regulation; Early Detection of Cancer; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Lung Neoplasms; Mice; Positron-Emission Tomography; Quinazolines; Signal Transduction; Treatment Outcome; Xenograft Model Antitumor Assays | 2008 |
[Sequential administration of gefitinib and docetaxel as second-line therapy for advanced non-small cell lung cancer: analysis of 82 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome | 2008 |
Erlotinib combined with cyclosporine in a liver-transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclosporine; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2009 |
Wood-smoke exposure (WSE) as a predictor of response and survival in erlotinib-treated non-small cell lung cancer (NSCLC) patients.
Topics: Adenocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhalation Exposure; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Smoke; Survival Rate; Wood | 2009 |
Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Folliculitis; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Skin | 2009 |
[Economic impact of second- and third-line erlotinib treatment of non small-cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antiemetics; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Drug Utilization; Erlotinib Hydrochloride; Female; France; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2008 |
A quantitative volumetric micro-computed tomography method to analyze lung tumors in genetically engineered mouse models.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antineoplastic Agents; Cell Proliferation; Cone-Beam Computed Tomography; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Genes, p53; Genes, ras; Lung Neoplasms; Male; Mice; Mice, Transgenic; Neovascularization, Pathologic; Quinazolines; Tumor Burden | 2009 |
Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Risk Factors; Smoking | 2009 |
Erlotinib for the treatment of non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Lung Neoplasms; Mice; Mutation; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Sirolimus | 2009 |
Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting - does it matter ? A single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2009 |
A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Follow-Up Studies; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Quinazolines; Risk Assessment | 2009 |
Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Caspase 12; Caspase 3; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endoplasmic Reticulum; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Glycosylation; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Transcription Factor CHOP; Tunicamycin | 2009 |
ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC).
Topics: Antineoplastic Agents; Base Sequence; Blotting, Western; Cadherins; Carcinoma, Non-Small-Cell Lung; Cohort Studies; DNA Primers; Enzyme Inhibitors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Immunoprecipitation; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor, ErbB-3 | 2009 |
Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice.
Topics: Animals; Antineoplastic Agents; Carcinogens, Environmental; Cell Growth Processes; Cell Line, Tumor; Cell Transformation, Neoplastic; ErbB Receptors; Female; Gefitinib; Lung; Lung Neoplasms; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Nitrosamines; Pulmonary Fibrosis; Quinazolines; Smoking; Tumor Burden | 2009 |
Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fatal Outcome; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Multiple Primary; Quinazolines; Sequence Deletion; Treatment Outcome | 2009 |
Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts.
Topics: Animals; Carbon Radioisotopes; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Tissue Distribution; Transplantation, Heterologous | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor Protein-Tyrosine Kinases; Remission Induction; Smoking | 2009 |
The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Gefitinib; Gene Expression Regulation; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Rad51 Recombinase; Sulfonamides | 2009 |
PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans.
Topics: Adult; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Ligands; Lung Neoplasms; Male; Metabolic Clearance Rate; Positron-Emission Tomography; Quinazolines; Radiometry; Radiopharmaceuticals; Tissue Distribution; Tomography, X-Ray Computed; Young Adult | 2009 |
Arsenic activates EGFR pathway signaling in the lung.
Topics: Adult; Aged; Amphiregulin; Analysis of Variance; Arsenic; Arsenites; Biomarkers; Bronchi; Cells, Cultured; Cyclin D1; Cycloheximide; EGF Family of Proteins; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Glycoproteins; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Lung; Lung Neoplasms; Middle Aged; Nails; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sodium Compounds | 2009 |
Effect of low-dose aspirin for skin rash associated with erlotinib therapy in patients with lung cancer.
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Platelet Activation; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Quinazolines; Thromboxane B2; Treatment Outcome | 2009 |
[Long-term remission after erlotinib therapy in an elderly patient with advanced non-small-cell lung cancer. Case report and conclusions for clinical practice].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction | 2008 |
[Sensitivity of two cell lines with acquired resistance to gefitinib to several chemotherapeutic drugs].
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromones; Docetaxel; Drug Resistance, Neoplasm; Gefitinib; Glutamates; Guanine; Humans; Integrin beta1; Lung Neoplasms; Morpholines; Pemetrexed; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Taxoids | 2008 |
[Erlotnib in the treatment of advanced non-small cell lung cancer failed to previous chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Remission Induction; Treatment Failure; Young Adult | 2008 |
Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dual Specificity Phosphatase 1; ErbB Receptors; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tyrphostins | 2009 |
Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Models, Biological; Multivariate Analysis; Prognosis; Quinazolines; Reproducibility of Results; Salvage Therapy; Survival Analysis; Treatment Outcome | 2009 |
ACR appropriateness criteria on nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Diagnostic Imaging; Dose Fractionation, Radiation; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoplasm Staging; Palliative Care; Quinazolines; Radiotherapy Dosage | 2009 |
Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Depsipeptides; Drug Synergism; Enzyme Inhibitors; Erlotinib Hydrochloride; Female; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Xenograft Model Antitumor Assays | 2009 |
Prolonged remission of disseminated atypical adenomatous hyperplasia under gefitinib.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Hyperplasia; Lung; Lung Neoplasms; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines; Remission Induction; Tomography, X-Ray Computed | 2009 |
Benzo[a]pyrene promotes proliferation of human lung cancer cells by accelerating the epidermal growth factor receptor signaling pathway.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzo(a)pyrene; Cell Culture Techniques; Cell Division; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Signal Transduction | 2009 |
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Quinazolines; Recurrence; Treatment Outcome | 2009 |
Gefitinib as targeted therapy for mucoepidermoid carcinoma of the lung: possible significance of CRTC1-MAML2 oncogene.
Topics: Carcinoma, Mucoepidermoid; DNA-Binding Proteins; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Quinazolines; Trans-Activators; Transcription Factors | 2009 |
Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Expression; Genes, erbB-1; Humans; Japan; Lung Neoplasms; Male; Mutation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Treatment Outcome | 2009 |
Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; E2F1 Transcription Factor; ErbB Receptors; Fluorouracil; Gefitinib; Gene Amplification; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mutation; Oxonic Acid; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Quinazolines; Tegafur; Thymidylate Synthase | 2009 |
Rare cutaneous side-effect of gefitinib masquerading as superficial dermatophytosis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dermatomycoses; Drug Eruptions; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Perineum; Quinazolines; Scalp Dermatoses; Treatment Outcome | 2009 |
Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Expression; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome | 2009 |
MYC and EIF3H Coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Eukaryotic Initiation Factor-3; Female; Gefitinib; Gene Amplification; Genes, myc; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Gefitinib plus docetaxel in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2009 |
Gefitinib plus docetaxel in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Endpoint Determination; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2009 |
Gefitinib plus docetaxel in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2009 |
Erlotinib-induced pustular eruption.
Topics: Acneiform Eruptions; Administration, Cutaneous; Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Erythromycin; Gels; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2009 |
The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index | 2009 |
Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2009 |
Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells.
Topics: Animals; Apoptosis; Blotting, Western; Bone Density Conservation Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Survival; Diphosphonates; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Organophosphonates; Quinazolines; Transplantation, Heterologous; Zoledronic Acid | 2009 |
Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.
Topics: Animals; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoblotting; Immunoprecipitation; Indoles; Luciferases; Lung Neoplasms; Magnetic Resonance Imaging; Mice; Mice, Nude; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptors, Growth Factor; RNA, Small Interfering; Sulfonamides; Xenograft Model Antitumor Assays | 2008 |
The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells.
Topics: Benzodioxoles; Cell Line, Tumor; Cell Movement; Chromones; Focal Adhesion Protein-Tyrosine Kinases; Humans; Janus Kinase 3; Lung Neoplasms; Morpholines; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation-Sensitizing Agents; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor | 2009 |
Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Receptors, Growth Factor; Wound Healing | 2009 |
[Description of erlotinib-related skin effects management in France. Results of the PRECEDE study].
Topics: Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Female; France; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2009 |
EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Female; Gefitinib; Genes, erbB-2; Genes, ras; Genome; Humans; In Situ Hybridization, Fluorescence; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Probability; Prognosis; Quinazolines; Retrospective Studies; Sensitivity and Specificity; Statistics, Nonparametric; Survival Analysis | 2009 |
Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Quinazolines; Retrospective Studies; Treatment Outcome | 2009 |
A case report of thyroid cancer showing a remarkable effect of gefitinib.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Papillary; Female; Gefitinib; Head and Neck Neoplasms; Humans; Incidental Findings; Lung Neoplasms; Lymph Nodes; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Quinazolines; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2009 |
Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer.
Topics: Acidosis, Lactic; Adenocarcinoma; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Metformin; Quinazolines | 2009 |
Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Salvage Therapy | 2009 |
A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cyclin D1; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Quinazolines; Survival Rate | 2009 |
Histoculture drug response assay for gefitinib in non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Smoking; Tissue Culture Techniques | 2009 |
Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Dinoprostone; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genistein; Humans; Lung Neoplasms; NF-kappa B; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines | 2009 |
Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
Topics: Aminoglycosides; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Enediynes; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2009 |
Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Survival; Depsipeptides; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Oncogene Proteins v-erbB; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2009 |
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromosome Aberrations; Cluster Analysis; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Gene Deletion; Gene Expression; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines | 2009 |
Inhibition of heme oxygenase-1 with an epidermal growth factor receptor inhibitor and cisplatin decreases proliferation of lung cancer A549 cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Heme Oxygenase-1; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Tyrphostins | 2010 |
Persistent hair growth during treatment with the EGFR inhibitor erlotinib.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Hair; Hair Color; Humans; Hypertrichosis; Lung Neoplasms; Neoplasm Proteins; Paronychia; Protein Kinase Inhibitors; Quinazolines; Remission Induction | 2009 |
[A case of non-small cell lung cancer with EGFR mutation responding to S-1 after a therapy with gefitinib].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Oxonic Acid; Quinazolines; Tegafur; Tomography, X-Ray Computed | 2009 |
Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; China; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis | 2009 |
Metabolic profiling identifies lung tumor responsiveness to erlotinib.
Topics: Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Metabolome; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines | 2009 |
Toward noninvasive genomic screening of lung cancer patients.
Topics: Antineoplastic Agents; Biomarkers, Tumor; DNA; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Genetic Testing; Humans; Lung Neoplasms; Mass Screening; Mutation; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2009 |
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Everolimus; Gefitinib; Humans; Immunosuppressive Agents; Lung Neoplasms; Phosphorylation; Quinazolines; Ribosomal Protein S6 Kinases; Signal Transduction; Sirolimus | 2009 |
Radiosensitizing effects of gefitinib at different administration times in vitro.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Dose-Response Relationship, Radiation; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; X-Rays | 2009 |
Quantum dot-based quantification revealed differences in subcellular localization of EGFR and E-cadherin between EGFR-TKI sensitive and insensitive cancer cells.
Topics: Antineoplastic Agents; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Endosomes; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lung Neoplasms; Lysosomes; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quantum Dots; Quinazolines; Signal Transduction | 2009 |
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; NIH 3T3 Cells; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Transfection; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2009 |
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Enzyme-Linked Immunosorbent Assay; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Meta-Analysis as Topic; Piperidines; Predictive Value of Tests; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Analysis of ErbB receptors in pulmonary carcinoid tumors.
Topics: Adult; Aged; Base Sequence; Carcinoid Tumor; Cell Proliferation; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoblotting; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphorylation; Polymorphism, Single Nucleotide; Quinazolines; ras Proteins; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Signal Transduction | 2009 |
Erlotinib and bevacizumab have synergistic activity against melanoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Immunoblotting; Immunohistochemistry; Ki-67 Antigen; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, SCID; Platelet Endothelial Cell Adhesion Molecule-1; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective.
Topics: Antineoplastic Agents; Brazil; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost Control; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Sensitivity and Specificity; Taxoids | 2008 |
Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Culture Media, Serum-Free; Dose-Response Relationship, Drug; ErbB Receptors; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2009 |
[Potent and continuous relief of spinal bone pain due to metastasis of non-small cell lung cancer by treatment with gefitinib--a case report].
Topics: Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Pain; Quinazolines; Spine; Tomography, X-Ray Computed | 2009 |
Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2010 |
Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Introns; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2010 |
Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Immunohistochemistry; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Neoplasms; Meningitis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Risk Assessment; Tomography, X-Ray Computed | 2009 |
Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib.
Topics: Adenocarcinoma; Aged; Artifacts; Biopsy; Bone and Bones; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radionuclide Imaging; Retrospective Studies | 2009 |
Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Predictive Value of Tests; Prospective Studies; Quinazolines; Radiopharmaceuticals; Survival Rate; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; ErbB Receptors; Gefitinib; Gene Amplification; Humans; Immunohistochemistry; Lung Neoplasms; Mutation; Neoplasm Invasiveness; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; RNA, Small Interfering; src-Family Kinases | 2009 |
Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Base Sequence; Cell Line, Tumor; DNA Primers; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Phosphorylation; Piperidines; Polymerase Chain Reaction; Quinazolines; Receptor, IGF Type 1; Signal Transduction | 2009 |
Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; K562 Cells; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Substrate Specificity; Tumor Cells, Cultured; Vincristine | 2009 |
Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.
Topics: Adenosine Triphosphatases; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Multiple; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2010 |
Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; Disease Models, Animal; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mice, SCID; Middle Aged; Neoplasm Proteins; Quinazolines; Treatment Outcome; Xenograft Model Antitumor Assays | 2009 |
Persistent corneal epithelial defect associated with erlotinib treatment.
Topics: Aged; Cataract Extraction; Corneal Diseases; Epithelium, Corneal; Erlotinib Hydrochloride; Female; Humans; Keratitis; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Staphylococcal Infections; Staphylococcus epidermidis | 2009 |
A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Furans; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrimidines; Quinazolines; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2009 |
Role of tyrosine kinase inhibitors in lung cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2009 |
A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Alopecia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inflammation; Lung Neoplasms; Middle Aged; Quinazolines | 2009 |
Molecular imaging of EGFR: it's time to go beyond receptor expression.
Topics: Adult; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Ligands; Lung Neoplasms; Male; Metabolic Clearance Rate; Molecular Probe Techniques; Positron-Emission Tomography; Quinazolines; Radiometry; Radiopharmaceuticals; Tissue Distribution; Tomography, X-Ray Computed; Young Adult | 2009 |
Assessment of erlotinib in chemoresponse assay.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2009 |
Combination effect between bortezomib and tumor necrosis factor alpha on gefitinib-resistant non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Pyrazines; Quinazolines; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2009 |
Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Quinazolines; Survival Rate | 2009 |
Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Analysis | 2010 |
[Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Remission Induction; Survival Rate; Young Adult | 2009 |
Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Smoking; Treatment Outcome | 2009 |
Key questions for perioperative chemotherapy in resectable lung cancer: not pre vs post, but who and what?
Topics: Antigens, Neoplasm; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Proteins; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2009 |
Gefitinib in combination with gemcitabine and carboplatin in never smokers with non-small cell lung carcinoma: a retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Epidermal growth factor receptor exon 19 deletions predict complete regression of multiple intracranial metastases in two cases of non-small cell lung cancer treated with erlotinib.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Exons; Fatal Outcome; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2009 |
Gefitinib and a ventriculo-peritoneal shunt to manage carcinomatous meningitis from non-small-cell lung cancer: report of two cases.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Quinazolines; Treatment Outcome; Ventriculoperitoneal Shunt | 2009 |
Erlotinib for the treatment of relapsed non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Technology Assessment, Biomedical | 2009 |
Age at diagnosis predicts outcomes in gefitinib-treated female patients with non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Early Detection of Cancer; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Quinazolines | 2010 |
Outpacing cancer.
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Mutation; Piperazines; Pyrimidines; Quinazolines | 2009 |
Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Genetic Association Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Proto-Oncogene Proteins c-met; Quinazolines | 2010 |
Gefitinib plus paclitaxel after failure of gefitinib in non-small cell lung cancer initially responding to gefitinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quinazolines; Survival Analysis | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors and depression.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Depression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2009 |
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers.
Topics: Adult; Aged; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Mutation; Quinazolines; RNA, Antisense; Signal Transduction; Smoking; Tyrphostins | 2009 |
Combined treatment with TNF-alpha/gefitinib alleviates the resistance to gefitinib in PC-9 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Cycle Proteins; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Tumor Necrosis Factor-alpha | 2009 |
Complete regression of choroidal metastasis secondary to non-small-cell lung cancer with intravitreal bevacizumab and oral erlotinib combination therapy.
Topics: Administration, Oral; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Choroid Neoplasms; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Humans; Injections, Intraocular; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Vitreous Body | 2009 |
Wood-smoke exposure as a response and survival predictor in erlotinib-treated nonsmall cell lung cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Smoke; Survival Rate; Wood | 2009 |
[Predictive factors for response and survival of gefitinib-treated locally advanced or metastatic non-small cell lung cancer patients: a retrospective analysis of two phase II clinical trials].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Disease Progression; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2009 |
[A case of lung cancer combined with pregnancy; dramatically deteriorating condition after caesarian section].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Cesarean Section; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Quinazolines | 2009 |
The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells.
Topics: Animals; Anticarcinogenic Agents; Carcinoma, Non-Small-Cell Lung; Catechin; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Male; Mice; Mice, SCID; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Sulfonamides; Xenograft Model Antitumor Assays | 2009 |
Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; ErbB Receptors; Europe; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Failure; United States; United States Food and Drug Administration | 2009 |
Gefitinib: phoenix from the flames.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2009 |
Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA-Binding Proteins; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Prognosis; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Y-Box-Binding Protein 1 | 2009 |
Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment.
Topics: Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mutation; Quinazolines; ROC Curve; Sensitivity and Specificity; Smoking | 2009 |
Gefitinib-induced interstitial lung disease-addition of intravenous cyclophosphamide to corticosteroids is a valuable treatment option: A case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Infusions, Intravenous; Lung Diseases, Interstitial; Lung Neoplasms; Methylprednisolone; Muscular Diseases; Prednisolone; Quinazolines | 2010 |
Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Smoking; Survival Analysis | 2010 |
Fatal cystic change of brain metastasis after response to gefitinib in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cysts; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2009 |
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Genotype; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor Protein-Tyrosine Kinases; Sex Factors; Treatment Outcome | 2009 |
Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activation; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Phosphorylation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Stability; Proto-Oncogene Proteins c-akt; Quinazolines; Rad51 Recombinase; Signal Transduction; Transfection | 2009 |
Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Phosphorylation; Quinazolines; Tyrosine | 2009 |
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Databases, Factual; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Online Systems; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Registries | 2009 |
Lung cancer trials probe effects of maintenance therapy, targeted agents.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2009 |
Erlotinib activates mitochondrial death pathways related to the production of reactive oxygen species in the human non-small cell lung cancer cell line A549.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Respiration; Enzyme Activation; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Membrane Glycoproteins; Mitochondria; NADPH Oxidase 2; NADPH Oxidases; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; Signal Transduction | 2009 |
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; Disease Models, Animal; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Phosphorylation; Promoter Regions, Genetic; Pulmonary Surfactant-Associated Protein C; Quinazolines; Receptor, ErbB-3; Smoking | 2009 |
Estrogen replacement in female lung cancer during gefitinib therapy.
Topics: Animals; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Estrogen Replacement Therapy; Estrogens; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2009 |
Personalized medicine and inhibition of EGFR signaling in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2009 |
Screening for epidermal growth factor receptor mutations in lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sex Distribution; Survival Analysis; Young Adult | 2009 |
[Comparative evaluation of adverse reactions between gefitinib and erlotinib treatments in the same patients].
Topics: Aged; Anorexia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
[A case of lung adenocarcinoma successfully treated with dose-reescalated gefitinib after resistance was acquired].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2009 |
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Spinal Cord Neoplasms; Treatment Outcome | 2009 |
Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2009 |
Bronchioloalveolar carcinoma: not as easy as "BAC".
Topics: Adenocarcinoma, Bronchiolo-Alveolar; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Effect of gefitinib on warfarin antithrombotic activity.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Blood Coagulation; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Female; Gefitinib; Humans; International Normalized Ratio; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Prothrombin Time; Quinazolines; Retrospective Studies; Time Factors; Warfarin | 2009 |
[Epidermal growth factor receptor aberrations in malignant mesotheliomas].
Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mesothelioma; Quinazolines | 2009 |
I am no one. No one is perfect...Therefore I am perfect.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis; Taxoids | 2009 |
Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sex Factors; Smoking | 2009 |
Gefitinib for non-small cell lung cancer patients with liver cirrhosis.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Liver Cirrhosis; Lung Neoplasms; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2009 |
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.
Topics: Afatinib; Amphiregulin; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Disease Models, Animal; Drug Resistance, Neoplasm; EGF Family of Proteins; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Mice; Mice, Nude; Mice, Transgenic; Mutation; Neoplasm Transplantation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 2009 |
Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lovastatin; Lung Neoplasms; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction | 2010 |
Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2010 |
Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Black or African American; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genetic Predisposition to Disease; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Probability; Quinazolines; ras Proteins; Risk Assessment; White People | 2009 |
Lessons from the lung for targeted anticancer drugs.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung; Lung Neoplasms; Quinazolines | 2009 |
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Base Sequence; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2009 |
Comparison of four antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Insurance, Health, Reimbursement; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results | 2010 |
Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities.
Topics: Animals; Antineoplastic Agents; Biotransformation; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP3A; ErbB Receptors; Gefitinib; Glutathione; Hepatocytes; Humans; Lung; Lung Neoplasms; Mice; Microsomes; Microsomes, Liver; Quinazolines | 2009 |
Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptor, ErbB-3; Receptors, Growth Factor; Signal Transduction; src-Family Kinases; Thiazoles | 2010 |
The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2009 |
Development of rheumatoid arthritis during the course of gefitinib therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Interactions; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prednisolone; Quinazolines; Sulfasalazine | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; Epithelium; ErbB Receptors; Erlotinib Hydrochloride; Humans; Inflammation; Lung Neoplasms; Male; Mesoderm; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Signal Transduction | 2009 |
Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.
Topics: Amphiregulin; Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytoplasm; Drug Resistance, Neoplasm; EGF Family of Proteins; ErbB Receptors; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mitochondria; Quinazolines | 2010 |
Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation.
Topics: Amphiregulin; Animals; Antigens, Nuclear; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Drug Resistance, Neoplasm; EGF Family of Proteins; ErbB Receptors; Female; Gefitinib; Glycoproteins; Histone Acetyltransferases; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Ku Autoantigen; Lung Neoplasms; Mice; Quinazolines; Subcellular Fractions; Vorinostat | 2010 |
Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Keratin-19; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Peptides; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2010 |
[A case of non-small cell lung cancer treated safely by whole brain radiation therapy and erlotinib].
Topics: Adenocarcinoma; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2009 |
Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Coculture Techniques; Drug Resistance, Neoplasm; ErbB Receptors; Fibroblasts; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, Nude; Mice, SCID; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor Cross-Talk; Stromal Cells; Xenograft Model Antitumor Assays | 2009 |
Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Treatment Failure | 2009 |
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Imidazoles; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Quinolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2009 |
[Erlotinib and nonsmall cell lung cancer with brain metastases: a case study with a complete and prolonged response over 17 months].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2009 |
Successful treatment of lung cancer with gefitinib and EGFR mutation status determination using EBUS-TBNA samples in an extremely old patient.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Biopsy, Fine-Needle; Endosonography; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Treatment Outcome | 2009 |
Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2010 |
EGFR-TKI treatment and surgical resection for oligometastatic NSCLC?
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2009 |
Down-staging of EGFR mutation-positive advanced lung carcinoma with gefitinib followed by surgical intervention: follow-up of two cases.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2009 |
Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Molecular Conformation; Neoplasm Transplantation; Pyrrolidines; Quinazolines; Rats; Receptor, ErbB-2; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous | 2009 |
Massive hematuria from the bilateral upper urinary tract in a patient treated for advanced lung cancer with gefitinib.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Hematuria; Humans; Lung Neoplasms; Prognosis; Quinazolines; Treatment Outcome; Urinary Tract | 2010 |
Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cancer Care Facilities; Carcinoma, Non-Small-Cell Lung; Community Health Services; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Time Factors | 2009 |
Clinical significance of the KRAS mutation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Precision Medicine; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2009 |
[A case of adenocarcinoma of the lung with a long-term therapeutic effect due to S-1 administered as the sixth regimen].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Combinations; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Quinazolines; Taxoids; Tegafur | 2009 |
Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Gene Deletion; Genes, erbB-1; Humans; In Situ Hybridization, Fluorescence; Indicators and Reagents; Insulin-Like Growth Factor Binding Proteins; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2010 |
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Guidelines as Topic; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dermatitis, Seborrheic; Disease Progression; Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Follow-Up Studies; Hand Dermatoses; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Syndrome | 2009 |
Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
Topics: Animals; Apoptosis; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Female; HSP90 Heat-Shock Proteins; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Paclitaxel; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Successful treatment of pyogenic granulomas following gefitinib therapy with partial matricectomy and phenolization.
Topics: Aged; Anti-Infective Agents, Local; Antineoplastic Agents; Female; Gefitinib; Granuloma, Pyogenic; Humans; Lung Neoplasms; Nails, Ingrown; Phenol; Quinazolines; Toes; Treatment Outcome | 2009 |
Erlotinib-induced skin manifestations.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2009 |
A case of bullous dermatitis induced by erlotinib.
Topics: Adenocarcinoma; Dermatitis; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Skin Diseases, Vesiculobullous | 2009 |
Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Estrogen Receptor beta; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Quinazolines; Receptor Cross-Talk; Signal Transduction; Tamoxifen | 2010 |
Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.
Topics: Adenocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gene Deletion; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2010 |
[Successful gefitinib every other day administration in an advanced lung cancer patient with brain metastasis after gamma knife radiotherapy and chemotherapy].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Radiosurgery | 2009 |
[A case of meningeal carcinomatosis of lung adenocarcinoma well controlled by re-treatment with gefitinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Drug Resistance, Neoplasm; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Meningeal Neoplasms; Mutation; Paclitaxel; Quinazolines | 2009 |
Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Quinazolines; Skin Diseases | 2009 |
CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glycoproteins; Hematopoietic Stem Cells; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Peptides; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib | 2010 |
Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer.
Topics: Budgets; Carcinoma, Non-Small-Cell Lung; Cost Control; Cost-Benefit Analysis; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Economic; Protein Synthesis Inhibitors; Quinazolines | 2010 |
Treatment of lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Paclitaxel; Proportional Hazards Models; Quinazolines; Survival Analysis | 2009 |
New-onset acute interstitial lung disease after treatment with erlotinib in a patient with metastatic squamous cell carcinoma of the lung.
Topics: Aged; Biopsy; Brain Neoplasms; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Pneumonia; Quinazolines; Tomography, X-Ray Computed | 2011 |
Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas.
Topics: Adenocarcinoma; Animals; Chimera; Disease Models, Animal; Embryonic Stem Cells; ErbB Receptors; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Phenotype; Piperazines; Proto-Oncogene Proteins p21(ras); Quinazolines; Respiratory Insufficiency; Signal Transduction | 2010 |
Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib.
Topics: Analgesics; Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines | 2010 |
[Lung cancer: an update in 2010].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Small Cell Lung Carcinoma | 2010 |
Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis.
Topics: Adenocarcinoma; Antineoplastic Agents; Biopsy, Needle; Clinical Trials, Phase II as Topic; DNA Mutational Analysis; ErbB Receptors; Female; Fluoroscopy; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiography, Interventional; ras Proteins; Tomography, X-Ray Computed | 2010 |
Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease.
Topics: Adenocarcinoma; Adult; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Diarrhea; DNA; Female; Gefitinib; Genotype; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Genetic; Quinazolines | 2010 |
[Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Remission Induction; Survival Rate | 2010 |
Gefitinib as first-line therapy for advanced or metastatic non-small cell lung cancer patients in southern Taiwan.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Rate; Taiwan; Young Adult | 2010 |
Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Disease Models, Animal; Female; Immunoenzyme Techniques; Kidney Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2009 |
Treatment of lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Paclitaxel; Proportional Hazards Models; Quinazolines | 2009 |
Treatment of lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Paclitaxel; Quinazolines; Survival Rate | 2009 |
Treatment of lung cancer.
Topics: ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2009 |
Trichomegaly secondary to erlotinib.
Topics: Adenocarcinoma; Aged; ErbB Receptors; Erlotinib Hydrochloride; Eyebrows; Eyelashes; Humans; Hypertrichosis; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2009 |
Epidermal growth factor receptor signaling in nonsmall cell lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Clinical Trials as Topic; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2010 |
Randomized clinical trials with biomarkers: design issues.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; DNA-Binding Proteins; Endonucleases; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Staurosporine | 2010 |
Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Retrospective Studies; Survival Rate | 2010 |
Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mass Spectrometry; Mutation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2010 |
Histology matters: individualizing treatment in non-small cell lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; SEER Program | 2010 |
Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue.
Topics: Antineoplastic Agents; ErbB Receptors; Fixatives; Formaldehyde; Gefitinib; Humans; Lung Neoplasms; Mutation; Nucleic Acid Amplification Techniques; Paraffin Embedding; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sequence Analysis, DNA; Tissue Fixation | 2010 |
MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Lung Neoplasms; Mice; MicroRNAs; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Japan; Logistic Models; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Factors | 2010 |
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.
Topics: Afatinib; Amino Acid Substitution; Animals; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Furans; Humans; Lung Neoplasms; Molecular Structure; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2010 |
Second-line therapy for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effective as for younger patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2010 |
First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Biomarkers, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Triad of trichomegaly, alopecia and male-pattern hair growth during treatment with erlotinib in non-small-cell lung cancer.
Topics: Adenocarcinoma; Alopecia; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Quinazolines | 2011 |
Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression.
Topics: Adenoma; Animals; Antineoplastic Agents; Cadherins; Cytochrome P-450 Enzyme System; Dinoprostone; Epoprostenol; ErbB Receptors; Female; Gefitinib; Intramolecular Oxidoreductases; Lung Neoplasms; Male; Mice; Mice, Transgenic; Protein Kinase Inhibitors; Quinazolines; Rats; Signal Transduction | 2010 |
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2010 |
Vascular endothelial growth factor concentration as a predictive marker: ready for primetime?
Topics: Biomarkers, Tumor; Blood Chemical Analysis; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Piperidines; Predictive Value of Tests; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2010 |
High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.
Topics: Adenocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion.
Topics: Aniline Compounds; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Inhibitory Concentration 50; Lung Neoplasms; Magnetic Resonance Spectroscopy; Mass Spectrometry; Models, Molecular; Quinazolines; Structure-Activity Relationship | 2010 |
[A case of complete response treated by S-1 with concurrent radiotherapy for a gefitinib-resistant non-small cell lung cancer patient].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Combinations; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Oxonic Acid; Positron-Emission Tomography; Quinazolines; Remission Induction; Tegafur; Tomography, X-Ray Computed | 2010 |
Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion; Predictive Value of Tests; Quinazolines; Survival Analysis | 2010 |
Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
Economics and the new generation of targeted therapies for non-small cell lung cancer.
Topics: Angiogenesis Inhibitors; Canada; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; United States | 2010 |
Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Canada; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Female; Hospitalization; Humans; International Cooperation; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2010 |
[Henoch-schönlein purpura induced by erlotinib (Tarceva): a case report].
Topics: Adenocarcinoma; Aged; Erlotinib Hydrochloride; Female; Humans; IgA Vasculitis; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
[4, 8-disubstituted-8, 9-dihydro-pyrazine[2,3-g]quinazoline-7(6H)-ketones: a novel class of antitumor agents].
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; K562 Cells; Lung Neoplasms; Molecular Structure; Pyrazines; Quinazolines; Stomach Neoplasms; Structure-Activity Relationship | 2010 |
[Two cases of non-small cell lung cancer which developed central nervous system metastases during gefitinib treatment, improving after changing to erlotinib treatment].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2010 |
De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate | 2010 |
Association between gefitinib and hemorrhagic cystitis and severely contracted bladder: a case report.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cystitis; Gefitinib; Hematuria; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Urinary Bladder Diseases | 2010 |
Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Osteoblasts; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging.
Topics: Adenocarcinoma; Amino Acid Substitution; Animals; Antineoplastic Agents; Aspartic Acid; Cyclin-Dependent Kinases; Diagnostic Imaging; Disease Models, Animal; Drug Evaluation, Preclinical; Genes, ras; Glycine; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutant Proteins; Pyrazoles; Quinazolines; Treatment Outcome | 2010 |
Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Signet Ring Cell; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids | 2010 |
Human papillomavirus is frequently detected in gefitinib-responsive lung adenocarcinomas.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclin-Dependent Kinase Inhibitor p16; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Papillomaviridae; Papillomavirus Infections; Prevalence; Quinazolines; Retinoblastoma Protein; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53 | 2010 |
Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Multicenter Studies as Topic; Prognosis; Quinazolines; Retrospective Studies | 2011 |
Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Hyponatremia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quinazolines; Treatment Outcome; Whole-Body Irradiation | 2010 |
Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Heterocyclic Compounds, 4 or More Rings; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2009 |
Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Renal Dialysis; Tissue Distribution; Treatment Outcome | 2010 |
The close correlation between 8-hydroxy-2'-deoxyguanosine and epidermal growth factor receptor activating mutation in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; Deoxyadenosines; DNA Damage; DNA Glycosylases; DNA Repair; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Y-Box-Binding Protein 1 | 2010 |
BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Separation; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Mutation; Proto-Oncogene Proteins; Quinazolines; RNA Interference; RNA, Small Interfering | 2011 |
A state space representation of VAR models with sparse learning for dynamic gene networks.
Topics: Cells, Cultured; Computational Biology; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Regulatory Networks; Humans; Lung; Lung Neoplasms; Models, Biological; Models, Statistical; Neoplasm Proteins; Pattern Recognition, Automated; Probability; Protein Kinase Inhibitors; Quinazolines; Regression Analysis; Time Factors | 2010 |
Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis | 2009 |
Diagnosis of synchronous primary lung adenocarcinomas based on epidermal growth factor (EGFR) gene status: A case report.
Topics: Adenocarcinoma; Aged; Diagnosis, Differential; DNA Mutational Analysis; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Pneumonectomy; Quinazolines; Radiography, Thoracic | 2010 |
[Maintenance treatment of non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2010 |
Network meta-analysis: importance of appropriate trial selection.
Topics: Antineoplastic Agents; Biomedical Research; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Confidence Intervals; Docetaxel; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Meta-Analysis as Topic; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Taxoids | 2010 |
Gefitinib as an effective therapy for advanced hepatocellular carcinoma with lung metastasis?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carcinoma, Ductal, Breast; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Killer Cells, Natural; Lapatinib; Lung Neoplasms; Middle Aged; Prognosis; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Taxoids; Trastuzumab | 2011 |
Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief report.
Topics: Adenocarcinoma; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Osteoblasts; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines.
Topics: Antibodies, Blocking; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hydrogen-Ion Concentration; Kidney; Lung Neoplasms; Octamer Transcription Factor-1; Organic Cation Transport Proteins; Organic Cation Transporter 2; Phosphorylation; Quinazolines; RNA, Messenger | 2010 |
Cancer: drug-tolerant insurgents.
Topics: Biological Evolution; Cell Line, Tumor; Cisplatin; Clone Cells; Drug Resistance, Neoplasm; Drug Tolerance; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Biological; Quinazolines; Retinoblastoma-Binding Protein 2; Selection, Genetic | 2010 |
Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Quinazolines | 2010 |
Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Prognosis; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2010 |
Serious hematologic complications following erlotinib treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Erlotinib Hydrochloride; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2010 |
Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.
Topics: Animals; Antineoplastic Agents; Butadienes; Carcinoma, Non-Small-Cell Lung; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; HeLa Cells; Humans; Lung Neoplasms; Mice; Mutation; Nitriles; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Quinazolines | 2010 |
Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Exanthema; Female; Humans; Japan; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Quinazolines; Risk | 2010 |
Establishment and characterization of a new drug surviving cell line Am1010, derived directly from muscle metastases of a human lung adenocarcinoma patient with multi-drug-resistance to cisplatin, taxol, and gefitinib.
Topics: Adenocarcinoma; Adult; Animals; Cell Line, Tumor; Cell Proliferation; Chromosomes; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Quinazolines | 2010 |
Safety of concomitant administration of seasonal and/or H1N1 flu vaccination in patients receiving erlotinib for advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Seasons; Vaccination | 2010 |
Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Furans; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mutation; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Pyridines; Pyrimidines; Quinazolines; TOR Serine-Threonine Kinases | 2010 |
EGFR mutations in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Quinazolines; Taxoids | 2010 |
Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cetuximab; DNA Primers; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transfection | 2010 |
Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Replication; Dose-Response Relationship, Drug; Endothelial Cells; ErbB Receptors; Gene Amplification; Humans; Lapatinib; Lung Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stem Cells; Time Factors; Xenograft Model Antitumor Assays | 2010 |
Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2010 |
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Erlotinib Hydrochloride; Gemcitabine; Genetic Engineering; Humans; Lung Neoplasms; Mice; Mutation; Neoplasms; Proto-Oncogene Proteins p21(ras); Quinazolines; Survival Analysis; Vascular Endothelial Growth Factor A | 2010 |
A case of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Quinazolines | 2011 |
In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Drug Administration Schedule; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Phosphorylation; Quinazolines; Signal Transduction | 2011 |
High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Russia; Treatment Outcome | 2010 |
A case of radiation recall pneumonitis induced by erlotinib, which can be related to high plasma concentration.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis | 2010 |
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2010 |
Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Gefitinib; Humans; Lung Neoplasms; Male; Point Mutation; Prognosis; Quinazolines | 2010 |
Prognostic value of E-cadherin expression in non-small cell lung cancer treated with gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cadherins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2010 |
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Topics: Afatinib; Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; E2F1 Transcription Factor; ErbB Receptors; Fluorouracil; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Mice; Mutation; Oxonic Acid; Pemetrexed; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Mas; Quinazolines; Tegafur; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2010 |
Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2010 |
Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytochromes b5; Cytoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Membrane Proteins; Models, Biological; Protein Kinase Inhibitors; Quinazolines; Receptors, Progesterone; RNA Interference | 2010 |
The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2011 |
[Satisfactory outcome with erlotinib after failure with gefitinib in a patient with meningeal carcinomatosis secondary to non-small cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2010 |
Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Recurrence; Retreatment; Retrospective Studies; Treatment Failure | 2010 |
Surgical resection of lung adenocarcinoma without EGFR mutation after neoadjuvant gefitinib treatment.
Topics: Adenocarcinoma; Aged; Biopsy, Needle; Chemotherapy, Adjuvant; Female; Gefitinib; Genes, erbB-1; Humans; Infant; Lung Neoplasms; Mutation; Neoadjuvant Therapy; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2010 |
Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer.
Topics: Antibodies; Antibody Specificity; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Gene Amplification; Gene Deletion; Humans; Immunohistochemistry; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; Lung Neoplasms; Mice; Molecular Structure; Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
Denaturing capillary electrophoresis for automated detection of L858R mutation in exon 21 of the epidermal growth factor receptor gene in prediction of the outcome of lung cancer therapy.
Topics: Adenocarcinoma; Automation; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Electrophoresis, Capillary; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Nucleic Acid Denaturation; Pharmacogenetics; Point Mutation; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Treatment Outcome | 2010 |
Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Quinazolines; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Quinazolines; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cost-Benefit Analysis; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Markov Chains; Neoplasm Staging; Pemetrexed; Placebos; Quinazolines; Remission Induction; Survival Rate; Treatment Outcome | 2010 |
Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes.
Topics: Acneiform Eruptions; Adolescent; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cell Line; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Interleukin-1; Keratinocytes; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptors, Interleukin-1; Receptors, Interleukin-1 Type II; RNA, Messenger; Signal Transduction | 2010 |
Targeted therapies: Importance of patient selection for EGFR TKIs in lung cancer.
Topics: Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2011 |
Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.
Topics: Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2011 |
Erlotinib-based perioperative adjuvant therapy for a case of unresectable stage IIIA (N2) nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2010 |
Modulation of P-gp expression by lapatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epidermal Growth Factor; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2011 |
One more fallen star--ZODIAC and its implications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Endpoint Determination; Humans; Lung Neoplasms; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Taxoids | 2010 |
The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bronchi; Cell Line, Tumor; Cetuximab; DNA Breaks, Double-Stranded; DNA Damage; DNA Repair; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Quinazolines; RNA, Small Interfering; Signal Transduction | 2010 |
Three years of erlotinib in routine practice for non-small cell lung cancer in South East Scotland.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Scotland; Survival Rate; Treatment Outcome | 2010 |
Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Remission Induction; Salvage Therapy; Survival Rate; Treatment Failure; Treatment Outcome | 2010 |
Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Face; Female; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2010 |
[Drug resistance mechanism of non small cell lung cancer PC9/AB2 cell line with acquired drug resistance to gefitinib].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Humans; Integrin beta1; Lung Neoplasms; Quinazolines | 2010 |
The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Humans; Immunosuppressive Agents; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Purines; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sirolimus; Tumor Cells, Cultured | 2010 |
Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinogens; Chemoprevention; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Mice; Molecular Targeted Therapy; Neovascularization, Pathologic; Piperidines; Protein Kinase Inhibitors; Quinazolines; Urethane; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
[Lung cancer].
Topics: Administration, Oral; Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2010 |
[Safety analysis of eight patients treated with erlotinib after severe gefitinib-induced liver injury].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Enzyme Inhibitors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Structure; Quinazolines | 2010 |
Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Serum concentrations of Erlotinib at a dose of 25 mg daily.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Cetuximab; Disease-Free Survival; Drug Synergism; ErbB Receptors; Gefitinib; Gene Dosage; Gene Knockdown Techniques; Humans; Immunohistochemistry; Lung Neoplasms; Nuclear Receptor Coactivator 3; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Signal Transduction | 2010 |
Salvage surgery for advanced non-small cell lung cancer after response to gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Time Factors; Treatment Outcome | 2010 |
Bilateral anterior uveitis secondary to erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Uveitis | 2010 |
Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Female; Gefitinib; Genes, ras; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mesoderm; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2010 |
Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cells, Cultured; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction; Sirolimus; Small Cell Lung Carcinoma; TOR Serine-Threonine Kinases; Xenopus Proteins | 2010 |
[A case of Henoch-Schönlein purpura which was difficult to distinguish from a skin rash associated with gefitinib].
Topics: Antineoplastic Agents; Diagnosis, Differential; Exanthema; Female; Gefitinib; Humans; IgA Vasculitis; Lung Neoplasms; Middle Aged; Paraneoplastic Syndromes; Quinazolines; Small Cell Lung Carcinoma | 2010 |
Antitumor activity of ribonuclease multimers created by site-specific covalent tethering.
Topics: Animals; Antineoplastic Agents; Cattle; Cell Proliferation; Enzyme Inhibitors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Prostatic Neoplasms; Protein Binding; Quinazolines; Ribonuclease, Pancreatic; Sulfhydryl Compounds; Tumor Cells, Cultured | 2010 |
First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Methylation; Middle Aged; Mutation; Neoplasm Proteins; Neoplasm Staging; Poly-ADP-Ribose Binding Proteins; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Ubiquitin-Protein Ligases | 2011 |
Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: a retrospective case-matching cohort study.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Case-Control Studies; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Point Mutation; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Analysis; Treatment Outcome | 2010 |
Targeted therapy at the end of life for patients with lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Delivery Systems; Drug Utilization; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patient Selection; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Singapore; Sirolimus; Terminal Care; Time Factors; Treatment Outcome | 2010 |
TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer.
Topics: Animals; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Lung Neoplasms; Mesoderm; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transforming Growth Factor beta | 2010 |
TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.
Topics: Animals; Antibodies, Monoclonal; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Primers; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Elevated international normalized ratio associated with concomitant warfarin and erlotinib.
Topics: Adenocarcinoma; Anticoagulants; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; International Normalized Ratio; Lung Neoplasms; Male; Middle Aged; Quinazolines; Thromboembolism; Warfarin | 2010 |
Quantifying the sensitivities of EGF receptor (EGFR) tyrosine kinase inhibitors in drug resistant non-small cell lung cancer (NSCLC) cells using hydrogel-based peptide array.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Equipment Design; Equipment Failure Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hydrogels; Lung Neoplasms; Peptides; Protein Array Analysis; Protein-Tyrosine Kinases; Quinazolines | 2010 |
Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; DNA-Binding Proteins; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Quinazolines; Radiation-Sensitizing Agents; Tumor Suppressor Proteins | 2010 |
Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Fatigue; Female; Folliculitis; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paronychia; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2010 |
Gefitinib. Still no convincing results in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2010 |
Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; EGF Family of Proteins; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
[A case of advanced adenocarcinoma of the lung which maintained complete response for 5 years by treatment with gefitinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2010 |
Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Point Mutation; Polymerase Chain Reaction; Prognosis; Quinazolines; Sequence Deletion | 2010 |
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Cetuximab; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2010 |
Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity.
Topics: Aged, 80 and over; Aspartate Aminotransferases; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Green Fluorescent Proteins; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Monitoring, Physiologic; Neoplasm Metastasis; Quinazolines; Recurrence | 2010 |
Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Chemotherapy, Adjuvant; Cholecystitis; Cisplatin; Combined Modality Therapy; DNA Mutational Analysis; Female; Gefitinib; Genes, erbB-1; Genetic Predisposition to Disease; Humans; Incidental Findings; Lung Neoplasms; Mutation; Neoplasm Staging; Pedigree; Pneumonectomy; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vinblastine; Vinorelbine | 2010 |
Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Feasibility Studies; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Radiotherapy; Withholding Treatment | 2011 |
Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Survival Analysis | 2011 |
Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Mutation; Quinazolines | 2010 |
Supersensitive mutation: two case reports of non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
Restoration of gefitinib efficacy following chemotherapy in a patient with metastatic non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Treatment Outcome | 2010 |
Toxicity manifesting as cosmetic hair alterations during erlotinib treatment.
Topics: Adenocarcinoma; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Hypertrichosis; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2011 |
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Gefitinib-induced epidermal growth factor receptor-independent keratinocyte apoptosis is mediated by the JNK activation pathway.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunoblotting; Keratinocytes; Lung Neoplasms; Quinazolines; Signal Transduction | 2011 |
Radiosynthesis and initial in vitro evaluation of [18F]F-PEG6-IPQA--a novel PET radiotracer for imaging EGFR expression-activity in lung carcinomas.
Topics: Cell Line, Tumor; Chromatography, High Pressure Liquid; ErbB Receptors; Fluorine Radioisotopes; Humans; In Vitro Techniques; Lung Neoplasms; Positron-Emission Tomography; Quinazolines; Small Cell Lung Carcinoma | 2011 |
[Feasibility of erlotinib after gefitinib failure in patients with advanced pulmonary adenocarcinoma previously responding to gefitinib].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Tolerance; Erlotinib Hydrochloride; Feasibility Studies; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Treatment Outcome | 2010 |
Compassionate use programs or phase IV trials of innovative molecular targeted drugs in lung cancer: deal or no deal?
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase IV as Topic; Compassionate Use Trials; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer.
Topics: Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Clindamycin; Dermatologic Agents; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Isotretinoin; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2010 |
Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mutation; Quinazolines; Taxoids; Xenograft Model Antitumor Assays | 2010 |
A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Phosphorylation; Pilot Projects; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Survival Rate; Tissue Distribution; Tyrosine | 2010 |
Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Quinazolines; Tomography, X-Ray Computed | 2011 |
Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cluster Analysis; Enzyme Activation; ErbB Receptors; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel; Phenotype; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, ErbB-2 | 2010 |
Fatal necrotizing pancreatitis during combined treatment with erlotinib and sunitinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Pancreatitis, Acute Necrotizing; Pyrroles; Quinazolines; Sunitinib | 2010 |
Interstitial lung disease and gefitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Incidence; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Product Surveillance, Postmarketing; Quinazolines | 2010 |
[Re-treatment with epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)for lung adenocarcinoma].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2010 |
Interstitial lung disease and gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Incidence; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Quinazolines | 2010 |
Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; Early Growth Response Protein 1; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2010 |
Predictive biomarkers in the management of EGFR mutant lung cancer.
Topics: Adenocarcinoma; Aged; Apoptosis; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genetic Therapy; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; White People | 2010 |
Downregulated ABCG2 enhances sensitivity to topoisomerase I inhibitor in epidermal growth factor receptor tyrosine kinase inhibitor-resistant non-small cell lung cancer.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; DNA Topoisomerases, Type I; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Genotype; Humans; Lung Neoplasms; Mutation; Neoplasm Proteins; Polymerase Chain Reaction; Protein Tyrosine Phosphatases; Quinazolines; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Tyrphostins | 2010 |
ILD during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Prognosis; Quinazolines | 2010 |
Chemotherapy-associated recurrent pneumothoraces in lymphangioleiomyomatosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Lung Neoplasms; Lymphangioleiomyomatosis; Middle Aged; Neoplasms, Second Primary; Oxygen Inhalation Therapy; Pneumothorax; Quinazolines; Trastuzumab | 2010 |
Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pharmacogenetics; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2010 |
Targeted therapies: Molecular selection for 'smart' study design in lung cancer.
Topics: Antineoplastic Agents; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Genetic Markers; Humans; Lung Neoplasms; Pharmacogenetics; Piperidines; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2010 |
Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2010 |
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Knockout Techniques; Humans; Lung Neoplasms; Mice; Neoplasms, Experimental; Quinazolines; Snail Family Transcription Factors; Transcription Factors | 2011 |
Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a.
Topics: Alternative Splicing; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Caspase 9; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Isoenzymes; Lung Neoplasms; Mutation; Nuclear Proteins; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA-Binding Proteins; RNA, Messenger; Serine-Arginine Splicing Factors; Signal Transduction | 2010 |
[TARCEVA Clinical Registry].
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Registries | 2010 |
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Array Analysis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptors, Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2010 |
Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasm Staging; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2010 |
Anti-tumor effects of B-2, a novel 2,3-disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazoline derivative, on the human lung adenocarcinoma A549 cell line in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Survival; ErbB Receptors; Flow Cytometry; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Confocal; Mitogen-Activated Protein Kinases; Molecular Dynamics Simulation; Phosphorylation; Quinazolines; Xenograft Model Antitumor Assays | 2011 |
Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21.
Topics: Amphiregulin; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; EGF Family of Proteins; Erlotinib Hydrochloride; Female; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Retrospective Studies; Transforming Growth Factor alpha | 2010 |
Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity.
Topics: Amino Acid Sequence; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatography, Liquid; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Immunoprecipitation; Lung Neoplasms; Mice; Mice, Nude; Molecular Sequence Data; Peptide Fragments; Peptide Mapping; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry; Xenograft Model Antitumor Assays | 2011 |
Erlotinib resistance is altered after gemcitabine chemotherapy for recurrent non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines | 2011 |
[Analysis of prognostic factors of 80 advanced NSCLC patients treated with gefitinib for more than 6 months].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines | 2010 |
[Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine].
Topics: Adenocarcinoma, Scirrhous; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lung Neoplasms; Lymph Node Excision; Mastectomy; Middle Aged; Quinazolines; Receptor, ErbB-2 | 2010 |
New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Research Design; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Long-lasting drop in perfusion of a non-small cell lung cancer induced by monotherapy with the epithelial growth factor receptor inhibitor erlotinib persisting despite tumor progression at remote sites.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2010 |
Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Oncogene Proteins, Fusion; Quinazolines | 2010 |
Different efficacies of erlotinib and gefitinib in taiwanese patients with advanced non-small cell lung cancer: a retrospective multicenter study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Taiwan | 2011 |
One patient with metastastic colorectal cancer successfully treated by combination of targeted agents after failure of chemotherapy.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Catheter Ablation; Cetuximab; Cytokine-Induced Killer Cells; Deoxycytidine; Disease-Free Survival; Drug Delivery Systems; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Immunotherapy, Adoptive; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Oxaloacetates; Positron-Emission Tomography; Quality of Life; Quinazolines; Sigmoid Neoplasms; Tomography, X-Ray Computed | 2010 |
Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model.
Topics: Animals; Apoptosis; Benzodioxoles; Blotting, Western; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Disease Models, Animal; Female; Fibrosarcoma; Fluorescent Antibody Technique; Focal Adhesion Kinase 1; Lung Neoplasms; Mice; Mice, Inbred C3H; Phosphorylation; Quinazolines; Sarcoma, Experimental; src-Family Kinases; Survival Rate; Tumor Cells, Cultured | 2010 |
[Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Codon; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Genes, erbB-1; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sex Factors; Smoking; Young Adult | 2010 |
Targeted therapy for non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2010 |
The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antibody Specificity; ErbB Receptors; Female; Gefitinib; Genetic Association Studies; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Point Mutation; Quinazolines; Sequence Deletion | 2011 |
Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Genetic Association Studies; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Mutation, Missense; Quinazolines; Sequence Deletion | 2011 |
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Drugs, Chinese Herbal; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organoplatinum Compounds; Outpatients; Paclitaxel; Platinum Compounds; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Necrotizing vasculitis triggered by gefitinib: an unusual clinical presentation.
Topics: Antineoplastic Agents; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; Lower Extremity; Lung Neoplasms; Male; Middle Aged; Necrosis; Neoplasm Invasiveness; Neoplasm Staging; Prednisolone; Quinazolines; Risk Assessment; Skin Diseases, Vascular; Treatment Outcome; Vasculitis | 2011 |
Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Coculture Techniques; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Fibroblast Growth Factor 2; Fibroblast Growth Factor 7; Fibroblasts; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2010 |
Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Genes, erbB-1; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Membrane Proteins; Microtubule-Associated Proteins; Mutation; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; RNA, Messenger; Survivin | 2010 |
Lung cancer: recent advances.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Global Health; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2010 |
Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Acinar Cell; Cell Line, Tumor; Cell Movement; Cell Shape; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Quinazolines; Sequence Deletion | 2011 |
EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Microtubule-Associated Proteins; Middle Aged; Mutation; Oncogene Proteins, Fusion; Quinazolines; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Translocation, Genetic | 2011 |
Erlotinib and pantoprazole: a relevant interaction or not?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Quinazolines | 2010 |
Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Amino Acids, Cyclic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; ErbB Receptors; Fusion Regulatory Protein-1; Gefitinib; Humans; Immunohistochemistry; Large Neutral Amino Acid-Transporter 1; Leucine; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; RNA, Messenger; TOR Serine-Threonine Kinases | 2010 |
Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment--case report.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Dyspnea; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis; Radiosurgery; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retreatment; Retrospective Studies; Treatment Outcome | 2011 |
Aurora-A promotes gefitinib resistance via a NF-κB signaling pathway in p53 knockdown lung cancer cells.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Aurora Kinases; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; I-kappa B Proteins; Lung Neoplasms; Mutation; NF-kappa B; NF-KappaB Inhibitor alpha; Protein Serine-Threonine Kinases; Quinazolines; Transcriptional Activation; Tumor Suppressor Protein p53 | 2011 |
Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT.
Topics: Amino Acid Substitution; Animals; Binding, Competitive; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mice; Mice, Nude; Molecular Imaging; Mutant Proteins; Mutation; Positron-Emission Tomography; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Tomography, X-Ray Computed; Xenograft Model Antitumor Assays | 2011 |
Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Furans; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, SCID; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
Prospective study of second-line chemotherapy for non-small cell lung cancer selected according to EGFR gene status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines; Survival Rate | 2010 |
Rapid and accurate ranking of binding affinities of epidermal growth factor receptor sequences with selected lung cancer drugs.
Topics: Computer Simulation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Models, Molecular; Mutation; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Structure, Tertiary; Purines; Quinazolines | 2011 |
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Repair; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Genes, BRCA1; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; RNA, Messenger; Treatment Outcome | 2011 |
The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Exons; Female; Gene Expression Regulation, Neoplastic; Humans; Karnofsky Performance Status; Lipoproteins, HDL; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Sex Factors; Survival Analysis; Time Factors; Weight Loss | 2011 |
Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Signal Transduction; Transforming Growth Factor alpha | 2011 |
Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Mutation; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Treatment Failure; Tumor Cells, Cultured | 2011 |
Fatal interstitial lung disease associated with gemcitabine and erlotinib therapy for lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2012 |
Effectiveness of erlotinib against recurrent pulmonary adenocarcinoma unresponsive to gefitinib: report of a case.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Quinazolines | 2011 |
DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; DNA-Binding Proteins; Endonucleases; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Quinazolines; Smoking; X-ray Repair Cross Complementing Protein 1 | 2011 |
Analysis of tumor burden versus progression-free survival for Phase II decision making.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Decision Making; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Regression Analysis; Survival Rate; Trastuzumab; Tumor Burden | 2011 |
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lapatinib; Lung Neoplasms; Membrane Potential, Mitochondrial; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Tumor Cells, Cultured; Vorinostat | 2011 |
Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.
Topics: Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Treatment Outcome | 2011 |
Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Quinazolines; Retrospective Studies; Time Factors; Treatment Failure | 2011 |
Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Quinazolines | 2011 |
An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2011 |
C-erbB-3 expression in non-small cell lung cancer (NSCLC) patients treated by Erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Survival Rate | 2011 |
Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Quinazolines | 2011 |
[Pleural metastases from bronchial carcinoma: is a cure possible?].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Piperidines; Pleural Neoplasms; Quinazolines; Radiotherapy; Receptor Protein-Tyrosine Kinases; Retreatment; Survivors; Thoracotomy | 2011 |
Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Budgets; Carcinoma, Non-Small-Cell Lung; Centers for Medicare and Medicaid Services, U.S.; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Models, Economic; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Registries; Taxoids; United States | 2011 |
More on aprepitant for erlotinib-induced pruritus.
Topics: Adenocarcinoma; Aprepitant; Drug Interactions; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Off-Label Use; Protein Kinase Inhibitors; Pruritus; Quinazolines | 2011 |
Is FISH floating or still swimming in the lung cancer ocean?
Topics: Antineoplastic Agents; Biomarkers, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Meta-Analysis as Topic; Molecular Diagnostic Techniques; Mutation; Quinazolines; Small Cell Lung Carcinoma; Treatment Outcome | 2011 |
Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; Drug Discovery; Drug Industry; Gefitinib; Humans; Lung Neoplasms; Politics; Quinazolines; United States; United States Food and Drug Administration | 2011 |
Screening for EGFR mutations in lung cancer, a report from India.
Topics: Age Factors; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; India; Lung Neoplasms; Middle Aged; Mutation, Missense; Polymorphism, Single Nucleotide; Prevalence; Quinazolines; Sequence Deletion; Sex Factors | 2011 |
Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Cadherins; Drug Resistance, Neoplasm; Early Growth Response Protein 1; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Fibronectins; gamma Catenin; Gefitinib; Gene Expression Regulation; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins | 2011 |
First case of A859T epidermal growth factor receptor mutation responding to erlotinib.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Middle Aged; Mutation; Polymerase Chain Reaction; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.
Topics: Adenocarcinoma; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Trastuzumab and chemotherapy after the treatment failure of lapatinib for HER2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Failure | 2010 |
Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Paronychia; Quinazolines; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction | 2012 |
Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth.
Topics: Adenocarcinoma; Animals; Blotting, Western; Cell Proliferation; Chemotaxis; Culture Media, Conditioned; Enzyme-Linked Immunosorbent Assay; Humans; Immunoenzyme Techniques; In Vitro Techniques; Lung Neoplasms; Melanoma; Mice; Mice, Inbred BALB C; Mice, SCID; Neutrophil Infiltration; Quinazolines; Receptors, Interleukin-8B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spheroids, Cellular; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Diarrhea; Female; Gefitinib; Genome-Wide Association Study; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Genetic; Precision Medicine; Quinazolines; Treatment Outcome | 2011 |
Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Quinazolines; Radiation Injuries; Radiotherapy Dosage; Tumor Burden | 2011 |
NSCLC drug targets acquire new visibility.
Topics: Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Tetrahydronaphthalenes; Treatment Outcome | 2011 |
Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2011 |
[A case of lung cancer with skin metastases responding to erlotinib].
Topics: Aged; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Skin Neoplasms | 2011 |
[A case of lung adenocarcinoma with postoperative recurrence maintaining complete remission by treatment with gefitinib].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Recurrence; Remission Induction; Tomography, X-Ray Computed | 2011 |
[Limitation of apoptosis induced by gefitinib in a long-surviving postoperative recurrent lung cancer case].
Topics: Aged; Apoptosis; Female; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Recurrence; Remission Induction; Time Factors; Tomography, X-Ray Computed | 2011 |
Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Liver Function Tests; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Population Groups; Quinazolines; Retrospective Studies; Skin Diseases; Treatment Failure | 2011 |
Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Combinations; ErbB Receptors; Fluorouracil; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Piperidines; Quinazolines; Tegafur; Tumor Cells, Cultured | 2011 |
[Survival-related clinical factors of patients with advanced non-small cell lung cancer after 2000].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Survival Rate | 2011 |
Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Pyridines; Quinazolines; RNA Interference; STAT3 Transcription Factor; Tumor Suppressor Protein p53; Tyrphostins | 2011 |
Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Base Sequence; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Salvage Therapy | 2011 |
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines | 2011 |
Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; C-Reactive Protein; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Quinazolines | 2010 |
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.
Topics: Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; fas Receptor; Genes, erbB-1; Humans; I-kappa B Proteins; Lung Neoplasms; Models, Biological; Mutant Proteins; Mutation; NF-kappa B; Quinazolines; RNA Interference; Signal Transduction | 2011 |
Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2011 |
Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry | 2011 |
Focal leptomeningeal metastasis following curative surgery for lung cancer: case report.
Topics: Adenocarcinoma; Antineoplastic Agents; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Neoplasms, Multiple Primary; Quinazolines | 2011 |
Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
Topics: Adult; Aged; Antibodies, Monoclonal; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; DNA; ErbB Receptors; Exons; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Pleural Effusion, Malignant; Polymerase Chain Reaction; Quinazolines; Recurrence; Sensitivity and Specificity; Sequence Deletion | 2011 |
Malignant pleural effusion from lung adenocarcinoma treated by gefitinib.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Apoptosis; Drainage; Gefitinib; Humans; Lung Neoplasms; Male; Pleural Effusion, Malignant; Quinazolines; Treatment Outcome | 2011 |
β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Integrin beta1; Lung Neoplasms; Membrane Proteins; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Transplantation; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Transplantation, Heterologous | 2011 |
Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Aged; Alopecia; Carcinoma, Non-Small-Cell Lung; Cicatrix; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines | 2011 |
"Un-slugging" resistance to epidermal growth factor receptor inhibition. A positive outlook for the future of lung cancer therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Snail Family Transcription Factors; Transcription Factors | 2011 |
EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells.
Topics: Cell Line, Tumor; Cytotoxicity, Immunologic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Killer Cells, Natural; Lung Neoplasms; Protein Kinase C; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transcription Factor AP-2 | 2011 |
Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Liver; Lung Neoplasms; Mutation; Quinazolines; Transaminases; Treatment Outcome | 2011 |
Prevention of bronchial hyperplasia by EGFR pathway inhibitors in an organotypic culture model.
Topics: Bronchi; Butadienes; Cell Line, Tumor; Cyclin D1; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hyperplasia; Luciferases; Lung Neoplasms; MAP Kinase Kinase Kinases; Models, Biological; Nitriles; Organ Culture Techniques; Quinazolines; RNA, Small Interfering | 2011 |
Tyrosine kinase inhibitors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer: to test or not to test?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Genetic Testing; Humans; Lung Neoplasms; Mutation; Pharmacogenetics; Protein-Tyrosine Kinases; Quinazolines; Taiwan; Treatment Outcome | 2011 |
Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Genes, erbB-1; Genetic Testing; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pharmacogenetics; Quinazolines; Retrospective Studies; Taiwan; Treatment Outcome | 2011 |
Multigene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Biopsy, Fine-Needle; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Quinazolines; Retrospective Studies; Ultrasonography, Interventional | 2011 |
Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genes, erbB-1; Humans; Insurance Benefits; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Patient Selection; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Failure | 2011 |
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2011 |
Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib.
Topics: Aged; Algorithms; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Disease Progression; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2011 |
First- or second-line gefitinib therapy in unknown epidermal growth factor receptor mutants of non-small-cell lung cancer patients treated in Taiwan.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Taiwan; Treatment Outcome | 2011 |
MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; bcl-X Protein; Biphenyl Compounds; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Mice; Nitrophenols; Peptide Fragments; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Sulfonamides; Transplantation, Heterologous | 2011 |
An early event of EGFR mutation in pleomorphic carcinoma of the lung.
Topics: Antineoplastic Agents; Carcinoma; Cell Transformation, Neoplastic; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
[Clinical case of the month. A patient with advanced non-small-cell lung cancer presenting with an exceptional response to targeted therapies].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib | 2011 |
[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Taxoids | 2011 |
Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: a GFPC study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Follow-Up Studies; France; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Sex Factors; Smoking; Survival Analysis; Withholding Treatment | 2011 |
[Factors affecting the sensitivity of EGFR-TKI treatment in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2011 |
[A case of adenocarcinoma of the lung with a pulmonary thromboembolism which improved with gefitinib].
Topics: Adenocarcinoma; Antineoplastic Agents; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Pulmonary Embolism; Quinazolines | 2011 |
Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib.
Topics: Blood-Brain Barrier; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Quinazolines | 2012 |
Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
Topics: Adenocarcinoma; Biomarkers, Tumor; Blotting, Western; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Proliferation; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mutation; Oligonucleotide Array Sequence Analysis; Protein Array Analysis; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Tumor Cells, Cultured | 2011 |
[Histology-based algorithm in the molecular diagnosis of mutations of the Epidernal Growth Factor Receptor (EGFR) in non-small cell lung cancer].
Topics: Adenocarcinoma; Algorithms; Austria; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2011 |
EGFR upregulates inflammatory and proliferative responses in human lung adenocarcinoma cell line (A549), induced by lower dose of cadmium chloride.
Topics: Adenocarcinoma; Antineoplastic Agents; Cadmium Chloride; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclooxygenase 2; Dose-Response Relationship, Drug; Environmental Pollutants; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Lethal Dose 50; Lung Neoplasms; Microscopy, Acoustic; Proliferating Cell Nuclear Antigen; Quinazolines; Up-Regulation | 2011 |
P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Oncogene Protein v-akt; Phosphorylation; Quinazolines; RNA, Small Interfering; Transfection; Tumor Suppressor Protein p53 | 2011 |
Salvage with erlotinib plus bevacizumab: not in NSCLC.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Survival Rate; Vascular Endothelial Growth Factor A | 2011 |
Palmar bullous blistering induced by erlotinib.
Topics: Adenocarcinoma; Blister; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Hand Dermatoses; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Successful erlotinib rechallenge after erlotinib-induced interstitial lung disease.
Topics: Adenocarcinoma; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography; Retreatment; Treatment Outcome | 2011 |
Long-term survival in a smoking caucasian male patient treated with gefitinib for spinal cord compression secondary to lung cancer.
Topics: Antineoplastic Agents; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Smoking; Spinal Cord Compression; Survivors; Treatment Outcome | 2011 |
Safety of erlotinib treatment in outpatients with previously treated non-small-cell lung cancer in Japan.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Outpatients; Protein Kinase Inhibitors; Quinazolines | 2011 |
The influence of intracellular epidermal growth factor receptor (EGFR) signal activation on the outcome of EGFR tyrosine kinase inhibitor treatment for pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Quinazolines; Signal Transduction | 2011 |
[Antitumor effects of gefitinib for metastatic brain tumors from lung carcinomas with EGFR mutation].
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines | 2011 |
Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Technology Assessment, Biomedical; Treatment Outcome | 2011 |
[Screening and identification of microRNAs related to acquired gefitinib-resistance in lung adenocarcinoma cell lines].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; MicroRNAs; Oligonucleotide Array Sequence Analysis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mucin-1; Quinazolines | 2011 |
EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.
Topics: Autophagy; Autophagy-Related Protein 5; Autophagy-Related Protein 7; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Lysosomes; Microscopy, Confocal; Microscopy, Electron; Microtubule-Associated Proteins; Phagosomes; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Ribosomal Protein S6 Kinases, 70-kDa; RNA Interference; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Ubiquitin-Activating Enzymes | 2011 |
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Markov Chains; Medical Oncology; Middle Aged; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Sensitivity and Specificity | 2012 |
Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Palliative Care; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2011 |
Molecular selection trumps clinical selection.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Paclitaxel; Precision Medicine; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Erlotinib or gefitinib for non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Erlotinib or gefitinib for non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Myocardial Ischemia; Protein Kinase Inhibitors; Quinazolines; Stroke | 2011 |
[Erlotinib in non-small cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2011 |
Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Detection of the EGFR mutation in exhaled breath condensate from a heavy smoker with squamous cell carcinoma of the lung.
Topics: Brain Neoplasms; Breath Tests; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Exhalation; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Remission Induction; Sequence Deletion; Smoking | 2011 |
Increase of ascites and pleural effusion misleading assessment of antitumor response to erlotinib in adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Ascites; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Pleural Effusion, Malignant; Prednisolone; Quinazolines | 2011 |
Papulopustular eruptions in a 32-year-old woman after lung cancer treatment.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Dermatologic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hydrocortisone; Lung Neoplasms; Metronidazole; Mupirocin; Quinazolines | 2011 |
Ileal perforation induced by acute radiation injury under gefitinib treatment.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enteritis; ErbB Receptors; Female; Gefitinib; Humans; Intestinal Mucosa; Intestine, Small; Lung Neoplasms; Peritonitis; Quinazolines; Radiation Injuries; Radiotherapy; Wound Healing | 2011 |
Tumor-to-tumor metastasis: lung adenocarcinoma metastasizing to a follicular variant of papillary thyroid carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Combined Modality Therapy; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2011 |
Gefitinib versus docetaxel for previously treated NSCLC--letter.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Quinazolines; Taxoids | 2011 |
Valuable lessons from treatment of non-small cell lung cancer with erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2008 |
Surgical resection of locally advanced pulmonary adenocarcinoma after gefitinib therapy.
Topics: Adenocarcinoma; Administration, Oral; Biopsy, Needle; Female; Follow-Up Studies; Gefitinib; Genes, erbB-1; Humans; Immunohistochemistry; Lung Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Pneumonectomy; Positron-Emission Tomography; Quinazolines; Risk Assessment; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Quinazolines; RNA | 2012 |
The use of erlotinib in daily practice: a study on adherence and patients' experiences.
Topics: Antineoplastic Agents; Attitude to Health; Carcinoma, Non-Small-Cell Lung; Culture; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Monitoring; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Informed Consent; Lung Neoplasms; Medication Adherence; Multicenter Studies as Topic; Patient Selection; Patients; Prospective Studies; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Research Design | 2011 |
Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Treatment Outcome | 2011 |
Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Aged; Alanine Transaminase; Anti-Inflammatory Agents; Antineoplastic Agents; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Function Tests; Lung Diseases, Interstitial; Lung Neoplasms; Male; Methylprednisolone; Muscle Weakness; Quinazolines; Radiography, Thoracic | 2011 |
Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Peptide Fragments; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2012 |
Afatinib (BIBW 2992) development in non-small-cell lung cancer.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2011 |
Recovery from carcinomatous meningitis by erlotinib.
Topics: Adenocarcinoma; Aged; Brain Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Spectrophotometry, Ultraviolet | 2011 |
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; MAP Kinase Signaling System; Marsdenia; Mutation; Phosphorylation; Plant Extracts; Proteasome Endopeptidase Complex; Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases | 2012 |
The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mutation; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
[What choice of first-line treatment?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Evidence-Based Medicine; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Survival Analysis; Translocation, Genetic | 2011 |
[Inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase: similarity and differences].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Odds Ratio; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2011 |
[What is the best sequence of treatment for patients with EGFR mutations?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Evidence-Based Medicine; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome | 2011 |
[Management of patients with resistance to EGFR-TKI].
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis; Treatment Outcome | 2011 |
[Biomarkers and targeted therapies in non-small cell lung cancer: present and future treatments].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Gefitinib; Gene Amplification; Genes, erbB-1; Humans; Lung Neoplasms; Medical Oncology; Mutation; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome | 2011 |
Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Quinazolines | 2012 |
Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2011 |
Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retreatment; Retrospective Studies | 2011 |
Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: genome-wide analysis of genetic data.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Gefitinib; Genome-Wide Association Study; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Polymorphism, Single Nucleotide; Quinazolines; Retrospective Studies | 2011 |
Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Erlotinib-induced rash spares previously irradiated skin.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Fatal Outcome; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis; Radiotherapy, Adjuvant; Tomography, X-Ray Computed | 2011 |
Drug-induced effects on erlotinib metabolism.
Topics: Adenocarcinoma; Aged; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines | 2011 |
Proteomic biomarkers for acute interstitial lung disease in gefitinib-treated Japanese lung cancer patients.
Topics: Asian People; Biomarkers; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Databases, Protein; Discriminant Analysis; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Peptides; Phenotype; Proteomics; Quality Control; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry | 2011 |
Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Lung Neoplasms; Membrane Potential, Mitochondrial; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sirolimus; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Recurrence | 2011 |
A case of colorectal cancer with double-activating epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Immunohistochemistry; Leucovorin; Lung Neoplasms; Mutation; Neoplasms, Second Primary; Organoplatinum Compounds; Quinazolines; Thyroid Neoplasms; Transcriptional Activation; Treatment Failure; Treatment Outcome | 2011 |
Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Review Literature as Topic; Treatment Outcome | 2011 |
[A case of alveolar hemorrhage caused by gefitinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Hemorrhage; Humans; Lung Diseases; Lung Neoplasms; Pulmonary Alveoli; Quinazolines | 2011 |
Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tomography, X-Ray Computed | 2011 |
Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Anaplastic Lymphoma Kinase; Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Female; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Metastasis; Phosphorylation; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2011 |
EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cellular Senescence; Cetuximab; DNA Breaks, Double-Stranded; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Tumor Suppressor Protein p53 | 2011 |
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Time Factors; Withholding Treatment | 2011 |
Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Curcumin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Intestinal Mucosa; Intestines; Lung Neoplasms; Mice; Mice, SCID; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Quinazolines; Ubiquitination; Xenograft Model Antitumor Assays | 2011 |
[Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib
in Patients with Non-small Cell Lung Cancer].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome | 2011 |
Prediction of response to targeted therapies in lung cancer using dynamic imaging: still far from clinical implementation.
Topics: Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Quinazolines | 2011 |
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Osteosclerotic lesions in patients treated with gefitinib for lung adenocarcinomas: a sign of favorable therapeutic response.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Osteosclerosis; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Basic clinical parameters predict gefitinib efficacy in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2011 |
[Efficacy and safety of gefitinib or docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed previous platinum-based first-line chemotherapy].
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Docetaxel; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Platinum; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Survival Rate; Taxoids | 2011 |
[Association of serum EGFR protein concentration with the efficacy of Gefitinib in the treatment of advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Remission Induction; Survival Rate | 2011 |
[Value of serum carcinoembryonic antigen in prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor].
Topics: Aged; Antineoplastic Agents; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate | 2011 |
Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Quinazolines; Retrospective Studies; Taxoids; Tegafur; Treatment Outcome | 2012 |
Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study.
Topics: Aged; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Biomarkers, Tumor; Blood Proteins; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mass Spectrometry; Mice; Middle Aged; Molecular Sequence Data; Neuroendocrine Cells; Nuclear Proteins; Proteins; Proteome; Proteomics; Quinazolines; RNA Interference; RNA, Small Interfering; Small Cell Lung Carcinoma; Thyroid Nuclear Factor 1; Transcription Factors | 2011 |
Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure.
Topics: Adenocarcinoma; Adult; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphangitis; Lymphatic Metastasis; Neoplasm Staging; Pleural Effusion, Malignant; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Third; Quinazolines; Remission Induction; Respiratory Insufficiency; Sequence Deletion; Term Birth | 2011 |
A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Case-Control Studies; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2011 |
[Classification and regression tree analysis of clinical patterns that predict survival in 127 Chinese patients with advanced non-small cell lung cancer treated by gefitinib who failed to previous chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Regression Analysis; Retrospective Studies; Survival Analysis; Young Adult | 2011 |
Exacerbation of radiation fibrosis with erlotinib: another pattern of radiation recall phenomenon.
Topics: Aged; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis | 2011 |
NICE guidance on erlotinib for the maintenance treatment of non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Congresses as Topic; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; United Kingdom | 2011 |
EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis.
Topics: Adenoviridae; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Therapy; Genetic Vectors; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Recombinant Proteins; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Investigation of acquired resistance to EGFR-targeted therapies in lung cancer using cDNA microarrays.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Profiling; Genetic Markers; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA | 2012 |
Imaging patterns and prognosis of patients with gefitinib-related interstitial lung disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Radiography, Thoracic; Retrospective Studies; Tomography, X-Ray Computed | 2011 |
Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Heparitin Sulfate; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Failure | 2011 |
Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2012 |
Maintenance therapy comes of age for non-small-cell lung cancer, but at what cost?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2011 |
Erlotinib and maintenance therapy of non-small cell lung cancer. Inadequate assessment; authorisation unjustified.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines | 2011 |
Survival and death signals can predict tumor response to therapy after oncogene inactivation.
Topics: Animals; Apoptosis; Blotting, Western; Cell Proliferation; Computer Simulation; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Genotype; Humans; Lung Neoplasms; Lymphoma; Mice; Mice, Transgenic; Models, Theoretical; Oncogenes; Polymerase Chain Reaction; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Quinazolines; Tumor Cells, Cultured | 2011 |
Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Cornea; Corneal Diseases; Diagnosis, Differential; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lung Neoplasms; Microscopy, Acoustic; Piperidines; Quinazolines; Visual Acuity | 2011 |
Rapid symptomatic improvement in gefitinib-treated patients with EGFR-mutated lung cancer: possible role of downregulation of inflammatory molecules?
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; DNA Mutational Analysis; Down-Regulation; ErbB Receptors; Female; Gefitinib; Humans; Inflammation Mediators; Lung Neoplasms; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Quinazolines; Tomography, X-Ray Computed | 2011 |
EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology.
Topics: Adult; Aged; Aged, 80 and over; Binding Sites; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Fluorescent Antibody Technique; Gefitinib; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Tissue Array Analysis | 2011 |
Case records of the Massachusetts General Hospital. Case 31-2011. A 55-year-old man with oligometastatic lung cancer.
Topics: Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Staging; Protein-Tyrosine Kinases; Quinazolines; Radiography | 2011 |
Osteoblastic healing response: discordant PET/CT findings.
Topics: Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Multimodal Imaging; Osteoblasts; Positron-Emission Tomography; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Deliberating Tarceva: A case study of how British NHS managers decide whether to purchase a high-cost drug in the shadow of NICE guidance.
Topics: Carcinoma, Non-Small-Cell Lung; Decision Making; Decision Support Techniques; Erlotinib Hydrochloride; Female; Health Care Costs; Humans; Lung Neoplasms; Middle Aged; Pharmacopoeias as Topic; Protein Kinase Inhibitors; Quinazolines; State Medicine; Tape Recording; United Kingdom | 2011 |
Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Transformed; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Signaling System; Morphine; Quinazolines; Receptors, Opioid, mu | 2011 |
Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib.
Topics: Adenocarcinoma; Adult; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.
Topics: Adenocarcinoma; Aged; Anaplastic Lymphoma Kinase; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gene Rearrangement; Humans; Lung Neoplasms; Mutation; Quinazolines; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2011 |
[Classification and regression tree analysis of clinical patterns to predict the survival of patients with advanced non-small cell lung cancer treated with erlotinib].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Regression Analysis; Treatment Outcome | 2011 |
Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenosquamous; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Mutation; Positron-Emission Tomography; Prognosis; Quinazolines; Radiopharmaceuticals; Survival Rate; Tomography, X-Ray Computed | 2012 |
Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chromones; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Morpholines; Mutation; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2011 |
Pharmacokinetics of gefitinib and erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2011 |
Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.
Topics: Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines | 2011 |
Tracheal granuloma pyogenicum with erlotinib treatment for lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Granuloma, Pyogenic; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tracheal Diseases | 2011 |
Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; British Columbia; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Taxoids | 2011 |
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Hepatocyte Growth Factor; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2011 |
Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Amplification; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Real-Time Polymerase Chain Reaction | 2011 |
Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Survival Analysis | 2011 |
Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2011 |
[New 'targeted therapy' for lung cancer].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Treatment Outcome | 2011 |
Erlotinib in metastatic bronchopulmonary mucoepidermoid carcinoma.
Topics: Adult; Carcinoma, Mucoepidermoid; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mediastinal Neoplasms; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Splenic Neoplasms | 2011 |
PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
Mechanistic insights into the activation of oncogenic forms of EGF receptor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Epidermal Growth Factor; ErbB Receptors; HEK293 Cells; Humans; Kinetics; Lapatinib; Lung Neoplasms; Models, Molecular; Mutation; Quinazolines; Tumor Suppressor Proteins | 2011 |
[Effection and mechanism of radiosensitivity of non-small cell lung cancer cell line H358 following gefitinib treatment].
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Nucleus; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; X-Rays | 2011 |
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Quinazolines | 2011 |
Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Laboratory Techniques; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Health Services; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Office Visits; Pemetrexed; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Taxoids; United States | 2012 |
EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Cell Cycle Proteins; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microtubule-Associated Proteins; Middle Aged; Multivariate Analysis; Mutation Rate; Oncogene Proteins, Fusion; Pleural Effusion, Malignant; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Smoking; Translocation, Genetic | 2012 |
[Complete remission of multiple brain metastases of non-small cell lung cancer induced by gefitinib monotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Brain Neoplasms; Cranial Irradiation; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Neoplasm Staging; Quinazolines; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted | 2011 |
Does chemotherapy have a role after erlotinib treatment in NSCLC?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2012 |
Diffuse interstitial lung disease linked to vandetanib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Hypersensitivity; Drug Substitution; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines; Spirometry; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Pneumocystis jiroveci Pneumonia in an Atypical Host.
Topics: Adrenal Cortex Hormones; Anti-Infective Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bevacizumab; Breast Neoplasms; CD4 Lymphocyte Count; Clinical Trials, Phase I as Topic; Dexamethasone; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Paclitaxel; Pneumocystis carinii; Pneumonia, Pneumocystis; Quinazolines; Trimethoprim, Sulfamethoxazole Drug Combination | 2012 |
EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoembryonic Antigen; Drainage; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleura; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Quinazolines; Thoracic Surgery, Video-Assisted; Tissue Polypeptide Antigen; Treatment Outcome | 2012 |
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Costs; Erlotinib Hydrochloride; Female; France; Germany; Glutamates; Guanine; Humans; Italy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Spain | 2012 |
Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2012 |
Targeted therapy in patients with non-small cell lung cancer previously treated with chemotherapy.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2011 |
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; MicroRNAs; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction | 2011 |
WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors.
Topics: Acrylamides; Adenocarcinoma; Aged; Aged, 80 and over; Aniline Compounds; Anoikis; Benzodioxoles; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Therapy, Combination; ErbB Receptors; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Middle Aged; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Quinazolines; src-Family Kinases; Sulfonamides | 2012 |
Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Genistein; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Erlotinib treatment for persistent spontaneous pneumothorax in non-small cell lung cancer: a case report.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Pneumothorax; Protein Kinase Inhibitors; Quinazolines | 2010 |
Erlotinib prevents experimental metastases of human small cell lung cancer cells with no epidermal growth factor receptor expression.
Topics: Animals; Bone Neoplasms; Carcinoma, Small Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Osteoblasts; Osteoclasts; Protein Kinase Inhibitors; Quinazolines; RANK Ligand | 2012 |
Pneumatosis cystoides intestinalis after gefitinib therapy for pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Pneumatosis Cystoides Intestinalis; Quinazolines; Radiography | 2012 |
EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Azabicyclo Compounds; Biomarkers, Tumor; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Humans; Immunoblotting; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Prognosis; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Tumor Cells, Cultured | 2012 |
Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anoikis; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor, Notch1; RNA, Small Interfering; Signal Transduction; Tumor Stem Cell Assay | 2012 |
EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2012 |
Overexpressed HER2 in NSCLC is a possible therapeutic target of EGFR inhibitors.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Mice; Mutation; Neoplasm Transplantation; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2011 |
Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer.
Topics: Adult; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Treatment Outcome | 2011 |
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
A high-throughput cell-based screening for L858R/T790M mutant epidermal growth factor receptor inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Gefitinib; High-Throughput Screening Assays; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2012 |
Drug approvals 2011: focus on companion diagnostics.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Brentuximab Vedotin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Approval; Female; Humans; Imidazoles; Immunoconjugates; Indazoles; Indoles; Ipilimumab; Lung Neoplasms; Male; Melanoma; Molecular Targeted Therapy; Neoplasms; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyridines; Quinazolines; Rare Diseases; Sulfonamides; Survival Analysis; United States; United States Food and Drug Administration; Vemurafenib | 2012 |
Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Female; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.
Topics: Adenocarcinoma; Adult; Afatinib; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Erlotinib as maintenance therapy shows PFS benefit for lung cancer patients with EGFR-mutated tumors.
Topics: Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoplasm Invasiveness; Prognosis; Protein Kinase Inhibitors; Quinazolines; Transcription Factors; Transfection | 2012 |
[Clinical response to gefitinib retreatment of lung adenocarcinoma patients who benefited from an initial gefitinib therapy: a retrospective analysis].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retreatment; Retrospective Studies; Treatment Outcome | 2012 |
The management of EGFR inhibitor adverse events: a case series and treatment paradigm.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fluorescent Antibody Technique; Fulvestrant; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, SCID; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-3 | 2012 |
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Progression; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Neovascularization, Pathologic; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2012 |
Beyond first-line NSCLC therapy: chemotherapy or erlotinib?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2012 |
Optimising therapy for EGFR-addicted NSCLC: just the start.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy.
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Vimentin; Young Adult | 2012 |
Impacts of treatment lines and initiation timing of erlotinib for advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate | 2012 |
Erlotinib after failure of gefitinib treatment of more than 6 months in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2012 |
Effectiveness of erlotinib in advanced non-small cell lung cancer in cases of gefitinib resistance after treatment of more than 6 months.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Dosage; Genes, ras; Humans; Lung Neoplasms; Mutation; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor | 2012 |
Severe bronchorrhea in a patient with bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Biopsy; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Sputum; Tomography, X-Ray Computed | 2012 |
Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, SCID; Mutation; Piperazines; Protein-Tyrosine Kinases; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
Crotoxin enhances the antitumor activity of gefinitib (Iressa) in SK-MES-1 human lung squamous carcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Caspase 3; Cell Cycle; Cell Line, Tumor; Crotoxin; Drug Synergism; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.
Topics: Adenocarcinoma; Afatinib; Aged; Amino Acid Sequence; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Prognosis; Protein Kinases; Quinazolines; Receptor, ErbB-2; Sequence Homology, Amino Acid | 2012 |
RET, ROS1 and ALK fusions in lung cancer.
Topics: 3T3 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Adult; Age Factors; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Animals; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cytoskeletal Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Middle Aged; Neoplasm Staging; Oncogene Proteins, Fusion; Piperidines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Receptor Protein-Tyrosine Kinases; Sex Factors | 2012 |
KIF5B-RET fusions in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Animals; Cell Transformation, Neoplastic; ErbB Receptors; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; Japan; Kinesins; Lung Neoplasms; Mice; NIH 3T3 Cells; Norway; Oncogene Proteins, Fusion; Piperidines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; United States | 2012 |
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Dasatinib; Discoidin Domain Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; src-Family Kinases; Thiazoles | 2011 |
Subacute transient encephalopathy induced by erlotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Central Nervous System Diseases; Confusion; Erlotinib Hydrochloride; Female; Humans; Irritable Mood; Lethargy; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Seizures; Unconsciousness; Urinary Incontinence | 2011 |
3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Image Processing, Computer-Assisted; Lung Neoplasms; Mice; Mice, Inbred BALB C; Multimodal Imaging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Sulfonamides; Tomography, X-Ray Computed | 2012 |
[Evaluating the short-term effect of gefitinib in advanced lung adenocarcinoma with positive EGFR-mutant by dual source volume perfusion CT].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Cone-Beam Computed Tomography; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome | 2011 |
[Efficacy of combination therapy with EGFR-TKI and cytotoxic drug in lung adenocarcinoma already treated with EGFR-TKI].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy | 2012 |
A case of choroidal metastasis of lung cancer successfully treated with erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Choroid Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines | 2012 |
[Prognostic relevance of body mass index and rash for patients with metastatic non-small-cell lung cancer under therapy with erlotinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Body Height; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sex Factors; Smoking; Statistics as Topic; Survival Analysis | 2012 |
The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Predictive Value of Tests; Proportional Hazards Models; Quinazolines; Smoking; Taxoids; Tubulin | 2012 |
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Methionine; Mice; Mice, Nude; Mice, SCID; Molecular Conformation; Mutation; Neoplasm Transplantation; Pyrimidines; Quinazolines; Structure-Activity Relationship; Threonine; Transplantation, Heterologous | 2012 |
Manifestation of leukoencephalopathy in a patient with advanced non-small cell lung cancer following treatment with gefitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Leukoencephalopathies; Lung Neoplasms; Middle Aged; Quinazolines | 2011 |
Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Conformation; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Budgets; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Models, Economic; Pemetrexed; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Thailand; Treatment Outcome | 2012 |
Painful annular pustular drug eruption induced by erlotinib in a patient with non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Pain; Protein Kinase Inhibitors; Quinazolines | 2011 |
Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases.
Topics: Acrylamides; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Mice; Mice, Inbred ICR; Models, Molecular; Mutation; Oxazoles; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, ErbB-2; Stomach Neoplasms; Structure-Activity Relationship | 2012 |
Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Child; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Young Adult | 2012 |
Inhibiting the aurora B kinase potently suppresses repopulation during fractionated irradiation of human lung cancer cell lines.
Topics: Apoptosis; Aurora Kinase B; Aurora Kinases; Carcinoma, Non-Small-Cell Lung; Cell Culture Techniques; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cobalt Radioisotopes; Combined Modality Therapy; Dose Fractionation, Radiation; Enzyme Inhibitors; G2 Phase; Humans; Lung Neoplasms; Neoplasm Proteins; Polyploidy; Protein Serine-Threonine Kinases; Quinazolines; Tumor Stem Cell Assay | 2012 |
HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Cell Line, Tumor; Humans; Lapatinib; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Small Cell Lung Carcinoma; Transfection; Up-Regulation | 2012 |
The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2013 |
Differential efficacy of gefitinib across age groups in treatment of advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aging; Antineoplastic Agents; Disease Progression; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Retrospective Studies; Software; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and CISH-negative EGFR gene alterations.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; In Situ Hybridization; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Analysis | 2012 |
Pneumatosis intestinalis and portal venous gas secondary to Gefitinib therapy for lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Embolism, Air; Female; Gefitinib; Humans; Lung Neoplasms; Pneumatosis Cystoides Intestinalis; Portal Vein; Protein Kinase Inhibitors; Quinazolines | 2012 |
A study of electrochemical biosensor for analysis of three-dimensional (3D) cell culture.
Topics: Antineoplastic Agents; Biosensing Techniques; Cell Count; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Collagen; Drug Combinations; Electrochemical Techniques; Erlotinib Hydrochloride; Gels; Humans; Laminin; Lung Neoplasms; Proteoglycans; Quinazolines; Spheroids, Cellular | 2012 |
Retrospective study of erlotinib in patients with advanced squamous lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
[A case of bronchioloalveolar carcinoma successfully treated with low-dose, alternate-day administration of erlotinib].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2012 |
Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Mutation; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines | 2012 |
[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and apoptosis of lung adenocarcinoma cell H1975].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 8; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Taxoids | 2012 |
Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors.
Topics: Antigens, CD; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Lung Neoplasms; Phenotype; Protein Kinase Inhibitors; Quinazolines; Tumor Stem Cell Assay | 2012 |
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cetuximab; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Phenotype; Protein Kinase Inhibitors; Quinazolines; RNA Interference; RNA, Small Interfering; Transfection | 2012 |
Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Crown Ethers; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2012 |
FoxM1 mediated resistance to gefitinib in non-small-cell lung cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Forkhead Box Protein M1; Forkhead Transcription Factors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Time Factors | 2012 |
Gefitinib for a poor performance status patient with squamous cell carcinoma of the lung harboring EGFR mutation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; ErbB Receptors; Fatal Outcome; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Palliative Care; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index; Smoking; Taxoids; Tomography, X-Ray Computed | 2012 |
A new generation of EGFR tyrosine-kinase inhibitors in NSCLC.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2012 |
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2012 |
Second-line erlotinib for non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2012 |
Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Multimodal Imaging; Mutation; Neoplasm Staging; Neoplasms, Multiple Primary; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP).
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Glycoproteins; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Mutation; Neoplasm Proteins; Neoplastic Stem Cells; Peptides; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survivors | 2012 |
Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2012 |
Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis Regulatory Proteins; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Death-Associated Protein Kinases; DNA Methylation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lung Neoplasms; Promoter Regions, Genetic; Quinazolines; RNA Interference; RNA, Small Interfering | 2012 |
[Evaluation of gefitinib plus radiotherapy in non-small-cell lung cancer patients with brain metastases].
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Mutation; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2012 |
3rd line Erlotinib for lung cancer in Asia may be as cost-effective as in the Western world.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2012 |
Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering | 2012 |
[Carcinomatous meningitis in a post-operative patient with lung adenocarcinoma for which erlotinib was effective - a case report].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2012 |
Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Exanthema; Female; Gefitinib; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Phenotype; Polymorphism, Single Nucleotide; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Treatment Outcome | 2012 |
EGFR-mediated stimulation of sodium/glucose cotransport promotes survival of irradiated human A549 lung adenocarcinoma cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Glucose; Head and Neck Neoplasms; Humans; Lung Neoplasms; Membrane Potentials; Patch-Clamp Techniques; Phlorhizin; Protein-Tyrosine Kinases; Quinazolines; Radiation Dosage; Sodium-Glucose Transport Proteins; Tumor Cells, Cultured | 2012 |
Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Radiography, Thoracic; Time Factors; Treatment Outcome | 2013 |
Src-signaling interference impairs the dissemination of blood-borne tumor cells.
Topics: Animals; Benzodioxoles; Cell Line, Tumor; Humans; Lung Neoplasms; Mice; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; src-Family Kinases | 2012 |
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Discriminant Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Quinazolines; Radiopharmaceuticals; Retrospective Studies; ROC Curve | 2012 |
Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Base Sequence; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Increase in claudin-2 expression by an EGFR/MEK/ERK/c-Fos pathway in lung adenocarcinoma A549 cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Binding Sites; Butadienes; Cell Line, Tumor; Claudins; Epidermal Growth Factor; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; MAP Kinase Signaling System; Nitriles; Promoter Regions, Genetic; Protease Inhibitors; Protein Binding; Proto-Oncogene Proteins c-fos; Quinazolines; RNA, Messenger; RNA, Small Interfering; Transcription Factor AP-1; Tyrphostins | 2012 |
Method to our madness or madness in our methods? Pitfalls in trial methodology.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Ipilimumab; Lung Neoplasms; Male; Melanoma; Paclitaxel; Quinazolines; Smoking; Solvents | 2012 |
Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Crizotinib; Drug Resistance, Neoplasm; Endothelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Fibroblasts; Gene Amplification; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Mice; Mice, SCID; Mutation, Missense; Oncogene Proteins, Fusion; Paracrine Communication; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2012 |
Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Estradiol; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Receptors, Estrogen; Signal Transduction; Up-Regulation | 2012 |
[Mutation testing for non-small-cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Point Mutation; Polymerase Chain Reaction; Precision Medicine; Protein Kinase Inhibitors; Quinazolines | 2012 |
A case of rapid improvement of severe psoriasis during molecular-targeted therapy using an epidermal growth factor receptor tyrosine kinase inhibitor for metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Comorbidity; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Colorectal Neoplasms; Corneal Perforation; Ectropion; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Keratoplasty, Penetrating; Lung Neoplasms; Male; Middle Aged; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Visual Acuity | 2012 |
Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma of Lung; Cell Death; Cell Line, Tumor; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 22; Epithelial Cells; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mutation; Neurofibromin 1; Nuclear Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; raf Kinases; Shelterin Complex; Signal Transduction; SOS1 Protein; Telomere-Binding Proteins | 2011 |
Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing EGFR mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Biopsy; Brain Neoplasms; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2012 |
Secondary resistance to erlotinib: acquired T790M mutation and small-cell lung cancer transformation in the same patient.
Topics: Adult; Biopsy; Bronchoscopy; Cell Transformation, Neoplastic; Diagnosis, Differential; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Follow-Up Studies; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2012 |
Occupy EGFR.
Topics: Animals; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Kinetics; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Lapatinib; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; Lung Neoplasms; Male; Quinazolines; Receptor, IGF Type 1; Signal Transduction | 2012 |
Dermatomyositis and chest radiography leading to the diagnosis of lung cancer and subsequent confusions in staging due to the presence of tuberculosis.
Topics: Aged; Antitubercular Agents; Dermatomyositis; Diagnosis, Differential; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiography, Thoracic; Tomography, X-Ray Computed; Tuberculosis, Pulmonary | 2012 |
Gefitinib-related interstitial lung disease in Taiwanese patients with non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cough; Dyspnea; Female; Gefitinib; Hospital Mortality; Humans; Hypoxia; Incidence; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Taiwan | 2013 |
Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Product Surveillance, Postmarketing; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Smoking; Survival Rate; Young Adult | 2012 |
The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials.
Topics: Adenocarcinoma, Papillary; Adult; Afatinib; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Ovarian Neoplasms; Paclitaxel; Pelvic Neoplasms; Phthalazines; Piperazines; Quinazolines; Uterine Cervical Neoplasms | 2012 |
[Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intra-Arterial; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nimustine; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Skin Diseases; Survival Analysis; Treatment Outcome | 2012 |
Human papillomavirus in non-small-cell lung cancer: the impact of EGFR mutations and the response to erlotinib.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Proteins; Papillomavirus Infections; Prevalence; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Spain | 2013 |
Purpuric drug eruption and alopecia induced by erlotinib.
Topics: Adenocarcinoma; Aged; Alopecia; Dermis; Drug Eruptions; Erlotinib Hydrochloride; Humans; Leg; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2012 |
Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
Patient comprehension and attitudes toward maintenance chemotherapy for lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Comprehension; Female; Focus Groups; Health Knowledge, Attitudes, Practice; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Patient Preference; Perception; Qualitative Research; Quality of Life; Quinazolines; Texas; Treatment Outcome | 2012 |
Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Movement; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Genes, ras; Humans; Lung Neoplasms; Mice; Mice, SCID; Mutation; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Transplantation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Receptors, Tumor Necrosis Factor; Signal Transduction; Tumor Cells, Cultured; TWEAK Receptor | 2012 |
[Multidisciplinary treatment of leptomeningeal metastasis in patients with lung adenocarcinoma: the triple modality combination of EGFR-TKI, VP shunt and irradiation].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Ventriculoperitoneal Shunt | 2012 |
Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.
Topics: Active Transport, Cell Nucleus; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Factor 6; Kruppel-Like Transcription Factors; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Real-Time Polymerase Chain Reaction; Signal Transduction; Transcription, Genetic; Trifluoperazine; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Temporal resolution of autophosphorylation for normal and oncogenic forms of EGFR and differential effects of gefitinib.
Topics: Apoptosis; Cell Differentiation; Cell Proliferation; Down-Regulation; Drug Delivery Systems; Drug Design; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Quinazolines; Spectrometry, Mass, Electrospray Ionization; Time Factors; Tyrosine | 2012 |
Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Genes, MDR; Humans; Lung Neoplasms; Microtubules; Mutation; Paclitaxel; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tubulin Modulators | 2012 |
Long-term survival of a patient with carcinomatous meningitis due to non-small cell lung cancer treated with erlotinib following gefitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Spinal Puncture | 2011 |
[Effect and mechanism of gefitinib inhibition on non-small cell lung cancer radiosensitivity of HCC827 and H358 cell lines].
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Nucleus; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Histones; Humans; Lung Neoplasms; Quinazolines; Radiation Tolerance; Survival Analysis | 2012 |
[A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Cross-Sectional Studies; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Public Health Practice; Quality of Life; Quinazolines; Retrospective Studies; Safety; Survivors; Time Factors; Treatment Outcome | 2012 |
Unilateral onycholysis in a patient taking erlotinib (Tarceva).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Onycholysis; Protein Kinase Inhibitors; Quinazolines; Thoracic Surgery, Video-Assisted; Tomography, X-Ray Computed | 2011 |
Salvage surgery for a super-responder by gefitinib therapy for advanced lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Lymph Nodes; Neoplasm, Residual; Quinazolines; Salvage Therapy | 2012 |
Platelet-lowering therapy with anagrelide as an adjuvant therapy for treatment of primary pulmonary neoplasm-associated extreme thrombocytosis.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Femoral Vein; Humans; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Syndromes; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocytosis | 2012 |
[A case of a corneal disorder after lung cancer treatment with erlotinib].
Topics: Corneal Diseases; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2012 |
Alveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR-dependent mechanism.
Topics: Animals; Antioxidants; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Blotting, Western; Butylated Hydroxytoluene; Carcinogens; Cell Proliferation; Cytokines; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Hypoxia; Immunoenzyme Techniques; Lung Neoplasms; Methylcholanthrene; Mice; Neovascularization, Pathologic; Piperidines; Proto-Oncogene Proteins c-myc; Pulmonary Alveoli; Quinazolines; Sleep Apnea Syndromes; Urethane; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth.
Topics: Amino Acid Motifs; Amino Acid Sequence; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Sequence Data; Peptide Fragments; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; Serine; Tandem Mass Spectrometry; Tyrosine | 2012 |
Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Smoking; Survival Rate | 2012 |
JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Genes, erbB-1; Humans; Janus Kinase 2; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Management of non-small cell lung cancer: focus on erlotinib. Foreword.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation, Missense; Quinazolines | 2012 |
Rare and novel epidermal growth factor receptor mutations in non-small-cell lung cancer and lack of clinical response to gefitinib in two cases.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Prognosis; Quinazolines; Survival Rate; Tomography, X-Ray Computed | 2012 |
MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.
Topics: Antineoplastic Agents; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Lung Neoplasms; Proto-Oncogene Proteins c-met; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2012 |
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisplatin; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Female; Fluorodeoxyglucose F18; Humans; Indoles; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Radiopharmaceuticals; Sorafenib; Sunitinib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed | 2012 |
Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dideoxynucleosides; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Quinazolines; Radionuclide Imaging; Radiopharmaceuticals; Sequence Deletion | 2012 |
Detecting the effect of targeted anti-cancer medicines on single cancer cells using a poly-silicon wire ion sensor integrated with a confined sensitive window.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Biosensing Techniques; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Delivery Systems; Gefitinib; Humans; Ions; Lung Neoplasms; Propylamines; Quinazolines; Silanes; Silicon; Single-Cell Analysis; Staurosporine | 2012 |
Erlotinib-induced generalized eczema craquelé and follicular rash sparing the previous radiation field.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Eruptions; Eczema; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Recurrence; Risk Factors | 2012 |
On Bayesian methods of exploring qualitative interactions for targeted treatment.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Carboplatin; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Computer Simulation; ErbB Receptors; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Mutation; Paclitaxel; Pharmacogenetics; Quinazolines; Regression Analysis; Survival Analysis | 2012 |
Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Signal Transduction; Tankyrases; Wnt Proteins; Xenograft Model Antitumor Assays | 2012 |
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Topics: Adult; Aged; Animals; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells.
Topics: Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Transforming Growth Factor beta | 2012 |
Novel liposomal gefitinib (L-GEF) formulations.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Antineoplastic Agents; beta-Cyclodextrins; Cell Line, Tumor; Drug Stability; Gefitinib; Humans; Liposomes; Lung Neoplasms; Mice; Mice, Inbred ICR; Particle Size; Quinazolines | 2012 |
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Retrospective Studies | 2012 |
Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Linear Models; Lung Neoplasms; Multivariate Analysis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Membrane; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Quinazolines | 2013 |
[Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Survival Rate | 2012 |
Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
Topics: Aminopyridines; Animals; Antibodies; Antibody Specificity; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Models, Biological; Mutation; Neovascularization, Pathologic; Piperazines; Proto-Oncogene Proteins c-met; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2012 |
A novel EGFR mutation in exon 19 showed stable disease after TKI treatment.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation, Missense; Quinazolines | 2012 |
HGFK1 is associated with a better prognosis and reverses inhibition by gefitinib in NSCLC cases.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Kaplan-Meier Estimate; Kringles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Phosphorylation; Proportional Hazards Models; Quinazolines; STAT5 Transcription Factor; Tumor Burden | 2012 |
Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Disease-Free Survival; Ephrins; Epithelial Cells; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Multivariate Analysis; Mutation, Missense; Neoplasm Invasiveness; Occludin; Proportional Hazards Models; Quinazolines; Receptor, EphA4 | 2012 |
A case report: successful treatment of meningeal metastasis with concurrent whole brain radiotherapy and erlotinib in a patient with non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.
Topics: Alleles; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Polymorphism, Single-Stranded Conformational; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2012 |
Anti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cells.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cytoplasm; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Triazoles | 2012 |
Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.
Topics: Adenocarcinoma; Adult; Disease Progression; Drug Eruptions; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Support Vector Machine | 2012 |
Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Topics: Acrylamides; Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, SCID; Microvessels; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Chromatography, High Pressure Liquid; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tandem Mass Spectrometry | 2013 |
The impact of local and regional disease extent on overall survival in patients with advanced stage IIIB/IV non-small cell lung carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Radiography; Tumor Burden | 2012 |
Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Transforming Growth Factor alpha; Up-Regulation | 2012 |
KRAS wild-type lung cancer: a moving target in an era of genotype migration.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2012 |
[Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting].
Topics: Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoglobulins, Intravenous; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Precision Medicine; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quality Control; Quinazolines | 2012 |
MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor.
Topics: 3' Untranslated Regions; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; In Situ Hybridization; Lung Neoplasms; Lymphatic Metastasis; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction | 2012 |
[Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
[Pharmacoeconomic analysis of gefitinib therapy in patients with non-cell cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Female; Gefitinib; Humans; Life Expectancy; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Russia; Survival Analysis; Treatment Outcome | 2012 |
Fatal asymmetric interstitial lung disease after erlotinib for lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Topics: Afatinib; Animals; Autocrine Communication; Carcinoma, Non-Small-Cell Lung; Cell Communication; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Fibroblasts; Humans; Interleukin-6; Janus Kinase 1; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Receptors, Interleukin-6; Signal Transduction; STAT3 Transcription Factor; Stromal Cells; Xenograft Model Antitumor Assays | 2012 |
Follow-up of erlotinib related uveitis.
Topics: Adenocarcinoma; Aged; Diagnosis, Differential; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Uveitis; Visual Acuity | 2012 |
Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Radiography; Treatment Outcome | 2012 |
Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Malaysia; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2012 |
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Quinazolines; Salvage Therapy | 2013 |
[Four cases of interstitial lung disease induced by erlotinib and a review of the literatures].
Topics: Aged; Antineoplastic Agents; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2012 |
Analysis of chemotherapy and molecular therapy efficiency in advanced or metastatic non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2012 |
[EGFR mutations in patients with advanced NSCLC].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2012 |
[Gefitinib in patients with advanced non-small-cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Poland; Quinazolines | 2012 |
Erlotinib-associated dermatological toxicity.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Facial Dermatoses; Female; Humans; Lung Neoplasms; Quinazolines | 2013 |
Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Everolimus; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus | 2012 |
Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Treatment Failure; Vinblastine; Vinorelbine | 2012 |
Stearoyl-CoA desaturase activity modulates the activation of epidermal growth factor receptor in human lung cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Stearoyl-CoA Desaturase; TOR Serine-Threonine Kinases | 2012 |
Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naïve Asian NSCLC patients.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crizotinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Oligonucleotide Array Sequence Analysis; Point Mutation; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Transcriptome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
EGFR tyrosine kinase inhibition induces autophagy in cancer cells.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 7; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; HeLa Cells; Humans; Lung Neoplasms; Mouth Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; RNA Interference; RNA, Small Interfering; Sirolimus; Ubiquitin-Activating Enzymes | 2012 |
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA, Small Interfering | 2012 |
Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Cystadenocarcinoma, Mucinous; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vascular Endothelial Growth Factors; Young Adult | 2012 |
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
Topics: Acrylamides; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 1; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, ErbB-2 | 2012 |
Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Transcription Factors | 2012 |
Advanced non-small cell lung cancer (NSCLC): maintenance therapy for all?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Induction Chemotherapy; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Platinum; Quinazolines | 2012 |
Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Chromatography, Liquid; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Tandem Mass Spectrometry | 2013 |
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; France; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Risk Factors; Survival Rate | 2012 |
Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Theoretical; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution; Tumor Cells, Cultured | 2012 |
EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.
Topics: Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2012 |
The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Estrogen Receptor alpha; Estrogen Receptor beta; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression; Humans; Inhibitory Concentration 50; Lung Neoplasms; MAP Kinase Signaling System; Nitriles; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Triazoles | 2012 |
Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dihematoporphyrin Ether; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Photochemotherapy; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor | 2012 |
Gefitinib-induced paronychia: response to autologous platelet-rich plasma.
Topics: Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Paronychia; Platelet-Rich Plasma; Quinazolines | 2012 |
A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by [(18)F]fluorothymidine-positron emission tomography.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Fluorine Radioisotopes; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Pilot Projects; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Receptor, IGF Type 1; Thymidine; Triazines; Tumor Burden | 2013 |
Epidermal growth factor receptor (EGFR) inhibitors and derived treatments.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Quinazolines; Quinolines; Translational Research, Biomedical; Treatment Outcome | 2012 |
[EGFR gene mutation statuses in advanced non-small cell lung cancer patients and their influence on effect of gefitinib].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Young Adult | 2012 |
Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Gene Amplification; Gene Expression; Hepatocyte Growth Factor; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Retrospective Studies | 2012 |
Histone deacetylase inhibitor trichostatin A enhances anti-tumor effects of docetaxel or erlotinib in A549 cell line.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; G2 Phase; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Lung Neoplasms; Quinazolines; Taxoids; Tubulin | 2012 |
[Timing the change of chemotherapy for non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2012 |
[Efficacy of erlotinib after gefitinib administration in patients with non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Retrospective Studies | 2012 |
Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
Topics: Acneiform Eruptions; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome; Tumor Cells, Cultured | 2012 |
Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Disease-Free Survival; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Multicenter Studies as Topic; Multivariate Analysis; Quinazolines; Treatment Outcome | 2012 |
Survival of lung adenocarcinoma patients with malignant pleural effusion.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Prospective Studies; Quinazolines; Sequence Analysis, DNA; Time Factors; Treatment Outcome | 2013 |
Miliary brain metastases in 2 cases with advanced non-small cell lung cancer harboring EGFR mutation during gefitinib treatment.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines | 2012 |
Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer.
Topics: Animals; Antipsychotic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Gefitinib; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Quinazolines; Random Allocation; Sensitivity and Specificity; Trifluoperazine; Tumor Cells, Cultured | 2012 |
NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Humans; Lung Neoplasms; Mutation; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines; Treatment Outcome; United Kingdom | 2012 |
Epidermal growth factor receptor tyrosine kinase defines critical prognostic genes of stage I lung adenocarcinoma.
Topics: Adenocarcinoma; Cell Line, Tumor; Computational Biology; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Quinazolines; Reproducibility of Results | 2012 |
Flare phenomenon following gefitinib treatment of lung adenocarcinoma with bone metastasis.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Alkaline Phosphatase; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polyphosphates; Quinazolines; Radionuclide Imaging; Technetium Compounds; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib.
Topics: Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Adenosquamous; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Middle Aged; Mutation; Mutation, Missense; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2012 |
Impact of the integrin signaling adaptor protein NEDD9 on prognosis and metastatic behavior of human lung cancer.
Topics: Adaptor Proteins, Signal Transducing; Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Crk-Associated Substrate Protein; Disease-Free Survival; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Gene Knockdown Techniques; Humans; Integrins; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Multivariate Analysis; Neoplasm Transplantation; Phosphoproteins; Phosphorylation; Proportional Hazards Models; Protein Processing, Post-Translational; Quinazolines; Receptor Cross-Talk; Retrospective Studies; RNA, Small Interfering; Signal Transduction | 2012 |
Erlotinib in patients with advanced lung squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
[Personalised treatment of lung cancer].
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Molecular Targeted Therapy; Positron-Emission Tomography; Precision Medicine; Quinazolines | 2012 |
Erlotinib-induced bullous pemphigoid.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Pemphigoid, Bullous; Quinazolines | 2012 |
The pharmacokinetics and long-term therapeutic effects of gefitinib in patients with lung adenocarcinoma harboring the epidermal growth factor receptor(EGFR)mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies | 2012 |
Prognostic significance of NSE mRNA in advanced NSCLC treated with gefitinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Phosphopyruvate Hydratase; Prognosis; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger | 2013 |
Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.
Topics: Adenocarcinoma; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Practice Patterns, Physicians'; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate | 2013 |
Positron emission tomography and circulating tumor cells to monitor a dramatic response to gefitinib.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplastic Cells, Circulating; Positron-Emission Tomography; Prognosis; Quinazolines | 2012 |
A novel EGFR mutation in exon 18 with high sensitivity to EGFR TKI treatment with reduced dose.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation, Missense; Quinazolines | 2012 |
Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.
Topics: Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2012 |
Who should receive EGFR tyrosine-kinase inhibitors?
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2012 |
Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins c-met; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Failure; Tumor Burden | 2013 |
T-type Ca2+ channel blocker, KYS05047 induces G1 phase cell cycle arrest by decreasing intracellular Ca2+ levels in human lung adenocarcinoma A549 cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Calcium; Calcium Channel Blockers; Calcium Channels, T-Type; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; G1 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Quinazolines; Transplantation, Heterologous | 2012 |
A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Cisplatin; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Quinazolines; Small Cell Lung Carcinoma; Taxoids | 2012 |
Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cytochrome P-450 CYP2D6; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Biomarkers, Tumor; Carcinoembryonic Antigen; Cell Adhesion; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
[The TULUNG clinical registry].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Czech Republic; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Registries | 2012 |
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib.
Topics: Animals; Benzimidazoles; Blotting, Western; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; GTP Phosphohydrolases; Humans; Lung Neoplasms; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2013 |
Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.
Topics: Apoptosis; Autophagy; Autophagy-Related Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Epithelial Cells; Erlotinib Hydrochloride; Humans; Inhibitory Concentration 50; Lung Neoplasms; Quinazolines; RNA Interference; TOR Serine-Threonine Kinases; Ubiquitin-Conjugating Enzymes | 2012 |
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prognosis; Proteins; Proteomics; Quinazolines; Survival Analysis | 2013 |
Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Cisplatin; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Fluorescent Antibody Technique; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2013 |
Modeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expression.
Topics: Carcinoma, Non-Small-Cell Lung; Computer Simulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Models, Biological; Models, Statistical; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; STAT3 Transcription Factor | 2012 |
Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Lymph Nodes; Magnetic Resonance Imaging; Male; Meningeal Carcinomatosis; Middle Aged; Mutation, Missense; Neoplasm Invasiveness; Neoplasm Staging; Pemetrexed; Pneumonectomy; Quinazolines; Radiotherapy, Adjuvant; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Comparative Genomic Hybridization; DNA Copy Number Variations; DNA Mutational Analysis; Drug Synergism; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Indazoles; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Signal Transduction; Sulfonamides; Transcriptome; Xenograft Model Antitumor Assays | 2012 |
Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status.
Topics: Adult; Base Sequence; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Mutation; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Tomography, X-Ray Computed | 2013 |
Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Quinazolines; Treatment Outcome | 2013 |
Multiple analyses of G-protein coupled receptor (GPCR) expression in the development of gefitinib-resistance in transforming non-small-cell lung cancer.
Topics: Adenosine A2 Receptor Antagonists; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fibroblasts; Gefitinib; Humans; Lung; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Pyrimidines; Quinazolines; Receptor, Adenosine A2A; Receptors, G-Protein-Coupled; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcriptome; Triazoles | 2012 |
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Retrospective Studies; Survival Rate; Young Adult | 2012 |
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Catheter Ablation; Combined Modality Therapy; Crizotinib; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Survival Rate; Young Adult | 2012 |
Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cytoskeletal Proteins; Female; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Oncogene Proteins, Fusion; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transplantation, Heterologous; Tumor Cells, Cultured | 2012 |
Interaction of radiation and gefitinib on a human lung cancer cell line with mutant EGFR gene in vitro.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Flow Cytometry; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Signal Transduction | 2012 |
Disseminated herpes simplex virus infection following epidermal growth factor tyrosine kinase inhibitor therapy for non-small-cell lung carcinoma.
Topics: Acyclovir; Afatinib; Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Non-Small-Cell Lung; Cystitis; ErbB Receptors; Esophagitis; Hematuria; Herpes Simplex; Humans; Intestinal Perforation; Lung Neoplasms; Male; Molecular Targeted Therapy; Neoplasm Proteins; Peritonitis; Protein Kinase Inhibitors; Quinazolines; Valacyclovir; Valine; Viremia; Virus Activation | 2012 |
[Clinical observation of icotinib hydrochloride for patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diarrhea; Disease Progression; ErbB Receptors; Exanthema; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate | 2012 |
Strides in personalized medicine.
Topics: Afatinib; Gastrointestinal Stromal Tumors; Humans; Lung Neoplasms; Melanoma; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins B-raf; Pyridines; Quinazolines | 2012 |
Gastric perforation secondary to regression of lung adenocarcinoma after gefitinib treatment.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Gefitinib; Humans; Lung Neoplasms; Male; Prognosis; Quinazolines; Remission Induction; Stomach Rupture; Tomography, X-Ray Computed | 2013 |
Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Immunoglobulin G; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2013 |
Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue.
Topics: Calibration; Chromatography, High Pressure Liquid; Edetic Acid; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Quinazolines; Sensitivity and Specificity; Tandem Mass Spectrometry | 2012 |
First-line erlotinib inferior to chemo in advanced lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Health Care Costs; Humans; Lung Neoplasms; Pemetrexed; Quinazolines | 2012 |
Gefitinib analogue V1801 induces apoptosis of T790M EGFR-harboring lung cancer cells by up-regulation of the BH-3 only protein Noxa.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Quinazolines; Treatment Outcome; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
[Perforation of the nasal septum: a rare complication of bevacizumab].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Middle Aged; Nasal Septal Perforation; Neoplasm Proteins; Pemetrexed; Quinazolines; Respiratory Insufficiency; Salvage Therapy; Vascular Endothelial Growth Factor A | 2012 |
[109th Scientific Meeting of the Japanese Society of Internal Medicine: symposium: 1. Recent treatments and progress in malignant tumors--chemotherapy and molecular targeting agents. Antibody therapy; 3) Non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2012 |
Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genetic Predisposition to Disease; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Quinazolines; Real-Time Polymerase Chain Reaction | 2012 |
Prognosis in patients with non-small cell lung cancer who received erlotinib treatment and subsequent dose reduction due to skin rash.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Comorbidity; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Prevalence; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome | 2012 |
Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2013 |
Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: a retrospective, observational, multicentric study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Hep G2 Cells; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Effects of voltage-gated K+ channel blockers in gefitinib-resistant H460 non-small cell lung cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Kv1.1 Potassium Channel; Lung Neoplasms; Male; Mice; Mice, Nude; Peptides; Quinazolines; RNA, Messenger; Xenograft Model Antitumor Assays | 2012 |
Noncovalent wild-type-sparing inhibitors of EGFR T790M.
Topics: Acrylamides; Amino Acid Substitution; Animals; Area Under Curve; Base Sequence; Carbazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoblotting; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; RNA Interference; Staurosporine; Xenograft Model Antitumor Assays | 2013 |
Patients with advanced lung cancer: is there scope to discontinue inappropriate medication?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Interactions; England; Erlotinib Hydrochloride; Humans; Inappropriate Prescribing; Lung Neoplasms; Polypharmacy; Prevalence; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies | 2013 |
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
Topics: Analysis of Variance; Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Membrane; Cell Survival; Cetuximab; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Stability; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2012 |
The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2013 |
Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
Topics: Aged; Aged, 80 and over; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2013 |
How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?
Topics: Aged; Aged, 80 and over; Base Sequence; Carcinoma, Squamous Cell; Confidence Intervals; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion | 2013 |
EGFR mutations in squamous cell lung cancer in never-smokers.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Epidural Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Quinazolines; Smoking; Thoracic Vertebrae | 2013 |
[Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Chromones; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2012 |
The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
Second line treatment in advanced non-small cell lung cancer (NSCLC): comparison of efficacy of erlotinib and chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Failure | 2013 |
Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Retrospective Studies | 2013 |
Spared pre-irradiated area in pustular lesions induced by icotinib showing decreased expressions of CD1a+ langerhans cells and FGFR2.
Topics: Acneiform Eruptions; Adenocarcinoma; Adenocarcinoma of Lung; Antigens, CD1; Antineoplastic Agents; Biopsy; Blister; Chemotherapy, Adjuvant; Crown Ethers; Dose Fractionation, Radiation; Down-Regulation; Drug Eruptions; Enzyme Inhibitors; ErbB Receptors; Face; Folliculitis; Humans; Immunohistochemistry; Ki-67 Antigen; Langerhans Cells; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; Skin; Thoracic Wall | 2013 |
Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Gene Targeting; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering | 2013 |
Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines.
Topics: Adenocarcinoma; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flow Cytometry; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; MAP Kinase Kinase Kinases; Membrane Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering; Tumor Cells, Cultured | 2013 |
Epithelial mesenchymal transition is required for acquisition of anoikis resistance and metastatic potential in adenoid cystic carcinoma.
Topics: Animals; Anoikis; Antineoplastic Agents; Apoptosis; Carcinoma, Adenoid Cystic; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Salivary Gland Neoplasms; Snail Family Transcription Factors; Transcription Factors | 2012 |
Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catalytic Domain; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Models, Molecular; Mutation, Missense; Phosphorylation; Protein Binding; Protein Processing, Post-Translational; Protein Stability; Protein Structure, Secondary; Quinazolines; Quinazolinones; Sf9 Cells; Spodoptera | 2013 |
Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Genes, erbB-1; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Piperidines; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Long-term gefitinib treatment of occult lung carcinoma with multiple brain metastases.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Keratin-7; Lung; Lung Neoplasms; Middle Aged; Mutation; Nuclear Proteins; Protein Kinase Inhibitors; Quinazolines; Thyroid Nuclear Factor 1; Time Factors; Transcription Factors; Treatment Outcome | 2013 |
[Efficacy of erlotinib after the failure of gefitinib in patients with metastasis of non-small cell lung cancer with unknown EGFR mutation status].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate | 2012 |
[Efficacy and safety of docetaxol, pemetrexed and EGFR-TKIs as second-line treatment for patients with advanced non-small-cell lung cancer].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Taxoids | 2012 |
[Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Carcinoma, Neuroendocrine; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Grading; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2013 |
Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Survival Rate; Tumor Burden | 2013 |
Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; Erlotinib Hydrochloride; Female; Follow-Up Studies; Health Plan Implementation; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Neoplasm Staging; Patient Compliance; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate | 2013 |
Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mutation; Quinazolines; Retrospective Studies; Treatment Outcome | 2013 |
The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
Topics: Animals; Antineoplastic Agents; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, SCID; Mutation; Neoplasm Transplantation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; Tetrazolium Salts; Thiazoles; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
[The mechanism of gefitinib resistance induced by hepatocyte growth factor in sensitive non-small cell lung cancer cells in vitro].
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-met; Quinazolines | 2013 |
Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activation.
Topics: Adenocarcinoma; Animals; Blotting, Western; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Neuregulin-1; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Signal Transduction; Spheroids, Cellular; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Exons; Female; Humans; Lapatinib; Lung Neoplasms; Middle Aged; Mutation; Prognosis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vascular Endothelial Growth Factor A | 2013 |
Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta2; Tumor Cells, Cultured | 2013 |
Preclinical pharmacokinetic/pharmacodynamic models to predict schedule-dependent interaction between erlotinib and gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Protein Kinase Inhibitors; Quinazolines | 2013 |
To target or not to target, that is the question.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2013 |
Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation.
Topics: Adult; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Family Health; Fatal Outcome; Female; Germ-Line Mutation; Humans; In Situ Hybridization; Lung; Lung Neoplasms; Middle Aged; Mutation, Missense; Neoplasms, Squamous Cell; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2013 |
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.
Topics: Adenocarcinoma; Amides; Animals; Antineoplastic Agents; Apoptosis; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Decision Support Techniques; Disease-Free Survival; Drug Costs; ErbB Receptors; Gefitinib; Humans; Life Expectancy; Lung Neoplasms; Markov Chains; Medical Assistance; Models, Economic; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines; Survival Analysis; Time Factors; Treatment Outcome; Uncertainty | 2013 |
Sorting nexin 2-mediated membrane trafficking of c-Met contributes to sensitivity of molecular-targeted drugs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Lysosomes; Membrane Transport Proteins; Molecular Targeted Therapy; Mutation; Protein Transport; Proto-Oncogene Proteins c-met; Quinazolines; Sorting Nexins | 2013 |
A mathematical model for microRNA in lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Computer Simulation; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Models, Genetic; Mutation; Oncogene Protein p21(ras); Proto-Oncogene Proteins c-myc; Quinazolines; Signal Transduction | 2013 |
The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Eruptions; Erlotinib Hydrochloride; Female; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
T-cadherin loss promotes experimental metastasis of squamous cell carcinoma.
Topics: Animals; Cadherins; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Endothelial Cells; ErbB Receptors; Gefitinib; Human Umbilical Vein Endothelial Cells; Humans; Immunoblotting; Keratinocytes; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Microscopy, Confocal; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Skin Neoplasms; Transendothelial and Transepithelial Migration; Transplantation, Heterologous | 2013 |
Quantitative chemical proteomics profiling differentiates erlotinib from gefitinib in EGFR wild-type non-small cell lung carcinoma cell lines.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphate; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; LIM Domain Proteins; Lung Neoplasms; Membrane Proteins; Microfilament Proteins; Molecular Conformation; Molecular Docking Simulation; Protein Binding; Protein Serine-Threonine Kinases; Proteomics; Quinazolines; Signal Transduction | 2013 |
High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well.
Topics: Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Thoracic Diseases; Treatment Outcome | 2013 |
EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Membrane Proteins; Mice; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Tumor Burden; Vorinostat; Xenograft Model Antitumor Assays | 2013 |
Lack of improvement in overall survival with gemcitabine/ erlotinib maintenance and its relationship with pemetrexed use in the second-line setting.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
Erlotinib plus parenteral nutrition: an opportunity to get through the hardest days of advanced non-small cell lung cancer with cancer anorexia-cachexia syndrome.
Topics: Anorexia; Cachexia; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Parenteral Nutrition; Quinazolines; Syndrome | 2013 |
Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models.
Topics: Animals; Antineoplastic Agents; Benzamides; Butylamines; Cell Line, Tumor; Chromones; Cysteine; Kinesins; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Structure-Activity Relationship; Transplantation, Heterologous | 2013 |
A C++ program to calculate sample sizes for cost-effectiveness trials in a Bayesian framework.
Topics: Antineoplastic Agents; Bayes Theorem; Clinical Trials as Topic; Cost-Benefit Analysis; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Sample Size; Software | 2013 |
Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Synergism; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tumor Cells, Cultured | 2013 |
Gefitinib (Iressa) for advanced non-small cell lung cancer.
Topics: Biological Availability; Carcinoma, Non-Small-Cell Lung; Controlled Clinical Trials as Topic; Diarrhea; Drug Interactions; ErbB Receptors; Gefitinib; Half-Life; Lung Neoplasms; Multicenter Studies as Topic; Quinazolines | 2002 |
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mesothelioma; Phosphorylation; Pleural Neoplasms; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2002 |
Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Colorectal Neoplasms; Cross-Sectional Studies; Fatigue; Female; Fever; Fluorouracil; Humans; Inflammation; Interleukin-6; Liver Neoplasms; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Quinazolines; Thiophenes; Thymidylate Synthase; Tumor Necrosis Factor-alpha | 2002 |
Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines.
Topics: Amphiregulin; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Culture Media, Conditioned; Dose-Response Relationship, Drug; EGF Family of Proteins; Gefitinib; Glycoproteins; HeLa Cells; Humans; Intercellular Signaling Peptides and Proteins; Jurkat Cells; Kinetics; Lung Neoplasms; Phosphorylation; Precipitin Tests; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1; Time Factors; Tumor Cells, Cultured; Tyrosine; Tyrphostins | 2002 |
Surprise phase III failure for ZD1839.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Survival Analysis; Treatment Outcome | 2002 |
Cancer drugs. Smart weapons prove tough to design.
Topics: Advisory Committees; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Drug Industry; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasms; Patient Selection; Piperazines; Pyrimidines; Quinazolines; United States; United States Food and Drug Administration | 2002 |
Relationship of EGFR signal-transduction modulation by tyrosine kinase inhibitors to chemosensitivity and programmed cell death in lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Humans; Lung Neoplasms; Phosphorylation; Precipitin Tests; Protein Tyrosine Phosphatases; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Tyrphostins | 2003 |
Despite concerns, FDA panel backs EGFR inhibitor.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States; United States Food and Drug Administration | 2002 |
Demand grows for early access to promising cancer drugs.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Approval; Drug Costs; Drugs, Investigational; Gefitinib; Health Services Accessibility; Humans; Lung Neoplasms; Neoplasms; Patient Advocacy; Quinazolines; United States; United States Food and Drug Administration | 2002 |
What went wrong with Iressa?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy, Combination; Endpoint Determination; Gefitinib; Humans; Lung Neoplasms; Neoadjuvant Therapy; Quinazolines; Treatment Outcome | 2002 |
Severe acute interstitial pneumonia and gefitinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Female; Gefitinib; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2003 |
Expression of uracil DNA glycosylase (UDG) does not affect cellular sensitivity to thymidylate synthase (TS) inhibition.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Survival; Comet Assay; DNA Damage; DNA Glycosylases; DNA Repair; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Lung Neoplasms; N-Glycosyl Hydrolases; Quinazolines; Thiophenes; Thymidylate Synthase; Transfection; Tumor Cells, Cultured; Uracil-DNA Glycosidase | 2003 |
27th ESMO Congress, Nice, 18-22 October 2002. Iressa disappoints in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Congresses as Topic; Deoxycytidine; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Quinazolines; Treatment Failure | 2003 |
Necrolytic migratory erythema (glucagenoma)-like skin lesions induced by EGF-receptor inhibition.
Topics: Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Erythema; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Severe liver dysfunction after raltitrexed administration in an HCV-positive colorectal cancer patient.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Chemical and Drug Induced Liver Injury; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Enzyme Inhibitors; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Viremia | 2003 |
Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy-lung scale.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Health Status Indicators; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Surveys and Questionnaires; Treatment Outcome | 2003 |
A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Quinazolines; Treatment Outcome | 2003 |
Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Salvage Therapy; Taxoids; Treatment Outcome | 2003 |
Commentary on ZD1839 (Iressa) in non small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
[14th EORTC-NCI-AAACR Symposium on New Molecular Targets and Cancer Therapeutics].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Gefitinib; Germany; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Aged; Aged, 80 and over; Biopsy, Needle; Enzyme Inhibitors; Female; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Paronychia; Quinazolines; Risk Assessment; Severity of Illness Index | 2003 |
FDA announces fast track approval of new drug for lung cancer.
Topics: Antineoplastic Agents; Drug Approval; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States; United States Food and Drug Administration | 2003 |
Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate | 2003 |
Biologists take tentative steps towards bespoke cancer drugs.
Topics: Antineoplastic Agents; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Pharmacogenetics; Pneumonia; Polymorphism, Single Nucleotide; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Pulmonary Alveoli; Quinazolines | 2003 |
More haste, less speed.
Topics: Antineoplastic Agents; Australia; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Approval; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Research Design; Treatment Failure; United States; United States Food and Drug Administration | 2003 |
Gene-expression profiles of human tumor xenografts in nude mice treated orally with the EGFR tyrosine kinase inhibitor ZD1839.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA, Complementary; Down-Regulation; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Protein-Tyrosine Kinases; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA; Time Factors; Up-Regulation | 2003 |
Is there a role for the assessment of health-related quality of life in the clinical evaluation of novel cytostatic agents?: Commentary re: P. M. LoRusso, Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Health Status; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2003 |
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Quality of Life; Quinazolines | 2003 |
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; Cetuximab; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Kinase Kinase 1; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinazolines | 2003 |
Clinical efficacy and toxicity of gefitinib in patients with lung cancer.
Topics: Antineoplastic Agents; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Pulmonary Fibrosis; Quinazolines; Radiography | 2003 |
Clinical efficacy and toxiciy of gefitinib in patients with lung cancer.
Topics: Aged; Antineoplastic Agents; Ascites; Carcinoma, Non-Small-Cell Lung; Gefitinib; Hepatitis C, Chronic; Humans; Hypoalbuminemia; Liver Cirrhosis; Lung Diseases, Interstitial; Lung Neoplasms; Male; Quinazolines | 2003 |
Iressa : first angiogenesis inhibitor approved for the treatment of advanced NSCLC.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States | 2003 |
A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ("Iressa").
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Hypoxia; Lung Neoplasms; Middle Aged; Quinazolines; Radiography; Sputum | 2003 |
Gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2003 |
ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib.
Topics: Administration, Oral; Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Epidermal Growth Factor; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Pneumonectomy; Postoperative Care; Quinazolines; Risk Assessment; Sampling Studies; Wound Healing | 2003 |
Acute lung injury as a possible adverse drug reaction related to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Respiratory Distress Syndrome | 2003 |
[Alveolar hemorrhage as a possible adverse drug reaction by gefitinib (ZD1839, Iressa)].
Topics: Adenocarcinoma; Antineoplastic Agents; Gefitinib; Hemorrhage; Humans; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Pulmonary Alveoli; Quinazolines; Respiratory Insufficiency | 2003 |
Fatal pneumopathy and gefitinib.
Topics: Enzyme Inhibitors; Humans; Japan; Lung Neoplasms; Quinazolines | 2003 |
Successful treatment of multifocal bronchioloalveolar cell carcinoma with ZD1839 (Iressa) in two patients.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Administration, Oral; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2003 |
Selection bias, phase II trials, and the FDA accelerated approval process.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Drug Approval; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Quinazolines; Selection Bias; Treatment Outcome; United States; United States Food and Drug Administration | 2003 |
Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gefitinib; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Lung; Lung Neoplasms; Quinazolines; Tomography, X-Ray Computed | 2003 |
[Radiation recall pneumonitis induced by Gefitinib (Iressa): a case report].
Topics: Aged; Antineoplastic Agents; Carcinoma, Large Cell; Combined Modality Therapy; Enzyme Inhibitors; Gefitinib; Humans; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Quinazolines; Radiation Pneumonitis | 2003 |
The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Tumor Cells, Cultured | 2003 |
Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Nail Diseases; Paronychia; Quinazolines; Risk Assessment; Severity of Illness Index | 2003 |
Clinically meaningful response to the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non small cell lung cancer.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines | 2003 |
Pulmonary toxicity due to chemotherapy how is the risk and benefit from ZD1839 treatment against non-small cell lung cancer?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Diseases; Lung Neoplasms; Quinazolines | 2003 |
For investigational targeted drugs, combination trials pose challenges.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Industry; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Lymphoma, B-Cell; Multiple Myeloma; National Institutes of Health (U.S.); Quinazolines; Receptor, ErbB-2; Rituximab; Thalidomide; Trastuzumab; United States | 2003 |
The 'Iressa' Clinical Experience Meeting. June 2003, Madrid, Spain. Proceedings and abstracts.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2003 |
Extensive experience of disease control with gefitinib and the role of prognostic markers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quinazolines; Survival Analysis | 2003 |
Lessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Female; Gefitinib; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines | 2003 |
Highlights from the 10th World Conference on Lung Cancer. Vancouver, British Columbia, Canada, August 10-14, 2003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Taxoids | 2003 |
Antitumor activity and tolerability of gefitinib in patients with non-small-cell lung cancer treated in an expanded access program.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2003 |
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis | 2004 |
Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Retreatment; Taxoids | 2004 |
Pharmacy practice issues with targeted therapy for lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Costs; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Insurance, Health, Reimbursement; Lung Neoplasms; Patient Compliance; Patient Education as Topic; Pharmaceutical Services; Quinazolines; United States | 2003 |
Epidermal growth factor receptor-targeted therapy and symptom improvement in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; United States | 2003 |
[A case of peritonitis carcinomatosa of pulmonary adenocarcinoma in which gefitinib was effective].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Ascitic Fluid; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Peritonitis; Quinazolines | 2004 |
New drugs 04, part 1.
Topics: Adalimumab; Alefacept; alpha-Galactosidase; Anisoles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antioxidants; Antiprotozoal Agents; Antirheumatic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Drug Approval; Drug Therapy; Fabry Disease; Gefitinib; Humans; Iduronidase; Indoles; Isoenzymes; Lentigo; Lung Neoplasms; Migraine Disorders; Mucopolysaccharidosis I; Nitro Compounds; Patient Education as Topic; Propylamines; Psoriasis; Pyrrolidines; Quinazolines; Recombinant Fusion Proteins; Serotonin Receptor Agonists; Thiazoles; Tryptamines | 2004 |
[Transient liver injury caused by gefitinib].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Female; Gefitinib; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2004 |
Response to gefitinib in pericardial effusion due to lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Pericardial Effusion; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Lung cancer: looking ahead in 2004.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.
Topics: Adolescent; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Administration Schedule; Drug Approval; ErbB Receptors; Female; Gefitinib; Humans; Inhibitory Concentration 50; Lung Neoplasms; Male; Middle Aged; Models, Chemical; Quinazolines; Treatment Outcome; United States; United States Food and Drug Administration | 2004 |
Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor.
Topics: Acneiform Eruptions; Adenocarcinoma; Antineoplastic Agents; Drug Eruptions; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2004 |
Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2004 |
[Advanced lung cancer of performance status 3 successfully treated by gefitinib--a case report].
Topics: Administration, Oral; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pain, Intractable; Quality of Life; Quinazolines | 2004 |
Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bronchoalveolar Lavage Fluid; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Female; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Smoking | 2004 |
Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor.
Topics: Acneiform Eruptions; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paronychia; Quinazolines; Retrospective Studies; Signal Transduction; Skin; Urticaria | 2004 |
Predictors of clinical response of non-small cell cancer to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
Gefitinib for advanced or metastatic non-small cell lung cancer.
Topics: Antineoplastic Agents; Australia; Canada; Carcinoma, Non-Small-Cell Lung; Drug Approval; Drug Costs; Epidermal Growth Factor; Humans; Japan; Lung Neoplasms; Neoplasm Staging; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome; United States | 2004 |
[Screening of antiangiogenic compound].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cyclooxygenase 2; Drug Screening Assays, Antitumor; Gefitinib; Humans; Interleukin-1; Isoenzymes; Lung Neoplasms; Membrane Proteins; Mice; Prostaglandin-Endoperoxide Synthases; Quinazolines; Transforming Growth Factor alpha | 2004 |
Targeting targeted therapy.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Genes, erbB-1; Heterozygote; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2004 |
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Heterozygote; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Protein-Tyrosine Kinases; Quinazolines; Sequence Deletion | 2004 |
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Topics: Adenocarcinoma; Amino Acid Motifs; Amino Acid Sequence; Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Controlled Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Japan; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Mutation, Missense; Phosphorylation; Protein Conformation; Protein Structure, Tertiary; Quinazolines; Sequence Deletion; Treatment Outcome; United States | 2004 |
Medicine. Why a new cancer drug works well, in some patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2004 |
Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Confounding Factors, Epidemiologic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
Protein kinase inhibitors: novel tools in cancer therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Transformation, Neoplastic; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Signal Transduction | 2004 |
A deadly disease, a promising drug.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States | 2004 |
Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Enzyme Inhibitors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2004 |
Severe acute interstitial pnuemonia and gefitinib.
Topics: Acute Disease; Adenocarcinoma; Antineoplastic Agents; Fatal Outcome; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Effect of gefitinib (ZD1839) on metastatic brain tumour.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Enzyme Inhibitors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Salvage Therapy; Treatment Outcome | 2004 |
Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Time Factors; Xenograft Model Antitumor Assays | 2004 |
The miracle of Iressa.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2004 |
Selecting the right patient for tumor therapy.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Patient Selection; Quinazolines | 2004 |
Cancer. A bull's eye for targeted lung cancer therapy.
Topics: Adenocarcinoma; Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Controlled Clinical Trials as Topic; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Japan; Ligands; Lung Neoplasms; Mutation; Phosphorylation; Protein Structure, Tertiary; Quinazolines; Sequence Deletion; Smoking; Treatment Outcome; United States | 2004 |
Japanese chest physicians face hopes and enigmas of gefitinib, a molecular targeting drug for lung cancer.
Topics: Antineoplastic Agents; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
From bench to bedside and back again?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Orphan Drug Production; Quinazolines; Research Design | 2004 |
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Membrane; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2004 |
Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy.
Topics: Aged; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasms, Squamous Cell; Nephrotic Syndrome; Quinazolines | 2004 |
Epidermal growth factor receptor mutations: a new insight.
Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Ligands; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Predictive Value of Tests; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2004 |
[Interstitial pneumonia due to gefitinib followed in detail by high-resolution CT in a patient with adenocarcinoma of the lung].
Topics: Adenocarcinoma; Aged; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Tomography, X-Ray Computed | 2004 |
Cancer: understanding the target.
Topics: Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Pharmacogenetics; Quinazolines; Randomized Controlled Trials as Topic | 2004 |
The story of gefitinib, an EGFR kinase that works in lung cancer.
Topics: Antineoplastic Agents; Enzyme Inhibitors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Prognosis; Quinazolines; Salvage Therapy; Sex Factors; Time Factors; Treatment Outcome | 2004 |
Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2004 |
[Efficacy of gefitinib (Iressa) in the treatment of an inoperable bronchioloalveolar cell carcinoma].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
Early-stage lung cancer findings end a debate, put focus on next steps.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Canada; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; Cisplatin; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Patient Selection; Quinazolines; Randomized Controlled Trials as Topic; Selection Bias; Survival Analysis; Treatment Outcome; United States; Vinblastine; Vinorelbine | 2004 |
[Gefitinib for advanced bronchioloalveolar carcinoma].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2004 |
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Catalytic Domain; Cell Line; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Milk Proteins; Mitogen-Activated Protein Kinases; Mutation; Mutation, Missense; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering; Sequence Deletion; Signal Transduction; STAT5 Transcription Factor; Trans-Activators; Transfection; Tyrosine | 2004 |
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mitogen-Activated Protein Kinases; Phosphorylation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
Cell growth after withdrawal of gefitinib ("Iressa", ZD1839) in human lung cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; Coloring Agents; Dose-Response Relationship, Drug; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Quinazolines; Tetrazolium Salts; Thiazoles; Time Factors | 2004 |
Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Predictive Value of Tests; Prognosis; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Treatment Outcome | 2004 |
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Endothelium, Vascular; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Immunohistochemistry; Ki-67 Antigen; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Necrosis; Neoplasm Transplantation; Neovascularization, Pathologic; Organophosphorus Compounds; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Time Factors | 2004 |
2004 highlights from: 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, June 2004.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Congresses as Topic; ErbB Receptors; Erlotinib Hydrochloride; Ethnicity; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Societies, Medical; United States | 2004 |
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
Topics: Adenocarcinoma; Amino Acid Sequence; Base Sequence; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Quinazolines | 2004 |
[Recurrence of non-small cell lung cancer after successful treatment with gefitinib--report of three cases].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2004 |
Pharmacogenomics. Cancer sharpshooters rely on DNA tests for a better aim.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Mutation; Pharmacogenetics; Quinazolines | 2004 |
Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; ErbB Receptors; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Psoriasis; Quinazolines; Recurrence; Severity of Illness Index | 2004 |
Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 8; Caspases; CDC2-CDC28 Kinases; Cell Cycle Proteins; Cell Division; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinases; Enzyme Activation; fas Receptor; G1 Phase; Gefitinib; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2004 |
Research unveils the 'who' and 'why' of gefitinib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Mutation; Piperazines; Pyrimidines; Quinazolines; Trastuzumab | 2004 |
EGFR mutations and sensitivity to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2004 |
EGFR mutations and sensitivity to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Quinazolines | 2004 |
EGFR mutations and sensitivity to gefitinib.
Topics: Antineoplastic Agents; Brain Neoplasms; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2004 |
[Clinical observation of ZD1839 in treating 32 cases of non-small-cell lung cancer].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2004 |
Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2; Time Factors; Treatment Outcome | 2004 |
Gefitinib (Iressa) in metastatic patients with non-small cell lung cancer: preliminary experience in a Brazilian center.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines | 2004 |
Lung cancer: intragenic ERBB2 kinase mutations in tumours.
Topics: Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Models, Molecular; Mutation; Neoplasms; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2 | 2004 |
Gefitinib as a first line of therapy in non-small cell lung cancer with brain metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Sex Factors; Smoking; Survival Analysis; Treatment Outcome | 2004 |
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 3; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2004 |
Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ("Iressa", ZD1839).
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Small Cell; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Immunoprecipitation; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Tumor Cells, Cultured; Tyrosine | 2004 |
Gefitinib: new preparation. Non small-cell lung cancer: stricter assessment needed.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; France; Japan; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; United States | 2004 |
[Two cases of lung cancer in the third decade of life].
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Radiography, Thoracic; Tomography, X-Ray Computed | 2004 |
Approved use of gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; Drug Labeling; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States | 2004 |
Immunity in medicine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Cetuximab; Female; Gefitinib; Humans; Immunotherapy; Lung Neoplasms; Male; Prognosis; Quinazolines; Risk Assessment; Survival Rate; Treatment Outcome | 2004 |
[Tyrosine kinase inhibitor erlotinib (Tarceva) improves survival of patients with multiple previous treatments].
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Multicenter Studies as Topic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Retreatment; Survival Rate | 2004 |
Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Enzyme Inhibitors; Female; Gefitinib; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate | 2005 |
Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Phosphorylation; Quinazolines; Time Factors; Treatment Outcome | 2004 |
ERBB2 kinase mutations in lung-cancer tumours.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2 | 2004 |
Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroendocrine Tumors; Quinazolines; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Failure; Treatment Outcome | 2005 |
Inhibition of mutant EGF receptors by gefitinib: targeting an Achilles' heel of lung cancer.
Topics: ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2004 |
Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer.
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Female; Gefitinib; Humans; Hyperpigmentation; Lung Neoplasms; Middle Aged; Paronychia; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Acute gefitinib-induced pneumonitis.
Topics: Acute Disease; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Pneumonia; Quinazolines; Respiratory Insufficiency | 2004 |
Combining targeted agents in lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus | 2004 |
Practical management of patients with non-small-cell lung cancer treated with gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Interactions; ErbB Receptors; Exanthema; Eye; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Patient Education as Topic; Quinazolines; Radiography | 2005 |
Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Sputum | 2005 |
Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2004 |
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gefitinib; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Tyrosine; Xenograft Model Antitumor Assays | 2004 |
CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Keratin-19; Keratins; Lung Neoplasms; Male; Prognosis; Quinazolines | 2005 |
High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Phosphorylation; Quinazolines; Sequence Homology, Nucleic Acid; Taiwan | 2004 |
ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Endothelial Cells; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Oxygen; Piperidines; Quinazolines; Radiotherapy; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2004 |
[New era in cancer therapy. Gefitinib: small molecule--strong action].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Time Factors | 2004 |
Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2005 |
KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth.
Topics: Angiogenesis Inhibitors; Animals; Cell Proliferation; Colonic Neoplasms; Endothelial Cells; Enzyme Activation; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Phosphorylation; Prostatic Neoplasms; Quinazolines; Rats; Rats, Nude; Transplantation, Heterologous; Tyrosine; Umbilical Veins; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
Emerging role of erlotinib (OSI-774) in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Quinazolines | 2004 |
Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2005 |
[A case of postoperative recurrent lung cancer with chronic renal failure and respiratory failure successfully treated with gefitinib].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Gefitinib; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Postoperative Period; Quality of Life; Quinazolines; Respiratory Insufficiency | 2005 |
Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer?
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor, ErbB-2 | 2005 |
Gefitinib and cisplatin-based chemotherapy in non-small-cell lung cancer: simply a bad combination?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Quinazolines | 2005 |
Keeping pace with innovation.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States; United States Food and Drug Administration | 2005 |
Iressa's fall from grace points to need for better clinical trials.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Rate | 2005 |
Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2005 |
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Decision Making; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2005 |
The effects of S-phase kinase-associated protein 2 (SKP2) on cell cycle status, viability, and chemoresistance in A549 lung adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carrier Proteins; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cisplatin; Cyclin E; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Quinazolines; S-Phase Kinase-Associated Proteins; Tyrphostins | 2004 |
Gefitinib in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2005 |
The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.
Topics: Adult; Aged; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Sequence Homology, Amino Acid; Smoking; Survival Analysis; Treatment Outcome | 2005 |
Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases.
Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Comorbidity; Gefitinib; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Quinazolines; Treatment Outcome | 2005 |
Failing survival advantage in crucial trial, future of Iressa is in jeopardy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Survival Analysis; Treatment Failure; United States; United States Food and Drug Administration | 2005 |
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Models, Structural; Molecular Structure; Neoplasm Recurrence, Local; Point Mutation; Quinazolines; RNA, Neoplasm; Sequence Analysis, DNA; Sequence Analysis, RNA | 2005 |
Chasing mutations in the epidermal growth factor in lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, abl; Humans; Lung Neoplasms; Mutation; Quinazolines | 2005 |
APL during gefitinib treatment for non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Gefitinib; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Quinazolines | 2005 |
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; CHO Cells; Cricetinae; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3 | 2005 |
EGFR mutations in non-small cell lung carcinomas may predict response to gefitinib: extension of an emerging paradigm.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2005 |
[IRESSA in the treatment of advanced non-small-cell lung cancer patients who failed to respond previous chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Remission Induction | 2004 |
Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 3; Quinazolines; Receptors, Estrogen; Xenograft Model Antitumor Assays | 2005 |
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
Gefitinib ('Iressa', ZD1839) is active against brain metastases in a 77 year old patient.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Treatment Outcome | 2005 |
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2005 |
Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).
Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neoplasm Proteins; Phosphorylation; Quinazolines; Tumor Cells, Cultured | 2005 |
Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Radiation Tolerance; Transcriptional Activation | 2005 |
Radiosensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa).
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance | 2005 |
Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.
Topics: Adaptor Proteins, Signal Transducing; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Genes, erbB-1; GRB2 Adaptor Protein; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mutation; Phosphorylation; Quinazolines; Son of Sevenless Protein, Drosophila | 2005 |
A man whose scapula was spared a drug-associated rash.
Topics: Antineoplastic Agents; Drug Eruptions; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Peripheral Nervous System Neoplasms; Phrenic Nerve; Protein Kinase Inhibitors; Quinazolines; Scapula; Sebaceous Glands | 2005 |
Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Mutation; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2005 |
Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2005 |
[Gefitinib therapy in non-small-cell lung cancer].
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Finland; Gefitinib; Humans; Lung Neoplasms; Male; Prognosis; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Predictors of the response to gefitinib in refractory non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Quinazolines; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2005 |
Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Synergism; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lovastatin; Lung Neoplasms; Mevalonic Acid; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2005 |
Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cough; Dyspnea; Fatal Outcome; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Pulmonary Fibrosis; Quinazolines | 2005 |
Gefitinib does not increase survival in lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Gefitinib; Genotype; Humans; Lung Neoplasms; Quinazolines; Treatment Failure; United States; United States Food and Drug Administration | 2005 |
FDA Oncology Committee debates Iressa's status following negative trial results.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Treatment Failure; United States; United States Food and Drug Administration | 2005 |
EGFR pharmacogenomics: the story continues to mutate and evolve.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pharmacogenetics; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic | 2005 |
Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Models, Chemical; Mutation; Neoplasm Transplantation; Neoplasms; Quinazolines; Rats; Rats, Nude; Scintillation Counting; Signal Transduction; Time Factors; Tissue Distribution | 2005 |
Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; DNA-Binding Proteins; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Phosphorylation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Quinazolines; Rad51 Recombinase; Radiation-Sensitizing Agents; Signal Transduction; Xenograft Model Antitumor Assays | 2005 |
EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Carcinoma, Squamous Cell; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Frequency; Genotype; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Mutation, Missense; Polymerase Chain Reaction; Quinazolines | 2005 |
Pulmonary adenocarcinomas with mutant epidermal growth factor receptors.
Topics: Adenocarcinoma; Antineoplastic Agents; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Ligands; Lung Neoplasms; Mutation, Missense; Quinazolines; Sequence Deletion; Stromal Cells; Transforming Growth Factor alpha | 2005 |
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Female; Gefitinib; Humans; Incidence; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Neoplasm Staging; Quinazolines; Survival Rate; Treatment Failure | 2005 |
Third-line chemotherapy for advanced non-small-cell lung cancer--is there enough evidence to support its use?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome | 2005 |
Interstitial pneumonia during gefitinib treatment of non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Glucocorticoids; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Quinazolines; Radiography; Treatment Outcome | 2005 |
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Primers; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Spain; Treatment Outcome | 2005 |
EGFR tyrosine kinase domain mutations in human gliomas.
Topics: Astrocytoma; Brain Neoplasms; Carcinoma; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genetic Testing; Glioblastoma; Glioma; Humans; Lung Neoplasms; Mutation; Oligodendroglioma; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines | 2005 |
[Treatment of non-small cell lung cancer with gefitinib].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Treatment Outcome | 2005 |
Will lung cancer targeting hit its mark?
Topics: Antineoplastic Agents; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers.
Topics: Apoptosis; Cell Cycle Proteins; Cell Growth Processes; Cell Line, Tumor; Down-Regulation; Dual Specificity Phosphatase 1; Enzyme Inhibitors; ErbB Receptors; Humans; Immediate-Early Proteins; Lung Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Phosphoprotein Phosphatases; Phosphorylation; Protein Phosphatase 1; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins; Quinazolines; Receptor, Notch3; Receptors, Cell Surface; Receptors, Notch; Transfection; Tyrphostins | 2005 |
A curious link between epidermal growth factor receptor amplification and survival: effect of "allele dilution" on gefitinib sensitivity?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2005 |
Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).
Topics: Adenocarcinoma; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Profiling; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Molecular Sequence Data; Mutation; p38 Mitogen-Activated Protein Kinases; Phosphoric Monoester Hydrolases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2005 |
Lung cancer - Second Annual Winter Conference.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Paclitaxel; Pyrazines; Quinazolines | 2005 |
Changes in angiogenic growth factor levels after gefitinib treatment in non-small cell lung cancer.
Topics: Adult; Aged; Angiogenesis Inducing Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Fibroblast Growth Factor 2; Gefitinib; Humans; Lung Neoplasms; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Quinazolines; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Vascular Endothelial Growth Factors | 2005 |
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.
Topics: Aminoquinolines; Aniline Compounds; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplasm Recurrence, Local; Organic Chemicals; Phosphorylation; Quinazolines; Quinolines; Receptor, ErbB-2; Sequence Analysis, DNA; Signal Transduction; Tumor Cells, Cultured | 2005 |
HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Topics: Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Drug; ErbB Receptors; G1 Phase; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Transfection; Tumor Suppressor Proteins | 2005 |
EGFR mutation and response of lung cancer to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Point Mutation; Quinazolines | 2005 |
[Non-small-cell lung cancer third-line therapy with gefitinib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2005 |
Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Databases, Factual; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Quinazolines | 2005 |
EGFR mutations in malignant pleural effusion of non-small cell lung cancer: a case report.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Polymerase Chain Reaction; Positron-Emission Tomography; Quinazolines; Treatment Outcome | 2005 |
Gefitinib has the potential of activating cell immunity against malignant cells.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Immunity, Cellular; Lung Neoplasms; Quinazolines | 2005 |
Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; North America; Predictive Value of Tests; Quinazolines; Retrospective Studies; White People | 2005 |
Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Quinazolines; Retrospective Studies; Survival Analysis | 2005 |
Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Quinazolines; Retrospective Studies; Smoking; Survival Analysis | 2005 |
Updated data from the Iressa survival in lung cancer trial.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Multicenter Studies as Topic; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Smoking | 2005 |
Novel effects of gefitinib on mucin production in bronchioloalveolar carcinoma; two case reports.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; Dyspnea; Female; Gefitinib; Humans; Lung Neoplasms; Mucins; Quinazolines | 2005 |
Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunoblotting; Inhibitory Concentration 50; Lung Neoplasms; Models, Statistical; Polymerase Chain Reaction; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Rhodamine 123; Tetrazolium Salts; Thiazoles | 2005 |
The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; China; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Phosphorylation; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2005 |
Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Clinical Trials, Phase I as Topic; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Glioma; Humans; Lung Neoplasms; Mutation; Patient Selection; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2005 |
Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Binding Sites; Carcinoma, Non-Small-Cell Lung; China; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Homology, Amino Acid; Sequence Homology, Nucleic Acid; Treatment Outcome | 2005 |
Clinical responses to gefinitib after failure of treatment with cetuximab in advanced non-small-cell lung cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Failure | 2005 |
Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Immunoblotting; Immunoprecipitation; Ligands; Lung Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Quinazolines; Receptors, Bombesin; Signal Transduction; Transforming Growth Factor alpha | 2005 |
Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catalysis; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering | 2005 |
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Polymerase Chain Reaction; Predictive Value of Tests; Prognosis; Quinazolines; Retrospective Studies | 2005 |
Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Death; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Gene Expression Profiling; Genes, ras; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; PTEN Phosphohydrolase; Quinazolines; Sirolimus; Tumor Cells, Cultured | 2006 |
Drug interaction between gefitinib and warfarin.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Interactions; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Thrombosis; Warfarin | 2005 |
Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2005 |
Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small cell lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Enzyme-Linked Immunosorbent Assay; Gefitinib; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Mucin 5AC; Mucins; Oncogene Protein v-akt; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Cells, Cultured | 2005 |
Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.
Topics: Adult; Aged; Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Quinazolines; Regression Analysis; Sex Factors; Smoking; Survival Analysis; Treatment Outcome | 2005 |
Targeting EGFR in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2005 |
EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2005 |
An overview of Eastern Cooperative Oncology Group stage III non-small cell lung cancer studies.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Quinazolines | 2005 |
Gefitinib is also active for carcinomatous meningitis in NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Male; Meningitis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Spinal Cord Neoplasms; Treatment Outcome | 2005 |
Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cisplatin; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Polymerase Chain Reaction; Quinazolines | 2005 |
Brain metastases in metastatic non-small cell lung cancer responding to single-agent gefitinib: a case report.
Topics: Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2005 |
Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2005 |
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Gene Dosage; Gene Expression Profiling; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma.
Topics: Adenocarcinoma; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Mesothelioma; Point Mutation; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
Gefitinib in patients with non-small cell lung cancer: symptomatic improvement within a few days.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Salvage Therapy; Time Factors; Treatment Outcome | 2005 |
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Dinoprostone; Disease Progression; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Taxoids; Treatment Outcome | 2005 |
Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Gefitinib; Gene Amplification; Genes, erbB-1; Genetic Heterogeneity; Humans; Lung Neoplasms; Mutation; Peptide Nucleic Acids; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity | 2005 |
Gefitinib versus cetuximab in lung cancer: round one.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2 | 2005 |
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cetuximab; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines | 2005 |
Gefitinib in colorectal cancer: if wishes were horses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Drug Approval; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Genotype; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Asian People; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dinucleotide Repeats; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genotype; Humans; Introns; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Protein-Tyrosine Kinases; Quinazolines; RNA, Messenger; Survival Analysis; Treatment Outcome; White People | 2005 |
Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pleural Effusion; Quinazolines; Recurrence; Retreatment; Time Factors | 2005 |
Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2005 |
Interstitial lung disease associated with gefitinib.
Topics: Aged; Antineoplastic Agents; Bronchoalveolar Lavage Fluid; Carcinoma, Non-Small-Cell Lung; Chemokine CXCL10; Chemokines, CC; Chemokines, CXC; Female; Gefitinib; Glucocorticoids; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Quinazolines; Radiography; Respiratory Function Tests; Retrospective Studies | 2006 |
Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Amplification; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Sensitivity and Specificity; Sex Characteristics | 2005 |
Hair growth after gefitinib treatment.
Topics: Alopecia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; ErbB Receptors; Gefitinib; Hair; Humans; Hypertrichosis; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2005 |
Conflicting signals on US accelerated approvals.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Drugs, Investigational; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States; United States Food and Drug Administration | 2005 |
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer.
Topics: Aged; Antineoplastic Agents; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemokine CCL4; Cytokines; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Macrophage Inflammatory Proteins; Male; Middle Aged; Phenotype; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Risk Factors; Skin | 2005 |
Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2005 |
Simultaneous bilateral spontaneous pneumothorax observed during the administration of gefitinib for lung adenocarcinoma with multiple lung metastases.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Agents; Gefitinib; Humans; Lung Neoplasms; Male; Pneumothorax; Quinazolines; Radiography | 2005 |
SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; In Vitro Techniques; Injections, Subcutaneous; Lung Neoplasms; Male; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Piperidines; Proto-Oncogene Mas; Quinazolines; src-Family Kinases; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2005 |
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Glucose Tolerance Test; Gonanes; Humans; Hyperglycemia; Hypoglycemic Agents; Lung Neoplasms; Male; Metformin; Mice; Mice, SCID; Neutrophils; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pioglitazone; Quinazolines; Thiazolidinediones; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorine Radioisotopes; Gefitinib; Humans; Hypoxia; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nitroimidazoles; Oxidation-Reduction; Oxygen; Positron-Emission Tomography; Quinazolines; Tissue Distribution | 2005 |
Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R.
Topics: Adenocarcinoma; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2005 |
Gefitinib treatment for non-small cell lung cancer -- a study including patients with poor performance status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2005 |
Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Treatment Outcome | 2006 |
Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity; Stomach Neoplasms | 2005 |
Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; DNA Methylation; DNA Mutational Analysis; DNA Primers; ErbB Receptors; Exons; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Promoter Regions, Genetic; Protein Structure, Tertiary; Proto-Oncogene Proteins p21(ras); Quinazolines; Smoking; Tumor Suppressor Proteins | 2005 |
Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chlorocebus aethiops; COS Cells; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Immunoprecipitation; Lung Neoplasms; Mutation; Phosphorylation; Quinazolines; Tumor Cells, Cultured; Tyrosine; Ubiquitin | 2006 |
Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Safety; Survival Rate; Treatment Outcome | 2005 |
Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; EGF Family of Proteins; Enzyme-Linked Immunosorbent Assay; Female; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Quinazolines; Transforming Growth Factor alpha | 2005 |
Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mesoderm; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2005 |
Improvements in quality of life and disease-related symptoms in patients with advanced non-small cell lung cancer treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines | 2005 |
Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2005 |
Erlotinib in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Placebos; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate | 2005 |
Erlotinib in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines | 2005 |
Erlotinib in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Interactions; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Quinazolines; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured | 2005 |
Systemic tumor embolism mimicking gefitinib ('IRESSA')-induced interstitial lung disease in a patient with lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Diagnosis, Differential; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Quinazolines | 2005 |
Biomarkers of response to gefitinib in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Quinazolines | 2004 |
First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Base Sequence; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Quinazolines; Sequence Deletion; Treatment Outcome | 2005 |
New approaches in the management of lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins; Quinazolines | 2005 |
Gefitinib for previously untreated patients with non-small cell lung cancer (NSCLC)--a retrospective study of 12 patients treated in one institution.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Diarrhea; Drug Eruptions; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies | 2005 |
Emerging trends in combinations of gefitinib and cytotoxic agents: new opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy; Gefitinib; Humans; Lung Neoplasms; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Quinazolines | 2005 |
HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Amplification; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Quinazolines; Receptor, ErbB-3; Sex Factors; Survival Analysis | 2005 |
Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Bronchoalveolar Lavage Fluid; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2006 |
Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2005 |
Acute myocardial infarction with lung cancer during treatment with gefitinib: the possibility of gefitinib-induced thrombosis.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Myocardial Infarction; Quinazolines; Thrombosis | 2005 |
Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Quinazolines | 2005 |
Severe cutaneous toxicity following treatment with gefitinib (ZD1839).
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Eruptions; ErbB Receptors; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2005 |
EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Gefitinib; Humans; Japan; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2006 |
Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Phosphorylation; Prognosis; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Survival Rate; Tissue Array Analysis | 2005 |
Targeted kinase inhibitors in lung cancer: from EGFR to patients.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
EGFR tyrosine kinase inhibitors in non-small cell lung cancer: report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatients.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quinazolines; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Terminal Care; Treatment Outcome | 2005 |
EGFR mutation in gefitinib-responsive small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Treatment Outcome | 2006 |
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, ras; Humans; Ligands; Lung Neoplasms; Mice; Mice, Knockout; Mutation; Neoplasms, Glandular and Epithelial; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Tumor Cells, Cultured; Tyrosine | 2005 |
BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.
Topics: Animals; Apoptosis; Biological Transport; Carrier Proteins; Cell Proliferation; Choriocarcinoma; Enzyme Inhibitors; Female; Folate Receptors, GPI-Anchored; Folic Acid; Humans; Idoxuridine; Iodine Radioisotopes; Leukemia L1210; Lung Neoplasms; Membrane Transport Proteins; Mice; Mice, Nude; Ovarian Neoplasms; Quinazolines; Receptors, Cell Surface; Reduced Folate Carrier Protein; Thymidylate Synthase; Tissue Distribution; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Erlotinib in patient with non-small cell lung cancer: significant symptomatic improvement within a few days but without change in chest X-ray.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography | 2006 |
Epithelial to Mesenchymal Transition Tumors: Fallacious or Snail's Pace?
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epithelium; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mesoderm; Mice; Protein Kinase Inhibitors; Quinazolines | 2005 |
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelium; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Genes, Neoplasm; Humans; Immunohistochemistry; Lung Neoplasms; Mesoderm; Mutation; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Phenotype; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Vimentin | 2005 |
Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Small Cell; Cell Line, Tumor; Cell Proliferation; Endothelium, Vascular; Humans; Killer Cells, Natural; Lung Neoplasms; Lymphocyte Depletion; Mice; Mice, SCID; Neovascularization, Pathologic; Piperidines; Quinazolines; RNA, Messenger; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Xenograft Model Antitumor Assays | 2005 |
Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 8; Caspases; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; NF-kappa B; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tumor Necrosis Factor-alpha | 2005 |
[A case of lung adenocarcinoma of the lung with disappearance of brain metastasis by re-treatment with gefitinib].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Brain; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Quinazolines; Remission Induction; Retreatment; Tomography, X-Ray Computed | 2005 |
The role of EGFR-TK inhibition in non-small cell lung cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quinazolines; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Terminal Care; Treatment Outcome | 2005 |
PPAR-gamma agonist increase gefitinib's antitumor activity through PTEN expression.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dose-Response Relationship, Drug; Gefitinib; Humans; Lung Neoplasms; PPAR gamma; PTEN Phosphohydrolase; Quinazolines; Rosiglitazone; Statistics, Nonparametric; Thiazolidinediones; Tumor Cells, Cultured | 2006 |
Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2005 |
Complete response to erlotinib treatment in brain metastases from recurrent NSCLC.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome | 2006 |
ZD6474 headed for phase III trials in the fall.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Humans; Lung Neoplasms; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction | 2005 |
Gefitinib-induced lung injury successfully treated with high-dose corticosteroids.
Topics: Acute Disease; Anti-Inflammatory Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Photomicrography; Quinazolines; Tomography, X-Ray Computed | 2006 |
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; Homeodomain Proteins; Humans; Lung Neoplasms; Predictive Value of Tests; Prognosis; Quinazolines; Transcription Factors; Transfection; Zinc Finger E-box-Binding Homeobox 1 | 2006 |
[Current status of the study of the mechanism of epidermal growth factor receptor targeting drug therapy and their related markers].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
[Advances in the molecular target therapy in lung cancer].
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Pyrimidines; Quinazolines | 2005 |
Gefitinib for refractory advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Smoking; Survival Rate | 2006 |
Gefitinib for refractory advanced non-small-cell lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Smoking | 2006 |
An acneiform eruption due to erlotinib: prognostic implications and management.
Topics: Acneiform Eruptions; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Prognosis; Quinazolines | 2006 |
Peroxisome proliferator-activated receptor-gamma inhibits cigarette smoke solution-induced mucin production in human airway epithelial (NCI-H292) cells.
Topics: Carcinoma, Mucoepidermoid; Cell Line, Tumor; Down-Regulation; Enzyme Inhibitors; ErbB Receptors; Humans; Hypoglycemic Agents; Lung Neoplasms; Mucin 5AC; Mucins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; PPAR gamma; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Respiratory Mucosa; Rosiglitazone; Smoking; Thiazolidinediones; Tumor Necrosis Factor-alpha; Tyrosine; Tyrphostins | 2006 |
Assessing EGFR mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Paraffin Embedding; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Survival Analysis | 2006 |
Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2006 |
A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatography, High Pressure Liquid; Deoxyribonuclease I; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Exons; Female; Formaldehyde; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Paraffin Embedding; Predictive Value of Tests; Quinazolines; Sensitivity and Specificity | 2006 |
Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
Topics: Aged; Bronchi; Cell Adhesion; Cell Growth Processes; Cell Transformation, Neoplastic; Dual Specificity Phosphatase 6; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genes, p16; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Oncogenes; Phosphorylation; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; STAT3 Transcription Factor; Telomerase; Transfection; Up-Regulation | 2006 |
Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Diarrhea; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Retrospective Studies | 2006 |
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.
Topics: Adenocarcinoma; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genes, erbB-1; Humans; Incidence; Lung Neoplasms; Male; Molecular Biology; Mutation; Protein Kinase Inhibitors; Quinazolines; ROC Curve; Smoking | 2006 |
Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gene Deletion; Humans; Lung Neoplasms; Point Mutation; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Treatment Outcome | 2006 |
EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Quinazolines | 2006 |
[A new medication for lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Multicenter Studies as Topic; Palliative Care; Quality of Life; Quinazolines; Survival Analysis | 2005 |
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Fluorescence; Topoisomerase I Inhibitors; Topotecan | 2006 |
[Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2005 |
What's the rush? The dissemination and adoption of preliminary research results.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Congresses as Topic; Diffusion of Innovation; Evidence-Based Medicine; Female; Gefitinib; Humans; Information Dissemination; Lung Neoplasms; Multicenter Studies as Topic; Neoplasms; Practice Patterns, Physicians'; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome; United States | 2006 |
Gefitinib-induced interstitial lung disease showing improvement after cessation: disassociation of serum markers.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers; Biopsy; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Mucin-1; Mucins; Pulmonary Surfactant-Associated Protein A; Pulmonary Surfactant-Associated Protein D; Quinazolines; Tomography, X-Ray Computed | 2006 |
Analgesic effect of gefitinib in the treatment of non-small cell lung cancer.
Topics: Aged; Analgesics; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Osteoarthritis; Quinazolines | 2006 |
Long-term survival in three patients with metastatic non-small cell lung cancer treated with gefitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Survival Rate; Time Factors | 2006 |
High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cohort Studies; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Amplification; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Saudi Arabia; Tissue Array Analysis | 2006 |
Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Diagnosis, Differential; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Incidence; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radiography, Thoracic; Retrospective Studies; Tomography, X-Ray Computed | 2006 |
[Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].
Topics: Acneiform Eruptions; Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Disease Susceptibility; Drug Eruptions; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Proteins; Quinazolines; Staphylococcal Skin Infections; Superinfection | 2006 |
EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2006 |
Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Patient Selection; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Receptor, IGF Type 1; Survival Analysis | 2006 |
[Gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Female; Gefitinib; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate | 2006 |
[A case of complete response in a primary lesion treated by gefitinib for two years after surgery of brain metastasis from lung cancer].
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cerebellar Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Remission Induction; Vinblastine; Vinorelbine | 2006 |
Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2006 |
Clustered incidence of acute promyelocytic leukemia during gefitinib treatment for non-small-cell lung cancer: experience at a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; ErbB Receptors; Female; Gefitinib; Humans; Incidence; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2006 |
Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome | 2006 |
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Dosage; Genes, ras; Humans; In Situ Hybridization; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Patient Selection; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Survival Analysis | 2006 |
Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Retrospective Studies; United States | 2006 |
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Line; Cyclin-Dependent Kinase Inhibitor p16; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Knockout; Mutation; Protein Isoforms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Tumor Suppressor Protein p14ARF | 2006 |
Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Inflammatory Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clindamycin; Drug Eruptions; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Sulfacetamide; Triamcinolone | 2006 |
Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Protein Kinase Inhibitors; Quinazolines; Radiography, Thoracic; Tomography, X-Ray Computed; X-Ray Film | 2006 |
Erlotinib: optimizing therapy with predictors of response?
Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; Drug Resistance, Neoplasm; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Forecasting; Gene Amplification; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2006 |
Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Dosage; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Quinazolines; RNA, Messenger; Survival Analysis; Treatment Outcome | 2006 |
Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Mice; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Deletion; Survival Rate; Tumor Cells, Cultured | 2006 |
[From ASCO and WCLC 2005 to the clinical practice: targeted therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Forecasting; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Patient Selection; Placebos; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sex Factors; Smoking; Time Factors; Vascular Endothelial Growth Factor A | 2006 |
Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Japan; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; Risk Factors | 2006 |
Three-year survival in metastatic non-small cell lung cancer treated with gefitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Rate; Time Factors | 2006 |
Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cytotoxins; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Vinblastine; Vinorelbine; Weight Loss; Xenograft Model Antitumor Assays | 2007 |
The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors.
Topics: Algorithms; Anti-Bacterial Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dermatologic Agents; Dermatology; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Eye Diseases; Female; Humans; Interprofessional Relations; Lung Neoplasms; Medical Oncology; Middle Aged; Ophthalmology; Quinazolines; Referral and Consultation; Skin Diseases; Tacrolimus | 2006 |
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Protein Structure, Tertiary; Quinazolines; Quinolines | 2006 |
Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Gene Dosage; Genotype; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Quinazolines | 2006 |
Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Enzyme Activation; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 3; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2006 |
Erlotinib induced skin rash spares skin in previous radiotherapy field.
Topics: Adenocarcinoma; Back; Brain Neoplasms; Chemotherapy, Adjuvant; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Reoperation; Skin; Thoracic Wall | 2006 |
Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Incidence; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Risk Factors; Sex Factors; Smoking; Survival Analysis; Treatment Outcome | 2006 |
Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Liver Neoplasms; Lung Neoplasms; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Matrix Metalloproteinases, Membrane-Associated; Neoplasm Metastasis; Piperidines; Quinazolines; Quinazolinones; Rats; Rats, Inbred F344 | 2006 |
Gefitinib efficacy in relapsed small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome | 2006 |
ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Piperidines; Pleural Effusion, Malignant; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Gefitinib for epidermal growth factor receptor mutant lung cancers: searching for a weapon of mass destruction.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Prospective Studies; Quinazolines | 2006 |
Erlotinib prevents pulmonary metastasis in curatively resected breast carcinoma using a mouse model.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines | 2006 |
Synchronous multiple primary lung cancers with different response to gefitinib.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Male; Neoplasms, Multiple Primary; Quinazolines; Tomography, X-Ray Computed | 2006 |
[Gefitinib treatment for carcinomatous meningitis in non-small cell lung cancer].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cranial Irradiation; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Meningitis; Middle Aged; Neoplasm Proteins; Paclitaxel; Palliative Care; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Vinblastine; Vinorelbine | 2006 |
[Gefitinib-induced perforating dermatosis].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Eruptions; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Skin Ulcer | 2006 |
Smoking history: tumor biology and clinical pharmacokinetic implications in patients with lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2006 |
Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus, Type 2; Erlotinib Hydrochloride; Female; Glyburide; Humans; Lung Neoplasms; Pioglitazone; Quinazolines; Thiazolidinediones | 2006 |
Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor receptor genes.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Resistance, Neoplasm; Gefitinib; Genes, erbB-1; Humans; Laminectomy; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Spinal Neoplasms | 2006 |
Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Female; Gefitinib; Humans; Liver; Lung Neoplasms; Middle Aged; Quinazolines | 2006 |
Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Gemcitabine; Genes, erbB-1; Genes, ras; Humans; Immunohistochemistry; Lung Neoplasms; Mutation; Paclitaxel; Proto-Oncogene Proteins c-akt; Quinazolines; Retrospective Studies | 2006 |
Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Transformed; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Interleukin-3; Lung Neoplasms; Quinazolines; Quinolines; Receptor, ErbB-2 | 2006 |
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Point Mutation; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Rate; Treatment Outcome | 2006 |
Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biopsy; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Mutation; Quinazolines; Recurrence | 2006 |
Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Korea; Lung Neoplasms; Middle Aged; Multivariate Analysis; Odds Ratio; Proportional Hazards Models; Quinazolines; Retrospective Studies; Time Factors; Treatment Outcome | 2006 |
A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer.
Topics: Biopsy; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Models, Biological; Point Mutation; Predictive Value of Tests; Quinazolines; Sensitivity and Specificity; Treatment Failure | 2006 |
Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; CD4 Antigens; Chemokine CCL5; Female; Gefitinib; Humans; Lung Neoplasms; Lymphocyte Activation; Male; Middle Aged; Neoplasm Staging; P-Selectin; Prognosis; Quinazolines; Receptors, Interleukin-2 | 2006 |
Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib.
Topics: Aged; Alopecia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Inflammation; Lung Neoplasms; Quinazolines; Time Factors | 2006 |
Gefitinib: a cause of pyogenic granulomalike lesions of the nail.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Female; Gefitinib; Granuloma, Pyogenic; Humans; Lung Neoplasms; Nail Diseases; Quinazolines | 2006 |
Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib.
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Meningitis; Quinazolines | 2006 |
Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2006 |
Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Quinazolines; Survival Rate | 2006 |
K-ras mutations in lung cancer: the "mysterious mutation".
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2006 |
Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA Primers; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Quinazolines | 2006 |
Pulmonary fibrosis in a patient treated with erlotinib.
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines | 2006 |
Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Cadherins; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; Drug Screening Assays, Antitumor; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Gene Expression Profiling; Humans; Inhibitory Concentration 50; Lung Neoplasms; Multigene Family; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proteome; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome; Tumor Cells, Cultured | 2006 |
L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Gefitinib; Genotype; Humans; Japan; Linear Models; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Statistics, Nonparametric; Survival Rate | 2006 |
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
Topics: Alleles; Animals; Apoptosis; Base Sequence; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mice; Mutation, Missense; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; RNA Interference; Transfection; Xenograft Model Antitumor Assays | 2006 |
Adverse reactions to gefitinib (Iressa): revealing sycosis- and pyoderma gangrenosum-like lesions.
Topics: Antineoplastic Agents; Folliculitis; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Pyoderma Gangrenosum; Quinazolines | 2006 |
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.
Topics: Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Methionine; Mutation; Polymerase Chain Reaction; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Threonine | 2006 |
[Lung cancer with bone metastasis].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids | 2006 |
Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Cycle; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Rabbits; Radiation Tolerance; Sulfonamides | 2006 |
Influence of whole-brain radiotherapy on remission of brain metastases.
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Time Factors; Treatment Outcome | 2006 |
Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; ErbB Receptors; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Mutation; Pleural Effusion, Malignant; Polymerase Chain Reaction; Predictive Value of Tests; Quinazolines; Treatment Outcome | 2006 |
Severe enteropathy associated with raltitrexed and oxaliplatin chemotherapy: report of two patients experiencing this rare, potentially lethal gastrointestinal adverse event.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonoscopy; Colorectal Neoplasms; Diabetes Complications; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Enterocolitis; Fatal Outcome; Female; Gastrointestinal Diseases; Humans; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2006 |
Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colorectal Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Ribosomal Protein S6 Kinases; Signal Transduction; TOR Serine-Threonine Kinases | 2006 |
Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts.
Topics: Animals; Cisplatin; Colonic Neoplasms; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Semaphorin-3A; Signal Transduction; Triazoles; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2006 |
Significance of the papillary subtype in relation to durable response to gefitinib in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2006 |
EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Interleukin-3; Lung Neoplasms; Models, Molecular; Mutation; Phosphorylation; Protein Binding; Quinazolines | 2007 |
Correlation of HER1/EGFR expression and degree of radiosensitizing effect of the HER1/EGFR-tyrosine kinase inhibitor erlotinib.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2005 |
Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Sex Characteristics; Smoking; Survival Analysis | 2006 |
Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Risk Factors | 2006 |
Lymphangitis carcinomatosis as a potential predictor for a response to gefitinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma; Female; Forecasting; Gefitinib; Humans; Lung Neoplasms; Lymphangitis; Male; Quinazolines; Treatment Outcome | 2006 |
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2006 |
Smoking history and prior surgical resection predict sensitivity to gefitinib in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Prognosis; Quinazolines; Retrospective Studies; Smoking; Survival Analysis; Treatment Outcome | 2006 |
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasms, Squamous Cell; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Smoking; Survival Analysis; Survival Rate; Treatment Outcome | 2006 |
Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Belgium; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2007 |
Follicular rash during therapy with erlotinib (Tarceva).
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Facial Dermatoses; Folliculitis; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pruritus; Quinazolines; Treatment Outcome | 2006 |
Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation.
Topics: Apoptosis; Beta Particles; Carcinoma, Non-Small-Cell Lung; DNA Repair; DNA Replication; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gamma Rays; Gefitinib; Genes, erbB-1; Genes, p53; Humans; Lung Neoplasms; Mutation; Neoplasm Proteins; Protein Structure, Tertiary; Quinazolines; Radiation Tolerance; Recombinant Fusion Proteins; Sequence Deletion; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2006 |
A case of acute promyelocytic leukemia during gefitinib treatment.
Topics: Adenocarcinoma; Antineoplastic Agents; Female; Gefitinib; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Quinazolines; Remission Induction; Tretinoin | 2006 |
Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorodeoxyglucose F18; Gefitinib; Glucose; Humans; Lung Neoplasms; Quinazolines; Radionuclide Imaging | 2006 |
Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorodeoxyglucose F18; Gefitinib; Glucose; Humans; Lung Neoplasms; Mice; Mice, SCID; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Sensitivity and Specificity; Treatment Outcome; Tumor Cells, Cultured | 2006 |
Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
Topics: Amino Acid Sequence; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Sequence Data; Point Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Homology, Amino Acid | 2006 |
[Prolonged survival of gefitinib treatment in patients with advanced and previously treated non-small cell lung cancer].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Rate | 2006 |
Gefitinib-induced acute generalized exanthematous pustulosis in two patients with advanced non-small-cell lung cancer.
Topics: Acute Disease; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Skin Diseases, Vesiculobullous | 2006 |
[Two lung adenocarcinoma patients with multiple brain metastasis treated with Gefitinib and surviving more than 2 years].
Topics: Adenocarcinoma, Papillary; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiotherapy Dosage; Survivors | 2006 |
Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L.
Topics: Adenocarcinoma; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Isoleucine; Leucine; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Serine; Valine | 2006 |
Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Membrane; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Mice; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Receptors, Somatomedin; RNA, Messenger; Signal Transduction; Survivin; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2006 |
Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Nucleic Acid Heteroduplexes; Quinazolines; Treatment Outcome | 2006 |
Molecular on/off switch.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Treatment Outcome | 2006 |
Gefitinib is an additional prognostic factor in metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Asian People; Drug Resistance; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Prognosis; Quinazolines; Treatment Outcome | 2006 |
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2007 |
EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Polymerase Chain Reaction; Prognosis; Quinazolines; Sensitivity and Specificity; Treatment Outcome | 2006 |
Can a single pill replace doublet chemotherapy in first-line therapy of advanced non-small cell lung cancer?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2006 |
Erlotinib-induced breast cancer regression.
Topics: Adult; Breast Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines; Radiography; Remission Induction | 2006 |
Effect of gefitinib on brain metastases from non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2006 |
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
Topics: Adenocarcinoma; Amino Acid Sequence; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Humans; In Situ Hybridization; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Discriminant Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Reproducibility of Results; Tumor Cells, Cultured | 2006 |
Should every lung cancer patient be tested for EGFR mutation?
Topics: Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Patient Selection; Pharmacogenetics; Quinazolines | 2006 |
Detection of epidermal growth factor receptor variations by partially denaturing HPLC.
Topics: Antineoplastic Agents; Biopsy; Chromatography, High Pressure Liquid; Codon; ErbB Receptors; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity | 2007 |
Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy.
Topics: Adenoviridae; Adenoviridae Infections; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; eIF-2 Kinase; Enzyme Inhibitors; Epidermal Growth Factor; Gefitinib; Gene Expression Regulation, Neoplastic; Genetic Therapy; Genetic Vectors; Humans; Interleukins; Lung Neoplasms; Mutation; Quinazolines | 2007 |
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus | 2006 |
Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients.
Topics: Adult; Aged; Aurora Kinase B; Aurora Kinases; Benzamides; Carcinoma, Non-Small-Cell Lung; Cyclin-Dependent Kinase Inhibitor p16; Enzyme Inhibitors; Female; Genes, p16; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Male; Microtubule-Associated Proteins; Middle Aged; Neoplasm Proteins; Protein Serine-Threonine Kinases; Quinazolines; Survival Analysis; Survivin; Tumor Cells, Cultured; Up-Regulation | 2006 |
Paired drugs give advanced lung cancer a double punch.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Celecoxib; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Sulfonamides | 2006 |
[Meningeal carcinomatosis in patients with lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cerebrospinal Fluid; Combined Modality Therapy; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Quality of Life; Quinazolines; Retrospective Studies; Survival Rate | 2006 |
Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Mice; Mice, Nude; Mutation; Predictive Value of Tests; Quinazolines; Signal Transduction; Structure-Activity Relationship; Transplantation, Heterologous | 2006 |
Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dose-Response Relationship, Radiation; Endothelial Cells; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Radiation, Ionizing; Receptors, Vascular Endothelial Growth Factor; Time Factors; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2006 |
Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclin D; Cyclin-Dependent Kinases; Cyclins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutant Proteins; Mutation, Missense; Oligonucleotide Array Sequence Analysis; Piperidines; Quinazolines; Signal Transduction; Transcription, Genetic; Transfection | 2006 |
Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; DNA Mutational Analysis; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; In Situ Hybridization, Fluorescence; Ligands; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2006 |
[Gefitinib in the treatment of advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Treatment Outcome | 2006 |
Recurrent responses to non-small cell lung cancer brain metastases with erlotinib.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
[Efficacy of gefitinib on advanced non-small cell lung cancer in expanded access program (EAP)].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Rate; Young Adult | 2006 |
Resistance to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Point Mutation; Quinazolines | 2006 |
Decreased internalisation of erbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Computer Simulation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Models, Biological; Mutation; Quinazolines; Signal Transduction | 2006 |
Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer.
Topics: Animals; Antineoplastic Agents; Chemoprevention; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Gene Expression; Genes, ras; Lung Neoplasms; Mice; Mutation; Phosphorylation; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Quinazolines | 2006 |
The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dinucleotide Repeats; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Polymorphism, Genetic; Promoter Regions, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2007 |
[New medications; erlotinib].
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Division; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2006 |
[Relationship of the curative effects of gefitinib on non-small cell lung carcinoma to gender and to epithelial growth factor receptor status].
Topics: Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Prognosis; Quinazolines; Sex Factors; Treatment Outcome | 2006 |
Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2007 |
Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; MAP Kinase Kinase 4; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Survival Rate; Transplantation, Heterologous; Vinblastine; Vinorelbine | 2007 |
Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
Topics: Animals; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gefitinib; Gemcitabine; Humans; In Vitro Techniques; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Stomach Neoplasms; Tegafur; Trastuzumab; Uracil; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2007 |
Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancer.
Topics: Age Factors; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
[Two cases of meningeal carcinomatosis during gefitinib therapy for non-small cell lung cancer].
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Quinazolines | 2006 |
Response to erlotinib in first-line treatment of non-small-cell lung cancer in a white male smoker with squamous-cell histology.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Smoking | 2006 |
Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Dermatitis, Phototoxic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2007 |
Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Mutation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Transfection | 2007 |
p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cell Nucleus; ErbB Receptors; fas Receptor; Gefitinib; Humans; Lung Neoplasms; Oligonucleotides, Antisense; Quinazolines; Transfection; Tumor Suppressor Protein p53 | 2007 |
Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cetuximab; DNA, Complementary; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Neuregulin-1; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2007 |
[Mutational analysis of EGFR and K-RAS in Chinese patients with non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines | 2007 |
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2007 |
Proteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Algorithms; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; ErbB Receptors; Fatty Acid Binding Protein 3; Fatty Acid-Binding Proteins; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proteomics; Quinazolines | 2007 |
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Endothelium, Vascular; ErbB Receptors; Flow Cytometry; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Inbred CBA; Neovascularization, Pathologic; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2007 |
Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit.
Topics: Animals; Cell Hypoxia; Cell Proliferation; Colorectal Neoplasms; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred CBA; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Survival Rate; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2007 |
[A case of lung adenocarcinoma keeping complete remission by treatment with gefitinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Administration Schedule; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Radiosurgery; Remission Induction; Smoking | 2007 |
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Dosage; Genes, erbB-2; Genes, ras; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Mutation; Quinazolines; Treatment Outcome | 2007 |
Clairvoyance or reliable prediction of the future?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Patient Selection; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome | 2007 |
Lung cancer: not just for smokers. People who never smoked may have a different form of the disease that responds better to a new generation of targeted medications.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Pyrimidines; Quinazolines; Tobacco Smoke Pollution | 2007 |
Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.
Topics: Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Molecular Sequence Data; Mutation; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Tumor Cells, Cultured | 2007 |
Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.
Topics: Animals; Antineoplastic Agents; Baculoviridae; Catalysis; Cells, Cultured; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutant Proteins; Phosphotransferases; Quinazolines; Spodoptera; Substrate Specificity | 2007 |
[Lung cancer: targeted therapy].
Topics: Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Lung Neoplasms; Models, Biological; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.
Topics: Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Crystallography, X-Ray; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lapatinib; Lung Neoplasms; Models, Molecular; Mutation; Protein Conformation; Protein Structure, Tertiary; Purines; Quinazolines; Staurosporine | 2007 |
Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.
Topics: Antibodies; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; ErbB Receptors; Gastrin-Releasing Peptide; Gastrointestinal Agents; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Bombesin; Signal Transduction; src-Family Kinases; Transfection | 2007 |
[A case of pulmonary hypertrophic osteoarthropathy associated with primary lung cancer in a young adult successfully treated with gefitinib].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Bone and Bones; Female; Gefitinib; Genes, erbB-1; Humans; Lung Diseases; Lung Neoplasms; Mutation; Osteoarthropathy, Secondary Hypertrophic; Quinazolines; Radionuclide Imaging; Tomography, X-Ray Computed | 2007 |
Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Piperidines; Pulmonary Embolism; Quinazolines; Skin Neoplasms; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2007 |
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.
Topics: Administration, Oral; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Drug Administration Schedule; Female; Follow-Up Studies; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Quinazolines; Retrospective Studies; Treatment Outcome | 2007 |
Significant drug interaction: phenytoin toxicity due to erlotinib.
Topics: Anticonvulsants; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Phenytoin; Protein Kinase Inhibitors; Quinazolines; Seizures | 2007 |
Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Smoking | 2007 |
Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mutation; Quinazolines; Retrospective Studies | 2007 |
An unusual terminal hair growth on the nose tip associated with gefitinib therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Hypertrichosis; Lung Neoplasms; Nose; Quinazolines | 2007 |
Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gefitinib; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Piperazines; Pyrimidines; Quinazolines | 2007 |
Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens.
Topics: Adult; Aged; Antineoplastic Agents; Base Sequence; Biopsy; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Quinazolines; Receptor, ErbB-2 | 2007 |
The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor, ErbB-2; Sensitivity and Specificity; Transfection; Tumor Cells, Cultured | 2007 |
Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA, Neoplasm; ErbB Receptors; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Knowledge of efficacy of treatments in lung cancer is not enough, their clinical effectiveness should also be known.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Meta-Analysis as Topic; Quinazolines; Research Design | 2006 |
Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoplasm Staging; Probability; Proportional Hazards Models; Quinazolines; Retrospective Studies; Risk Assessment; Survival Analysis; Taiwan; Treatment Outcome | 2006 |
Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Salvage Therapy; Statistics, Nonparametric; Survival Analysis; Taiwan; Taxoids; Treatment Outcome | 2006 |
PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Female; Gefitinib; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins; Survival Rate | 2006 |
Mutation and polymorphism in the EGFR-TK domain associated with lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Smoking | 2006 |
Efficacy of gefitinib in a patient with lung cancer associated with idiopathic pulmonary fibrosis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines | 2006 |
Clinico-pathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2006 |
Increasing osteoblastic lesions as a manifestation of a major response to gefitinib.
Topics: Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2006 |
Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Eyelashes; Female; Follow-Up Studies; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Neoplasm Staging; Quinazolines; Risk Assessment; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2006 |
Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Middle Aged; Palliative Care; Protein Kinase Inhibitors; Quinazolines | 2007 |
Hypoxia increases the motility of lung adenocarcinoma cell line A549 via activation of the epidermal growth factor receptor pathway.
Topics: Adenocarcinoma; Cell Adhesion; Cell Hypoxia; Cell Line, Tumor; Cell Movement; ErbB Receptors; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Quinazolines; Signal Transduction; Tyrphostins | 2007 |
Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dinucleotide Repeats; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Introns; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Genetic; Quinazolines | 2007 |
[Outpatient chemotherapy for lung cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2007 |
Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib.
Topics: Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome | 2007 |
Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; CA-19-9 Antigen; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Quinazolines; Survival Analysis; Treatment Outcome | 2007 |
The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Postoperative Care; Quinazolines; Treatment Failure | 2008 |
An inflammatory response with worsening of pleural effusion on treatment with erlotinib in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Pneumonia; Protein Kinase Inhibitors; Quinazolines; Radiography; Treatment Outcome | 2007 |
[Successful individualized and targeted therapy of an NSCLC patient with Gefitinib based on a predictive assessment of the EGF-receptor mutation status].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Sequence Deletion | 2007 |
Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines.
Topics: Active Transport, Cell Nucleus; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Nucleus; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Retinoblastoma Protein; RNA, Small Interfering; S Phase; Up-Regulation | 2007 |
Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors | 2007 |
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gefitinib; Gene Amplification; Humans; Indoles; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-3; Receptors, Growth Factor; Signal Transduction; Sulfones | 2007 |
Erlotinib-associated acute pneumonitis: report of two cases.
Topics: Acute Disease; Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Glucocorticoids; Humans; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Pneumonia; Protein Kinase Inhibitors; Quinazolines; Shock, Septic | 2007 |
Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Somatomedins; Survivin; Up-Regulation | 2007 |
The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib.
Topics: Aged; Aneuploidy; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chromosomes, Human, Pair 7; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Logistic Models; Lung Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2007 |
Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2007 |
Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.
Topics: Alleles; Amino Acid Substitution; Animals; Cell Survival; Cells, Cultured; DNA Primers; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Peptide Fragments; Phosphorylation; Point Mutation; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Quinazolines; Quinolines; Retroviridae; Sequence Deletion | 2007 |
[Differences in the therapeutic strategies for lung cancer between Europe/United States and Japan].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Europe; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tegafur; United States; Uracil | 2007 |
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2007 |
Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Rectal Neoplasms; Rosacea | 2007 |
Temporal dependence of the effect of radiation on erlotinib-induced skin rash.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
EGFR expression and mutational analysis as a predictive test.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Predictive Value of Tests; Quinazolines | 2007 |
Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice.
Topics: Amphiregulin; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; EGF Family of Proteins; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Hypercalcemia; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Parathyroid Hormone-Related Protein; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA, Messenger; Signal Transduction; Xenograft Model Antitumor Assays | 2007 |
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Circadian Rhythm; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2007 |
Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gefitinib; Head and Neck Neoplasms; Lung Neoplasms; Mesoderm; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Quinazolines | 2007 |
Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Glutamates; Guanine; Humans; Lung Neoplasms; Models, Biological; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2007 |
The epidermal growth factor receptor D761Y mutation and effect of tyrosine kinase inhibitor.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm, Residual; Protein Kinase Inhibitors; Quinazolines | 2007 |
Serum proteomic classifier for predicting response to epidermal growth factor receptor inhibitor therapy: have we built a better mousetrap?
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Proteomics; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2007 |
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Proteomics; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate; Treatment Outcome | 2007 |
Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Costs and Cost Analysis; Drug Costs; Female; Gefitinib; Humans; Lung Neoplasms; Male; Markov Chains; Middle Aged; Quinazolines; Survival Analysis | 2007 |
Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adenomatosis, Pulmonary; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Genes, erbB-1; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Mutation; Neoplasms, Multiple Primary; Quinazolines; Retrospective Studies | 2007 |
Massive thrombosis of brachiocephalic veins and superior vena cava syndrome in a patient with non-small cell lung cancer treated with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Antineoplastic Agents; Brachiocephalic Veins; Carcinoma, Non-Small-Cell Lung; Cyanosis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Superior Vena Cava Syndrome; Syncope; Tomography, X-Ray Computed; Venous Thrombosis | 2007 |
[Medical treatment for stage III non-small-cell lung cancer (NSCLC)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Gefitinib; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Mitomycin; Neoplasm Staging; Paclitaxel; Pneumonectomy; Quinazolines; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Rate | 2007 |
To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Adjuvant chemotherapy of stage I non-small cell lung cancer in North America.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Quinazolines | 2007 |
Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Exons; Female; Follow-Up Studies; Gefitinib; Genes, erbB-1; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2007 |
Endothelial growth factor receptor inhibition after radiotherapy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radiation Injuries; Receptors, Vascular Endothelial Growth Factor; Skin | 2007 |
A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protein Array Analysis; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; RNA, Small Interfering | 2007 |
Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer.
Topics: Adult; Amino Acid Sequence; Base Sequence; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Tomography, X-Ray Computed | 2007 |
Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a "never-smoked" female patient with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Autopsy; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Fatal Outcome; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Neoplasm Proteins; Quinazolines; Radiography, Thoracic; Smoking; Tomography, X-Ray Computed | 2007 |
Fulminant hepatic failure secondary to erlotinib.
Topics: Administration, Oral; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Liver Failure, Acute; Liver Neoplasms; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.
Topics: Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cohort Studies; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Dosage; Genes, erbB-2; Humans; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Polymorphism, Single Nucleotide; Protein Structure, Tertiary; Quinazolines; Retrospective Studies; Sequence Analysis, DNA | 2007 |
Assessment of 11C-labeled-4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression.
Topics: Animals; Biomarkers, Tumor; Carbon Radioisotopes; Cell Line, Tumor; ErbB Receptors; Female; Humans; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Organ Specificity; Positron-Emission Tomography; Quinazolines | 2007 |
Personalized medicine and proteomics: lessons from non-small cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Neoplasm Proteins; Proteomics; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2007 |
[Efficacy and safety of gefitinib monotherapy for Chinese elderly patients with advanced non-small cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Survival Analysis; Treatment Outcome | 2007 |
Gefitinib administration in a patient with lung cancer undergoing hemodialysis.
Topics: Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Quinazolines; Renal Dialysis | 2007 |
Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer.
Topics: Aged; Carcinoma, Small Cell; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines; Remission Induction | 2007 |
EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Humans; Immunoprecipitation; Lung Neoplasms; Phosphorylation; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; Quinazolines; Sequence Deletion; Tyrosine | 2008 |
Potential interaction of chemotherapy and gefitinib in the induction of hematologic neoplasia.
Topics: Adenocarcinoma; Aged; Anemia, Refractory; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Interactions; ErbB Receptors; Gefitinib; Gemcitabine; Hematopoiesis; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Neoplasm Proteins; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines | 2007 |
Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature.
Topics: Acneiform Eruptions; Adenocarcinoma, Bronchiolo-Alveolar; Aged, 80 and over; Antineoplastic Agents; Blepharitis; Carcinoma, Small Cell; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Gefitinib; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Quinazolines; Retrospective Studies | 2007 |
[Erlotinib in second/third line treatment for non-small cell lung cancer (NSCLC)].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Optimizing targeted therapy in patients with lung cancer with a performance status of 2.
Topics: Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cause of Death; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; Quinazolines; Tomography, X-Ray Computed | 2007 |
EGFR exon 20 insertion mutation in Japanese lung cancer.
Topics: Aged; Asian People; Base Sequence; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Neoplasm Recurrence, Local; Quinazolines; Tomography Scanners, X-Ray Computed | 2007 |
Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts.
Topics: Animals; Antibodies, Neoplasm; Antibodies, Phospho-Specific; Antineoplastic Agents; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Phosphotyrosine; Quinazolines; Reproducibility of Results; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2007 |
Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3 | 2007 |
GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; G(M3) Ganglioside; Gefitinib; Humans; Immunoblotting; Immunoprecipitation; Lung Neoplasms; Mice; Middle Aged; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Sialyltransferases; Tumor Cells, Cultured | 2007 |
Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Germ-Line Mutation; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Quinazolines; Survival Rate | 2008 |
Epidermal growth factor receptor inhibitor-related folliculitis.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Face; Folliculitis; Humans; Lung Neoplasms; Male; Neck; Protein Kinase Inhibitors; Quinazolines | 2007 |
[EGFR gene mutation status among lung cancer patients in China].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Gene Frequency; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Sex Factors; Smoking; Treatment Outcome | 2007 |
[EGFR mutation predicts response and prognosis in iressa-treated advanced-stage non-small cell lung cancer].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Point Mutation; Prognosis; Quinazolines; Sequence Deletion | 2007 |
Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Drug Interactions; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protease Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Tumor Cells, Cultured | 2007 |
Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2007 |
Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mucin-1; Mutation; Prognosis; Quinazolines; Retrospective Studies | 2008 |
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Tomography, X-Ray Computed | 2007 |
Exacerbated radiodermatitis and bilateral subdural hemorrhage after whole brain irradiation combined with epidermal growth factor receptor tyrosine kinase inhibitors for brain metastases in lung cancer.
Topics: Brain Neoplasms; Erlotinib Hydrochloride; Fatal Outcome; Hematoma, Subdural; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis | 2008 |
Erlotinib effective against refractory bronchorrhea from advanced non-small cell lung cancer.
Topics: Biopsy; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Hemoptysis; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography, Thoracic | 2007 |
Exfoliative eruption secondary to gefitinib (ZD1839).
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2007 |
Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity | 2007 |
Pulmonary toxicity associated with erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2007 |
Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Arginine; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Leucine; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2007 |
Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain.
Topics: Bacterial Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Luminescent Proteins; Lung Neoplasms; Microscopy, Fluorescence; Mutagenesis, Site-Directed; Point Mutation; Polymorphism, Genetic; Quinazolines; Sequence Deletion | 2007 |
Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; DNA Repair; Epidermal Growth Factor; ErbB Receptors; Feasibility Studies; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Pleural Effusion; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2007 |
EGFR inhibitors in the treatment of lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2007 |
Treating non-small-cell lung cancer first line with erlotinib monotherapy in elderly patients: discussion of a case series.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2007 |
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Endpoint Determination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Sample Size; Sorafenib; Treatment Outcome | 2007 |
CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2007 |
Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Immunoprecipitation; Insulin Receptor Substrate Proteins; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Quinazolines; Receptor Cross-Talk; Receptors, Somatomedin; Signal Transduction | 2008 |
PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Cell Line, Tumor; DNA Methylation; ErbB Receptors; Gefitinib; Humans; Hydroxamic Acids; Lung Neoplasms; Polymerase Chain Reaction; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Sequence Analysis, DNA | 2007 |
Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed | 2008 |
Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Phosphorylation; Purines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor alpha; Xenograft Model Antitumor Assays | 2007 |
Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
[Financial aspects of targeted therapy of lung cancer as compared to conventional chemotherapy].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hungary; Immunohistochemistry; Lung Neoplasms; Mutation; Patient Selection; Protein Kinase Inhibitors; Quinazolines; ras Proteins | 2007 |
Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects.
Topics: Adenocarcinoma; Back; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Eruptions; Epidermal Growth Factor; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Skin | 2007 |
Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.
Topics: Adenocarcinoma; Animals; Apoptosis; bcl-Associated Death Protein; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Humans; Lung Neoplasms; Mice; Mutation; Quinazolines; Sensitivity and Specificity | 2007 |
Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cetuximab; Dose-Response Relationship, Drug; Down-Regulation; ErbB Receptors; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kinetics; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2007 |
Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Amplification; Gene Dosage; Genes, erbB-1; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Smoking | 2008 |
[An octogenarian case of postoperative recurrent lung cancer responding to treatments with radiation plus gefitinib].
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Quinazolines | 2007 |
Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2007 |
Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Division; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Prostaglandins E; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured | 2007 |
Response of intracranial metastases to erlotinib therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2007 |
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines | 2007 |
Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
Topics: Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Biphenyl Compounds; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Mutation; Nitrophenols; Piperazines; Proto-Oncogene Proteins; Quinazolines; Sulfonamides | 2007 |
Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
Topics: Cell Line, Tumor; Cyclin-Dependent Kinase 4; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2007 |
Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; MAP Kinase Signaling System; Mouth Mucosa; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; Signal Transduction; Time Factors | 2007 |
Gemcitabine resistance in a highly metastatic subpopulation of a pulmonary adenocarcinoma cell line resistant to gefitinib.
Topics: Adenocarcinoma; Antineoplastic Agents; bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines; RNA, Small Interfering; Transfection | 2007 |
'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Frequency; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2007 |
KL-6 and poor prognosis in NSCLC patients treated with gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Mucin-1; Quinazolines | 2008 |
Acneiform reaction to erlotinib.
Topics: Acneiform Eruptions; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2007 |
[A case of postoperative recurrent lung cancer with long survival due to gefitinib efficacy].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoembryonic Antigen; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Quinazolines; Survivors | 2007 |
Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice.
Topics: Adenoma; Animals; Antineoplastic Agents; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Injections, Intraperitoneal; Lung Neoplasms; Male; Mice; Mice, Inbred Strains; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Sex Factors | 2008 |
In Australia, patients and government at odds over mesothelioma treatment costs.
Topics: Abdominal Neoplasms; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asbestos; Australia; Canada; Carcinogens; Cisplatin; Cost-Benefit Analysis; Environmental Exposure; Glutamates; Government; Guanine; Health Care Costs; Humans; Incidence; Lobbying; Lung Neoplasms; Mesothelioma; Patient Advocacy; Pemetrexed; Quinazolines; Thiophenes; Thoracic Neoplasms; United Kingdom | 2007 |
Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cesarean Section; Disease Progression; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Infant, Newborn; Lung Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Quinazolines; Withholding Treatment | 2008 |
[Gefitinib in the treatment of male patients with advanced non-small-cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; ErbB Receptors; Exanthema; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Remission Induction; Survival Rate | 2007 |
[Cytotoxic effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with oxaliplatin on lung cancer cell line A549].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Quinazolines; Tumor Burden | 2007 |
[In these days molecule target drug in advanced non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2007 |
Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Quinazolines; Time Factors | 2008 |
Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.
Topics: Antineoplastic Agents; Biomedical Research; Carcinoma, Non-Small-Cell Lung; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2008 |
Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; BH3 Interacting Domain Death Agonist Protein; Carcinoma, Non-Small-Cell Lung; Caspase 9; Cell Line, Tumor; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Humans; Lung Neoplasms; Membrane Proteins; Mitochondria; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; RNA, Small Interfering; Signal Transduction | 2007 |
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Cloning, Molecular; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Oncogene Proteins v-erbB; Quinazolines; Quinazolinones | 2007 |
Erlotinib-associated alopecia in a lung cancer patient.
Topics: Aged; Alopecia; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk Assessment | 2007 |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Chromosomes, Human, Pair 7; Cohort Studies; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Quinazolines | 2007 |
[TRUST study: general practice relevant data on erlotinib in NSCLC].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2007 |
Sparing of previously irradiated skin from erlotinib-induced acneiform rash.
Topics: Acne Vulgaris; Adult; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Skin | 2008 |
Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bisbenzimidazole; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Sulfonamides | 2008 |
Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Postoperative Period; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2007 |
Signaling networks assembled by oncogenic EGFR and c-Met.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Models, Biological; Neoplasm Metastasis; Phosphotyrosine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction | 2008 |
[A case of lung cancer with alkaline phosphatase flare phenomenon during gefitinib therapy].
Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Antineoplastic Agents; Bone Neoplasms; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2007 |
[Molecular targeted therapy and tailor-made therapy for lung cancer].
Topics: Antineoplastic Agents; Drug Delivery Systems; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies | 2008 |
Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; Lung Neoplasms; Mutation; Quinazolines; Taxoids | 2007 |
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catalysis; Cell Cycle; Cell Death; Cell Extracts; Cell Line, Tumor; Chromones; Drug Screening Assays, Antitumor; Drug Synergism; E2F1 Transcription Factor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Folic Acid Antagonists; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Lung Neoplasms; Morpholines; Pemetrexed; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Messenger; Tetrahydrofolate Dehydrogenase; Thymidylate Synthase | 2008 |
Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment.
Topics: Adult; Antineoplastic Agents; Carcinoma, Mucoepidermoid; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Predictors of survival in patients with bone metastasis of lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sex Factors; Time Factors; Treatment Outcome | 2008 |
Short-term gefitinib treatment brought about a long-term regression of bronchioloalveolar carcinoma without EGFR gene alterations: a case report.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Remission Induction | 2007 |
Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Lapatinib; Lung Neoplasms; Models, Molecular; Mutant Proteins; Phosphorylation; Polymorphism, Single Nucleotide; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship; Tumor Cells, Cultured | 2008 |
E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib.
Topics: Cadherins; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Treatment Outcome | 2008 |
[Analysis of therapeutic efficacy in 49 patients with advanced non-small cell cancer treated with gefitinib].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Exanthema; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate; Vomiting | 2007 |
Late fatal recurrence in gefitinib-treated NSCLC patients.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Tomography, X-Ray Computed | 2007 |
Molecule of the month. Overcoming resistance.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Design; Drug Resistance; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Salvage Therapy | 2008 |
Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutations.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Sequence Deletion | 2008 |
Case report: dramatic recovery of lung adenocarcinoma-associated dermatomyositis with targeted lung cancer therapy alone.
Topics: Adenocarcinoma; Antineoplastic Agents; Dermatomyositis; Female; Gefitinib; Glucocorticoids; Humans; Lung Neoplasms; Middle Aged; Paraneoplastic Syndromes; Quinazolines; Treatment Outcome | 2008 |
Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Genotype; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Quinazolines; Treatment Outcome | 2008 |
[Establishment of a model to assess the clinical efficacy of Gefitinib in treatment of non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Retrospective Studies; Treatment Outcome | 2007 |
Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression; Genes, erbB-1; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphorylation; Polymerase Chain Reaction; Quinazolines | 2008 |
Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Green Fluorescent Proteins; Humans; Interleukins; Lung Neoplasms; MAP Kinase Signaling System; Mutant Proteins; Organ Specificity; p38 Mitogen-Activated Protein Kinases; Quinazolines; Recombinant Fusion Proteins; Tumor Stem Cell Assay | 2008 |
Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation.
Topics: Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Sequence Data; Oligonucleotides; Peptide Nucleic Acids; Point Mutation; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity | 2008 |
Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Prognosis; Quinazolines; Sex Factors; Smoking; Treatment Outcome | 2008 |
Validation of treatment induced specific adverse effect as a predictor of treatment benefit: a case study of NCIC CTG BR21.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Time Factors | 2008 |
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzylidene Compounds; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; DNA Damage; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Hydantoins; Lung Neoplasms; Models, Biological; Phosphorylation; Quinazolines; Tumor Suppressor Protein p53 | 2008 |
Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; Comet Assay; DNA Repair; Electrophoresis, Gel, Pulsed-Field; Fluorescent Antibody Technique; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Quinazolines; Radiation Tolerance; Radiotherapy | 2008 |
Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity.
Topics: Bacteremia; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Skin; Staphylococcal Infections | 2008 |
Severe purpuric xerotic dermatitis associated with gefitinib therapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erythema; Female; Gefitinib; Humans; Leg; Lung Neoplasms; Male; Purpura; Quinazolines | 2008 |
Tumor resensitization to erlotinib following brief substitution of cetuximab.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Neoplasms; Cetuximab; Deoxycytidine; Drug Eruptions; Drug Interactions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Differential sensitivity of A549 non-small lung carcinoma cell responses to epidermal growth factor receptor pathway inhibitors.
Topics: Antibodies, Blocking; Antineoplastic Agents; Biological Assay; Carcinoma, Non-Small-Cell Lung; Cell Movement; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Tyrphostins | 2008 |
Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromones; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Farnesyltranstransferase; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Morpholines; Phosphatidylinositols; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins; Sirolimus | 2008 |
Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Genes, erbB-1; Genes, ras; Humans; In Situ Hybridization; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2008 |
EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Gefitinib; Gene Expression; Genes, erbB-1; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; Survival Analysis | 2008 |
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplasms, Squamous Cell; Ovarian Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2008 |
Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC).
Topics: Adult; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Vascular Endothelial Growth Factor A | 2008 |
Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines | 2008 |
Re: Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small cell lung cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Endpoint Determination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Research Design; Sorafenib; Treatment Outcome | 2008 |
siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma; DNA Mutational Analysis; DNA, Neoplasm; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Silencing; Gene Targeting; Genes, ras; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering | 2008 |
Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Female; Gefitinib; Humans; Incidence; Japan; Kaplan-Meier Estimate; Logistic Models; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Risk Factors | 2008 |
Images in clinical medicine. Erlotinib-induced hair alterations.
Topics: Erlotinib Hydrochloride; Hair Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2008 |
Recurrent gefitinib-induced interstitial lung disease.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines; Recurrence; Tomography, X-Ray Computed | 2008 |
Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Probes; Down-Regulation; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Thymidylate Synthase | 2008 |
Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cetuximab; Chlorocebus aethiops; COS Cells; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Lapatinib; Lung Neoplasms; Mutation; Quinazolines | 2008 |
Treatment of breast cancer with trastuzumab during pregnancy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature; Lapatinib; Lung Neoplasms; Mastectomy, Modified Radical; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Quinazolines; Trastuzumab | 2008 |
The role of repair protein Rad51 in synergistic cytotoxicity and mutagenicity induced by epidermal growth factor receptor inhibitor (Gefitinib, IressaR) and benzo[a]pyrene in human lung cancer.
Topics: Antineoplastic Agents; Benzo(a)pyrene; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Kinase 1; Mutagens; Proteasome Endopeptidase Complex; Quinazolines; Rad51 Recombinase; RNA Interference | 2008 |
Does gefitinib shorten lung cancer survival? Chaos redux.
Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Rate; Time Factors | 2008 |
Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2008 |
Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.
Topics: Adenocarcinoma; Aged; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Tomography Scanners, X-Ray Computed; Treatment Failure | 2008 |
18F-fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Peritoneal carcinomatosis in lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Quinazolines; Retrospective Studies; Taiwan | 2008 |
Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Exons; Female; Gefitinib; Genes, erbB-1; Humans; Immunoblotting; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Signal Transduction; Transfection | 2008 |
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Survival; Disease Models, Animal; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mice, Transgenic; NIH 3T3 Cells; Phosphorylation; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Src inhibitors in early breast cancer: a methodology, feasibility and variability study.
Topics: Animals; Benzodioxoles; Breast Neoplasms; CSK Tyrosine-Protein Kinase; Feasibility Studies; Female; Focal Adhesion Kinase 1; Humans; Immunoenzyme Techniques; Lung Neoplasms; Paxillin; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Rats; Rats, Nude; src-Family Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
[A case of lung adenocarcinoma effectively treated with sivelestat and corcicosteroid for drug-induced lung disease due to gefitinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Gefitinib; Glycine; Humans; Lung Diseases; Lung Neoplasms; Male; Prednisolone; Quinazolines; Serine Proteinase Inhibitors; Sulfonamides | 2008 |
High-throughput lung cancer cell line screening for genotype-correlated sensitivity to an EGFR kinase inhibitor.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2008 |
Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors.
Topics: Actins; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Endoplasmic Reticulum; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazoles; Quinazolines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides | 2008 |
The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cells, Cultured; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Mice; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Quinolines | 2008 |
EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genetic Markers; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2008 |
[Efficacy of erlotinib on advanced non-small cell lung cancer].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2008 |
Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene.
Topics: Adenocarcinoma; Antineoplastic Agents; Combined Modality Therapy; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Meningitis; Middle Aged; Mutation; Quinazolines; Radiotherapy | 2008 |
Acute and fatal diarrhoea after erlotinib plus abdominal palliative hypofractionated radiotherapy in a metastatic non-small cell lung cancer patient: a case report.
Topics: Acute Disease; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Pain Management; Palliative Care; Quinazolines; Radiotherapy; Shock; Spinal Cord Compression | 2008 |
Gefitinib-associated Propionibacterium acnes pleural empyema.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Empyema, Pleural; Female; Gefitinib; Gram-Positive Bacterial Infections; Humans; Lung Neoplasms; Middle Aged; Pleurodesis; Propionibacterium acnes; Quinazolines | 2008 |
[Acneiforme rash in woman with pulmonary adenocarcinoma].
Topics: Acneiform Eruptions; Adenocarcinoma; Aged; Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Topics: Aged; Biopsy, Needle; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Probability; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis; Treatment Outcome | 2008 |
The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis.
Topics: Animals; Anticarcinogenic Agents; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Lung; Lung Neoplasms; Mice; Nicotinic Acids; Oleanolic Acid; Protein Kinase Inhibitors; Quinazolines; Tetrahydronaphthalenes | 2008 |
Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Salvage Therapy; Smoking; Survival Analysis | 2008 |
Bilateral eardrum perforation after long-term treatment with erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tympanic Membrane Perforation | 2008 |
Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line.
Topics: Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Endocytosis; Endosomes; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Lysosomes; Microscopy, Fluorescence; Phosphorylation; Quinazolines; Signal Transduction; Sorting Nexins; Vesicular Transport Proteins | 2008 |
Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo.
Topics: Adenocarcinoma; Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Quinazolines; Xenograft Model Antitumor Assays | 2009 |
Iv administration of a water-insoluble antimitotic compound entrapped in liposomes. Preliminary report on infusion of large volumes of liposomes to man.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Carcinoma, Small Cell; Female; Humans; Infusions, Parenteral; Leukemia, Erythroblastic, Acute; Liposomes; Lung Neoplasms; Male; Middle Aged; Neoplasms; Quinazolines | 1983 |
Distribution in man of 111In-labelled liposomes containing a water-insoluble antimitotic agent.
Topics: Antineoplastic Agents; Humans; Indium; Liposomes; Lung Neoplasms; Male; Quinazolines; Radioisotopes; Radionuclide Imaging; Tissue Distribution | 1984 |
Cross-resistance to thymidylate synthase inhibitors in P-glycoprotein and non-P-glycoprotein cell lines.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Cycle; Cell Line; Clone Cells; Doxorubicin; Drug Resistance, Multiple; Fluorodeoxyuridylate; Fluorouracil; Humans; Lung Neoplasms; Quinazolines; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured | 1994 |
[Effects of platelet aggregating inhibitor on pulmonary metastases of tumor cells after surgical resection].
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Transplantation; Platelet Aggregation Inhibitors; Quinazolines; Rats; Rats, Inbred Strains | 1993 |
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Candidiasis; Cell Division; Cell Line; Crystallography, X-Ray; Drug Design; Drug Resistance, Multiple; Enzyme Inhibitors; Folic Acid Antagonists; Humans; Lung Neoplasms; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mice, Nude; Mice, SCID; Models, Molecular; Molecular Conformation; Molecular Structure; Molecular Weight; Pneumonia, Pneumocystis; Protein Structure, Secondary; Quinazolines; Structure-Activity Relationship; Toxoplasma; Tumor Cells, Cultured | 1996 |
Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: involvement of receptor-directed protein tyrosine phosphatase(s).
Topics: Adenocarcinoma; Benzylidene Compounds; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Membrane; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; G(M3) Ganglioside; Humans; Lung Neoplasms; Nitriles; Phosphorylation; Protein Tyrosine Phosphatases; Quinazolines; Radioligand Assay; Signal Transduction; Tumor Cells, Cultured; Tyrphostins | 1997 |
Inhibition of tyrosine kinase activity decreases expression of surfactant protein A in a human lung adenocarcinoma cell line independent of epidermal growth factor receptor.
Topics: Benzylidene Compounds; Binding, Competitive; Blotting, Northern; Blotting, Western; Cell Survival; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Genistein; Humans; Isoflavones; Lung; Lung Neoplasms; Nitriles; Phosphorylation; Protein-Tyrosine Kinases; Proteolipids; Pulmonary Surfactant-Associated Protein A; Pulmonary Surfactant-Associated Proteins; Pulmonary Surfactants; Quinazolines; RNA, Messenger; Tumor Cells, Cultured; Tyrphostins | 1997 |
Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Electrocardiography; Female; Fluorouracil; Heart; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Quinazolines; Sigmoid Neoplasms; Thiophenes; Thymidylate Synthase | 1998 |
Alfuzosin is not associated with dermatomyositis.
Topics: Adrenergic alpha-Antagonists; Carcinoma; Dermatomyositis; Humans; Lung Neoplasms; Male; Quinazolines; Time Factors | 1999 |
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Temozolomide; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2000 |
Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331.
Topics: Antineoplastic Agents; Apoptosis; DNA Repair; Humans; Lung Neoplasms; Pyrophosphatases; Quinazolines; Thymidylate Synthase; Tumor Cells, Cultured | 2000 |
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Topics: Aminopterin; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carboplatin; Cell Division; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Time Factors; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Vulvar Neoplasms | 2000 |
[New targets in the treatment of lung cancer. Role of EGF-R tyrosine kinase inhibitors].
Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2000 |
Synthesis and cytotoxic activity of 7-oxo-7H-dibenz[f,ij]isoquinoline and 7-oxo-7H-benzo[e]perimidine derivatives.
Topics: Animals; Antineoplastic Agents; Cell Survival; Colonic Neoplasms; Doxorubicin; Drug Design; Drug Resistance, Neoplasm; Humans; Indicators and Reagents; Isoquinolines; Jurkat Cells; Leukemia P388; Lung Neoplasms; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Conformation; Molecular Structure; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 2001 |
Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Division; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Kinetics; Ligands; Lung Neoplasms; Mammary Neoplasms, Experimental; Phthalimides; Quinazolines; Rats; Signal Transduction; Tumor Cells, Cultured | 2001 |
Inhibitory effects of evodiamine on in vitro invasion and experimental lung metastasis of murine colon cancer cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Cell Division; Colonic Neoplasms; Female; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasm Transplantation; Plant Extracts; Quinazolines; Tumor Cells, Cultured | 2001 |
ZD-1839 (AstraZeneca).
Topics: Anemia; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Diarrhea; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Tolerance; Drugs, Investigational; Economics, Pharmaceutical; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Nausea; Pancreatic Neoplasms; Quinazolines; Tumor Cells, Cultured | 2001 |
Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2002 |
Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Bradykinin; Bradykinin Receptor Antagonists; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Division; Cisplatin; Dimerization; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Etoposide; Gefitinib; Humans; Infusion Pumps; Injections, Intralesional; Injections, Intraperitoneal; Injections, Subcutaneous; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Oligopeptides; Paclitaxel; Quinazolines; Time Factors; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2002 |
Cancer medicine hits a target.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; Drug Delivery Systems; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States; United States Food and Drug Administration | 2002 |
Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole.
Topics: Cell Division; Cell Survival; Deoxyuracil Nucleotides; Dipyridamole; DNA Damage; Drug Synergism; Folic Acid; Humans; Lung Neoplasms; Quinazolines; Thymidine; Thymidylate Synthase; Time Factors; Tumor Cells, Cultured | 1991 |
Inhibitory effects of DN-9693 on platelet-enhanced tumor cell attachment to cultured endothelium.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Platelets; Calcium; Cells, Cultured; Endothelium, Vascular; Lung Neoplasms; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Microscopy, Electron, Scanning; Neoplasms, Experimental; Platelet Activation; Platelet Aggregation Inhibitors; Pulmonary Artery; Quinazolines; Tumor Cells, Cultured | 1990 |
Phase II study of trimetrexate and cyclophosphamide in previously untreated patients with inoperable non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Remission Induction; Trimetrexate | 1990 |
Quality of life assessment during chemotherapy for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Drug Evaluation; Female; Folic Acid Antagonists; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Trimetrexate | 1990 |
Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Trimetrexate | 1989 |
The quantitation by radioimmunoassay of 2'-deoxyuridine 5'-triphosphate in extracts of thymidylate synthase-inhibited cells.
Topics: Antineoplastic Agents; Cell Line; Cross Reactions; Deoxyuracil Nucleotides; Folic Acid; Humans; Immune Sera; Lung Neoplasms; Quinazolines; Radioimmunoassay; Thymidylate Synthase; Tumor Cells, Cultured | 1989 |
Clinical response to trimetrexate as sole therapy for nonsmall cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Trimetrexate | 1988 |
Trimetrexate and cyclophosphamide for metastatic inoperable nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Trimetrexate | 1988 |
Trimetrexate combined with cisplatin or etoposide in the treatment of non-small cell lung cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Trimetrexate | 1988 |
Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks.
Topics: Adenocarcinoma; Adult; Aged; Bone Marrow; Chromatography, High Pressure Liquid; Deoxyuridine; Drug Evaluation; Female; Hematopoietic Stem Cells; Humans; Kinetics; Lung Neoplasms; Mathematics; Middle Aged; Quinazolines; Thrombocytopenia; Trimetrexate | 1987 |
Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells.
Topics: Carcinoma; Cell Survival; Dipyridamole; DNA; Drug Synergism; Folic Acid; Folic Acid Antagonists; Humans; Lung Neoplasms; Quinazolines; Thymidine; Thymidylate Synthase; Tumor Cells, Cultured | 1988 |